APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES This application claims priority to U.S. Patent Application Serial No. 12/631,367, filed December 4, 2009, which is incorporated by reference in its entirety. FIELD OF THE INVENTION This invention pertains to compounds which inhibit the activity of Bcl-2 anti-apoptotic proteins, compositions containing the compounds, and methods of treating diseases during which anti-apoptotic Bcl-2 proteins are expressed. BACKGROUND OF THE INVENTION Anti-apoptotic Bcl-2 proteins are associated with a number of diseases. There is therefore an existing need in the therapeutic arts for compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins. Overexpression of Bcl-2 proteins correlates with resistance to chemotherapy, clinical outcome, disease progression, overall prognosis or a combination thereof in various cancers and disorders of the immune system. Involvement of Bcl-2 proteins in bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer, spleen cancer, and the like is described in commonly-owned PCT US 2004/36770, published as WO 2005/049593, and PCT US 2004/37911, published as WO 2005/024636. Involvement of Bcl-2 proteins in immune and autoimmune diseases is described in Current Allergy and Asthma Reports 2003, 3, 378-384; British Journal of Haematology 2000, 110(3), 584-90; Blood 2000,95(4), 1283-92; and New England Journal of Medicine 2004, 351(14), 1409-1418. Involvement of Bcl-2 proteins in arthritis is disclosed in commonly-owned United States Provisional Patent Application Serial No. 60/988,479. Involvement of Bcl-2 proteins in bone marrow transplant rejection is disclosed in commonly-owned United States Patent Application Serial No. 11/941,196. SUMMARY OF THE INVENTION 2 One embodiment of this invention, therefore, pertains to compounds or therapeutically acceptable salts, prodrugs or salts of prodrugs thereof, which are useful as inhibitors of anti-apoptotic Bcl-2 proteins, the compounds having Formula I I D^ A^ B^ (I), wherein A'isNorC(A^); A^ is H, R', OR', SR', S(0)R\ SO2R', C(0)R', C(0)0R', 0C(0)R', NHR', N(R')2, C(0)NHR\ C(0)N(R*)2, NHC(0)R\ NR'C(0)R\ NHC(0)0R\ NR^C(0)0R', NHC(0)NH2, NHC(0)NHR\ NHC(0)N(R^)2, NR^C(0)NHR\ NR^C(0)N(R')2, SO2NH2, SO2NHR', S02N(R')2, NHSO2R', NR'S02R', NHSO2NHR', NHS02N(R')2, NR'S02NHR\ NR'S02N(R')2, C(0)NHN0H, C(0)NHN0R\ C(0)NHS02R\ C(NH)NH2, C(NH)NHR\ C(NH)N(R')2 NHSO2NHR', NHS02N(CH3)R', N(CH3)S02N(CH3)R', F, CI, Br, I, CN, NO2, N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)0R'^; B' is H, R\ 0R\ SR\ S(0)R\ SOJR', C(0)R\ C(0)0R\ 0C(0)R\ NHR\ N(R')2, C(0)NHR', C(0)N(R')2, NHC(0)R', NR'C(0)R\ NHC(0)0R', NR'C(0)0R', NHC(0)NH2, NHC(0)NHR', NfHC(0)N(R')2, NR'C(0)NHR\ NR*C(0)N(R')2, SO2NH2, SO2NHR', S02N(R')2, NHSO2R', NR'S02R\ NHSO2NHR', NHS02N(R')2, NR'S02NHR', NR'S02N(R')2, C(0)NHN0H, C(0)NHN0R\ C(0)NHS02R', C(NH)NH2, C(NH)NHR\ C(NH)N(R')2 NHS02NHR\ NHS02N(CH3)R\ N(CH3)S02N(CH3)R\ F, CI, Br, I, CN, NO2, N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)0R'''; D' is H, R\ 0R\ SR\ S(0)R\ S02R\ C(0)R\ C(0)0RS 0C(0)R\ NHR\ N(R^)2, C(0)NHR\ C(0)N(R')2, NHC(0)R\ NR'C(0)R\ NHC(0)0R\ NR^C(0)0R\ NHC(0)NH2, NHC(0)NHR', NHC(0)N(R')2, NR'C(0)NHR', NR'C(0)N(R')2, SO2NH2, S02NHR\ S02N(R^)2, NHS02R\ NR'S02R\ NHS02NHR\ NHS02N(R')2, NR'S02NHR\ NR'S02N(R')2, C(0)NHN0H, C(0)NHN0R', C(0)NHS02R', C(NH)NH2, C(NH)NHR', C(NH)N(R')2 NHSO2NHR', NHS02N(CH3)R\ N(CH3)S02N(CH3)R\ F, Cl, Br. I, CN, NO2, N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)0R'^; E' is H, R\ OR', SR', S(0)R', SO2R', C(0)R', C(0)0R', 0C(0)R', NHR', N(R')2, C(0)NHR', C(0)N(R')2, NHC(0)R', NR'C(0)R', NHC(0)0R', NR'C(0)0R', NHC(0)NH2, NHC(0)NHR', NHC(0)N(R')2, NR'C(0)NHR', NR'C(0)N(R')2, SO2NH2, 3 SO2NHR', S02N(R')2, NHSO2R', NR'SOZR', NHS02NHR\ NHS02N(R')2, NR'S02NHR\ NR'S02N(R')2. C(0)NHN0H, C(0)NHN0R', C(0)NHS02R\ C(NH)NH2, C(NH)NHR\ C(NH)N(R')2 NHSO2NHR', NHS02N(CH3)R\ N(CH3)S02N(CH3)R\ F, CI, Br, I, CN, NO2, N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)0R''^; and Y^ is H, CN, NO2, C(0)OH, F, CI, Br, I, CF3, OCF3, CF2CF3, OCF2CF3, R", OR", C(0)R", C(0)0R", SR'^ SO2R", NH2, NHR'\ N(R'^)2, NHC(0)R", C(0)NH2, C(0)NHR'\ C(0)N(R")2, NHS(0)R'^ or NHSO2R"; or E' and Y', together with the atoms to which they are attached, are benzene, nq)hthylene, heteroarene cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; and A^ B\ and D' are independently selected H, R\ 0R\ SR', S(0)R', SO2R', C(0)R', C(0)0R', 0C(0)R', NHR\ N(R')2, C(0)NHR', C(0)N(R')2, NHC(0)R', NR'C(0)R', NHC(0)0R\ NR'C(0)0R', NHC(0)NH2, NHC(0)NHR', NHC(0)N(R')2, NR'C(0)NHR\ NR'C(0)N(R^)2, SO2NH2, S02NHR\ S02N(R^)2, NHS02R\ NR^S02R\ NHSO2NHR', NHS02N(R')2, NR'S02NHR\ NR'S02N(R')2, C(0)NHN0H, C(0)NHN0R', C(0)NHS02R', C(NH)NH2, C(NH)NHR\ C(NH)N(R')2 NHSO2NHR', NHS02N(CH3)R\ N(CH3)S02N(CH3)R\ F, CI, Br, I, CN, N02,N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)0R'^; or Y^ and B\ together with the atoms to which they are attached, are benzene, naphthylene, heteroarene cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; and A^ D\ and E^ are independently selected H, R', 0R\ SR', S(0)R', SO2R', C(0)R', C(0)0R', 0C(0)R\ NHR\ N(R^)2, C(0)NHR', C(0)N(R^)2, NHC(0)R', NR^C(0)R\ NHC(0)0R\ NR^C(0)0R', NHC(0)NH2, NHC(0)NHR', NHC(0)N(R')2, NR'C(0)NHR\ NR'C(0)N(R')2, SO2NH2, S02NHR\ S02N(R')2, NHSO2R', NR'SOZR', NHS02NHR\ NHS02N(R')2, NR'S02NHR\ NR'S02N(R')2, C(0)NHN0H, C(0)NHN0R\ C(0)NHS02R\ C(NH)NH2, C(NH)NHR\ C(NH)N(R')2.NHS02NHR', NHS02N(CH3)R\ N(CH3)S02N(CH3)R\ F, CI, Br, I, CN, N02,N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)0H, C(0)NH2 or C(0)0R''^; or A^ and B\ together with the atoms to which they are attached, are benzene, naphthylene, heteroarene cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; and D\ E\ and Y' are independently selected H, R', OR', SR\ S(0)R', SO2R', C(0)RC(0)0R\ 0C(0)R', NHR', N(R')2, C(0)NHR\ C(0)N(R')2, NHC(0)R\ NR'C(0)R', 4 NHC(0)0R\ NR^C(0)0R\ NHC(0)NH2, NHC(0)NHR', NHC(0)N(R')2, NR'C(0)NHR\ NR'C(0)N(R')2, SO2NH2, S02NHR\ S02N(R')2, NHS02R\ NR'S02R\ NHS02NHR\ NHS02N(R')2, NR'S02NHR\ NR^S02N(R')2, C(0)NHN0H, C(0)NHN0R\ C(0)NHS02R\ C(NH)NH2, C(NH)NHR', C(NH)N(R')2 NHS02NHR\ NHS02N(CH3)R\ N(CH3)S02N(CH3)R', F, CI, Br, I, CN, NO2. N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)0R''^; or A^ and D', together with the atoms to which they are attached, are benzene, naphthalene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; and B\ E\ and Y' are independently selected H, R', 0R\ SR\ S(0)R\ S02R\ C(0)R\ C(0)0R', 0C(0)R\ NHR', N(R')2, C(0)NHR', C(0)N(R')2, NHC(0)R', NR'C(0)R', NHC(0)0R', NR'C(0)0R', NHC(0)NH2, NHC(0)NHR', NHC(0)N(R')2, NR'C(0)NHR', NR'C(0)N(R^)2, SO2NH2, S02NHR\ S02N(R')2, NHS02R\ NR'S02R\ NHSO2NHR', NHS02N(R')2, NR^S02NHR\ NR^S02N(R^)2, C(0)NHN0H, C(0)NHN0R\ C(0)NHS02R\ C(NH)NH2, C(NH)NHR\ C(NH)N(R')2 NHS02NHR\ NHS02N(CH3)R\ N(CH3)S02N(CH3)R', F, CI, Br, I, CN, N02,N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)OR^'^; R' is R^ R^ R"* or R^ R'^ is cycloalkyl, cycloalkenyl or cycloalkynyl; R^ is phenyl, which is unfused or fused with benzene, heteroarene or R^^; R^^ is cycloalkane or heterocycloalkane; R^ is heteroaryl, which is unfused or fused with benzene, heteroarene or R^'^; R^'^ is cycloalkane or heterocycloalkane; R'* is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R*'^; R'*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R* is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R^ NCCR^'^XR^^), R^ OR^ SR\ S(0)R\ S02R\ NHR^ N(R^)2, C(0)R\ C(0)NH2, C(0)NHR\ C(0)N(R^)2, NHC(0)R^ NR^C(0)R\ NHSO2R', NHC(0)0R\ SO2NH2, SOZNHR'', S02N(R')2, NHC(0)NH2, NHC(0)NHR'', NHC(0)CH(CH3)NHC(0)CH(CH3)NH2, NHC(0)CH(CH3)NHC(0)CH(CH3)NHR\ OH, (O), C(0)0H, N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I; R* is C2-C5-spiroalkyl, each of which is unsubstituted or substituted with OH, (O), N3, CN, CF3, CF2CF3, F, CI, Br, I, NH2, NH(CH3) or N(CH3)2; 5 R^'^ and R^^ are independently selected alkyl or, together with the N to which they are attached, R^; R^ is aziridin-1-yl, azetidin-1-yl, pyrrolidin-l-yl orpiperidin-l-yl, each having one CHi moiety unreplaced or replaced with O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH; R^sR^R^R'%rR"; R^ is phenyl, which is unfused or fused with benzene, heteroarene or R*'^; R*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R' is heteroaryl, which is unfused or fused with benzene, heteroarene or R^'^; R^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^° is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl each of which is unfused or fused with benzene, heteroarene or R'''^; R'"'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R" is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R'^ OR^^, SR'^ S(0)R'^ S02R'^ C(0)R'^ CO(0)R*^ OC(0)R'^ OC(0)OR'^ NH2, NHR'^ N(R'^)2, NHC(0)R'^ NR>^C(0)R'^ NHS(0)2R'\ NR'^S(0)2R'^ NHC(0)OR'^ NR'^C(0)OR'^ NHC(0)NH2, NHC(0)NHR'^ NHC(0)N(R'^)2, NR'^C(0)NHR'^ NR'^C(0)N(R^^)2, C(0)NH2, C(0)NHR'^ C(0)N(R^^)2, C(0)NHOH, C(0)NH0R'^ C(0)NHS02R'^ C(0)NR'^S02R'^ SO2NH2, S02NHR'^ S02N(R^^)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR'^ C(N)N(R'^)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I; R'2isR",R^R'^orR'^; R" is phenyl, which is unfused or fused with benzene, heteroarene or R""^; R""^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'"* is heteroaryl, which is unfused or fused with benzene, heteroarene or R*''^; R^'*^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'* is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene, each of which is unfused or fused with benzene, heteroarene or R'^"^; R'*"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'* is alkyl, alkenyl or alkynyl; R^'isR^R'',R2%rR^>; R'* is phenyl, which is unfused or fused with benzene, heteroarene or R'*^; R'*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'' is heteroaryl, which is unfused or fused with benzene, heteroarene or R"'^; R'^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; 6 R^" is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl each of which is unfused or fused with benzene, heteroarene or R ; R is cycloalkane, cycloalkene, heterocycloalkane or heteiocycloalkene; R^' is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R^^ 0R^^ SR^^ S(0)R^^, S02R^^ C(0)R^\ CO(0)R^^ OC(0)R^, OC(0)OR^^ NH2, NHR^\ N(R^^)2, NHC(0)R^^ NR^^C(0)R^^ NHS(0)2R^^ NR^^S(0)2R^^ NHC(0)OR^^ NR^^C(0)OR^^ NHC(0)NH2, NHC(0)NHR^^ NHC(0)N(R^^)2, NR^^C(0)NHR^^ NR^^C(0)N(R^^)2, C(0)NH2, C(0)NHR^^ C(0)N(R^^)2, C(0)NHOH, C(0)NHOR^^ C(0)NHS02R^^ C(0)NR^^S02R^^ SO2NH2, S02NHR^^ S02N(R^^)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR^^ C(N)N(R^^)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I; R22isR2^R^orR^; R is phenyl, which is unfused or fused with benzene, heteroarene or R ; R is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^"* is heteroarene, which is unfused or fused with benzene, heteroarene or R^'*'^; R^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^^ is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl each of which is unfused or fused with benzene, heteroarene or R^^"^; R^"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; Z'isR^^orR"; Z^isR2«,R^%rR^°; Z^^ and Z^^ are both absent or are taken together to form CH2, CH2CH2 or Z'^'^; Z'^^ is C2-C6-alkylene having one or two CH2 moieties replaced by NH, N(CH3), S, S(0) or SO2; L' is a R", OR", SR", S(0)R", SO2R", C(0)R", C0(0)R", 0C(0)R", 0C(0)0R", NHR", C(0)NH, C(0)NR", C(0)NH0R", C(0)NHS02R", SO2NH, SO2NHR", C(N)NH, C(N)NHR"; R is phenylene, which is unfused or fused with benzene or heteroarene or R ; R is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^^ is heteroarylene, which is unfused or fused with benzene or heteroarene or R^^'^; R^^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^* is phenylene, which is unfused or fused with benzene, heteroarene or R^*'^; R^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; 7 R^' is heteroarylene, which is unfused or fused with benzene or heteroarene or R^^'^; R^''^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene ; R^" is cycloalkylene, cycloalkenylene, heterocycloalkylene or heterocycloalkenylene, each of which is unfused or fused with benzene, heteroarene or R ; R is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R" is a bond or R^^'^' R^^'^is alkylene, alkenylene, or alkynylene, each of which is unsubstituted or substituted with one or two or three independently selected R"^, OR"^, SR"^, S(0)R"^, SOZR"^, C(0)R"^, C0(0)R"^, 0C(0)R"^, 0C(0)0R"^, NH2, NHR^'^, N(R^^^)2, NHC(0)R"^, NR'^^C(0)R"^, NHS(0)2R^™, NR"^S(0)2R"^, NHC(0)0R"^, NR"^C(0)0R"'*, NHC(0)NH2, NHC(0)NHR"^, NHC(0)N(R"^)2, NR^^^C(0)NHR^™, NR"^C(0)N(R^''^)2, C(0)NH2, C(0)NHR^^^, C(0)N(R"^)2, C(0)NH0H, C(0)NH0R"^, C(0)NHS02R"^, C(0)NR"^S02R"^. SO2NH2, S02NHR^'^, S02N(R^™)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR"^, C(N)N(R"^)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br and I substituents; R^^^ is alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloaUcyl, or heterocycloalkenyl; Z^isR^«,R^'orR^°; R is phenyl, which is unfused or fused with benzene, heteroarene or R ; R is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' is heteroaryl, which is unfused or fused with benzene, heteroarene or R^''^; R^^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R"*" is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fiised with benzene, heteroarene or R'*"'^; R'*"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; wherein the moieties represented by R^^ and R^' are substituted (i.e., if z''^ and T}^ are absent) or further substituted (i.e., if l)^ and Z^'^ are present) with one or two or three or four of independenUy selected R'*', 0R'*\ SR^\ S(0)R'", S02R^\ C(0)R''\ C0(0)R'*', OC(0)R^\ OC(0)OR''\ NH2, NHR'*', N(R'*')2, NHC(0)R'*', NR^'^QOR'", NHS(0)2R^NR^'S(0)2R''\ NHC(0)OR'*\ NR'"C(0)OR'", NHC(0)NH2, NHC(0)NHR^NHC(0)N(R^')2, NR'"C(0)NHR^', NR'"C(0)N(R^')2, C(0)NH2, C(0)NHR^', C(0)N(R^')2, C(0)NHOH, C(0)NHOR'", C(0)NHS02R'*\ C(0)NR^'S02R^', SO2NH2, S02NHR^S02N(R^')2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR'", C(N)N(R^')2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I; 8 R'*^ is phenyl, which is unfused or fused with benzene, heteroarene or R''^'^; R'*^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R"*^ is heteroaryl, which is unfused or fused with benzene, heteroarene or R"*^^; R"*^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R"*^ is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R''^'^; R**"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R''^ is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R'^, OR'^^ SR'^, S(0)R''^ SOaR'^, C(0)R'^, CO(0)R^^ OC(0)R'^, OC(0)OR^^ NH2, NHR^^ N(R'*^)2, NHC(0)R^^ NR^C(0)R^, NHS(0)2R'*^ NR^S(0)2R'^, NHC(0)OR^, NR^*C(0)OR^, NHC(0)NH2, NHC(0)NHR'*^ NHC(0)N(R'**)2, NR'*^C(0)NHR^^ NR'^C(0)N(R''^)2, C(0)NH2, C(0)NHR^, C(0)N(R^^)2, C(0)NHOH, C(0)NHOR^, C(0)NHS02R^^ C(0)NR'^S02R'^, SO2NH2, S02NHR'*^ S02N(R^)2, C(0)H, C(0)0H, C(N)NH2, C(N)NHR'^, C(N)N(R'^)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I; R^^ is alkyl, alkenyl, alkynyl, R*\ R'^ or R'*^ R"*' is phenyl, which is unfused or fused with benzene, heteroarene or R''^'^; R'*^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'*^ is heteroaryl, which is unfused or fiised with benzene, heteroarene or R"**"^; R"**^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R"" is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R'"'^; R'*''^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; wherein the moieties represented by R'•^ R^^^, R'*\ R"^^, R'", R'"'^, R^^ R^^^, R'*^ j^4SA^ R"*', and R"*^^ are independently substituted with one or two or three or four of independently selected R^°, 0R^°, SR^", S(0)R*°, SOzR^", C(0)R*°, CO(0)R^'', 0C(0)R^*', OC(0)OR^°, NH2, NHR^°, N(R^°)2, NHC(0)R*°, NR^''C(0)R^°, NHS(0)2R''', NR^^SCOZR^", NHC(0)0R'°, NR'''C(0)0R^'', NHC(0)NH2, NHC(0)NHR^'', NHC(0)N(R^°)2, NR^°C(0)NHR^°, NR^°C(0)N(R^'')2, C(0)NH2, C(0)NHR^°, C(0)N(R^°)2, C(0)NH0H, C(0)NHOR^°, C(0)NHS02R^, C(0)NR^S02R^°, SO2NH2, S02NHR'°, S02N(R^°)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR^°, C(N)N(R^'')2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I; R'°isR'\R",R5^orR^^; 9 R^' is phenyl, which is unfused or fused with benzene, heteroarene or R^'^; R^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^^ is heteroaryl, which is unfused or fused with benzene, heteroarene or R^^'^; R^^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^^ is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^^^; R^^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^'* is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independenUy selected R^^ OR", SR^^ S(0)R", S02R^^ C(0)R^^ C0(0)R", OC(0)R'^ OC(0)OR*^ NHz, NHR", N(R'^)2, NHC(0)R'^ NR"C(0)R^^ NHS(0)2R^^ NR"S(0)2R", NHC(0)OR^^ NR^^C(0)OR^^ NHC(0)NH2, NHC(0)NHR^^ NHC(0)N(R")2, NR''C(0)NHR^', NR'^C(0)N(R")2, C(0)NH2, C(0)NHR'^ C(0)N(R^')2, C(0)NHOH, C(0)NHOR'^ C(0)NHS02R", C(0)NR"S02R^^ SO2NH2, S02NHR^^ S02N(R^^)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR^^ C(N)N(R^^)2, CNOH, CNOCH3,OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I; R^^ is alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl; and wherein each foregoing cyclic moiety is independently unsubstituted, further unsubstituted, substituted or further substituted with one or two or three or four or five of independently selected R"^, R^^ OR", SR^\ S(0)R", SO2R", C(0)R", C0(0)R", 0C(0)R", 0C(0)0R", NH2, NHR", N(R")2, NHC(0)R", NR^^C(0)R", NHS(0)2R", NR^^S(0)2R", NHC(0)0R^^ NR"C(0)0R", NHC(0)NH2, NHC(0)NHR^^ NHC(0)N(R")2, NR"C(0)NHR", NR"C(0)N(R")2, C(0)NH2, C(0)NHR'^ C(0)N(R")2, C(0)NHOH, C(0)NH0R", C(0)NHS02R", C(0)NR"S02R^\ SO2NH2, SO2NHR", S02N(R")2, C(0)H, C(0)0H, C(N)NH2, C(N)NHR^^ C(N)N(R^^)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I; R^^'^ is spirocyclyl; R^^isR^^R^^R«'orR^^ R'* is phenyl, which is unfused or fused with benzene, heteroarene or R^*'^; R^*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^^ is heteroaryl, which is unfused or fused with benzene, heteroarene or R^^'^; R^''^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; 10 R^ is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R*''^; R^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R*' is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independenUy selected R^^ 0R^^ SR^^ S(0)R^^ S02R*^ C(0)R^\ CO(0)R*^ OC(0)R^^ OC(0)OR^^ NH2, NHR^^ N(R^^)2, NHC(0)R*^ NR^^C(0)R^^ NHS(0)2R*^ NR^^S(0)2R^^ NHC(0)OR*^ NR^^C(0)OR*^ NHC(0)NH2, NHC(0)NHR*^ NHC(0)N(R*^)2, NR*^C(0)NHR^^ NR^^C(0)N(R*^)2, C(0)NH2, C(0)NHR^^ C(0)N(R*^)2, C(0)NHOH, C(0)NHOR*^ C(0)NHS02R^^ C(0)NR"S02R^^ SO2NH2, S02NHR*^ S02N(R*^)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR^^ C(N)N(R*^)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I; R^^isR*^R^,R«o^R^; R is phenyl, which is unfused or fused with benzene, heteroarene or R ; R is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^ is heteroaryl, which is unfused or fused with benzene, heteroarene or R^'^; R^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R ^ is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^*'^; R*^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^ is alkyl, alkenyl or alkenyl, each of which is unsubstituted or substituted with one or two or three of independenUy selected R^^ OR*', SR*'', S(0)R*\ S02R*\ C(0)R*\ CO(0)R*^ OC(0)R*\ 0C(0)0R*\ NH2, NHR*\ N(R*')2, NHC(0)R*^ NR*'C(0)R*\ NHS(0)2R*\ NR*'S(0)2R*\ NHC(0)OR*^ NR*'C(0)0R*^ NHC(0)NH2, NHC(0)NHR*^ NHC(0)N(R*'')2, NR*'C(0)NHR*^ NR*'C(0)N(R*')2, C(0)NH2, C(0)NHR*^ C(0)N(R*')2, C(0)NHOH, C(0)NHOR*\ C(0)NHS02R*^ C(0)NR*'S02R*\ SO2NH2, SOzNHR*^ S02N(R*')2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR*\ C(N)N(R*')2, CNOH, CNOCH3,OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I substituents; R*' is alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl; wherein the moieties represented by R"^, R^^ R^^ R^, R*^ R^, R*^ and R*' are unsubstituted or substituted with one or two or three or four of independenUy selected R^, OR^, SR^, S(0)R^, S02R^, C(0)R^, CO(0)R**, OC(0)R^, 0C(0)0R^, NH2, NHR^, N(R^)2, NHC(0)R^, NR^C(0)R^, NHS(0)2R*^ NR^S(0)2R**, NHC(0)0R^, NR^C(0)0R^, NHC(0)NH2, NHC(0)NHR^, NHC(0)N(R^)2, NR^C(0)NHR^, 11 NR^C(0)N(R^)2, C(0)NH2, C(0)NHR^, C(0)N(R^)2, C(0)NHOH, C(0)NHOR^, C(0)NHS02R^, C(0)NR^S02R^, SO2NH2, S02NHR^, S02N(R**)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR^, C(N)N(R^)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I; R^isR^,R™,R^'orR'^ R*^ is phenyl, which is unfused or fused with benzene, heteroarene or R^^; R^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^° is heteroaryl, which is unfused or fiised with benzene, heteroarene or R"^^; R™'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^''^; R'''^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^^ is alkyl, alkenyl or alkenyl, each of which is unsubstituted or substituted with one or two or three of independently selected R^^ OR", SR", S(0)R", SO2R", C(0)R", C0(0)R", OC(0)R'^ 0C(0)0R", NH2, NHR", N(R")2, NHC(0)R''^ NR"C(0)R''^ NHS(0)2R", NR"S(0)2R", NHC(0)0R", NR"C(0)0R", NHC(0)NH2, NHC(0)NHR''^ NHC(0)N(R")2, NR"C(0)NHR", NR"C(0)N(R")2, C(0)NH2, C(0)NHR", C(0)N(R''^)2, C(0)NHOH, C(0)NH0R", C(0)NHS02R", C(0)NR"S02R", SO2NH2, SO2NHR", S02N(R''^)2, C(0)H, C(0)0H, C(N)NH2, C(N)NHR'^ C(N)N(R''^)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I; R'^ is alkyl, alkenyl, alkenyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl; and the moieties represented by R^, R^°, and R^' are unsubstituted or substituted with one or two or three or four of independently selected NH2, C(0)NH2, C(0)NHOH, SO2NH2, CF3, CF2CF3, C(0)H, C(0)OH, C(N)NH2, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I. Another embodiment pertains to a compound having Formula (II) 12 11 T J-(R^°^)m I 7? ai), or a therapeutically acceptable salt thereof, wherein R'°° is as described for substituents on R^*; n is 0, 1, 2, or 3; R'"^ is as described for substituents on R*^; m is 1, 2, 3,4, or 5; VisNorC(A^); A^ is H, R\ OR', SR', S(0)R', SOZR', C(0)R\ C(0)0R', 0C(0)R\ NHR', N(R')2, C(0)NHR\ C(0)N(R')2, NHC(0)R', NR'C(0)R\ NHC(0)0R\ NR'C(0)0R', NHC(0)NH2, NHC(0)NHR', NHC(0)N(R')2, NR'C(0)NHR\ NR'C(0)N(R')2, SO2NH2, SOZNHR', S02N(R')2, NHSO2R', NR'S02R\ NHSO2NHR', NHS02N(R')2, NR'SOZNHR', NR'S02N(R')2, C(0)NHN0H, C(0)NHN0R\ C(0)NHS02R', C(NH)NH2, C(NH)NHR\ C(NH)N(R')2 NHS02NHR\ NHS02N(CH3)R\ N(CH3)S02N(CH3)R\ F, CI, Br, I, CN, NO2, N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)0R''^; B' is H, R', 0R\ SR\ S(0)R\ SO2R', C(0)R\ C(0)0R\ 0C(0)R\ NHR\ N(R')2, C(0)NHR\ C(0)N(R')2, NHC(0)R\ NR'C(0)R', NHC(0)0R', NR'C(0)0R', NHC(0)NH2, NHC(0)NHR', NHC(0)N(R')2, NR'C(0)NHR', NR'C(0)N(R')2, SO2NH2, SO2NHR', S02N(R')2, NHS02R\ NR'S02R\ NHSO2NHR', NHS02N(R')2, NR'S02NHR\ NR'S02N(R')2, C(0)NHN0H, C(0)NHN0R\ C(0)NHS02R', C(NH)NH2, C(NH)NHR\ C(NH)N(R')2 NHS02NHR\ NHS02N(CH3)R\ N(CH3)S02N(CH3)R\ F, CI, Br, I, CN, NO2. N3, OH, C(0)H, CHNOH, CHCNOCHj), CF3, C(0)OH, C(0)NH2 or C(0)0R'^; D' is H, R', 0R\ SR', S(0)R', S02R\ C(0)R', C(0)0R\ 0C(0)R\ NHR', N(R')2, C(0)NHR\ C(0)N(R')2, NHC(0)R\ NR'C(0)R\ NHC(0)0R\ NR'C(0)0R13 NHC(0)NH2, NHC(0)NHR', NHC(0)N(R')2, NR'C(0)NHR', NR'C(0)N(R')2, SO2NH2, S02NHR\ S02N(R')2, NHSO2R', NR'S02R', NHS02NHR\ NHS02N(R')2, NR'S02NHR\ NR'S02N(R')2, C(0)NHN0H, C(0)NHN0R\ C(0)NHS02R\ C(NH)NH2, C(NH)NHR\ C(NH)N(R')2 NHS02NHR\ NHS02N(CH3)R\ N(CH3)S02N(CH3)R\ F, CI, Br, I, CN, NO2, N3, OH, C(0)H, CHNOH, CHCNOCHj), CF3, C(0)OH, C(0)NH2 or C(0)OR^^; E' is H, R', 0R\ SR\ S(0)R\ S02R\ C(0)R\ C(0)0R\ 0C(0)R\ NHR\ N(R')2, C(0)NHR', C(0)N(R')2, NHC(0)R', NR'C(0)R', NHC(0)0R', NR'C(0)0R', NHC(0)NH2, NHC(0)NHR\ NHC(0)N(R*)2, NR^C(0)NHR\ NR*C(0)N(R')2, SO2NH2, SO2NHR', S02N(R')2, NHS02R\ NR'S02R', NHSO2NHR', NHS02N(R')2, NR'S02NHR\ NR'S02N(R')2, C(0)NHN0H, C(0)NHN0R\ C(0)NHS02R', C(NH)NH2, C(NH)NHR', C(NH)N(R')2 NHSO2NHR', NHS02N(CH3)R\.N(CH3)S02N(CH3)R', F, CI, Br, I, CN, NO2, N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)0R'^; and Y^ is H, CN, NO2, C(0)OH, F, CI, Br, I, CF3, OCF3, CF2CF3, OCF2CF3, R'^ OR", C(0)R''', C(0)0R", SR'^ SO2R", NH2, NHR", N(R")2, NHC(0)R", C(0)NH2, C(0)NHR", C(0)N(R'^)2, NHS(0)R" or NHS02R^^; or E' and Y', together with the atoms to which they are attached, are benzene, naphthylene, heteroarene cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; a^d A^ B\ and D' are independently selected H, R', 0R\ SR\ S(0)R', S02R\ C(0)R\ C(0)0R\ 0C(0)R\ NHR\ N(R')2, C(0)NHR\ C(0)N(R')2, NHC(0)R\ NR'C(0)R', NHC(0)0R\ NR^C(0)0R', NHC(0)NH2, NHC(0)NHR', NHC(0)N(R')2, NR'C(0)NHR', NR'C(0)N(R')2, SO2NH2, SO2NHR', S02N(R')2, NHSO2R', NR^SOIR', NHSO2NHR', NHS02N(R')2, NR^S02NHR', NR'S02N(R')2, C(0)NHN0H, C(0)NHN0R\ C(0)NHS02R\ C(NH)NH2, C(NH)NHR\ C(NH)N(R')2 NHS02NHR\ NHS02N(CH3)R\ N(CH3)S02N(CH3)R\ F, CI, Br, I, CN, NO2.N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)OR^^; or Y' and B\ together with the atoms to which they are attached, are benzene, naphthylene, heteroarene cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; and A^ D\ and E^ are independenUy selected H, R', OR', SR\ S(0)R', SO2R', C(0)RC(0)0R\ 0C(0)R\ NHR\ N(R')2, C(0)NHR', C(0)N(R')2, NHC(0)R\ NR'C(0)R', NHC(0)0R\ NR'C(0)0R\ NHC(0)NH2, NHC(0)NHR', NHC(0)N(R')2, NR'C(0)NHRNR'C(0)N(R')2, SO2NH2, S02NHR\ S02N(R')2, NHS02R\ NR'S02R', NHSO2NHR', NHS02N(R')2, NR'S02NHR\ NR*S02N(R')2, C(0)NHN0H, C(0)NHN0R', 14 C(0)NHS02R\ C(NH)NH2, C(NH)NHR\ C(NH)N(R')2 NHS02NHR\ NHS02N(CH3)R\ N(CH3)S02N(CH3)R', F, CI, Br, I, CN, N02,N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)0R''^; or A^ and B\ together with the atoms to which they are attached, are benzene, naphthylene, heteroarene cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; and D", E', and Y' are independenUy selected H, R', OR', SR', S(0)R', SO2R', C(0)R', C(0)0R', 0C(0)R\ NHR', N(R')2, C(0)NHR\ C(0)N(R')2, NHC(0)R', NR'C(0)R\ NHC(0)0R\ NR'C(0)0R\ NHC(0)NH2, NHC(0)NHR\ NHC(0)N(R')2, NR^C(0)NHR\ NR'C(0)N(R')2, SO2NH2, S02NHR\ S02N(R')2, NHS02R\ NR'SOZR', NHSO2NHR', NHS02N(R')2, NR'S02NHR\ NR'S02N(R')2, C(0)NHN0H, C(0)NHN0R\ C(0)NHS02R', C(NH)NH2, C(NH)NHR', C(NH)N(R')2 NHSO2NHR', NHS02N(CH3)R\ N(CH3)S02N(CH3)R', F, CI, Br, I, CN, NO2, N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)OR^^; or A^ and D', together with the atoms to which they are attached, are benzene, naphthalene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; and B\ E\ and Y^ are independently selected H, R\ 0R\ SR', S(0)R\ S02R\ C(0)R\ C(0)0R\ 0C(0)R\ NHR\ N(R')2, C(0)NHR\ C(0)N(R')2, NHC(0)R', NR'C(0)R', NHC(0)0R\ NR^C(0)0R\ NHC(0)NH2, NHC(0)NHR\ NHC(0)N(R')2, NR'C(0)NHR', NR'C(0)N(R')2, SO2NH2, S02NHR\ S02N(R^)2, NHSO2R', NR'S02R\ NHSO2NHR', NHS02N(R')2, NR^S02NHR\ NR'S02N(R')2, C(0)NHN0H, C(0)NHN0R', C(0)NHS02R\ C(NH)NH2, C(NH)NHR\ C(NH)N(R')2 NHS02NHR\ NHS02N(CH3)R\ N(CH3)S02N(CH3)R\ F, CI, Br, I, CN. N02,N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)0H, C(0)NH2 or C(0)0R'^; R'isR^R^R%rR^; R'^ is cycloalkyl, cycloalkenyl or cycloalkynyl; R^ is phenyl, which is unfused or fused with benzene, heteroarene or R^'^; R^'^ is cycloalkane or heterocycloalkane; R^ is heteroaryl, which is unfused or fused with benzene, heteroarene or R^"^; R^'^ is cycloalkane or heterocycloalkane; R"* is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R'*'^; R'*^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; 15 R^ is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independenUy selected R^, NC(R^'^)(R^'*), R^ OR^ SR\ S(0)R^ S02R\ NHR', N(R')2, C(0)R\ C(0)NH2, C(0)NHR\ C(0)N(R^)2, NHCCOR', NR'C(0)R^ NHSO2R'', NHC(0)0R\ SO2NH2, S02NHR'', S02N(R^)2, NHC(0)NH2, NHC(0)NHR\ NHC(0)CH(CH3)NHC(0)CH(CH3)NH2,NHC(0)CH(CH3)NHC(0)CH(CH3)NHR',0H, (O), C(0)OH, N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I; R^ is C2-C5-spiroalkyl, each of which is unsubstituted or substituted with OH, (O), N3, CN, CF3, CF2CF3, F, CI, Br, I, NH2, NH(CH3) or N(CH3)2; R^"^ and R^® are independently selected alkyl or, together with the N to which they are attached, R^; R^ is aziridin-l-yl, azetidin-1-yl, pyrrolidin-l-yl orpiperidin-1-yl, each having one CH2 moiety unreplaced or replaced with O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH; R'isR^R^R^%rR"; R* is phenyl, which is unfiised or fused with benzene, heteroarene or R*'^; R*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R' is heteroaryl, which is unfused or fused with benzene, heteroarene or R^'^; R^*^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'° is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl each of which is unfused or fused with benzene, heteroarene or R'""^; R*°^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R" is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independenUy selected R'^ 0R'^ SR'^ S(0)R'^ S02R'\ C(0)R'^ CO(0)R'^ OC(0)R'^ OC(0)OR'^ NH2, NHR^^ N(R^^)2, NHC(0)R'^ NR'^C(0)R'^ NHS(0)2R'^ NR'^S(0)2R'^ NHC(0)OR'^ NR'^C(0)OR'^ NHC(0)NH2, NHC(0)NHR'^ NHC(0)N(R'^)2, NR^^C(0)NHR'^ NR^^C(0)N(R^^)2, C(0)NH2, C(0)NHR'^ C(0)N(R'^)2, C(0)NHOH, C(0)NHOR'^ C(0)NHS02R'^ C(0)NR'^S02R'^ SO2NH2, S02NHR'^ S02N(R^^)2, C(0)H, C(0)0H, C(N)NH2, C(N)NHR'^ C(N)N(R'^)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I; R^MsR",R'^R'^orR'^ R" is phenyl, which is unfused or fused with benzene, heteroarene or R'^^; R'^"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'"* is heteroaryl, which is unfused or fused with benzene, heteroarene or R'"'^; R''*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; 16 R'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene, each of which is unfiised or fused with benzene, heteroarene or R'^"^; R'^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'*^ is alkyl, alkenyl or alkynyl; R^'isR'^R'^R^%rR^'; R'* is phenyl, which is unfused or fused with benzene, heteroarene or R'*'^; R'*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'' is heteroaryl, which is unfused or fused with benzene, heteroarene or R'^"^; R^^"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^" is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl each of which is unfused or fused with benzene, heteroarene or R ; R is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independentiy selected R^^ 0R^^ SR^^ S(0)R^^ S02R^^ C(0)R^, C0(0)R", 0C(0)R^, OC(0)OR^^ NH2, NHR", N(R^^)2, NHC(0)R^^ NR^^CCOR^^ NHS(0)2R^\ NR^^S(0)2R^^ NHC(0)OR^^ NR^^C(0)OR^^ NHC(0)NH2, NHC(0)NHR^^ NHC(0)N(R^^)2, NR^^C(0)NHR^^ NR^^C(0)N(R^^)2, C(0)NH2, C(0)NHR^, C(0)N(R^^)2, C(0)NHOH, C(0)NHOR^^ C(0)NHS02R", C(0)NR^^S02R^^ SO2NH2, S02NHR^^ S02N(R^^)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR^^ C(N)N(R^^)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I; R^^isR^',R^orR'^; R^^ is phenyl, which is unfused or fused with benzene, heteroarene or R^'^; R^^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^ is heteroarene, which is unfused or fused with benzene, heteroarene or R^'^; R^'*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^^ is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl each of which is unfiised or fused with benzene, heteroarene or R^^'^; R^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; zMsR2^R^%rR^°; Z^^ and Z^'^ are both absent or are taken together to form CH2, CH2CH2 or Z'^^; Z'^^ is C2-C6-alkylene having one or two CH2 moieties replaced by NH, N(CH3), S, S(0)orS02; 17 L' is a R^\ 0R^\ SR^\ S(0)R", SO2R", C(0)R", C0(0)R^^ 0C(0)R", 0C(0)0R", NHR", C(0)NH, C(0)NR", C(0)NH0R^\ C(0)NHS02R^^, SO2NH, SO2NHR", C(N)NH, C(N)NHR"; R'^* is phenylene, which is unfused or fused with benzene, heteroarene or R^*'^; R^*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' is heteroarylene, which is unfused or fused with benzene or heteroarene or R^^'^; R^'"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene ; R^'' is cycloalkylene, cycloalkenylene, heterocycloalkylene or heterocycloalkenylene, each of which is unfused or fused with benzene, heteroarene or R ; R is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R" is a bond or R^''^' R^^'^is alkylene, alkenylene, or alkynylene, each of which is unsubstituted or substituted with one or two or three independently selected R^^®, OR^'®, SR"^, S(0)R^™, S02R^™, C(0)R^^°, C0(0)R"^, 0C(0)R"^, 0C(0)0R"^, NH2, NHR"^, N(R"^)2, NHC(0)R^''^, NR"^C(0)R"^, NHS(0)2R"^, NR"^S(0)2R"^, NHC(0)0R^^^, NR"^C(0)0R"^, NHC(0)NH2, NHC(0)NHR"^, NHC(0)N(R^'"*)2, NR"^C(0)NHR^™, NR"^C(0)N(R^™)2, C(0)NH2, C(0)NHR^'^, C(0)N(R"^)2, C(0)NH0H, C(0)NH0R^^^, C(0)NHS02R"®, C(0)NR"®S02R"^, SO2NH2, S02NHR"^, S02N(R"^)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR"^, C(N)N(R"®)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br and I substituents; R^^® is alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl; Z^isR^«,R^%rR^°; R^* is phenyl, which is unfused or fused with benzene, heteroarene or R^*^; R^*^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' is heteroaryl, which is unfiised or fused with benzene, heteroarene or R^^'^; R^''^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'*" is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfiised or fused with benzene, heteroarene or R"*""^; R"*"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; wherein the moieties represented by R'*^ are independently substituted with one or two or three or four of independently selected R^", 0R^°, SR^°, S(0)R^°, S02R^°, C(0)R^°, CO(0)R^'', OC(0)R^°, OC(0)OR^°, NH2, NHR'°, NCR^'^Z, NHC(0)R'°, NR^°C(0)R^'', NHS(0)2R^°, NR^°S(0)2R^^ NHC(0)OR^°, NR^°C(0)OR^'', NHC(0)NH2, NHCCONHR^", 18 NHC(0)N(R*°)2, NR^''C(0)NHR^°, NR*°C(0)N(R^°)2, C(0)NH2, C(0)NHR^°, C(0)N(R^°)2, C(0)NHOH, C(0)NHOR^°, C(0)NHS02R^^ CCONR^^SOaR^", SO2NH2, S02NHR^°, S02N(R^'')2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR^", C(N)N(R^'')2, CNOH, CNOCH3. OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I; R^°isR^^R^^R^^o^R^; R^^ is phenyl, which is unfused or fused with benzene, heteroarene or R^'^; R^^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^^ is heteroaryl, which is unfused or fused with benzene, heteroarene or R^^'^; R^^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R*^ is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^^'^; R^^"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^'* is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R^^ 0R^^ SR^^ S(0)R^^ S02R'^ C(0)R^^ CO(0)R^^ OC(0)R^^ OC(0)OR^^ NH2, NHR^^ N(R^^)2, NHC(0)R^^ NR'^C(0)R^^ NHS(0)2R'^ NR"S(0)2R^^ NHC(0)OR^^ NR^^C(0)OR^^ NHC(0)NH2, NHC(0)NHR", NHC(0)N(R")2, NR^^C(0)NHR^^ NR^^C(0)N(R")2, C(0)NH2, C(0)NHR^^ C(0)N(R^^)2, C(0)NHOH, C(0)NHOR^^ C(0)NHS02R'^ C(0)NR'^S02R^^ SO2NH2, SO2NHR", S02N(R")2, C(0)H, C(0)0H, C(N)NH2, C(N)NHR^^ C(N)N(R")2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I; R^^ is alkyl, alkenyl, aDcynyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl; and wherein R is further unsubstituted or further substituted and each foregoing cyclic moiety are independently unsubstituted, further unsubstituted, substituted or further substituted with one or two or three or four or five of independently selected R^'^, R^^, OR^^, SR", S(0)R", SO2R", C(0)R", C0(0)R", 0C(0)R", 0C(0)0R", NH2, NHR", N(R")2, NHC(0)R", NR"C(0)R", NHS(0)2R", NR^^S(0)2R^\ NHC(0)0R^^ NR^^C(0)0R", NHC(0)NH2, NHC(0)NHR", NHC(0)N(R")2, NR^^C(0)NHR^\ NR^''C(0)N(R")2, C(0)NH2, C(0)NHR", C(0)N(R")2, C(0)NH0H, C(0)NH0R", C(0)NHS02R", C(0)NR"S02R", SO2NH2, SO2NHR", S02N(R")2, C(0)H, C(0)0H. C(N)NH2, C(N)NHR", C(N)N(R")2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3,F, CI,BrorI; R^^^ is spirocyclyl; R"isR^^R'^R«'orR^^ 19 R** is phenyl, which is unfused or fused with benzene, heteroarene or R^*'^; R**'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R*' is heteioaryl, which is unfused or fused with benzene, heteroarene or R^'^; R^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'* is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^'^; R^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R*^ 0R*^ SR^^ S(0)R^^ S02R*^ C(0)R^^ CO(0)R^^ OC(0)R*^ OC(0)OR^^ NH2, NHR^^ N(R%', NHC(0)R*\ NR^^C(0)R^^ NHS(0)2R^^ NR^^S(0)2R^^ NHC(0)OR^^ NR^^C(0)OR*^ NHC(0)NH2, NHC(0)NHR*^ NHC(0)N(R^^)2, NR*^C(0)NHR^^ NR^^C(0)N(R^^)2, C(0)NH2, C(0)NHR^\ C(0)N(R*^)2, C(0)NHOH, C(0)NHOR*^ C(0)NHS02R'*^ C(0)NR**^S02R*^ SO2NH2, S02NHR'*^ S02N(R*^)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR^^ C(N)N(R*^)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I; R^^isR^^R",R®'orR^; R^^ is phenyl, which is unfused or fused with benzene, heteroarene or R^^'^; R*^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^ is heteroaryl, which is unfused or fused with benzene, heteroarene or R^^; R^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^^ is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^^'^; R*^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^ is alkyl, alkenyl or alkenyl, each of which is unsubstituted or substituted with one or two or three of independenUy selected R*^ OR^^ SR*'', S(0)R*^ SO2R*'', C(0)R^\ CO(0)R^^ OC(0)R^\ OC(0)OR^^ NH2, NHR^\ N(R^'')2, NHC(0)R^^ NR*^C(0)R*\ NHS(0)2R^^ NR^^S(0)2R^^ NHC(0)OR*^ NR^^C(0)OR*\ NHC(0)NH2, NHC(0)NHR^^ NHC(0)N(R^^)2, NR*'C(0)NHR^^ NR^^C(0)N(R^^)2, C(0)NH2, C(0)NHR*^, C(0)N(R^^)2, C(0)NHOH, C(0)NHOR^\ C(0)NHS02R*^ C(0)NR*^S02R^^ SO2NH2, S02NHR^^ S02N(R*')2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR^'', C(N)N(R^^)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I substituents; R^^ is alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl; 20 wherein the moieties represented by R"^, R^^ R^^ R^, R^^ R^, R*^ and R^^ are unsubstituted or substituted with one or two or three or four of independently selected R^*, OR^, SR^, S(0)R^, S02R^, C(0)R^, CO(0)R^, OC(0)R^, 0C(0)0R^, NH2, NHR^, N(R'*)2, NHC(0)R^, NR^C(0)R^, NHS(0)2R^, NR^S(0)2R^, NHC(0)0R^, NR^C(0)OR^, NHC(0)NH2, NHC(0)NHR^, NHC(0)N(R^)2, NR^C(0)NHR^, NR^C(0)N(R^)2, C(0)NH2, C(0)NHR^, C(0)N(R^)2, C(0)NH0H, C(0)NH0R^, C(0)NHS02R^, C(0)NR^S02R^, SO2NH2, SO2NHR**, S02N(R^)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR^, C(N)N(R^)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I; R^isR«',R™,R^'orR'^ R^' is phenyl, which is unfused or fused with benzene, heteroarene or R^^; R^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'" is heteroaryl, which is unfused or fiised with benzene, heteroarene or R^°^; R^°^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^''^; R^''^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^^ is alkyl, aUcenyl or alkenyl, each of which is unsubstituted or substituted with one or two or three of independenUy selected R^^ OR", SR", S(0)R", S02R'^ C(0)R", C0(0)R", OC(0)R■'^ 0C(0)0R", NH2, NHR", N(R'^)2, NHC(0)R''^ NR"C(0)R^^ NHS(0)2R", NR"S(0)2R", NHC(0)OR^^ NR"C(0)0R", NHC(0)NH2, NHC(0)NHR", NHC(0)N(R^^)2, NR"C(0)NHR''^ NR"C(0)N(R'^)2, C(0)NH2, C(0)NHR^\ C(0)N(R^^)2, C(0)NHOH, C(0)NH0R". C(0)NHS02R", C(0)NR"S02R", SO2NH2, SO2NHR", S02N(R^^)2, C(0)H, C(0)0H, C(N)NH2, C(N)NHR", C(N)N(R")2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I; R'^ is alkyl, alkenyl, alkenyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl; and the moieties represented by R*^, R'°, and R^' are unsubstituted or substituted with one or two or three or four of independently selected NH2, C(0)NH2, C(0)NHOH, SO2NH2, CF3, CF2CF3, C(0)H, C(0)OH, C(N)NH2, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I. Still another embodiment pertains to a compound of Formula I or Formula II, wherein A' is C(A^); and A^ is H. 21 Still another embodiment pertains to a compound of Formula I or Formula II, wherein A' is C(A^) or N; A^ is H; and B' is NHR'. Still another embodiment pertains to a compound of Formula I or Formula II, wherein A' is C(A^) or N; A^ is H; B' is NHR'; and D' is H. Still another embodiment pertains to a compound of Formula I or Formula II, wherein A' is C(A^) or N; A^ is H; B' is NHR^ D' is H; and E' is H. Still another embodiment pertains to a compound of Formula I or Formula II, wherein A' is C(A^) or N; A^ is H; B^ is NHR'; D' is H; E^ is H; and Y' is NO2. Still another embodiment pertains to compounds having Formula I, which are 4-(4-((4'-chloro-1, r-biphenyl-2-yl)mediyl)piperazin-1 -yl)-2-(3-((dimethylamino)methyl)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1-yl)-2-(3-(methylamino)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-((2-methyl-lH-indol-5-yl)oxy)-N-((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-((2-methyl-lH-indol-5-yl)oxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(2-chlorophenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-chlorophenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(4-chlorophenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmediyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-nitrophenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin- l-yl)-2-(3-(hydroxymethyl)phenoxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1-yl)-2-(2-chlorophenoxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1,1'-biphenyl-2-yl)methyl)piperazin-1-yl)-2-(2-chlorophenoxy)-N-((4-((3- (dimethylamino)propyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 22 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1-yl)-2-(3-chlorophenoxy)-N-((4-((3- morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1-yl)-2-(4-chloiophenoxy)-N-((4-((3- morpholin-4-ylpiDpyl)amino)-3 -nitrophenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-chlorophenoxy)-N-((4-((3- (dimethylamino)propyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin- l-yl)-2-(4-chloiophenoxy)-N-((4-((3- (dimethylamino)propyl)amino)-3-mtrophenyl)sulfonyl)benzamide; 4.(4.((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-((3- (dimethylamino)propyl)amino)-3-nitrophenyl)sulfonyl)-2-((l-methyl-lH-indol-4- yl)oxy)benzaniide; 2-(3-(acetylamino)phenoxy)-4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl) -N- ((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 2-(4-aminophenoxy)-4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)tnethyl)piperazin-1 -yl)-N-((3-nitio- 4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 2-(3-aminophenoxy)-4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((3-nitro- 4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-methoxyphenoxy)-N-((3- nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1,1 '-bipheny l-2-yl)methyl)piperaziii-1 -yl)-2-(3 -(dimethylamino)phenoxy)-N- ((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-cyanophenoxy)-N-((3-nitro- 4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-((2-methyl-1,3-benzothiazol-6- yl)oxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-((2-methyl-1,3-benzothiazol-5- yl)oxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4.(4.((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-((3- (dimethylamino)propyl)amino)-3-nitrophenyl)sulfonyl)-2-((2-methyl-l,3-benzothiazol-5- yl)oxy)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(2-(3-(dimethylamino)-3- oxopropyl)phenoxy)-N-((3-nitTO-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 23 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(2-(2-(dimethylamino)-2- oxoethyl)phenoxy)-N-((3-nitro-4-((tetrahydio-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yI)methyl)piperazin-1 -yl)-2-(2-(3- (dimethylamino)propyl)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzaniide; 4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(2-(2- (dimethylamino)ethyl)phenoxy)-N-((3-nitio-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 2-(5-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-nitro-4-((tetrahydro-2H-pyran- 4-yl)methylamino)phenylsulfonylcarbamoyl)phenoxy)-N,N-dimethylbenzamide; 4-(4-((4'-chloro-1, l'-biphenyl-2-yl)methyI)piperazin-1 -yl)-2-(2- ((dimethylanuno)methyl)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-((3- (dimethylamino)propyl)amino)-3-nitrophenyl)sulfonyl)-2-(3-morpholin-4- ylphenoxy)benzamide; 4-(4-((4'-ch]oro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(3 -(2,4-dimethyl-1,3-thiazol-5- yl)phenoxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-mtrophenyl)sulfonyl)benzamide; 2-(2-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1- yl)methyl)piperazin-1 -yl)-N-((4-(( 1 -methylpiperidin-4-yl)amino)-3- nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-2-(3,5- dichlorophenoxy)-N-((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide; 2-(3-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl)methyl)piperazin-1 -yl)-N-((4-(( 1 -methylpiperidin-4-yl)amino)-3 - nitrophenyl)sulfonyI)benzamide; 4-(4-((4'-chloro-4-(2-(dimethylamino)ethoxy)-1, r-biphenyl-2-yl)methyl)piperazin- l-yl)-2- (3-chlorophenoxy)-N-((4-((l-methylpiperidin-4-yl)amino)-3- nitrophenyl)sulfonyl)benzamide; 2-(2-chlorophenoxy)-4-(4-((4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3- yl)methyl)piperazin-1 -yl)-N-((4-(( 1 -methylpiperidin-4-yl)amino)-3- nitrophenyl)sulfonyl)benzamide; 24 4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-(2- (dimethylamino)ethoxy)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 2-(4-amino-3-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl)methyl)piperazin-1 -yl)-N-((4-(( 1 -methylpiperidin-4-yl)amino)-3- nitrophenyl)sulfonyl)benzamide; 2-(2-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl)methyl)piperazin-l-yl)-N-((4-((l-isopiopylpiperidin-4-yl)amino)-3- nitrophenyl)sulfonyl)benzamide; 2-(2-bromophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl)methyl)piperazin-1 -yl)-N-((4-(( 1 -methylpiperidin-4-yl)amino)-3- mtrophenyl)sulfonyl)benzamide; 2-(2-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)cyclohex-l-en-l-yl)methyl)piperazin-l-yl)-N- ((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl)methyl)piperazin-1 -yl)-2-((3- methyl-lH-indazol-4-yl)oxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3- nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl)methyl)piperazin-1 -yl)-2-(2,3- difluorophenoxy)-N-((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide; 2-(3-bromophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl)methyl)piperazin-1 -yl)-N-((4-(( 1 -methylpiperidin-4-yl)amino)-3- nitrophenyl)sulfonyl)benzamide; 2-(2-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1- yl)methyl)piperazin-1 -yl)-N-((4-(( 1 -ethylpiperidin-4-yl)amino)-3- nitrophenyl)sulfonyl)benzamide; 2-(2-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1- yl)methyl)piperazin-l-yl)-N-((3-nitro-4-((l,2,2,6,6-pentamethylpiperidin-4- yl)amino)phenyI)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-2-(2,3- difluorophenoxy)-N-((3-nitro-4-((l-tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino)phenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-((7- fluoro-lH-indol-5-yl)oxy)-N-((4-((l-methylpiperidin-4-yl)amino)-3- nitrophenyl)sulfonyl)benzamide; 25 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl)methyl)piperazin-1 -yl)-2-(2,3- difluorophenoxy)-N-((4-((3-moipholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 2-(4-amino-3-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl)methyl)piperazin-l-yl)-N-((4-((3-morpholin-4-ylpropyl)amino)-3- mtrophenyl)sulfonyl)benzamide; 2-(3-chlorophenoxy)-4-(4-((4'-chloro-4-(2-pyiTOlidin-1 -ylethyl)-1,1 '-biphenyl-2- yl)methyl)piperazin-1 -yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl)methyl)piperazin-1 -yl)-2-(2,3- dicMorophenoxy)-N-((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyI)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-((3- methyl-lH-indazol-4-yl)oxy)-N-((4-((l-methylpiperidin-4-yl)ammo)-3- nitrophenyl)sulfonyl)benzamide; 2-(2-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)cyclohept-l-en-l-yl)methyl)piperazin-l-yl)- N-((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-N-((4-(( 1- methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)-2-(3- (trifluoromethyl)phenoxy)benzamide; 4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-((3- (dimethylamino)propyl)amino)-3-nitrophenyl)sulfonyl)-2-((2-oxo-l,2,3,4-tetrahydroquinolin- 5-yl)oxy)benzamide; 2-(2-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl)methyl)piperazin-1 -yl)-N-((4-(( 1 -methylpiperidin-4-yl)amino)-3- ((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-2-(2,5- dichlorophenoxy)-N-((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide; 2-(2-chloro-4-fluorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl)methyl)piperazin-1 -yl)-N-((4-(( 1 -methylpiperidin-4-yl)amino)-3- nitrophenyl)sulfonyl)benzamide; 2-(2-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclopent-1 -en-1 - yl)methyl)piperazin-1-yl)-N-((4-(( 1-methylpiperidin-4-yl)amino)-3- nitrophenyl)sulfonyl)benzamide; 26 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-2-((3- methyl-lH-indol-4-yl)oxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3- nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl)methyl)piperazin-1 -yl)-2-(2- chloro-3-(trifluoromethyl)phenoxy)-N-((4-((l-methylpiperidin-4-yl)amino)-3- nitrophenyl)suIfonyl)benzamide; 2-(2-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl)methyl)piperazin-1 -yl)-N-((4-(( 1 -cyclopropylpiperidin-4-yl)amino)-3- mtrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl)methyl)piperazin-1 -yl)-2-((3- methyl-1 H-indol-4-yI)oxy)-N-((4-(( 1 -methylpiperidin-4-yl)aniino)-3- nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-2-(2,5- dichlorophenoxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3- nitrophenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(( 1 -methyl-1 H-indol-4-yl)oxy)- N-((4-((3-morpholm-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(3-morpholin-4-ylphenoxy)-N- ((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-((3- (dimethylamino)propyl)amino)-3-mtrophenyl)sulfonyl)-2-((3-(3-morpholin-4-yl-3- oxopropyl)-lH-indol-5-yl)oxy)benzamide; 2-(3-(benzyloxy)phenoxy)-4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin- l-yl)-N-((3- nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(4-cyanophenoxy)-N-((3-nitro- 4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-((3-(3-morpholin-4-yl-3- oxopropyl)-1 H-indol-5-yl)oxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-((3-(3-morpholin-4-ylpropyl)- lH-indol-5-yl)oxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 27 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(4- ((dimethylamino)methyl)phenoxy)-N-((3-nitro-4-((tetrahyclro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(4-( IH-imidazol-1 -yl)phenoxy)- N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-ch]oro-1,1'-biphenyl-2-yl)methyl)piperazin-1-yl)-2-(3-nitrophenoxy)-N-((4- ((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; tert-butyl 4-(5-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-((((3-nitio-4- ((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)amino)carbonyl)phenoxy)benzyl(etiiyl)carbamate; tert-butyl 3-(5-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1-yl)-2-((((3-nitro-4- ((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)amino)caibonyl)phenoxy)benzyl(ethyl)carbamate; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(4- ((ethylamino)methyl)phenoxy)-N-((3-nitro-4-((tetrahydio-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1,1'-bipheny l-2-yl)methyl)piperazin-1 -y l)-2-(3 - ((ethylamino)methyl)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; I 2-(4-(acetylamino)phenoxy)-4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-N- ((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)araino)phenyl)sulfonyl)benzamide; tert-butyl 4-(5-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-2-((((3-nitio-4- ((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)amino)carbonyl)phenoxy)phenylcarbamate; 2-(l, l'-biphenyl-2-yloxy)-4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((3- nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; tert-butyl 3-(5-(4-((4'-chloro-l,l'-biphenyl-2-yl)niethyl)piperazin-l-yl)-2-((((3-nitro-4- ((tetrahydro-2H-pyran-4- ylmethyl)aniino)phenyl)sulfonyl)amino)carbonyl)phenoxy)phenylcarbamate; I 2-(l,r-biphenyl-3-yloxy)-4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((3- nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(4-(2- (dimethylamino)ethyl)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)aniino)phenyl)sulfonyl)benzamide; 28 2-(4-(benzyloxy)phenoxy)-4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((3- nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzami(le; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1-yl)-2-(3-moipholin-4-ylphenoxy)-N- ((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-((2-methyl-1,3-benzothiazol-5- yl)oxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; tert-butyl4-(3-(5-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-2-((((3-nitiio-4- ((tetrahydro-2H-pyran-4- yImethyl)amino)phenyl)sulfonyl)amino)carbonyl)phenoxy)phenyl)piperazine-l-carboxylate; 2-(3-(benzyloxy)phenoxy)-4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4- ((3-(dimethylamino)propyl)amino)-3-nitrophenyl)su]fonyl)benzamide; 2-(3-(benzyloxy)phenoxy)-4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4- ((3-morpholin-4-ylpropyl)amino)-3-nitiophenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(4-(2-morpholin-4- ylethoxy)phenoxy)-N-((3-nitro-4-((tetTahydro-2H-pyran-4- ylmethyl)aniino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((3-nitro-4-((tetrahydro-2H- pyran-4-ylmethyl)ainino)phenyl)sulfonyl)-2-((2-oxo-1,2,3,4-tetrahydroquinolin-5- ylX)xy)benzamide; 2-(4-(benzyloxy)phenoxy)-4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4- ((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide; tert-butyl 4-(4-(5-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-((((4-((3- morpholin-4-ylpropyl)amino)-3 - nitrophenyl)sulfonyl)amino)carbonyl)phenoxy)phenyl)piperazine-l-carboxylate; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-((3-morpholin-4- ylpropyI)amino)-3-nitrophenyl)sulfonyl)-2-(3-pyridin-4-ylphenoxy)benzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((4-((3-morpholin-4- ylpropyl)amino)-3-nitrophenyl)sulfonyl)-2-(4-pyridin-4-ylphenoxy)benzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin- l-yl)-N-((4-((3-morpholin-4- y]propy])amino)-3-nitiophenyl)sulfonyl)-2-(4-pyridin-3-ylphenoxy)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(4-(2-(dimethylamino)-2- oxoethoxy)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 29 4-(4-((4'-ch]oro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(( 1 -methyl-1 H-benzimidazol-5- yl)oxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-(methylcaibamoyl)phenoxy)-N-(4- (3-moTpholinopropylamino)-3-nitrophenylsulfonyl)benzamide; 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-N-(4-(3-(dimethylamino)propylamino)- 3-nitrophenylsulfonyl)-2-(3-(methylcarbamoyl)phenoxy)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-(2-(dimethylanuno)-2- oxoethoxy)phenoxy)-N-((3-mtro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-((3-(3-(dimethylamino)propyl)- lH-indol-5-yl)oxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyI)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-((3- (dimethylamino)propyl)amino)-3-nitrophenyl)sulfonyl)-2-(3- (hydroxymethyl)phenoxy)benzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-((4-methoxybenzyl)oxy)-N-((3- nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; N-(4-((4-aminotetrahydro-2H-pyran-4-yl)methylamino)-3-nitrophenylsulfonyl)-2-(3- chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l- yl)benzamide; 4-(4-(l-(4'-chlorobiphenyl-2-yl)ethyl)piperazin-l-yl)-2-(2-chlorophenoxy)-N-(3-nitro-4- ((tetrahydro-2H-pyran-4-yl)methylamino)phenylsulfonyl)benzamide; N- {[4- {4- [(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazm-1 -yl} -2-(3,5- dichlorophenoxy)phenyl]sulfonyl)-4-[(l-methylpiperidin-4-yl)amino]-3-nitrobenzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-(3- fluorophenoxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3-mtrophenyl}sulfonyl)benzamide; 4-(4- {[2-(4-ch]orophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl} piperazin-1 -yl)-2-(3- fluorophenoxy)-N-({3-nitro-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4- yl)aniino]phenyl} sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-2-(3- fluorophenoxy)-N-({4-[(3-morpholin-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)benzamide; 2-(2-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l -en-1 - yl]methyl} piperazin- l-yl)-N-({ 3-nitro-4- [(1 -tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl} sulfonyl)benzamide; 30 2-(2-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl} piperazin-1 -yl)-N-({ 4-[(3-morpholin-4-ylpropyl)amino]-3- nitrophenyl} sulfonyl)benzamide; 2-(2-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({4-[(l-cyclopentylpiperidin-4-yl)amino]-3- nitxophenyl }sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(4- fluorophenoxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitrophenyl)sulfonyl)benzamide; 2-(3-chlorophenoxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-N-({4-[(l-cyclopropylpiperidin-4-yl)amino]-3- nitrophenyl }sulfonyl)benzamide; 2-(2-chloro-4-fluorophenoxy)-4-(4- {[2-(4-chlorophenyI)-4,4-dimethylcyclohex- 1-en-1- yl]methyl}piperazin-l-yl)-N-({4-[(3-moTpholin-4-ylpropyl)amino]-3- nitrophenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl} piperazin- l-yl)-N-({ 4- [(1 -cyclopropylpiperidin-4-yl)amino]-3-nitrophenyl} sulfonyl)-2-(2,3- difluorophenoxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-2-(2- fluorophenoxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N-( {4- [(l-cyclopropylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(2- fluoiophenoxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yllinethyl}piperazin- l-yl)-2-(2- fluorophenoxy)-N-( {3 -nitro-4- [(1 -tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl)sulfonyl)benzaniide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-(2- fluorophenoxy)-N-({4-[(3-morpholin-4-yIpropyl)amino]-3-nitrophenyl}sulfonyl)benzamide; 4-(4-([2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(2- fluorophenoxy)-N-({ 4-[(2-morpholin-4-ylethyl)amino] -3-nitrophenyl} sulfonyl)benzamide; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl }piperazin-1 -yl)-N-({ 3-nitro-4- [(1 -tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl}sulfonyl)benzamide; 31 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({4-[(3-morpholin-4-ylpropyl)amino]-3- nitrophenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl ] piperazin-1 -yl)-2-(3- fluorophenoxy)-N-({4-[(2-morpholin-4-ylethyl)amino]-3-nitrophenyl}sulfonyl)benzamide; 2-(3-chlorophenoxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-N-({4-[(l-cyclopentylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-1- yl]methyl ] piperazin-1 -yl)-N-( {4- [(1 -methy lpiperidin-4-yl)amino]-3 - [(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-N-({4- [(l-cyclopropylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(3- fluorophenoxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-N-({4- [(l-cyclopentylpiperidin-4-yl)amino]-3-nitrophenyl)sulfonyl)-2-(2,3- difluorophenoxy)benzamide; 4-(4-{[2-(4-clilorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-N-({4- [(l-cyclopentylpiperidin-4-yl)amino]-3-nitrophenyl)sulfonyl)-2-(2- fluorophenoxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-(2,3 - difluorophenoxy)-N-({4-[(2-morpholin-4-yIethyl)aminol-3-nitxophenyl}sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimetliyIcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-(2,3 - difluorophenoxy)-N-[(3-nitro-4- {[ l-(thien-3-ylmethyl)piperidin-4- yl ]amino) phenyl)sulfonyl]benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-N-[(4- {[3-(dimethylamino)propyl]amino}-3-nitrophenyl)sulfonyl]-2-(2-fluorophenoxy)benzamide; 4-(4- {[2-(4-ch]orophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl) piperazin-1 -yl)-N- [(4- {[3-(dimethylainino)propyl]amino) -3-nitrophenyl)sulfonyl]-2-(3-fluorophenoxy)benzaniide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N- [(4- {[3-(dimethylaniino)propyl]amino}-3-nitrophenyl)sulfonyl]-2-(4-fluorophenoxy)benzaniide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl) piperazin-1 -yl)-2-(2,3- difluorophenoxy)-N-[(4-{[ 1-(2-fluoroethyl)piperidin-4-yl]amino}-3- nitrophenyl)sulfonyl]benzaniide; 32 2-(3-chlorophenoxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-N-({4-[(2-morpholin-4-ylethyl)amino]-3- nitrophenyl} sulfonyl)benzamide; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl} piperazin-1 -yl)-N-[(4- {[3-(dimethylamino)propyl]amino} -3- nitrophenyl)sulfonyl]benzamide; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-[(4-{[3-(4-methylpiperazin-l-yl)propyl]amino}-3- nitrophenyl)sulfonyl]benzamide; 2-(3-chlorophenoxy)-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3- yl]methyl}piperazin-l-yl)-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 4-(4- {[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3 -yl] methyl} piperazin-1 -yl)- 2-(2,3-difluorophenoxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; N-({4-[(l-allylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4- dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -y l)-2-(2,3 -difluorophenoxy)benzamide; 2-(3-chloro-2-fluorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]niethyl}piperazin-l-yl)-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 2-(3-chloro-2-fluorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1- yl]methyl}piperazin-l-yl)-N-({4-[(3-morpholin-4-ylpropyl)amino]-3- nitrophenyl }sulfonyl)benzamide; 2-(3-chloro-2-fluorophenoxy)-4-(4-{[2-(4-chlorophenyl)-4,4-diniethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-N-({3-nitro-4-[(3-pyrrolidin-l- ylpropyl)amino]phenyl} sulfonyl)benzamide; 2-(3-chloro-2-fluorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yI)-N-({4-[(2-morpholin-4-ylethyl)amino]-3- nitrophenyl} su]fonyl)benzamide; 2-(2-chloro-6-fluorophenoxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yljmethyl} piperazin-1 -yl)-N-( {4- [(1 -methy lpiperidin-4-yl)amino] -3 - nitrophenyl} sulfonyl)benzaniide; 33 2-(2-chloro-6-fluorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1- yljmethyl} piperazin-1 -yl)-N-( {3-nitro-4- [(1 -tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-2- [(6- fluoro-lH-indol-5-yl)oxy]-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl }sulfonyl)benzamide; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chloroplienyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-[(4-{[(l-methylpiperidin-4-yl)methyl]amino)-3- nitrophenyl)sulfonyl]benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-2-(2,3- difluorophenoxy)-N-[(4- {[(l-methylpiperidin-4-yl)methyl]amino} -3- nitiophenyl)sulfonyl]benzaniide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-[(4- fluoro- lH-indol-5-yl)oxy]-N-({4-[(l -methylpiperidin-4-yl)amino]-3- ' nitrophenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl ]methyl) piperazin-1 -yl)-2- [3- (methoxymethoxy)-2-methylphenoxy]-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(3- hydroxy-2-methylphenoxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 2-(3-bromophenoxy)-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3- yl]methyl}piperazin-l-yl)-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yI)- 2-(3-iodophenoxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-[(4-{[l-(2-hydroxyethyl)piperidin-4-yl]amino}-3- nitrophenyl)sulfonyl]benzamide; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-[(3-nitro-4-{[l-(2-phenylethyl)piperidin-4- yl]amino}phenyl)sulfonyl]benzamide; 34 4 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(3,4- dichlorophenoxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitrophenyl]sulfonyl)benzamide; 2-(2-chloro-3,5-difluoiophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl} piperazin-1 -yl)-N-( {4- [(1 -methylpiperidin-4-yl)amino] -3- nitrophenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chloropheny l)-4,4-dimethylcyclohex-1 -en-1 -yl ]methyl} piperazin-1 -y 1 )-2-(3- methoxyphenoxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl) piperazin-1-yl)-2-[3- (hydioxymethyl)phenoxy]-N-({4-[(l-methylpiperidin-4-yl)aniino]-3- nitrophenyl} sulfonyl)benzamide; 2-(2-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl} piperazin-1 -yl)-N-({ 4-[( 1,4-dimethylpiperidin-4-yl)amino]-3- nitiophenyl} sulfonyl)benzamide; 2-(3 -chlorophenoxy )-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl) piperazin-1 -yl)-N-( {4- [(1,4-dimethylpiperidin-4-yl)amino] -3 - nitiophenyl} sulfonyl)benzamide; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-{[4-({l-[2-(2-methoxyethoxy)ethyl]piperidin-4-yl}amino)-3- nitrophenyljsulfonyl }benzamide; 2-(2-chloro-3-hydroxyphenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yljmethyl} piperazin-1 -yl)-N-( {4-[( l-methylpiperidin-4-yl)amino]-3- nitiophenyl} sulfonyl)benzamide; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl} piperazin-1 -yl)-N- [(3 -nitro-4- {[ 1 -(3-phenylpropyl)piperidin-4- yl]amino}phenyl)sulfonyl]benzamide; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-1 - yl]methyl} piperazin-1 -yI)-N- [(4- {[ 1 -(2-methoxyethyl)piperidin-4-yl] amino} -3 - nitrophenyl)sulfonyl]benzamide; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl} piperazin-1 -yl)-N-( {4- [(1 -ethylpiperidin-4-yl)amino]-3 - nitrophenyl) sulfonyl)benzamide; 35 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({4-[(l-isopropylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl} piperazin-1 -yl)-2-(3- hydroxyphenoxy)-N-( {4- [(1 -methylpiperidin-4-yl)amino] -3-nitrophenyl} sulfonyl)benzamide; 2-(2-chloro-3-fluorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl}sulfonyl)benzamide; 2-(2-chloro-3-fluorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1- yl]methyl}piperazin-l-yl)-N-({3-nitro-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl}sulfonyl)benzamide; 2-(2-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yljmethyl ] piperazin-1 -yl)-N- [(4- {[3-(dimethylamino)propyl]amino} -3- nitrophenyl)sulfonyl]benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(2- methoxyphenoxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl }sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-2-(2- methylphenoxy)-N-( {4- [(1 -methylpiperidin-4-yl)amino]-3-nitrophenyl} sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(3- methylphenoxy)-N-( {4-[( 1 -methylpiperidin-4-yl)amino]-3-nitrophenyl} sulfonyl)benzamide; 2-(2-chlorophenoxy)-4-(4- {[6-(4-chlorophenyl)-1,3-benzodioxol-5-yl]methyl }piperazin-1- yl)-N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitxophenyl}sulfonyl)benzamide; 2-(2-chlorophenoxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-N-({4-[(4-methylpiperazin-l-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 2-(3-chlorophenoxy)-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3- yl]methyl}piperazin-l-yl)-N-({4-[(4-methylpiperazin-l-yl)amino]-3- nitrophenyl)sulfonyl)benzamide; 4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl)piperazin-l-yl)- 2T(2,3-difluorophenoxy)-N-((4-[(4-methylpiperazin-l-yl)aniino]-3- nitrophenyl }sulfonyl)benzamide; 36 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-[(4-{[l-(cyclopropylmethyl)piperidin-4-yl]aniino)-3- nitrophenyl)sulfonyl]benzamide; 2-(2-chlorDphenoxy)-4-(4- {[2-(4-chloropheny l)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-[(4-{[l-(cyclopropylmethyl)piperidin-4-yl]amino}-3- nitrophenyl)sulfonyl]benzamide; 2-(3 -chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl} piperazin- l-yl)-N- {[4-( {1 -[2-(dimethylamino)-2-oxoethyl]piperidin-4-yl} amino)- 3-nitrophenyl]sulfonyl} benzamide; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-[(4-{[l-(2-morpholin-4-ylethyl)piperidin-4-yl]amino}-3- nitrophenyl)sulfonyl]benzamide; N-[(4-{[(4-aminotetrahydro-2H-pyran-4-yl)methyl]amino}-3-nitiophenyl)sulfonyl]-2-(2- chlorophenoxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)benzamide; 2-(2-chlorophenoxy)-4-(4- {[2-(4-chlorophenyI)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl} piperazin-1 -yl)-N- [(4- {[(4-hydroxy-1 -methylpiperidin-4-yl)methyl] amino} -3 - nitrophenyl)sulfonyl]benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-2-[(6- fluoro-lH-indol-5-yl)oxy]-N-({3-nitro-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl} sulfonyl)benzamide; 2-(3 -chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-[(4-{[(3S)-l-methylpyrrolidin-3-yl]anuno}-3- nitrophenyl)sulfonyl]benzamide; 2-(3 -chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-[(4-{[(3R)-l-methylpyrrolidin-3-yl]amino)-3- nitrophenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N-( {4- [(l-methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-[3-(lH-pyrrol-2- yl)phenoxy]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl} piperazin- l-yl)-2-(3- fluorophenoxy)-N- [(4- {[(4-hydroxy-1 -niethylpiperidin-4-yl)methyl]aniino} -3- nitrophenyl)sulfonyl]benzamide; 37 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({4-[(4-methylpiperazin-l-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yljmethyl} piperazin-1 -yl)-2-[(6,7- difluoro-lH-indol-5-yl)oxy]-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl }sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-[(6,7- difluoio-lH-indol-5-yl)oxy]-N-({3-nitro-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl }sulfonyl)benzamide; tert-butyl 4-(5 -(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 - yl)-2- {[({4-[( 1 -methylpiperidin-4-yl)amino]-3- nitrophenyl) sulfonyl)amino]carbonyl} phenoxy)-1 H-indole-1 -carboxylate; 2-(3 -chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-[(4-{[4-(dimethylamino)cyclohexyl]amino}-3- nitrophenyl)sulfonyl]benzamide; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-[(4-{[4-(diethylamino)cyclohexyl]amino}-3- nitiophenyl)sulfonyl]benzaniide; Trans-2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 - yl]methyl}piperazin-l-yl)-N-({4-[(4-morpholin-4-ylcyclohexyl)amino]-3- nitrophenyl} sulfonyl)benzamide; 4- {4- [ 1 -(4'-chloro-1,1 '-biphenyl-2-yl)ethyl]piperazin-1 -yl ] -2-(2-chlorophenoxy)-N-( {4- [(1 - methylpiperidin-4-yl)amino]-3-nitrophenyl} sulfonyl)benzamide; 2-(2-chloro-4-hydroxyphenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl) sulfonyl)benzamide; 2-(2-chloro-4-hydroxyphenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({4-[(4-methylpiperazin-l-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2- [(6- fluoro-lH-indol-4-yl)oxy]-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 38 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl} piperazin-1 -yl)-2-[(6- fluoro-lH-indol-4-yl)oxy]-N-({3-nitro-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl} sulfonyl)benzanude; 2-(2-chloro-4-hydroxyphenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yljmethyl} piperazin-1 -yl)-N-( {4- [(4-methy Ipiperazin-1 -yl)amino]-3 - [(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide; 2-( {1,3 -bis[(4-methy Ipiperazin-1 -yl)methyl] -1 H-indol-4-yl} oxy)-4-(4- {[2-(4-chlorophenyl)- 4,4-dimethylcyclohex-1 -en- l-yl]niethyl }piperazin-1 -yl)-N- [(4- {[3- (diniethylamino)propyl] amino} -3-nitrophenyl)sulfonyl]benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-[(4- {[3-(dimethylamino)propyl]amino}-3-nitrophenyl)sulfonyl]-2-({3-[(4-methylpiperazin-l- yl)methyl]- lH-indol-4-yl ]oxy)benzamide; 2-(5-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin- l-yl)-2-(4-( 1 - methylpiperidin-4-ylamino)-3-nitiophenylsulfonylcarbamoyl)phenoxy)-N,N- dimethylbenzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl) piperazin-1 -yl)-N-( {3- nitro-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]phenyl}sulfonyl)-2-{[2- (trifluoromethyl)-lH-indol-4-yl]oxy}benzamide; 2-(2-chloro-4-hydroxyphenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl) piperazin-1 -yl)-N-( {3-nitro-4- [(1 -tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl }sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-N-( {4- [(l-methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-{[6-(trifluoromethyl)-lH-indol-5- yl ]oxy} benzamide; 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1-yljmethyl Ipiperazin- l-yl)-N-({ 3- nitro-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]phenyl}sulfonyl)-2-{[6- (trifluoromethyl)-1 H-indol-5-yl]oxy} benzamide; 2-[(2-amino-1,3-thiazol-4-yl)methoxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 - en-1 -yl] methyl} piperazin-1 -yl)-N-( {3 -nitro-4- [(1 -tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yljmethyl) piperazin-1 -yl)-2- [(6,7- difluoro-lH-indol-5-yl)oxy]-N-({4-[(4-methylpiperazin-l-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 39 4-(4-{[2-(4-ch]orophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-[(6- fluoro-1 H-indol-5 -yl)oxy ] -N-( {4- [(4-methylpiperazin-1 -yl)amino] -3- nitrophenyl} sulfonyl)benzamide; tert-butyl 4-[(5-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l -en- l-yl]methyl }piperazin-1- yl)-2- {[({4-[( 1 -methylpiperidin-4-yl)amino]-3- nitrophenyl}sulfonyl)amino]carbonyl}phenoxy)methyl]-l,3-thiazol-2-ylcarbamate; 2-[(2-amino-l,3-thiazol-4-yl)methoxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-1 -yl]methyl} piperazin- l-yl)-N-( {4-[(l -methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzanude; 2-[3-(acetylamino)phenoxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl)piperazin-l-yl)-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 2-[3-(acetylamino)phenoxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl }piperazin- l-yl)-N-({ 3-nitro-4-[(l -tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl} sulfonyl)benzamide; 2- [(2-chlorophenyl)amino]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl} piperazin-1 -yl)-N-( {3 -nitro-4- [(1 -tetrahydro-2H-pyran-4-ylpiperidin-4- yl)aniino]phenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]inethyl} piperazin-1 -yl)-2- [(6- methoxy-lH-indol-5-yl)oxy]-N-({3-nitro-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl} sulfonyl)benzaniide; 2-[(2-amino-l,3-benzothiazol-6-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-1 -yl]methyl} piperazin- 1-y l)-N-( {4- [(1 -methy lpiperidin-4-yl)amino]-3- nitrophenyl}sulfonyl)benzamide; 2- [(2-chlorophenyl)amino] -4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; tert-butyl 5- [5-(4- ([2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl} piperazin-1- yl)-2-({ [(4-{ [3-(dimethylamino)propyl]amino }-3- nitrophenyl)sulfonyl] amino} carbonyl)phenoxy ] -1 H-indole-1 -carboxylate; 2-[(2-aniino-1,3-benzothiazol-6-yl)oxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 - en-1 -yl]methyl }piperazin-1 -yI)-N-( {3-nitro-4-[(l -tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl }sulfonyl)benzamide; 40 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -y 1 Jmethyl) piperazin-1 -yl)-2- [(6-fluoro- lH-indol-5-yl)oxy]-N-[(3-nitro-4- {[3-(3-oxopiperazin-1-yl)propyl]amino)phenyl)sulfonyl]benzamide; Trans-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl} piperazin-1 -yl)-2-[(6-fluoro-lH-indol-5-yl)oxy]-N-({4-[(4-morpholin-4-ylcyclohexyl)aniino]-3-nitrophenyl} sulfonyl)benzamide; Trans-4-(4- {[2-(4-chlorophenyl)-4,4-dimethy Icyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-[(6,7-difluoro-lH-indol-5-yl)oxy]-N-({4-[(4-morpholin-4-ylcyclohexyl)amino]-3-nitrophenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl} piperazin-1 -yl)-N-[(4-{[ 1 -(cyclopropylmethyl)piperidin-4-yl]amino} -3-nitrophenyl)sulfonyl]-2-[(6-fluoro-1H-indol-5-yl)oxy]benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-[(4-{[l-(cyclopropylmethyl)piperidin-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-[(6,7-difluoro-lH-indol-5-yl)oxy]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl ] piperazin-1 -yl)-2- [(6-fluoro- lH-indol-5-yl)oxy]-N-({ 3-nit^o-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]pheny 1 } sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-[(6,7-difluoro-lH-indol-5-yl)oxy]-N-[(3-nitro-4-{[3-(3-oxopiperazin-l-yl)propyl]amino}phenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethy Icyclohex-1 -en-1 -yl]methyl ] piperazin-1 -yl)-2- [(6-fluoro-lH-indol-5-yl)oxy]-N-({4-[(2-hydroxy-l-tetrahydro-2H-pyran-4-ylethyl)amino]-3-nitrophenyl} sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-2-[(6-fluoro-lH-indol-5-yl)oxy]-N-{[4-({[4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl]methyl} amino)-3-nitrophenyl]sulfonyl jbenzamide; 2-[(6-chloro-lH-indol-5-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl} piperazin-1 -yl)-N-( {3-nitro-4- [(1 -tetrahy dro-2H-pyran-4-ylpiperidin-4-yl)amino]phenyl}sulfonyl)benzanude; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethy Icyclohex-1 -en-1 -yl]methyl ] piperazin-1 -yl)-2- [(6,7-difluoro-1 H-indol-5-yl)oxy]-N-( {3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]pheny 1} sulfonyl)benzamide; 41 2- [(6-chloro-1 H-indol-5 -yl)oxy ] -4-(4- {[2-(4-chlorophenyl)-4,4-dimethy Icyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({4-[(4-methylpiperazin-l-yl)amino]-3- nitxophenyl} sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-2-[(6- fluoro-lH-indol-5-yl)oxy]-N-[(3-nitro-4-{[l-(l,3-thiazol-4-ylmethyl)piperidin-4- yl]amino}phenyl)sulfonyl]benzamide; 2-(3-chlorophenoxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl]piperazin-l-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)benzamide; 2-(4-amino-3-chlorophenoxy)-4-(4- {[2-(4-chloiophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]pheny 1} sulfonyl)benzamide; N-[(4- {[(4-aminotetrahydro-2H-pyran-4-yl)methyl]amino} -3-nitrophenyl)sulfonyl]-4-(4- {[2- (4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-[(6-fluoro-lH- indol-5-yl)oxy]benzaniide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethy Icyclohex-1 -en-1 -yl ]methyl} piperazin-1 -yl)-2- [(6- fluoro-lH-indol-5-yl)oxy]-N-[(4-{[(3S,4R)-3-hydroxy-l-(l,3-thiazol-4-ylmethyl)piperidin-4- yl]aniino)-3-nitrophenyl)sulfonyl]benzamide; 2-(2-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl} piperazin-1 -yl)-N- {[4-( {[4-(hydroxymethyl)tetrahydro-2H-pyran-4- yljmethyl} anuno)-3-nitrophenyl]sulfonyl }benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethy Icyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-2- [(6- fluoro-lH-indol-5-yl)oxy]-N-([3-nitro-4-(tetrahydro-2H-pyran-4- ylamino)phenyl]sulfonyl }benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethy Icyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-2- [(6- fluoro- lH-indol-5-yl)oxy]-N- {[4-(morpholin-4-ylamino)-3-nitrophenyl]sulfonyl }benzamide; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl} piperazin- l-yl)-N- {[4-(morpholin-4-ylamino)-3-nitrophenyl]sulfonyl} benzamide; 2-(2-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-[(3-nitro-4-{[3-(3-oxopiperazin-l- yl)propyl]aniino}phenyl)sulfonyl]benzamide; 2-(6-aminopyridin-3-yl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({3-nitro-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl}sulfonyl)benzamide; 42 4-(4- {1 -[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]ethyl }piperazin-1 -yl)-2-[(6- fluoro-lH-indol-5-yl)oxy]-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]pheny 1} sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-[(6- fluoro- lH-indol-4-yl)oxy]-N-[(3-nitro-4- {[3-(3-oxopiperazin-1 - yl)propyl]amino}phenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl} piperazin-1 -yl)-2-[(6- fluoro- lH-indol-5-yl)oxy]-N-[(3-nitro-4- {[(3S)-tetrahydio-2H-pyran-3- ylmethyl]amino}phenyl)sulfonyl]benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-[(6- fluoro- lH-indol-5-yl)oxy]-N-[(3-nitro4- {[(3R)-tetrahydro-2H-pyran-3- ylmethyl]amino}phenyl)sulfonyl]benzamide; tert-butyl5-(5-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l- yl)-2- {[({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)araino]phenyl]sulfonyl)amino]carbonyl}phenoxy)-3,4-dihydroisoquinoline-2(lH)- carboxylate; 2-[(6-anunopyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl} piperazin-1 -yl)-N-( {3-nitro-4- [(1 -tetrahydio-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl} siilfonyl)benzamide; 4-(4- {[2-(4-ch]orophenyl)-5,5-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2- [(6- fluoro-lH-indol-5-yl)oxy]-N-({3-nitrc)-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2- [(6- fluoro-1 H-indol-5 -yl)oxy ]-N-( {4- [(2-methoxyethyl)amino]-3 - nitrophenyl} sulfonyl)benzamide; 4-(4- {[2-(4-cMorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2- [(6- fluoro-lH-indol-5-yl)oxy]-N-{[3-nitro-4-(tetTahydro-2H-pyran-4- ylmethoxy)phenyl]sulfonyl)benzamide; 2-[(3-chloro- IH-indol-5-yl)oxy]-4-(4- {[2-(4-chloiophenyl)-4,4-dimethylcyclohex-l-en-1- yl]methyl} piperazin-1 -yl)-N-( {3 -mtro-4- [(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)benzamide; 2-[(3-chloro-lH-indol-4-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl Imethyl} piperazin-1 -yl)-N-( {3-nitro-4- [(tetrahydro-2H-pyran-4- ylmethyl)amino]pheny 1} sulfonyl)benzamide; 43 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-({3- nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-[(2-oxo-2,3-dihydro- lH-indol-5 -yl)oxy]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl ] piperazin-1 -yl)-N-({ 3- nitK)-4-[(tetTahydro-2H-pyran-4-ylniethyl)amino]phenyl}sulfonyl)-2-[(2-oxo-2,3-dihydro- lH-indol-4-yl)oxy]benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-[(6- fluoro-lH-indol-4-yl)oxy]-N-({4-[(2-methoxyethyl)amino]-3- nitrophenyl} sulfonyl)benzamide; tert-butyl 5-(5 -(4- {[2-(4-chlorophenyl)-4,4-dimethy Icyclohex-1 -en-1 -yl]methyl} piperazin-1 - yl)-2- {[({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)amino]carbonyl}phenoxy)pyridin-2-ylcarbamate; tert-butyl 4-(5 -(4- {[2-(4-chlorophenyl)-4,4-dimethy Icyclohex-1 -en-1 -yl]methyl} piperazin-1 - yl)-2- {[({3-nitro-4- [(1 -tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl}sulfonyl)amino]carbonyl}phenoxy)pyridin-2-ylcatbamate; 2-[(6-aminopyridin-3-yl)oxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl} piperazin-1-yl)-N-( {3-nitro-4-[(tetrahydro-2H-pyran-4- ylraethyl)amino]phenyl} sulfonyl)benzamide; 2-[(2-aminopyridin-4-yl)oxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl} piperazin-1 -yl)-N-({ 3-nitro-4- [(1 -tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl} sulfonyl)benzamide; 2-[(5-bromopyridin-3-yl)oxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1- yl]methyl}piperazin-l-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]pheny 1} sulfonyl)benzamide; 2-[(6-chloro- lH-indol-5-yl)oxy]-4-(4- {[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H- pyran-3-yl]methyl}piperazin-l-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)ainino]pheny 1} sulfonyl)benzaniide; 2-[(6-chloro-lH-indol-5-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl} piperazin-1 -yl)-N-({ 3-nitro-4- [(tetrahydro-2H-pyran-4- ylmethyl)amino]pheny 1} sulfonyl)benzamide; 4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- 2-[(6-fluoro-lH-indol-5-yl)oxy]-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)benzamide; 44 lert-butyl 5-(5 -(4- {[2-(4-chlorophenyl)-4,4-dimethyIcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-2-{[({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)amino]carbonyl}phenoxy)pyridin-3-ylcarbamate; 2-[(5-aminopyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl} piperazin-1 -yl)-N-( {3 -nitro-4- [(tetrahydro-2H-pyran-4-ylniethyl)amino]phenyl}sulfonyl)benzamide; teit-butyl 4-(5-(4- {[2-(4-chlorophenyl)-4,4-dimethylcycloiiex-1 -en-1-yljmethyl} piperazin-1 -yl)-2- {[({3-nitro-4-[(tetrahydK)-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)amino]carbonyl }phenoxy)pyridin-2-ylcaibamate; 2-[(3-chloro-lH-indol-5-yl)oxy]-4-(4-{[2-(4-chloiDphenyl)-4,4-dimethylcyclohex-l-en-l-yljmethyl} piperazin-1 -yl)-N-({ 3-nitro-4- [(1 -tet^ahydro-2H-py^an-4-ylpiperidin-4-yl)amino Jphenyl } sulfonyl)benzamide; 2- [(2-aminopyridin-4-yl)oxy J -4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-N-( {3-nitro-4- [(tetrahydro-2H-pyran-4-ylmethyl)aminoJphenyl}sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-2-[(6-hydroxypyridin-3-yl)oxyJ-N-({3-nitio-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino Jpheny 1} sulfonyl)benzamide; 2- {[6-(benzyloxy)pyridin-3-ylJoxy} -4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-N-( {3 -nitro-4- [(tetrahydro-2H-pyran-4-ylmethyl)aminoJphenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yljmethyl Jpiperazin-1 -yl)-N- {[4-(l,4-dioxan-2-ylmethoxy)-3-nitTophenylJsulfonylJ-2-[(6-fluoro-lH-indol-5-yl)oxyJbenzamide; 2-[(3-chloro-lH-indol-4-yl)oxyJ-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yljmethyl Jpiperazin- l-yl)-N-({ 4-[(4-methylpiperazin- l-yl)aminoJ-3-nitrophenyl }suIfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-ylJmethylJpiperazin-l-yl)-N-({4-[(4-methylpiperazin-l-yl)aminoJ-3-nitrophenylJsulfonyl)-2-[(2-oxo-2,3-dihydro-lH-indol-4-yl)oxyJbenzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yljmethyl} piperazin-1 -yl)-N-({ 4-[(l-methylpiperidin-4-yl)aminoJ-3-nitrophenylJsulfonyl)-2-[(2-oxo-2,3-dihydro-lH-indol-4-yl)oxyJbenzamide; 45 4-(4- {[2-(4-chlorophenyl)-4,4-dimefliylcyclohex- 1-en-1 -yljmethyl }piperazin-1 -yl)-N-( {3- nitro-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]phenyl}sulfonyl)-2-[(2-oxo-2,3- dihydro-1 H-indol-4-yl)oxy]benzamide; 2-[(6-ch]oro-lH-indol-5-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl} piperazin-1 -yl)-N- {[4-( 1,4-dioxan-2-ylmethoxy)-3 - nitrophenyljsulfonyl }benzamide; 2- [(6-chloio-1 H-indol-S -yl)oxy] -4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl} piperazin-1 -yl)-N-({ 4- [(1,4-dioxan-2-ylmethyl)amino]-3- nitrophenyl} sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl]piperazin-l-yl)-N-({4- [(l,4-dioxan-2-ylmethyl)aniino]-3-nitrophenyl}sulfonyl)-2-[(6-fluoro-lH-indol-5- yl)oxy]benzamide; Trans-2-[(6-chloio-lH-indol-5-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-l-yl]methyl}piperazin-l-yl)-N-({4-[(4-morpholin-4-ylcyclohexyl)amino]-3- nitrophenyl }sulfonyl)benzamide; Trans-2-[(6-chloro-lH-indol-5-yl)oxy]-4-(4-{[4-(4-ch]orophenyl)-6,6-dimethyl-5,6-dihydro- 2H-pyran-3-yl]methyl}piperazin-l-yl)-N-({4-[(4-morpholin-4-ylcyclohexyl)amino]-3- nitrophenyl }sulfonyl)benzamide; 4-(4- {[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl }piperazin- 1-yl)- 2-[(6-fluoro-lH-indol-5-yl)oxy]-N-({4-[(4-morpholin-4-ylcyclohexyl)anainol-3- nitrophenyl} sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-2-[(6- fluoro-lH-indol-5-yl)oxy]-N-({4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3- nitrophenyl} sulfonyl)benzamide; 4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- 2-[(6-fluoro-lH-indol-5-yl)oxy]-N-({4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3- nitrophenyl}sulfonyl)benzamide; 4-(4-{[4-(4-ch]orophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- N- {[5-cyano-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl} -2-[(6-fluoro-1H- indol-5-yl)oxy]benzamide; 2- {[3-(2-aminoethyl)- lH-indol-5-yl]oxy} -4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en- l-yl]methyl} piperazin-1 -yl)-N-( {3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)benzamide; 46 2- {[3-(2-aminoethyl)- lH-indol-5-yl]oxy} -4-(4-{ [2-(4-ch]o^ophenyl)-4,4-dimethylcyclohex-l -en-1 -yl]methyl} piperazin-1 -yl)-N-( {4- [(4-methylpiperazin-1 -yl)amino]-3-nitrophenyl}sulfonyl)benzamide; 4.(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yljmethyl jpiperazin-1 -yl)-N- {[5-cyano-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-[(6-fluoro-lH-indol-5-yl)oxy]benzamide; 2-[(6-amino-5-fluoropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-1-yl]methyl} piperazin-1-yl)-N-( {3-mtro-4-[(tetTahydro-2H-pyran-4-ylmethyl)amino]pheny 1} sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-{[5-chloro-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-[(6-fluoro-lH-indol-5-yl)oxy]benzamide; Trans-4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl }piperazin-1 -yl)-N-({4.[(4-morpholin-4-ylcyclohexyl)amino]-3-nitrophenyl}sulfonyl)-2-[(l-oxo-l,2,3,4-tetrahydroisoquinolin-5-yl)oxy]benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-{[5-cyano-6-(l,4-dioxan-2-ylmethoxy)pyridin-3-yl]sulfonyl}-2-[(6-fluoro-lH-indol-5-yl)oxy]benzamide; N- {[5-bromo-6-( 1,4-dioxan-2-ylmethoxy)pyridin-3-yl]sulfonyl} -4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl }piperazin-1 -yl)-2-[(6-fluoro- lH-indol-5-yl)oxy]benzamide; Trans-N-( {5-bromo-6-[(4-morpholin-4-ylcyclohexyl)amino]pyridin-3-yl} sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-[(6-fluoro-lH-indol-5-yl)oxy]benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-N-({5-cyano-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-[(6-fluoro-1 H-indol-5 -yl)oxy]benzamide; 2-(3-amino-5-chlorophenoxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl} piperazin-1 -yl)-N-( {3-nitro-4-[(tetrahydro-2H-pyran-4-yrmethyl)amino]phenyI} sulfonyl)benzamide; 4-(4- {[2-(4-ch]orophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl} piperazin-1 -yl)-N- {[5-cyano-6-(2-niorpholin-4-ylethoxy)pyridin-3-yl]sulfonyl} -2-[(6-fluoro- lH-indol-5-yl)oxy]benzamide; 47 Trans-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yljmethyl} piperazin-1 -yl)-2- [(6-fluoro-lH-indol-5-yl)oxy]-N-({4-[(4-morpholin-4-ylcyclohexyl)oxy]-3- nitxophenyl} sulfonyl)benzamide; N-( {5 -bromo-6-[( 1 -tetrahydro-2H-pyraii-4-ylpiperidin-4-yl)amino]pyridin-3 -y 1} sulfony l)-4- (4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2- [(6- fluoro-lH-indol-5-yl)oxy]benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-N-({4- [(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3-nitrophenyl} sulfonyl)-2- [(2-oxo-2,3- dihydro-1 H-indol-4-yl)oxy]benzamide; Trans-2-[(6-chloro-lH-indol-5-yl)oxy]-4-(4-{[5-(4-chlorophenyl)-2,3,6,7-tetrahydrooxepin- 4-yl]methyl}piperazin-l-yl)-N-({4-[(4-morpholin-4-ylcyclohexyl)aniino]-3- [(trifluoromethyl)sulfonyl]phenyl} sulfonyl)benzamide; Trans-2- [(6-chloro-1 H-indol-5-yl)oxy]-4-(4- {[5-(4-chlorophenyl)-2,3,6,7-tetrahydrooxepin- 4-yl]methyl)piperazin-l-yl)-N-({4-[(4-morpholin-4-ylcyclohexyl)amino]-3- nitrophenyl} sulfony l)benzamide; 4-(4- {[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3 -yl]mediyl) piperazin-1 -yl)- 2-[(6-fluoro-lH-indol-5-yl)oxy]-N-({4-[(4-methylpiperazin-l-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2- [(6- fluoro-lH-indol-5-yl)oxy]-N-({4-[(4-morpholin-4-ylbut-2-ynyl)oxy]-3- nitrophenyl} sulfonyl)benzamide; 2-[(6-araino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en- l-yl]methyl jpiperazin- l-yl)-N-( {3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2- [(6- fluoro-lH-indol-5-yl)oxy]-N-[(4-{[l-(methylsulfonyl)piperidin-4-yl]amino}-3- nitrophenyl)sulfonyl]benzamide; Trans-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yljmethyl} piperazin-1 -yl)-N- ({4- [(4-morpholin-4-ylcyclohexyl)amino]-3-nitrophenyl} sulfonyl)-2-[(2-oxo-2,3-dihydro- lH-indol-4-yl)oxy]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N-( {4- [(2-medioxyethyl)amino]-3-nitrophenyl} sulfonyl)-2-[(2-oxo-2,3-dihydro-1 H-indol-4- yl)oxy]benzamide; 48 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl }piperazin-1 -yl)-N- {[5- ethynyl-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-[(6-fluoro-lH-indol- 5-yl)oxy]benzamide; 4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- N-{[5-ethynyl-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-[(6-fluoro-lH- indol-5-yl)oxy]benzamide; Trans-2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4- dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-({4-[(4-morpholin-4- ylcyclohexyl)amino]-3-nitrophenyl}sulfonyl)benzamide; 4-(4- {[2-(4-cMorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N-( {5- cyano-6-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4-yl)oxy]pyridin-3-yl}sulfonyl)-2-[(6-fluoro- lH-indol-5-yl)oxy]benzamide; N-({5-chloro-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-2- [(6-fluoro- 1 H-indol-5-yl)oxy]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimetiiylcyclohex-1 -en-1 -yl]mediyl ] piperazin-1 -yl)-N-( {4- [(l-cyclopropylpiperidin-4-yl)amino]-3-nitrophenyl} sulfonyl)-2-[(6-fluoro- lH-indol-5- yl)oxy]benzamide; 4-(4- ([2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N-( {4- [(4-ethylmorpholin-3-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-[(6-fluoK)-lH-indol-5- yl)oxy]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl J piperazin-1 -yl)-2- [(6- fluoro- lH-indol-5-yl)oxyJ-N-[(3-nitro-4- {[(3S)-1 -tetrahydro-2H-pyran-4-ylpiperidin-3- ylJamino)phenyl)sulfonylJbenzamide; 2-[(6-amino-5-chloropyridin-3-yl)oxyJ-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-l-yl]methyl}piperazin-l-yl)-N-({4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxyJ-3- nitrophenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-N-( {4- [(1, l-dioxidothiomorpholin-4-yl)aminoJ-3-nitrophenyl} sulfonyl)-2-[(6-fluoro-1 H-indol-5- yl)oxy]benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-ylJmethyl}piperazin-l-yl)-2-[(6- fluoro-lH-indol-5-yl)oxyJ-N-({3-nitro-4-[(tetrahydrofuran-3- ylraethyl)aminoJphenyl}sulfonyl)benzamide; 49 Trans-N-( {5-biomo-6-[(4-morpholin-4-ylcyclohexyl)oxy ]pyridin-3-yl} sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl }piperazin-1 -yl)-2- [(6-fluoro- IH- indol-5-yl)oxy]benzamide; Trans-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N- [(4-{[4-(dicyclopropylaniino)cyclohexyl]amino}-3-mtrophenyl)sulfonyl]-2-[(6-fluoro-lH- indol-5-yl)oxy]benzamide; Trans-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2- [(6-fluoK)- lH-indol-5-yl)oxy]-N-[(3-nitro-4- {[4-(tetrahydro-2H-pyran-4- ylaniino)cyclohexyl]amino}phenyl)sulfonyl]benzamide; Trans-4-(4- {[2-(4-chloropheny l)-4,4-dimethylcycIohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2- [(6-fluoro-1 H-indol-5-yl)oxy]-N-[(3-nitix)-4- {[4-(4-tetrahydro-2H-pyran-4-ylpiperazin-1 - yl)cyclohexyl]amino}phenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2- [(6- fluoro- lH-indol-5 -yl)oxy ] -N- [(4- {[(4-fluorotetrahydro-2H-pyran-4-yl)methyl] amino} -3 - nitrophenyl)sulfonyl]benzamide; Trans-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-2- [(6-fluoro-lH-indol-5-yl)oxy]-N-[(4-{[(4-hydroxycyclohexyl)methyl]aniino}-3- nitrophenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-( {3 - [3 - (dimethylamino)propyl] -1 H-indol-4-yl} oxy)-N-( {3-nitro-4- [(tetrahydro-2H-pyran-4- ylmethyl)amino]pheny 1} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl} piperazin-1 -yl)-2-( {3-[3- (dimethylamino)propyl]- lH-indol-4-yl} oxy)-N-( {4- [(4-methylpiperazin-1 -yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl ] piperazin-1 -yl)-N-( {4- [(l-cyclopropyl-4-fluoropiperidin-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-[(6-fluoro-lH- indol-5-yl)oxy]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2- {[ 1 -(4- methoxybenzyl)-lH-l,2,3-benzotriazol-4-yl]oxy}-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylniethyl)amino]phenyl} sulfonyl)benzamide; 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-1 -yl]methyl} piperazin-1 -yl)-N-( {4- [(4-methylpiperazin-1 -yl)amino]-3- nitrophenyl }sulfonyl)benzamide; 50 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-{[4-(l,4-dioxan-2-ylmethoxy)-3-nitrophenyljsulfonyl }benzamide; Trans-2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl} piperazin-1 -y 1)-N- [(4- {[(4-methoxycyclohexyl)methyl]amino]-3-nitrophenyl)sulfonyl]benzamide; 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-1 -yl]methyl} piperazin-1 -yl)-N-( {4- [(1,4-dioxan-2-ylmethyl)amino] -3-nitrophenyl} sulfonyl)benzamide; 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-({4-[(3-morpholin-4-ylpropyl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl} sulfonyl)benzamide; 2-[(6-amino-5-chloiopyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-1 -yl]methyl} piperazin-1 -yl)-N-( {4- [(4-fluorotetrahydro-2H-pyran-4-y l)methoxy ]-3 -[(trifluoromethyl)sulfonyl]phenyl} sulfonyl)benzamide; 2-[(6-amino-5-chloropyridin-3-yl)oxy]-N-({5-chloro-6-[(4-fluorotetTahydio-2H-pyran-4-yl)methoxy]pyridin-3-yl} sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yljmethyl} piperazin-1 -yl)benzamide; 2-[(6-amino-5-bK)mopyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl Ipiperazin- l-yl)-N-( {3-nit^o-4-[(tetrahyd^o-2H-py^an-4-ylmethyl)anlino]pheny 1 } sulfonyl)benzamide; 2-amino-5-(5-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-2- {[({3-nitro-4-[(tetrahydio-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)amino]carbonyl}phenoxy)mcotinamide; 2-[(6-amino-5-cyanopyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-1 -yl]methyl} piperazin-1 -yl)-N-( {3 -nitro-4- [(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl }sulfonyl)benzamide; 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en- l-yl]methyl Ipiperazin- l-yl)-N-[(4- {[(3R)- l-(2,2-difluoroethyl)pynolidin-3-yl]amino} -3-nitrophenyl)sulfonyl]benzamide; 2-[(6-anuno-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-1 -yl]methyl} piperazin-1 -yl)-N-( {4-[( 1 -methylpiperidin-4-yl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide; 51 2- {[6-(acetylamino)pyridin-3-yl]oxy} -4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl) piperazin- l-yl)-N-( {3-iiitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]pheny 1} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl} piperazin-1 -yl)-2-( {6- [(methylsulfonyl)amino]pyridin-3-yl}oxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylniethyI)amino]pheny 1} sulfonyl)benzamide; 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl )piperazin- l-yl)-N- {[4- ({(3 R)-1 - [2-fluoro-1 -(fluoromethyl)ethyl]pyrrolidin-3-yl} amino)-3 -nitrophenyl] sulfonyl} -2- [(6-fluoro-1 H-indol-5-yl)oxy]benzamide; 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-l-yl]meihyl}piperazin-l-yl)-N-({4-[(l-cyclopropylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 2-[(6-amino-5-bromopyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-1 -yl]methyl} piperazin-1 -yl)-N-( {4- [(4-methylpiperazin-1 -yl)amino] -3- nitrophenyl} sulfonyl)benzamide; 2-[(6-amino-5-bromopyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-l-yl]methyl}piperazin-l-yl)-N-({4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3- nitrophenyl} sulfonyl)benzamide; 2-[(6-amino-5-bromopyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-l-yl]methyl}piperazin-l-yl)-N-({4-[(l,4-dioxan-2-ylmethyl)amino]-3- nitrophenyl }sulfonyl)benzamide; 2-[(6-amino-5-methylpyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-1 -yl]methyl} piperazin-1 -yl)-N-( {3 -nitro-4- [(tetrahydro-2H-pyran-4- ylmethyl)amino]pheny 1} sulfonyl)benzamide; 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en- l-yl]methyl }piperazin- l-yl)-N-[(4- {[(4-fluorotetrahydro-2H-pyran-4-yl)methyl]amino }-3- nitrophenyl)sulfonyl]benzamide; 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1- • en-l-yl]methyI}piperazin-l-yl)-N-({3-mtro-4-[(l-oxetan-3-ylpiperidin-4- yl)aniino]phenyl} sulfonyl)benzanude; 2-[(6-aniino-5-isopropylpyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl} piperazin-1 -yl)-N-( {3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)benzamide; 52 2-[(6-amino-5-cyclopropylpyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4- dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -y l)-N-( {3 -nitro-4- [(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)benzamide; Trans-2-[(6-amino-5-bromopyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4- dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -y 1)-N- [(4- {[(4- methoxycyclohexyl)niethyl]aniino)-3-nitrophenyl)sulfonyl]benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]niethyl}piperazin-l-yl)-2-[(3- methyl-2-oxo-2,3-dihydro-lH-benzimidazol-4-yl)oxy]-N-({3-nitro-4-[(tetrahydro-2H-pyran- 4-ylmethyl)amino]phenyl} sulfonyl)benzaniide; 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-1 -yljmethyl} piperazin-1 -yl)-N-[(4- {[(4-cyclopropylmorpho]in-2-yl)methyI]amino} -3- nitrophenyl)sulfonyl]benzamide; 2-[(6-aniino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en- l-yl]methyl Ipiperazin- l-yl)-N-[(4- {[(3R)-l-cyclopropylpym)lidin-3-yl]amino }-3- nitropiienyl)sulfonyl]benzamide; 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-l-yl]methyl}piperazin-l-yl)-N-{[4-({4-fluoio-l-[2-fluoro-l- (fluoromethyl)ethyl]piperidin-4-yl}methoxy)-3-nitropiienyl]sulfonyl}benzamide; tert-butyl6-bromo-4-(5-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yljmethyl} piperazin-1 -yl)-2- {[({3-nitro-4- [(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)amino]carbonyl }phenoxy)pyridin-2-ylcarbamate; tert-butyl4-(5-(4-((2-(4-chloiophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)- 2-(3-nitro-4-((tetrahydro-2H-pyran-4- yl)methylaniino)phenylsulfonylcarbamoyl)phenoxy)pyridine-2,6-diyldicarbamate; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2- {[6- (cyclopropylamino)pyridin-3-yl]oxy}-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)benzamide; Trans-4-(4- {[2-(4-ciUorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl} piperazin-1 -yl)-2- ({6-[(2,2-difluoroethyl)amino]pyridin-3-yl}oxy)-N-[(4-{[(4- methoxycycIohexyl)methyl]amino)-3-nitrophenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl ] piperazin- l-yl)-2-( {6- [(2,2-difluoroethyl)amino]pyridin-3-yl}oxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)benzamide; 53 2-{[5-chloro-6-(methylammo)pyridin-3-yl]oxy}-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -y l)-N-( {3 -nitro-4- [(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)beiizamide; 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-1 -yljmethyl} piperazin-1 -yl)-N-( {4- [({4- [2-fluoro-1 -(fluoiomethyl)ethyl]morpholin-2-yl} methyl)aniino]-3-nitrophenyl} sulfonyI)benzamide; 2-[(2-amino-6-bromopyTidin-4-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-1 -yl]methyl) piperazin-1 -yl)-N -({3 -nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]pheny 1} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl ] piperazin- 1-yl)-2-[(2,6-diaminopyridin-4-yl)oxy]-N-({3-nit^o-4-[(tet^ahydro-2H-py^an-4-ylmethyl)amino]pheny 1} sulfonyl)benzamide; 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en- l-yl]methyl }piperazin- l-yl)-N-{ [3-nitro-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]sulfonyl}benzamide; 2-[(6-araino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-1 -yljmethyl} piperazin-1 -yl)-N- {[4-( {(3R)-1 - [2-fluoro-1 -(fluoromethyl)ethyl]piperidin-3 -yl) amino)-3-nitrophenyl]sulfonyl} benzamide; tert-butyl 5-bromo-4-(5-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1-yl]methyl)piperazin-l-yl)-2-{[({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)amino]carbonyl}phenoxy)pyridin-2-ylcarbamate; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl) piperazin-1 -yl)-2- [(4-chloro-lH-pyrrolo[2,3-b]pyridin-5-yl)oxy]-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl} piperazin-1 -yl)-N-({ 3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-({6-[(2,2,2-trifluoroethyl)amino]pyridin-3-yl} oxy)benzamide; 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en- l-yl]methyl }piperazin- l-yl)-N-[(4- {[(4-hydroxycyclohexyl)methyl]amino }-3-nitrophenyl)sulfonyl]benzamide; 2-[(6-aniino-5-chloropyridin-3-yl)oxy]-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)benzamide; 54 N-({5-chloro-6-[(4-fluorotetrahyclro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- {[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl} piperazin-1 -yl)-2-[(6- fluoro-lH-indol-5-yl)oxy]benzamide; 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-l-yl]methyl}piperazin-l-yl)-N-({3-nitro-4-[(tetrahydrofuran-3- y]methy])amino]phenyl}su]fony])benzamide; 2-[(6-amino-5-chloropyridin-3-yl)oxy]-N-({5-chloro-6-[(4-fluorotetrahydro-2H-pyran-4- yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H- pyran-3-yl]methyl}piperazin-l-yl)benzamide; 2-[(6-araino-5-chloropyridin-3-yl)oxy]-4-[4-({9-(4-chlorophenyl)-3-[2-fluoro-l- (fluoromethyl)ethyl]-3-azaspiro[5.5]undec-8-en-8-yl}methyl)piperazin-l-yl]-N-({3-nitro-4- [(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)benzamide; 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[9-(4-chlorophenyl)-3-isopropyl-3- azaspiro[5.5]undec-8-en-8-yl]methyl}piperazin-l-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)benzamide; 2-[(6-amino-5-chloropyridin-3-yl)oxy]-N-[(5-chloro-6-{[l-(N,N-dimethylglycyl)-4- fluoropiperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4- dimethylcyclohex-1 -en- l-yl]methyl} piperazin-1 -y l)benzamide; 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-1 -yl] methyl} piperazin-1 -yl)-N- {[4-( {(3R)-1 - [2-fluoio-1 -(fluoronaethyl)ethyl]pyrrolidin-3 - yl}amino)-3-nitrophenyl]sulfonyl)benzamide; 2-[(2-amino-5-biomopyridin-4-yl)oxy]-4-(4-{[2-(4-ch]oropheny])-4,4-dimethylcyclohex-l- en-1 -yl]methyl} piperazin-1 -yl)-N-( {3 -nitro-4- [(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)benzamide; 2-[(6-amino-5-ch]oropyridin-3-yl)oxy]-4-(4-{t2-(4-ch]orophenyl)-4,4-dimethylcyc]ohex-l- en-1 -yljmethyl }piperazin- l-yl)-N-[(4- {[(4,4-difluorocyclohexyl)methyI]amino} -3- nitrophenyl)sulfonyl]benzamide; 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-[4-({4'-chloro-3-[2-(dimethylamino)ethoxy]-l,r- biphenyl-2-yl }methyl)piperazin-1 -yl]-N-({ 3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]pheny 1} suIfonyl)benzamide; 2-[(6-amino-5-chloropyridin-3-yl)oxy]-N-{[5-chloro-6-({(3R)-l-[2-fluoro-l- (fluoromethyl)ethyl]pyrrolidin-3-yl}methoxy)pyridin-3-yl]sulfonyl}-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl }piperazin-1 -yl)benzamide; 55 2-[(6-amino-5-chloropyridin-3-yl)oxy]-N-[(5-chloro-6- {[(3R)-1-(2,2- difluoroethyl)pyrrolidin-3-yl]methoxy }pyridin-3-yl)sulfonyl]-4-(4- {[2-(4-chlorophenyl)-4,4- dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)benzamide; Trans-2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4- dimethylcyclohex-1 -en- l-yl]methyl jpiperazin-1 -yl)-N-[(4- {[(4- cyanocyclohexyl)methyl]amino} -3-nitrophenyl)sulfonyl]benzamide; 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chIorophenyl)-4,4-dimethylcyclohex-l- en-l-yl]methyl}piperazin-l-yl)-N-({5-fluoro-6-[(4-fluorotetrahydio-2H-pyran-4- yl)methoxy]pyridin-3-yl} sulfonyl)benzamide; 2-[(6-aniino-5-chloropyridin-3-yl)oxy]-N-[(5-chloro-6-{[l-(2,2-difluoroethyl)-4- fluoropiperidin-4-yl] methoxy} pyridin-3 -yl)sulfony 1] -4-(4- {[2-(4-chlorophenyl)-4,4- dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -y l)benzamide; 2-[(6-amino-5-chloropyridin-3-yl)oxy]-N-({3-chloro-4-[(4-fluorotetrahydro-2H-pyran-4- yl)methoxy]phenyl} sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)benzamide; 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-1 -yljmethyl }piperazin- l-yl)-N- {[6-( {4-fluoio-1 -[2-fluoro-1 - (fluoromethyl)ethyl]piperidin-4-yl}methoxy)-5-(trifluoromethyl)pyridin-3- yl]sulfonyl }benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl )piperazin-1 -yl)-N-( {3- nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-[2-(lH-pyrazol-4- yl)phenoxy]benzamide; 2-[2-(2-aminopyridin-3-yl)phenoxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl)piperazin-l-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]pheny 1} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl ] piperazin-1 -yl)-N-( {3- nitro-4-[(tetrahydro-2H-pyTan-4-ylmethyl)amino]phenyl}sulfonyl)-2-[2-(lH-pyrazol-5- yl)phenoxy]benzamide; 2-[(6-amino-5 -chloropyridin- 3-yl)oxy ] -N-( {5 -chloro-6- [(4,4- difluorocyclohexyl)methoxy]pyridin-3-yl} sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4- dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -y l)benzamide; N-({5-chloro-6-[(4,4-difluorocyclohexyl)methoxy]pyridin-3-yl }sulfonyl)-4-(4- {[4-(4- chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)-2-[(6-fluoro- lH-indol-5-yl)oxy]benzamide; 56 4-(4- {[2-(4-ch]orophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl) piperazin-1 -yl)-N-[(4- {[(4,4-difluorocyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-[(6-fluoro-lH-indol-5- yl)oxy]benzamide; N-({3-chloro-4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-[(6-fluoro-lH- indol-5-yl)oxy]benzamide; N-( {3-chloro-4- [(4-fluorotetrahydro-2H-pyran-4-y l)methoxy]phenyl} sulfonyl)-4-(4- {[4-(4- chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl)piperazin-l-yl)-2-[(6-fluoro- lH-indol-5-yI)oxy]benzamide; N-({5-chloro-6-[(trans-4-hydroxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2- [(6-fluoro-1H- indazol-4-yl)oxy]benzamide; N-( {5-chloro-6- [(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl} sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-[(6-fluoro- lH-indazol-4-yl)oxy]benzaniide; tert-butyl 5-[(4-{4-[({5-chloro-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3- yl) sulfonyl)carbamoyl] -3-[(6-fluoro-1 H-indol-5 -yl)oxy Jphenyl) piperazin-1 -yl)niethyl] -4-(4- chlorophenyl)-3,6-dihydropyridine-l(2H)-carboxylate; N-( {5-cMoro-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl} sulfonyl)-4-(4- {[4-(4-chloiophenyl)-l-(l,3-difluoropropan-2-yl)-l,2,5,6-tetrahydropyridin-3- yl]methyl}piperazin-l-yl)-2-[(6-fluoro-lH-indol-5-yl)oxy]benzamide; 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl }piperazin- l-yl)-2-[(6- fluoro-lH-indazol-4-yl)oxy]-N-[(4-{[(4-fluorotetrahydro-2H-pyran-4-yl)methyl]amino}-3- nitTophenyl)sulfonyl]benzamide; N-( {5 -chloro-6- [(trans-4-hydroxycyclohexyl)methoxy]pyridin-3 -yl} sulfonyl)-4-(4- {[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl }piperazin-1 -yl)-2- [(7-fluoro- IH- indazol-4-yl)oxy]benzamide; N-({5-chloro-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl)sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-[(7-fluoro- lH-indazol-4-yl)oxy]benzanaide; 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1- en-1-yl]methyl) piperazin-1-yl)-N-{[3-nitro-4-( {[4-(oxetan-3-yl)morpholin-2- yl]methyl}amino)phenyl]sulfonyl}benzamide; 57 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-l(6- fluoro-1 H-indol-5 -yl)oxy ] -N- {[3-nitro-4-( {[4-(oxetan-3 -yl)moipholin-2- yl]methyl} amino)phenyl]sulfonyl }benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl]piperazin-l-yl)-2-[(7- fluoro-lH-indazol-4-yl)oxy]-N-[(4-{[(4-fluorotetrahydro-2H-pyran-4-yl)methyl]amino}-3- nitrophenyl)sulfonyl]benzamide; N-( {5 -chloro-6- [(trans-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3 -yl} sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-2-[(6-fluoro- lH-indazol-4-yl)oxy]benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-{[5- chloro-6-(tetrahydio-2H-pyran-4-ylniethoxy)pyridin-3-yl]sulfonyl}-2-[(3-methyl-2-oxo-2,3- dihydro-lH-benzimidazol-4-yl)oxy]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N-( {4- [(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-[(3-methyl-2-oxo- 2,3-dihydro-lH-benzimidazol-4-yl)oxy]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl} piperazin-1 -yl)-N- [(4- {[(txans-4-methoxycyclohexyl)niethyl]amino}-3-nitrophenyl)sulfonyl]-2-[(3-methyl-2-oxo- 2,3-dihydro-lH-benzimidazol-4-yl)oxy]benzamide; 2-[(3-amino-1 H-indazol-4-yl)oxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl ] piperazin-1 -yl)-N- [(4- {[(4-fluorotetrahydro-2H-pyran-4-yl)methyl] amino} -3- nitrophenyl)sulfonyl]benzamide; 2-[(3-amino-1 H-indazol-4-yl)oxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1- yl]methyl}piperazin-l-yl)-N-({4-[(4-fluorotetrahydro-2H-pyran-4-yl)niethoxy]-3- nitrophenyl} sulfonyl)benzamide; 2-[(3-amino-lH-indazol-4-yl)oxy]-N-({5-chloro-6-[(4-fluorotetrahydro-2H-pyran-4- yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl} piperazin-1 -yl)benzamide; 2-[(3-amino-1 H-indazol-4-yl)oxy]-4-(4- {[2-(4-chloiophenyl)-4,4-dimethylcyclohex-1 -en-1- yl]methyl} piperazin-1 -yl)-N-({ 3-nitro-4- [(tetrahydro-2H-pyran-4- ylmethyl)amino]pheny 1} sulfonyl)benzamide; 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-1 -yl]methyl} piperazin-1 -yl)-N-[(4- {[4-fluoro-1 -(oxetan-3-yl)piperidin-4-yl]methoxy} -3- nitrophenyl)sulfonyl]benzaniide; 58 4-(4- {[2-(4-chlorophenyl)-4,4-dimethy Icyclohex-1 -en-1 -y IJmethy 1} piperazin-1 -yl)-2- [(6- fluoro-lH-indazol-4-yl)oxy]-N-({4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3- nitxophenyl} sulfonyl)benzamide; 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en- l-yl]methyl }piperazin- l-yl)-N-[(4- {[(trans-4-hydroxy-4- methylcyclohexyl)methyl]amino} -3-nitrophenyl)sulfonyl]benzamide; 2-[(3-aniino-1 H-indazol-4-yl)oxy]-4-(4- {[2-(4-chloiophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-[(4-{[(trans-4-methoxycyclohexyl)methyl]amino)-3- nitiophenyl)sulfonyl]benzanude; 2-[(6-ainino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-1 -yl]methyl} piperazin-1 -yl)-N-( {4- [(cis-4-hydroxy-4-niethylcyclohexyl)methoxy]-3- nitiophenyl }sulfonyl)benzamide; 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-l-yl]methyl}piperazin-l-yl)-N-[(4-{[(cis-4-hydroxy-4-methylcyclohexyl)methyl]amino}- 3-nitiophenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethy Icyclohex-1-en-1 -yl]methyl} piperazin-1 -yl)-N- {[3- chloro-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]sulfonyl)-2-[(3-methyl-2-oxo-2,3- dihydro-lH-benzimidazol-4-yl)oxy]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N- [(4- {[(4-cyclopropylmoipholin-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-[(3-methyl-2-oxo- 2,3-dihydro-lH-benzimidazol-4-yl)oxy]benzamide; 2-[(6-amino-5-chloix)pyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-l-yl]methyl}piperazin-l-yl)-N-{[3-nitro-4-(2-oxaspiro[3.5]non-7- ylraethoxy)phenyl]sulfonyl)benzamide; 2-[(6-aniino-5-chloropyridin-3-yl)oxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1- en-l-yl]methyl}piperazin-l-yl)-N-({4-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]-3- nitrophenyl} sulfonyl)behzamide; 2-[(6-amino-5-chloiopyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-1 -yl]methyl }piperazin- l-yl)-N- {[4-( {[(2S)-4-cyclopropylmorpholin-2-yl]methyl} amino)- 3-nitrophenyl]sulfonyl} benzamide; 2-[(6-amino-5-chloropyridin-3-yl)oxy]-N-({5-chloro-6-[(trans-l-fluoro-4-hydroxy-4- methylcyclohexyl)methoxy]pyridin-3-yl} sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4- dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -y l)benzaniide; 59 2-[(6-amino-5-chloropyridin-3-yl)oxy]-N-({5-chloro-6-[(cis-l-fluoro-4-hydroxy-4- methylcyclohexyl)methoxy]pyridin-3-yl} sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4- dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -y l)benzamide; 2-[(3-amino-lH-indazol-4-yl)oxy]-N-({5-chloro-6-[(trans-4-hydroxy-4- methylcyclohexyl)methoxy]pyridin-3-yl }sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4- dimethylcyclohex-1 -en- l-yl]methyl}piperazin-l -yl)benzamide; N-({5-chloro-6-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-2-[(3- chloro- lH-indazol-4-yl)oxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1- yl]methyl }piperazin-l-yl)benzamide; 2-[(6-aniino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en- l-yl]methyl }piperazin- l-yl)-N-[(4- {[(cis-4-ethyl-4-hydroxycyclohexyl)methyl]amino} -3- nitiDphenyl)sulfonyl]benzamide; 2-[(6-amino-5-chloiopyridin-3-yl)oxy]-4-(4-{[2-(4-chloiophenyl)-4,4-dimethylcyclohex-l- en-l-yl]methyl}piperazin-l-yl)-N-{[3-nitro-4-({[(2S)-4-(oxetan-3-yl)morpholin-2- yl]methyl} amino)phenyl]sulfonyl }benzamide; 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en- l-yl]methyl }piperazin- l-yl)-N-( {5-nitro-6-[(tetiahydro-2H-pyran-4- ylmethyl)amino]pyridin-3-yl) sulfonyl)benzamide; 2- [(6-amino-5 -chloiopyridin-3-yl)oxy] -4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 - en-l-yl]methyl}piperazin-l-yl)-N-({3-nitro-4-[(2-oxaspiro[3.5]non-7- ylmethyl)amino]phenyl}sulfonyl)benzamide; 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-1 -yl] methyl }piperazin-1 -yl)-N- {[4-( {[txans-4-(morpholin-4- yl)cyclohexyl]methyl}amino)-3-nitrophenyl]sulfonyl}benzamide; 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en- l-yl]methyl }piperazin- l-yl)-N-[(4- {[cis-4-(morpholin-4-yl)cyclohexyl]amino} -3- nitrophenyl)sulfonyl]benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-({5- cyano-6-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-2-[(6-fluoro- lH-indazol-4-yl)oxy]benzanaide; 2-[(6-aniino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-1 -yl]methyl }piperazin-1 -yl)-N- {[4-( {[4-( {[4-(methoxymethyl)cyclohexyl]methyl} amino)- 3-mtrophenyl]sulfonyl} amino)-3-nitrophenyl]sulfonyl) benzamide; 60 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-l-yl]methyl}piperazin-l-yl)-N-[(3-nitro-4-{[(3R)-l-(oxetan-3-yl)pyrrolidin-3- yl]amino}phenyl)sulfonyl]benzamide; 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-l-yl]methyl}piperazin-l-yl)-N-[(3-nitro-4-{[(3S)-l-(oxetan-3-yl)pyiTolidin-3- yl]amino]phenyl)sulfonyl]benzamide; N-[4-({2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4- dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)benzoyl} sulfamoyl)-2- nitiophenyl]morpholine-4-carboxainide; N-[4-({2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4- dimethylcyclohex-1 -en- l-yl]methyl }piperazin-l -yl)benzoyl} sulfamoyl)-2-nitrophenyl]-4- cyanopiperidine-1-carboxamide; and therapeutically acceptable salts, prodrugs, salts of prodrugs and metabolites thereof. Still another embodiment pertains to 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl) sulfonyl)benzamide; and therapeutically acceptable salts, prodrugs, salts of prodrugs and metabolites thereof. Still another embodiment pertains to Trans-2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-({4-[(4-morpholin-4-ylcyclohexyl)amino]-3-nitrophenyl} sulfonyl)benzamide; and therapeutically acceptable salts, prodrugs, salts of prodrugs and metabolites thereof. Still another embodiment pertains to 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chloK)phenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-[(3-nitro-4-{[(3R)-l-(oxetan-3-yl)pyrrolidin-3-yl]amino}phenyl)sulfonyl]benzamide; and therapeutically acceptable salts, prodrugs, salts of prodrugs and metabolites thereof. Still another embodiment pertains to Trans-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-[(6-fluoro-lH-indol-5-yl)oxy]-N-[(3-nitro-4- {[4-(tetrahydro-2H-pyran-4-ylamino)cyclohexyl]amino) phenyl)sulfonyl]benzamide; and therapeutically acceptable salts, prodrugs, salts of prodrugs and metabolites thereof. Still another embodiment pertains to 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-[(6-fluoro-lH-indol-5-yl)oxy]-N-[(3-nitro-4-{[(3S)-tetrahydro-2H-pyran-3-ylmethyl]amino]phenyl)sulfonyl]benzamide; and therapeutically acceptable salts, prodrugs, salts of prodrugs and metabolites thereof. 61 Still another embodiment pertains to 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl Ipiperazin-1 -yl)-2-[(6-fluoro- lH-indol-4-yl)oxy]-N-[(3-nitro-4- {[3-(3-oxopiperazin-1 -yl)propyl]amino }phenyl)sulfonyl]benzamide; and therapeutically acceptable salts, prodrugs, salts of prodrugs and metabolites thereof. Still another embodiment pertains to 2-(2-chlorophenoxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl] methyl} piperazin-1 -yl)-N- [(4- {[3-(dimethylamino)propyl]amino}-3-nitrophenyl)sulfonyl]benzamide; and therapeutically acceptable salts, prodrugs, salts of prodrugs and metabolites thereof. Still another embodiment pertains to 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -y l)-2-(3,4-dichlorophenoxy)-N-( {4- [(1 -methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)benzamide; and therapeutically acceptable salts, prodrugs, salts of prodrugs and metabolites thereof. Still another embodiment pertains to 2-(2-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-N-((4-((l-isopropylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide; and therapeutically acceptable salts, prodrugs, salts of prodrugs and metabolites thereof. Still another embodiment pertains to 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(2-(2-(dimethylamino)ethyl)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; and therapeutically acceptable salts, prodrugs, salts of prodrugs and metabolites thereof. Still another embodiment pertains to 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-((2-methyl-1,3-benzothiazol-6-yl)oxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-y]methyl)amino)phenyl)sulfonyl)benzamide; and therapeutically acceptable salts, prodrugs, salts of prodrugs and metabohtes thereof. Still another embodiment pertains to 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(4-chlorophenoxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide; and therapeutically acceptable salts, prodrugs, salts of prodrugs and metabolites thereof. Still another embodiment pertains to 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1 -yl)methyl)piperazin-1 -yl)-2-((2-methyl- lH-indol-5-yl)oxy)-N-((4-(( 1 -methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide; and therapeuticaUy acceptable salts, prodrugs, salts of prodrugs and metabolites thereof. Another embodiment pertains to a composition for treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, 62 colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, chronic lymphocytic leukemia, myeloma, prostate cancer, small cell lung cancer or spleen cancer, said composition comprising an excipient and a therapeutically effective amount of the compound of Formula (I). Another embodiment pertains to a method of treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, chronic lymphocytic leukemia, myeloma, prostate cancer, small cell lung cancer or spleen cancer in a patient, said method comprising administering to the patient a therapeutically effective amount of Formula (I). Another embodiment pertains to a method of treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell limg cancer, chronic lymphocytic leukemia, myeloma, prostate cancer, small cell lung cancer or spleen cancer in a patient, said method comprising administering to the patient therapeutically effective amount of the compound of Formula (I) and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent. DETAILED DESCRIPTION OF THE INVENTION Variable moieties herein are represented by identifiers (capital letters with numerical and/or alphabetical superscripts) and may be specifically embodied. It is meant to be understood that proj)er valences are maintained for all moieties and combinations thereof, that monovalent moieties having more than one atom are drawn from left to right and are attached through their left ends, and that divalent moieties are also drawn from left to right. It is also meant to be understood that a specific embodiment of a variable moiety herein may be the same or different as another specific embodiment having the same identifier. 63 The term "alkenyl" as used herein, means a straight or branched hydrocarbon chain containing from 2 to 10 carbons and containing at least one carbon-carbon double bond. The term "Cx-Cy alkyl" means a straight or branched hydrocarbon chain containing at least one carbon-carbon double bond containing x to y carbon atoms. The term "C2-C4 alkenyl" means an alkenyl group containing 2-4 carbon atoms. Representative examples of alkenyl include, but are not limited to buta-2,3-dienyl, ethenyl, 2-propenyl, 2-methyl-2-propenyl, 3-butenyl, 4-pentenyl, 5-hexenyl, 2-heptenyl, 2-methyl-l-heptenyl, and 3-decenyl. The term "alkenylene" means a divalent group derived ftxam a straight or branched chain hydrocarbon of 2 to 4 carbon atoms and contains at least one carbon-carbon double bond. The term "Cx-Cy alkylene" means a a divalent group derived from a straight or branched hydrocarbon chain containing at least one carbon-carbon double bond and containing x to y carbon atoms. Representative examples of alkenylene include, but are not limited to, -CH=CH- and -CH2CH=CH-. The term "alkyl" as used herein, means a straight or branched, saturated hydrocarbon chain containing from 1 to 10 carbon atoms. The term "Cx-Cy alkyl" means a straight or branched chain, saturated hydrocarbon containing x to y carbon atoms. For example "C2-C10 alkyl" means a straight or branched chain, saturated hydrocarbon containing 2 to 10 carbon atoms. Examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, 3-methylhexyl, 2,2-dimethylpentyl, 2,3-dimethylpentyl, n-heptyl, n-octyl, n-nonyl, and n-decyl. The term "alkylene" means a divalent group derived from a straight or branched, saturated hydrocarbon chain of 1 to 10 carbon atoms, for example, of 1 to 4 carbon atoms. The term "Cx-Cy alkylene" means a divalent group derived from a straight or branched chain, saturated hydrocarbon containing x to y carbon atoms. For example "Cz-Ce alkylene" means a straight or branched chain, saturated hydrocarbon containing 2 to 6 carbon atoms. Examples of alkylene include, but are not limited to, -CH2-, -CH2CH2-, -CH2CH2CH2-, -CH2CH2CH2CH2-, and -CH2CH(CH3)CH2-. The term "alkynyl" as used herein, means a straight or branched chain hydrocarbon group containing from 2 to 10 carbon atoms and containing at least one carbon-carbon triple bond. The term "Cx-Cy alkynyl" means a straight or branched chain hydrocarbon group containing from x to y carbon atoms. Representative examples of alkynyl include, but are not limited, to acetylenyl, l-propynyl, 2-propynyl, 3-butynyl, 2-pentynyl, and 1-butynyl. 64 The term "alkynylene," as used herein, means a divalent radical derived from a straight or branched chain hydrocarbon group containing firom 2 to 10 carbon atoms and containing at least one carbon-carbon triple bond. The term "aryl" as used herein, means phenyl. The term "cyclic moiety," as used herein, means benzene, phenyl, phenylene, cycloalkane, cycloalkyl, cycloalkylene, cycloalkene, cycloalkenyl, cycloalkenylene, cycloalkyne, cycloalkynyl, cycloalkynylene, heteroarene, heteroaryl, heterocycloalkane, heterocycloalkyl, heterocycloalkene, heterocycloalkenyl and sptroalkyl. The term "cycloalkylene" or cycloalkyl" or "cycloalkane" as used herein, means a monocyclic or bridged hydrocarbon ring system. The monocyclic cycloalkyl is a carbocyclic ring system containing three to eight carbon atoms, zero heteroatoms and zero double bonds. Examples of monocyclic ring systems include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. The monocyclic ring may contain one or two alkylene bridges, each consisting of one, two, or three carbon atoms, each linking two non-adjacent carbon atoms of the ring system. Non-limiting examples of such bridged cycloalkyl ring systems include bicyclo[3.1.1]heptane, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.2]nonane, bicyclo[3.3.1]nonane, bicyclo[4.2.1]nonane, tryyclo[3.3.1.0^'^]nonane (octahydro-2,5-methanopentalene or noradamantane), and tricyclo[3.3.1.1^'^]decane (adamantane). The monocyclic and bridged cycloalkyl can be attached to the parent molecular moiety through any substitutable atom contained within the ring system. The term "cycloalkenylene," or "cycloalkenyl" or "cycloalkene" as used herein, means a monocyclic or a bridged hydrocarbon ring system. The monocyclic cycloalkenyl has four-, five-, six-, seven- or eight carbon atoms and zero heteroatoms. The four-membered ring systems have one double bond, the five-or six-membered ring systems have one or two double bonds, and the seven- or eight-membered ring systems have one, two, or three double bonds. Representative examples of monocyclic cycloalkenyl groups include, but are not limited to, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl. The monocyclic cycloalkenyl ring may contain one or two alkylene bridges, each consisting of one, two, or three carbon atoms, each linking two non-adjacent carbon atoms of the ring system. Representative examples of the bicyclic cycloalkenyl groups include, but are not limited to, 4,5,6,7-tetrahydro-3aH-indene, octahydronaphthalenyl, and 1,6-dihydro-pentalene. The monocyclic and bicyclic cycloalkenyl can be attached to the parent molecular moiety through any substitutable atom contained within the ring systems. 65 The term "cycloalkyne," or "cycloalkynyl," or "cycloalkynylene," as used herein, means a monocyclic or a bridged hydrocarbon ring system. The monocyclic cycloalkynyl has eight or more carbon atoms, zero heteroatoms, and one or more triple bonds. The monocyclic cycloalkynyl ring may contain one or two alkylene bridges, each consisting of one, two, or three carbon atoms, each linking two non-adjacent carbon atoms of the ring system. The monocyclic and bridged cycloalkynyl can be attached to the parent molecular moiety through any substitutable atom contained within the ring systems. The term "heteroarene," or "heteroaryl," or "heteroarylene," as used herein, means a five-membered or six-membered aromatic ring having at least one carbon atom and one or more than one independently selected nitrogen, oxygen or sulfur atom. The heteroarenes of this invention are connected through any adjacent atoms in the ring, provided that proper valences are maintained. Representative examples of heteroaryl include, but are not limited to, furanyl (including, but not limited thereto, furan-2-yl), imidazolyl (including, but not limited thereto, lH-imidazol-1-yl), isoxazolyl, isothiazolyl, oxadiazolyl, oxazolyl, pyridinyl (e.g. pyridin-4-yl, pyridin-2-yl, pyridin-3-yl), pyridazinyl, pyrimidinyl, pyrazinyl, pyrazolyl, pyrrolyl, tetrazolyl, thiadiazolyl, thiazolyl, thienyl (including, but not limited thereto, thien-2-yl, thien-3-yl), triazolyl, and triazinyl. The term "heterocycloalkane," or "heterocycloalkyl," or "heterocycloalkylene," as used herein, means monocyclic or bridged three-, four-, five-, six-, seven-, or eight-membered ring containing at least one heteroatom independently selected from the group consisting of O, N, and S and zero double bonds. The monocyclic and bridged heterocycloalkane are connected to the parent molecular moiety through any substitutable carbon atom or any substitutable nitrogen atom contained within the rings. The nitrogen and sulfur heteroatoms in the heterocycle rings may optionally be oxidized and the nitrogen atoms may optionally be quartemized. Representative examples of heterocycloalkane groups include, but are not limited to. Representative examples of heterocycloalkane groups include, but are not limited to, morpholinyl, tetrahydropyranyl, pyrrolidinyl, piperidinyl, dioxolanyl, tetrahydrofuranyl, thiomorpholinyl, dioxanyl, tetrahydrothienyl, tetrahydrothiopyranyl, oxetanyl, piperazinyl, imidazolidinyl, azetidine, azepanyl, aziridinyl, diazepanyl, dithiolanyl, dithianyl, isoxazolidinyl, isothiazolidinyl, oxadiazolidinyl, oxazolidinyl, pyrazolidinyl, tetrahydrothienyl, thiadiazolidinyl, thiazolidinyl, thiomorpholinyl, trithianyl, and trithianyl. The term "heterocycloalkene," or "heterocycloalkenyl," or "heterocycloalkenylene," as used herein, means monocyclic or bridged three-, four-, five-, six-, seven-, or eight- membered ring containing at least one heteroatom independently selected from the group 66 consisting of O, N, and S and one or more double bonds. The monocyclic and bridged heterocycloalkene are connected to the parent molecular moiety through any substitutable carbon atom or any substitutable nitrogen atom contained within the rings. The nitrogen and sulfur heteroatoms in the heterocycle rings may optionally be oxidized and the nitrogen atoms may optionally be quartemized. Representative examples of heterocycloalkene groups include, but are not limited to, tetrahydrooxocinyl, 1,4,5,6-tetrahydropyridazinyl, 1,2,3,6-tetrahydropyridinyl, dihydropyranyl, imidazolinyl, isothiazolinyl, oxadiazolinyl, isoxazolinyl, oxazolinyl, pyranyl, pyrazolinyl, pyrrolinyl, thiadiazolinyl, thiazolinyl, and thiopyranyl. The term "phenylene," as used herein, means a divalent radical formed by removal of a hydrogen atom from phenyl. The term "spiroalkyl," as used herein, means alkylene, both ends of which are attached to the same carbon atom and is exemplified by Cz-spiioalkyl, Cs-spiroalkyl, C4-spiroalkyl, Cs-spiroalkyl, Ce-spiioalkyl, Cv-spiroalkyl, Cg-spiroalkyl, Cg-sptroalkyl and the like. The term "spiroheteroalkyl," as used herein, means spiroalkyl having one or two CH2 moieties replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N. The term "spiroheteroalkenyl," as used herein, means spiroalkenyl having one or two CH2 moieties replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties uiueplaced or replaced with N and also means spiroalkenyl having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties replaced with N. The term, "spirocyclo," as used herein, means two substituents on the same carbon atom, that, together with the carbon atom to which they are attached, form a cycloalkane, heterocycloalkane, cycloalkene, or heterocycloalkene ring. The term "C2-C5-spiroalkyl," as used herein, means C2-spiroalkyl, Cs-spiroalkyl, C4-spiroaIkyl, and Cs-spiroalkyl. The term "C2-spiroalkyl," as used herein, means eth-l,2-ylene, both ends of which replace hydrogen atoms of the same CH2 moiety. The term "Cs-spiroalkyl," as used herein, means prop-l,3-ylene, both ends of which replace hydrogen atoms of the same CH2 moiety. The term "C4-spiroalkyl," as used herein, means but-l,4-ylene, both ends of which replace hydrogen atoms of the same CH2 moiety. 67 The term "Cs-spiroalkyl," as used herein, means pent-l,5-ylene, both ends of which replace hydrogen atoms of the same CH2 moiety. The teim "Ce-spiroalkyl," as used herein, means hex-l,6-ylene, both ends of which replace hydrogen atoms of the same CH2 moiety. The term "NH protecting group," as used herein, means trichloroethoxycarbonyl, tribromoethoxycarbonyl, benzyloxycarbonyl, para-nitrobenzylcarbonyl, ortho-bromobenzyloxycarbonyl, chloroacetyl, dichloroacetyl, trichloroacetyl, trifluoroacetyl, phenylacetyl, formyl, acetyl, benzoyl, tert-amyloxycarbonyl, tert-butoxycarbonyl, para-methoxybenzyloxycarbonyl, 3,4-dimethoxybenzyl-oxycarbonyl, 4-(phenylazo)benzyloxycarbonyl, 2-furfuryl-oxycarbonyl, diphenylmethoxycarbonyl, 1,1-dimethylpropoxy-caibonyl, isopropoxycarbonyl, phthaloyl, succinyl, alanyl, leucyl, 1-adamantyloxycarbonyl, 8-quinolyloxycarbonyl, benzyl, diphenylmethyl, triphenylmethyl, 2-nitrophenylthio, meihanesulfonyl, para-toluenesulfonyl, N,N-dimethylaminomethylene, benzylidene, 2-hydroxybenzylidene, 2-hydroxy-5-chlorobenzylidene, 2-hydroxy-l-naphthyl-methylene, 3-hydroxy-4-pyridylmethylene, cyclohexylidene, 2-ethoxycarbonylcyclohexylidene, 2-ethoxycarbonylcyclopentylidene, 2-acetylcyclohexylidene, 3,3-dimethyl-5-oxycyclo-hexylidene, diphenylphosphoiyl, dibenzylphosphoryl, 5-methyl-2-oxo-2H-l,3-dioxol-4-yl-methyl, trimethylsilyl, triethylsilyl, and triphenylsilyl. The term "C(0)OH protecting group," as used herein, means methyl, ethyl, n-propyl, isopropyl, 1,1-dimethylpropyl, n-butyl, tert-butyl, phenyl, naphthyl, benzyl, diphenylmethyl, triphenylmethyl, para-nitrobenzyl, para-methoxybenzyl, bis(para-methoxyphenyl)methyl, acetylmethyl, benzoylmethyl, para-nitrobenzoylmethyl, para-bromobenzoylmethyl, para-methanesulfonylbenzoylmethyl, 2-tetrahydropyranyl 2-tetrahydrofuranyl, 2,2,2-trichloro-ethyl, 2-(trimethylsilyl)ethyl, acetoxymethyl, propionyloxymethyl, pivaloyloxymethyl, phthalimidomethyl, succinimidomethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, methoxymethyl, methoxyethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, benzyloxymethyl, methylthiomethyl, 2-methylthioethyl, phenylthiomethyl, l,l-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, trimethylsilyl, triethylsilyl, triisopropylsilyl, diethylisopropylsilyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, diphenylmethylsilyl, and tert-butylmethoxyphenylsilyl. The term "OH or SH protecting group," as used herein, means benzyloxycarbonyl, 4- nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl, methoxycaibonyl, ethoxycarbonyl, tert-butoxycarbonyl, 68 1,1-dimethylpropoxycarbonyl, isopropoxycarbonyl, isobutyloxycarbonyl, diphenylmethoxycarbonyl, 2,2,2-trichloioethoxycarbonyl, 2,2,2-tribromoethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, 2-(phenylsulfonyl)ethoxycarbonyl, 2-(triphenylphosphonio)ethoxycarbonyl, 2-furfuryloxycarbonyl, 1-adamantyloxycarbonyl, vinyloxycarbonyl, allyloxycaibonyl, S-benzylthiocarbonyl, 4-ethoxy-l-naphthyloxycarbonyl, 8-quinolyloxycarbonyl, acetyl, formyl, chloroacetyl, dichloroacetyl, trichloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, pivaloyl, benzoyl, methyl, tert-butyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, I,l-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, benzyl (phenylmethyl), para-methoxybenzyl, 3,4-dimethoxybenzyl, diphenylmethyl, triphenylmethyl, tetrahydrofuryl, tetrahydropyranyl, tetrahydrothiopyranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2-methoxyethoxymethyl, 2,2,2-trichIoro-ethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, 1-ethoxyethyl, methanesulfonyl, para-toluenesulfonyl, trimethylsilyl, triethylsilyl, tiiisopropylsilyl, diethylisopropylsilyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, diphenylmethylsilyl, and tert-butylmethoxyphenylsilyl. Compounds Geometric isomers may exist in the present compounds. Compounds of this invention may contain carbon-carbon double bonds or carbon-nitrogen double bonds in the E or Z configuration, wherein the term "E" represents higher order substituents on opposite sides of the carbon-carbon or carbon-nitrogen double bond and the term "Z" represents higher order substituents on the same side of the carbon-carbon or carbon-nitrogen double bond as determined by the Cahn-Ingold-Prelog Priority Rules. The compounds of this invention may also exist as a mixture of "E" and "Z" isomers. Substituents around a cycloalkyl or heterocycloalkyl are designated as being of cis or trans configuration. Furthermore, the invention contemplates the various isomers and mixtures thereof resulting from the disposal of substituents around an adamantane ring system. Two substituents around a single ring within an adamantane ring system are designated as being of Z or E relative configuation. For examples, see C. D. Jones, M. Kaselj, R. N. Salvatore, W. J. le Noble J. Org. Chem. 1998, 63,2758-2760 and E. L. Eliel, and S.H. Wilen. (1994) Stereochemistry of Organic Compounds. New York, NY: John Wiley & Sons, Inc. Compounds of this invention may contain asymmetrically substituted carbon atoms in the R or S configuration, in which the terms "R" and "S" are as defined by the lUPAC 1974 Recommendations for Section E, Fundamental Stereochemistry, Pure Appl. Chem. (1976) 45, 13-10. Compounds having asymmetrically substituted carbon atoms with equal amounts of R and S configurations are racemic at those carbon atoms. Atoms with an excess of one 69 configuration over the other are assigned the configuration present in the higher amount, preferably an excess of about 85%-90%, more preferably an excess of about 95%-99%, and still more preferably an excess greater than about 99%. Accordingly, this invention includes racemic mixtures, relative and absolute stereoisomers, and mixtures of relative and absolute stereoisomers. Compounds of this invention containing NH, C(0)OH, OH or SH moieties may have attached thereto prodrug-forming moieties. The prodrug-forming moieties are removed by metabolic processes and release the compounds having the freed hydroxyl, amino or carboxylic acid in vivo. Prodrugs are useful for adjusting such pharmacokinetic properties of the compounds as solubility and/or hydrophobicity, absorption in the gastrointestinal tract, bioavailability, tissue penetration, and rate of clearance. An example of a compound with a prodrug-forming moiety is [3-chloro-5-(5-(4-{[2-(4-chloiophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-{[({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)amino]carbonyl)phenoxy)-2-iminopyTidin-l(2H)-yl]methyl dihydrogen phosphate (EXAMPLE 397), which is a prodrug of 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl )piperazin-l -yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)benzamide (EXAMPLE 318). Isotope Enriched or Labeled Compounds Compounds of the invention can exist in isotope-labeled or isotope-enriched form containing one or more atoms having an atomic mass or mass number different from the atonaic mass or mass number most abundantly found in nature. Isotopes can be radioactive or non-radioactive isotopes. Isotopes of atoms such as hydrogen, carbon, phosphorous, sulfur, fluorine, chlorine, and iodine include, but are not limited to, ^H, ^H, "C, ''*C, '^N, '*0, ^^P, ^'S, '*F, ^*C1, and '^I. Compounds that contain other isotopes of these and/or other atoms are within the scope of this invention. In another embodiment, the isotope-labeled compounds contain deuterium (^H), tritium (^H) or ''^C isotopes. Isotope-labeled compounds of this invention can be prepared by the general methods well known to persons having ordinary skill in the art. Such isotope-labeled compounds can be conveniently prepared by carrying out the procedures disclosed in the Examples disclosed herein and Schemes by substituting a readily available isotope-labeled reagent for a non-labeled reagent. In some instances, compounds may be treated with isotope-labeled reagents to exchange a normal atom with its isotope, for example, hydrogen for deuterium can be exchanged by the action of a deuteric acid such as D2SO4/D2O. In 70 addition to the above, relevant procedures and intermediates are disclosed, for instance, in Lizondo, J et al.. Drugs Fut, 21(11), 1116 (1996); Brickner, S J etal., J Med Chem, 39(3), 673 (1996); Mallesham, B et al., Org Lett, 5(7), 963 (2003); PCT publications WO1997010223, WO2005099353, WO1995007271, WO2006008754; US Patent Nos. 7538189;7534814; 7531685; 7528131; 7521421; 7514068; 7511013; and US Patent Application Publication Nos. 20090137457; 20090131485; 20090131363; 20090118238; 20090111840; 20090105338; 20090105307; 20090105147; 20090093422; 20090088416;and 20090082471, the methods are hereby incorporated by reference. The isotope-labeled compounds of the invention may be used as standards to determine the effectiveness of Bcl-2 inhibitors in binding assays. Isotope containing compounds have been used in pharmaceutical research to investigate the in vivo metabolic fate of the compounds by evaluation of the mechanism of action and metabolic pathway of the nonisotope-labeled parent compound (Blake et al. /. Pharm. Sci. 64, 3, 367-391 (1975)). Such metabolic studies are important in the design of safe, effective therapeutic drugs, either because the in vivo active compound administered to the patient or because the metabolites produced from the parent compound prove to be toxic or carcinogenic (Foster et al.. Advances in Drug Research Vol. 14, pp. 2-36, Acadenaic press, London, 1985; Kato et al., J. Levelled Comp. Radiopharmaceut., 36(10):927-932 (1995); Kushner et al.. Can. J. Physiol. Pharmacol., 11, 79-88 (1999). In addition, non-radio active isotope containing drugs, such as deuterated drugs called "heavy drugs," can be used for the treatment of diseases and conditions related to Bcl-2 activity. Increasing the amount of an isotope present in a compound above its natural abundance is called enrichment. Examples of the amount of enrichment include from about 0.5,1, 2, 3,4, 5, 6, 7, 8, 9,10, 12,16, 21, 25, 29, 33, 37,42, 46, 50, 54, 58, 63, 67,71, 75, 79, 84, 88, 92, 96, to about 100 mol %. Replacement of up to about 15% of normal atom with a heavy isotope has been effected and maintained for a period of days to weeks in mammals, including rodents and dogs, with minimal observed adverse effects (Czajka D M and Finkel A J, Ann. N.Y. Acad. Sci. 1960 84: 770; Thomson J F, Ann. New York Acad. Sci 1960 84: 736; Czakja D M et al., Am. J. Physiol. 1961 201: 357). Acute replacement of as high as 15%-23% in human fluids with deuterium was found not to cause toxicity (Blagojevic N et al. in "Dosimetry & Treatment Planning for Neutron Capture Therapy", Zamenhof R, Solares G and Harling O Eds. 1994. Advanced Medical Publishing, Madison Wis. pp. 125-134; Diabetes Metab. 23: 251 (1997)). 71 Stable isotope labeling of a drug can alter its physico-chemical properties such as pKa and lipid solubiUty. These effects and alterations can affect the pharmacodynamic response of the drug molecule if the isotopic substitution affects a region involved in a ligand-receptor interaction. While some of the physical properties of a stable isotope-labeled molecule are different from those of the unlabeled one, the chemical and biological properties are the same, with one important exception: because of the increased mass of the heavy isotope, any bond involving the heavy isotope and another atom will be stronger than the same bond between the light isotope and that atom. Accordingly, the incorporation of an isotope at a site of metabolism or enzymatic transformation will slow said reactions potentially altering the pharmacokinetic profile or efficacy relative to the non-isotopic compound. Amides, Esters and Prodrugs Prodrugs are derivatives of an active drug designed to ameliorate some identified, undesirable physical or biological property. The physical properties are usually solubility (too much or not enough lipid or aqueous solubility) or stability related, while problematic biological properties include too rapid metabolism or poor bioavailability which itself may be related to a physicochemical property. Prodrugs are usually prepared by: a) formation of ester, hemi esters, carbonate esters, nitrate esters, amides, hydroxamic acids, carbamates, imines, Mannich bases, phosphates, phosphate esters, and enamines of the active drug, b) fiinctionaUzing the drug with azo, glycoside, peptide, and ether functional groups, c) use of aminals, hemi-aminals, polymers, salts, complexes, phosphoramides, acetals, hemiacetals, and ketal forms of the drug. For example, see Andrejus Korolkovas^s, "Essentials of Medicinal Chemistry", John Wiley-Interscience Publications, John Wiley and Sons, New York (1988), pp. 97-118, which is incorporated in its entirety by reference herein. Esters can be prepared from substrates of formula (I) containing either a hydroxyl group or a carboxy group by general methods known to persons skilled in the art. The typical reactions of these compounds are substitutions replacing one of the heteroatoms by another atom, for example: 72 Scheme 1 o ° HC^Cl * ®OCH2CH3 *■ H3C OCH2CH3 * ^ Acyl Chloride Alkoxide Ester Amides can be prepared from substrates of formula (I) containing either an amino group or a carboxy group in similar fashion. Esters can also react with amines or ammonia to form amides. Scheme 2 JL R_l_o-R' " R-l-O-R' ^ A * H-O-R' r ©NH3 NH2 ^ :NH3 Another way to make amides from compounds of formula (I) is to heat carboxylic acids and amines together. Scheme 3 o heat ^ R-ILOH "" HN(R')2 R-ILNCR-J^ In Schemes 2 and 3 above, R and R' are independently substrates of formula (I), alkyl or hydrogen. Suitable groups for for A\ B\ D\ E\ Y', L\ Z^^, Z^^, Z\ Z^ and Z^ in compounds of Formula (I) are independently selected. The described embodiments of the present invention may be combined. Such combination is contemplated and within the scope of the present invention. For example, it is contemplated that embodiments for any of A', B', D', E\ Y\ L', Z^^, Z^^, Z\ Z}, and Z^ can be combined with embodiments defined for any other of A\ B\ D\ E\ Y', L\ Z'^ Z^^ Z\ Z^ and ZOne embodiment of this invention, therefore, pertains to compounds or therapeutically acceptable salts, prodrugs or salts of prodrugs thereof, which are useful as inhibitors of anti-apoptotic Bcl-2 proteins, the compounds having Formula (I) I D^ A- B^ 2IA 73 (I), wherein AMsNorC(A^); A^ is H, R\ 0R\ SR\ S(0)R\ S02R\ C(0)R\ C(0)0R\ 0C(0)R\ NHR\ N(R')2, C(0)NHR\ C(0)N(R')2, NHC(0)R\ NR^C(0)R', NHC(0)0R\ NR'C(0)0R', NHC(0)NH2, NHC(0)NHR', NHC(0)N(R')2, NR'C(0)NHR\ NR'C(0)N(R^)2, SO2NH2, S02NHR\ S02N(R')2, NHSO2R', NR'S02R\ NHSO2NHR', NHS02N(R')2, NR'SOZNHR', NR'S02N(R')2, C(0)NHN0H, C(0)NHN0R', C(0)NHS02R', C(NH)NH2, C(NH)NHR', C(NH)N(R')2 NHS02NHR\ NHS02N(CH3)R\ N(CH3)S02N(CH3)R\ F, CI, Br, I, CN, NO2, N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)0R'^; B' is H, R', 0R\ SR', S(0)R', SO2R', C(0)R', C(0)0R', 0C(0)R', NHR', N(R')2, C(0)NHR\ C(0)N(R')2, NHC(0)R\ NR*C(0)R\ NHC(0)0R\ NR^C(0)0R\ NHC(0)NH2, NHC(0)NHR\ NHC(0)N(R')2, NR'C(0)NHR', NR'C(0)N(R^)2, SO2NH2, S02NHR\ S02N(R^)2, NHSO2R', NR'S02R\ NHS02NHR\ NHS02N(R')2, NR^S02NHR\ NR*S02N(R')2, C(0)NHN0H, C(0)NHN0R\ C(0)NHS02R\ C(NH)NH2, C(NH)NHR\ C(NH)N(R')2 NHSO2NHR', NHS02N(CH3)R', N(CH3)S02N(CH3)R', F, CI, Br, I, CN, NO2. N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or CCOJOR''^; D' is H, R\ OR', SR\ S(0)R\ S02R\ C(0)R', C(0)0R\ 0C(0)R', NHR', N(R')2, C(0)NHR\ C(0)N(R')2, NHC(0)R', NR'C(0)R\ NHC(0)0R\ NR'C(0)0R\ NHC(0)NH2, NHC(0)NHR\ NHC(0)N(R')2, NR'C(0)NHR\ NR'C(0)N(R^)2, SO2NH2, SO2NHR', S02N(R')2, NHSO2R', NR'S02R', NHSO2NHR', NHS02N(R')2, NR'S02NHR\ NR'S02N(R')2, C(0)NHN0H, C(0)NHN0R\ C(0)NHS02R\ C(NH)NH2, C(NH)NHR\ C(NH)N(R')2 NHS02NHR\ NHS02N(CH3)R\ N(CH3)S02N(CH3)R', F, Cl, Br, I, CN, NO2, N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)0R'^; E' is H, R\ 0R\ SR\ S(0)R\ SO2R', C(0)R\ C(0)0R\ 0C(0)R\ NHR', N(R')2, C(0)NHR', C(0)N(R')2, NHC(0)R\ NR'C(0)R', NHC(0)0R', NR'C(0)0R', NHC(0)NH2, NHC(0)NHR\ NHC(0)N(R')2, NR'C(0)NHR', NR'C(0)N(R')2, SO2NH2, SO2NHR', S02N(R')2, NHSO2R', NR'S02R\ NHS02NHR\ NHS02N(R')2, NR'S02NHR\ NR'S02N(R')2, C(0)NHN0H, C(0)NHN0R', C(0)NHS02R', C(NH)NH2, C(NH)NHR', C(NH)N(R')2 NHSO2NHR', NHS02N(CH3)R',.N(CH3)S02N(CH3)R', F, Cl, Br, I, CN, NO2, N3, OH, C(0)H, CHNOH, CHCNOCHj), CF3, C(0)OH, C(0)NH2 or C(0)OR^^; and Y' is H, CN, NO2, C(0)OH, F, Cl, Br, I, CF3, OCF3, CF2CF3, OCF2CF3, R", OR", C(0)R", C(0)0R'^ SR'\ SO2R", NH2, NHR'^ N(R'^)2, NHC(0)R'', C(0)NH2, C(0)NHR", C(0)N(R")2, NHS(0)R" or NHS02R'^; or 74 E' and Y\ together with the atoms to which they are attached, are benzene, naphthylene, heteroarene cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; and A^ B', and D' are independently selected H, R\ 0R\ SR', S(0)R\ SOZR', C(0)R\ C(0)0R', 0C(0)R\ NHR', N(R')2, C(0)NHR', C(0)N(R')2, NHC(0)R', NR'C(0)R', NHC(0)0R\ NR'C(0)0R', NHC(0)NH2, NHC(0)NHR', NHC(0)N(R')2, NR'C(0)NHR', NR'C(0)N(R')2, SO2NH2, S02NHR\ S02N(R')2. NHSOZR', NR'S02R\ NHSO2NHR', NHS02N(R')2, NR'S02NHR', NR'S02N(R')2, C(0)NHN0H, C(0)NHN0R\ C(0)NHS02R', C(NH)NH2, C(NH)NHR\ C(NH)N(R')2 NHS02NHR\ NHS02N(CH3)R\ N(CH3)S02N(CH3)R\ F, CI, Br, I, CN, N02,N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)0R'^; or Y' and B\ together with the atoms to which they are attached, are benzene, naphthylene, heteroarene cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; and A^ D\ and E^ are independenUy selected H, R\ 0R\ SR\ S(0)R\ SO2R', C(0)R\ C(0)0R', 0C(0)R', NHR', N(R')2, C(0)NHR', C(0)N(R')2, NHC(0)R', NR'C(0)R', NHC(0)0R\ NR'C(0)0R', NHC(0)NH2, NHC(0)NHR', NHC(0)N(R')2, NR'C(0)NHR', NR'C(0)N(R')2, SO2NH2, S02NHR\ S02N(R')2, NHSO2R', NR'S02R', NHSO2NHR', NHS02N(R')2, NR'S02NHR\ NR^S02N(R^)2, C(0)NHN0H, C(0)NHN0R\ C(0)NHS02R\ C(NH)NH2, C(NH)NHR\ C(NH)N(R')2 NHS02NHR\ NHS02N(CH3)R', N(CH3)S02N(CH3)R', F, CI, Br, I, CN, NO2.N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)0R"^; or A^ and B\ together with the atoms to which they are attached, are benzene, naphthylene, heteroarene cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; and D\ E\ and Y' are independenUy selected H, R', OR', SR\ S(0)R', SO2R', C(0)R', C(0)0R\ 0C(0)R\ NHR\ N(R')2, C(0)NHR\ C(0)N(R^)2, NHC(0)R\ NR^C(0)R\ NHC(0)0R\ NR^C(0)0R', NHC(0)NH2, NHC(0)NHR\ NHC(0)N(R')2, NR'C(0)NHR\ NR'C(0)N(R')2, SO2NH2, S02NHR\ S02N(R^)2, NHSO2R', NR'SOZR', NHSO2NHR', NHS02N(R')2, NR'S02NHR\ NR'S02N(R')2, C(0)NHN0H, C(0)NHN0R', C(0)NHS02R\ C(NH)NH2, C(NH)NHR\ C(NH)N(R')2 NHS02NHR\ NHS02N(CH3)R\ N(CH3)S02N(CH3)R\ F, Cl, Br, I, CN, NO2, N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)0R''^; or 75 A^ and D\ together with the atoms to which they are attached, are benzene, naphthalene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; and B', E\ and Y' are independently selected H, R\ OR', SR', S(0)R', SOIR', C(0)R\ C(0)0R\ 0C(0)R\ NHR', N(R^)2, C(0)NHR', C(0)N(R')2, NHC(0)R', NR'C(0)R', NHC(0)0R\ NR'C(0)0R', NHC(0)NH2, NHC(0)NHR', NHC(0)N(R')2, NR'C(0)NHR', NR'C(0)N(R')2, SO2NH2, SO2NHR', S02N(R')2, NHSO2R', NR'S02R', NHSO2NHR', NHS02N(R')2, NR'S02NHR\ NR^S02N(R')2, C(0)NHN0H, C(0)NHN0R', C(0)NHS02R\ C(NH)NH2, C(NH)NHR\ C(NH)N(R')2 NHS02NHR\ NHS02N(CH3)R\ N(CH3)S02N(CH3)R', F, CI, Br, I, CN, NO2.N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)0R'^; R' is R^ R^ R^ or R^ R'^ is cycloalkyl, cycloalkenyl or cycloalkynyl; R^ is phenyl, which is unfused or fused with benzene, heteroarene or R^^; R^^ is cycloalkane or heterocycloalkane; R^ is heteroaryl, which is unfused or fused with benzene, heteroarene or R^'^; R^'^ is cycloalkane or heterocycloalkane; R"* is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R"*^; R'*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^ is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R^ NC(R^'^)(R*^), R^, OR^, SR^ S(0)R^ S02R^ NHR^ N(R^)2, C(0)R^ C(0)NH2, C(0)NHR^ C(0)N(R^)2, NHC(0)R\ NR^C(0)R^ NHSO2R'', NHC(0)0R', SO2NH2, SOzNHR^ S02N(R'')2, NHC(0)NH2, NHC(0)NHR^ NHC(0)CH(CH3)NHC(0)CH(CH3)NH2,NHC(0)CH(CH3)NHC(0)CH(CH3)NHR',0H, (O), C(0)OH, N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I; R^ is C2-C5-spiroalkyl, each of which is unsubstituted or substituted with OH, (O), N3, CN, CF3, CF2CF3, F, CI, Br, I, NH2, NH(CH3) or N(CH3)2; R^^ and R*^ are independently selected alkyl or, together with the N to which they are attached, R^; R^ is aziridin-1-yl, azetidin-1-yl, pyrrolidin-1-yl or piperidin-1-yl, each having one CH2 moiety unreplaced or replaced with O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH; R^sR^R^R"'orR"; 76 R* is phenyl, which is unfused or fused with benzene, heteroarene or R^^; R^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R' is heteroaryl, which is unfused or fused with benzene, heteroarene or R^'^; R^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'° is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl each of which is unfused or fiised with benzene, heteroarene or R''*'^; R'"'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R" is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independentiy selected R'^ 0R'^ SR'^ S(0)R'^ SOZR'^ C(0)R'^ C0(0)R'^ OC(0)R'^ OC(0)OR'^ NH2, NHR'^ N(R'^)2, NHC(0)R'^ NR'^C(0)R'^ NHS(0)2R'^, NR'^S(0)2R'^ NHC(0)OR'^ NR^^C(0)OR'^ NHC(0)NH2, NHC(0)NHR'^ NHC(0)N(R'^)2, NR'^C(0)NHR'^ NR'^C(0)N(R'^)2, C(0)NH2, C(0)NHR'^ C(0)N(R'^)2, C(0)NHOH, C(0)NH0R'^ C(0)NHS02R'^ C(0)NR'^S02R'^ SO2NH2, S02NHR'^ S02N(R^^)2, C(0)H, C(0)0H, C(N)NH2, C(N)NHR'^ C(N)N(R'^)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I; R'2isR'^R'^R'^orR'^; R^^ is phenyl, which is unfused or fused with benzene, heteroarene or R"'^; R""^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R''* is heteroaryl, which is unfused or fiised with benzene, heteroarene or R''*'^; R''*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene, each of which is unfused or fused with benzene, heteroarene or R'^"^; R'^"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^^ is alkyl, alkenyl or alkynyl; R"isR^R'',R^''orR^'; R'* is phenyl, which is unfused or fused with benzene, heteroarene or R'*^; R'*"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' is heteroaryl, which is unfused or fiised with benzene, heteroarene or R'''^; R'^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^° is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl each of which is unfused or fused with benzene, heteroarene or R^""^; R^"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or diree of independently selected R^, OR^^ SR^^ S(0)R^^ S02R^, C(0)R^^ 77 C0(0)R", 0C(0)R^, 0C(0)0R^^ NHZ, NHR^^ N(R^^)2, NHC(0)R^^ NR^^C(0)R^^ NHS(0)2R^^ NR^^S(0)2R^^ NHC(0)OR^^ NR^^C(0)OR^^ NHC(0)NH2, NHC(0)NHR^^ NHC(0)N(R^^)2, NR^^C(0)NHR^^ NR^^C(0)N(R^^)2, C(0)NH2, C(0)NHR^^ C(0)N(R^^)2, C(0)NHOH, C(0)NH0R", C(0)NHS02R^^ C(0)NR^^S02R^^ SO2NH2, SO2NHR", S02N(R^^)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR^^ C(N)N(R^^)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I; R"isR",R^orR"; R^^ is phenyl, which is unfused or fused with benzene, heteroarene or R^'^; R^^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^* is heteroarene, which is unfused or fused with benzene, heteroarene or R^'*^; R^'*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^^ is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl each of which is unfused or fused with benzene, heteroarene or R^'^; R^^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; Z'isR^^orR"; z2isR2«,R2%rR'''; T}^ and i}^ are both absent or are taken together to form CH2, CH2CH2 or Z'^^; T}^^ is C2-C6-alkylene having one or two CH2 moieties replaced by NH, N(CH3), S, S(0)orS02; L' is a R", Q^\ SR", S(0)R", SO2R", C(0)R", C0(0)R", 0C(0)R", 0C(0)0R", NHR", C(0)NH, C(0)NR^^ C(0)NH0R", C(0)NHS02R^^ SO2NH, SO2NHR", C(N)NH, C(N)NHR"; R^* is phenylene, which is unfused or fused with benzene or heteroarene or R^*^; R^^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^^ is heteroarylene, which is unfused or fused with benzene or heteroarene or R^^"^; R^^"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^* is phenylene, which is unfused or fused with benzene, heteroarene or R^*"^; R^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' is heteroarylene, which is unfused or fused with benzene or heteroarene or R^''^; R^''^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene ; R^" is cycloalkylene, cycloalkenylene, heterocycloaDcylene or heterocycloalkenylene, each of which is unfused or fiised with benzene, heteroarene or R^'''^; R^^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^^ is a bond or R^'^' 78 R^^'^is alkylene, alkenylene, or alkynylene, each of which is unsubstituted or substituted with one or two or three independently selected R"^, OR"^, SR"^, S(0)R"^, SOaR"^, C(0)R^'^, C0(0)R"^, 0C(0)R"^, 0C(0)0R^'^, NH2, NHR^'^, N(R"^)2, NHC(0)R^™, NR"^C(0)R^™, NHS(0)2R^'®, NR"^S(0)2R"^, NHC(0)0R"^, NR"^C(0)0R^'^, NHC(0)NH2, NHC(0)NHR"^, NHC(0)N(R"^)2, NR"^C(0)NHR"^, NR"^C(0)N(R^™)2, C(0)NH2, C(0)NHR^^^, C(0)N(R"^)2, C(0)NH0H, C(0)NH0R^™, C(0)NHS02R"^, C(0)NR^™S02R"°, SO2NH2, S02NHR^^^, S02N(R^™)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR"®, C(N)N(R"®)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br and I substituents; R^^^ is alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl; zMsR^«,R^''orR^°; R^* is phenyl, which is unfused or fused with benzene, heteroarene or R^*^; R^*"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' is heteroaryl, which is unfused or fused with benzene, heteroarene or R^'"^; R^^"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'"' is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R'*°^; R'""^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; wherein the moieties represented by R and R are substituted (i.e., if Z and Z are absent) or further substituted (i.e., if Z''^ and T}^ are present) with one or two or three or four of independenUy selected R"", 0R'*\ SR"*', S(0)R'", S02R''\ C(0)R''\ C0(0)R'", OC(0)R''\ OC(0)OR'*\ NH2, NHR'", N(R'*')2, NHC(0)R'", NR'"C(0)R^', NHS(0)2R^', NR'*'S(0)2R''\ NHC(0)OR^', NR'"C(0)OR'*', NHC(0)NH2, NHC(0)NHR''\ NHC(0)N(R'*^)2, NR^^C(0)NHR'", NR^'C(0)N(R'")2, C(0)NH2, C(0)NHR'", C(0)N(R'")2, C(0)NHOH, C(0)NHOR''', C(0)NHS02R'", C(0)NR^'S02R'*\ SO2NH2, SO2NHR'", S02N(R'*')2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR^', C(N)N(R'")2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I; R^'isR^^R^^R^orR^^ R''^ is phenyl, which is unfused or fused with benzene, heteroarene or R'*^'^; R'*^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R"*^ is heteroaryl, which is unfused or fused with benzene, heteroarene or R''^'^; R'*^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; 79 R"*^ is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R**^; R'"'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'*^ is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R^, OR^^ SR^, S(0)R'•^ SOiR'^, C(0)R^, COCOR'*^ OCCOR'^, OC(0)OR'^, NHz, NHR^^, N(R''^)2, NHC(0)R'*^ NR**C(0)R^, NHS(0)2R^, NR^S(0)2R''^ NHC(0)OR^^ NR'**C(0)OR'^, NHC(0)NH2, NHC(0)NHR'*^ NHC(0)N(R''^)2, NR^C(0)NHR''^ NR^^C(0)N(R''^)2, C(0)NH2, C(0)NHR^, C(0)N(R'*^)2, C(0)NHOH, CCONHOR'^, C(0)NHS02R'*^ C(0)NR'**S02R'^, SO2NH2, SOzNHR'^, S02N(R'*^)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR'^, C(N)N(R''*)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I; R^* is alkyl, alkenyl, alkynyl, R''^ R^ or R^^; R"*^ is phenyl, which is unfused or fused with benzene, heteroarene or R"*^"^; R"*^"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R"** is heteroaryl, which is unfused or fused with benzene, heteroarene or R'**'^; R"**^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'*' is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R'"'^; R'*''^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; wherein the moieties represented by R'*^ R'*^, R''^ R"^^, R^, R'^^, R^\ R'*'"^, R^*, j^48A^ R"*', and R''^'^ are independently substituted with one or two or three or four of independently selected R*°, OR^", SR^°, S(0)R^°, S02R^'', C(0)R^°, CO(0)R^°, 0C(0)R^°, OC(0)OR^°, NHz, NHR^°, N(R^°)2, NHC(0)R^°, NR*°C(0)R^°, NHS(0)2R'", NR'°S(0)2R*°, NHC(0)0R''', NR^V(0)0R^", NHC(0)NH2, NfHC(0)NHR'°, NHC(0)N(R^°)2, NR^''C(0)NHR^°, NR^''C(0)N(R'°)2, C(0)NH2, C(0)NHR^'', C(0)N(R^°)2, C(0)NH0H, C(0)NHOR^^ C(0)NHS02R^, C(0)NR^S02R^°, SO2NH2, S02NHR^'', S02N(R^°)2, C(0)H, C(0)0H, C(N)NH2, C(N)NHR^°, C(N)N(R^°)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I; R^''isR^',R",R^^orR^''; R^' is phenyl, which is unfused or fused with benzene, heteroarene or R^''^; R*'"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^^ is heteroaryl, which is unfused or fused with benzene, heteroarene or R^^'^; R^^"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; 80 R^^ is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^^'^; R'^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^"* is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R^\ 0R^^ SR'^ S(0)R^^ S02R^^ C(0)R^^ CO(0)R^^ OC(0)R^^ OC(0)OR^^ NH2, NHR^^ N(R*^)2, NHC(0)R*^ NfR^^C(0)R^^ NHS(0)2R", NR^^S(0)2R^^ NHC(0)OR'^ NR'^C(0)0R", NHC(0)NH2. NHC(0)NHR'^ NHC(0)N(R^^)2, NR"C(0)NHR^^ NR^'C(0)N(R^^)2, C(0)NH2, C(0)NHR^^ C(0)N(R'^)2, C(0)NHOH, C(0)NHOR^^ C(0)NHS02R^^ C(0)NR^^S02R^^ SO2NH2, S02NHR^^ S02N(R*^)2, C(0)H, C(0)0H, C(N)NH2, C(N)NHR^^ C(N)N(R^')2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I; R^^ is alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl; and wherein each foregoing cychc moiety is independently unsubstituted, further unsubstituted, substituted or further substituted with one or two or three or four or five of independently selected R"^ R", OR", SR", S(0)R", SO2R", C(0)R", C0(0)R", 0C(0)R", 0C(0)0R", NH2, NHR", N(R")2, NHC(0)R", NR"C(0)R", NHS(0)2R", NR^^S(0)2R", NHC(0)0R", NR^^C(0)0R", NHC(0)NH2, NHC(0)NHR", NHC(0)N(R")2, NR^^C(0)NHR", NR"C(0)N(R^'')2, C(0)NH2, C(0)NHR", C(0)N(R")2, C(0)NHOH, C(0)NH0R", C(0)NHS02R", C(0)NR"S02R", SO2NH2, SO2NHR", S02N(R")2, C(0)H, C(0)0H, C(N)NH2, C(N)NHR", C(N)N(R^')2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I; R^^"^ is spirocyclyl; R^^isR^^R^^R«'orR*'; R^* is phenyl, which is unfused or fused with benzene, heteroarene or R^*^; R^*^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^^ is heteroaryl, which is unfused or fiised with benzene, heteroarene or R*'"^; R^''^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^ is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^^; R^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R^\ 0R^\ SR^^ S(0)R^^ S02R^^ C(0)R^^ C0(0)R^^ OC(0)R^\ 0C(0)0R^^ NH2, NHR^^ N(R^^)2, NHC(0)R^^ NR^^C(0)R^^ 81 NHS(0)2R^^ NR^^S(0)2R^^ NHC(0)OR^\ NR^^C(0)OR^^ NHC(0)NH2, NHC(0)NHR^^ NHC(0)N(R^^)2, NR*^C(0)NHR'*^ NR^^C(0)N(R^^)2, C(0)NH2, C(0)NHR^^ C(0)N(R*^)2, C(0)NHOH, C(0)NHOR*^ C(0)NHS02R^^ CCONR^^SOzR*^ SO2NH2, S02NHR^^ S02N(R^^)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR^\ C(N)N(R^^)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I; R^^isR^^R^,R^orR^; R^^ is phenyl, which is unfused or fused with benzene, heteroarene or R^^'^; R^^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^ is heteroaryl, which is unfused or fused with benzene, heteroarene or R^'^; R^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^^ is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R*^'^; R^^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^ is alkyl, aUcenyl or alkenyl, each of which is unsubstituted or substituted with one or two or three of independenUy selected R*^ 0R*\ SR^\ S(0)R*\ S02R*^ C(0)R*^ CO(0)R^\ OC(0)R*^ OC(0)OR^'', NH2, NHR^'', N(R^'')2, NHC(0)R*'', NR^''C(0)R^^ NHS(0)2R^^ NR*^S(0)2R^\ NHC(0)OR*\ NR^^C(0)OR*^ NHC(0)NH2, NHC(0)NHR*\ NHC(0)N(R^^)2, NR^^C(0)NHR*^ NR^^C(0)N(R^\, C(0)NH2, C(0)NHR^^ C(0)N(R*^)2, C(0)NHOH, C(0)NHOR^\ C(0)NHS02R^'', C(0)NR*''S02R^\ SO2NH2, S02NHR^^ S02N(R^')2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR^\ C(N)N(R^^)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I substituents; R^^ is alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl; wherein the moieties lepiesented by R"^, R^*, R^^ R^, R*^ R^, R*^ and R*^ are unsubstituted or substituted with one or two or three or four of independently selected R^, OR^, SR^, S(0)R^, S02R^, C(0)R^, CO(0)R^, OC(0)R^, 0C(0)0R^, NH2, NHR^, N(R^)2, NHC(0)R^, NR^C(0)R^, NHS(0)2R^, NR^S(0)2R^, NHC(0)0R^*, NR^C(0)OR^, NHC(0)NH2, NHC(0)NHR^, NHC(0)N(R^)2, NR^C(0)NHR^, NR^C(0)N(R^)2, C(0)NH2, C(0)NHR^, C(0)N(R**)2, C(0)NH0H, C(0)NHOR^, C(0)NHS02R^, C(0)NR^S02R^, SO2NH2, SOzNHR^, S02N(R^)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR^, C(N)N(R^)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I; R^isR^,R™,R^'orR'^ 82 R^^ is phenyl, which is unfused or fused with benzene, heteroarene or R^"^; R*"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'° is heteroaryl, which is unfused or fused with benzene, heteroarene or R'"'^; R^"'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^''^; R^''^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'^ is alkyl, alkenyl or alkenyl, each of which is unsubstituted or substituted with one or two or three of independenUy selected R", OR", SR", S(0)R", S02R''^ C(0)R''^ C0(0)R", 0C(0)R'^ 0C(0)0R", NH2. NHR", N(R")2, NHC(0)R", NR"C(0)R'^ NHS(0)2R", NR"S(0)2R", NHC(0)0R''^ NR"C(0)0R", NHC(0)NH2, NHC(0)NHR^^ NHC(0)N(R")2, NR"C(0)NHR^^ NR"C(0)N(R")2, C(0)NH2, C(0)NHR'^ C(0)N(R")2, C(0)NHOH, C(0)NH0R", C(0)NHS02R", C(0)NR"S02R", SO2NH2, SO2NHR", S02N(R")2, C(0)H, C(0)0H, C(N)NH2, C(N)NHR", C(N)N(R")2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I; R^^ is alkyl, alkenyl, alkenyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl; and the moieties represented by R , R , and R are unsubstituted or substituted with one or two or three or four of independently selected NH2, C(0)NH2, C(0)NHOH, SO2NH2, CF3, CF2CF3, C(0)H, C(0)OH, C(N)NH2, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I. Another embodiment of this invention pertains to compounds of Formula (I), wherein A' is N or C(A^); A^ is H, R\ 0R\ SR', S(0)R\ S02R\ C(0)R', C(0)0R\ 0C(0)R', NHR', N(R')2, C(0)NHR\ C(0)N(R')2, NHC(0)R', NR'C(0)R', NHC(0)0R\ NR'C(0)0R\ NHC(0)NH2, NHC(0)NHR', NHC(0)N(R')2, NR'C(0)NHR', NR'C(0)N(R')2, SO2NH2, S02NHR\ S02N(R')2, NHS02R\ NR'S02R\ NHSOZNHR', NHS02N(R')2, NR'S02NHR\ NR'S02N(R')2. C(0)NHN0H, C(0)NHN0R', C(0)NHS02R', C(NH)NH2, C(NH)NHR', C(NH)N(R')2 NHSO2NHR', NHS02N(CH3)R\ N(CH3)S02N(CH3)R', F, Cl, Br, I, CN, NO2, N3, OH, C(0)H, CHNOH, CHCNOCHj), CF3, C(0)OH, C(0)NH2 or C(0)OR^^; B' is H, R', OR', SR\ S(0)R\ S02R\ C(0)R\ C(0)0R', 0C(0)R', NHR', N(R')2, C(0)NHR\ C(0)N(R')2, NHC(0)R\ NR'C(0)R\ NHC(0)0R\ NR'C(0)0RNHC(0)NH2, NHC(0)NHR\ NHC(0)N(R')2, NR'C(0)NHR', NR'C(0)N(R')2, SO2NH2, S02NHR\ S02N(R')2, NHS02R\ NR'S02R', NHS02NHR\ NHS02N(R')2, NR'S02NHR83 NR'S02N(R')2, C(0)NHN0H, C(0)NHN0R', C(0)NHS02R', C(NH)NH2, C(NH)NHR\ C(NH)N(R')2 NHS02NHR\ NHS02N(CH3)R\ N(CH3)S02N(CH3)R', F, CI, Br, I, CN, NO2, N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)0R'^; D' is H, R\ OR', SR', S(0)R', SOZR', C(0)R', C(0)0R', 0C(0)R', NHR', N(R')2, C(0)NHR\ C(0)N(R')2, NHC(0)R\ NR'C(0)R\ NHC(0)0R\ NR'C(0)0R', NHC(0)NH2, NHC(0)NHR', NHC(0)N(R')2, NR'C(0)NHR', NR'C(0)N(R')2, SO2NH2, S02NHR\ S02N(R')2, NHSO2R', NR'S02R\ NHSO2NHR', NHS02N(R')2, NR'S02NHR\ NR'S02N(R')2, C(0)NHN0H, C(0)NHN0R', C(0)NHS02R', C(NH)NH2, C(NH)NHR', C(NH)N(R')2 NHSO2NHR', NHS02N(CH3)R\ N(CH3)S02N(CH3)R', F, CI, Br, I, CN, NO2, N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)0R'^; E' is H, R', OR', SR', S(0)R', SO2R', C(0)R', C(0)0R', 0C(0)R', NHR', N(R')2, C(0)NHR', C(0)N(R')2, NHC(0)R', NR'C(0)R', NHC(0)0R', NR'C(0)0R', NHC(0)NH2, NHC(0)NHR', NHC(0)N(R')2, NR'C(0)NHR', NR'C(0)N(R')2, SO2NH2, SO2NHR', S02N(R')2, NHSO2R', NR'S02R', NHSO2NHR', NHS02N(R')2, NR'SOINHR', NR'S02N(R')2, C(0)NHN0H, C(0)NHN0R', C(0)NHS02R', C(NH)NH2, C(NH)NHR', C(NH)N(R')2 NHSO2NHR', NHS02N(CH3)R',.N(CH3)S02N(CH3)R', F, CI, Br, I, CN, NO2, N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)0R'^; and Y' is H, CN, NO2, C(0)OH, F, CI, Br, I, CF3, OCF3, CF2CF3, OCF2CF3, R'^ 0R'\ C(0)R'^ C(0)0R'^ SR'^ S02R'\ NH2, NHR'^ N(R'^)2, NHC(0)R", C(0)NH2, C(0)NHR", C(0)N(R'')2, NHS(0)R'^ or NHSO2R''; or E' and Y', together with the atoms to which they are attached, are benzene, naphthylene, heteroarene cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; and A^ B', and D' are independenUy selected H, R', OR', SR', S(0)R', SO2R', C(0)R', C(0)0R', 0C(0)R', NHR', N(R')2, C(0)NHR', C(0)N(R')2, NHC(0)R', NR'C(0)R', NHC(0)0R', NR'C(0)0R', NHC(0)NH2, NHC(0)NHR', NHC(0)N(R')2, NR'C(0)NHR', NR'C(0)N(R')2, SO2NH2, SO2NHR', S02N(R')2, NHSO2R', NR'SOZR', NHSO2NHR', NHS02N(R')2, NR'S02NHR', NR'S02N(R')2, C(0)NHN0H, C(0)NHN0R', C(0)NHS02R', C(NH)NH2, C(NH)NHR', C(NH)N(R')2 NHSO2NHR', NHS02N(CH3)R', N(CH3)S02N(CH3)R', F, CI, Br, I, CN, N02,N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)0R"^; or Y and B , together with the atoms to which they are attached, are benzene, naphthylene, heteroarene cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; and 84 A^ D', and E^ are independently selected H, R\ 0R\ SR', S(0)R\ SO2R', C(0)R\ C(0)0R\ 0C(0)R\ NHR\ N(R')2, C(0)NHR', C(0)N(R')2, NHC(0)R', NR'C(0)R\ NHC(0)0R\ NR'C(0)0R', NHC(0)NH2, NHC(0)NHR', NHC(0)N(R')2, NR'C(0)NHR', NR'C(0)N(R')2, SO2NH2, S02NHR\ S02N(R')2, NHS02R\ NR'SOZR', NHSO2NHR', NHS02N(R')2, NR'S02NHR\ NR'S02N(R')2, C(0)NHN0H, C(0)NHN0R\ C(0)NHS02R', C(NH)NH2, C(NH)NHR\ C(NH)N(R^)2 NHS02NHR\ NHS02N(CH3)R', N(CH3)S02N(CH3)R', F, CI, Br, I, CN, N02,N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(P)OR^\ or A^ and B', together with the atoms to which they are attached, are benzene, naphthylene, heteroarene cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; and D', E', and Y' are independently selected H, R', OR', SR', S(0)R', SO2R', C(0)R', C(0)0R\ 0C(0)R\ NHR\ N(R')2, C(0)NHR', C(0)N(R')2, NHC(0)R', NR'C(0)R\ NHC(0)0R\ NR'C(0)0R', NHC(0)NH2, NHC(0)NHR\ NHC(0)N(R')2, NR'C(0)NHR', NR'C(0)N(R')2, SO2NH2, S02NHR\ S02N(R')2, NHS02R\ NR'S02R', NHSO2NHR', NHS02N(R')2, NR'S02NHR\ NR'S02N(R')2, C(0)lSrHNOH, C(0)NHN0R', C(0)NHS02R', C(NH)NH2, C(NH)NHR\ C(NH)N(R')2 NHS02NHR\ NHS02N(CH3)R\ N(CH3)S02N(CH3)R', F, CI, Br, I, CN, NO2, N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or CCOOR'"^; or A^ and D\ together with the atoms to which they are attached, are benzene, naphthalene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; and B\ E\ and Y' are independently selected H, R\ 0R\ SR', S(0)R\ S02R\ C(0)R\ C(0)0R\ 0C(0)R\ NHR\ N(R')2, C(0)NHR\ C(0)N(R')2, NHC(0)R\ NR'C(0)R\ NHC(0)0R\ NR'C(0)0R', NHC(0)NH2, NHC(0)NHR', NHC(0)N(R')2, NR'C(0)NHR', NR'C(0)N(R')2, SO2NH2, S02NHR\ S02N(R')2, NHS02R\ NR^S02R\ NHS02NHR\ NHS02N(R')2, NR'S02NHR\ NR'S02N(R')2, C(0)NHN0H, C(0)NHN0R', C(0)NHS02R\ C(NH)NH2, C(NH)NHR\ C(NH)N(R^)2 NHS02NHR\ NHS02N(CH3)R\ N(CH3)S02N(CH3)R\ F, CI, Br, I, CN, N02,N3, OH, C(0)H, CHNOH, CHCNOCHj), CF3, C(0)OH, C(0)NH2 or C(0)0R'^; R'isR^R^R''orR^; R^^ is cycloalkyl, cycloalkenyl or cycloalkynyl; R^ is phenyl, which is unfused or fused with benzene, heteroarene or R^'^; R^"^ is cycloalkane or heterocycloalkane; 85 R^ is heteroaryl, which is unfused or fused with benzene, heteroarene or R^"^; R^'^ is cycloalkane or heterocycloalkane; R'' is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fiised with benzene, heteroarene or R'''^; R'*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^ is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independenUy selected R^ NC(R*''^)(R^^), R'', 0R\ SR\ S(0)R^ SOiR^ NHR^ N(R^)2, C(0)R\ C(0)NH2, C(0)NHR^ C(0)N(R^)2, NHC(0)R', NR'C(0)R^ NHSO2R'', NHC(0)0R\ SO2NH2, SO2NHR'', S02N(R^)2, NHC(0)NH2, NHC(0)NHR\ NHC(0)CH(CH3)NHC(0)CH(CH3)NH2,NHC(0)CH(CH3)NHC(0)CH(CH3)NHR',0H, (O), C(0)OH, N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I; R^ is Cz-Cs-spiroalkyl, each of which is unsubstituted or substituted with OH, (O), N3, CN, CF3, CF2CF3, F, CI, Br, I, NH2, NH(CH3) or N(CH3)2; R^"^ and R^^ are independently selected alkyl or, together with the N to which they are attached, R^; R^ is aziridin-1-yl, azetidin-1-yl, pyrrolidin-1-yl or piperidin-1-yl, each having one CH2 moiety unreplaced or replaced with O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH; R'isR^R^R'%rR"; R* is phenyl, which is unfused or fused with benzene, heteroarene or R*^; R*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R' is heteroaryl, which is unfused or fused with benzene, heteroarene or R^'^; R^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'*' is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl each of which is unfused or fused with benzene, heteroarene or R'""^; R'""^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R" is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R'^ OR'^ SR'^ S(0)R'^ S02R'^ C(0)R^^ CO(0)R'^ 0C(0)R'^ OC(0)OR'^ NH2, NHR'^ N(}0\, NHC(0)R'^ NR'^C(0)R'^ NHS(0)2R'^ NR'^S(0)2R'^ NHC(0)0R'^ NR'^C(0)0R'^ NHC(0)NH2, NHC(0)NHR'^ NHC(0)N(R'^)2, NR'^C(0)NHR'^ NR'^C(0)N(R'^)2, C(0)NH2, C(0)NHR'^ C(0)N(R'^)2, C(0)NHOH, C(0)NHOR'^ C(0)NHS02R'^ C(0)NR'^S02R'^ SO2NH2, S02NHR'^ S02N(R'^)2, C(0)H, C(0)0H, C(N)NH2, C(N)NHR'^ C(N)N(R'^)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3. CF2CF3, OCF3, OCF2CF3, F, CI, Br or I; R'^isR",R'^R'^orR'^ 86 R'^ is phenyl, which is unfused or fused with benzene, heteroarene or R'^'^; R'^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^"* is heteroaryl, which is unfused or fused with benzene, heteroarene or R''*'^; R^'*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene, each of which is unfused or fused with benzene, heteroarene or R'^"^; R'^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'^ is alkyl, alkenyl or alkynyl; R"isR'«,R'',R^%rR^'; R^* is phenyl, which is unfused or fused with benzene, heteroarene or R'*^; R'*"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R" is heteroaryl, which is unfused or fused with benzene, heteroarene or R'^'^; R''^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^*' is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl each of which is unfused or fused with benzene, heteroarene or R^°^; R^°^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R^, 0R^^ SR^^ S(0)R", S02R^, C(0)R^^ C0(0)R", OC(0)R^^ OC(0)OR^^ NH2, NHR^^ N(R")2, NHC(0)R", NR^^C(0)R^^ NHS(0)2R^^ NR^^S(0)2R^^ NHC(0)OR^^ NR^^C(0)OR^^ NHC(0)NH2, NHC(0)NHR^^ NHC(0)N(R^^)2, NR^^C(0)NHR^^ NR^^C(0)N(R^^)2, C(0)NH2, C(0)NHR^^ C(0)N(R^^)2, C(0)NHOH, C(0)NHOR^^ C(0)NHS02R^^ C(0)NR^^S02R^^ SO2NH2, SOzNHR^^ S02N(R^^)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR^^ C(N)N(R^^)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I; R22isR^,R2%rR^^ R^^ is phenyl, which is unfused or fused with benzene, heteroarene or R^^"^; R^^"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^ is heteroarene, which is unfused or fused with benzene, heteroarene or R^"*^; R^"*"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^^ is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl each of which is unfused or fused with benzene, heteroarene or R^^'^; R^^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; Z'isR^^orR"; Z^isR2^R^'orR^''; 87 Z'"^ and Z^'^ are both absent or are taken together to forai CH2, CH2CH2 or Z'^"^; T}^^ is C2-C6-alkylene having one or two CH2 moieties replaced by NH, NCCHs), S, S(0)orS02; L' is a R", OR", SR", S(0)R", SO2R", C(0)R", C0(0)R", 0C(0)R", 0C(0)0R", NHR", C(0)NH, C(0)NR", C(0)NH0R", C(0)NHS02R", SO2NH, SO2NHR", C(N)NH, C(N)NHR"; R^^ is phenylene, which is unfused or fused with benzene or heteroarene or R^*"^; R^^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' is heteroarylene, which is unfused or fused with benzene or heteroarene or R^^'^; R^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^* is phenylene, which is unfused or fused with benzene, heteroarene or R^*"^; R^"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' is heteroarylene, which is unfused or fused with benzene or heteroarene or R^^^; R^'"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene ; R^° is cycloalkylene, cycloalkenylene, heterocycloalkylene or heterocycloalkenylene, each of which is unfused or fused with benzene, heteroarene or R ; R is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R"isabondorR"^= R^^^is alkylene, alkenylene, or alkynylene, each of which is unsubstituted or substituted with one or two or three independently selected R"^, OR"^, SR"®, S(0)R"^, SOZR"^, C(0)R"^, C0(0)R"^, 0C(0)R"^, 0C(0)0R"^, NH2, NHR"^, N(R"^)2, NHC(0)R"^, NR"^C(0)R"^, NHS(0)2R^™, NR"^S(0)2R"^, NHC(0)0R"^, NR"^C(0)0R"^, NHC(0)NH2, NHC(0)NHR"^, NHC(0)N(R"^)2, NR"^C(0)NHR"^, NR"^C(0)N(R"^)2, C(0)NH2, C(0)NHR"^, C(0)N(R"°)2, C(0)NH0H, C(0)NH0R"^, C(0)NHS02R"^, C(0)NR"^S02R"^, SO2NH2, SOZNHR"^, S02N(R"^)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR"^, C(N)N(R"'*)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br and I substituents; R^^^ is alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl; zMsR^«,R''orR^°; R^* is phenyl, which is unfused or fused with benzene, heteroarene or R^*'^; R^*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' is heteroaryl, which is unfused or fused with benzene, heteroarene or R^''^; R^^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; 88 R'*° is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, hetenoaiene or R'*"^; R'*^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; wherein the moieties represented by R^* and R^'are substituted with OR"*'; R^MsR^^R^^R^orR^^ R"*^ is phenyl, which is unfused or fused with benzene, heteroarene or R"*^^; R'*^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'*^ is heteroaryl, which is unfused or fused with benzene, heteroarene or R'*^'^; R"*^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R** is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R''^'^; R'*^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'*^ is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independenUy selected R'^, 0R*^ SR*^ S(0)R*^ S02R'^, C(0)R^, CO(0)R''^ OC(0)R'^, OCCOPR"^, NH2, NHR'*^ N(R'*^)2, NHCCOR'^, NR'*^C(0)R'^, NHS(0)2R''^ NR^S(0)2R'^, NHC(0)OR'•^ NR'*^C(0)OR'*^, NHC(0)NH2, NHC(0)NHR'•^ NHC(0)N(R'^)2, NR'**C(0)NHR^, NR'^C(0)N(R''*)2, C(0)NH2, C(0)NHR^, C(0)N(R'*^)2, C(0)NHOH, CCONHOR'^^ C(0)NHS02R^^ C(0)NR''*S02R^^ SO2NH2, S02NHR''^ S02N(R*^)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR'^, C(N)N(R%, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I; R^^ is alkyl, alkenyl, alkynyl, R^\ R"^ or R''^ R"*^ is phenyl, which is unfused or fused with benzene, heteroarene or R''^'^; R**^"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R"** is heteroaryl, which is unfused or fused with benzene, heteroarene or R'**'^; R'**'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R"' is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R'*''^; R'"'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; wherein the moieties represented by R''^ R*^^, R^^ R"^^, R**, R*^^, R^'', R''"'^, R^*, jj48A^ R"', and R'*^^ independently substituted with one or two or three or four of independendy selected R^°, 0R'°, SR^°, S(0)R^°, S02R^°, C(0)R^°, CO(0)R^°, 0C(0)R^'', OC(0)OR^", NH2, NHR^", N(R^°)2, NHC(0)R'°, NR*°C(0)R^", NHS(0)2R^'', NR^°S(0)2R^°, NHC(0)0R'°, NR^°C(0)0R'^ NHC(0)NH2, NHC(0)NHR'°, NHC(0)N(R^'^)2, NR*''C(0)NHR*°, NR^''C(0)N(R^°)2, C(0)NH2, C(0)NHR^°, C(0)N(R^°)2, C(0)NH0H, 89 C(0)NHOR^'', C(0)NHS02R^, C(0)NR'°S02R^'', SO2NH2, SOzNHR^", S02N(R^'')2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR'°, C(N)N(R^°)2, CNOH, CNOCHj.OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I; R'°isR^^R^^R^^orR^; R^' is phenyl, which is unfused or fused with benzene, heteroarene or R^'"^; R^''^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^^ is heteroaryl, which is unfused or fused with benzene, heteroarene or R^^'^; R^^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^^ is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^^"^; R^^"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'"* is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R^^ 0R'^ SR'^ S(0)R", S02R^^ C(0)R^^ CO(0)R^^ OC(0)R^^ OC(0)OR^^ NH2, NHR^^ N(R'^)2, NHC(0)R^^ NR^^C(0)R^^ NHS(0)2R^^ NR^*S(0)2R^^ NHC(0)OR^^ NR^^C(0)OR^^ NHC(0)NH2, NHC(0)NHR^^ NHC(0)N(R^^)2, NR^^C(0)NHR'^ NR^'C(0)N(R^^)2, C(0)NH2, C(0)NHR^^ C(0)N(R'^)2, C(0)NHOH, C(0)NHOR^^ C(0)NHS02R'^ C(0)NR^^S02R'^ SO2NH2, S02NHR^^ S02N(R^^)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR", C(N)N(R'^)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I; R^^ is alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl; and wherein each foregoing cyclic moiety is independently unsubstituted, further unsubstituted, substituted or further substituted with one or two or three or four or five of independently selected R"'^, R", OR", SR", S(0)R", SO2R", C(0)R^', C0(0)R", 0C(0)R", 0C(0)0R", NH2, NHR^^ N(R")2, NHC(0)R", NR"C(0)R", NHS(0)2R", NR"S(0)2R", NHC(0)0R", NR"C(0)0R", NHC(0)NH2, NHC(0)NHR", NHC(0)N(R")2, NR^^C(0)NHR", NR^^C(0)N(R")2, C(0)NH2, C(0)NHR*\ C(0)N(R")2, C(0)NH0H, C(0)NH0R", C(0)NHS02R^', C(0)NR"S02R", SO2NH2, SO2NHR", S02N(R")2, C(0)H, C(0)0H, C(N)NH2, C(N)NHR", C(N)N(R'')2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I; R^^sR^^R^^R«'orR^^ R^^"^ is spirocyclyl; R'* is phenyl, which is unfused or fused with benzene, heteroarene or R^*"^; R^^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; 90 R^' is heteroaryl, which is unfused or fused with benzene, heteroarene or R^''^; R^''^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^ is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfiised or fused with benzene, heteroarene or R^'^; R*''^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^^ is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R*\ OR^^ SR*^ S(0)R*^ SOzR^^, C(0)R*^ CO(0)R^^ OC(0)R^^ OC(0)OR^^ NH2, NHR^^ N(R^^)2, NHC(0)R*^ NR^^C(0)R^^ NHS(0)2R^^ NR^^S(0)2R^^ NHC(0)OR^\ NR^^C(0)OR^^ NHC(0)NH2, NHC(0)NHR^^ NHC(0)N(R^^)2, NR^^C(0)NHR^^ NR^^C(0)N(R^^)2, C(0)NH2, C(0)NHR^, C(0)N(R^^)2, C(0)NHOH, C(0)NHOR^^ C(0)NHS02R'*^ C(0)NR*^S02R^^ SO2NH2, S02NHR^^ S02N(R*^)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR*^ C(N)N(R%, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3. OCF2CF3, F, CI, Br or I; R^'isR^^R^,R**orR^; R^^ is phenyl, which is unfused or fused with benzene, heteroarene or R^'^; R^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R" is heteroaryl, which is unfused or fused with benzene, heteroarene or R^"^; R^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^^ is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^^'^; R^^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^ is alkyl, alkenyl or alkenyl, each of which is unsubstituted or substituted with one or two or three of independenUy selected R^\ OR^'', SR^'', S(0)R^\ S02R^\ C(0)R^\ CO(0)R*'', OC(0)R*^ OC(0)OR*^ NH2, NHR^\ NiR^\, NHC(0)R*\ NR*'C(0)R*\ NHS(0)2R*^ NR*^S(0)2R^'', NHC(0)OR^^ NR^'C(0)OR*^ NHC(0)NH2, NHC(0)NHR^^ NHC(0)N(R^^)2, NR^'C(0)NHR^'', NR^^C(0)N(R^'')2, C(0)NH2, C(0)NHR*'', C(0)N(R*')2, C(0)NHOH, C(0)NHOR^\ C(0)NHS02R^^ C(0)NR*'S02R^\ SO2NH2, S02NHR*^ S02N(R*')2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR*^ C(N)N(R*^)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I substituents; R^^ is alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl; wherein the moieties represented by R^''^, R*^ R^', R^, R^^ R", R*^ and R^^ are unsubstituted or substituted with one or two or three or four of independenUy selected R^, OR^, SR^, S(0)R^, SOzR**, C(0)R^, CO(0)R^, OC(0)R^, 0C(0)0R^, NH2, NHR^, 91 N(R^*)2, NHC(0)R^, NR^C(0)R^, NHS(0)2R*^ NR*'S(0)2R^, NHC(0)0R'*, NR^C(0)OR^, NHC(0)NH2, NHC(0)NHR^, NHC(0)N(R^)2, NR^C(0)NHR^, NR^C(0)N(R^)2, C(0)NH2, C(0)NHR^, C(0)N(R^)2, C(0)NHOH, C(0)NHOR^, C(0)NHS02R^, C(0)NR^S02R^, SO2NH2, SO2NHR*, S02N(R^)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR^, C(N)N(R^)2, CNOH, CNOCH3, OH, (0), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I; R^isR^,R''',R''orR^2; R^' is phenyl, which is unfiised or fused with benzene, heteroarene or R®'^; R^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'° is heteroaryl, which is unfused or fused with benzene, heteroarene or R™'^; R^''^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^^^; R^*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^^ is alkyl, alkenyl or alkenyl, each of which is unsubstituted or substituted with one or two or three of independently selected R", OR", SR", S(0)R'^ SO2R", C(0)R^^ C0(0)R", OC(0)R^^ 0C(0)0R", NH2, NHR", N(R^^)2, NHC(0)R", NR'^C(0)R^^ NHS(0)2R^^ NR"S(0)2R", NHC(0)0R", NR"C(0)0R", hfHC(0)NH2, NHC(0)NHR", NHC(0)N(R")2, NR^^C(0)NHR", NR"C(0)N(R")2, C(0)NH2, C(0)NHR''^ C(0)N(R^')2, C(0)NHOH, C(0)NH0R", C(0)NHS02R", C(0)NR"S02R", SO2NH2, SO2NHR", S02N(R")2, C(0)H, C(0)0H, C(N)NH2, C(N)NHR", C(N)N(R^\, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I; R^^ is alkyl, alkenyl, alkenyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl; and the moieties represented by R®, R™, and R^' are unsubstituted or substituted with one or two or three or four of independently selected NH2, C(0)NH2, C(0)NHOH, SO2NH2, CF3, CF2CF3, C(0)H, C(0)OH, C(N)NH2, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I. In one embodiment of Formula (I), A' is N. In another embodiment of Formula (I), A' is C(A^). In another embodiment of Formula (I), A' is C(A^); and A^ is H. In one embodiment of Formula (I), B' is NHC(0)R', NHSO2R', 0R\ or NHR'. In another embodiment of Formula (I), A' is C(A^); A^ is H; and B^ is NHR\ In another embodiment of Formula (I), A' is C(A^); A^ is H; and B' is 0R^ In another embodiment of Formula (I), A^ is C(A^); A^ is H; and B' is NHS02R^ In another embodiment of Formula 92 (I), A' is C(A^); A^ is H; and B' is NHC(0)R\ In another embodiment of Formula (I), A' is C(A^) or N; A^ is H; and B' is NHR^ In another embodiment of Formula (I), A' is C(A^) or N; A^ is H; and B^ is OR'. In another embodiment of Formula (I), A' is C(A^) or N; A^ is H; and B' is NHSO2R*. In another embodiment of Formula (I), A' is C(A^) or N; A^ is H; and B' is NHC(0)R'. In one embodiment of Formula (I), D' is H. In another embodiment of Formula (I), A' is C(A^); A^ is H; B' is NHR'; and D' is H. hi another embodiment of Formula (I), A' is C(A^); A^ is H; B' is OR'; and D' is H. In another embodiment of Formula (I), A' is C(A^); A^ is H; B' is NHSO2R'; and D' is H. In another embodiment of Formula (I), A' is C(A^); A^ is H; B' is NHC(0)R' ; and D' is H. hi another embodiment of Formula (I), A' is C(A^) or N; A^ is H; B' is NHR'; and D' is H. In another embodiment of Formula (I), A' is C(A^) or N; A^ is H; B' is OR'; and D' is H. In another embodiment of Formula (I), A' is C(A^) or N; A^ is H; B' is NHSO2R'; and D' is H. In another embodiment of Formula (I), A' is C(A^) or N; A^ is H; B' is NHC(0)R'; and D' is H. In one embodiment of Formula (I), E' is H. In another embodiment of Formula (I), A' is C(A^); A^ is H; B' is NHR'; D' is H; and E' is H. In another embodiment of Formula (I), A' is C(A^); A^ is H; B' is OR'; D' is H; and E' is H. hi another embodiment of Formula (I), A' is C(A^); A^ is H; B' is NHSO2R'; D' is H; and E' is H. In another embodiment of Formula (I), A' is C(A^); A^ is H; B' is NHC(0)R'; D' is H; and E' is H. hi another embodiment of Formula (I), A' is C(A^) or N; A^ is H; B' is NHR'; D' is H; and E' is H. hi another embodiment of Formula (I), A' is C(A^) or N; A^ is H; B' is OR'; D' is H; and E' is H. In another embodiment of Formula (I), A' is C(A^) or N; A^ is H; B' is NHSO2R'; D' is H; and E' is H. In another embodiment of Formula (I), A' is C(A^) or N; A^ is H; B' is NHC(0)R' ; D' is H; and E' is H. In one embodiment of Formula (I), Y' is H, CN, NO2, F, CI, Br, CF3, R'^, or SO2R". In another embodiment of Formula (I), Y' is NO2. In anodier embodiment of Formula (I), Y' is CI. In another embodiment of Formula (I), Y' is S02R'^; wherein R'^ is as defined herein. In another embodiment of Formula (I), Y' is S02R'^; wherein R" is alkyl. In another embodiment of Formula (I), Y' is R"; wherein R" is alkynyl. In another embodiment of Formula (I), A' is C(A^); A^ is H; B' is NHR'; D' is H; E' is H; and Y' is NO2 or SOaR'^; wherein R'^ is alkyl or alkynyl. In another embodiment of Formula (I), A' is C(A^); A^ is H; B' is NHR'; D' is H; E' is H; and Y' is NO2. In another embodiment of Formula (I), A' is C(A^); A^ is H; B' is NHR'; D' is H; E' is H; and Y* is SOZR'^ wherein R" is alkyl substituted with three F. In another embodiment of Formula (I), A' is C(A^); A^ is H; B' is 93 OR'; D' is H; E' is H; and Y' is CI. In another embodiment of Formula (I), A' is C(A^) or N; A^ is H; B' is NHR'; D' is H; E' is H; and Y' is NO2 or SO2R"; wherein R'' is alkyl or alkynyl. In another embodiment of Formula (I), A' is C(A^) or N; A^ is H; B' is NHR^; D' is H; E' is H; and Y' is NO2. In another embodiment of Formula (I), A' is C(A^) or N; A^ is H; B' is NHR'; D' is H; E' is H; and Y' is SOIR'^ wherein R" is alkyl substituted with three F. In another embodiment of Formula (I), A' is C(A^) or N; A^ is H; B' is OR'; D' is H; E' is H; and Y' is CI. In one embodiment of Formula (I), R' is R^, and R^ is phenyl. In another embodiment of Formula (I), R' is R^ and R^ is phenyl which is substituted with NO2, and NHR^In one embodiment of Formula (I), R' is R'* or R^. In one embodiment of Formula (I), R' is R\ In one embodiment of Formula (I), R' is R^. In one embodiment of Formula (I), R' is R''; and R'* is cycloalkyl, or heterocycloalkyl. In one embodiment of Formula (I), R' is R"*; and R" is cycloalkyl. In one embodiment of Formula (I), R' is R"*; and R'* is heterocycloalkyl. In one embodiment of Formula (I), R' is R'*; and R'* is cycloalkyl; wherein R'' is unsubstituted or substituted as defined herein. In another embodiment of Formula (I), R' is R'*; and R'* is cycloalkyl; wherein the cycloalkyl ring is substituted as defined herein. In another embodiment of Formula (I), R' is R'*; and R"* is cycloalkyl; wherein the cycloalkyl ring is substituted with R^^, NHR^^, or N(R'^)2. In another embodiment of Formula (I), R' is R'*; and R'* is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and wherein the cyclohexyl ring is substituted with R^^; and R^' is R^. In another embodiment of Formula (I), R' is R"; R'' is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and wherein the cyclohexyl ring is substituted with R^^; R^' is R^; and R^ is heterocycloalkyl. In another embodiment of Formula (I), R' is R"*; R'* is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and wherein the cyclohexyl ring is substituted with R^^; R^' is R*; R is heterocycloalkyl; wherein the heterocycloalkyl ring is morpholinyl or piperazinyl. In another embodiment of Formula (I), R' is R''; and R'' is cycloalkyl; wherein the cycloalkyl ring is substituted with N(R^^)2. In another embodiment of Formula (I), R' is R'*; and R'* is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and wherein the cyclohexyl ring is substituted with N(R'^)2. In another embodiment of Formula (I), R' is R"*; and R"* is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and wherein the cyclohexyl ring is substituted with N(R^^)2, R" is R", and R^' is alkyl which is unsubstituted. In another embodiment of Formula (I), R' is R''; and R'* is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and wherein the cyclohexyl ring is substituted with N(R^^)2, R^^ is R*^, and R*" is cycloalkyl which is unsubstituted. In another embodiment of Formula (I), R' is R'*; and R'* is 94 cycloalkyl; wherein the cycloalkyl ring is substituted with NHR*^. In another embodirnent of Formula (I), R' is R"*; and R'' is cycloallQ'l; wherein the cycloalkyl ring is cyclohexyl; and wherein the cyclohexyl ring is substituted with NHR^^. In another embodiment of Formula (I), R' is R"*; and R'* is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and wherein the cyclohexyl ring is substituted with NHR^', R*' is R^, and R^ is heterocycloalkyl which is unsubsdtuted. In one embodiment of Formula (I), R' is R*; and R'* is heterocycloalkyl; wherein R'' is unsubstituted or substituted as defined herein. In another embodiment of Formula (I), R' is R''; and R"* is heterocycloalkyl; wherein the heterocycloalkyl ring is substituted as defined herein. In another embodiment of Formula (I), R' is R'*; and R'* is heterocycloalkyl; wherein the heterocycloalkyl ring is substituted with R^^. In another embodiment of Formula (I), R' is R'*; and R^ is heterocycloalkyl; wherein the heterocycloalkyl ring is piperidinyl, pyrrohnyl, morpholinyl, or piperizinyl; and wherein the heterocycloalkyl ring is substituted with one or two or three or four or five more R^^ SOiR^Vr OH, and R^' is R^ or R^'. In another embodiment of Formula (I), R' is R*; R* is heterocycloalkyl; wherein the heterocycloalkyl ring is piperidinyl, pyrrolinyl, morpholinyl, or piperizinyl; and wherein the piperidinyl, pyrrolinyl, morpholinyl, or piperizinyl; ring is substituted with R^'; R^^ is R** or R*'; R^ is cycloalkyl or heterocycloalkyl; and R*^ is alkyl. In another embodiment of Formula (I), R' is R"*; R'* is heterocycloalkyl; wherein the heterocycloalkyl ring is piperidinyl, pyrrolinyl, morpholinyl, or piperizinyl; and wherein the piperidinyl, pyrrolinyl, morpholinyl, or piperizinyl; ring is substimted with R"; R^^ is R*"; R** is heterocycloalkyl, wherein the heterocycloalkyl is morpholinyl, tetrahydropyranyl or oxetanyl. In another embodiment of Formula (I), R' is R*; R'* is heterocycloalkyl; wherein the heterocycloalkyl ring is piperidinyl, pyrrolinyl, morpholinyl, or piperizinyl; and wherein the piperidinyl, pyrrolinyl, morpholinyl, or piperizinyl; ring is substituted with R^^; R^^ is R*; R®' is cycloalkyl, wherein the cycloalkyl is cyclopropyl or cyclopentyl. In another embodiment of Formula (I), R' is R''; R"* is heterocycloalkyl; wherein the heterocycloalkyl ring is piperidinyl, pyrrolinyl, morpholinyl, or piperizinyl, and wherein the piperidinyl, pyrrohnyl, morphoUnyl, or piperizinyl ring is substituted with one or two or three or four or five R^^; R^^ is R*'; R^' is alkyl; and the alkyl is Ci-alkyl, Ci-alkyl, or Cs-alkyl. In another embodiment of Formula (I), R^ is R'*; R'* is heterocycloalkyl; wherein the heterocycloalkyl ring is piperidinyl, pyrrohnyl, morphohnyl, or piperizinyl, and wherein the piperidinyl, pyrrolinyl, morpholinyl, or piperizinyl ring is substituted with one or two or three or four or five R^'; R^^ is R^'; R^' is alkyl; and the alkyl 95 is Ci-alkyl, Ci-alkyl, or C3-alkyl; wherein the d-alkyl, Ca-alkyl, or Ca-alkyl are unsubstituted or substituted. In one embodiment of Formula (I), R' is R^; and R^ is alkyl which is unsubstituted or substituted. In one embodiment of Formula (I), R' is R^; and R^ is alkyl which is unsubstituted or substituted with R^, 0R\ N(R^)2, or OH. In one embodiment of Formula (I), R^ is R'° or R" which are unsubstituted or substituted as defined herein. In another embodiment of Formula (I), R^ is R'° which is unsubstituted or substituted as defined herein. In another embodiment of Formula (I), R^ is R" which is unsubstituted or substituted as defined herein. In one embodiment of Formula (I), R'" is cycloalkyl or heterocycloalkyl which are unsubstituted or substituted as defined herein. In another embodiment of Formula (I), R'" is heterocycloalkyl which is unsubstituted or substituted as defined herein. In another embodiment of Formula (I), R''' is tetrahydrofuranyl, tetrahydropyranyl, morphoUnyl, dioxanyl, piperidinyl, piperizinyl, or pyrrolidinyl, which are unsubstituted or substituted as defined herein. In another embodiment of Formula (I), R'" is tetrahydropyranyl, which is unsubstituted or substituted as defined herein. In another embodiment of Formula (I), R"* is morpholinyl, which is unsubstituted or substituted as defined herein. In another embodiment of Formula (I), R'" is cycloalkyl which is unsubstituted or substituted as defined herein. In another embodiment of Formula (I), R^" is cyclohexyl which is unsubstituted or substituted as - defined herein. In one embodiment of Formula (I), R" is alkyl which is unsubstituted. In another embodiment of Formula (I), R" is methyl, which is unsubstituted or substituted as defined herein. In another embodiment of Formula (I), R" is alkyl, which is substituted as defined herein. In another embodiment of Formula (I), R" is alkyl, which is substituted with OR'^, R'^ is R'^ and R'* is alkyl. Another embodiment of this invention pertains to compounds of Formula (I), wherein A' is N or C(A^); A^ is H; B' is 0R\ NHC(0)R\ NHR\ or NHSOaR^ D'isH; E' is H; and Y' is H, CN, NO2, F, CI, Br, CF3, R'^ or SOZR'^; R'isR^R%rR^•, R^ is phenyl; 96 R"* is cycloalkyl, or heterocycloalkyl; R* is alkyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R', OR', N(R^)2, OH, F, CI, Br or I; R^sR'%rR"; R'° is cycloalkyl or heterocycloalkyl; R" is alkyl, each of which is unsubstituted or substituted with one or two or three of independently selected F, CI, Br or I; R"isR^'; R^^ is alkyl, or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected F, CI, Br or I; Z'isR^^ Z^isR^"; Z'^ and T}-'^ are both absent; L' is a R"; R^^ is phenylene; R^" is heterocycloalkylene; R"isR^^^^ R^'^is alkylene, alkenylene, or alkynylene, each of which is unsubstituted or substituted with one or two or three independently selected F, CI, Br and I substituents; Z^isR^^orR^; R^* is phenyl, which is unfused or fused with R^^^; R^*"^ is heterocycloalkane; R'*" is cycloalkenyl, or heterocycloalkenyl; wherein the moieties represented by R and R are substituted (i.e., if Z and Z are absent) or further substituted (i.e., if T}^ and T}^ are present) with one or two or three or four of independenUy selected R'", OR''', or NHR'*'; R'*MsR'*^R''^orR'•^ R"*^ is phenyl, which is unfused or fused with heteroarene or R'*^'^; R''^'^ is heterocycloalkane; R''^ is heteroaryl, which is unfused or fused with heteroarene; R'*' is alkyl, each of which is unsubstituted or substituted with one or two or three of independently selected R''^, F, CI, Br or I; R^^isR^^o^R*«; R'*^ is phenyl; R''* is heteroaryl; 97 wherein the moieUes represented by R*\ R*^\ R^^ R^^^, R^, R"^^, R^', R^'^, R'*^ jj48A^ R'*', and R"*'^ are independently substituted with one or two or three or four of independently selected R^°, 0R^°, COCOR'", NHZ, NHR^", N(R^°)2, NHCCOR'", NHS(0)2R^'', NHC(0)0R^°, , C(0)NH2, C(0)NHR^°, C(0)N(R^°)2, OH, (O), CN, NO2, CF3, F, CI, Br or I; R*%sR^',R",R^^orR^'*; R^' is phenyl; R^^ is heteroaryl; R^^ is cycloalkyl or heterocycloalkyl; R^"* is alkyl, each of which is unsubstituted or substituted with one or two or three of independently selected R^^ OR", C(0)R", NH2, NHR", N(R")2, NR"C(0)0R", C(0)N(R")2, OH, F, CI, Br or I; R'^ is alkyl, phenyl, or heterocycloalkyl; and wherein each foregoing cycUc moiety is independently unsubstituted, further unsubstituted, substituted or further substituted with one or two or three or four or five of independently selected R""^, R", OR", SO2R", C(0)R", C0(0)R", NH2, NHR^^ N(R")2, OH, (O), CN, NO2, F, CI, Br or I; R^^'^ is spirocyclyl; R"isR'^R^o^R^^ R^* is phenyl; R^ is cycloalkyl, or heterocycloalkyl; R^' is alkyl, or alkenyl, each of which is unsubstituted or substituted with one or two or three of independently selected R^^ 0R*^ N(R*^)2, C(0)N(R^^)2, OH, F, CI, Br or I; R^^isR*^R^,R^^o^R^; R^^ is phenyl; R^ is heteroaryl; R is cycloalkyl, or heterocycloalkyl; R is alkyl, each of which is unsubstituted or substituted with one or two or three of independently selected OR*^, F, CI, Br or I substituents; R^' is alkyl; wherein the moieties represented by R"'^, R^*, R^, R^^ R", and R^^ are unsubstituted or substituted with one or two or three or four of independently selected R^, F, CI, Br or I; R^isR^'orR^^ R^* is heterocycloalkyl; 98 R^^ is alky] which is is unsubstituted or substituted with one or two or three of independently selected OR^^, F, CI, Br or I; and R" is alkyl. Still another embodiment pertains to compounds having Fonxiula (I), which are 4-(4-((4'-ch]oro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(3-((dimethylamino)methyl)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(3-(methylamino)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethy]cyclohex-l-en-l-yl)methyl)piperazin-l-yl)-2-((2-methyl-lH-indoI-5-yl)oxy)-N-((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl)methyl)piperazin-1 -yl)-2-((2-methyl-lH-indol-5-yl)oxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitiophenyl)sulfonyl)benzamide; 4-(4-((4'-ch]oro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(2-chlorophenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-ch]oro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-chloK)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(4-chlorophenoxy)-N-((3 -nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-nitrophenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(3-(hydroxymethyl)phenoxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((4'.chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(2-chlorophenoxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin- l-yl)-2-(2-chlo^ophenoxy)-N-((4-((3-(dimethylamino)propyl)amino)-3-nit^ophenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-chlorophenoxy)-N-((4-((3-moipholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(4-chlorophenoxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 99 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(3-chlorophenoxy)-N-((4-((3- (dimethylaniino)propyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1-yl)-2-(4-chlorophenoxy)-N-((4-((3- (dimethylamino)propyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((4-((3- (dimethylamino)propyl)amino)-3-nitrophenyl)sulfonyI)-2-((l-methyl-lH-indol-4- yl)oxy)benzamide; 2-(3-(acetylamino)phenoxy)-4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-N- ((3-mtro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 2-(4-aminophenoxy)-4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((3-nitro- 4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 2-(3-aminophenoxy)-4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((3-nitro- 4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(3 -methoxyphenoxy)-N-((3- nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-ch]oro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(3-(dimethylamino)phenoxy)-N- ((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-cyanophenoxy)-N-((3-nitro- 4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-ch]oro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-((2-methyl-1,3 -benzothiazol-6- yl)oxy)-N-((3-nitK)-4-((tetrahydio-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-((2-methyl-1,3-benzothiazol-5- yl)oxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyI)benzamide; 4-(4-((4'-chloro-1,1 •-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((4-((3- (dimethylamino)propyl)amino)-3-nitrophenyl)sulfonyl)-2-((2-methyl-l,3-benzothiazol-5- yl)oxy)benzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(2-(3-(dimethylaraino)-3- oxopiopyl)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(2-(2-(dimethylamino)-2- oxoethyl)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 100 4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(2-(3- (dimethylamino)propyl)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-ch]oro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(2-(2- (dimethylamino)ethyl)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 2-(5-(4-((4'-chloiobiphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-nitro-4-((tetrahydro-2H-pyran- 4-yl)methylamino)phenylsuIfonylcarbamoyl)phenoxy)-N,N-dimethylbenzamide; 4-(4-((4'-cWoro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(2- ((dimethylamino)methyl)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1, l'-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((4-((3- (dimethylamino)propyl)amino)-3-nitrophenyl)sulfonyl)-2-(3-moipholin-4- ylphenoxy)benzamide; 4-(4-((4'.chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(3-(2,4-dimethyl-1,3-thiazol-5- yl)phenoxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 2-(2-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl)methyl)piperazin-1 -yl)-N-((4-(( 1 -methylpiperidin-4-yl)amino)-3- nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-diniethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(3,5 - dichlorophenoxy)-N-((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide; 2-(3-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl)methyl)piperazin-1 -yl)-N-((4-(( 1 -methylpiperidin-4-yl)ammo)-3- nitrophenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-4-(2-(dimethylamino)ethoxy)-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2- (3-cMoK)phenoxy)-N-((4-(( 1-methylpiperidin-4-yl)amino)-3- nitrophenyl)sulfonyl)benzamide; 2-(2-chlorophenoxy)-4-(4-((4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3- yl)methyl)piperazin-1 -yl)-N-((4-(( 1 -methylpiperidin-4-yl)amino)-3- nitrophenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(3-(2- (dimethylamino)ethoxy)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 101 2-(4-aniino-3-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl)methyl)piperazin-1 -yl)-N-((4-(( 1 -methylpiperidiii-4-yl)amino)-3- nitxophenyl)sulfonyl)benzamide; 2-(2-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl)methyl)piperazin-l-yl)-N-((4-((l-isopropylpiperidin-4-yl)amino)-3- nitrophenyl)sulfony])benzamide; 2-(2-bromophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl)methyl)piperazin-l-yl)-N-((4-((l-methylpiperidin-4-yl)amino)-3- nitrophenyl)suIfonyl)benzamide; 2-(2-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)cyclohex-l-en-l-yl)methyl)piperazin-l-yl)-N- ((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-((3- methyl-lH-indazol-4-yl)oxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3- nitrophenyl)sulfonyl)benzainide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl)methyl)piperazin-1 -yl)-2-(2,3- difluorophenoxy)-N-((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzaniide; 2-(3-broinophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl)methyl)piperazin-1 -yl)-N-((4-(( 1 -methylpiperidin-4-yl)amino)-3- nitrophenyl)sulfonyl)benzamide; 2-(2-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1- yl)methyl)piperazin-1 -yl)-N-((4-(( 1 -ethylpiperidin-4-yl)amino)-3- mtrophenyl)sulfonyl)benzamide; 2-(2-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl)raethyl)piperazin-l-yl)-N-((3-nitro-4-((l,2,2,6,6-pentamethylpiperidin-4- yl)amino)phenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-2-(2,3- difluorophenoxy)-N-((3-nitro-4-((l-tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino)phenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yI)methyl)piperazin-l-yl)-2-((7- fluoro-lH-indol-5-yl)oxy)-N-((4-((l-methylpiperidin-4-yl)amino)-3- mtrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-diniethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(2,3- difluorophenoxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 102 2-(4-amino-3-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl)methyl)piperazin-l-yl)-N-((4-((3-morpholin-4-ylpropyl)amino)-3- nitrophenyl)sulfonyl)benzamide; 2-(3-chlorophenoxy)-4-(4-((4'-chloro-4-(2-pynx)lidin- 1-ylethyl)-1,1 '-biphenyl-2- yl)methyl)piperazin-1 -yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl)methyl)piperazin-1 -yl)-2-(2,3- dich]orophenoxy)-N-((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl)methyl)piperazin-1 -yl)-2-((3- methyl-lH-indazol-4-yl)oxy)-N-((4-((l-methylpiperidin-4-yl)amino)-3- nitrophenyl)sulfonyl)benzamide; 2-(2-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)cyclohept-1 -en- l-yl)methyl)piperazin-1 -yl)- N-((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-N-((4-((l- methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)-2-(3- (trifluoromethyl)phenoxy)benzaniide; 4-(4-((4'-chloro-1, l'-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((4-((3- (dimethylamino)propyl)amino)-3-nitrophenyl)sulfonyl)-2-((2-oxo-l,2,3.4-tetrahydroquinolin- 5-yl)oxy)benzamide; 2-(2-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl)methyl)piperazin-1 -yl)-N-((4-(( 1 -methylpiperidin-4-yl)amino)-3- ((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-2-(2,5- dichlorophenoxy)-N-((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide; 2-(2-chloro-4-fluorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl)methyl)piperazin-1 -yl)-N-((4-(( 1 -methylpiperidin-4-yl)amino)-3- nitrophenyl)sulfonyl)benzamide; 2-(2-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclopent-1 -en-1 - yl)methyl)piperazin-1 -yl)-N-((4-(( 1 -methylpiperidin-4-yl)amino)-3- nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-2-((3- niethyl-lH-indol-4-yl)oxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3- nitrophenyl)sulfonyl)benzanude; 103 4-(4-((2-(4-chlorophenyl)-4,4-dimethy]cyclohex- 1-en-1 -yl)methyl)piperazin-1 -yl)-2-(2- chloro-3-(trifluoromethyl)phenoxy)-N-((4-((l-methylpiperidin-4-yl)amino)-3- nitrophenyl)sulfonyl)benzamide; 2-(2-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl)methyl)piperazin-l-yl)-N-((4-((l-cyclopropylpiperidin-4-yl)amino)-3- nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl)methyl)piperazin-1 -yl)-2-((3- methyl-lH-indol-4-yl)oxy)-N-((4-((l-methylpiperidin-4-yl)ainino)-3- nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl)methyl)piperazin-1 -yl)-2-(2,5- dichlorophenoxy)-N-((4-((3-morpholin-4-ylpropyl)aniino)-3- nitrophenyl)sulfonyl)benzamide; 4-(4-((4'-ch]oro-1,1'-biphenyl-2-yl)methyl)piperazin-1-yl)-2-(( 1-methyl-1 H-indol-4-yl)oxy)- N-((4-((3-morpholin-4-ylpiopyl)amino)-3-nitrophenyl)sulfonyl)benzaniide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-morpholin-4-ylphenoxy)-N- ((4-((3-morpholin-4-ylpropyl)aniino)-3-nitrophenyl)sulfonyl)benzan(iide; 4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-((3- (dimethylamino)propyl)amino)-3-nitiophenyl)sulfonyl)-2-((3-(3-morpholin-4-yl-3- oxopropyl)-lH-indol-5-yl)oxy)benzamide; 2-(3-(benzyloxy)phenoxy)-4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((3- nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(4-cyanophenoxy)-N-((3-nitro- 4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)suIfonyl)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-((3-(3-morphoIin-4-yl-3- oxopropyl)-lH-indol-5-yl)oxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-((3-(3-morpholin-4-ylpropyl)- lH-indol-5-yI)oxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin- l-yI)-2-(4- ((dimethylamino)methyl)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)ami no)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(4-(lH-imidazol-l-yl)phenoxy)- N-((3-nitix)-4-((tetrahydro-2H-pyran-4-ylmethyl)aniino)phenyl)sulfonyl)benzamide; 104 4-(4-((4'-chloro-1,1 '-bipheny l-2-yl)methyl)piperazin-1 -yl)-2-(3 -nitrophenoxy)-N-((4- ((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; tert-butyl4-(5-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-((((3-nitro-4- ((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)araino)caibonyl)phenoxy)benzyl(ethyl)carbamate; tert-butyl 3-(5-(4-((4'-chloro-1,1'-biphenyl-2-yl)methyl)piperazin-1-yl)-2-((((3-nitro-4- ((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)amino)caibonyl)phenoxy)benzyl(ethyl)carbamate; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin- l-yl)-2-(4- ((ethylamino)methyl)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-ch]oro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(3- ((ethyIamino)methyl)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 2-(4-(acetylamino)phenoxy)-4-(4-((4'-ch]oro-1, r-biphenyl-2-yl)methyl)piperazin-1-yl)-N- ((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyI)benzamide; tert-butyl 4-(5-(4-((4'-chloro-1,1 '-biphenyl-2-yl)niethyl)piperazin-1 -yl)-2-((((3-nitro-4- ((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)amino)carbonyl)phenoxy)phenylcarbamate; 2-(l, l'-biphenyl-2-yloxy)-4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)raethyl)piperazin-l-yl)-N-((3- nitro-4-((tetrahydro-2H-pyran-4-ylinethyl)amino)phenyl)sulfonyl)benzamide; tert-butyl 3-(5-(4-((4'-chloro-1, l'-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-((((3-nitro-4- ((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)aniino)cart)onyl)phenoxy)phenylcari?amate; 2-(l, 1 •-biphenyI-3-yloxy)-4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((3- nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(4-(2- (dimethylamino)ethyl)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 2-(4-(benzyloxy)phenoxy)-4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((3- nitro-4-((tetrahydio-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-ch]oro-1,1 '-biphenyl-2-yI)methyl)piperazin-1 -yl)-2-(3-morpholin-4-ylphenoxy)-N- ((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 105 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-((2-methyl-1,3-benzothiazol-5- yl)oxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; tert-butyl4-(3-(5-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-2-((((3-nitio-4- ((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)amino)carbonyl)phenoxy)phenyl)piperazine-l-carboxylate; 2-(3-(benzy loxy)phenoxy)-4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((4- ((3-(dimethylainino)propyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 2-(3-(benzyloxy)phenoxy)-4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4- ((3-morpholin-4-ylpropyl)aniino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(4-(2-morpholin-4- ylethoxy)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((3 -nitro-4-((tetrahydro-2H- pyran-4-ylmethy])aniino)pheny])sulfonyl)-2-((2-oxo-l,2,3,4-tetrahydroquinolin-5- yl)oxy)benzamide; 2-(4-(benzyloxy)phenoxy)-4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyI)piperazin-1 -yl)-N-((4- ((3-moipholin-4-ylpropyl)aiiiino)-3-nitrophenyl)sulfonyl)benzamide; tert-butyl 4-(4-(5-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-((((4-((3- morpholin-4-ylpropyl)amino)-3 - nitrophenyl)sulfonyl)amino)carbonyl)phenoxy)phenyl)piperazine-l-carboxylate; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((4-((3-morpholin-4- ylpropyl)amino)-3-nitrophenyl)sulfonyl)-2-(3-pyridin-4-ylphenoxy)benzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1-yl)-N-((4-((3-morpholin-4- ylpropyl)amino)-3-nitrophenyl)sulfonyl)-2-(4-pyridin-4-ylphenoxy)benzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((4-((3-morpholin-4- ylpropyl)aniino)-3-nitrophenyl)sulfonyl)-2-(4-pyridin-3-ylphenoxy)benzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1-yl)-2-(4-(2-(dimethylamino)-2- oxoethoxy)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(( 1 -methyl-1 H-benzimidazol-5- yl)oxy)-N-((4-((3-morpholin-4-ylprc)pyl)amino)-3-nitrophenyl)sulfonyl)benzainide; 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-(methylcarbanioyl)phenoxy)-N-(4- (3-morpholinopropylamino)-3-nitrophenylsulfonyl)benzamide; 106 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-N-(4-(3-(diinethylamino)propylamino)- 3-nitTophenylsulfonyI)-2-(3-(methylcarbamoyl)phenoxy)benzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1-yl)-2-(3-(2-(dimethylanuno)-2- oxoethoxy)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-((3-(3-(dimethylamino)propyl)- lH-indol-5-yl)oxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)anuno)phenyl)sulfonyl)benzamide; 4.(4.((4'.chloro-1, l'-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((4-((3- (dimethylamino)propyl)amino)-3-nitrophenyl)sulfonyl)-2-(3- (hydroxymethyl)phenoxy)benzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-((4-methoxybenzyl)oxy)-N-((3- nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)ammo)phenyl)sulfonyl)benzamide; N-(4-((4-aminotetrahydro-2H-pyran-4-yl)methylamino)-3-nitrophenylsulfonyl)-2-(3- chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l- yl)benzamide; 4-(4-(l-(4'-chlorobiphenyl-2-yl)ethyl)piperazin-l-yl)-2-(2-chlorophenoxy)-N-(3-nitro-4- ((tetrahydro-2H-pyran-4-y])methylaraino)phenylsulfonyl)benzamide; N- {[4- {4-[(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl} -2-(3,5- dichlorophenoxy)phenyl]sulfonyl} -4- [(1 -methylpiperidin-4-yl)amino]-3-nitrobenzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yljmethyl) piperazin-1 -yl)-2-(3- fluorophenoxy)-N-({4-[(l-niethylpiperidin-4-yl)amino]-3-nitxophenyl}sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(3- fluorophenoxy)-N-({3-nitro-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl}sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-2-(3- fluorophenoxy)-N-({ 4-[(3-morpholin-4-ylpropyl)amino]-3-nitrophenyl} sulfonyl)benzamide; 2-(2-chloiophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl} piperazin-1 -yl)-N-( {3 -nitro-4- [(1 -tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl} sulfonyl)benzanude; 2-(2-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl} piperazin-l-yl)-N-({ 4-[(3-morpholin-4-ylpropyl)amino]-3- nitrophenyl} sulfonyl)benzamide; 107 2-(2-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({4-[(l-cyclopentylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl]piperazin-l-yl)-2-(4- fluorophenoxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)benzamide; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({4-[(l-cyclopropyIpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 2-(2-chloro-4-fluorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1- yl]methyl}piperazin-l-yl)-N-({4-[(3-morpholin-4-ylpropyl)amino]-3- nitrophenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-diniethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N-( {4- [(l-cyclopropylpiperidin-4-yl)amino]-3-nitiophenyl}sulfonyl)-2-(2,3- difluorophenoxy)benzaniide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(2- fluorophenoxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitrophenyl}su]fonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethy Icyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-N-( {4- [(l-cyclopropylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(2- fIuorophenoxy)benzamide; 4-(4- {[2-(4-ch]orophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-(2- fluorophenoxy)-N-({3-nitro-4-[(l-tetrahydiio-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl }sulfonyl)benzainide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl} piperazin-1 -yI)-2-(2- fluorophenoxy)-N-({ 4-[(3-morpholin-4-ylpropyl)amino]-3-nitrophenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethy Icyclohex- 1-en-1 -yl]methyl} piperazin-1 -yl)-2-(2- fluorophenoxy)-N-({ 4-[(2-morpholin-4-ylethyl)amino] -3-nitrophenyl} sulfonyl)benzainide; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl} piperazin- l-yl)-N-({ 3-nitro-4- [(1 -tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl} sulfonyl)benzamide; 2-(3-ch]orophenoxy)-4-(4- {[2-(4-chloropheny])-4,4-dimethy]cyc]ohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({4-[(3-morpholin-4-ylpropyl)amino]-3- nitrophenyl) sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl] piperazin- l-yl)-2-(3- fluorophenoxy)-N-({4-[(2-morpholin-4-ylediyl)amino]-3-nitrophenyl}sulfonyl)benzamide; 108 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]inethyl}piperazin-l-yI)-N-({4-[(l-cyclopentylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-diraethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({4-[(l-methylpiperidin-4-yl)aniino]-3- [(tTifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide; 4-(4-{[2-(4-ch]orophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-N-({4- [(1 -cyclopropylpiperidin-4-yl)amino]-3-nitK)phenyl} sulfonyl)-2-(3- fluorophenoxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-N-({4- [(l-cyclopentyIpiperidin-4-yl)aniino]-3-nitrophenyl)sulfony])-2-(2,3- difluorophenoxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N-( {4- [(l-cyclopentylpiperidin-4-yl)amino]-3-nitrophenyl)sulfonyl)-2-(2- fluorophenoxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl) piperazin-1 -y])-2-(2,3- difluorophenoxy)-N-({4-[(2-morpholin-4-ylethyl)amino]-3-nitrophenyl}sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-diniethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-(2,3 - difluorophenoxy)-N-[(3-nitro-4- {[ 1 -(thien-3-ylmethyl)piperidin-4- yl]amino)phenyl)sulfonyl]benzamide; 4-(4- {[2-(4-ch]orophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N- [(4- {[3-(dimethylamino)propyl]amino]-3-nitiophenyl)sulfonyl]-2-(2-fluorophenoxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl ] piperazin-1 -yl)-N- [(4- {[3-(dimethylaniino)propyl]amino}-3-nitrophenyl)sulfonyl]-2-(3-fluorophenoxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-diniethylcyclohex-1 -en-1 -yljmethyl) piperazin-1 -yl)-N- [(4- {[3-(dimethylamino)propyl]amino) -3-nit3ophenyl)sulfonyl]-2-(4-fluorophenoxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl ] piperazin-1 -yl)-2-(2,3- difluorophenoxy)-N-[(4- {[ 1 -(2-fluoroethyl)piperidin-4-ylJ amino} -3- nitrophenyl)sulfonylJbenzamide; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - ylJmethyl}piperazin-l-yl)-N-({4-[(2-morpholin-4-ylethyl)aminoJ-3- nitrophenyl} sulfonyl)benzamide; 109 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yljmethyl} piperazin-1 -yl)-N- [(4- {[3-(dimethylamino)piopyl]amino) -3 - nitrophenyl)sulfonyl]benzanude; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl} piperazin-1 -yl)-N-[(4-{ [3-(4-methylpiperazin-1 -yl)propyl]amino} -3- nitrophenyl)sulfonyl]benzaniide; 2-(3-chlorophenoxy)-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3- yl]methyl}piperazin-l-yl)-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzaniide; 4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- 2-(2,3-difluorophenoxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitiophenyl }sulfonyl)benzamide; N-({4-[(l-allylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4- dimethylcyclohex-1 -en-1 -yljmethyl ] piperazin-1 -y l)-2-(2,3 -difluorophenoxy)benzamide; 2-(3-chloro-2-fluorophenoxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl} piperazin-1 -yl)-N-( {4- [(1 -methy lpiperidin-4-yl)amino] -3 - nitrophenyl} sulfonyl)benzamide; 2-(3-chlo.io-2-fluorophenoxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-N-({4-[(3-morpholin-4-ylpropyl)amino]-3- nitrophenyl} sulfonyl)benzamide; 2-(3-chloro-2-fluorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1- yljmethyl} piperazin-1 -yl)-N-( {3 -nitro-4- [(3 -pyrrolidin-1 - ylpropyl)amino]pheny 1} sulfonyl)benzamide; 2-(3-chloro-2-fluorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1- yl]methyl}piperazin-l-yl)-N-({4-[(2-morpholin-4-ylethyl)amino]-3- nitrophenyl} sulfonyl)benzamide; 2-(2-chloro-6-fluorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 2-(2-chloro-6-fluorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1- yl]methyl}piperazin-l-yl)-N-({3-nitro-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl} sulfonyl)benzamide; 110 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl Jmethyl }piperazin-1 -yl)-2-[(6-fluoro-lH-indol-5-yl)oxy]-N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitrophenyl }sulfonyl)benzamide; 2-(3 -chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethyIcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N- [(4- {[(1 -methylpiperidin-4-yl)methyl]amino} -3-nitrophenyl)sulfonyl]benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(2,3-difluorophenoxy)-N-[(4-{[(l-methylpiperidin-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-[(4-fluoro-lH-indol-5-ylX>xy]-N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitrophenyl} sulfonyObenzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-2- [3-(methoxymethoxy)-2-methylphenoxy]-N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitrophenyl} sulfonyl)benzaniide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-2-(3-hydroxy-2-methylphenoxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitrophenyl} sulfonyl)benzamide; 2-(3-bromophenoxy)-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl Imethyl} piperazin-1 -yl)-N-( {4- [(1 -methy lpiperidin-4-yl)amino]-3-nitrophenyl} sulfonyl)benzamide; 4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)-2-(3-iodophenoxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)benzamide; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyI}piperazin-l-yl)-N-[(4-{[l-(2-hydroxyethyl)piperidin-4-yl]amino}-3-nitrophenyl)sulfonyl]benzamide; 2-(3-chIorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl] piperazin- I-yl)-N-[(3-nitro-4-{ [ l-(2-phenylethyl)piperidin-4-yl]amino}phenyl)sulfonyl]benzamide; 4-(4-{[2-(4-clilorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-2-(3,4-dichlorophenoxy)-N-({4-[(l-methylpiperidin-4-yl)aniino]-3-nitrophenyl}sulfonyl)benzamide; 111 2-(2-chloro-3,5-difluorophenoxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl }piperazin- l-yl)-N-({ 4-[( l-methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yljmethyl} piperazin-1 -yl)-2-(3- methoxyphenoxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-2-[3- (hydroxyraethyl)phenoxy]-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 2-(2-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({4-[(l,4-dimethylpiperidin-4-yI)amino]-3- nitrophenyl) sulfonyl)benzamide; 2-(3 -chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yljmethy] ] piperazin-1 -yl)-N-({ 4-[(l ,4-dimethylpiperidin-4-yI)amino]-3- nitrophenyl} sulfonyl)benzamide; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-1 - yljmethyl} piperazin- l-yl)-N- {[4-( {1 -[2-(2-methoxyethoxy )ethyl]piperidin-4-yl} amino)-3- nitrophenyl]sulfonyl }benzaniide; 2-(2-chloro-3-hydroxyphenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yljmethyl} piperazin-1 -yl)-N-[(3-nitro-4- {[ l-(3-phenylpropyl)piperidin-4- yl]amino}phenyl)sulfonyl]benzamide; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-[(4-{[l-(2-methoxyethyl)piperidin-4-yl]amino}-3- nitrophenyl)sulfonyl]benzaniide; 2-(3 -chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl ] piperazin-1 -yl)-N-( {4- [(1 -ethylpiperidin-4-yl)amino]-3 - nitrophenyl} sulfonyl)benzaniide; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyI)-4,4-dimethylcyclohex-1 -en-1 - yljmethyl} piperazin-1 -yl)-N-( {4-[( 1 -isopropylpip)eridin-4-yl)aminoJ-3- nitrophenyl} suIfonyl)benzamide; 112 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl]piperazin- l-yl)-2-(3-hydroxyphenoxy)-N-({4-[(l-methylpiperidin-4-yl)aniino]-3-nitrophenyl}sulfonyl)benzamide; 2-(2-chloro-3-fluorophenoxy)-4-(4-{[2-(4-chlorophenyI)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitrophenyl }sulfonyl)benzamide; 2-(2-chloro-3-fluorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl ] piperazin-1 -yl)-N-({ 3-nitro-4- [(1 -tetrahydio-2H-pyran-4-ylpiperidin-4-yl)amino]phenyl}sulfonyl)benzamide; 2-(2-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-N- [(4- {[3-(dimethyIamino)propyl]amino} -3 -nitrophenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- l-en-1 -yl]methyl} piperazin-1-yl)-2-(2-methoxyphenoxy)-N-({4-[(l-raethylpipe^idin-4-yl)a^lino]-3-nitrophenyl }sulfonyl)benzamide; 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1-yljmethyl} piperazin- 1-yl )-2-(2-methylphenoxy)-N-({ 4- [(1 -methylpiperidin-4-yl)amino]-3-nitrophenyl) sulfonyl)benzamide; 4-(4-{[2-(4-ch]orophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl]piperazin-l-yl)-2-(3-methylphenoxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitiophenyl}sulfonyl)benzamide; 2-(2-chlorophenoxy)-4-(4- {[6-(4-chlorophenyl)- l,3-benzodioxol-5-yl]methyl }piperazin-1-yl)-N-( {4- [(1 -methyIpiperidin-4-yl)amino] -3-nitrophenyl} sulfonyl)benzamide; 2-(2-chlorophenoxy)-4-(4- {[2-(4-chIorophenyl)-4,4-dimethyIcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-N-( {4- [(4-methylpiperazin-1 -yl)amino]-3 -nitrophenyl} sulfonyl)benzamide; 2-(3-chlorophenoxy)-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)-N-({4-[(4-methylpiperazin-l-yl)amino]-3-nitrophenyl} sulfonyl)benzamide; 4-(4- {[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl Jpiperazin-1 -yl)-2-(2,3-difluorophenoxy)-N-({4-[(4-methylpiperazin-l-yl)amino]-3-nitrophenyl} sulfonyl)benzamide; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-N- [(4- {[ 1 -(cycIopropylmethyl)piperidin-4-yl Jamino} -3 -nitrophenyl)sulfonylJbenzamide; 113 2-(2-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-diraethylcyclohex-1 -en-1 - yljmethyl} piperazin-1 -yl)-N- [(4- {[ 1 -(cyclopropylmethyl)piperidin-4-yl]amino} -3- nitrophenyl)sulfonyl]benzamide; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yljmethyl} piperazin-1 -yl)-N- {[4-( {1 -[2-(dimethylamino)-2-oxoethyl]piperidin-4-yl} amino)- 3-nitrophenyl]sulfonyl }benzamide; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl)piperazin-l-yl)-N-[(4-{[l-(2-moipholin-4-ylethyl)pipeiidin-4-yl]aniino}-3- nitrophenyl)sulfonyl]benzamide; N-[(4- {[(4-aminotetrahydro-2H-pyran-4-yl)methyl]amino} -3-nitiophenyl)sulfonyl]-2-(2- chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 - yljmethyl} piperazin-1 -yl)benzamide; 2-(2-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - ylJmethyl)piperazin-l-yl)-N-[(4-{[(4-hydroxy-l-methylpiperidin-4-yl)methylJamino}-3- nitrophenyl)sulfonylJbenzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-2-[(6- fluoro- lH-indol-5-yl)oxyJ-N-({ 3-nitro-4-[( I-tetrahydro-2H-pyran-4-ylpiperidin-4- yl)aminoJphenyl} sulfonyl)benzamide; 2-(3 -chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yljmethyl} piperazin-1 -yl)-N-[(4- {[(3S)-1 -methylpyrrolidin-3-ylJamino} -3- nitrophenyl)sulfonylJbenzamide; 2-(3 -chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yljmethyl} piperazin-1 -yl)-N-[(4- {[(3R)-1 -methylpyrrolidin-3-ylJamino} -3- nitrophenyl)sulfonylJbenzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-ylJmethyl)piperazin-l-yl)-N-({4- [(l-methylpiperidin-4-yl)aminoJ-3-nitrophenyl}sulfonyl)-2-[3-(lH-pyrrol-2- yl)phenoxyJbenzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl J piperazin-1 -yl)-2-(3- fluorophenoxy)-N- [(4- {[(4-hydroxy-1 -methylpiperidin-4-yl)methylJamino} -3- nitrophenyl)sulfonyljbenzamide; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - ylJmethyl]piperazin-l-yl)-N-({4-[(4-methylpiperazin-l-yl)aminoJ-3- nitrophenyl ] sulfonyl)benzamide; 114 4-(4-{ [2-(4-ch]orophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl}piperazin- l-yl)-2-[(6,7- difluoro-lH-indol-5-yl)oxy]-N-({4-[(l-raethylpiperidin-4-yl)amino]-3- nitrophenyl }suIfonyl)benzamide; 4-(4-{ [2-(4-ch]orophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl)piperazin- l-yl)-2-[(6,7- difluoro-1 H-indol-5-yl)oxy]-N-( {3 -nitro-4- [(1 -tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl} sulfonyl)benzamide; tert-butyl 4-(5 -(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 - yl)-2-{[({4-[(l-meihylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)araino]carbonyl }phenoxy)-1H-indole-1 -carboxylate; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-[(4-{[4-(dimethy]amino)cyclohexyl]amino)-3- mtiophenyl)sulfonyl]benzamide; 2-(3 -chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl)piperazin-l-yl)-N-[(4-{[4-(diethylamino)cyclohexyl]amino}-3- nitrophenyl)sulfonyl]benzamide; Trans-2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({4-[(4-moipholin-4-ylcyclohexyl)amino]-3- nitrophenyl} sulfonyl)benzainide; 4-{4-[l-(4'-chloro-l,l'-biphenyl-2-yl)ethyl]piperazin-l-yl}-2-(2-chlorophenoxy)-N-({4-[(l- methylpiperidin-4-yl)amino]-3-nitrophenyl} sulfonyl)benzamide; 2-(2-chloro-4-hydroxyphenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 2-(2-chloro-4-hydroxyphenoxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-N-({4-[(4-methylpiperazin-l-yl)amino]-3- nitrophenyl }sulfonyl)benzaniide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl) piperazin-1 -yl)-2- [(6- fluoro-lH-indoI-4-yl)oxy]-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl) sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-2- [(6- fluoro-lH-indol-4-yl)oxy]-N-({3-nitro-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl)sulfonyl)benzamide; 115 2-(2-chloro-4-hydroxyphenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yljmethyl} piperazin-1 -yl)-N-( {4- [(4-niethylpiperazin-1 -yl)amino] -3 - [(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide; 2-( {1,3-bis[(4-methylpiperazin-1 -yl)methyl] -1 H-indol-4-yl} oxy)-4-(4- {[2-(4-chlorophenyl)- 4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-[(4-{[3- (dimethylaniino)propyl]amino} -3-nitrophenyl)sulfonyl]benzaniide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl ] piperazin-1 -yl)-N- [(4- {[3-(dimethylamino)propyl]amino} -3-nitrophenyl)sulfonyl]-2-( {3- [(4-niethylpiperazin-1- yl)methyl]-lH-indol-4-yl}oxy)benzamide; 2-(5-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-2-(4-(l- methylpiperidin-4-ylamino)-3-nitrophenylsulfonylcarbamoyl)phenoxy)-N,N- dimethylbenzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N-( {3- nitro-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]phenyl]sulfonyl)-2-{[2- (trifluoromethyl)-lH-indol-4-yl]oxy}benzamide; 2-(2-chloro-4-hydroxyphenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcycIohex-1 -en-1 - yljmethyl} piperazin-1 -yl)-N-( {3 -nitro-4- [(1 -tetrahydro-2H-pyran-4-ylpiperidin-4- yl)aminoJphenyl}sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yljmethyl} piperazin-1 -yl)-N-( {4- [(l-methylpiperidin-4-yl)aminoJ-3-nitrophenyl}sulfonyl)-2-{[6-(trifluoromethyl)-lH-indol-5- yljoxy }benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-N-( {3- nitro-4-[( l-tetrahydro-2H-pyran-4-ylpiperidin-4-yl)aminoJphenyl} sulfonyl)-2- {[6- (trifluoromethyl)-lH-indol-5-ylJoxy}benzamide; 2-[(2-amino-1,3-thiazol-4-yl)methoxyJ-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 - en-1 -yljmethyl Jpiperazin- l-yl)-N-({ 3-nitro-4-[(l -tetrahydro-2H-pyran-4-ylpiperidin-4- yl)aminoJphenyl}sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-ylJmethyl}piperazin-l-yl)-2-[(6,7- difluoro-lH-indol-5-yl)oxyJ-N-({4-[(4-methylpiperazin-l-yl)aminoJ-3- nitrophenyl ] sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethyIcyclohex-l-en-l-ylJmethyl}piperazin-l-yl)-2-[(6- fluoro-1 H-indol-5 -yl)oxy J -N-( {4- [(4-methylpiperazin-1 -yl)amino J -3 - nitropheny 1} sulfonyl)benzamide; 116 tert-butyl 4-[(5-(4- {[2-(4-chlorophenyl)-4,4-diniethylcyclohex-1 -en- 1-ylJmethyl jpiperazin-1- yl)-2- {[({4-[( 1 -methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)anuno]carbonyl} phenoxy)methyl]-1,3-thiazol-2-ylcarbamate; 2-[(2-amino-1,3-thiazol-4-yl)methoxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 - en-l-yl]methyl}piperazin-l-yl)-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 2-[3-(acetylamino)phenoxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1- yl]methyl} pipejazin-1 -yl)-N-({ 4-[( 1 -methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 2-[3-(acetylamino)phenoxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl} piperazin-1 -yl)-N-( {3-nitro-4- [(1 -tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl}sulfonyl)benzamide; 2-[(2-chlorophenyl)amino]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1- yl]methyl Ipiperazin-1 -yl)-N-({ 3-nitro-4- [(1 -tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl}sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl) piperazin-1 -yl)-2- [(6- methoxy-1 H-indol-5-yl)oxy ]-N-( {3 -nitro-4- [(1 -tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl }sulfonyl)benzamide; 2-[(2-amino-1,3-benzothiazol-6-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en- l-yl]methyl }piperazin- l-yl)-N-( {4-[(l -methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 2-[(2-chlorophenyl)amino]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; tert-butyl 5-[5-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyI}piperazin-l- yl)-2-({[(4-{[3-(dimethylamino)propyl]amino}-3- nitrophenyl)sulfonyl]amino} carbonyl)phenoxy]-1 H-indole-1 -carboxylate; 2-[(2-amino-1,3-benzothiazol-6-yl)oxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 - en-1 -yljmethyl} piperazin-1 -yl)-N-( {3 -nitro-4- [(1 -tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl }sulfonyl)benzaniide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethyIcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-[(6- fluoro-lH-indol-5-yl)oxy]-N-[(3-nitro-4-{[3-(3-oxopiperazin-1- yl)propyl]amino}phenyl)suIfonyl]benzamide; 117 Trans-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yljmethyl jpiperazin-1 -yl)-2- [(6-fluoro-lH-indol-5-yl)oxy]-N-({4-[(4-morpholin-4-ylcyclohexyl)amino]-3- nitrophenyl} sulfonyl)benzamide; Trans-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl} piperazin-1 -yl)-2- [(6,7-difluoro-lH-indol-5-yl)oxy]-N-({4-[(4-morphoIin-4-ylcyclohexyl)amino]-3- nitrophenyl }sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-N- [(4- {[l-(cyclopropylmethyl)piperidin-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-[(6-fluoro-lH- indol-5-yl)oxy]benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-N-[(4- {[l-(cyclopropylmethyl)piperidin-4-yl]amino} -3-nitrophenyl)sulfonyl]-2-[(6,7-difluoro-1H- indol-5-yl)oxy]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl )piperazin- l-yl)-2-[(6- fluoro- lH-indol-5-yl)oxy]-N-({ 3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl) piperazin-1 -y l)-2- [(6,7- difluoro-lH-indol-5-yl)oxyJ-N-[(3-nitro-4-{[3-(3-oxopiperazin-l- yl)propylJamino}phenyl)sulfonylJbenzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-2- [(6- fluoro-lH-indol-5-yl)oxyJ-N-({4-[(2-hydroxy-l-tetrahydro-2H-pyran-4-ylethyl)aminoJ-3- nitrophenyl }sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-2- [(6- fluoro-1 H-indol-5 -yl)oxy J-N- {[4-( {[4-(hydroxymethyl)tetrahydro-2H-pyran-4- yljmethyl} amino)-3-nitrophenylJsulfonyl Jbenzamide; 2-[(6-chloro- lH-indol-5-yl)oxyJ-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - ylJmethyl}piperazin-l-yl)-N-({3-nitro-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4- yl)aminoJphenyl}sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-ylJmethyl}piperazin-l-yl)-2-[(6,7- difluoro-1 H-indol-5-yl)oxyJ-N-( {3-nitro-4- [(tetrahydro-2H-pyran-4- ylmethyl)amino Jphenyl} sulfonyl)benzamide; 2-[(6-chloro-lH-indol-5-yl)oxyJ-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- ylJmethyl}piperazin-l-yl)-N-({4-[(4-methylpiperazin-l-yl)aminoJ-3- nitrophenyl} sulfonyl)benzamide; 118 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-ylJmethyl}piperazin-l-yl)-2-I(6-fluoro-lH-indol-5-yl)oxy]-N-[(3-nitro-4-{[l-(l,3-thiazol-4-ylmethyl)piperidin-4-yl]amino}phenyl)sulfonyl]benzamide; 2-(3 -chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-l-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)aiiiino]phenyl}sulfonyl)benzamide; 2-(4-amino-3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyI)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl }piperazin- l-yl)-N-({ 3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)benzamide; N-[(4-{[(4-aniinotetrahydro-2H-pyran-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-[(6-fluoro-1H-indol-5-yl)oxy]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-2- [(6-fluoro- lH-indoI-5-yl)oxy]-N-[(4- {[(3S,4R)-3-hydroxy-1 -(1,3-thiazoI-4-ylmethyI)piperidin-4-yI]araino}-3-nitrophenyl)sulfonyl]benzamide; 2-(2-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-N- {[4-( {[4-(hydroxymethyl)tetrahydro-2H-pyran-4-yljmethyl} amino)-3-nitrophenyl]sulfonyl} benzamide; 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl)piperazin- l-yl)-2-[(6-fluoro- lH-indol-5-yl)oxy]-N- {[3-nitro-4-(tetrahydro-2H-pyran-4-ylamino)phenyl]sulfonyl}benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl ] piperazin-1 -yl)-2- [(6-fluoro- lH-indol-5-yl)oxy]-N- {[4-(morpholin-4-ylamino)-3-nitiophenyl]sulfonyl jbenzamide; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-l-yl)-N-{[4-(morpholin-4-ylamino)-3-nitrophenyl]sulfonyl}benzamide; 2-(2-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-l-yl)-N-[(3-nitro-4-{[3-(3-oxopiperazin-l-yl)propyl]amino} phenyl)sulfonyl]benzamide; 2-(6-aminopyridin-3-yl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-l-yl)-N-({3-nitro-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4-yI)amino]phenyI} sulfonyl)benzamide; 4-(4- {1 -[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]ethyl} piperazin-1 -yl)-2- [(6-fluoro- lH-indol-5-yl)oxy]-N-({ 3-nit^o-4-[(tet^ahydIO-2H-py^an-4-ylmethyl)araino]pheny 1 } sulfonyl)benzamide; 119 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl) piperazin-1 -yl)-2-[(6- fluoro- lH-indol-4-yl)oxy]-N-[(3-nitro-4- {[3-(3-oxopiperazin-1 - yl)propyl]aniino}phenyl)sulfonyl]benzamide; 4-(4-{ [2-(4-ch]orophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl}piperazin- l-yl)-2-[(6- fluoro- lH-indol-5-yl)oxy]-N-[(3-nitro-4- {[(3S)-tetrahydro-2H-pyran-3- ylmethyl]amino}phenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-2- [(6- fluoro- lH-indol-5-yl)oxy]-N-[(3-nitro-4- {[(3R)-tetrahydro-2H-pyran-3- ylmethyl]amino}phenyl)sulfonyl]benzamide; tert-butyl 5-(5 -(4- {[2-(4-chlorophenyl)-4,4-dimethy Icyclohex-1 -en-1 -yl]methyl} piperazin-1 - yl)-2- {[({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)amino]carbonyl}phenoxy)-3,4-dihydroisoquinoline-2(lH)- carboxylate; 2-[(6-aminopyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin- l-yl)-N-({ 3-nitro-4-[(l -tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl} sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-t(6- fluoro- lH-indol-5-yl)oxy]-N-({ 3-mtio-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]pheny 1} su]fonyl)benzamide; 4-(4- {[2-(4-ch]orophenyl)-4,4-dimethy Icyclohex-1 -en-1 -yljmethyl) piperazin-1 -yl)-2- [(6- fluoro-lH-indol-5-yl)oxy]-N-({4-[(2-methoxyethyl)amino]-3- nitrophenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-2- [(6- fluoro-1 H-indol-5 -yl)oxy J -N- {[3-nitro-4-(tetrahydio-2H-pyran-4- ylmethoxy)phenylJsulfonyl)benzamide; 2-[(3-chloro- lH-indol-5-yl)oxyJ-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - ylJmethyl]piperazin-l-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)aminoJphenyl} sulfonyl)benzamide; 2-[(3-chloro- lH-indol-4-yl)oxyJ-4-(4- {[2-(4-chlorophenyl)-4,4-dimethy Icyclohex- 1-en-1- yljmethyl ] piperazin-1 -yl)-N-({ 3-nitro-4- [(tetrahydro-2H-pyran-4- ylmethyl)aminoJphenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl) piperazin-1 -yl)-N-({ 3- nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)aminoJphenyl}sulfonyl)-2-[(2-oxo-2,3-dihydro- 1 H-indoI-5-yl)oxyJbenzamide; 120 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl }piperazin- l-yl)-N-({3- mtro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-[(2-oxo-2,3-dihydro- 1 H-indol-4-yl)oxy]benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-[(6- fluoro- lH-indol-4-yl)oxy]-N-({ 4-[(2-methoxyethyl)amino]-3- nitrophenyl }sulfonyl)benzamide; tert-butyl 5-(5 -(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 - yl)-2-{[({3-nitro-4-[(tetrahydio-2H-pyran-4- ylmethyl)aimno]phenyl} sulfonyl)amino]carbonyl }phenoxy)pyridin-2-ylcarbamate; tert-butyl 4-(5-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]niethyl}piperazin-l- yl)-2- {[({3-nitro-4-[( 1 -tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl}sulfonyl)amino]carbonyl}phenoxy)pyridin-2-ylcarbamate; 2-[(6-aminopyridin-3-yl)oxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl} piperazin-1 -yl)-N-( {3-nitro-4- [(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)benzamide; 2- [(2-aminopyridin-4-yl)oxy] -4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({3-nitro-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl} sulfonyl)benzamide; 2-[(5-bromopyridin-3-yl)oxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl]piperazin-l-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)benzamide; 2-[(6-chloro-lH-indol-5-yl)oxy]-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H- pyran-3-yl]methyl}piperazin-l-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)benzamide; 2-[(6-chloK)-lH-indol-5-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl} piperazin-1 -yl)-N-( {3 -nitro-4- [(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)benzamide; 4-(4-{[4-(4-ch]orophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- 2-[(6-fluoro-lH-indol-5-yl)oxy]-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)benzamide; tert-butyl 5-(5-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl}piperazin-1 - yl)-2- {[({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]pheny 1} sulfonyl)aniino]carbonyl ] phenoxy)pyridin-3-ylcarbamate; 121 2-[(5-aminopyridin-3-yl)oxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl]piperazin-l-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- yImethyl)amino]phenyl} sulfonyl)benzamide; tert-butyl4-(5-(4-{[2-(4-chlorophenyl)-4,4-diraethylcyclohex-l-en-l-yl]methyl}piperazin-l- yl)-2- {[({3-nitro-4-[(tetrahydio-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)amino]carbonyl}phenoxy)pyridin-2-ylcarbamate; 2-[(3-chloro-lH-indol-5-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yljmethyl }piperazin-1 -yl)-N-({ 3-nitro-4- [(1 -tetrahydro-2H-pyran-4-y]piperidin-4- yl)amino]phenyl} sulfonyl)benzanude; 2-[(2-aminopyridin-4-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yljmethyl} piperazin-1 -yl)-N-({ 3-nitro-4- [(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyI)-4,4-diniethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-2- [(6- hydioxypyridin-3-yl)oxy]-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]pheny 1} sulfonyl)benzamide; 2- {[6-(benzyloxy)pyridin-3-yl]oxy} -4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yljmethyl} piperazin-1-yl)-N-( {3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]pheny 1} sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-{[4- (1,4-dioxan-2-ylmethoxy)-3 -nitrophenyl]sulfonyl} -2- [(6-fluoro-1 H-indol-5 - yl)oxy]benzamide; 2-[(3-chloK)- lH-indol-4-yl)oxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1- yl]methyl}piperazin-l-yl)-N-({4-[(4-methylpiperazin-l-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl ] piperazin-1 -yl)-N-( {4- [(4-methylpiperazin-l-yl)amino]-3-nitrophenyl}sulfonyl)-2-[(2-oxo-2,3-dihydro-lH-indol-4- yl)oxy]benzaniide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N-( {4- [(1 -methylpiperidin-4-yl)amino]-3-nitrophenyl} sulfonyl)-2-[(2-oxo-2,3-dihydro-1 H-indol-4- yl)oxy]benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-N-({3- nitro-4-I(l -tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]phenyl} sulfonyl)-2-[(2-oxo-2,3- dihydro-lH-indol-4-yl)oxy]benzamide; 122 2-[(6-chloiD- lH-indol-5-yl)oxy]-4-(4- {[2-(4-chlorophenyl)-4,4-diniethylcyclohex-1 -en-1- yl]methyl} piperazin-1 -yl)-N- {[4-( 1,4-dioxan-2-ylmethoxy)-3 - nitrophenyl]sulfonyl }benzamide; 2-[(6-chloK)- lH-indol-5-yl)oxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1- yl]methyl}piperazin-l-yl)-N-({4-[(l,4-dioxan-2-ylmethyl)amino]-3- nitrophenyl}sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl ] piperazin-1 -yl)-N-( {4- [(l,4-dioxan-2-ylmethyl)amino]-3-nitrophenyl}sulfonyl)-2-[(6-fluoro-lH-indol-5- yl)oxy]benzamide; Trans-2-[(6-chloro-lH-indol-5-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-l-yl]methyl}piperazin-l-yl)-N-({4-[(4-morpholin-4-ylcyclohexyl)amino]-3- nitrophenyl} sulfonyl)benzamide; Trans-2-[(6-chloro-lH-indol-5-yl)oxy]-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro- 2H-pyran-3-yl]methyl}piperazin-l-yl)-N-({4-[(4-morpholin-4-ylcyclohexyl)amino]-3- nitrophenyl} sulfonyl)benzamide; 4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl]piperazin-l-yl)- 2-[(6-fluoro-lH-indol-5-yl)oxy]-N-({4-[(4-morpholin-4-ylcyclohexyl)amino]-3- nitrophenyl) sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2- [(6- fluoro-lH-indol-5-ylX>xy]-N-({4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3- nitrophenyl }sulfonyl)benzamide; 4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- 2-[(6-fluoro-lH-indol-5-yl)oxy]-N-({4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3- nitrophenyl} sulfonyl)benzamide; 4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- N-{[5-cyano-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-[(6-fluoro-lH- indol-5-yl)oxy]benzamide; 2- {[3-(2-aminoethyl)- lH-indol-5-yl]oxy} -4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1-yl]methyl} piperazin-1-yl)-N-( {3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl) sulfonyl)benzamide; 2- {[3-(2-aminoethyl)- lH-indol-5-yl]oxy} -4-(4- {[2-(4-chlorophenyl)-4,4-diniethylcyclohex- 1 -en-1 -yl]methyl} piperazin-1 -yl)-N-( {4-[(4-methylpiperazin-1 -yl)amino]-3- nitrophenyl }sulfonyI)benzamide; 123 4-(4- {l2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl} piperazin-1 -yl)-N- {[5- cyano-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-[(6-fluorD-lH-indol-5- yl)oxy]benzaniide; 2-[(6-amino-5-fluoropyridin-3-yI)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-l-yl]methyl}piperazin-l-yl)-N-({3-mtro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl ] sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N- {[5 - chloro-6-(tetrahydro-2H-pyran-4-ylmeth6xy)pyridin-3-yl]sulfonyl}-2-[(6-fluoro-lH-indol-5- yl)oxy]benzamide; Trans-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-1 -yl]methyl} piperazin-1 -yl)-N- ({4-[(4-morpholin-4-ylcyclohexyl)amino]-3-nitrophenyl}sulfonyl)-2-[(l-oxo-l,2,3,4- tetrahydroisoquinolin-5-yl)oxy]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl)piperazin- l-yl)-N- {[5- cyano-6-(l,4-dioxan-2-ylmethoxy)pyridin-3-yl]sulfonyl]-2-[(6-fluoro-lH-indol-5- yl)oxy]benzamide; N- {[5-bromo-6-( 1,4-dioxan-2-ylniethoxy)pyridin-3-yl]sulfonyl) -4-(4- {[2-(4-chlorophenyl)- 4,4-dimethylcyclohex-1 -en- l-yljmethyl }piperazin-1 -yl)-2- [(6-fluoro- lH-indol-5- yl)oxy]benzamide; Trans-N-( {5 -bromo-6-[(4-morpholin-4-ylcyclohexyl)amino]pyridin-3-yl) sulfonyl)-4-(4- {[2- (4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl }piperazin-1 -yl)-2-[(6-fluoro- IH- indol-5-yl)oxy]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-N-( {5- cyano-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-[(6-fluoro- lH-indol-5-yl)oxy]benzamide; 2-(3-amino-5-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl} piperazin-1 -yl)-N-({ 3-nitro-4- [(tetTahydro-2H-pyran-4- ylmethyl)aniino]phenyl}suIfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-N- {[5- cyano-6-(2-morpholin-4-ylethoxy)pyridin-3-yl]sulfonyl}-2-[(6-fluoro-lH-indol-5- yl)oxy]benzamide; Trans-4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2- [(6-fluoro-1 H-indol-5-yl)oxy]-N-( {4-[(4-morpholin-4-ylcyclohexyl)oxy]-3- nitrophenyl} sulfonyl)benzaniide; 124 N-( {5-bromo-6-[(1-tetrahydro-2H-pyran-4-ylpiperidin-4-yl)aminoJpyridin-3-y 1} sulfony l)-4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl }piperazin-1 -yl)-2-[(6-fluoro- lH-indol-5-yl)oxy]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl ] piperazin-1 -yl)-N-({ 4- [(4-fluorotetrahydro-2H-pyran-4-yl)raethoxy]-3-nitrophenyl}sulfonyl)-2-[(2-oxo-2,3- dihydro-lH-indol-4-yl)oxy]benzamide; Trans-2-[(6-chloro-lH-indol-5-yl)oxy]-4-(4-{[5-(4-chlorophenyl)-2,3,6,7-tetrahydrooxepin- 4-yl]methyl)piperazin-l-yl)-N-({4-[(4-morpholin-4-ylcyclohexyl)amino]-3- [(trifluoromethyl)sulfonyl]phenyl} sulfonyl)benzamide; Trans-2-[(6-chloio-lH-indol-5-yl)oxy]-4-(4-{[5-(4-chlorophenyl)-2,3,6,7-tetrahydrooxepin- 4-yl]methyl} piperazin-1-yl)-N-({ 4-[(4-niorpholin-4-ylcyclohexyl)aniino]-3- nitrophenyl} sulfony l)benzamide; 4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- 2- [(6-fluoro-1 H-indol-5-yl)oxy]-N-( {4- [(4-methylpiperazin-1 -yl)anuno]-3- nitrophenyl} sulfony l)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -y])-2-[(6- fluoro-lH-indol-5-yl)oxy]-N-({4-[(4-morpholin-4-ylbut-2-ynyl)oxy]-3- nitrophenyl} sulfonyl)benzamide; 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcycIohex-l- en-l-yl]methyl}piperazin-l-yl)-N-({3-nitro-4-[(tetTahydro-2H-pyran-4- ylmethyl)araino]phenyl} sulfonyl)benzamide; 4-(4- {[2-(4-ch]orophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-[(6- fluoro-lH-indol-5-yl)oxy]-N-[(4-{[l-(methylsulfonyl)piperidin-4-yl]amino}-3- nitiophenyl)sulfonyl]benzamide; Trans-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl )piperazin-1 -yl)-N- ({4-[(4-morpholin-4-ylcyclohexyl)amino]-3-nitrophenyl}sulfonyl)-2-[(2-oxo-2,3-dihydro- 1 H-indol-4-yl)oxy]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl }piperazin-1 -yl)-N-({ 4- [(2-methoxyethyl)amino]-3-mtrophenyl}sulfonyl)-2-[(2-oxo-2,3-dihydro-lH-indol-4- yl)oxy]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl ] piperazin-1 -yl)-N- {[5- ethynyl-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-[(6-fluoro-1 H-indol- 5-yl)oxy]benzamide; 125 4-(4-{[4-(4-ch]orophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-ylJmethyl}piperazin-l-yl)- N-{[5-ethynyl-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-[(6-fluoro-lH- indol-5 -yl)oxy]benzamide; Trans-2-[(6-amino-5-chloropyTidin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4- diraethylcyclohex- 1-en- l-yl]methyl }piperazin-1 -yl)-N-({ 4-[(4-morpholin-4- ylcyclohexyl)amino]-3-nitiophenyl}sulfonyl)benzamide; 4-(4- {[2-(4-ch]orophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N-( {5- cyano-6-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4-yl)oxy]pyridin-3-yl}sulfonyl)-2-[(6-fluoro- lH-indol-5-yl)oxy]benzamide; N-({5-cMoro-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- {[2-(4-ch]orophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-[(6-fluoro- lH-indol-5-yl)oxy]benzanude; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N-( {4- [(l-cyclopropylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-[(6-fluoro-lH-indol-5- yl)oxy]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N-( {4- [(4-ethylmorpholin-3-yl)methoxy]-3-nitrophenyl]sulfonyl)-2-[(6-fluoro-lH-indol-5- yl)oxy]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2- [(6- fluoro-lH-indol-5-yl)oxy]-N-[(3-nitro-4-{[(3S)-l-tetrahydro-2H-pyran-4-ylpiperidin-3- yljamino} phenyl)sulfonyl]benzanude; 2-[(6-amino-5-chloiopyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-l-yl]methyl}piperazin-l-yl)-N-({4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3- nitrophenyl }sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-({4- [(l,l-dioxidothiomorpholin-4-yl)amino]-3-nitTophenyl}sulfonyl)-2-[(6-fluoro-lH-indol-5- yl)oxy]benzaniide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-[(6- fluoro-lH-indol-5-yl)oxy]-N-({3-nitro-4-[(tetrahydrofuran-3- ylmethyl)amino]phenyl ] sulfonyl)benzamide; Trans-N-( {5-bromo-6-[(4-morpholin-4-ylcyclohexyl)oxy]pyridin-3-yl} sulfonyl)-4-(4- {[2-(4- chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl }piperazin-1 -yl)-2-[(6-fluoro-1H- indol-5-yl)oxy]benzamide; 126 Trans-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yljmethyl} piperazin-1 -yl)-N- [(4- {[4-(dicyclopropylamino)cyclohexyl]amino} -3-nitrophenyl)sulfonyl]-2-[(6-fluoro-1H- indol-5-yl)oxy]benzamide; Trans-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl} piperazin-1 -yl)-2- [(6-fluoio-lH-indol-5-yl)oxy]-N-[(3-nitro-4-{[4-(tetrahydro-2H-pyran-4- ylaniino)cyclohexyl]amino}phenyl)sulfonyl]benzaniide; Trans-4-(4- {[2-(4-chloropheny l)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl) -2- [(6-fluoro-1 H-indol-5-yl)oxy]-N-[(3-nitro-4- {[4-(4-tetrahydK)-2H-pyran-4-ylpiperazin-1 - yl)cyclohexyl]amino}phenyl)sulfonyl]benzamide; 4-(4-{[2-(4-ch]orophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-[(6- fluoro-lH-indol-5-yl)oxy]-N-[(4-{[(4-fluorotetrahydro-2H-pyran-4-yl)methyl]amino}-3- nitrophenyl)sulfony]]benzamide; Trans-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl} piperazin-1 -yl)-2- [(6-fluoro-lH-indol-5-yl)oxy]-N-[(4-{[(4-hydroxycyclohexyl)methyl]amino}-3- nitrophenyl)sulfonyl]benzamide; 4-(4- {[2-(4-ch]oropheny])-4,4-dimethylcyclohex- 1-en-1 -yljmethyl jpiperazin-1 -yl)-2-( {3-[3- (dimethylamino)propyl]- lH-indol-4-yl} oxy)-N-( {3-nitro-4- [(tetrahydro-2H-pyran-4- ylmethyl)amino]pheny 1} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-( {3- [3 - (dimethylamino)propyl] -1 H-indol-4-yl} oxy)-N-( {4- [(4-methylpiperazin-1 -yI)amino]-3 - nitrophenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N-( {4- [(l-cyclopropyl-4-fluoropiperidin-4-yl)methoxy]-3-nitrophenyl}suIfonyl)-2-[(6-fluoro-lH- indol-5-yl)oxy]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2- {[ 1 -(4- methoxybenzyl)- IH-1,2,3-benzotriazol-4-yl]oxy} -N-( {3-nitro-4-[(tetrahydro-2H-pyran-4- ylniethyl)amino]phenyl}sulfonyl)benzamide; 2-[(6-amino-5-chIoropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en- l-yl]methyl jpiperazin- l-yl)-N-( {4-[(4-methylpiperazin- l-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-1 -yljmethyl) piperazin-1 -yl)-N- {[4-( 1,4-dioxan-2-ylmethoxy)-3- nitrophenyljsulfonyl} benzamide; 127 Trans-2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4- dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-N-[(4- {[(4- methoxycyclohexyl)methyl]amino)-3-nitrDphenyl)sulfonyl]benzamide; 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-1 -yl]methyl} piperazin-1 -yl)-N-( {4- [(1,4-dioxan-2-ylmethyl)amino] -3- nitrophenyl }sulfonyl)benzamide; 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-l-yl]methyl}piperazin-l-yl)-N-({4-[(3-morpholin-4-ylpropyl)amino]-3- [(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide; 2-[(6-amino-5-chloiopyTidin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-l-yl]methyl}piperazin-l-yl)-N-({4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3- [(trifluoromethyl)sulfonyl]phenyl} sulfonyl)benzamide; 2-[(6-aniino-5-chloropyridin-3-yl)oxy]-N-({5-chloro-6-[(4-fluorotetrahydro-2H-pyran-4- yl)methoxy]pyridin-3 -yl} sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yljmethyl} piperazin-1 -yl)benzamide; 2-[(6-amino-5-bromopyridin-3-yl)oxy]-4-(4- {[2-(4-ch]orophenyl)-4,4-dimethyIcyclohex-1 - en- l-yl]methyl }piperazin- l-yl)-N-( {3-nitro-4-[(tetTahydro-2H-pyran-4- ylmethyl)amino]pheny 1} sulfonyl)benzamide; 2-amino-5-(5-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl]piperazin-l- yl)-2- {[({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)amino]carbonyl}phenoxy)nicotinamide; 2-[(6-amino-5-cyanopyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-l-yI]methyl}piperazin-l-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]pheny 1} sulfonyl)benzamide; 2-[(6-amino-5-chloropyridin-3-yI)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en- l-yl]methyl} piperazin- l-yl)-N-[(4- {[(3R)-1 -(2,2-difluoroethyl)pyrrolidin-3-yl]amino} -3- nitrophenyl)sulfonyl]benzamide; 2-[(6-amino-5-chloiopyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-l-yl]methyl}piperazin-l-yl)-N-({4-[(l-methylpiperidin-4-yl)amino]-3- [(trifluoromethyl)sulfonyl]phenyl} sulfonyl)benzamide; 2- {[6-(acetylamino)pyridin-3-yl]oxy} -4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl}piperazin-l-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}suJfonyl)benzamide; 128 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl Jmethyl} piperazin-1 -yl)-2-( {6- [(methylsulfonyl)amino]pyridin-3-yl}oxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-N-{[4- ({(3R)-l-[2-fluoro-l-(fluoromethyl)ethyl]pyrrolidin-3-yl}amino)-3-nitrophenyl]sulfonyl}-2- [(6-fluoro-1 H-indol-5-yl)oxy]benzamide; 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-l-yl]methyl}piperazin-l-yl)-N-({4-[(l-cyclopropylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 2-[(6-amino-5-bromopyridin-3-yl)oxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 - en-l-yl]methyl}piperazin-l-yl)-N-({4-[(4-methylpiperazin-l-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 2-[(6-amino-5-biomopyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-l-yl]methyl}piperazin-l-yl)-N-({4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3- mtrophenyl}sulfonyl)benzamide; 2-[(6-amino-5-bromopyridin-3-yl)oxy]-4-(4- {[2-(4-chloropheny])-4,4-dimethylcyclohex-1 - en-l-yl]methyl}piperazin-l-yl)-N-({4-[(l,4-dioxan-2-ylmethyl)amino]-3- nitrophenyl} sulfonyl)benzamide; 2-[(6-amino-5-methylpyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-1 -yl]methyl} piperazin- l-yl)-N-( (3 -nitro-4- [(tetrahydro-2H-pyran-4- ylniethyl)amino]phenyl} su]fonyl)benzamide; 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-l-yl]methyl}piperazin-l-yl)-N-[(4-{[(4-fluorotetrahydro-2H-pyran-4-yl)methyl]amino}-3- nit3X)phenyl)sulfonyl]benzamide; 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-1 -yl]methyl} piperazin-1 -yl)-N-( {3 -nitro-4- [(1 -oxetan-3 -ylpiperidin-4- yl)amino]phenyl} sulfonyl)benzamide; 2-[(6-aniino-5-isopropylpyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en-1 -yllmethyl} piperazin-1 -yl)-N-( {3-nitro-4- [(tetrahydro-2H-pyran-4- ylmethyl)anuno]phenyl}sulfonyI)benzamide; 2-[(6-aniino-5-cyclopropylpyridin-3-yl)oxy]-4-(4-([2-(4-chlorophenyI)-4,4- dimethylcyclohex-1 -en- l-yl]methyl} piperazin-1 -yl)-N-({ 3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)ainino]phenyl}su]fonyl)benzamide; 129 Trans-2-[(6-amino-5-bromopyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -y 1)-N- [(4- {[(4-methoxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-2- [(3-methyl-2-oxo-2,3-dihydro-lH-benzimidazol-4-yl)oxy]-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)benzamide; 2-[(6-aniino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en- 1-yl] methyl} piperazin- l-yl)-N-[(4- {[(4-cyclopropylmorpholin-2-yl)methyl]amino) -3-nitxophenyl)sulfonyl]benzamide; 2-[(6-anuno-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-1 -yl] methyl} piperazin-1 -yl)-N-[(4- {[(3R)-1 -cyclopropylpyiTolidin-3-yl]amino} -3-nitrophenyl)sulfonyl]benzamide; 2-[(6-amino-5-chloropyTidin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-1-yljmethyl }piperazin- l-yl)-N-{ [4-({4-fluoro-l-[2-fluoro-l-(fluoromethyl)ethyl]piperidin-4-yl}methoxy)-3-nitrophenyl]sulfonyl}benzamide; tert-butyl 6-bromo-4-(5 -(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -ylJmethyl)piperazin-l-yl)-2-{[({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)amino]carbonyl }phenoxy)pyridin-2-ylcarbamate; tert-butyl 4-(5-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-2-(3-nitro-4-((tetrahydro-2H-pyran-4- yl)methylamino)phenylsulfonylcarbamoyl)phenoxy)pyridine-2,6-diyldicarbamate; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl J piperazin-1 -yl)-2- {[6-(cyclopropylamino)pyridin-3-ylJoxy}-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)aminoJphenyl}sulfonyl)benzamide; Trans-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yljmethyl} piperazin-1 -yl)-2-({6-[(2,2-difluoroethyl)aminoJpyridin-3-yl}oxy)-N-[(4-{[(4-methoxycyclohexyl)methylJamino)-3-nitrophenyl)sulfonylJbenzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl) piperazin-1 -yl)-2-( {6-[(2,2-difluoroethyl)aminoJpyridin-3-yl}oxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino Jpheny 1} sulfonyl)benzamide; 2-{[5-chloro-6-(methylamino)pyridin-3-ylJoxy}-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- 1-yl Jmethyl} piperazin-1 -yl)-N-({ 3-nitro-4-[(tet^ahyd^o-2H-py^an-4-ylmethyl)aminoJphenyl } sulfonyl)benzamide; 130 2-[(6-amino-5-chloropyridin-3-yl)oxyJ-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-l-yl]methyl}piperazin-l-yl)-N-({4-[({4-[2-fluoro-l-(fluoromethyl)ethyl]niorpholin-2- yl} methyl)amino]-3-nitrophenyl} sulfonyl)benzamide; 2-[(2-amino-6-bromopyridin-4-yl)oxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 - en-1-yl] methyl} piperazin-1-yl)-N-( {3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yljmethyl ] piperazin- l-yl)-2- [(2,6- diaminopyridin-4-yl)oxy] -N-( {3-nitro-4- [(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)benzamide; 2-[(6-aniino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-1 -yl]methyl} piperazin-1 -yl)-N- {[3-nitro-4-(tetrahydro-2H-pyran-4- ylmethoxy)phenyl]sulfonyl]benzamide; 2-[(6-amino-5-chloiopyridin-3-yl)oxy]-4-(4-{[2-(4-chloiophenyl)-4,4-dimethylcyclohex-l- en-1 -yl] methyl} piperazin-1 -yl)-N- {[4-( {(3R)-1 - [2-fluoro-1 -(fluoromethyl)ethyl]piperidin-3 - yl} amino)-3-nitrophenyl]sulfonyl} benzamide; tert-butyl 5-bromo-4-(5-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl} piperazin-1 -yl)-2- {[({3-nitro-4- [(tetxahydro-2H-pyran-4- ylmethyl)amino]pheny 1} sulfonyl)amino]carbonyl }phenoxy)pyridin-2-ylcarbamate; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl ] piperazin-1 -yl)-2- [(4- chloro-lH-pyrrolo[2,3-b]pyridin-5-yl)oxy]-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)benzamide; 4-(4-{[2-(4-chIorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-({3- nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)-2-( {6- [(2,2,2- trifluoroethyl)amino]pyridin-3-yl} oxy)benzamide; 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-l-yl]methyl}piperazin-l-yl)-N-[(4-{[(4-hydioxycyclohexyl)methyl]amino}-3- nitrophenyl)sulfonyl]benzamide; 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro- 2H-pyran-3-yl]methyl }piperazin-1 -yl)-N-({ 3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)benzamide; N-( {5-chloro-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl} sulfonyl)-4-(4- {[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)-2-[(6- fluoro- lH-indoI-5-yl)oxy]benzamide; 131 2-[(6-amino-5-ch]oropyridin-3-y])oxyJ-4-(4-{ [2-(4-ch]oropheny])-4,4-diinethy]cyc]ohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N-( {3 -nitro-4- [(tetrahydrofuran-3-ylmethyl)amino]phenyl}sulfonyl)benzamide; 2-[(6-amino-5-chloropyridin-3-yl)oxy]-N-({5-chloro-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl} sulfonyl)-4-(4- {[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl jpiperazin-1-yl)benzamide; 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-[4-({9-(4-chlorophenyl)-3-[2-fluoro-l-(fluoiomethyl)ethyl]-3-azaspiro[5.5]undec-8-en-8-yl}methyl)piperazin-l-yl]-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl ] sulfonyl)benzamide; 2-[(6-aniino-5-chloropyridin-3-yl)oxy]-4-(4-{[9-(4-chlorophenyl)-3-isopropyl-3-azaspiro[5.5]undec-8-en-8-yl]methyl}piperazin-l-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)benzamide; 2-[(6-amino-5-chloropyridin-3-yl)oxy]-N-[(5-chloro-6- {[ l-(N,N-dimethylglycyl)-4-fluo^opiperidin-4-yl]methoxy } pyridin-3 -yl)sulfonyl]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl} piperazin-1 -yl)benzamide; 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-1 -yljmethyl} piperazin- l-yl)-N- {[4-( {(3R)-1- [2-fluoro-1 -(fluoromethyl)ethyl]pyrrolidin-3-yl)amino)-3-nitrophenyl]sulfonyl}benzamide; 2-[(2-amino-5-bromopyridin-4-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)benzamide; 2-[(6-amino-5-chloropyridin-3-yl)oxyJ-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-[(4-{[(4,4-difluorocyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]benzamide; 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-[4-({4'-chloio-3-[2-(dimethylamino)ethoxy]-l,r-biphenyl-2-yl} nnethyl)piperazin-1 -yl]-N-({ 3-nitro-4- [(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyI} sulfonyl)benzamide; 2-[(6-amino-5-chloropyridin-3-yl)oxy]-N-{[5-chloix)-6-({(3R)-l-[2-fluoro-l-(fIuoromethyl)ethyl]pyrrolidin-3-yl} methoxy)pyridin-3-yl]sulfonyl} -4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-1 -yljmethyl} piperazin-1 -yl)benzamide; 2-[(6-amino-5-chloropyridin-3-yl)oxy]-N-[(5-chloro-6-{[(3R)-l-(2,2-difIuoroethyl)pyrrolidin-3-yl]methoxy )pyridin-3-yl)sulfonyl]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)benzamide; 132 Trans-2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4- dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N-[(4- {[(4- cyanocyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]benzamide; 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-l-yl]methyl}piperazin-l-yl)-N-({5-fluoro-6-[(4-fluorotetrahydro-2H-pyran-4- yl)methoxy]pyridin-3-yl} sulfonyl)benzaniide; 2-[(6-amino-5-chloropyridin-3-yl)oxy]-N-[(5-chloro-6-{[l-(2,2-difluoroethyl)-4- fluoropiperidin-4-yl]methoxy)pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4- dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -y l)benzamide; 2-[(6-ainino-5-chloropyridin-3-yl)oxy]-N-({3-chloro-4-[(4-fluorotetrahydro-2H-pyran-4- yl)methoxy]phenyl} sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yljmethyl} piperazin-1 -yl)benzamide; 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-l-yl]methyl }piperazin-l-yl)-N-{[6-( {4-fluoro-1-[2-fluoro-1- (fluoromethyI)ethyl]piperidin-4-yl}methoxy)-5-(trifluoromethyl)pyridin-3- yljsulfonyl} benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-({3- nitio-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-[2-(lH-pyrazol-4- yl)phenoxy]benzamide; 2-[2-(2-aminopyridin-3-yl)phenoxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl}piperazin-l-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N-( {3- nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-[2-(lH-pyrazol-5- yl)phenoxy]benzamide; 2-[(6-amino-5-chloropyridin-3-yl)oxy]-N-({5-chloro-6-[(4,4- difluorocyclohexyl)methoxy]pyridin-3-yl} sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4- dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)benzamide; N-({5-chloro-6-[(4,4-difluorocyclohexyl)methoxy]pyTidin-3-yl}sulfonyl)-4-(4-{[4-(4- chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)-2-[(6-fluoro- 1 H-indol-5 -yl)oxy ]benzamide; 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en- l-yl]methyl) piperazin- l-yl)-N-[(4- {[(4,4-difluorocycIohexyl)methyl]aniino}-3-nitrophenyI)sulfonylI-2-[(6-fluoro-lH-indol-5- yl)oxy]benzamide; 133 N-({3-chloro-4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2- [(6-fluoro-1H- indol-5-yl)oxy]benzamide; N-( {3-chloro-4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]phenyl} sulfonyl)-4-(4- {[4-(4- chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)-2-[(6-fluoro- 1 H-indol-5-yl)oxy]benzamide; N-( {5 -chloro-6- [(trans-4-hydroxycyclohexyl)methoxy ]pyridin-3 -yl} sulfonyI)-4-(4- {[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yljmethyl }piperazin-1 -yl)-2- [(6-fluoro- IH- indazol-4-yl)oxy]benzaniide; N-({5-chloK)-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-2-[(6-fluoro- lH-indazol-4-yl)oxy]benzamide; tert-butyl5-[(4-{4-[({5-chloro-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3- yl)sulfonyl)carbamoyl]-3-[(6-fluoro-lH-indol-5-yl)oxy]phenyl}piperazin-l-yl)methyl]-4-(4- chlorophenyl)-3,6-dihydropyridine-l(2H)-carboxylate; N-({5-chloro-6-[(4-fluorotetrahydro-2H-pyran-4-yl)niethoxy]pyridin-3-yl}sulfonyl)-4-(4- {[4-(4-chlorophenyl)-l-(l,3-difluoropropan-2-yl)-l,2,5,6-tetrahydropyridin-3- yljmethyl} piperazin-1 -yl)-2-[(6-fluoro-1 H-indol-5 -yl)oxy]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-2- [(6- fluoro-lH-indazol-4-yl)oxy]-N-[(4-{[(4-fluorotetrahydro-2H-pyran-4-yl)methyl]amino}-3- nitiophenyl)sulfonyl]benzamide; N-( {5-chloro-6-[(trans-4-hydroxycyclohexyl)methoxy]pyridin-3-yl} sulfonyl)-4-(4- {[2-(4- chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-[(7-fluoro-lH- indazol-4-yl)oxy]benzamide; N-( {5 -chloro-6- [(4-fluorotetrahydro-2H-pyran-4-yl)methoxy ]pyridin-3-yl} sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-2- [(7-fluoro- lH-indazol-4-yl)oxy]benzamide; 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-l-yl]methyl}piperazin-l-yl)-N-{[3-nitro-4-({[4-(oxetan-3-yl)morpholin-2- yl]methyl} amino)phenyl]sulfonyl} benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-[(6- fluoro-lH-indol-5-yl)oxy]-N-{[3-nitro-4-({[4-(oxetan-3-yl)morpholin-2- yl]methyl) amino)phenyl]sulfonyl }benzamide; 134 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-2-[(7- fluoro-1 H-indazol-4-yl)oxy ] -N- [(4- {[(4-fluorotetrahydro-2H-pyran-4-yl)methyl] amino} -3- nitiophenyl)sulfonyl]benzamide; N-({5-chloro-6-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl]sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-2-[(6-fluoro- 1 H-indazol-4-yl)oxy]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl }piperazin- l-yl)-N- {[5- chloro-6-(tetrahydio-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-[(3-methyl-2-oxo-2,3- dihydro-1 H-benzimidazol-4-yl)oxy]benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-({4- [(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-[(3-methyl-2-oxo- 2,3-dihydro-1 H-benzimidazol-4-yl)oxy]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N- [(4- {[(trans-4-methoxycyclohexyl)mediyl]amino}-3-nitrophenyl)sulfonyl]-2-[(3-methyl-2-oxo- 2,3-dihydro-lH-benzimidazol-4-yl)oxy]benzamide; 2-[(3-amino-1 H-indazol-4-yl)oxy]-4-(4- {[2-(4-ch]orophenyl)-4,4-dimethylcyclohex-1 -en-1- yl]methyl}piperazin-l-yl)-N-[(4-{[(4-fluorotetrahydro-2H-pyran-4-yI)methyl]amino}-3- nitrophenyl)sulfonyl]benzamide; 2-[(3-amino-lH-indazol-4-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-N-({4-[(4-fluorotetTahydro-2H-pyran-4-yl)methoxy]-3- nitiophenyl} sulfonyl)benzamide; 2-[(3-amino-1 H-indazol-4-yl)oxy]-N-( {5-chloro-6-[(4-fluorotetrahydro-2H-pyran-4- yl)methoxy]pyridin-3-yl} sulfony])-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 - yljmethyl }piperazin-1 -yl)benzamide; 2-[(3-amino-IH-indazol-4-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yljmethyl} piperazin- l-yl)-N-({ 3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)benzamide; 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-I-yl]methyl}piperazin-l-yl)-N-[(4-{[4-fluoro-l-(oxetan-3-yl)piperidin-4-yl]methoxy}-3- nitrophenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yljmethyl }piperazin-1 -yl)-2- [(6- fluoro-lH-indazol-4-yl)oxyJ-N-({4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxyJ-3- nitrophenyl} sulfonyl)benzamide; 135 2-[(6-aniino-5-chloropyridin-3-yl)oxy]-4-(4- {t2-(4-chlorophenyl)-4,4-dimethylcyclohex-1- en- l-yl]methyl Ipiperazin- l-yl)-N-[(4- {[(trans-4-hydroxy-4- methylcyclohexyl)methyl]amino} -3-nitrophenyl)sulfonyl]benzamide; 2- [(3 -amino-1 H-indazol-4-yl)oxy]-4-(4- {[2-(4-chloiophenyl)-4,4-dimethylcyclohex-1 -en-1 - yljmethyl} piperazin-1 -yl)-N- [(4- {[(trans-4-methoxycyclohexyl)methyl]amino} -3 - nitrophenyl)sulfonyl]benzamide; 2-[(6-aniino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-l-yl]methyl}piperazin-l-yl)-N-({4-[(cis-4-hydroxy-4-methylcyclohexyl)methoxy]-3- nitrophenyl} sulfonyl)benzamide; 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-l-yl]methyl}piperazin-l-yl)-N-[(4-{[(cis-4-hydroxy-4-methylcyclohexyl)methyl]amino}- 3-nitiophenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N- {[3 - chloro-4-(tetrahydio-2H-pyran-4-ylmethoxy)phenyl]sulfonyl}-2-[(3-methyl-2-oxo-2,3- dihydio-1 H-benzimidazol-4-yl)oxy]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N-[(4- {[(4-cyclopropylmoipholin-2-yl)methyl]amino} -3-nitiophenyl)sulfonyl]-2-[(3-raethyl-2-oxo- 2,3-dihydro-lH-benzinaidazol-4-yl)oxy]benzamide; 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-l-yl]methyl}piperazin-l-yl)-N-{[3-nitro-4-(2-oxaspiro[3.5]non-7- ylmethoxy)phenyl]sulfonyl}benzamide; 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-l-yl]methyl}piperazin-l-yl)-N-({4-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]-3- nitrophenyl} sulfonyl)benzamide; 2-[(6-amino-5-chloiopyridin-3-yl)oxy]-4-(4- {[2-(4-ch]orophenyl)-4,4-dimethylcyclohex-1 - en-1 -yljmethyl} piperazin- l-yl)-N- {[4-( {[(2S)-4-cyclopropylmorpholin-2-yl]methyl} amino)- 3-nitrophenyl]sulfonyl} benzamide; 2-[(6-amino-5-chloropyridin-3-yl)oxy]-N-({ 5-chloro-6-[(trans-1 -fluoro-4-hydroxy-4- methylcyclohexyl)niethoxy]pyridin-3-yl} sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4- dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -y l)benzamide; 2-[(6-amino-5-chloropyridin-3-yl)oxy]-N-({5-chloro-6-[(cis-l-fluoro-4-hydix)xy-4- methylcyclohexyl)methoxy]pyridin-3-yl }sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4- dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -y l)benzamide; 136 2-[(3-aniino-lH-indazol-4-yl)oxy]-N-({5-chloro-6-[(trans-4-hydroxy-4- methylcyclohexyl)methoxy]pyridin-3-yl }sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4- dimethylcyclohex-1 -en-1 -yljmethyl }piperazin-1 -yl)benzamide; N-( {5 -chloro-6- [(trans-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl} sulfonyl)-2- [(3 - chloro- lH-indazol-4-yl)oxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1- yl]methyl} piperazin-1 -yl)benzamide; 2-[(6-amino-5-chloiopyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-1 -yljmethyl Ipiperazin- l-yl)-N-[(4- {[(cis-4-ethyl-4-hydroxycyclohexyl)methyI]amino} -3- nitrDphenyl)sulfonyl]benzaniide; 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-1 -yljmethyl }piperazin-1 -yl)-N- {[3-nitro-4-( {[(2S)-4-(oxetan-3-yl)morpholin-2- ylJmethyl}amino)phenylJsulfonyl}benzamide; 2-[(6-amino-5-chloiopyridin-3-yl)oxyJ-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-1 -yljmethyl} piperazin-1 -yl)-N-( {5 -nitro-6- [(tetrahydro-2H-pyran-4- ylmethyl)aminoJpyridin-3-yl} sulfonyl)benzamide; 2-[(6-amino-5-chloropyridin-3-yl)oxyJ-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 - en-l-ylJmethy]}piperazin-l-yl)-N-({3-mtro-4-[(2-oxaspiro[3.5Jnon-7- ylmethyl)aminoJphenyl}sulfonyl)benzamide; 2- [(6-amino-5 -chloropyridin-3-yl)oxyJ -4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 - en-1 -yljmethyl} piperazin-1 -yl)-N- {[4-( {[trans-4-(morpholin-4- yl)cyclohexylJmethyl J amino)-3-nitrophenylJsulfonyl Jbenzamide; 2-[(6-amino-5-chloropyridin-3-yl)oxyJ-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-1-ylJmethyl Jpiperazin- l-yl)-N-[(4- {[cis-4-(morpholin-4-yl)cyclohexylJamino} -3- nitrophenyl)sulfonylJbenzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-ylJmethylJpiperazin-l-yl)-N-({5- cyano-6-[(trans-4-hydroxy-4-methylcyclohexyl)methoxyJpyridin-3-ylJsulfonyl)-2-[(6-fluoro- 1 H-indazol-4-yl)oxyJbenzamide; 2-[(6-amino-5-chIoropyridin-3-yl)oxyJ-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-1 -yljmethyl Jpiperazin- l-yl)-N- {[4-( {[4-( {[4-(methoxymethyl)cyclohexylJmethyl} amino)- 3-nitrophenylIsulfonyl}amino)-3-nitrophenylJsulfonyl}benzamide; 2-[(6-amino-5-chloropyridin-3-yl)oxyJ-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-l-ylJmethylJpiperazin-l-yl)-N-[(3-nitro-4-{[(3R)-l-(oxetan-3-yl)pyrrolidin-3- ylJaminoJphenyl)sulfonylJbenzamide; 137 2-[(6-amino-5-chloropyiidin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-1-yl]methyl} piperazin-l-yl)-N-[(3-nitio-4-{[(3S)-1-(oxetan-3-yl)pyrrolidin-3-yl]amino}phenyl)sulfonyl]benzamide; N-[4-({2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -y l)benzoyl} sulfamoy l)-2-nitrophenyl]morpholine-4-carboxamide; N-[4-({2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chloiophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)benzoyl} sulf amoy l)-2-nitrophenyl] -4-cyanopiperidine-l-carboxamide; and therapeutically acceptable salts, prodrugs, salts of prodrugs and metabolites thereof. Still another embodiment pertains to 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]pheny 1 ] sulfonyl)benzamide; and therapeutically acceptable salts, prodrugs, salts of prodrugs and metabolites thereof. Still another embodiment pertains to Trans-2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- l-en-l-yl]methyl }piperazin-1 -yl)-N-( {4-[(4-morphohn-4-ylcyclohexyl)amino]-3-nitrophenyl} sulfonyl)benzamide; and therapeutically acceptable salts, prodrugs, salts of prodrugs and metabolites thereof. Still another embodiment pertains to [3-chloro-5-(5-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl} piperazin-1 -y l)-2- {[({3-nitro-4- [(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)amino]carbonyl}phenoxy)-2-iminopyridin-l(2H)-yl]methyl dihydrogen phosphate; and therapeutically acceptable salts, and metaboUtes thereof. Still another embodiment pertains to 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl }piperazin-1 -yl)-N- [(3-nitro-4-{[(3R)-1 -(oxetan-3-yl)pyrrolidin-3-yl]amino}phenyl)sulfonyl]benzamide; and therapeutically acceptable salts, prodrugs, salts of prodrugs and metabolites thereof. Still another embodiment pertains to Trans-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-[(6-fluoro-lH-indol-5-yl)oxy]-N-[(3-nitro-4-{[4-(tetrahydro-2H-pyran-4-ylamino)cyclohexyl]amino}phenyl)sulfonyl]benzamide; and therapeutically acceptable salts, prodrugs, salts of prodrugs and metabolites thereof. Still another embodiment pertains to 4-(4-{[2-(4-chlorophenyl)-4,4- dimethylcyclohex-1 -en- l-yl]methyl} piperazin-1 -yl)-2-[(6-fluoro- lH-indol-5-yl)oxy]-N-[(3- nitro-4-{[(3S)-tetrahydro-2H-pyran-3-ylmethyl]amino}phenyl)sulfonyl]benzamide; and therapeutically acceptable salts, prodrugs, salts of prodrugs and metabolites thereof. 138 Still another embodiment pertains to 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-[(6-fluoro-lH-indol-4-yl)oxy]-N-[(3-nitro-4- {[3-(3-oxopiperazin-1 -yl)propyl]amino }phenyl)sulfonyl]benzamide; and therapeutically acceptable salts, prodrugs, salts of prodrugs and metabolites thereof. Still another embodiment pertains to 2-(2-chlorophenoxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethyIcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-N- [(4- {[3-(dimethylamino)propyl]amino}-3-nitrophenyl)sulfonyl]benzamide; and therapeutically acceptable salts, prodrugs, salts of prodrugs and metabolites thereof. Still another embodiment pertains to 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-(3,4-dichlorophenoxy )-N-( {4- [(1 -methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)benzamide; and therapeutically acceptable salts, prodrugs, salts of prodrugs and metabolites thereof. Still another embodiment pertains to 2-(2-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-N-((4-(( 1 -isopropy lpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide; and therapeutically acceptable salts, prodrugs, salts of prodrugs and metabolites thereof. Still another embodiment pertains to 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(2-(2-(dimethylamino)ethyl)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; and therapeutically acceptable salts, prodrugs, salts of prodrugs and metabolites thereof. Still another embodiment pertains to 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-((2-methyl-1,3-benzothiazol-6-yl)oxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; and therapeutically acceptable salts, prodrugs, salts of prodrugs and metabolites thereof. Still another embodiment pertains to 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(4-chlorophenoxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide; and therapeutically acceptable salts, prodrugs, salts of prodrugs and metabolites thereof. Still another embodiment pertains to 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-((2-methyl-1 H-indol-5-yl)oxy)-N-((4-(( 1 -methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide; and therapeutically acceptable salts, prodrugs, salts of prodrugs and metabolites thereof. In another aspect, the present invention provides compounds of Formula (II) 139 I (11) and therapeutically acceptable salts, prodrugs, salts of prodrugs and metabolites thereof, wherein A\ B\ D\ E\ Y\ Z^, L', and Z^ are as described herein for Formula (I), n is 0,1, 2, or 3; describing the number of additional substituents on R^*, and R'"" is as described for substituents on R^*, m is 1, 2, 3, 4, or 5; describing the number of substituents on R"*^, and R"" is as described for substituents on R'*^. In one embodiment of Formula (II), A' is N. In another embodiment of Formula (II), A' is C(A^). In another embodiment of Formula (II), A' is C(A^); and A^ is H. In one embodiment of Formula (II), B' is NHC(0)R\ NHS02R\ 0R\ or NHR\ In another embodiment of Formula (II), A' is C(A^); A^ is H; and B' is NHR\ In another embodiment of Formula (II), A' is C(A^); A^ is H; and B' is OR'. In another embodiment of Formula (U), A' is C(A^); A^ is H; and B' is NHSO2R'. In another embodiment of Formula (U), A' is C(A^); A^ is H; and B' is NHC(0)R'. In another embodiment of Formula (U), A' is C(A^) or N; A^ is H; and B' is NHR'. In another embodiment of Formula (H), A' is C(A^) or N; A^ is H; and B' is 0R\ In another embodiment of Formula (H), A' is C(A^) or N; A^ is H; and B' is NHSO2R'. In another embodiment of Formula (H), A' is C(A^) or N; A^ is H; and B' is NHC(0)R'. In one embodiment of Formula (II), D' is H. In another embodiment of Formula (II), A' is C(A^); A^ is H; B' is NHR'; and D' is H. In another embodiment of Formula (II), A' is C(A^); A^ is H; B' is OR^ and D' is H. In another embodiment of Formula (H), A' is C(A^); A^ is H; B' is NHSO2R'; and D' is H. In another embodiment of Formula (II), A' is C(A^); A^ is H; B' is NHC(0)R'; and D' is H. In another embodiment of Formula (II), A' is C(A^) or N; A^ is H; B' is NHR^ and D' is H. In another embodiment of Formula (H), A' is C(A^) 140 or N; A^ is H; B' is OR*; and D' is H. In another embodiment of Formula (II), A' is C(A^) or N; A^ is H; B' is NHSO2R'; and D' is H. In another embodiment of Formula (11), A* is C(A^) or N; A^ is H; B' is NHC(0)R'; and D' is H. In one embodiment of Formula (II), EMS H. In another embodiment of Formula (II), A' is C(A^); A^ is H; B' is NHR'; D' is H; and E' is H. In another embodiment of Formula (11), A' is C(A^); A^ is H; B' is OR'; D' is H; and E' is H. In another embodiment of Formula (H), A' is C(A^); A^ is H; B' is NHSO2R'; D' is H; and E' is H. In another embodiment of Formula (E), A' is C(A^); A^ is H; B' is NHC(0)R'; D' is H; and E' is H. In another embodiment of Formula (H), A' is C(A^) or N; A^ is H; B' is NHR'; D' is H; and E' is H. In another embodiment of Formula (II), A' is C(A^) or N; A^ is H; B' is OR'; D' is H; and E' is H. In another embodiment of Formula (II), A' is C(A^) or N; A^ is H; B' is NHSO2R'; D' is H; and E' is H. In another embodiment of Formula (II), A' is C(A^) or N; A^ is H; B' is NHC(0)R'; D' is H; and E^ is H. In one embodiment of Formula ai), V is H, CN, NO2, F, CI, Br, CF3, R", or SO2R". In another embodiment of Formula (II), Y' is NO2. In another embodiment of Formula (II), Y' is CI. In another embodiment of Formula (H), Y' is S02R'^; wherein R" is as defined herein. In another embodiment of Formula (II), Y' is SO2R"; wherein R*' is alkyl. In another embodiment of Formula (11), Y' is R'^; wherein R'^ is alkynyl. In another embodiment of Formula (H), A' is C(A^); A^ is H; B' is NHR'; D' is H; E' is H; and Y' is NO2 or SO2R"; wherein R" is alkyl or alkynyl. In another embodiment of Formula (II), A' is C(A^); A^ is H; B' is NHR'; D' is H; E' is H; and Y' is NO2. In another embodiment of Formula (II), A' is C(A^); A^ is H; B' is NHR'; D' is H; E' is H; and Y' is SO2R", wherein R"is alkyl substituted with three F. In another embodiment of Formula (II), A' is C(A^); A^ is H; B' is OR'; D' is H; E' is H; and Y' is CI. In another embodiment of Formula (II), A' is C(A^) or N; A^ is H; B' is NHR'; D' is H; E' is H; and Y' is NO2 or SO2R"; wherein R'^ is alkyl or alkynyl. In another embodiment of Formula (11), A' is C(A^) or N; A^ is H; B' is NHR'; D' is H; E' is H; and Y' is NO2. In another embodiment of Formula (II), A' is C(A^) or N; A^ is H; B' is NHR'; D' is H; E' is H; and Y' is S02R'^ wherein R^' is alkyl substituted with three F. In another embodiment of Formula (II), A' is C(A^) or N; A^ is H; B' is OR'; D' is H; E' is H; and Y' is CI. In one embodiment of Formula (II), R' is R^, and R^ is phenyl. In another embodiment of Formula (II), R' is R^, and R^ is phenyl which is substituted with NO2, and NHR". 141 In one embodiment of Fonnula (II), R' is R"* or R^. In one embodiment of Formula (H), R' is R". In one embodiment of Fonnula (II), R' is R^. In one embodiment of Formula (H), R' is R'*; and R"* is cycloalkyl, or heterocycloaUcyl. In one embodiment of Formula (II), R' is R''; and R"* is cycloalkyl. In one embodiment of Formula (II), R' is R'*; and R'' is heterocycloalkyl. In one embodiment of Formula (II), R' is R"*; and R'* is cycloalkyl; wherein R" is unsubstituted or substituted as defined herein. In another embodiment of Formula (II), R' is R'*; and R'' is cycloalkyl; wherein the cycloalkyl ring is substituted as defined herein. In another embodiment of Formula (II), R' is R"*; and R'* is cycloalkyl; wherein the cycloalkyl ring is substituted with R^^, NHR^^, or N(R^')2. In another embodiment of Formula (11), R' is R"*; and R'* is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and wherein the cyclohexyl ring is substituted with R*^; and R^^ is R*. In another embodiment of Formula (II), R* is R'*; R'* is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and wherein the cyclohexyl ring is substituted with R^'; R^' is R^; and R^ is heterocycloalkyl. In another embodiment of Formula (II), R' is R"*; R'' is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and wherein the cyclohexyl ring is substituted with R^^; R^' is R^; R^ is heterocycloalkyl; wherein the heterocycloalkyl ring is morpholinyl or piperazinyl. In another embodiment of Formula (11), R' is R"*; and R'' is cycloalkyl; wherein the cycloalkyl ring is substituted with N(R^^)2. In another embodiment of Formula (11), R' is R'*; and R'' is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and wherein the cyclohexyl ring is substituted with N(R^^)2. In another embodiment of Formula (H), R' is R'*; and R"* is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and wherein the cyclohexyl ring is substituted with N(R^^)2, R^' is R*', and R^' is alkyl which is unsubstituted. In another embodiment of Formula (H), R' is R"*; and R"* is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and wherein the cyclohexyl ring is substituted with N(R^^)2, R^' is R^, and R*' is cycloalkyl which is unsubstituted. In another embodiment of Formula (II), R' is R'*; and R"* is cycloalkyl; wherein the cycloalkyl ring is substituted with NHR^^. In another embodiment of Formula (H), R' is R''; and R"* is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and wherein the cyclohexyl ring is substituted with NHR^', In another embodiment of Formula (H), R* is R'*; and R'* is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and wherein the cyclohexyl ring is substituted with NHR^^, R^' is R*, and R^ is heterocycloalkyl which is unsubstituted. In one embodiment of Fonnula (II), R' is R"*; and R'* is heterocycloalkyl; wherein R"* is unsubstituted or substituted as defined herein. In another embodiment of Formula (II), R' is 142 R ; and R is heterocycloalkyl; wherein the heterocycloalkyl ring is substituted as defined herein. In another embodiment of Formula (II), R' is R"; and R" is heterocycloalkyl; wherein the heterocycloalkyl ring is substituted with R^^. In another embodiment of Formula (II), R' is R ; and R is heterocycloalkyl; wherein the heterocycloalkyl ring is piperidinyl, pyrrolinyl, moipholinyl, or piperizinyl; and wherein the heterocycloalkyl ring is substituted with one or two or three or four or five more R"; S02R",or OH, and R" is R^ or R^'. In another embodiment of Formula (11), R' is R'*; R'' is heterocycloalkyl; wherein the heterocycloalkyl ring is piperidinyl, pyrrolinyl, morpholinyl, or piperizinyl; and wherein the piperidinyl, pyrrolinyl, morpholinyl, or piperizinyl; ring is substituted with R^'; R^^ is R*' or R^'; R^ is cycloaUcyl or heterocycloalkyl; and R*' is alkyl. In another embodiment of Formula (II), R' is R'*; R'* is heterocycloalkyl; wherein the heterocycloalkyl ring is piperidinyl, pyrrolinyl, morpholinyl, or piperizinyl; and wherein the piperidinyl, pyrrolinyl, morpholinyl, or piperizinyl; ring is substituted with R^^; R^' is R^"; R^ is heterocycloalkyl, wherein the heterocycloalkyl is morpholinyl, tetrahydropyranyl or oxetanyl. In another embodiment of Formula (H), R' is R"*; R'* is heterocycloalkyl; wherein the heterocycloalkyl ring is piperidinyl, pyrrolinyl, morpholinyl, or piperizinyl; and wherein the piperidinyl, pyrrolinyl, morpholinyl, or piperizinyl; ring is substituted with R^'; R^^ is R^; R^ is cycloalkyl, wherein the cycloalkyl is cyclopropyl or cyclopentyl. In another embodiment of Formula (H), R' is R"*; R"* is heterocycloalkyl; wherein the heterocycloalkyl ring is piperidinyl, pyrrolinyl, morpholinyl, or piperizinyl, and wherein the piperidinyl, pyrrolinyl, morpholinyl, or piperizinyl ring is substituted with one or two or diree or four or five R ; R is R ; R is alkyl; and the alkyl is Cj-aUcyl, C2-aIkyl, or Cs-alkyl. In another embodiment of Formula (II), R' is R"*; R'* is heterocycloalkyl; wherein the heterocycloalkyl ring is piperidinyl, pyrrolinyl, morpholinyl, or piperizinyl, and wherein the piperidinyl, pyrrolinyl, morpholinyl, or piperizinyl ring is substituted with one or two or diree or four or five R ; R is R ; R is alkyl; and the alkyl is Ci-alkyl, C2-aIkyl, or Cs-alkyl; wherein the Ci-alkyl, Ci-alkyl, or C3-alkyl are unsubstituted or substituted. In one embodiment of Formula (II), R' is R^; and R^ is alkyl which is unsubstituted or substituted. In one embodiment of Formula (II), R' is R^; and R^ is alkyl which is unsubstituted or substituted with R\ 0R\ N(R^)2, or OH. In one embodiment of Formula (II), R^ is R'° or R" which are unsubstituted or substituted as defined herein. In another embodiment of Formula (II), R^ is R'" which is unsubstituted or substituted as defined herein. In another embodiment of Formula (11), R^ is R" which is unsubstituted or substituted as defined herein. 143 In one embodiment of Formula (II), R"' is cycloalkyl or heterocycloalkyl which are unsubstituted or substituted as defined herein. In another embodiment of Formula (H), R*" is heterocycloalkyl which is unsubstituted or substituted as defined herein. In another embodiment of Formula (H), R'" is tetrahydrofuranyl, tetrahydropyranyl, morpholinyl, dioxanyl, piperidinyl, piperizinyl, or pyrrohdinyl, which are unsubstituted or substituted as defined herein. In another embodiment of Formula (II), R'" is tetrahydropyranyl, which is unsubstituted or substituted as defined herein. In another embodiment of Formula (H), R''' is morpholinyl, which is unsubstituted or substituted as defined herein. In another embodiment of Formula (II), R^° is cycloalkyl which is unsubstituted or substituted as defined herein. In another embodiment of Formula (II), R'" is cyclohexyl which is unsubstituted or substituted as defined herein. In one embodiment of Formula (II), R" is alkyl which is unsubstituted. In another embodiment of Formula (H), R" is methyl, which is unsubstituted or substituted as defined herein. In another embodiment of Formula (II), R" is alkyl, which is substituted as defined herein. In another embodiment of Formula (II), R" is alkyl, which is substituted with OR*^, R'^ is R'^ and R'^ is alkyl. In one embodiment of Formula (II), n is 0 and m is 1. In another embodiment of Formula (H), n is 0 and m is 2. Still another embodiment pertains to compounds having Formula (II), which are 4-(4-((4'-chloro-1,1 '-bipheny l-2-yl)methyl)piperazin-1 -yl)-2-(3 -((dimethylanuno)metiiyl)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyI)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-(methylamino)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)ben2amide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(2-chlorophenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-chlorophenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin- l-yl)-2-(4-chlorophenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin- l-yl)-2-(3-nit^ophenoxy)-N-((3-mtro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-(hydroxymethyl)phenoxy)-N- ((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 144 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(2-chIorophenoxy)-N-((4-((3- morpholin-4-ylpropyl)amino)-3 -nitrophenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(2-chloiiophenoxy)-N-((4-((3- (dimethylamino)propyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(3-chlorophenoxy)-N-((4-((3- morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(4-chlorophenoxy)-N-((4-((3- morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin- l-yl)-2-(3-chlorophenoxy)-N-((4-((3- (dimethylamino)propyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((4'-ch]oro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(4-chloiophenoxy)-N-((4-((3- (diinethylamino)propyl)amino)-3-nitrophenyl)sulfonyl)beiizamide; 2-(3-(acetylamino)phenoxy)-4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N- ((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)aniino)phenyl)sulfonyl)benzamide; 2-(4-aminophenoxy)-4-(4-((4'-chloro-1 ,r-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((3-nitro- 4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 2-(3-aminophenoxy)-4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((3-nitro- 4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-methoxyphenoxy)-N-((3- nitio-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(3-(dimethylamino)phenoxy)-N- ((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzanude; 4-(4-((4'-ch]oro-l,r-biphenyl-2-yl)methyI)piperazin-l-yl)-2-(3-cyanophenoxy)-N-((3-nitro- 4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(2-(3-(dimethylamino)-3- oxopropyl)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylinethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(2-(2-(dimethylamino)-2- oxoethyl)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(2-(3- (dimethylamino)propyl)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 145 4-(4-((4'-chloro-1, l'-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(2-(2- (dimethylamino)ethyl)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 2-(5-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-nitro-4-((tetrahydro-2H-pyran- 4-yl)methylamino)phenylsulfonylcarbamoyl)phenoxy)-N,N-dimethylbenzamide; 4-(4-((4'-ch]oro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(2- ((dimethylamino)methyl)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4.((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1-yl)-N-((4-((3- (dimethylamino)propyl)amino)-3-nitrophenyl)sulfonyl)-2-(3-morpholin-4- ylphenoxy)benzaniide; 4-(4.((4'-chloro-1, l'-biphenyl-2-yl)methyI)piperazin-1 -yl)-2-(3-(2,4-dimethyl-1,3-thiazol-5- yl)phenoxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 2-(2-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl)methyl)piperazin-1 -yl)-N-((4-(( 1 -methylpiperidin-4-yl)amino)-3- nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-2-(3,5- dichlo]X)phenoxy)-N-((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide; 2-(3-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl)methyl)piperazin-1 -yl)-N-((4-(( 1 -methylpiperidin-4-yl)amino)-3- nitrophenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-4-(2-(dimethylamino)ethoxy)-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2- (3-chlorophenoxy)-N-((4-((l-methylpiperidin-4-yl)amino)-3- mtrophenyl)sulfonyl)benzamide; 2-(2-chloiophenoxy)-4-(4-((4-(4-chloFophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3- yl)methyl)piperazin-1 -yl)-N-((4-(( 1 -methylpiperidin-4-yl)amino)-3- nitrophenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-(2- (dimethylamino)ethoxy)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 2-(4-aniino-3-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl)methyl)piperazin-1 -yl)-N-((4-(( 1 -mediylpiperidin-4-yl)amino)-3- nitrophenyl)sulfonyl)benzamide; 146 2-(2-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl)methyl)piperazin-l-yl)-N-((4-((l-isopropylpiperidin-4-yl)aniino)-3- nitrophenyl)sulfonyl)benzamide; 2-(2-bromophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl)methyl)piperazin-1 -yl)-N-((4-(( 1 -methylpiperidin-4-yl)amino)-3- nitrophenyl)sulfonyl)benzamide; 2-(2-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)cyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-N- ((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-2-(2,3- difluorophenoxy)-N-((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide; 2-(3-bromophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl)methyl)piperazin-1 -yl)-N-((4-(( 1 -methylpiperidin-4-yl)amino)-3 - nitrophenyl)sulfonyl)benzanude; 2-(2-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1- yl)methyl)piperazin-1 -yl)-N-((4-(( 1 -ethylpiperidin-4-yl)amino)-3- nitrophenyl)sulfonyl)benzamide; 2-(2-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl)methyl)piperazin-1 -yl)-N-((3-mtro-4-(( 1,2,2,6,6-pentamethylpiperidin-4- yl)amino)phenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl)methyl)piperazin-1 -yl)-2-(2,3- difluorophenoxy)-N-((3-nitro-4-((l-tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino)phenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dinaethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(2,3 - difluorophenoxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 2-(4-amino-3-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl)methyl)piperazin-1 -yl)-N-((4-((3-morpholin-4-ylpropyl)amino)-3- nitrophenyl)sulfonyl)benzamide; 2-(3-chlorophenoxy)-4-(4-((4'-chloro-4-(2-pyrrolidin- 1-ylethyl)-1,1 '-biphenyl-2- yl)methyl)piperazin-1 -yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-2-(2,3- dichlorophenoxy)-N-((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide; 2-(2-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)cyclohept-1 -en-1 -yl)methyl)piperazin-1 -yl)- N-((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide; 147 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-N-((4-((l- methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)-2-(3- (trifluoromethyl)phenoxy)benzamide; 2-(2-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl)methyl)piperazin-1 -yl)-N-((4-(( 1 -methylpiperidin-4-yl)amino)-3- ((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyI)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(2,5- dichIorc)phenoxy)-N-((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide; 2-(2-chloro-4-fluorophenoxy)-4-(4-((2-(4-chlorophenyI)-4,4-dimethylcyclohex-1 -en-1 - yl)methyl)piperazin-1 -yl)-N-((4-(( 1 -methylpiperidin-4-yl)amino)-3- nitrophenyl)sulfonyl)benzanude; 2-(2-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclopent-1 -en-1 - yl)methyl)piperazin-1 -yl)-N-((4-(( 1 -methylpiperidin-4-yl)amino)-3- nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(2- chloro-3-(trifluoromethyl)phenoxy)-N-((4-((l-methylpiperidin-4-yl)amino)-3- mtrophenyl)sulfonyl)benzamide; 2-(2-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl)methyl)piperazin-1 -yl)-N-((4-(( 1 -cyclopropylpiperidin-4-yl)amino)-3- nitrophenyl)sulfonyl)benzaniide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(2,5- dich]oiophenoxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3- nitiophenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(3-moipholin-4-ylphenoxy)-N- ((4-((3-moipholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 2-(3-(benzyloxy)phenoxy)-4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((3- nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)aniino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-y])methyl)piperazin-l-yl)-2-(4-cyanophenoxy)-N-((3-nitro- 4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(4- ((dimethylamino)methyl)phenoxy)-N-((3-nitTO-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzaniide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(4-( IH-imidazol-1 -yl)phenoxy)- N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 148 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(3-nitrophenoxy)-N-((4- ((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; tert-butyl 4-(5-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-((((3-nitro-4- ((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)aniino)caibonyl)phenoxy)benzyl(ethyl)carbamate; tert-butyl 3-(5-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-((((3-nitro-4- ((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)amino)carbony])phenoxy)benzyl(ethyl)carbamate; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(4- ((ethylamino)methyl)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1, l'-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(3- ((ethylamino)methyl)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 2-(4-(acetylainino)phenoxy)-4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N- ((3-nitro-4-((tetrahydro-2H-pyran-4-yImethyl)amino)phenyl)sulfonyl)benzamide; tert-butyl 4-(5-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-((((3-nitro-4- ((tetrahydro-2H-pyran-4- ylmethyl)aniino)phenyl)sulfonyl)amino)caibonyl)phenoxy)phenylcari?amate; 2-(l,l'-biphenyl-2-yloxy)-4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((3- nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; tert-butyl 3-(5-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-((((3-nitro-4- ((tetrahydro-2H-pyran-4- ylmethyl)aimno)phenyl)sulfonyl)amino)caibonyl)phenoxy)phenylcari5amate; 2-( 1, l'-biphenyl-3-yloxy)-4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((3- nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)aniino)phenyl)sulfonyl)benzamide; 4-(4-((4'-ch]oro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(4-(2- (dimethylaniino)ethyl)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 2-(4-(benzyloxy)phenoxy)-4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((3- nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-morpholin-4-ylphenoxy)-N- ((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 149 tert-bulyl4-(3-(5-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-((((3-nitro-4- ((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)amino)carbonyl)phenoxy)phenyl)piperazine-l-carboxylate; 2-(3-(benzyloxy)phenoxy)-4-(4'((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4- ((3-(dimethylamino)propyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 2-(3-(benzyloxy)phenoxy)-4-(4'((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin- l-yl)-N-((4- ((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1, r-biphenyl-2'yl)methyl)piperazin-1 -yl)-2-(4-(2-morpholiii-4- ylethoxy)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 2-(4-(benzyloxy)phenoxy)-4-(4'((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((4- ((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide; tert-butyl 4-(4-(5-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-l -yl)-2-((((4-((3- morpholin-4-ylpropyl)amino)-3 - nitrophenyl)sulfonyl)amino)caibonyl)phenoxy)phenyl)piperazine-l-caiboxylate; 4-(4-((4'-chloro-1, l'-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((4-((3-morpholin-4- ylpropyl)aiiiino)-3-nitrophenyl)sulfonyl)-2-(3-pyridin-4-ylphenoxy)benzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((4-((3-morpholin-4- ylpropyl)amino)-3-nitrophenyl)sulfonyl)-2-(4-pyridin-4-ylphenoxy)benzamide; 4-(4-((4'-chloro-1, l'-biphenyl-2'yl)methyl)piperazin-1 -yl)-N-((4-((3-morpholin-4- ylpropyl)amino)-3-nitrophenyl)sulfonyl)-2-(4-pyridin-3-ylphenoxy)benzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(4-(2-(dimethylanuno)-2- oxoethoxy)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-(methylcarbamoyl)phenoxy)-N-(4- (3-morpholinopiopylamino)-3-nitrophenylsulfonyl)benzainide; 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-N-(4-(3-(dimethylamino)propylaniino)- 3-nitrophenylsulfonyl)-2-(3-(m6thylcarbamoyl)phenoxy)benzamide; 4-(4-((4'-chloro-1, l'-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(3-(2-(dimethylamino)-2- oxoethoxy)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,l'-biphenyl-2'yl)methyl)piperazin-l-yl)-N-((4-((3- (dimethylamino)propyl)amino)'3-nitrophenyl)sulfonyl)-2-(3- (hydroxymethyl)phenoxy)benzamide; 150 N-(4-((4-aminotetrahydro-2H-pyran-4-yl)methylamino)-3-nitrophenylsulfonyl)-2-(3- chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l- yl)benzamide; 4-(4-(l-(4'-chlorobiphenyl-2-yl)ethyl)piperazin-l-yl)-2-(2-chlorophenoxy)-N-(3-nitro-4- ((tetrahydro-2H-pyran-4-yl)methylamino)phenylsulfonyl)benzamide; N- {[4- {4-[(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl} -2-(3,5- dichlorophenoxy)phenyl]sulfonyl}-4-[(l-methylpiperidin-4-yl)amino]-3-nitrobenzainide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(3- fluorophenoxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl jpiperazin-1 -yl)-2-(3- fluorophenoxy)-N-({3-nitro-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl}sulfonyl)benzamide; 4-(4- ([2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-(3- fluorophenoxy)-N-({4-[(3-morpholin-4-ylpropyl)anuno]-3-nitrophenyl}sulfonyl)benzamide; 2-(2-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yljmethyl} piperazin-1 -yl)-N-( {3-nitro-4- [(1 -tetrahydTO-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl} sulfonyl)benzamide; 2-(2-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({4-[(3-morpholin-4-ylpropyl)amino]-3- nitrophenyl} sulfonyl)benzamide; 2-(2-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({4-[(l-cyclopentylpiperidin-4-yl)aniino]-3- nitrophenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-2-(4- fluorophenoxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)benzamide; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({4-[(l-cyclopropylpiperidin-4-yl)ainino]-3- nitrophenyl} sulfonyl)benzamide; 2-(2-chloro-4-fluorophenoxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl]piperazin-l-yl)-N-({4-[(3-morpholin-4-ylpiopyl)amino]-3- nitrophenyl} sulfonyl)benzamide; 4-(4- [ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]niethyl) piperazin-1 -yl)-N-({4- [(l-cyclopropylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(2,3- difluoiophenoxy)benzamide; 151 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl} piperazin-1 -yl)-2-(2- fluorophenoxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)benzamide; 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl}piperazin- l-yl)-N-({4- [(l-cyclopropylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(2- fluorophenoxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl )piperazin-1 -yl)-2-(2- fluorophenoxy)-N-({3-nitro-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl}sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-2-(2- fluorophenoxy)-N-({4-[(3-morpholin-4-ylpropyl)amino]-3-nitrophenyl)sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-2-(2- fluorophenoxy)-N-({4-[(2-morpholin-4-ylethyl)aniino]-3-nitrophenyl}sulfonyl)benzamide; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl ] piperazin- l-yl)-N-({ 3-nitro-4- [(1 -tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl} sulfonyl)benzamide; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l -en-1 - yl]methyl]piperazin-l-yl)-N-({4-[(3-morpholin-4-ylpropyl)amino]-3- nitrophenyl} sulfonyl)benzainide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-2-(3- fluorophenoxy)-N-({4-[(2-morpholin-4-ylethyl)amino]-3-nitrophenyl}sulfonyl)benzamide; 2-(3 -chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({4-[(l-cyclopentylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl} piperazin-1 -yl)-N-( {4- [(1 -methy lpiperidin-4-yl)amino]-3 - [(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N-({ 4- [(l-cyclopropylpiperidin-4-yl)amino]-3-nitrophenyl} sulfonyl)-2-(3- fluorophenoxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N-( {4- [(l-cyclopentylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(2,3- difluorophenoxy)benzamide; 152 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl) piperazin- l-yl)-N-( {4- [(l-cyclopentylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(2- fluorophenoxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-2-(2,3- difluorophenoxy)-N-({4-[(2-morpholin-4-ylethyl)amino]-3-nitrophenyl}sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(2,3- difluorophenoxy)-N-[(3-nitro-4- {[ l-(thien-3-ylmethyl)piperidin-4- yl]amino}phenyl)sulfonyl]benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-[(4- {[3-(dimethylamino)propyl]amino}-3-nitrophenyl)sulfonyl]-2-(2-fluorophenoxy)benzamide; 4-(4- {[2-(4-chIorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]niethyl }piperazin-1 -yl)-N-[(4- {[3-(dimethylamino)propyl]ammo} -3-nitrophenyl)sulfonyl]-2-(3-fluorophenoxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-N- [(4- {[3-(dimethylamino)propyl]amino}-3-nitrophenyl)sulfonyl]-2-(4-fluorophenoxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-(2,3 - difluorophenoxy)-N-[(4- {[ 1 -(2-fluoroethyl)piperidin-4-yl]amino) -3- nitrophenyl)sulfonyl]benzamide; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({4-[(2-morpholin-4-ylethyl)amino]-3- nitrophenyl}sulfonyl)benzamide; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl)piperazin-l-yl)-N-[(4-{[3-(dimethylamino)propyl]aniino}-3- nitrophenyl)sulfonyl]benzamide; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl} piperazin- l-yl)-N- [(4- {[3-(4-methylpiperazin- l-yl)propyl]anaino} -3- nitrophenyl)sulfonyl]benzamide; 2-(3-chlorophenoxy)-4-(4- {[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3 - yl]methyl]piperazin-l-yl)-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- 2-(2,3-difluorophenoxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; N-({4-[(l-allylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4- dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(2,3-difluorophenoxy)benzamide; 153 2-(3-chloio-2-fluorophenoxy)-4-(4- {I2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1- yl]methyl} piperazin-1 -yl)-N-( {4-[( 1 -methylpiperidin-4-yl)amino] -3 - nitrophenyl} sulfonyl)benzaniide; 2-(3 -chloro-2-fluoiophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({4-[(3-morpholin-4-ylpropyl)amino]-3- nitrophenyl} sul fonyl)benzamide; 2-(3-chloro-2-fluorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1- yl]methyl} piperazin-1 -yl)-N-( {3-nitro-4- [(3 -pyrrolidin-1 - ylpropyl)amino]phenyl} sulfonyl)benzamide; 2-(3-chloro-2-fluorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({4-[(2-morpholin-4-ylethyl)amino]-3- nitrophenyl}sulfonyl)benzamide; 2-(2-chloio-6-fluorophenoxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 2-(2-chloro-6-fluorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({3-nitro-4-[(l-tetrahydio-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl}sulfonyl)benzamide; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-[(4-{[(l-methylpiperidin-4-yl)methyl]amino}-3- nitrophenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl) piperazin-1 -yl)-2-(2,3- difluorophenoxy)-N-[(4- {[(l-methylpiperidin-4-yl)methyl]amino} -3- nitrophenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2- [3- (methoxymethoxy)-2-methylphenoxy]-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yljmethyl} piperazin-1 -yl)-2-(3- hydroxy-2-methyIphenoxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl )sulfonyl)benzamide; 2-(3-bromophenoxy)-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3- yl]methyl} piperazin-1 -yl)-N-( {4-[( 1 -methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 154 4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)-2-(3-iodophenoxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitiophenyl} sulfonyl)benzamide; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin- l-yl)-N-[(4-{ [ l-(2-hydroxyethyl)piperidin-4-yl]amino} -3-nitrophenyl)sulfonyl]benzamide; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl]piperazin-l-yl)-N-[(3-nitro-4-{[l-(2-phenylethyl)piperidin-4-yl]amino}phenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl} piperazin-1 -yl)-2-(3,4-dichlorophenoxy)-N-({ 4- [(1 -methylpiperidin-4-yl)aniino]-3-nitrophenyl} sulfonyl)benzamide; 2-(2-chloro-3,5-difluoiophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1-yl)-N-({ 4-[(1-methylpiperidin-4-yl)amino]-3-nitrophenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl} piperazin-1 -yl)-2-(3-methoxyphenoxy)-N-( {4-[( 1-methylpiperidin-4-yl)a^lino]-3-nit^opheny 1 } sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]niethyl} piperazin-1 -yl)-2- [3-(hydroxymethyl)phenoxy]-N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitrophenyl} sulfonyl)benzanude; 2-(2-chlorophenoxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl} piperazin-1 -yl)-N-( {4- [(1,4-dimethy lpiperidin-4-yl)amino] -3 -nitrophenyl} sulfonyl)benzaniide; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-l-yl)-N-({4-[(l,4-dimethylpiperidin-4-yl)amino]-3-nitrophenyl} sulfonyl)benzamide; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin- l-yl)-N- {[4-( {1 -[2-(2-methoxyethoxy)ethyl]piperidin-4-yl} amino)-3-nitrophenyl]sulfonyl }benzainide; 2-(2-chloro-3-hydroxyphenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl ] piperazin-1 -yl)-N-( {4-[( 1 -methylpiperidin-4-yl)amino]-3-nitrophenyl} sulfonyl)benzamide; 155 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-[(3-nitro-4-{[l-(3-phenylpropyl)piperidin-4- yl]ainino)phenyl)sulfonyl]benzainide; 2-(3-chlorophenoxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yljmethyl} piperazin-1 -yl)-N- [(4- {[ 1 -(2-methoxyethyl)piperidin-4-yl] amino} -3 - nitrophenyl)sulfonyl]benzamide; 2-(3-chlorophenoxy)-4-(4-{l2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl} piperazin-1 -yl)-N-( {4-[( 1 -ethylpiperidin-4-yl)amino]-3 - nitrophenyl} sulfonyl)benzamide; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({4-[(l-isopropylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl }piperazin- l-yl)-2-(3- hydroxyphenoxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitxophenyl}sulfonyl)benzamide; 2-(2-chloro-3-fluorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1- yl]methyl) piperazin-1 -yl)-N-( {4-[( 1 -methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 2-(2-chloro-3-fluorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1- yl]methyl} piperazin- l-yl)-N-( {3 -nitro-4- [(1 -tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl} sulfonyl)benzamide; 2-(2-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-[(4-{l3-(dimethylamino)propyl]amino)-3- nitiDphenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl) piperazin-1 -yl)-2-(2- methoxyphenoxy )-N-( {4-[( 1 -methy lpiperidin-4-yl)amino] -3 - nitrophenyl} sulfonyl)benzaimde; 4-(4-([2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-2-(2- methylphenoxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl} piperazin-1 -yl)-2-(3- methylphenoxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)benzamide; 2-(2-chlorophenoxy)-4-(4- {[6-(4-chlorophenyl)-l ,3-benzodioxol-5-yl]methyl }piperazin-1- yl)-N-([4-[(l -niethylpiperidin-4-yl)aminol-3-nitrophenyl ] sulfonyl)benzamide; 156 2-(2-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({4-[(4-methylpiperazin-l-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 2-(3-chlorophenoxy)-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3- yl]methyl}piperazin-l-yl)-N-({4-[(4-methylpiperazin-l-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- 2-(2,3-difluorophenoxy)-N-({4-[(4-methylpiperazin-l-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-diniethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-[(4-{[l-(cyclopropylmethyl)piperidin-4-yl]amino}-3- nitrophenyl)sulfonyl]benzamide; 2-(2-chloiophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-[(4-{[l-(cyclopropylmethyl)piperidin-4-yl]amino}-3- mtiophenyl)sulfonyl]benzamide; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-diniethylcyclohex-1 -en-1 - yl]methyl} piperazin- l-yl)-N- {[4-( {1 -[2-(dimethylamino)-2-oxoethyl]piperidin-4-yl} amino)- 3-nitrophenyl]sulfonyl}benzamide; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl} piperazin-1 -yl)-N-[(4- {[ l-(2-morpholin-4-ylethyl)piperidin-4-yl]amino} -3- nitrophenyl)sulfonyl]benzamide; N-[(4- {[(4-aminotetrahydro-2H-pyran-4-yl)methyl]amino} -3-nitrophenyl)sulfonyl]-2-(2- chlorophenoxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)benzamide; 2-(2-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl ] piperazin-1 -yl)-N- [(4- {[(4-hydroxy-1 -methylpiperidin-4-yl)methyl]amino ] -3- nitrophenyl)sulfonyl]benzamide; 2-(3-chloiDphenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-[(4-{[(3S)-l-methylpyrrolidin-3-yl]amino}-3- nitrophenyl)sulfonyl]benzanude; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-[(4-([(3R)-l-methylpyrrolidin-3-yl]amino}-3- mtrophenyl)sulfonyl]benzamide; 157 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-({4- [(1 -methylpiperidin-4-yl)amino]-3-nitrophenyl} sulfonyl)-2- [3-( 1 H-pyiTol-2- yl)phenoxy]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-2-(3- fluorophenoxy)-N-[(4-{[(4-hydroxy-l-methylpiperidin-4-yl)methyl]amino}-3- nitrophenyl)sulfonyl]benzamide; 2-(3 -chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl} piperazin- l-yl)-N-( {4-[(4-methylpiperazin-1 -yl)amino]-3- nitrophenyl}sulfonyl)benzamide; 2-(3-chlorophenoxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl} piperazin-1 -yl)-N- [(4- {[4-(dimethylamino)cyclohexyl]amino} -3- nitrophenyl)sulfonyl]benzamide; 2-(3-chloiophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-[(4-{[4-(diethylamino)cyclohexyl]amino}-3- nitrophenyl)sulfonyl]benzamide; Trans-2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({4-[(4-morpholin-4-ylcyclohexyl)amino]-3- nitrophenyl} sulfonyl)benzamide; 4-{4-[l-(4'-chloro-l,l'-biphenyl-2-yl)ethyl]piperazin-l-yl}-2-(2-chlorophenoxy)-N-({4-[(l- methylpiperidin-4-yl)amino]-3-nitrophenyl} sulfonyl)benzamide; 2-(2-chloro-4-hydroxyphenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl)piperazin-l-yl)-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 2-(2-chloro-4-hydroxyphenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl} piperazin-1 -yl)-N-( {4- [(4-methy Ipiperazin-1 -y l)aniino]-3 - nitropheny 1} sulfony l)benzamide; 2-(2-chloro-4-hydroxyphenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-diniethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({4-[(4-methylpiperazin-l-yl)amino]-3- [(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide; 2-(5-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-2-(4-(l- metbylpiperidin-4-ylamino)-3-nitrophenylsulfonylcarbamoyl)phenoxy)-N,N- dimethylbenzamide; 158 2-(2-chloro-4-hydroxyphenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N-( {3-nitro-4- [(1 -tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]phenyl} sulfonyl)benzamide; 2-[3-(acetylamino)phenoxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-l-yl)-N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitrophenyl} sul fonyl)benzaniide; 2-[3-(acetylamino)phenoxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N-({ 3 -nitro-4- [(1 -tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]phenyl} sulfonyl)benzamide; 2-(3 -chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-l-yl)-N-({3-nitro-4-[(tetTahydro-2H-pyran-4-ylmethyI)amino]phenyl} sulfonyl)benzamide; 2-(4-aniino-3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N-({ 3-nitro-4- [(tetrahydro-2H-pyTan-4-ylmethyl)aniino]phenyl} sulfonyl)benzamide; 2-(2-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l -en-1 -yl]methyl }piperazin- l-yl)-N- {[4-( {[4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl]methyl) amino)-3-nitrophenyl]sulfonyl} benzamide; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-l-yl)-N-{[4-(morpholin-4-ylamino)-3-nitrophenyl]sulfonyl}benzamide; 2-(2-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l -en-1 -yljmethyl} piperazin-1 -yl)-N- [(3 -nitro-4- {[3-(3 -oxopiperazin-1 -yl)propyI]aniino}pheny])sulfonyl]benzamide; 2-(3-amino-5-chlorophenoxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimediylcyclohex-l-en-l-yl]methyl }piperazin- l-yl)-N-({ 3-nit^o-4-[(tet^ahyd^o-2H-pyran-4-y lmethyl)amino]phenyl ) sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-[2-(lH-pyrazol-4-yl)phenoxy]benzamide; 2-[2-(2-aminopyridin-3-yl)phenoxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin- l-yl)-N-( {3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)aniino]phenyl}sulfonyl)benzamide; 4-(4- {[2-(4-chIorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-N-( {3- nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-[2-(IH-pyrazol-5- 159 yl)phenoxy]benzamide; and therapeutically acceptable salts, prodrugs, salts of prodrugs and metabolites thereof. In another aspect, the present invention provides compounds of Formula (III) pi J^ R1 O*^ -NH D' I (in) and therapeutically acceptable salts, prodrugs, salts of prodrugs and metabolites thereof, wherein A', B', D', E', Y', Z^, L', and 7? are as described herein for Formula (I), n is 0,1,2, or 3; describing die number of additional substituents on R^^, and R'"" is as described for substituents on R , and at least one R is a substituent as described for substituents on R and R''^^, and the remainder are H. In one embodiment of Formula (IE), A* is N. In another embodiment of Formula (III), A' is C(A^). In another embodiment of Formula (HI), A' is C(A^); and A^ is H. In one embodiment of Formula (IE), B^ is NHC(0)R\ NHSOIR', OR', or NHR'. In another embodiment of Formula (III), A' is C(A^); A^ is H; and B' is NHR*. In another embodiment of Formula (III), A' is C(A^); A^ is H; and B' is OR'. In another embodiment of Formula (HI), A' is C(A^); A^ is H; and B' is NHSO2R'. In another embodiment of Formula (m). A' is C(A^); A^ is H; and B' is NHC(0)R'. In another embodiment of Formula (HI), A' is C(A^) or N; A^ is H; and B' is NHR'. In another embodiment of Formula (IH), A' is C(A^) or N; A^ is H; and B' is OR'. In another embodiment of Formula (HI), A' is C(A^) or N; A^ is H; and B' is NHSO2R'. In another embodiment of Formula (HI), A' is C(A^) or N; A^ is H; and B' is NHC(0)R'. In one embodiment of Formula (IH), D' is H. In another embodiment of Formula (HI), A' is C(A^); A^ is H; B' is NHR'; and D' is H. In another embodiment of Formula (IB), A' is C(A^); A^ is H; B' is OR'; and D' is H. In another embodiment of Formula (IH), A' is C(A^); A^ is H; B' is NHSO2R'; and D' is H. In another embodunent of Formula (III), A' is 160 C(A^); A^ is H; B* is NHC(0)R^ and D' is H. In another embodiment of Formula (UI), A' is C(A^) or N; A^ is H; B' is NHR^; and D' is H. In another embodiment of Formula (III), A' is C(A^) or N; A^ is H; B' is OR'; and D' is H. In another embodiment of Formula (III), A' is C(A^) or N; A^ is H; B' is NHSO2R'; and D' is H. In another embodiment of Formula (III), A' is C(A^) or N; A^ is H; B' is NHC(0)R'; and D^ is H. In one embodiment of Formula (III), E' is H. In another embodiment of Formula (HI), A' is C(A^); A^ is H; B' is NHR'; D' is H; and E' is H. In another embodiment of Formula (HI), A' is C(A^); A^ is H; B' is OR^ D' is H; and E' is H. In another embodiment of Formula (ffl), A' is C(A^); A^ is H; B' is NHSO2R'; D' is H; and E' is H. In another embodiment of Formula (HI), A' is C(A^); A^ is H; B' is NHC(0)R'; D' is H; and E' is H. In another embodiment of Formula (IH), A' is C(A^) or N; A^ is H; B' is NHR'; D' is H; and E' is H. In another embodiment of Formula (HI), A' is C(A^) or N; A^ is H; B' is OR'; D' is H; and E' is H. In another embodiment of Formula (HI), A' is C(A^) or N; A^ is H; B' is NHSO2R'; D' is H; and E' is H. In another embodiment of Formula (IE), A* is C(A^) or N; A^ is H; B' is NHC(0)R'; D' is H; and E' is H. In one embodiment of Formula (IH), Y' is H, CN, NO2, F, CI, Br, CF3, R'\ or S02R'^. In another embodiment of Formula (III), Y' is NO2. In another embodiment of Formula (HI), Y' is CI. In another embodiment of Formula (III), Y* is SO2R"; wherein R" is as defined herein. In anodier embodiment of Formula (HI), Y' is SO2R"; wherein R'' is alkyl. In another embodiment of Formula (HI), Y' is R"; wherein R^^ is alkynyl. In another embodiment of Formula (HI), A' is C(A^); A^ is H; B' is NHR'; D* is H; E' is H; and Y' is NO2 or SO2R''; wherein R" is alkyl or alkynyl. In another embodiment of Formula (in). A' is C(A^); A^ is H; B' is NHR'; D' is H; E' is H; and Y' is NO2. In another embodiment of Formula (HI), A' is C(A^); A^ is H; B' is NHR'; D' is H; E' is H; and Y' is SO2R", wherein R" is alkyl substituted with three F. In another embodiment of Formula (HI), A' is C(A^); A^ is H; B' is OR'; D' is H; E' is H; and Y' is CI. In another embodiment of Formula (HI), A' is C(A^) or N; A^ is H; B' is NHR'; D' is H; E' is H; and Y' is NO2 or SO2R"; wherein R" is alkyl or alkynyl. In another embodiment of Formula (HI), A' is C(A^) or N; A^ is H; B' is NHR'; D' is H; E' is H; and Y' is NO2. In another embodiment of Formula (IH), A' is C(A^) or N; A^ is H; B' is NHR'; D' is H; E' is H; and Y' is SO2R", wherein R" is alkyl substituted with three F. In another embodiment of Formula (HI), A' is C(A^) or N; A^ is H; B' is OR'; D' is H; E' is H; and Y' is CI. 161 In one embodiment of Formula (III), R' is R^, and R^ is phenyl. In another embodiment of Formula (HI), R' is R^, and R^ is phenyl which is substituted with NO2, and NHR". In one embodiment of Formula (in), R' is R"* or R^. In one embodiment of Formula (in), R' is R'*. In one embodiment of Formula (HI), R' is R^. In one embodiment of Formula (ni), R' is R'*; and R"* is cycloalkyl, or heterocycloalkyl. In one embodiment of Formula (III), R' is R'*; and R'* is cycloalkyl. In one embodiment of Formula (III), R' is R'*; and R'' is heterocycloalkyl. In one embodiment of Formula (IB), R' is R'*; and R'* is cycloalkyl; wherein R'* is unsubstituted or substituted as defined herein. In another embodiment of Formula (III), R' is R'*; and R'* is cycloalkyl; wherein the cycloalkyl ring is substituted as defined herein. In another embodiment of Formula (III), R' is R"*; and R"* is cycloalkyl; wherein the cycloalkyl ring is substituted with R'^, NHR^', or N(R^^)2. In another embodiment of Formula (HI), R' is R'*; and R'* is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and wherein the cyclohexyl ring is substituted with R^^; and R^' is R^. In another embodiment of Formula (III), R' is R'*; R'' is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and wherein the cyclohexyl ring is substituted with R*^; R^' is R^; and R** is heterocycloalkyl. In another embodiment of Formula (HI), R' is R''; R'' is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and wherein the cyclohexyl ring is substituted with R^^; R^' is R^; R^ is heterocycloalkyl; wherein the heterocycloalkyl ring is morpholinyl or piperazinyl. In another embodiment of Formula (HI), R' is R'*; and R'' is cycloalkyl; wherein the cycloalkyl ring is substituted widi N(R^^)2. In another embodiment of Formula (III), R' is R'*; and R'' is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and wherein the cyclohexyl ring is substituted with N(R^^)2. In another embodiment of Formula (HI), R' is R''; and R'* is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and wherein the cyclohexyl ring is substituted with N(R")2, R^^ is R^\ and R^' is alkyl which is unsubstituted. In another embodiment of Formula (III), R' is R'*; and R'' is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and wherein the cyclohexyl ring is substituted with N(R^^)2, R^^ is R^, and R*" is cycloalkyl which is unsubstitated. In another embodiment of Formula (IE), R' is R"; and R'' is cycloalkyl; wherein the cycloalkyl ring is substituted with NHR^^. In another embodiment of Formula (in), R' is R'*; and R'* is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and wherein the cyclohexyl ring is substituted with NHR^'. In another embodiment of Formula (HI), R' is R"*; and R"* is cycloalkyl; wherein the cycloalkyl ring is cyclohexyl; and 162 wherein the cyclohexyl ring is substituted with NHR", R^^ is R^, and R^ is heterocycloalkyl which is unsubstituted. In one embodiment of Formula (III), R' is R''; and R'* is heterocycloalkyl; wherein R"* is unsubstituted or substituted as defined herein. In another embodiment of Formula (in), R is R*; and R* is heterocycloalkyl; wherein the heterocycloalkyl ring is substituted as defined herein. In another embodiment of Formula (III), R' is R*; and R"* is heterocycloalkyl; wherein the heterocycloalkyl ring is substituted with R'^. In another embodiment of Formula (III), R' is R'*; and R* is heterocycloalkyl; wherein the heterocycloalkyl ring is piperidinyl, pjorolinyl, morpholinyl, or piperizinyl; and wherein the heterocycloalkyl ring is substituted with one or two or three or four or five more R"; SOzR^.or OH, and R" is R^ or R^'. In another embodiment of Formula (HI), R' is R''; R"* is heterocycloalkyl; wherein the heterocycloalkyl ring is piperidinyl, pyrrolinyl, morpholinyl, or piperizinyl; and wherein the piperidinyl, pyrrolinyl, morpholinyl, or piperizinyl; ring is substituted with R^'; R'^ is R^ or R^'; R^ is cycloalkyl or heterocycloalkyl; and R*' is alkyl. In another embodiment of Formula (in), R^ is R'*; R"* is heterocycloalkyl; wherein the heterocycloalkyl ring is piperidinyl, pyrrolinyl, morpholinyl, or piperizinyl; and wherein the piperidinyl, pyrrolinyl, morpholinyl, or piperizinyl; ring is substituted with R^^; R*^ is R^; R*' is heterocycloalkyl, wherein the heterocycloalkyl is morpholinyl, tetrahydropyranyl or oxetanyl. In another embodiment of Formula (III), R^ is R*; R* is heterocycloalkyl; wherein the heterocycloalkyl ring is piperidinyl, pyrrolinyl, morpholinyl, or piperizinyl; and wherein the piperidinyl, pyrrolinyl, morpholinyl, or piperizinyl; ring is substituted with R^^; R^' is R^; R^ is cycloalkyl, wherein the cycloallQ'l is cyclopropyl or cyclopentyl. In another embodiment of Formula (III), R^ is R"*; R* is heterocycloalkyl; wherein the heterocycloalkyl ring is piperidinyl, pyrrolinyl, morpholinyl, or piperizinyl, and wherein the piperidinyl, pyrrolinyl, morpholinyl, or piperizinyl ring is substituted with one or two or three or four or five R^^; R^^ is R^\ R^' is alkyl; and the alkyl is Ci-alkyl, C2-alkyl, or Cs-alkyl. In another embodiment of Formula (III), R' is R'*; R"* is heterocycloalkyl; wherein the heterocycloalkyl ring is piperidinyl, pyrrolinyl, morpholinyl, or piperizinyl, and wherein the piperidinyl, pyrrolinyl, morpholinyl, or piperizinyl ring is substituted with one or two or three or four or five R^'; R^^ is R*'; R*' is I alkyl; and the alkyl is Ci-alkyl, Ca-alkyl, or Cs-allcyl; wherein the Ci-alkyl, Ci-alkyl, or C3-alkyl are unsubstituted or substituted. In one embodiment of Formula (III), R' is R^; and R' is alkyl which is unsubstituted or substituted. In one embodiment of Formula (HI), R' is R^; and R^ is alkyl which is unsubstituted or substituted with R^, 0R\ N(R^)2, or OH. 163 In one embodiment of Formula (III), R^ is R'" or R" which are unsubstituled or substituted as defined herein. In another embodiment of Formula (HI), R^ is R'° which is unsubstituted or substituted as defined herein. In another embodiment of Formula (III), R' is R" which is unsubstituted or substituted as defined herein. In one embodiment of Formula (III), R'° is cycloalkyl or heterocycloalkyl which are unsubstituted or substituted as defined herein. In another embodiment of Formula (III), R"' is heterocycloalkyl which is unsubstituted or substituted as defined herein. In another embodiment of Formula (HI), R'" is tetrahydrofuranyl, tetrahydropyranyl, morpholinyl, dioxanyl, piperidinyl, piperizinyl, or pyrrolidinyl, which are unsubstituted or substituted as defined herein. In another embodiment of Formula (III), R'° is tetrahydropyranyl, which is unsubstituted or substituted as defined herein. In another embodiment of Formula (III), R'" is morpholinyl, which is unsubstituted or substituted as defined herein. In another embodiment of Formula (in), R'° is cycloaUcyl which is unsubstituted or substituted as defined herein. In another embodiment of Formula (IE), R'" is cyclohexyl which is unsubstituted or substituted as defined herein. In one embodiment of Formula (III), R" is alkyl which is unsubstituted. In another embodiment of Formula (III), R" is methyl, which is unsubstituted or substituted as defined herein. In another embodiment of Formula (IE), R'' is alkyl, which is substituted as defined herein. In another embodiment of Formula (IE), R" is alkyl, which is substituted with OR'^, R'^ is R'^ and R^^ is alkyl. In one embodiment of Formula (IE), n is 0. Still another embodiment pertains to compounds having Formula (IE), which are 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-((2- methyl-lH-indol-5-yl)oxy)-N-((4-((l-methylpiperidin-4-yl)amino)-3- nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl)methyl)piperazin-1 -yl)-2-((2- methyl-lH-indol-5-yl)oxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3- nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-2-((7- fluoro-lH-indol-5-yl)oxy)-N-((4-((l-methylpiperidin-4-yl)amino)-3- nitrophenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((4-((3- (dimethylamino)propyl)amino)-3-nitrophenyl)sulfonyl)-2-((3-(3-morpholin-4-yl-3- oxopropyl)-lH-indol-5-yl)oxy)benzamide; 164 4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-2-((3-(3-morpholin-4-yl-3- oxopropyl)-lH-indol-5-yl)oxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-((3-(3-morpholin-4-ylpropyl)- lH-indol-5-yl)oxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-((3-(3-(dimethylamino)propyl)- lH-indol-5-yl)oxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-([2-(4-chlorophenyl)-4,4-diniethylcyclohex-l-en-l-yllmethyl)piperazin-l-yl)-2-[(6- fluoro-lH-indol-5-yl)oxy]-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-[(4- fluoro-lH-indol-5-yl)oxy]-N-({4-[(l-methylpiperidin-4-yl)ainino]-3- nitrophenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-2- [(6- fluoro-lH-indol-5-yl)oxy]-N-({3-nitro-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl}sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl]piperazin-l-yl)-2-[(6,7- difluoro-lH-mdol-5-yl)oxy]-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-diniethylcyclohex- 1-en-1 -yljmethyl )piperazin-1 -yl)-2-l(6,7- difluoro-1 H-indol-5-yl)oxy]-N-( {3 -nitTO-4- [(1 -tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl}sulfonyl)benzamide; 4-(4- ([2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yllmethyl} piperazin- l-yl)-N-({4- [(l-methylpiperidin-4-yl)amino]-3-nitrophenyl }sulfonyl)-2- {[6-(trifluoromethyl)-l H-indol-5- yl]oxy }benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimetiiylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-N-({3- nitro-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]phenyl)sulfonyl)-2-{[6- (trifluoromethyl)-lH-indol-5-yl]oxy}benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-2-[(6,7- difluoro-lH-indol-5-yl)oxy]-N-({4-[(4-methylpiperazin-l-yl)amino]-3- nitrophenyl} sulfonyl)benzaniide; 165 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-2-[(6- fluoro-1 H-indol-5-yl)oxy ] -N-( {4- [(4-methylpiperazin-1 -yl)amino] -3- nitrophenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-2- [(6- methoxy-lH-indol-5-yl)oxy]-N-({3-nitro-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl} sulfonyl)benzamide; tert-butyl 5- [5-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 - yl)-2-({ [(4-{ [3-(dimethylamino)propyl]amino}-3- nitrophenyl)sulfonyl] amino} carbonyl)phenoxy ]- IH-indole-1 -carboxylate; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-[(6- fluoro- lH-indol-5-yl)oxy]-N-[(3-nitro-4- {[3-(3-oxopiperazin-l - yl)propyl] amino} phenyl)sulfonyl]benzamide; Trans-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2- [(6-fluoro-1 H-indol-5-yl)oxy]-N-( (4-[(4-morpholin-4-ylcyclohexyl)amino]-3- nitrophenyl} sulfonyl)benzamide; Trans-4-(4- {[2-(4-chlorophenyl)-4,4-dimediylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2- [(6,7-difluoro-lH-indol-5-yl)oxy]-N-({4-[(4-morpholin-4-ylcyclohexyl)amino]-3- nitrophenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N- [(4- {[ 1 -(cyclopropylmethyl)piperidin-4-yl]amino} -3 -nitrophenyl)sulfonyl] -2-[(6-fluoro-1H- indol-5-yl)oxy]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-N- [(4- {[l-(cyclopropylmethyl)piperidin-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-[(6,7-difluoro-lH- indol-5-yl)oxy]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2- [(6- fluoro-lH-indol-5-yl)oxy]-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)benzamide; 4-(4- ([2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl} piperazin-1 -yl)-2- [(6,7- difluoro-lH-indol-5-yl)oxy]-N-[(3-nitro-4-{[3-(3-oxopiperazin-l- yl)propyl]amino}phenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl) piperazin- l-yl)-2-[(6- fluoro-lH-indol-5-yl)oxy]-N-({4-[(2-hydroxy-l-tetrahydro-2H-pyran-4-ylethyl)amino]-3- nitxophenyl} sulfonyl)benzamide; 166 4-(4- {[2-(4-chloropheny l)-4,4-dimethylcyclohex- 1-en-1 -yljmethyl) piperazin-1 -yl)-2- [(6- fluoro-lH-indol-5-yl)oxy]-N-{[4-({[4-(hydroxymethyl)tetrahy(iro-2H-pyran-4- yl]methyl}amino)-3-nitrophenyl]sulfonyl}benzamide; 2-[(6-chloro- lH-indol-5-yl)oxy]-4-(4- {[2-(4-chloiophenyl)-4,4-dimethylcyclohex- 1-en-1- yl]methyl}piperazin-l-yl)-N-({3-nitro-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl) piperazin-1 -yl)-2- [(6,7- difluoro-lH-indol-5-yl)oxy]-N-({3-nitro-4-[(tetrahydio-2H-pyran-4- ylmethyl)aniino]phenyl}sulfonyl)benzamide; 2- [(6-chloro- lH-indol-5-yl)oxy] -4-(4- {[2-(4-chlorophenyl)-4,4-dimethy Icyclohex-1 -en-1 - yl]methyl jpiperazin-1 -yl)-N-( {4-[(4-methylpiperazin-l -yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-2-[(6- fluoro- lH-indol-5-yl)oxy]-N-I(3-nitro-4- {[ 1 -(1,3-thiazol-4-ylmethyl)piperidin-4- yl]amino} phenyl)sulfonyl]benzaniide; N-[(4- {[(4-aminotetrahydro-2H-pyran-4-yl)niethyl]ainino} -3-nitrophenyl)sulfonyl]-4-(4- {[2- (4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl }piperazin-1 -yl)-2-[(6-fluoro- IH- indol-5-yl)oxy]benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-2-[(6- fluoro-lH-indol-5-yl)oxy]-N-[(4-{[(3S,4R)-3-hydroxy-l-(l,3-thiazol-4-ylmethyl)piperidin-4- yl]amino} -3-nitrophenyl)sulfonyI]benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-2-[(6- fluoro- lH-indol-5-yl)oxy]-N- {[3-nitro-4-(tetrahydro-2H-pyran-4- ylamino)phenyl]sulfonyI}benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl) piperazin-1 -yl)-2- [(6- fluoro-lH-indol-5-ylX)xy]-N-{[4-(morpholin-4-ylamino)-3-nitrophenyl]su]fonyl}benzamide; 4-(4-{l-[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]ethyl)piperazin-l-yl)-2-[(6- fluoro- lH-indol-5-ylX)xy]-N-({ 3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)aniino]phenyl} sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethy Icyclohex-1-en-1-yljmethyl) piperazin-1-yl)-2-[(6- fluoro- lH-indol-5-yl)oxy]-N-[(3-nitro-4- {[(3S)-tetrahydro-2H-pyran-3- ylmethyl] amino} phenyl)sulfonyl]benzamide; 167 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-[(6- fluoro-lH-indol-5-yl)oxy]-N-[(3-nitro-4-{[(3R)-tetrahydio-2H-pyran-3- ylmethyl] amino} phenyl)sulfonyl]benzamide; 4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-l-en-l-yl]methyl]piperazin-l-yl)-2-[(6- fluoro-lH-indol-5-yl)oxy]-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]pheny 1} sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-[(6- fluoro- lH-indol-5-yl)oxy]-N-( {4-[(2-methoxyethyl)amino]-3- nitrophenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl) piperazin-1 -yl)-2- [(6- fluoro-lH-indol-5-yl)oxy]-N-{[3-nitro-4-(tetrahydro-2H-pyran-4- ylmethoxy)phenyl]sulfonyl)benzaniide; 2-[(3-chloro-lH-indol-5-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl ] piperazin-1 -yl)-N-( {3-nitro-4- [(tetTahydro-2H-pyran-4- ylmethyl)aniino]pheny 1} sulfonyl)benzamide; 2-[(6-chloro-lH-indol-5-yl)oxy]-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H- pyran-3-yl]methyl }piperazin- l-yl)-N-({ 3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)araino]phenyl} sulfonyl)benzamide; 2-[(6-chloio-lH-indol-5-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-N-({3-nitro-4-[(tetTahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)benzamide; 4-(4- {[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl} piperazin-1 -yl)- 2-[(6-fluoro-lH-indol-5-yl)oxy]-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)annino]phenyl) sulfonyl)benzamide; 2-[(3-chloro- lH-indol-5-yl)oxyl-4-(4- ([2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-1- yllmethyl Ipiperazin-1 -yl)-N-({ 3-nitro-4- [(1 -tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl}sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en- l-yl]methyl} piperazin- l-yl)-N- {[4- (l,4-dioxan-2-ylmethoxy)-3-nid:ophenyl]sulfonyl)-2-[(6-fluoro-lH-indol-5- yl)oxy]benzamide; 2-[(6-chloro- lH-indol-5-yl)oxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yllmethyl] piperazin- l-yl)-N- {[4-(l ,4-dioxan-2-ylmethoxy)-3- nitrophenyl]sulfonyl }benzamide; 168 2-[(6-chloK)-lH-indol-5-yl)o3cyj-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl} piperazin- l-yl)-N-( {4-[( 1,4-dioxan-2-ylmethyl)amino]-3- nitrophenyl} sulfonyl)benzamide; 4.(4. {[2-(4-ch]orophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl )piperazin-1 -yl)-N-( {4- [(l,4-dioxan-2-ylmethyl)amino]-3-nitrophenyl}sulfonyl)-2-[(6-fluoro-lH-indol-5- yl)oxy]benzamide; Trans-2-[(6-chloio-lH-indol-5-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-l-yl]methyl}piperazin-l-yl)-N-({4-[(4-morpholin-4-ylcyclohexyl)amino]-3- nitrophenyl} sulfonyl)benzamide; Trans-2-[(6-chloro-lH-indol-5-yl)oxy]-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro- 2H-pyran-3-yl]niethyl}piperazin-l-yl)-N-({4-[(4-moipholin-4-ylcyclohexyl)amino]-3- nitrophenyl} sulfonyl)benzamide; 4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- 2-[(6-fluoro-lH-indol-5-yl)oxy]-N-({4-[(4-morpholin-4-yIcyclohexyl)amino]-3- nitrophenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-2- [(6- fluoro-lH-indol-5-yl)oxy]-N-({4-[(4-fluorDtetrahydro-2H-pyran-4-yl)methoxy]-3- nitrophenyl ] sulfonyl)benzamide; 4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- 2-[(6-fluoro-lH-indol-5-yl)oxyl-N-({4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3- nitrophenyl} sulfonyl)benzamide; 4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- N- {[5-cyano-6-(tetrahydro-2H-pyran-4-yImethoxy)pyridin-3-yl]sulfonyl) -2-[(6-fluoro-1H- indol-5-yl)oxy]benzamide; 2-{[3-(2-aminoethyI)-lH-indoI-5-yI]oxy}-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl}piperazin- l-yl)-N-( {3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]pheny 1} suIfonyl)benzamide; 2- {[3-(2-aminoethyl)- lH-indol-5-yl]oxy} -4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -en-1 -yl]methyl} piperazin-1 -yl)-N-( (4- [(4-methylpiperazin-1 -yl)amino] -3- nitrophenyl} sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-{[5- cy ano-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl) -2-[(6-fluoro- lH-indol-5- yl)oxy]benzamide; 169 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-N-{[5- chloro-6-(tetrahydro-2H-pyran-4-yImethoxy)pyridin-3-yl]sulfonyl}-2-[(6-fluoro-lH-indoI-5- yl)oxy]benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-{[5- cyano-6-(l,4-dioxan-2-ylmethoxy)pyridin-3-yl]sulfonyl)-2-[(6-fluoro-lH-indol-5- yl)oxy]benzamide; N- {[5-bromo-6-( 1,4-dioxan-2-ylmethoxy)pyridin-3-yl]sulfonyl) -4-(4- {[2-(4-chlorophenyl)- 4,4-dimethylcydohex- 1-en- l-yl]methyl }piperazin-1 -yl)-2-[(6-fluoro- lH-indol-5- yl)oxy]benzamide; Trans-N-( {5-bromo-6-[(4-morpholin-4-ylcyclohexyl)amino]pyridin-3-yl} sulfonyl)-4-(4- {[2- (4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-[(6-fluoro-lH- indol-5 -yl)oxy]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl} piperazin- l-yl)-N-({ 5- cyano-6-[(4-fluorotetrahydro-2H-pyran-4-y])methoxy]pyridin-3-yl}su]fonyl)-2-[(6-fluoro- lH-indol-5-yl)oxy]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-N- {[5- cyano-6-(2-moipholin-4-yletlioxy)pyridin-3-yl]sulfonyl}-2-[(6-fluoro-lH-indol-5- yl)oxy]benzamide; Trans-4-(4- {[2-(4-chloropheny l)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2- [(6-fluoro-lH-indol-5-yl)oxy]-N-({4-[(4-morpholin-4-ylcyclohexyl)oxy]-3- nitrophenyl )sulfonyl)benzaniide; N-({5-bromo-6-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]pyridin-3-yl}sulfonyl)-4- (4- ([2-(4-cWorophenyl)-4,4-dimethy Icyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-[(6- fluoro- lH-indol-5-yl)oxy]benzamide; Trans-2-[(6-chloro-lH-indol-5-yl)oxy]-4-(4-{[5-(4-ch]orophenyl)-2,3,6,7-tetrahydrooxepin- 4-yl]methyl}piperazin-l-yl)-N-({4-[(4-morpholin-4-ylcyclohexyl)amino]-3- [(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide; Trans-2-[(6-chIoro-lH-indol-5-yl)oxy]-4-(4-{[5-(4-chIorophenyl)-2,3,6,7-tetrahydrooxepin- 4-yl]methyl)piperazin-l-yl)-N-({4-[(4-morpholin-4-ylcyclohexyl)amino]-3- nitrophenyl} sulfonyI)benzaniide; 4-(4-{[4-(4-chlorophenyl)-6,6-dinietiiyl-5,6-dihydro-2H-pyran-3-yl]methyl)piperazin-l-yI)- 2-[(6-fluoro-lH-indol-5-yl)oxy]-N-({4-[(4-methylpiperazin-l-yl)amino]-3- nitropheny 1} sulfony l)benzamide; 170 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl ] piperazin-1 -yl)-2- [(6- fIuoro-lH-mdol-5-yl)oxy]-N-({4-[(4-morphoIin-4-yIbut-2-ynyl)oxy]-3- nitrophenyl) sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-[(6- fluoro-lH-indol-5-yl)oxy]-N-[(4-{[l-(methylsulfonyl)piperidin-4-yllamino]-3- nitrophenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl ]piperazin-1 -yl)-N- {[5- ethynyl-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-[(6-fluoro-lH-indol- 5-yl)oxy]benzamide; 4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yllmethyl}piperazin-l-yl)- N-{[5-ethynyl-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridih-3-yl]sulfony]}-2-[(6-fluoro-lH- indol-5-yl)oxy]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl} piperazin- l-yl)-N-({ 5- cyano-6-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4-yl)oxy]pyridin-3-yl}sulfonyl)-2-[(6-fluoro- lH-indol-5-yl)oxy]benzamide; N-({ 5-chIoio-6-[(4-fluorotetrahydro-2H-pyran-4-yl)niethoxy]pyridin-3-yl} sulfonyl)-4-(4- {[2-(4-chloropheny l)-4,4-dimethylcyclohex-1 -en-1 -yl ]methyl) piperazin-1 -y I)-2-[(6-fluoro- lH-indol-5-yl)oxy]benzamide; 4-(4- ([2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-N-( {4- [(l-cyclopropyIpiperidin-4-yl)amino]-3-nitxophenyl}suIfonyl)-2-[(6-fluoro-lH-indol-5- yl)oxy]benzainide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-N-( {4- [(4-ethylmorpholin-3-yl)niethoxy]-3-nitrophenyl}sulfonyl)-2-[(6-fluoro-lH-indol-5- yl)oxy]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-2-[(6- fluoro-lH-indol-5-yl)oxy]-N-[(3-nitro-4-{[(3S)-l-tetrahydro-2H-pyran-4-ylpiperidin-3- yl]amino}phenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -y IJmethy 1} piperazin-1 -y l)-N-( {4- [(l,l-dioxidothiomorpholin-4-yl)anuno]-3-nitrophenyl}sulfonyl)-2-[(6-fluoro-lH-indol-5- yl)oxy]benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-[(6-fluoro-1 H-indol-5-yl)oxy]-N-( {3-nitro-4-[(tetrahydrofuran-3-y Imethy I)amino]pheny 1} sulfony l)benzamide; 171 Trans-N-( {5-biomo-6-[(4-morpholin-4-ylcyclohexyl)oxy ]pyridin-3-yl} sulfonyl)-4-(4- {[2-(4- chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl )piperazin-1 -yl)-2-[(6-fluoro- IH- indol-5-yl)oxy]benzamide; Trans-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-N- [(4-{[4-(dicyclopropylamino)cyclohexyl]amino)-3-nitrophenyl)sulfonyl]-2-[(6-fluoro-lH- indol-5 -y l)oxy ]benzamide; Trans-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-2- [(6-fluoro-lH-indol-5-yl)oxy]-N-[(3-nitro-4-{[4-(tetrahydro-2H-pyran-4- ylamino)cyclohexyl]amino}phenyl)sulfonyl]benzamide; Trans-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl]piperazin-l-yl)-2- [(6-fluoro-lH-indol-5-yl)oxy]-N-[(3-nitro-4-{[4-(4-tetrahydro-2H-pyran-4-ylpiperazin-l- yl)cyclohexyl]amino}phenyl)sulfonyl]benzamide; 4-(4- ([2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-2- [(6- fluoro-lH-indol-5-yl)oxy]-N-[(4-{[(4-fluorotetrahydro-2H-pyran-4-yl)methyl]amino}-3- nitrophenyl)sulfonyl]benzaniide; Trans-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l -en-l -yl]methyl) piperazin-1 -yl)-2- I(6-fluoro-lH-indol-5-yl)oxy]-N-[(4-{[(4-hydroxycyclohexyl)methyl]amino}-3- nitrophenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-N-( {4- [(l-cyclopropyl-4-fluoropiperidin-4-yl)metiioxy]-3-nitrophenyl}sulfonyl)-2-[(6-fluoro-lH- indol-5-yl)oxy]benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-N-{[4- ({(3R)-1 - [2-fluoro-1 -(fluoroniethyl)ethyl]pyrrolidin-3-y 1} amino)-3 -nitrophenyl]sulfonyl} -2- [(6-fluoro-1 H-indol-5-yl)oxy]benzamide; N-({5-chloro-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- {[4-(4-chlorophenyl)-6,6-dimediyl-5,6-dihydro-2H-pyran-3-yl]methyl)piperazin-l-yl)-2-[(6- fluoro-lH-indol-5-yl)oxy]benzamide; N-((5-chloro-6-[(4,4-difluorocyclohexyl)methoxy]pyridin-3-yl}suIfonyl)-4-(4-{[4-(4- chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)-2-[(6-fluoro- lH-indol-5-yl)oxy]benzaniide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyllpiperazin-l-yl)-N-[(4- {[(4,4-difluorocyclohexyl)methyl]amino)-3-nitrophenyl)sulfonyl]-2-[(6-fluoro-lH-indol-5- yl)oxy]benzamide; 172 N-( {3 -chloro-4- [(4-fluorotetrahydro-2H-pyran-4-y l)methoxy ]phenyl} sulfonyl)-4-(4- {[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl }piperazin- l-yl)-2-[(6-fluoro- IH- indol-5-yl)oxy]benzamide; N-( {3-chloro-4-[(4-fluorotetrahydro-2H-pyran-4-yl)naethoxy]pheny]} sulfonyl)-4-(4- {[4-(4- chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl)piperazin-l-yl)-2-[(6-fluoio- lH-indol-5-yl)oxy]benzaniide; tert-butyl5-[(4-{4-[({5-chloro-6-[(4-fluorotettahydro-2H-pyran-4-yl)methoxy]pyridin-3- yl}sulfonyl)carbamoyl]-3-[(6-fluoro-lH-indol-5-yl)oxy]phenyl}piperazin-l-yl)methyl]-4-(4- chlorophenyl)-3,6-dihydropyridine-l(2H)-carboxylate; N-({5-chloro-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- {[4-(4-chlorophenyl)-1 -(1,3-" (greater than) a certain numerical value, it is intended to mean that the binding affinity value is greater than the limits of detection of the assay used. Where the Ki for a compound is represented as "<" (less than) a certain numerical value, it is intended to mean that the binding affinity value is lower than the limit of detection of the assay used. TABLE 2. TR-FRET Bcl-2 Binding Ki (^iM) Example No. I TR-FRET I Example No. I TR-FRET Binding: Bcl-2 Binding: Bcl-2 Ki(^M) Ki(uM) 1 0.008354 232 0.001047 2 0.031467 233 0.000037 3 0.000827 234 0.000099 4 0.002474 235 0.000039 5 0.000746 236 0.000071 6 0.000787 237 0.000197 7 0.002592 238 0.000124 8 0.003451 239 0.000105 9 0.000754 240 0.000912 10 I 0.00072 I 241 I 0.000141 224 11 I 0.000171 I 242 I 0.000092 12 0.000331 243 0.000069 13 0.001621 244 0.001734 14 0.000079 245 0.00048 15 0.000586 246 0.000065 16 0.003039 247 0.000039 17 0.005578 248 0.000051 18 0.002487 249 0.000168 19 0.001679 250 0.000672 20 0.003965 251 0.000435 21 0.014054 252 0.001147 22 0.005455 253 0.00005 23 0.00827 254 0.000119 24 0.014984 255 0.007013 25 0.001501 256 0.000105 26 0.000511 257 0.000097 27 0.002212 258 0.000083 28 0.001326 259 0.000165 29 0.000903 260 0.011834 30 0.000071 261 0.000186 31 0.002007 262 0.000276 32 0.001584 263 0.00011 33 0.007173 264 0.000068 34 0.000049 265 0.000363 35 0.000022 266 0.00081 36 0.00007 267 0.028426 37 0.000005 268 0.000042 38 0.000013 269 0.000469 39 0.000019 270 >1.195000 40 0.000019 271 0.001908 41 0.000027 272 0.00124 42 0.00003 273 0.000516 43 0.000034 274 0.000936 44 0.000036 275 0.000081 45 0.000047 276 0.000199 46 0.000047 277 0.000017 47 0.00005 278 0.039967 48 0.000053 279 0.001703 49 0.000062 280 0.00755 50 0.000062 281 0.000111 51 0.000066 282 0.001012 52 0.000072 283 0.01721 53 0.000077 284 0.079348 54 0.000082 285 0.000037 55 0.00009 286 0.003181 56 0.000106 287 0.000131 57 0.000147 288 0.000017 58 I 0.000155 I 289 | <0.00001Q 225 59 I 0.000184 I 290 I 0.000251 60 0.000187 291 0.000273 61 0.00022 292 0.000191 62 0.000227 293 0.000233 63 0.000438 294 0.000127 64 0.000458 295 0.000077 65 0.00052 296 <0.000010 66 0.000592 297 <0.000010 67 0.000807 298 0.000054 68 0.005934 299 0.051687 69 0.008246 300 0.013659 70 0.020421 301 0.000113 71 0.031597 302 <0.000010 72 0.031666 303 0.000092 73 0.03226 304 0.000822 74 0.18943 305 0.000146 75 0.076832 306 0.QQ0671 76 0.2395 307 0.000524 77 0.45052 308 0.00004 78 >1.195000 309 0.00069 79 0.099826 310 0.000155 80 0.14872 311 0.000185 81 0.031048 312 0.000531 82 0.51156 313 <0.000010 83 >1.195000 314 0.003094 84 0.013654 315 0.004555 85 0.005626 316 0.000058 86 0.005263 317 0.000205 87 0.26427 318 <0.000010 88 >1.195000 319 0.000198 89 0.006111 320 0.000028 90 0.010626 321 0.000029 91 >1.195000 322 0.00453 92 0.002569 323 0.003484 93 0.01683 324 <0.000010 94 0.56121 325 0.000183 95 0.000428 326 0.000037 96 >1.195000 327 0.000212 97 0.14659 328 0.000068 98 0.000959 329 0.000108 99 0.071364 330 <0.000010 100 0.11299 331 0.000238 101 0.6695 332 0.000034 102 0.043518 333 0.000107 103 0.006755 334 0.000197 104 0.002321 335 <0.000010 105 0.003567 336 <0.000010 106 I 0.21452 I 337 | 0.00004"9 226 107 I 0.000331 I 338 I <0.000010 108 nd 339 0.000057 109 0.000237 340 0.000385 110 0.000039 341 0.000017 111 0.01744 3^ 0.003340 112 0.000042 343 0.000009 113 0.000032 344 0.000042 114 0.000036 345 0.000005 115 0.000042 346 < 0.000010 116 0.000123 347 0.000377 117 0.000072 348 0.003779 118 0.000151 349 0.000019 119 0.000156 350 < 0.000010 120 0.000214 351 0.002843 121 0.000081 352 0.000079 122 <0.000001 353^ 0.000016 123 0.00011 354 0.000114 124 0.000033 355 0.009567 125 0.000075 356 0.002822 126 0.000068 357 0.000177 127 0.00003 358 0.000062 128 0.000064 359 0.000110 129 0.000107 360 0.000050 130 0.000067 361 0.000015 131 0.000066 362 0.000033 132 0.000211 363 < 0.000010 133 0.000055 364 0.000014 134 0.000181 365 0.004551 135 0.000068 366 0.006052 136 0.000177 367 0.000012 137 0.000021 368 < 0.000010 138 0.000016 369 0.000014 139 0.000125 _370 < 0.000010 140 0.000223 371 < 0.000010 141 0.000482 372 0.014978 142 0.000071 373 1.195000 143 0.000053 374 0.005337 144 0.000028 375 0.327810 145 0.000057 376 0.057705 146 0.00004 377 0.002323 147 0.000127 378 < 0.000010 148 0.000106 379 0.017948 149 0.00003 380 0.008274 150 0.000759 381 0.000020 151 0.006935 382 0.000114 152 0.018589 383 0.427490 154 0.000012 384 0.006233 155 I 0.000062 I 385 | 0.049293 227 156 I 0.000035 I 386 I < 0.000010 ~ 157 0.00072 387 < 0.000010 158 0.000619 388 0.000020 159 0.000526 389 < 0.000010 160 0.000028 390 < 0.000010 161 0.000031 391 < 0.000010 162 0.000048 392 < 0.000010 163 0.000686 393 < 0.000010 164 0.000056 394 0.000018 165 0.00012 395 0.000077 166 0.000082 396 < 0.000010 167 0.001345 397 0.000137 168 0.028343 398 0.000175 169 0.000498 399 < 0.000010 170 0.000036 400 0.000082 171 0.000066 401 0.000035 172 0.000549 402 0.000039 173 0.000019 403 0.002136 174 0.000037 404 0.000069 175 0.000046 405 0.000354 176 0.00024 406 0.000166 177 0.000037 407 0.000946 178 0.000175 408 0.001160 179 0.000036 409 0.000686 180 0.000112 410 < 0.000010 181 0.000119 411 0.021291 182 0.000172 412 0.001125 183 0.00253 413 0.000739 184 0.000155 414 0.000014 185 0.000083 415 0.000013 186 0.000035 416 0.007436 187 0.000054 417 0.006876 188 0.000073 418 < 0.000010 189 0.000036 419 0.000012 190 0.000077 420 < 0.000010 191 0.000552 421 < 0.000010 192 0.000024 422 < 0.000010 193 0.000064 423 < 0.000010 194 0.000317 424 < 0.000010 195 0.000684 425 0.000013 197 0.00022 426 < 0.000010 198 <0.000010 427 < 0.000010 199 0.000244 428 < 0.000010 200 0.000081 429 < 0.000010 201 0.00001 430 < 0.000010 202 0.020043 431 < 0.000010 203 0.000084 432 < 0.000010 204 I 0.000075 | 433 | < 0.000010 228 205 I 0.000153 I 434 I < 0.000010 ^ 206 0.000037 435 0.000010 207 0.000074 436 < 0.000010 208 0.000261 437 < 0.000010 209 <0.000010 438 0.000031 210 0.00002 439 < 0.000010 211 0.001338 440 0.000022 212 0.000375 441 0.000054 213 0.000031 442 < 0.000010 214 0.000221 443 0.000029. 215 0.002954 444 0.000018 216 0.000027 445 < 0.000010 217 0.000174 446 0.000015 218 0.000175 447 0.000029 219 0.014857 448 < 0.000010 220 0.000127 449 < 0.000010 221 0.000227 450 < 0.000010 222 >1.195000 451 < 0.000010 223 0.010911 452 0.000112 224 0.005603 453 < 0.000010 225 0.003283 454 0.000024 226 0.007586 455 0.000011 227 0.000174 456 nd 229 0.001085 457 nd 230 0.002833 458 nd 231 I 0.036946 | | The inhibition constant (Ki) is the dissociation constant of an enzyme-inhibitor complex or a protein/small molecule complex, wherein the small molecule is inhibiting binding of one protein to another protein. So a large Ki value indicates a low binding affinity and a small Ki value indicates a high binding affinity. The data in TABLE 2 shows inhibition constants for the inhibition of a Bak BH3 peptide probe to Bcl-2 protein and indicate that compounds according to the invention have high binding affinities for anti-apoptotic Bcl-2 protein. The compounds are therefore expected to have utility in treatment of diseases during which anti-apoptotic Bcl-2 protein is expressed. It is expected that, because compounds having Formula I bind to Bcl-2, they would also have utihty as binders to anti-apoptotic proteins having close structural homology to Bcl-2, such as, for example, anti-apoptotic BC1-XL, Bcl-w, Mcl-l and Bfl-l/Al proteins. Involvement of Bcl-2 proteins in bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral 229 cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer, chronic lymphocytic leukemia, myeloma, prostate cancer spleen cancer, and the like is described in commonly-owned PCT US 2004/36770, published as WO 2005/049593, and PCT US 2004/37911, published as WO 2005/024636. Involvement of Be 1-2 proteins in immune and autoimmune diseases is described in Current Allergy and Asthma Reports 2003, 3, 378-384; British Journal of Haematology 2000, 110(3), 584-90; Blood 2000,95(4), 1283-92; and New England Journal of Medicine 2004, 351(14), 1409-1418. Involvement of Bcl-2 proteins in arthritis is disclosed in commonly-owned United States Provisional Patent Application Serial No. 60/988,479. Involvement of Bcl-2 proteins in bone marrow transplant rejection is disclosed in commonly-owned United States Patent Application Serial No. 11/941,196. Overexpression of Bcl-2 proteins correlates with resistance to chemotherapy, clinical outcome, disease progression, overall prognosis or a combination thereof in various cancers and disorders of the immune system. Cancers include, but are not limited to, hematologic and solid tumor types such as acoustic neuroma, acute leukemia, acute lymphoblastic leukemia, acute myelogenous leukemia (monocytic, myeloblastic, adenocarcinoma, angiosarcoma, astrocytoma, myelomonocytic and promyelocytic), acute t-cell leukemia, basal cell carcinoma, bile duct carcinoma, bladder cancer, brain cancer, breast cancer (including estrogen-receptor positive breast cancer), bronchogenic carcinoma, Burkitt's lymphoma, cervical cancer, chondrosarcoma, chordoma, choriocarcinoma, chronic leukemia, chronic lymphocytic leukemia, chronic myelocytic (granulocytic) leukemia, chronic myelogenous leukemia, colon cancer, colorectal cancer, craniopharyngioma, cystadenocarcinoma, dysproliferative changes (dysplasias and metaplasias), embryonal carcinoma, endometrial cancer, endotheliosarcoma, ependymoma, epithelial carcinoma, erythroleukemia, esophageal cancer, estrogen-receptor positive breast cancer, essential thrombocythemia, Ewing's tumor, fibrosarcoma, gastric carcinoma, germ cell testicular cancer, gestational trophobalstic disease, glioblastoma, head and neck cancer, heavy chain disease, hemangioblastoma, hepatoma, hepatocellular cancer, hormone insensitive prostate cancer, leiomyosarcoma, liposarcoma, lung cancer (including small cell lung cancer and non-small cell lung cancer), lymphangioendothelio-sarcoma, lymphangiosarcoma, lymphoblastic leukemia, lymphoma (lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, Hodgkin's lymphoma and non-Hodgkin's lymphoma), malignancies and hyperprohferative disorders of the bladder, breast, colon, lung, ovaries, pancreas, prostate, skin and uterus, lymphoid 230 malignancies of T-cell or B-cell origin, leukemia, medullary carcinoma, meduUoblastoma, melanoma, meningioma, mesothelioma, multiple myeloma, myelogenous leukemia, myeloma, myxosarcoma, neuroblastoma, oligodendroglioma, oral cancer, osteogenic sarcoma, ovarian cancer, pancreatic cancer, papillary adenocarcinomas, papillary carcinoma, peripheral T-cell lymphoma, pinealoma, polycythemia vera, prostate cancer (including hormone-insensitive (refractory) prostate cancer), rectal cancer, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, sarcoma, sebaceous gland carcinoma, seminoma, skin cancer, small cell lung carcinoma, solid tumors (carcinomas and sarcomas), stomach cancer, squamous cell carcinoma, synovioma, sweat gland carcinoma, testicular cancer (including germ cell testicular cancer), thyroid cancer, Waldenstrom's macroglobulinemia, testicular tumors, uterine cancer, Wilms' tumor and the like. It is also expected that compounds having Formula (I) would inhibit growth of cells expressing Bcl-2 proteins derived from a pediatric cancer or neoplasm including embryonal rhabdomyosarcoma, pediatric acute lymphoblastic leukemia, pediatric acute myelogenous leukemia, pediatric alveolar rhabdomyosarcoma, pediatric anaplastic ependymoma, pediatric anaplastic large cell lymphoma, pediatric anaplastic meduUoblastoma, pediatric atypical teratoid/rhabdoid tumor of the central nervous system, pediatric biphenotypic acute leukemia, pediatric Burkitts lymphoma, pediatric cancers of Ewing's family of tumors such as primitive neuroectodermal rumors, pediatric diffuse anaplastic Wilm's tumor, pediatric favorable histology Wilm's tumor, pediatric glioblastoma, pediatric meduUoblastoma, pediatric neuroblastoma, pediatric neuroblastoma-derived myelocytomatosis, pediatric pre-B-cell cancers (such as leukemia), pediatric psteosarcoma, pediatric rhabdoid kidney tumor, pediatric rhabdomyosarcoma, and pediatric T-cell cancers such as lymphoma and skin cancer and the like. Autoimmune disorders include acquired immunodeficiency disease syndrome (AIDS), autoimmune lymphoproliferative syndrome, hemolytic anemia, inflammatory diseases, and thrombocytopenia, acute or chronic immune disease associated with organ transplantation, Addison's disease, allergic diseases, alopecia, alopecia areata, atheromatous disease/arteriosclerosis, atherosclerosis, arthritis (including osteoarthritis, juvenile chronic arthritis, septic arthritis, Lyme arthritis, psoriatic arthritis and reactive arthritis), autoimmune bullous disease, abetalipoprotemia, acquired immunodeficiency-related diseases, acute immune disease associated with organ transplantation, acquired acrocyanosis, acute and chronic parasitic or infectious processes, acute pancreatitis, acute renal failure, acute rheumatic fever, acute transverse myelitis, adenocarcinomas, aerial ectopic beats, adult 231 (acute) respiratory distress syndrome, AIDS dementia complex, alcoholic cirrhosis, alcohol-induced liver injury, alcohol-induced hepatitis, allergic conjunctivitis, allergic contact dermatitis, allergic rhinitis, allergy and asthma, allograft rejection, alpha-1- antitrypsin deficiency, Alzheimer's disease, amyotrophic lateral sclerosis, anemia, angina pectoris, ankylosing spondylitis associated lung disease, anterior horn cell degeneration, antibody mediated cytotoxicity, antiphospholipid syndrome, anti-receptor hypersensitivity reactions, aortic and peripheral aneurysms, aortic dissection, arterial hypertension, arteriosclerosis, arteriovenous fistula, arthropathy, asthenia, asthma, ataxia, atopic allergy, atrial fibrillation (sustained or paroxysmal), atrial flutter, atrioventricular block, atrophic autoimmune hypothyroidism, autoimmune haemolytic anaemia, autoimmune hepatitis, type-1 autoimmune hepatitis (classical autoimmune or lupoid hepatitis), autoimmune mediated hypoglycaemia, autoimmune neutropaenia, autoimmune thrombocytopaenia, autoinmiune thyroid disease, B cell lymphoma, bone graft rejection, bone marrow transplant (BMT) rejection, bronchiohtis obliterans, bundle branch block, bums, cachexia, cardiac arrhythmias, cardiac stun syndrome, cardiac tumors, cardiomyopathy, cardiopulmonary bypass inflammation response, cartilage transplant rejection, cerebellar cortical degenerations, cerebellar disorders, chaotic or multifocal atrial tachycardia, chemotherapy associated disorders, chlamydia, choleosatatis, chronic alcoholism, chronic active hepatitis, chronic fatigue syndrome, chronic immune disease associated with organ transplantation, chronic eosinophilic pneumonia, chronic inflammatory pathologies, chronic mucocutaneous candidiasis, chronic obstructive pulmonary disease (COPD), chronic salicylate intoxication, colorectal common varied immunodeficiency (common variable hypogammaglobulinaemia), conjunctivitis, connective tissue disease associated interstitial lung disease, contact dermatitis, Coombs positive haemolytic anaemia, cor pulmonale, Creutzfeldt-Jakob disease, cryptogenic autoimmune hepatitis, cryptogenic fibrosing alveolitis, culture negative sepsis, cystic fibrosis, cytokine therapy associated disorders, Crohn's disease, dementia pugilistica, demyelinating diseases, dengue hemorrhagic fever, dermatitis, dermatitis scleroderma, dermatologic conditions, dermatomyositis/polymyositis associated lung disease, diabetes, diabetic arteriosclerotic disease, diabetes mellitus. Diffuse Lewy body disease, dilated cardiomyopathy, dilated congestive cardiomyopathy, discoid lupus erythematosus, disorders of the basal ganglia, disseminated intravascular coagulation, Down's Syndrome in middle age, drug-induced interstitial lung disease, drug-induced hepatitis, drug-induced movement disorders induced by drugs which block CNS dopamine, receptors, drug sensitivity, eczema, encephalomyelitis, endocarditis, endocrinopathy, enteropathic synovitis, epiglottitis, Epstein-Barr virus infection, 232 erythromelalgia, extrapyramidal and cerebellar disorders, familial hematophagocytic lymphohistiocytosis, fetal thymus implant rejection, Friedreich's ataxia, functional peripheral arterial disorders, female infertility, fibrosis, fibrotic lung disease, fungal sepsis, gas gangrene, gastric ulcer, giant cell arteritis, glomerular nephritis, glomerulonephritides, Goodpasture's syndrome, goitrous autoimmune hypothyroidism (Hashimoto's disease), gouty arthritis, graft rejection of any organ or tissue, graft versus host disease, gram negative sepsis, gram positive sepsis, granulomas due to intracellular organisms, group B streptococci (GBS) infection, Grave's disease, haemosiderosis associated lung disease, hairy cell leukemia, hairy cell leukemia, Hallerrorden-Spatz disease, Hashimoto's thyroiditis, hay fever, heart transplant rejection, hemachromatosis, hematopoietic malignancies (leukemia and lymphoma), hemolytic anemia, hemolytic uremic syndrome/thrombolytic thrombocytopenic purpura, hemorrhage, Henoch-Schoenlein purpurea. Hepatitis A, Hepatitis B, Hepatitis C, HIV infection/HIV neuropathy, Hodgkin's disease, hypoparathyroidism, Huntington's chorea, hyperkinetic movement disorders, hypersensitivity reactions, hypersensitivity pneumonitis, hyperthyroidism, hypokinetic movement disorders, hypothalamicrpituitary-adrenal axis evaluation, idiopathic Addison's disease, idiopathic leucopaenia, idiopathic pulmonary fibrosis, idiopathic ihrombocytopaenia, idiosyncratic liver disease, infantile spinal muscular atrophy, infectious diseases, inflammation of the aorta, inflammatory bowel disease, insulin dependent diabetes mellitus, interstitial pneumonitis, iridocyclitis/uveitis/optic neuritis, ischemia-reperfusion injury, ischemic stroke, juvenile pernicious anaemia, juvenile rheumatoid arthritis, juvenile spinal muscular atrophy, Kaposi's sarcoma, Kawasaki's disease, kidney transplant rejection, legionella, leishmaniasis, leprosy, lesions of the corticospinal system, linear IgA disease, lipidema, liver transplant rejection, Lyme disease, lymphederma, lymphocytic infiltrative lung disease, malaria, male infertility idiopathic or NOS, malignant histiocytosis, malignant melanoma, meningitis, meningococcemia, microscopic vasculitis of the kidneys, migraine headache, mitochondrial multisystem disorder, mixed connective tissue disease, mixed connective tissue disease associated lung disease, monoclonal gammopathy, multiple myeloma, multiple systems degenerations (Mencel Dejerine-Thomas Shi-Drager and Machado-Joseph), myalgic encephalitis/Royal Free Disease, myasthenia gravis, microscopic vasculitis of the kidneys, mycobacterium avium intracellulare, mycobacterium tuberculosis, myelodyplastic syndrome, myocardial infarction, myocardial ischemic disorders, nasopharyngeal carcinoma, neonatal chronic lung disease, nephritis, nephrosis, nephrotic syndrome, neurodegenerative diseases, neurogenic I muscular atrophies, neutropenic fever. Non-alcoholic Steatohepatitis, occlusion of the abdominal aorta and its branches, occlusive 233 arterial disorders, organ transplant rejection, orchitis/epidydiraitis, orchitis/vasectomy reversal procedures, organomegaly, osteoarthrosis, osteoporosis, ovarian failure, pancreas transplant rejection, parasitic diseases, parathyroid transplant rejection, Parkinson's disease, pelvic inflammatory disease, pemphigus vulgaris, pemphigus foliaceus, pemphigoid, perennial rhinitis, pericardial disease, peripheral atherlosclerotic disease, peripheral vascular disorders, peritonitis, pernicious anemia, phacogenic uveitis, Pneumocystis carinii pneumonia, pneumonia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome), post perfusion syndrome, post pump syndrome, post-MI cardiotomy syndrome, postinfectious interstitial lung disease, premature ovarian failure, primary biliary cirrhosis, primary sclerosing hepatitis, primary myxoedema, primary pulmonary hypertension, primary sclerosing cholangitis, primary vasculitis. Progressive supranucleo Palsy, psoriasis, psoriasis type 1, psoriasis type 2, psoriatic arthropathy, pulmonary hypertension secondary to connective tissue disease, pulmonary manifestation of polyarteritis nodosa, post-inflammatory interstitial lung disease, radiation fibrosis, radiation therapy, Raynaud's phenomenon and disease, Raynoud's disease, Refsum's disease, regular narrow QRS tachycardia, Reiter's disease, renal disease NOS, renovascular hypertension, reperfusion injury, restrictive cardiomyopathy, rheumatoid arthritis associated interstitial lung disease, rheumatoid spondylitis, sarcoidosis, Schmidt's syndrome, scleroderma, senile chorea. Senile Dementia of Lewy body type, sepsis syndrome, septic shock, seronegative arthropathies, shock, sickle cell anemia, Sjogren's disease associated lung disease, SjOrgren's syndrome, skin allograft rejection, skin changes syndrome, small bowel transplant rejection, sperm autoinmiunity, multiple sclerosis (all subtypes), spinal ataxia, spinocerebellar degenerations, spondyloarthropathy, spondyloarthopathy, sporadic, polyglandular deficiency type I sporadic, polyglandular deficiency type II, Still's disease, streptococcal myositis, stroke, structural lesions of the cerebellum. Subacute sclerosing panencephalitis, sympathetic ophthalmia. Syncope, syphilis of the cardiovascular system, systemic anaphylaxis, systemic inflammatory response syndrome, systemic onset juvenile rheumatoid arthritis, systemic lupus erythematosus, systemic lupus erythematosus-associated lung disease, systemic sclerosis, systemic sclerosis-associated interstitial lung disease, T-cell or FAB ALL, Takayasu's disease/arteritis. Telangiectasia, Th2 Type and Thl Type mediated diseases, thromboangitis obliterans, thrombocytopenia, thyroiditis, toxicity, toxic shock syndrome, transplants, trauma/hemorrhage, type-2 autoimmune hepatitis (anti-LKM antibody hepatitis), type B insulin resistance >yith acanthosis nigricans, type III hypersensitivity reactions, type IV hypersensitivity, ulcerative colitic arthropathy, ulcerative coUtis, unstable 234 angina, urenxia, urosepsis, urticaria, uveitis, valvular heart diseases, varicose veins, vasculitis, vasculitic diffuse lung disease, venous diseases, venous thrombosis, ventricular fibrillation, vitiligo acute Uver disease, viral and fungal infections, vital encephalitis/aseptic meningitis, vital-associated hemaphagocytic syndrome, Wegener's granulomatosis, Wernicke-Korsakoff syndrome, Wilson's disease, xenograft rejection of any organ or tissue, yersinia and salmonella-associated arthropathy and the like. Schemes and Experimentals The following abbreviations have the meanings indicated. ADDP means l,r-(azodicarbonyl)dipiperidine; AD-mix-P means a mixture of (DHQD)2PHAL, K3Fe(CN)6, K2CO3, and K2SO4; 9-BBN means 9-borabicyclo(3.3.1)nonane; Boc means tert-butoxycarbonyl; (DHQD)2PHAL means hydroquinidine 1,4-phthalazinediyl diethyl ether; DBU means l,8-diazabicyclo[5.4.0]undec-7-ene; DIBAL means diisobutylaluminum hydride; DIEA means diisopropylethylamine; DMA? means N,N-dimethylaminopyridine; DMF means N,N-dimethylformamide; dmpe means l,2-bis(dimethylphosphino)ethane; DMSO means dimethylsulfoxide; dppb means l,4-bis(diphenylphosphino)-butane; dppe means l,2-bis(diphenylphosphino)ethane; dppf means l,r-bis(diphenylphosphino)ferTocene; dppm means l,l-bis(diphenylphosphino)methane; EDAC-HCl means l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride; Fmoc means fluorenylmethoxycarbonyl; HATU means 0-(7-azabenzotriazol-l-yl)-N,N'N'N'-tetramethyluroniimi hexafluorophosphate; HMPA means hexamethylphosphoramide; IPA means isopropyl alcohol; MP-BH3 means macroporous triethylammonium methylpolystyrene cyanoborohydride; TEA means triethylamine; TFA means trifluoroacetic acid; THF means tetrahydrofiiran; NCS means N-chlorosuccinimide; NMM means N-methylmorpholine; NMP means N-methylpyrrolidine; PPh3 means triphenylphosphine. The following schemes are presented to provide what is believed to be the most useful and readily understood description of procedures and conceptual aspects of this invention. Compounds of this invention may be made by synthetic chemical processes, examples of which are shown herein. It is meant to be understood that the order of the steps in the processes may be varied, that reagents, solvents and reaction conditions may be substituted for those specifically mentioned, and that vulnerable moieties may be protected and deprotected, as necessary. 235 SCHEME 1 9^2R CO2R CO2R CO2H ^ — ^ — "^ —0 ^'" ■$." ,k°' St Compounds of Formula (4) can be prepared as shown in SCHEME 1, and can be used as described in SCHEME 8 to prepare compounds of Formula (I), which are representative of the compounds of the present invention. Compounds of Formula (1) wherein R is alkyl, can be converted to compounds of Formula (2) using Z^L'MgX', wherein X' is a halide, in a solvent such as but not limited to ether or tetrahydrofuran. Compounds of Formula (3) can be prepared from compounds of Formula (2) using a strong base such as NaH and R^'X^, wherein X^ is a halide and R^^ is as described herein. Compounds of Formula (3), when treated with aqueous NaOH or LiOH, will provide compounds of Formula (4). SCHEME 2 CO2R J^ X 1 6 _j!L Y .V B (5) R37A^Z2 ^^^ R^A^Z^ ^^^ As shown in SCHEME 2, compounds of Formula (5) can be reacted with compounds of Formula (6) and a reducing agent to provide compounds of Formula (7). Examples of reducing agents include sodium borohydride, sodium cyanoborohydride, sodium triacetoxyborohydride, polymer supported cyanoborohydride, and the like. The reaction is typically performed in a solvent such as but not limited to methanol, tetrahydrofuran, and dichloromethane or mixtures thereof. Compounds of Formula (8) can be prepared from compounds of Formula (7) as described in SCHEME 1, and can be used as described in SCHEME 8 to prepare compounds of Formula (I). 236 SCHEME 3 Br CO2R J CO2R CO2R CO2H c"] rt r'^ rt X Y Y Compounds of Formula (9), when reacted with a compound a Formula (10) wherein X is a halide or triflate, and a base will provide a compound of Formula (11). Bases useful in the reaction include triethylamine, diisopropylethylamine and the like. Compounds of Formula (13), wherein Y is as described herein for substituents on Z^, can be prepared from compounds of Formula (11) and compounds of Formula (12) using Suzuki coupling conditions known to those skilled in the art and readily available in the literature. Compounds of Formula (14) can be prepared from compounds of Formula (13) as described in SCHEME 1, and can be used as described in SCHEME 8 to prepare compounds of Formula (I). SCHEME 4 rr (17) (18) (19) (15) CO2R CO2H 0 0 (20) (21) As shown in SCHEME 4, compounds of Formula (17) can be prepared from compounds of Formula (15) and compounds of Formula (16), wherein R is alkyl and R^* is as described herein, using Suzuki coupling conditions known to those skilled in the art and readily available in the literature. Compounds of Formula (17) can be reduced to compounds 237 of Formula (18) using a reducing agent such as LiAlH4 in a solvent such as but not limited to diethyl ether or THF. Compounds of Formula (19) can be prepared from compounds of Formula (18) using Dess-Martin periodinane or Swem oxidation conditions known to those skilled in the art and readily available in the literature. Compounds of Formula (19) can be reacted with a compound of Formula (5) and a reducing agent to provide compounds of Formula (20). Examples of reducing agents include sodium borohydride, sodium cyanoborohydride, sodium triacetoxyborohydride, polymer supported cyanoborohydride, and the like. The reaction is typically performed in a solvent such as but not limited to methanol, tetrahydrofiiran, 1,2-dichloroethane, and dichloromethane or mixtures thereof. Compounds of Formula (21) can be prepared from compounds of Formula (20) as described in SCHEME 1, and can be used as described in SCHEME 8 to prepare compounds of Formula (I). SCHEME 5 CO2R CO2R ^3 (22) \, (23) As shown in SCHEME 5, compounds of Formula (22), wherein R is alkyl, may be converted to compounds of Formula (23) by reacting the former, wherein X^ is CI, Br, I, or CF3SO3-, and compounds of Formula R'*'-OH and a catalyst, with or without a first base. Examples of catalysts include copper(I) trifluoromethanesulfonate toluene complex, PdCh, Pd(0Ac)2, and Pd2(dba)3. Examples of first bases include triethylamine, N,N-diisopropylethylamine, CS2CO3, Na2C03, K3PO4, and mixtures thereof. Compounds of Formula (22) may also be converted to compounds of Formula (23) by reacting the former, when X' is CI, F, or NO2, and compounds of Formula R'^'-OH with a first base. Examples of first bases include triethylamine, N,N-diisopropylethylamine, CS2CO3, Na2C03, K3PO4, and mixtures thereof. 238 SCHEME 6 1 CO2R ^OH I W J (26) "tS —- ^^ —' y ^—- ^'^^' (25) CO2R CO2H ^"^ —' ^^ RseiO (27) pasikJ (28) Compounds of Formula (18) can be reacted with mesyl chloride and a base such as but not limited to triethylamine, followed by N-t-butoxycarbonylpiperazine, to provide compounds of Formula (24). Compounds of Formula (25) can be prepared by reacting compounds of Formula (24) with triethylsilane and trifluoroacetic acid. Compounds of Formula (25) can be reacted with compounds of Formula (26) and HK2PO4 to provide compounds of Formula (27) in a solvent such as but not limited to dimethylsulfoxide. Compounds of Formula (28) can be prepared from compounds of Formula (27) as described in SCHEME 1, and can be used as described in SCHEME 8 to prepare compounds of Formula (I). SCHEME 7 n f\y^ CO2R CO2H CO2R W^F-~^ (29) A. ^ 239 As shown in SCHEME 7, compounds of Formula (1) can be reacted with an appropriate triphenylphosphonium bromide of Formula (29) and a base such as but not limited to sodium hydride or n-butyllithium to provide compounds of Formula (30). The reaction is typically performed in a solvent such as THF or DMSO. Compounds of Formula (31) can be prepared from compounds of Formula (30) as described in SCHEME 1, and can be used as described in SCHEME 8 to prepare compounds of Formula (I). SCHEME 8 A.-^B' OMB. L/DA/B. (32) (33) ^ (I) As shown in SCHEME 8, compounds of Formula (32), which can be prepared as described herein, may be converted to compounds of Formula (33) by reacting the former with ammonia. Compounds of Formula (33) may be converted to compounds of Formula (I) by reacting the former and compounds of Formula (4), (8), (14), (21), (28), (31), or (38) and a coupling agent, with or without a first base. Examples of coupling agents include l-ethyl-3- [3-(dimethylamino)propyl]-carbodiimide hydrochloride, l,r-carbonyldiimidazole, and benzotriazol-l-yl-oxytripyrrolidinophosphonium hexafluorophosphate. Examples of first bases include triethylamine, N,N-diisopropylethylamine, 4-(dimethylamino)pyridine, and mixtures thereof. SCHEME 9 22A I ° (32) (33) Z (D Compounds of Formula (33), prepared as described in SCHEME 8, may also be converted to compounds of Formula (I) by reacting the former and compounds of Formula (34) and a first base. Examples of first bases include but are not limited to sodium hydride, triethylamine, N,N-diisopropylethylamine, 4-(dimethylamino)pyridine, and mixtures thereof. 240 SCHEME 10 H (^ ^ O^OR OyOH (35) N N (37) (38) As shown in SCHEME 10, compounds of Formula (35), wherein L is a bond, alkyl, O, S, S(0), S(0)2, NH, etc., can be reacted with compounds of Fonnula (36), to provide compounds of Formula (37). The reaction is typically performed at elevated temperatures in a solvent such as but not limited to dimethylsulfoxide, and may require the use of a base such as but not limited to potassium phosphate, potassium carbonate, and the like. Compounds of Formula (38) can be prepared from compounds of Formula (37) as described in SCHEME 1, and can be used as described in SCHEME 8 to prepare compounds of Formula (I). SCHEME 11 0 OH O OH 1 H ^xj ^xj Yr Y? (40) (41) Compounds of Formula (39), wherein Y is as described herein for substituents on Z^, can be prepared from compounds of Formula (39A) wherein X is a halide or triflate, and Y-B(0H)2 using Suzuki coupling conditions known to those skilled in the art and readily available in the literature. Compounds of Formula (39) can be reacted with tert-butyl piperazine-l-carboxylate and a reducing agent such as sodium triacetoxyborohydride to provide compounds of Formula (40). The reaction is typically performed in a solvent such as but not limited to methylene chloride. Compounds of Fonnula (41) can be prepared from compounds of Formula (40) by reacting the latter with R^^X, wherein X is a halide, and NaH in a solvent such as N,N-dimethylformamide, and then the resulting material can be treated 241 with triethylsilane and trifluoroacetic acid in dichloromethane. Compounds of Formula (41) can be used as described in Scheme 10 wherein \}-T^ is as shown in Formula (41). SCHEME 12 R37A (42) (43) As shown in SCHEME 12, substituted piperazin-2-ones wherein R^^ is alkyl, can be reacted with compounds of Formula (6) and a reducing agent such as sodium triacetoxyborohydride in dichloromethane to provide compounds of Formula (42). Compounds of Formula (42) can be reduced to compounds of Formula (43) using a reducing agent such as but not hmited to lithium aluminum hydride in a solvent such as but not limited to tetrahydrofuran. Compounds of Formula (43) can be used as described in Scheme 10 wherein \}-T^ is as shown in Formula (43). The following examples are presented to provide what is believed to be the most useful and readily understood description of procedures and conceptual aspects of this invention. The exemplified compounds were named using ACD/ChemSketch Version 5.06 (05 June 2001, Advanced Chemistry Development Inc. ,Toronto, Ontario), ACD/ChemSketch Version 12.01 (13 May 2009), Advanced Chemistry Development Inc., Toronto, Ontario), or ChemDraw® Ver. 9.0.5 (CambridgeSoft, Cambridge, MA). Intermediates were named using ChemDraw® Ver. 9.0.5 (CambridgeSoft, Cambridge, MA). EXAMPLE 1 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(3- ((dimethylamino)methyl)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide EXAMPLE lA tert-butyl 4-((4'-chlorobiphenyl-2-yl)methyl)piperazine-1 -carboxylate 242 4'-Chlorobiphenyl-2-carboxaldehyde (4.1 g), tert-butylpiperazine-l-carboxylate (4.23 g) and sodium triacetoxyborohydride (5.61 g) in CH2CI2 (60 mL) were stirred for 24 hours. The mixture was treated with methanol and poured into ether. The extract was washed with water and brine and concentrated. The concentrate was chromatographed on silica gel with 2-25% ethyl acetate/hexanes. EXAMPLE IB l-((4'-chlorobiphenyl-2-yl)methyl)piperazine EXAMPLE lA (3.0 g) and triethylsilane (1 mL) were stirred in dichloromethane (30 mL) and trifluoroacetic acid (30 mL) for 2 hours. The mixture was concentrated, taken up in ether and concentrated again. EXAMPLE IC methyl 2-bromo-4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)benzoate Methyl 2-bromo-4-fluorobenzoate (3 g), EXAMPLE IB (4.43 g), and K2CO3 (3.56 g) were stirred in DMSO (35 mL) at 125°C for 24 hours. The mixture was cooled, taken up in ethyl acetate (500 mL), washed with water and brine, dried over Na2S04, filtered and concentrated. The concentrate was chromatographed on silica gel with 5-25% ethyl acetate/hexanes. EXAMPLE ID 3-((dimethylamino)methyl)phenol 3-Hydroxybenzaldehyde (1.0 g), 2M dimethylamine in THE (5 mL), and sodium triacetoxyborohydride (2 g) in CH2CI2 (10 mL) were stirred for 24 hours. The mixture was treated with methanol and chromatographed on silica gel with 2-25% ethyl acetate/hexanes. EXAMPLE IE methyl 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)-2-(3-((dimethylamino)methyl)phenoxy)benzoate EXAMPLE IC (400 mg), EXAMPLE ID (260 mg), CS2CO3 (570 mg), 1-naphthoic acid (2.96 g), copper (I) triflate-toluene complex (245 mg), ethyl acetate (9 ^iL), and 4A sieves (30 mg) in toluene (2 mL) was stirred at 105°C for 24 hours. The mixture was cooled and taken up in ethyl acetate (100 mL) and water (40 mL). The layers were separated and the 243 extract was washed twice with NaiCOa solution and brine, dried, and concentrated. The concentrate was chromatographed on silica gel with 25-50% ethyl acetate/hexanes. EXAMPLE IF 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-((dimethylamino)methyl)phenoxy)benzoic acid EXAMPLE IE (750 mg) was stirred in 25 mL 2:1 dioxane/lM NaOH at 80°C for 4 hours. The solution was cooled and adjusted to pH 4 with NaH2P04 solution and concentrated HCl, and extracted with ethyl acetate. The extract was washed with brine, dried (Na2S04), and concentrated. EXAMPLE IG 3-nitro-4-((tetrahydro-2H-pyran-4-yl)methylamino)benzenesulfonamide 4-Ruoro-3-nitrobenzenesulfonamide (2.18 g), (tetrahydropyran-4-yl)methylamine (1.14 g), and triethylamine (1 g) were stirred in THE (30 mL) for 24 hours. The solution was diluted with ethyl acetate, washed with NaH2P04 solution and brine, and dried (Na2S04), filtered and concentrated. The product was triturated from ethyl acetate. EXAMPLE IH 4-(4-((4'-chloro-1,1'-bipheny l-2-yl)methyl)piperazin-l-yl)-2-(3-((dimethylamino)methyl)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide EXAMPLE IF (128 mg), EXAMPLE IG (73 mg), l-ethyl-3-(3-(dimethylamino)propyl)-carbodiimide hydrochloride (88 mg), and 4-dimethylaminopyridine (28 mg) were stirred in CH2CI2 (3 raL) for 24 hours. The mixture was cooled and chromatographed on silica gel with 0-10% methanol/ethyl acetate, 'H NMR (^OOMHZ, DMS0-d6) 6 11.15 (br s, IH), 8.63 (dd, IH), 8.49 (d, IH), 7.80 (dd, IH), 7.44-7.53 (m, 5H), 7.36 (m, 3H), 7.22 (m, 3H), 7.01 (s, IH), 6.92 (d, IH), 6.78 (d, IH), 6.44 (s, IH), 4.17 (m, 2H), 3.86 (dd, 2H), 3.33 (m, 6H), 3.16 (m, 4H), 2.66 (s, 6H), 2.37 (br s, 4H), 1.91 (m, IH), 1.63 (d,2H), 1.29 (m,2H). 244 EXAMPLE 2 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-(methylamino)phenoxy)-N- ((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide EXAMPLE 2A 3-(methylamino)phenol Ethylamine was bubbled into a solution of 4-hydroxybenzaldehyde (2.0 g) and sodium triacetoxyborohydride (5.2 g) in CH2CI2 (60 mL) for 1 hour, and the mixture was stoppered and stirred for 24 hours. IM NaOH solution was added (10 mL), and di-tert-butyl dicarbonate (3.57 g) and triethylamine (2.28 mL) were then added and the mixture was stirred for 24 hours. The solution was cooled and adjusted to pH 4 with NaH2P04 solution and concentrated HCl, and extracted with ethyl acetate. The extract was washed with brine, dried (Na2S04), and concentrated. The concentrate was chromatographed on silica gel with 20% ethyl acetate/hexanes. EXAMPLE2B methyl 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-(methylamino)phenoxy)benzoate EXAMPLE IC (457 mg), EXAMPLE 2A (225 mg), cesium carbonate (595 mg), copper(I) triflate toluene complex (41 mg), and ethyl acetate (0.016 mL) in toluene (5 mL) were stirred at 1WC for 72 hours. The mixture was cooled and chromatographed on silica gel with 5-25% ethyl acetate/hexanes. EXAMPLE 2C 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-(methylamino)phenoxy)benzoic acid This EXAMPLE was prepared by substituting EXAMPLE 2B for EXAMPLE IE in EXAMPLE IF. EXAMPLE 2D 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-(methylamino)phenoxy)-N- ((3-nitix)-4-((tetrahydro-2H-pyran-4-ylmethyI)amino)phenyl)sulfonyl)benzamide 245 This EXAMPLE was prepared by substituting EXAMPLE 2C for EXAMPLE IF in EXAMPLE IG. 'H NMR (500MHZ, DMSO-dg) 6 U.60 (brs, IH), 8.37 (s, IH), 7.69 (d, IH), 7.58 (d, IH), 7.47 (m, 5H), 7.38 (m, 3H), 7.24 (m, IH), 6.95 (d, IH), 6.89 (dd, IH), 6.61 (d, IH), 6.26 (s, IH), 6.13 (d, IH), 5.97 (s, IH), 5.92 (d, IH), 5.59 (br s, IH), 3.84 (dd, 2H), 3.37 (m, 6H), 3.03 (m, 4H), 2.89 (m, 2H), 2.59 (br s, 3H), 2.36 (br s, 4H), 1.91 (m, IH), 1.62 (d, 2H), 1.24 (m, 2H). EXAMPLE 3 4-(4-((2-(4-chlorophenyI)-4,4-dimethyIcycIohex-l-en-l-yI)methyl)piperazin-l-yI)-2-((2- methyI-lH-indoI-5-yl)oxy)-N-((4-((l-methyIpiperidin-4-yI)amino)-3- nitrophenyl)sulfonyl)benzaniide EXAMPLE 3A ethyl 4-fluoro-2-(2-methyl- lH-indol-5-yloxy)benzoate Ethyl 2,4-dinuorobenzoate (1.14 g). K3PO4 (1.30 g) and 2-methyl-5-indolol (0.90 g) were stirred at 110°C in diglyme (12 mL) for 24 hours. The mixture was cooled and poured into ether. The solution was washed three times with IM NaOH solution, and with brine, and dried. The solution was then concentrated. The concentrate was chromatographed on silica gel with 10% ethyl acetate/hexanes. EXAMPLE 3B methyl 4,4-dimethyl-2-(trifluoromethylsulfonyloxy)cyclohex-l-enecarboxylate To a suspension of hexane-washed NaH (17 g) in dichloromethane (700 mL) was added 5,5-dimethyl-2-methoxycarbonyIcyclohexanone (38.5 g) dropwise at O^C. After stirring for 30 minutes, the mixture was cooled to -78°C and trifluoroacetic anhydride (40 mL) was added. The mixture was warmed to room temperature and stirred for 24 hours. The extract was washed with brine, dried and concentrated. EXAMPLE 3C methyl 2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enecarboxylate EXAMPLE 3B (62.15g), 4-chlorophenylboronic acid (32.24 g), CsF (64 g) and tetrakis(triphenylphosphine)palladium(0) (2g) in 2:1 dimethoxyethane /methanol (600 mL) 246 were heated to l(fC for 24 hours. The mixture was concentrated. Ether was added, and the mixture was filtered and concentrated. EXAMPLE 3D (2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methanol To a mixture of LiBH4 (13g), EXAMPLE 3C (53.8 g) and ether (400 mL), methanol (25 mL) was added slowly by syringe. The mixture was stirred at room temperature for 24 hours. The mixture was quenched with IN HCl with ice-cooling. The mixture was diluted with water and extracted by ether (3x lOOmL). The extracts were dried, and concentrated. The concentrate was chromatographed on silica gel with 0-30% ethyl acetate/hexanes. EXAMPLE 3E tert-butyl 4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazine-1- carboxylate Mesyl chloride (7.5 mL) was added via syringe to EXAMPLE 3D (29.3 g) and triethylamine (30 mL) in CH2CI2 (500 mL) at O^C, and the mixture was stirred for 1 minute. N-t-butoxycarbonylpiperazine (25 g) was added and the mixture was stirred at room temperature for 24 hours. The suspension was washed with brine, dried, and concentrated. The concentrate was chromatographed on silica gel with 10-20% ethyl acetate/hexanes. EXAMPLE 3F l-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazine This EXAMPLE was prepared by substituting EXAMPLE 3E for EXAMPLE lA in EXAMPLE IB. EXAMPLE 3G ethyl 4-(4-((2-(4-chlorophenyl)-4,4-dimediylcyclohex-1 -enyl)methyl)piperazin-1 -yl)-2-(2- methyl-lH-indol-5-yloxy)benzoate EXAMPLE 3F (1008 mg), EXAMPLE 3A (900 mg), and HK2PO4 (550 mg) were stirred in DMSO (7 mL) at 140''C for 24 hours. The mixture was diluted with ethyl acetate, washed three times with water, washed with brine, dried, and concentrated. The concentrate was chromatographed on silica gel with 30% ethyl acetate/hexanes. 247 EXAMPLE 3H 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-2-(2-inethyl- lH-indol-5-yloxy)benzoic acid This EXAMPLE was prepared by substituting EXAMPLE 3G for EXAMPLE IE in EXAMPLE IF. EXAMPLE 31 4-(l-methylpiperidin-4-ylamino)-3-nitrobenzenesulfonainide This EXAMPLE was prepared by substituting 4-amino-N-methylpiperidine for 3-(N-morpholinyl)-!-propylamine in EXAMPLE 4A. EXAMPLE 3J 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-2-((2-methyl-lH-indol-5-yl)oxy)-N-((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide This EXAMPLE was prepared by substituting EXAMPLE 3H for EXAMPLE IF and EXAMPLE 31 for EXAMPLE IG in EXAMPLE IH. 'H NMR (300MHZ, DMSO-de) 5 10.98 (s, IH), 10.50 (br s, IH), 8.55 (dd, IH), 8.17 (d, IH), 7.88 (dd, IH), 7.51 (d, IH), 7.34 (d, 2H), 7.24 (d, IH), 7.14 (d, IH), 7.05 (d, 2H), 7.00 (d, IH), 6.72 (d, IH), 6.55 (d, IH), 6.08 (d, 2H), 3.85 (m, IH), 3.45 (m, 4H), 2.98 (br s, 4H), 2.85 (m, 2H), 2.71 (br s, 2H), 2.63 (s, 2H), 2.38 (s, 2H), 2.15 (m, 6H), 1.95 (m, 4H), 1.80 (m, 2H), 1.38 (m, 2H), 0.92 (s, 6H). EXAMPLE4 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-((2- methyl-lH-indol-5-yl)oxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3- nitrophenyl)sulfonyl)benzamide EXAMPLE 4A 4-(3-morpholinopropylaniino)-3-nitrobenzenesulfonamide 4-Fluoro-3-nitrobenzenesulfonainide (550 mg), 3-(N-morpholinyl)-l-propylamine (1.00 g), and triethylamine (1 g) were stirred in THF (30 mL) for 24 hours. The mixture was diluted with ethyl acetate, washed with NaH2P04 solution and brine, and dried (Na2S04), filtered and concentrated. The product was triturated from ethyl acetate. 248 EXAMPLE 4B 4-(4-((2-(4-chloiophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-((2-methyl-lH-indol-5-yl)oxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide This EXAMPLE was prepared by substituting EXAMPLE 4A for EXAMPLE IF and EXAMPLE 3H for EXAMPLE IG in EXAMPLE IH. 'H NMR (300MHZ, DMSO-de) 8 10.98 (m, 2H), 8.80 (dd, IH), 8.58 (d, IH), 7.82 (dd, IH), 7.50 (d, IH), 7.34 (d, 2H), 7.27 (d, IH), 7.05 (m, 4H), 6.75 (d, IH), 6.62 (d, IH), 6.10 (d, IH), 3.60 (m, 4H), 3.45 (m, 2H), 3.01 (br s, 4H), 2.71 (br s, 3H), 2.38 (m, 8H), 2.14 (br s, 6H), 1.95 (m, 2H), 1.81 (m, 2H), 1.38 (m, 2H), 0.92 (s, 6H). EXAMPLE 5 4-(4-((4'-chloro-l, r-biphenyl-2-yl)methyl)piperazin- l-yl)-2-(2-chlorophenoxy)-N-((3-nitro- 4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide EXAMPLE 5A methyl 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)-2-(2-chlorophenoxy)benzoate This EXAMPLE was prepared by substituting 2-chlorophenol for EXAMPLE ID in EXAMPLE IE. EXAMPLE 5B 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)-2-(2-chlorophenoxy )benzoic acid This EXAMPLE was prepared by substituting EXAMPLE 5A for EXAMPLE IE in EXAMPLE IF. EXAMPLE 5C 4-(4-((4'-chloro-l, r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(2-chlorophenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylinethyl)amino)phenyl)sulfonyI)benzamide This EXAMPLE was prepared by substituting EXAMPLE 5B for EXAMPLE IF in EXAMPLE IH. The crude product was purified by preparative HPLC using a 250 x 50 mm C18 column and eluting with 20-100% CH3CN vs. 0.1% trifluoroacetic acid in water, giving the product as a trifluoroacetate salt. 'H NMR (300 MHz, DMSO-de) 6 11.77 (br s, IH), 9.58 249 (v br s, IH), 8.63 (t, IH), 8.46 (d, IH), 7.79 (dd, IH), 7.71 (br s, IH), 7.52 (m, 5H), 7.35 (m, 4H), 7.15 (d, IH), 7.13 (m, IH), 6.99 (m, IH), 6.78 (dd.lH), 6.65 (d, IH), 6.40 (s, IH), 4.35 (v br s, IH), 3.90 (m, 2H), 3.80-2.80 (v br m, 7H), 3.36 (m, 4H), 3.27 (m, 2H), 1.90 (m, IH), 1.63 (m,2H), 1.28 (m,2H). EXAMPLE 6 4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-chlorophenoxy)-N-((3-nitro- 4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide EXAMPLE 6A methyl 4-(4-((4'-chlorobiphenyl-2-yl)methy])piperazin-1 -yl)-2-(3-chlorophenoxy)benzoate This EXAMPLE was prepared by substituting 3-chlorophenol for EXAMPLE ID in EXAMPLE IE. EXAMPLE 6B 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)-2-(3-chlorophenoxy)benzoic acid This EXAMPLE was prepared by substituting EXAMPLE 6A for EXAMPLE IE in EXAMPLE IF. EXAMPLE 6C 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-chlorophenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-y]methyl)amino)phenyl)sulfonyl)benzamide This EXAMPLE was prepared by substituting EXAMPLE 6B for EXAMPLE 5B in EXAMPLE 5C. 'H NMR (300 MHz, DMSO-de) 6 11.85 (br s, IH), 9.60 (v br s, IH), 8.63 (t, IH), 8.43 (d, IH), 7.72 (dd, IH), 7.70 (br s, IH), 7.50 (m, 5H), 7.40 (d, 2H), 7.35 (m, IH), 7.19 (dd, IH), 7.14 (d, IH), 6.95 (m, IH), 6.80 (dd, IH), 6.72 (m, IH), 6.70 (m, IH), 6.56 (d, IH), 4.35 (v br s, IH), 3.90 (m, 2H), 3.80-2.80 (v br m, 7H), 3.36 (m, 4H), 3.27 (m, 2H), 1.90 (m, IH), 1.63 (m, 2H), 1.28 (m, 2H). EXAMPLE 7 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(4-chlorophenoxy)-N-((3-nitro- 4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide 250 EXAMPLE 7A methyl 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)-2-(4-chlorophenoxy)benzoate This EXAMPLE was prepared by substituting 4-chlorophenol for EXAMPLE ID in EXAMPLE IE. EXAMPLE7B 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)-2-(4-chlorophenoxy)benzoic acid This EXAMPLE was prepared by substituting EXAMPLE 7A for EXAMPLE IE in EXAMPLE IF. EXAMPLE 7C 4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(4-chlorophenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide This EXAMPLE was prepared by substituting EXAMPLE 7B for EXAMPLE 5B in EXAMPLE 5C. 'H NMR (300 MHz, DMSO-de) 5 U.81 (br s, IH), 9.58 (v br s, IH), 8.63 (t, IH), 8.46 (d, IH), 7.73 (dd, IH), 7.71 (br s, IH), 7.50 (m, 5H), 7.38 (d, 2H), 7.33 (m, IH), 7.25 (m, 2H), 7.15 (d, IH), 6.79 (m, 3H), 6.50 (d, IH), 4.35 (v br s, IH), 3.90 (m, 2H), 3.80-2.80 (v br m, 7H), 3.36 (m, 4H), 3.27 (m, 2H), 1.90 (m, IH), 1.63 (m, 2H), 1.28 (m, 2H). EXAMPLE 8 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-nitrophenoxy)-N-((3-iiitro-4- ((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide EXAMPLE 8A methyl 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)-2-(3-nitiophenoxy)benzoate This EXAMPLE was prepared by substituting 3-nitrophenol for EXAMPLE ID in EXAMPLE IE. EXAMPLE 8B 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-nitrophenoxy)benzoic acid This EXAMPLE was prepared by substituting EXAMPLE 8A for EXAMPLE IE in EXAMPLE IF. 251 EXAMPLE 8C 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(3-nitrophenoxy)-N-((3-mtro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide This EXAMPLE was prepared by substituting EXAMPLE 8B for EXAMPLE 5B in EXAMPLE 5C. 'H NMR (300 MHz, DMSO-ds) 5 1L81 (br s, IH), 9.59 (v br s, IH), 8.60 (t, IH), 8.39 (d, IH), 7.70 (m, 3H), 7.50 (m, 6H), 7.38 (m,4H), 7.23 (m, IH), 7.10 (d, IH), 6.85 (dd, IH), 6.63 (d,lH), 4.35 (v br s, IH), 3.90 (m, 2H), 3.80-2.80 (v br m, 7H), 3.36 (m, 4H), 3.27 (m, 2H), L90 (m, IH), L63 (m, 2H), L28 (m, 2H). EXAMPLE 9 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(3-(hydroxymethyl)phenoxy)-N- ((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide EXAMPLE 9A methyl 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)-2-(3-(hydroxymethyl)phenoxy)benzoate This EXAMPLE was prepared by substituting 3-(hydroxymethyl)phenol for EXAMPLE ID in EXAMPLE IE. EXAMPLE 9B 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-(hydroxymethyl)phenoxy)benzoic acid * This EXAMPLE was prepared by substituting EXAMPLE 9A for EXAMPLE IE in EXAMPLE IF. EXAMPLE 9C 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(3-(hydroxymethyl)phenoxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide This EXAMPLE was prepared by substituting EXAMPLE 9B for EXAMPLE IF and EXAMPLE 4A for EXAMPLE IG in EXAMPLE IH, except that the purification was performed by HPLC according to EXAMPLE 5C. 'H NMR (300 MHz, DMSO-de) 6 11.63 (br s, IH), 9.60 (v br s, 2H), 8.70 (t, IH), 8.50 (d, IH), 7.80 (dd, IH), 7.67 (br s, IH), 7.50 252 (m, 5H), 7.40 (m,2H), 7.35 (br s, IH), 7.20 (m, 2H), 6.95 (d, IH), 6.75 (m, 3H), 6.40 (s, IH), 4.40 (s, 2H), 4.35-2.80 (m, 22 H), 1.98 (m, 2H). EXAMPLE 10 4-(4.((4'-chloio-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(2-chIorophenoxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)suIfonyl)benzamide This EXAMPLE was prepared by substituting EXAMPLE 5B for EXAMPLE IF and EXAMPLE 4A for EXAMPLE IG in EXAMPLE IH, except that the purification was performed by HPLC according to EXAMPLE 5C. 'H NMR (300 MHz, DMSO-de) 8 11.77 (br s, IH), 9.62 (v br s, 2H), 8.70 (t, IH), 8.50 (d, IH), 7.82 (dd, IH), 7.71 (br s, IH), 7.52 (m, 5H), 7.40 (m, 3H), 7.33 (br s, IH), 7.16 (m, 2H), 7.02 (m, IH), 6.79 (dd,lH), 6.70 (d, IH), 6.40 (s, IH), 4.35-2.80 (m, 22 H), 1.98 (m, 2H). EXAMPLE 11 4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(2-chlorophenoxy)-N-((4-((3- (dimethylamino)propyl)amino)-3-nitrophenyl)sulfonyl)benzamide EXAMPLE llA 4-(3-(dimethylaniino)propylamino)-3-nitrobenzenesulfonamide This EXAMPLE was prepared by substituting 3-(dimethylamino)-l-propylamine for 3-(N-morpholinyl)-l-propylamine in EXAMPLE 4A. EXAMPLE 1 IB 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(2-chlorophenoxy)-N-((4-((3-(dimethylamino)propyl)amino)-3-nitrophenyl)sulfonyl)benzamide This EXAMPLE was prepared by substituting EXAMPLE 5B for EXAMPLE IF and EXAMPLE 11A for EXAMPLE IG in EXAMPLE IH, except that the purification was performed by HPLC according to EXAMPLE 5C. 'H NMR (300 MHz, DMSG-de) 5 11.77 (br s, IH), 9.38 (v br s, 2H), 8.70 (t, IH), 8.50 (d, IH), 7.82 (dd, IH), 7.65 (br s, IH), 7.52 (m, 5H), 7.40 (m, 3H), 7.33 (br s, IH), 7.16 (m, 2H), 7.02 (m, IH), 6.79 (dd,lH), 6.70 (d, IH), 6.40 (s, IH), 4.35-2.80 (m, 12 H), 2.80 (s, 3H), 2.78 (s, 3H), 1.98 (m, 2H). 253 EXAMPLE 12 4.(4.((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-chlorophenoxy)-N-((4-((3-moipholin-4-ylpropyl)aniino)-3-nitrophenyl)sulfonyl)benzamide This EXAMPLE was prepared by substituting EXAMPLE 6B for EXAMPLE IF and EXAMPLE 4A for EXAMPLE IG in EXAMPLE IH, except that the purification was performed by HPLC according to EXAMPLE 5C. 'H NMR (300 MHz, DMSO-dg) 6 U .85 (br s, IH), 9.63 (v br s, 2H), 8.66 (t, IH), 8.43 (d, IH), 7.78 (dd, IH), 7.67 (br s, IH), 7.50 (m, 5H), 7.40 (d, 2H), 7.35 (m, IH), 7.20 (dd, IH), 7.14 (d, IH), 6.95 (m, IH), 6.80 (dd, IH), 6.72 (m, IH), 6.70 (m, IH), 6.53 (s, IH), 4.35-2.80 (m, 22 H), 1.98 (m, 2H). EXAMPLE 13 4.(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(4-chlorophenoxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide This EXAMPLE was prepared by substituting EXAMPLE 7B for EXAMPLE IF and EXAMPLE 4A for EXAMPLE IG in EXAMPLE IH, except that the purification was performed by HPLC according to EXAMPLE 5C. 'H NMR (300 MHz, DMSO-de) 6 11.81 (br s, IH), 9.63 (v br s, 2H), 8.70 (t, IH), 8.50 (d, IH), 7.80 (dd, IH), 7.69 (br s, IH), 7.50 (m, 5H), 7.38 (d, 2H), 7.33 (m, IH), 7.25 (m, 2H), 7.15 (d, IH), 6.79 (m, 3H), 6.50 (d, IH), 4.35-2.80 (m, 22 H), 1.98 (m, 2H). EXAMPLE 14 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-chlorophenoxy)-N-((4-((3-(dimethylamino)propyl)amino)-3-nitrophenyl)sulfonyl)benzamide This EXAMPLE was prepared by substituting EXAMPLE 6B for EXAMPLE IF and EXAMPLE llA for EXAMPLE IG in EXAMPLE IH, except that the purification was performed by HPLC according to EXAMPLE 5C. 'H NMR (300 MHz, DMSO-dg) 5 11.85 (br s, IH), 9.63 (v br s, 2H), 8.70 (t, IH), 8.45 (d, IH), 7.78 (dd, IH), 7.70 (br s, IH), 7.50 (m, 5H), 7.40 (d, 2H), 7.35 (m, IH), 7.20 (dd, IH), 7.14 (d, IH), 6.95 (m, IH), 6.80 (dd, IH), , 6.72 (m, IH), 6.70 (m, IH), 6.56 (s, IH), 4.35-2.80 (m, 12 H), 2.52 (s, 3H), 2.50 (s, 3H), 2.00 (m, 2H). 254 EXAMPLE 15 4-(4-((4'-ch]oro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(4-chlorophenoxy)-N-((4-((3 -(dimethylamino)propyl)amino)-3-nitrophenyl)sulfonyl)benzamide This EXAMPLE was prepared by substituting EXAMPLE 7B for EXAMPLE IF and EXAMPLE 11A for EXAMPLE IG in EXAMPLE IH, except that the purification was performed by HPLC according to EXAMPLE 5C. 'H NMR (300 MHz, DMSO-de) 5 1L81 (br s, IH), 9.38 (v br s, IH), 8.68 (t, IH), 8.50 (d, IH), 7.80 (dd, IH), 7.69 (br s, IH), 7.50 (in, 5H), 7.40 (d, 2H), 7.33 (m, IH), 7.25 (m, 2H), 7.15 (d, IH), 6.80 (m, 3H), 6.46 (s, IH), 4.35-2.80 (m, 12 H), 2.81 (s, 3H), 2.79 (s, 3H), 1.98 (m, 2H). EXAMPLE 16 4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-((3- (dimethylamino)propyl)amino)-3-nitrophenyl)sulfonyl)-2-((l-methyl-lH-indol-4- yl)oxy)benzamide EXAMPLE 16A l-(triisopropylsilyl)-lH-indol-4-ol 4-Benzyloxyindole (1 g) was treated with 60% oily NaH (135 mg) and triisopropylsilyl chloride (1 g) in THE, purified by flash chromatography (98/2 ethyl acetate/hexanes), then debenzylated in ethanol (35 mL) using Pearlman's catalyst (0.19 g) and a hydrogen balloon. EXAMPLE 16B methyl 2-(lH-indol-4-yloxy)-4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)benzoate This EXAMPLE was prepared by substituting EXAMPLE 16A for EXAMPLE ID in EXAMPLE IE. The crude material from the ether formation was desilylated using tetrabutyl ammonium fluoride in THF/water 95/5 for 1 hour prior to purification. EXAMPLE 16C methyl 4-(4-((4'-ch]orobiphenyl-2-yl)methyl)piperazin-1 -yl)-2-( 1 -methyl-1 H-indol-4- yloxy)benzoate 255 EXAMPLE 16B (148 mg), 60% oily NaH (9 mg) and methyl iodide (57 mg) in THE (1 mL) were stirred at room temperature overnight. The mixture was chromatographed on silica gel with 20% ethyl acetate in hexanes. EXAMPLE 16D 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)-2-(l -methyl-1 H-indol-4-yloxy)benzoic acid This EXAMPLE was prepared by substituting EXAMPLE 16C for EXAMPLE IE in EXAMPLE IF. EXAMPLE 16E 4-(4-((4'-chloro-1, l'-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((4-((3- (dimethylamino)propyl)amino)-3-nitrophenyl)sulfonyl)-2-((l-methyl-lH-indol-4- yl)oxy)benzamide This EXAMPLE was prepared by substituting EXAMPLE llA for EXAMPLE IG and EXAMPLE 16D for EXAMPLE IF in EXAMPLE IH, except that the purification was perfonned by HPLC according to EXAMPLE 5C. 'H NMR (300 MHz, DMSO-de) 6 11.58 (br s, IH), 9.42 (br s, 2H), 8.64 (t, IH), 8.44 (d, IH), 7.77 (dd, IH), 7.66 (br s, IH), 7.50 (m, 5H), 7.37 (d, 2H), 7.30 (m, IH), 7.25 (d, IH), 7.19 (d, IH), 7.06 (d, IH), 7.00 (dd, IH), 6.75 (dd, IH), 6.40 (d, IH), 6.38 (s, IH), 6.23 (d, IH), 4.35-2.80 (m, 12 H), 3.80 (s, 3H), 2.79 (s, 3H), 2.77 (s, 3H), 1.96 (m, 2H). EXAMPLE 17 2-(3-(acetylamino)phenoxy)-4-(4-((4'-chloro-1,1 '-biphenyl-2-y])methyl)piperazin- l-yl)-N- ((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide EXAMPLE 17A methyl 2-(3-acetamidophenoxy)-4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l- yl)benzoate This EXAMPLE was prepared by substituting 3-acetamidophenol for EXAMPLE ID in EXAMPLE IE. 256 EXAMPLE 17B 2-(3-acetamidophenoxy)-4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)benzoic acid This EXAMPLE was prepared by substituting EXAMPLE 17A for EXAMPLE IE in EXAMPLE IF. EXAMPLE 17C 2-(3-(acetylamino)phenoxy)-4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin- l-yl)-N-((3-mtro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide This EXAMPLE was prepared by substituting EXAMPLE 17B for EXAMPLE IF in EXAMPLE IH. 'H NMR (300 MHz, DMSO-dg) 8 1L48 (s, 1 H), 9.89 (s, IH), 8.59 (m, IH), 8.50 (d, IH), 7.71 (dd, IH), 7.47 (m, 6H), 7.36 (m, 2H), 7.24 (m, 2H), 7.14 (m, 3H), 6.75 (dd, IH), 6.50 (dd, IH), 6.39 (d, IH), 3.86 (dd, 2H), 3.37 (m, 2H), 3.30 (m, 6H), 3.16 (m, 4H), 2.35 (s, 4H), 2.00 (s, 3H), 1.89 (m, IH), 1.63 (dd, 2H), 1.27 (m, 2H). EXAMPLE 18 2-(4-aminophenoxy)-4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((3-nitro- 4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide EXAMPLE 18A methyl 2-(4-(tert-butoxycarbonylamino)phenoxy)-4-(4-((4'-chlorobiphenyl-2- yl)methyl)piperazin-1 -yl)benzoate This EXAMPLE was prepared by substituting N-tert-butoxycarbonyl-4-aminophenol for EXAMPLE ID in EXAMPLE IE. EXAMPLE 18B 2-(4-(tert-butoxycarbonylamino)phenoxy)-4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l- yl)benzoic acid This EXAMPLE was prepared by substituting EXAMPLE 18A for EXAMPLE IE in EXAMPLE IF. 257 EXAMPLE 18C tert-butyl 4-(5-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)-2-(3-nitro-4-((tetrahydro-2H-pyran-4-yl)methylamino)phenylsulfonylcarbamoyl)phenoxy)phenylcarbamate This EXAMPLE was prepared by substituting EXAMPLE 18B for EXAMPLE IF in EXAMPLE IH. EXAMPLE 18D 2-(4-aminophenoxy)-4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((3-nitr6-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzaniide This EXAMPLE was prepared by substituting EXAMPLE 18C for EXAMPLE 1A in EXAMPLE IB. 'H NMR (300 MHz, DMSO-dg) 5 ppm 1L41 (s, IH), 9.54 (s, IH), 8.66 (t, IH), 8.59 (d, IH), 7.86 (dd, IH), 7.67 (m, IH), 7.51 (dd, 5H), 7.38 (d, 2H), 7.31 (m, IH), 7.25 (d, IH), 6.82 (m, 4H), 6.69 (dd, IH), 6.24 (m, IH), 4.26 (s, 2H), 3.85 (dd, 2H), 3.35 (m, 4H), 3.26 (td, 4H), 3.04 (m, 4H), 2.81 (m, 2H), 1.91 (m, IH), 1.62 (dd, 2H), 1.26 (m, 2H). EXAMPLE 19 2-(3-aminophenoxy)-4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((3-nitro- 4-((tetrahydro-2H-pyran-4-ylniethyl)amino)phenyl)suIfonyl)benzainide EXAMPLE 19A methyl 2-(3-(tert-butoxycarbonylamino)phenoxy)-4-(4-((4'-chlorobiphenyl-2- yl)methyl)piperazin-1 -yl)benzoate This EXAMPLE was prepared by substituting N-tert-butoxycarbonyl-3-aminophenol for EXAMPLE ID in EXAMPLE IE. EXAMPLE 19B 2-(3-(tert-butoxycarbonylamino)phenoxy)-4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l- yl)benzoic acid This EXAMPLE was prepared by substituting EXAMPLE 19A for EXAMPLE IE in EXAMPLE IF. 258 EXAMPLE 19C tert-butyl 3-(5-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)-2-(3-nitro-4-((tetrahydro-2H-pyran-4-yl)methylamino)phenylsulfonylcarbamoyl)phenoxy)phenylcarbamate This EXAMPLE was prepared by substituting EXAMPLE 19B for EXAMPLE IF in EXAMPLE IH. EXAMPLE 19D 2-(3-aniinophenoxy)-4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide This EXAMPLE was prepared by substituting EXAMPLE 19C for EXAMPLE 1A in EXAMPLE IB. ^H NMR (300 MHz, DMSO-de) 5ppm n.39 (s, IH), 9.50 (s, IH), 8.64 (t, IH), 8.54 (d, IH), 7.75 (dd, 2H), 7.51 (d, 5H), 7.38 (m, 2H), 7.31 (m, IH), 7.16 (d, IH), 6.92 (t, IH), 6.73 (dd, IH), 6.38 (d, IH), 6.28 (m, IH), 6.09 (m, IH), 6.02 (d, IH), 5.24 (m, IH), 4.36 (m, IH), 3.86 (dd, 2H), 3.72 (m, IH), 3.28 (m, 8H), 3.20 (m, IH), 3.04 (m, 3H), 2.85 (m, IH), 1.90 (m, IH), 1.63 (dd, 2H), 1.27 (m, 2H). EXAMPLE 20 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(3-methoxyphenoxy)-N-((3- nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide EXAMPLE 20A methyl 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)-2-(3-methoxyphenoxy)benzoate This EXAMPLE was prepared by substituting 3-methoxyphenol for EXAMPLE ID in EXAMPLE IE. EXAMPLE 20B 4-(4-((4'-chlorobiphenyl-2-yl)methyI)piperazin-l-yl)-2-(3-methoxyphenoxy)benzoic acid This EXAMPLE was prepared by substituting EXAMPLE 20A for EXAMPLE IE in EXAMPLE IF. 259 EXAMPLE 20C 4-(4-((4'-chlorc)-1, l'-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(3-methoxyphenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzainide This EXAMPLE was prepared by substituting EXAMPLE 20B for EXAMPLE IF in EXAMPLE IH. 'H NMR (300 MHz, DMSO-dg) 5 ppm 1L57 (s, IH), 8.63 (t, IH), 8.47 (d, IH), 7.76 (dd, IH), 7.47 (m, 6H), 7.36 (m, 2H), 7.24 (m, IH), 7.11 (m, 2H), 6.76 (dd, IH), 6.53 (ddd, IH), 6.35 (m, 3H), 3.86 (m, 2H), 3.66 (s, 3H), 3.32 (m, 6H), 3.17 (m, 4H), 2.36 (m, 4H), 1.92 (m, IH), 1.64 (dd, 2H), 1.27 (m, 2H). EXAMPLE 21 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(3-(dimethylamino)phenoxy)-N- ((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzanude EXAMPLE 21A methyl 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin- l-yl)-2-(3-(dimethylamino)phenoxy)benzoate This EXAMPLE was prepared by substituting 3-(dimethylamino)phenol for EXAMPLE ID in EXAMPLE IE. EXAMPLE 21B 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-(dimethylamino)phenoxy)benzoic acid This EXAMPLE was prepared by substituting EXAMPLE 21A for EXAMPLE IE in EXAMPLE IF. EXAMPLE 21C 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(3-(dimethylamino)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide This EXAMPLE was prepared by substituting EXAMPLE 21B for EXAMPLE IF in EXAMPLE IH. 'H NMR (300 MHz, DMSO-de) 5 ppm 11.36 (s, IH), 8.63 (t, IH), 8.51 (d, IH), 7.79 (dd, IH), 7.46 (m, 6H), 7.36 (m, 2H), 7.24 (m, IH), 7.15 (d, IH), 7.04 (t, IH), 6.72 (dd, IH), 6.39 (dd, IH), 6.33 (d, IH), 6.24 (t, IH), 6.10 (dd, IH), 3.86 (dd, 2H), 3.32 (m, 6H), 3.13 (m, 4H), 2.83 (s, 6H), 2.34 (m, 4H), 1.90 (m, IH), 1.63 (dd, 2H), 1.27 (m, 2H). 260 EXAMPLE 22 4.(4-((4'-cliloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-cyanophenoxy)-N-((3-nitro- 4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide EXAMPLE 22A methyl 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yI)-2-(3-cyanophenoxy)benzoate This EXAMPLE was prepared by substituting 3-cyanophenol for EXAMPLE ID in EXAMPLE IE. EXAMPLE 22B 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)-2-(3-cyanophenoxy)benzoic acid A mixture of EXAMPLE 22A (0.081 g) in pyridine (2 mL) in a 10 mL microwave vial equipped with a magnetic stir bar was treated with Lil (0.402 g), flushed with nitrogen and heated in a CEM microwave reactor at 120°C for 30 minutes. The mixture was concentrated, acidified with IN HCl, extracted with ethyl acetate and dried (MgS04), filtered and concentrated. The concentrate was purified by column chromatography on silica gel, eluting with a gradient of 0-10% methanol in dichloromethane. EXAMPLE 22C 4-(4-((4'-chloro-Ll'-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-cyanophenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide This EXAMPLE was prepared by substituting EXAMPLE 22B for EXAMPLE IF in EXAMPLE IH. 'H NMR (300 MHz, DMSO-dg) 6ppm 11.78 (s, IH), 8.62 (t, IH), 8.41 (d, IH), 7.72 (dd, IH), 7.48 (m, 6H), 7.34 (m, 4H), 7.25 (m, IH), 7.08 (m, 3H), 6.82 (dd, IH), 6.54 (d, IH), 3.87 (dd, 2H), 3.33 (m, 6H), 3.22 (m, 4H), 2.38 (m, 4H), L93 (m, IH), 1.65 (dd, 2H), 1.29 (m, 2H). EXAMPLE 23 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-((2-methyl-l,3-benzothiazol-6-yl)oxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide 261 EXAMPLE 23A methyl 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-2-(2-methylbenzo[d]thiazol-6- yloxy)benzoate This EXAMPLE was prepared by substituting 2-methylbenzothiazol-6-ol for EXAMPLE ID in EXAMPLE IE. EXAMPLE 23B 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-2-(2-methylbenzo[d]thiazol-6- yloxy)benzoic acid This EXAMPLE was prepared by substituting EXAMPLE 23A for EXAMPLE IE in EXAMPLE IF. EXAMPLE 23C 4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-2-((2-methyl-l,3-benzothiazol-6-yl)oxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide This EXAMPLE was prepared by substituting EXAMPLE 23B for EXAMPLE IF in EXAMPLE IH. 'H NMR (300MHz, DMSO-de) 5 U.78 (s, IH), 8.56 (t, IH), 8.40 (d, IH), 7.71 (d, 2H), 7.64 (dd, IH), 7.51 (m, 5H), 7.37 (d, 2H), 7.32 (m, IH), 7.28 (d, IH), 6.98 (dd, IH), 6.79 (dd, IH), 6.51 (m, IH), 4.33 (br s, IH), 3.87 (dd, 2H), 3.69 (br s, 2H), 3.28 (m, 4H), 3.04 (br s, 2H), 2.84 (br s, IH), 2.74 (s, 3H), 2.49 (m, 4H), 1.90 (br s, IH), L63 (dd, 2H), 1.28 (m, 3H). EXAMPLE 24 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-((2-methyl-l,3-benzothiazol-5- yl)oxy)-N-((4-((3-moipholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide EXAMPLE 24A methyl 4-(4-((4'-chlorabiphenyl-2-yl)methyl)piperazin-l-yl)-2-(2-methylbenzo[d]thiazol-5- yloxy)benzoate This EXAMPLE was prepared by substituting 2-methylbenzothiazol-5-ol for EXAMPLE ID in EXAMPLE IE. 262 EXAMPLE 24B 4-(4-((4'-cMorobiphenyl-2-yl)methyl)piperazin-l-yl)-2-(2-methylbenzo[d]thiazol-5- yloxy)benzoic acid This EXAMPLE was prepared by substituting EXAMPLE 24A for EXAMPLE IE in EXAMPLE IF. EXAMPLE 24C 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-((2-methyl-l,3-benzothiazol-5- yl)oxy)-N-((4-((3-moipholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide This EXAMPLE was prepared by substituting EXAMPLE 24B and EXAMPLE 4A for EXAMPLE IF and EXAMPLE IG respectively, in EXAMPLE IH. 'H NMR (300MHZ, DMS0-d6) 5 n.83 (s, IH), 9.48 (br s, IH), 8.64 (t, IH), 8.45 (d, IH), 7.88 (d, IH), 7.76 (dd, IH), 7.50 (m, 5H), 7.37 (m, 2H), 7.30 (m, IH), 7.18 (m, IH), 7.04 (d, IH), 6.97 (dd, IH), 6.78 (dd, IH), 6.48 (br s, IH), 4.35 (br s, IH), 3.98 (m, 3H), 3.77 (br s, 2H), 3.60 (t, 4H), 3.49 (m, 2H), 3.15 (m, 4H), 3.04 (m, 4H), 2.75 (s, 3H), 2.56 (m, 2H), 1.94 (m, 2H). EXAMPLE 25 4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-((3- (dimethylaniino)propyl)amino)-3-nitrophenyl)sulfonyl)-2-((2-methyl-l,3-benzothiazol-5- yl)oxy)benzamide This EXAMPLE was prepared by substituting EXAMPLE 24B and EXAMPLE 11A for EXAMPLE IF and EXAMPLE IG respectively, in EXAMPLE IH. 'H NMR (300MHz, DMSO-de) 5 11.86 (s, IH), 9.23 (br s, IH), 8.63 (t, IH), 8.46 (d, IH), 7.88 (d, IH), 7.77 (dd, 2H), 7.51 (m, 6H), 7.39 (m, 3H), 7.32 (br s, IH), 7.19 (m, IH), 7.04 (d, IH), 6.98 (dd, IH), 6.79 (dd, IH), 6.49 (br s, IH), 4.37 (br s, IH), 3.76 (br s, 2H), 3.49 (m, 4H), 3.11 (m, 4H), 2.79 (s, 3H), 2.77 (s, 3H), 2.76 (s, 3H), 1.94 (m, 2H). EXAMPLE 26 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin- l-yl)-2-(2-(3-(dimethylamino)-3- oxopropyl)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide 263 EXAMPLE 26A 3-(2-hydroxyphenyl)-N,N-dimethylpropanamide A solution of chroman-2-one (444 mg) in THF (1 mL) was treated with dimethylamine (7.5 mL) and stirred at room temperature for 5 hoiffs. The solution was concentrated. The concentrate was filtered tiirough a small pad of silica gel. EXAMPLE 26B methyl 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)-2-(2-(3-(dimethylamino)-3- oxopropyl)phenoxy)benzoate This EXAMPLE was prepared by substituting EXAMPLE 26A for EXAMPLE ID in EXAMPLE IE. EXAMPLE 26C 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-2-(2-(3-(dimethylamino)-3- oxopropyl)phenoxy)benzoic acid This EXAMPLE was prepared by substituting EXAMPLE 26B for EXAMPLE IE in EXAMPLE IF. EXAMPLE 26D 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(2-(3-(dimethylamino)-3-oxopropyl)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide This EXAMPLE was prepared by substituting EXAMPLE 26C for EXAMPLE IF in EXAMPLE IH. 'H NMR (500 MHz, DMSO-de) 5 11.74 (s, IH), 8.65 (t, IH), 8.44 (d, IH), 7.73 (dd, 2H), 7.52 (m, 5H), 7.35 (d, 3H), 7.13 (dd, 2H), 6.96 (t, IH), 6.87 (t, IH), 6.75 (dd, IH), 6.44 (d, IH), 6.39 (d, IH), 3.87 (dd, 2H), 3.67 (br, 8H), 3.34 (t, 2H), 3.28 (t, 2H), 3.00 (br, 2H), 2.91 (s, 3H), 2.79 (s, 3H), 2.74 (t, 2H), 2.55 (t, 2H), 1.91 (m, IH), 1.64 (d, 2H), 1.29 (m, 2H). EXAMPLE 27 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(2-(2-(dimethylamino)-2- oxoethyl)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide 264 EXAMPLE 27A 2-(2-hydroxyphenyl)-N,N-dimethylacetamide This EXAMPLE was prepared by substituting benzofuran-2(3H)-one for chroman-2-one in EXAMPLE 26A. EXAMPLE 27B methyl 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)-2-(2-(2-(dimethylamino)-2- oxoethyl)phenoxy)benzoate This EXAMPLE was prepared by substituting EXAMPLE 27A for EXAMPLE ID in EXAMPLE IE. EXAMPLE 27C 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-2-(2-(2-(dimethylamino)-2- oxoethyl)phenoxy)benzoic acid This EXAMPLE was prepared by substituting EXAMPLE 27B for EXAMPLE IE in EXAMPLE IF. EXAMPLE 27D 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(2-(2-(dimethylamino)-2-oxoethyl)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide This EXAMPLE was prepared by substituting EXAMPLE 27C for EXAMPLE IF in EXAMPLE IH. 'H NMR (400 MHz, DMSO-de) 5 8.64 (t, IH), 8.52 (d, IH), 7.82 (dd, IH), 7.70 (s, IH), 7.52 (dd, 5H), 7.37 (d, 2H), 7.33 (s, IH), 7.19 (m, 2H), 7.14 (t, IH), 7.03 (t, IH), 6.70 (m, 2H), 6.23 (s, IH), 3.86 (dd, 2H), 3.64 (s, 2H), 3.40 (br, 12H), 3.25 (t, 2H), 2.92 (s, 3H), 2.72 (s, 3H), 1.91 (s, IH), 1.63 (d, 2H), 1.28 (m, 2H). EXAMPLE 28 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(2-(3- (dimethylamino)propyl)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide 265 EXAMPLE 28A methyl 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-2-(2-(3-(dimethylamino)propyl)phenoxy)benzoate A solution of EXAMPLE 26B (211 mg) in THE (1.7 mL) at room temperature was treated with borane (689 |LiL) and stirred for 24 hours. The mixture was quenched with IN HCl and heated at 50°C overnight. The solution was concentrated. The concentrate was purified by flash chromatography (0-5% 7N NH3 in 10% methanol/dichloromethane). EXAMPLE 28B 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)-2-(2-(3-(dimethylamino)propyl)phenoxy)benzoic acid This EXAMPLE was prepared by substituting EXAMPLE 28A for EXAMPLE IE in EXAMPLE IF. EXAMPLE 28C 4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)pipera2in-l-yl)-2-(2-(3-(dimethylamino)propyl)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide This EXAMPLE was prepared by substituting EXAMPLE 28B for EXAMPLE IF in EXAMPLE IH. 'H NMR (500 MHz, DMSO-de) 5 8.65 (t, IH), 8.44 (d, IH), 7.75 (dd, IH), 7.51 (m, 6H), 7.39 (d, 2H), 7.32 (s, IH), 7.16 (m, 2H), 6.98 (m, IH), 6.90 (t. IH), 6.76 (d, IH), 6.48 (d, IH), 6.37 (s, IH), 3.87 (d, 2H), 3.35 (m, 2H), 3.29 (m, 2H), 3.07 (s, 2H), 2.79 (s, 6H), 2.61 (t, 2H), 1.94 (s, 2H), 1.64 (d, 2H), 1.30 (m, 2H). EXAMPLE 29 4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(2-(2- (dimethylamino)ethyl)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide EXAMPLE 29A methyl 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)-2-(2-(2- (dimethylamino)ethyl)phenoxy)benzoate 266 This EXAMPLE was prepared by substituting EXAMPLE 27B for EXAMPLE 26B in EXAMPLE 28A. EXAMPLE 29B 4-(4-((4'-cWorobiphenyl-2-yl)methyl)piperazin-1 -yl)-2-(2-(2-(dimethylamino)ethyl)phenoxy)benzoic acid This EXAMPLE was prepared by substituting EXAMPLE 29A for EXAMPLE IE in EXAMPLE IF. EXAMPLE 29C 4-(4-((4'-chloro-1,1 •-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(2-(2-(dimethylamino)ethyl)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide This EXAMPLE was prepared by substituting EXAMPLE 29B for EXAMPLE IF in EXAMPLE IH. 'H NMR (400 MHz, DMSO-dg) 5 8.64 (t, IH), 8.44 (d, IH), 7.72 (m, 2H), 7.53 (m, 5H), 7.38 (d, 2H), 7.32 (m, IH), 7.19 (dd, IH), 7.15 (d, IH), 7.01 (td, IH), 6.90 (t, IH), 6.79 (dd, IH), 6.49 (d, IH), 6.42 (d, IH), 3.88 (m, 2H), 3.60 (br, lOH), 3.35 (t, 2H), 3.29 (t, 4H), 2.97 (m, 2H), 2.81 (m, 6H), 1.92 (s, IH), 1.65 (m, 2H), 1.30 (m, 2H). EXAMPLE 30 2-(5-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-nitro-4-((tetrahydro-2H-pyran- 4-yl)methylatnino)phenylsulfonylcarbamoyl)phenoxy)-N,N-diniethylbenzaniide EXAMPLE 30A methyl 4-(4-((4'-chloK)biphenyl-2-yl)methyl)piperazin- l-yl)-2-(2-(dimethylcarbamoyl)phenoxy)benzoate This EXAMPLE was prepared by substituting 2-hydroxy-N,N-dimethylbenzamide for EXAMPLE ID in EXAMPLE IE. EXAMPLE 30B 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-2-(2-(dimethylcarbamoyl)phenoxy)benzoic acid This EXAMPLE was prepared by substituting EXAMPLE 30A for EXAMPLE IE in EXAMPLE IF. 267 EXAMPLE 30C 2-(5-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-nitro-4-((tetrahydro-2H-pyran-4-yl)methylamino)phenylsulfonylcarbamoyl)phenoxy)-N,N-dimethylbenzamide This EXAMPLE was prepared by substituting EXAMPLE 30B for EXAMPLE IF in EXAMPLE IH. 'H NMR (400 MHz, DMSO-de) 8 8.63 (t, IH), 8.52 (d, IH), 7.83 (dd, IH), 7.71 (s, IH), 7.51 (m, 5H), 7.30 (m, 5H), 7.20 (d, IH), 7.13 (t, IH), 6.82 (d, IH), 6.74 (m, IH), 6.24 (d, IH), 4.30 (s, IH), 3.80 (br, IIH), 3.34 (t, 2H), 3.27 (t, 2H), 2.79 (s, 3H), 2.66 (s, 3H), 1.90 (s, IH), 1.62 (d, 2H), 1.27 (ddd, 2H). EXAMPLE 31 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin- l-yl)-2-(2- ((dimethylamino)methyl)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide EXAMPLE 31A methyl 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)-2-(2-((dimethylamino)methyl)phenoxy)benzoate This EXAMPLE was prepared by substituting EXAMPLE 30A for EXAMPLE 26B in EXAMPLE 28A. EXAMPLE 3 IB 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)-2-(2-((dimethy]amino)methyl)phenoxy)benzoicacid This EXAMPLE was prepared by substituting EXAMPLE 31A for EXAMPLE IE in EXAMPLE IF. EXAMPLE 31C 4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(2- ((dimethylamino)methyl)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylniethyl)amino)phenyl)sulfonyl)benzamide This EXAMPLE was prepared by substituting EXAMPLE 3IB for EXAMPLE IF in EXAMPLE IH. 'H NMR (400 MHz, DMSO-dg) 8 8.62 (m, IH), 8.38 (d, IH), 7.70 (dd, IH), 7.61 (d, IH), 7.51 (d, 4H), 7.39 (m, 4H), 7.33 (s, IH), 7.15 (m, 2H), 6.97 (t, IH), 6.84 (d, 268 AFEMA™ (fadrozole), FARESTON® (toremifene), FASLODEX® (fulvestrant), FEMARA® (letrozole), formestane, glucocorticoids, HECTOROL® (doxercalciferol), RENAGEL® (sevelamer carbonate), lasofoxifene, leuprolide acetate, MEGACE® (megesterol), MIFEPREX® (mifepristone), NILANDRON™ (nilutamide), NOLVADEX® (tamoxifen citrate), PLENAXIS™ (abarelix), prednisone, PROPECIA® (finasteride), rilostane, SUPREFACT® (buserelin), TRELSTAR® (luteinizing hormone releasing hormone (LHRH)), VANTAS® (Histrelin implant), VETORYL® (trilostane or modrastane), ZOLADEX® (fosrelin, goserelin) and the like. Deltoids and retinoids include seocalcitol (EB1089, CB1093), lexacalcitrol (KH1060), fenretinide, PANRETIN® (aliretinoin), ATRAGEN® (liposomal tretinoin), TARGRETIN® (bexarotene), LGD-1550 and the like. PARP inhibitors include ABT-888 (vehparib), olaparib, KU-59436, AZD-2281, AG-014699, BSI-201, BGP-15, INO-1001, ONO-2231 and the like. Plant alkaloids include, but are not limited to, vincristine, vinblastine, vindesine, vinorelbine and the like. Proteasome inhibitors include VELCADE® (bortezomib), MG132, NPI-0052, PR-171 and the like. Examples of immunologicals include interferons and other immune-enhancing agents. Interferons include interferon alpha, interferon alpha-2a, interferon alpha-2b, interferon beta, interferon gamma-la, ACTIMMUNE® (interferon gamma-lb) or interferon gamma-nl, combinations thereof and the like. Other agents include ALFAFERONE® ,(IFN-a), BAM-002 (oxidized glutathione), BEROMUN® (tasonermin), BEXXAR® (tositumomab), CAMPATH® (alemtuzumab), CTLA4 (cytotoxic lymphocyte antigen 4), decarbazine, denileukin, epratuzumab, GRANOCYTE® (lenograstim), lentinan, leukocyte alpha interferon, imiquimod, MDX-010 (anti-CTLA-4), melanoma vaccine, mitumomab, molgramostim, MYLOTARG™ (gemtuzumab ozogamicin), NEUPOGEN® (filgrastim), OncoVAC-CL, OVAREX® (oregovomab), pemtumomab (Y-muHMFGl), PROVENGE® (sipuleucel-T), sargaramostim, sizofilan, teceleukin, THERACYS® (Bacillus Calmette-Guerin), ubenimex, VIRULIZIN® (immunotherapeutic, Lorus Pharmaceuticals), Z-100 (Specific Substance of Maruyama (SSM)), WF-IO (Tetrachlorodecaoxide (TCDO)), PROLEUKIN® (aldesleukin), ZADAXIN® (thymalfasin), ZENAPAX® (daclizumab), ZEVALIN® (90Y-Ibritumomab tiuxetan) and the like. 218 IH), 6.61 (s, IH), 6.43 (d, IH), 4.33 (s, 2H), 3.88 (d, 2H), 3.55 (br, lOH), 3.35 (m, 2H), 3.29 (m, 2H), 2.78 (s, 6H), 1.92 (s, IH), 1.64 (d, 2H), 1.31 (m, 2H). EXAMPLE 32 4.(4.((4'.chloro-1, l'-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((4-((3- (dimethylamino)propyl)amino)-3-nitrophenyl)sulfonyl)-2-(3-morpholin-4- ylphenoxy)benzamide EXAMPLE 32A methyl 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-morpholinophenoxy)benzoate This EXAMPLE was prepared by substituting 3-morpholinophenol for EXAMPLE ID in EXAMPLE IE. EXAMPLE 32B 4-(4-((4'-chlorobiphenyI-2-yl)methyl)piperazin-1 -yl)-2-(3-morpholinophenoxy)benzoic acid This EXAMPLE was prepared by substituting EXAMPLE 32A for EXAMPLE IE in EXAMPLE IF. EXAMPLE 32C 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-((3- (dimethylamino)propyl)amino)-3-nitrophenyl)sulfonyl)-2-(3-morpholin-4- ylphenoxy)benzamide This EXAMPLE was prepared by substituting EXAMPLE 32B for EXAMPLE IF and EXAMPLE 1 lA for EXAMPLE IG in EXAMPLE IH. 'H NMR (4(X)MHZ, DMSO-de) 5 11.61 (brs, IH), 9.50 (br s, lH),8.69(t, 1H),8.51 (d, IH), 7.83 (dd, lH),7.68(m, IH). 7.50 (m, 5H), 7.39 (m, 2H), 7.31 (m, IH), 7.15 (d, IH), 7.08 (m, IH), 6.75 (dd, IH), 6.59 (dd, IH), 6.40 (m, 2H), 6.23 (m, IH), 3.71 (m, 4H), 3.52 (m, 4H), 3.40 (m, 4H), 3.13 (m, 4H), 3.00 (m, 6H), 2.78 (s, 6H), 1.96 (m, 2H). EXAMPLE 33 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(3-(2,4-dimethyl-1,3-thiazol-5- yl)phenoxy)-N-((4-((3-morpholin-4-ylpropyI)amino)-3-nitrophenyl)sulfonyl)benzamide 269 EXAMPLE 33A methyl 2-(3-(benzyloxy)phenoxy)-4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 - yl)benzoate This EXAMPLE was prepared by substituting 3-(benzyloxy)phenol for EXAMPLE ID in EXAMPLE IE. EXAMPLE 33B methyl 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)-2-(3-hydioxyphenoxy)benzoate EXAMPLE 33A (510 mg) in CH2CI2 (5 mL) was cooled to OX, treated with IM BBr3 in CH2CI2 (4 raiL), and stined at room temperature for 2 hours. The mixture was quenched with saturated NaHCOs solution and extracted with ethyl acetate. The extract was washed with water and brine, dried over Na2S04 and concentrated. The concentrate was purified by flash column chromatography on silica gel with 0-30% ethyl acetate in hexane. EXAMPLE 33C methyl 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)-2-(3-(trifluoromethylsulfonyloxy)phenoxy)benzoate EXAMPLE 333 (180 mg) in THE (5 mL) was cooled to -78°C, and 0.5 mL of IM lithium hexamethyldisilazide in THE was added. The mixture was stirred for 15 minutes then treated with l,l,l-trifluoro-N-phenyl-N-(trifluoromethylsulfonyl)methanesulfonamide (146 mg). The mixture was warmed to room temperature overnight, quenched with saturated NH4CI solution and extracted with ethyl acetate. The extract was washed with water and brine, dried over Na2S04 and concentrated. EXAMPLE 33D methyl 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)-2-(3-(2,4-dimethylthiazol-5- yl)phenoxy)benzoate EXAMPLE 33C (60 mg), 2,4-dimethyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)thiazole (36 mg) and dichlorobis(triphenylphosphine) palladium(II) (2 mg) were dissolved in 5 mL of a dimethoxyethane:ethanol:2M Na2C03 solution (7:2:2). The mixture was heated at 130*'C for 15 minutes in a microwave reactor and concentrated. The concentrate was purified by flash column chromatography with 0-30% ethyl acetate/hexanes. 270 EXAMPLE 33E 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-(2,4-dimethylthiazol-5- yl)phenoxy)benzoic acid This EXAMPLE was prepared by substituting EXAMPLE 33D for EXAMPLE IE in EXAMPLE IF. EXAMPLE 33F 4.(4.((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-(2,4-dimethyl-L3-thiazol-5-yl)phenoxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide This EXAMPLE was prepared by substituting EXAMPLE 33E for EXAMPLE IF and EXAMPLE 4A for EXAMPLE IG in EXAMPLE IH. 'H NMR (400MHZ, DMSO-de) 8 1L80 (br s, IH), 9.67 (br s, IH), 8.63(t, IH), 8.47(d, IH), 7.78 (dd, IH), 7.68 (m, IH), 7.52 (m, 5H), 7.35(m, 4H), 7.10 (d, IH), 7.05 (d,lH), 6.77 (m, 3H), 6.57 (m, IH), 3.95 (m, 2H), 3.60 (m, 6H), 3.45 (m, 6H), 3.16 (m, 4H), 3.07 (m, 4H), 2.51 (s, 3H), 2.26 (s, 3H), 1.95 (m, 2H). EXAMPLE 34 2-(2-chloiophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl)methyl)piperazin-l-yI)-N-((4-((l-methylpiperidin-4-yl)amino)-3- nitrophenyl)sulfonyl)benzamide EXAMPLE 34A ethyl 2-(2-chlorophenoxy)-4-fluorobenzoate This EXAMPLE was prepared by substituting 2-chlorophenol for 2-methyl-5-indolol in EXAMPLE 3A. EXAMPLE 34B ethyl 2-(2-chlorophenoxy)-4-(4-((2-(4-chloiophenyl)-4,4-dimethylcyclohex-1 - enyl)methyl)piperazin-1 -yl)benzoate This EXAMPLE was prepared by substituting EXAMPLE 34A for EXAMPLE 3A in EXAMPLE 3G. EXAMPLE 34C 271 2-(2-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-1 -yl)benzoic acid This EXAMPLE was prepared by substituting EXAMPLE 34B for EXAMPLE IE in EXAMPLE IF. EXAMPLE 34D 2-(2-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-N-((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide This EXAMPLE was prepared by substituting EXAMPLE 34C for EXAMPLE IF and EXAMPLE 31 for EXAMPLE IG in EXAMPLE IH. 'H NMR (500 MHz, pyridine-ds) 8 8.37 (d, IH), 8.08 (d, IH), 7.76 (dd, IH), 7.62 (d, IH), 7.36 (d, 2H), 7.35 (d, IH), 7.07 (d, 2H), 7.07-7.03 (m, 2H), 6.90 (td, IH), 6.71 (dd, IH), 6.55 (dd, IH), 6.26 (d, IH), 3.81 (m, IH), 3.21 (m, 2H), 3.08 (m, 4H), 2.86 (m, 2H), 2.76 (s, 2H), 2.63 (s, 3H), 2.28-2.04 (m, 8H), 1.97 (s, 2H), 1.76 (m, 2H), 1.40 (t, 2H), 0.94 (s, 6H). EXAMPLE 35 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-2-(3,5- dichlorophenoxy)-N-((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide EXAMPLE 35A ethyl 2-(3,5-dichlorophenoxy)-4-fluorobenzoate This EXAMPLE was prepared by substituting 3,5-dichlorophenol for 2-methyl-5-indolol in EXAMPLE 3A. EXAMPLE 35B ethyl 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-2-(3,5- dichlorophenoxy)benzoate This EXAMPLE was prepared by substituting EXAMPLE 35A for EXAMPLE 3A in EXAMPLE 3G. EXAMPLE 35C 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyI)methyl)piperazin-l-yl)-2-(3,5- dichlorophenoxy)benzoic acid 272 This EXAMPLE was prepared by substituting EXAMPLE 35B for EXAMPLE IE in EXAMPLE IF. EXAMPLE 35D 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-2-(3,5- dichlorophenoxy)-N-((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide This EXAMPLE was prepared by substituting EXAMPLE 35C for EXAMPLE IF and EXAMPLE 31 for EXAMPLE IG in EXAMPLE IH. 'H NMR (500 MHz, pyridine-ds) 8 9.14 (d, IH), 8.53 (m, IH), 8.31 (m, IH), 7.95 (d, IH), 7.46 (d, 2H), 7.11 (d, 2H), 6.99 (m, 3H), 6.81 (m, 2H), 3.73 (m, IH), 3.22 (m, 4H), 3.05 (m, 2H), 2.85 (s, 2H), 2.56 (m, 2H), 2.46 (s, 3H), 2.30 (m, 6H), 2.14 (m, 2H), 1.95 (m, 4H), 1.42 (m, 2H), 0.97 (s, 6H). EXAMPLE 36 2-(3-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimeihylcyclohex-l-en-l- yl)methyl)piperazin-l-yl)-N-((4-((l-methylpiperidin-4-yl)amino)-3- nitrophenyl)sulfonyl)benzamide EXAMPLE 36A ethyl 2-(3-chlorophenoxy)-4-fluorobenzoate This EXAMPLE was prepared by substituting 2-chlorophenol for 2-methyl-5-indolol in EXAMPLE 3A. EXAMPLE 36B ethyl 2-(3-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-diniethylcyclohex-1 - enyl)methyl)piperazin-1 -yl)benzoate This EXAMPLE was prepared by substituting EXAMPLE 36A for EXAMPLE 3A in EXAMPLE 3G. EXAMPLE 36C 2-(3-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-1 -yl)benzoic acid This EXAMPLE was prepared by substituting EXAMPLE 36B for EXAMPLE IE in EXAMPLE IF. 273 EXAMPLE 36D 2-(3-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin- l-yl)-N-((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide This EXAMPLE was prepared by substituting EXAMPLE 36C for EXAMPLE IF and EXAMPLE 31 for EXAMPLE IG in EXAMPLE IH. 'H NMR (500 MHz, pyridine-ds) 8 9.12 (d,lH), 8.51 (d, IH), 8.31 (dd, IH), 7.99 (d, IH), 7.45 (d, IH), 7.11 (m, 3H), 7.02 (m, 2H), 6.91 (dd, IH), 6.82 (dd, IH), 6.68 (d, 2H), 4.05 (br s, IH), 3.55 (br s, 2H), 3.31 (s, 6H), 2.99 (s, 2H), 2.85 (s, 3H), 2.51 (br s, 3H), 2.41 (s, 6H), 1.99 (s, 2H), 1.41 (t, 2H), 0.95 (s, 6H). EXAMPLE 37 4-(4-((4'-chloro-4-(2-(dimethylainino)ethoxy)-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-2- (3-ch]orophenoxy)-N-((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide EXAMPLE 37A 4'-chloro-4-hydroxybiphenyl-2-carbaldehyde 2-bromo-5-hydroxybenzaldehyde (20 g), 4-chlorophenylboronic acid (17.1 g) and dichlorobis(triphenylphosphine) palladium(II) (1.75 g) were dissolved in 475 mL of a dimethoxyethane:ethanol:2M Na2C03 solution (7:2:2). The mixture was heated to reflux for 1 hour. The reaction mixture was then diluted with ethyl acetate, washed thoroughly with water and with brine, dried over MgS04, filtered and concentrated. The resulting solid was slurried in 5(X) mL of hexane:ether mixture (2:1). The title compound was collected by filtration. EXAMPLE 37B tert-butyl 4-((4'-chloro-4-hydroxybiphenyl-2-yl)methyl)piperazine-l-carboxylate The tide compound was prepared by substituting EXAMPLE 37A for 4'-chlorobiphenyl-2-carboxaldehyde in EXAMPLE lA. EXAMPLE 37C tert-butyl 4-((4'-chloro-4-(2-(dimethylamino)ethoxy)biphenyl-2-yl)methyl)piperazine-1 - carboxylate 274 EXAMPLE 37B (2 g), 2-chloro-N,N-dimethylethanamine hydrochloric acid salt (2.15 g), and cesium carbonate (9.70 g) were combined in 10 mL of N.N-dimethylformamide. The resulting mixture was heated to 80''C overnight. The reaction was cooled to room temperature, diluted with ethyl acetate and poured into water. The aqueous layer was xtracted with ethyl acetate, and the combined organic layers were washed thoroughly with water and with brine, dried over MgS04, filtered and concentrated. The crude material was slurried in 100 mL of ether and the product was obtained by filtration. EXAMPLE 37D 2-(4'-chloro-2-(piperazin-l-ylmethyl)biphenyl-4-yloxy)-N,N-dimethylethanamine The title compound was prepared by substituting EXAMPLE 37C for EXAMPLE 1A in EXAMPLE IB. EXAMPLE 37E ethyl 4-(4-((4'-chloro-4-(2-(dimethylamino)ethoxy)biphenyl-2-yl)methyl)piperazin-1 -yl)-2- (3-chlorophenoxy)benzoate The tide compound was prepared by substituting EXAMPLE 36A for EXAMPLE 3A and EXAMPLE 37D for EXAMPLE 3F in EXAMPLE 3G. EXAMPLE 37F 4-(4-((4'-chloro-4-(2-(dimethylamino)ethoxy)biphenyl-2-yl)methyl)piperazin-l-yl)-2-(3- chlorophenoxy)benzoic acid The title compound was prepared by substituting EXAMPLE 37E for EXAMPLE IE in EXAMPLE IF. EXAMPLE 37G 4-(4-((4'-chloro-4-(2-(dimethylamino)ethoxy)-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(3-chlorophenoxy)-N-((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzaraide The title compound was prepared by substitiiting EXAMPLE 37F for EXAMPLE IF and EXAMPLE 31 for EXAMPLE IG in EXAMPLE IH. *H NMR (400MHz, dimethylsulfoxide-d6) 5 11.88 (br s, IH), 9.52 (br s, IH), 9.30 (br s, IH), 8.45 (m, IH), 8.21 (d, IH), 7.78 (dd, IH), 7.50 (m, 3H), 7.38 (m, 2H), 7.18 (m, 3H), 6.95 (m, IH), 6.81 (dd, IH), 6.72 (dd, IH), 6.68 (m, IH), 6.53 (m, IH), 4.35 (m, 2H), 3.53 (m, 2H), 3.28 (m, 2H), 3.21 (m, 275 4H), 3.08 (m, 2H), 2.88 (s, 6H), 2.73 (m, 2H), 2.64 (m, IH), 2.43 (s, 3H). 2.27 (m, 4H), 1.83 (m, 2H). EXAMPLE 38 2-(2-chlorophenoxy)-4-(4-((4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3- yl)methyl)piperazin-l-yl)-N-((4-((l-methylpiperidin-4-yl)an(iino)-3- nitrophenyl)sulfonyl)benzamide EXAMPLE 38A methyl 6,6-dimethyl-4-oxotetrahydro-2H-pyran-3-caiboxylate To a suspension of hexane-washed NaH (0.72g, 60%) in tetrahydrofuran (30 mL) was added a solution of 2,2-dimethyldihydro-2H-pyran-4(3H)-one (2.0 g) in tetrahydrofuran (20 mL). The suspension was stirred at room temperature for 30 minutes. Dimethylcarbonate (6.31 mL) was added dropwise by syringe. The mixture was heated to reflux for 4 hours. The mixture was acidified with 5% aqueous HCl and extracted with dichloromethane (100 mL x3) and washed with water and brine, and dried over Na2S04. After filtration and concentration, the crude product was loaded on a column and eluted with 10% ethyl acetate in hexane to give the product. EXAMPLE 38B methyl 6,6-dimethyl-4-(trifluoromethylsulfonyloxy)-5,6-dihydro-2H-pyran-3-carboxylate To a cooled (0°C) stirring suspension of NaH (0.983 g 60% in mineral oil, washed with hexane three times) in ether (50 mL) was added EXAMPLE 38A (3.2 g). The mixture was stirred at O^C for 30 minutes before the addition of triflic anhydride (4.2 mL). The mixture was then stirred at room temperature overnight. The mixture was diluted with ether (200 mL) and washed with 5% HCl, water and brine. After drying over Na2S04, evaporation of solvent gave the crude product which was used without further purification. EXAMPLE 38C methyl 4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-carboxylate To a solution of EXAMPLE 38B (2.88 g), 4-chlorophenylboronic acid (1.88 g) and tetrakis(triphenylphosphine)palladium(0) (0.578 g) in toluene (40 mL) and ethanol (10 mL) was added 2N aqueous Na2C03 (10 mL). The mixture was stirred at reflux overnight. The mixture was diluted with ether (300 mL) and washed with water, brine and dried over 276 Na2S04. After filtration and evaporation of solvent, the residue was loaded on a column and eluted with 3% ethyl acetate in hexane to give the product. EXAMPLE 38D (4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl)methanol To a solution of EXAMPLE 38C (1.6 g) in ether (20 mL) was added LiAlH4 (1.2 g). The mixture was stirred at room temperature for 4 hours. The mixture was acidified carefully with 5% aqueous HCl and extracted with ethyl acetate (100 mL x3) and the combined organic layers were washed with water, brine and dried over Na2S04. After filtration and evaporation of solvent, the crude product was loaded on a column and eluted with 10% ethyl acetate in hexane to give the product. EXAMPLE 38E 4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-carbaldehyde To a solution of oxalyl chloride (I.l g) in dichloromethane (30 mL) at -78°C was added dimethylsulfoxide (6.12 mL). The mixture was stirred at -78^C for 30 minutes, and then a solution of EXAMPLE 38D (1.2 g) in dichloromethane (10 mL) was added. The mixture was stirred at -78^C for 2 hours before the addition of triethylamine (10 mL). The mixture was stiixed overnight and the temperature was allowed to rise to room temperature. The mixture was diluted with ether (300 mL) and washed with water, brine and dried over Na2S04. After filtration and evaporation of solvent, the crude product was loaded on a column and eluted with 5% ethyl acetate in hexane to give the product. EXAMPLE 38F methyl 2-(2-chlorophenoxy)-4-(piperazin- l-yl)benzoate This example was prepared by substituting piperazine for EXAMPLE 3F and EXAMPLE 34A for EXAMPLE 3A in EXAMPLE 3G. EXAMPLE 38G methyl 2-(2-chlorophenoxy)-4-(4-((4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran- 3-yl)methyl)piperazin-1 -yl)benzoate To a solution of EXAMPLE 38E (100 mg) and EXAMPLE 38F (177 mg) in dichloromethane (10 mL) was added sodium triacetoxyborohydride (154 mg). The mixture 277 was stirred at room temperature overnight. The mixture was diluted with ethyl acetate (200 mL) and washed with 2 wt% aqueous NaOH, water and brine. After drying over Na2S04 and filtration, the solvent was evaporated under vacuum and the residue was loaded on a column and eluted with 30% ethyl acetate in hexane to give the product. EXAMPLE 38H 2-(2-chlorophenoxy)-4-(4-((4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl)methyl)piperazin- l-yl)benzoic acid To a solution of EXAMPLE 38G (254 mg) in tetrahydrofuran (4 mL), methanol (2 mL) and water (2 mL) was added LiOH H2O (126 mg). The mixture was stirred at room temperature overnight. The mixture was then neutralized with 5% aqueous HCl and diluted with ethyl acetate (200 mL). After washing with brine, it was dried over Na2S04. Filtration and evaporation of solvent gave the product. EXAMPLE 381 2-(2-chlorophenoxy)-4-(4-((4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl)methyl)piperazin-l-yl)-N-((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide The title compound was prepared as described in EXAMPLE IH by replacing EXAMPLE IF and EXAMPLE IG with EXAMPLE 38H and EXAMPLE 3L respectively. ^H NMR (300 MHz, dimethylsulfoxide-de) 6 8.33 (d, IH), 8.06 (d, IH), 7.71 (dd, IH), 7.64 (d, IH), 7.38 (d, 2H), 7.33 (dd, IH), 7.16 (d, 2H), 7.02 (m, 2H), 6.86 (m, IH), 6.69 (dd, IH), 6.49 (dd, IH), 6.25 (d, IH), 4.14 (m, 2H), 3.73 (m, IH), 3.04 (m, lOH), 2.87 (m, 2H), 2.42 (m, 4H), 2.22 (m, 6H), 1.69 (m, 2H), 1.21 (s, 6H). EXAMPLE 39 4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-(2- (dimethylamino)ethoxy)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide EXAMPLE 39A 2-(3-(benzyloxy)phenoxy)-N,N-dimethylethanamine 278 A solution of 3-(benzyloxy)phenol (2.002 g), 2-chloro-N,N-dimethylethanamine (1.459 g) in N,N-dimethylfonnamide (50 mL) was treated with cesium carbonate (3.91 g) and stirred at 50°C overnight. The mixture was diluted with ethyl acetate and IN aqueous NaOH and the layers were separated. The aqueous layer was extracted with ethyl acetate and the combined organic layers were dried over MgS04, filtered and concentrated. The residue was purified by flash chromatography (5% 7N NH3 in methanol - dichloromethane) to give the desired product. EXAMPLE 39B 3-(2-(dimethylamino)ethoxy)phenol EXAMPLE 39A (450 mg) was dissolved in ethyl acetate (10 mL). The flask was flushed with nitrogen three times followed by the addition of 10% Pd/C (45 mg). The reaction mixture was kept under 1 atm of hydrogen at room temperature overnight. The mixture was filtered and concentrated. The residue was filtered through a small pad of silica gel and used in the next step without further purification. EXAMPLE 39C methyl 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-(2-(dimethylamino)ethoxy)phenoxy)benzoate The title compound was prepared by substituting EXAMPLE 39B for EXAMPLE ID in EXAMPLE IE. EXAMPLE 39D 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-(2-(dimethylamino)ethoxy)phenoxy)benzoic acid The title compound was prepared by substituting EXAMPLE 39C for EXAMPLE IE in EXAMPLE IF. EXAMPLE 39E 4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-(2- (dimethylamino)ethoxy)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide 279 The title compound was prepared by substituting EXAMPLE 39D for EXAMPLE IF in EXAMPLE IH. 'H NMR (400MHZ, dimethylsulfoxide-dg) 6 n.69 (m, IH), 9.60 (m, IH), 8.64 (s, IH), 8.50 (d, IH), 7.80 (d, IH), 7.72 (s, IH), 7.52 (d, 5H), 7.38 (d, 2H), 7.33 (s, IH), 7.19 (m, 2H), 6.78 (d, IH), 6.65 (d, IH), 6.45 (dd, 3H), 4.24 (s, 2H), 3.86 (d, 2H), 3.67 (s, lOH), 3.48 (s, 2H), 3.35 (t, 2H), 3.27 (t, 2H), 2.85 (s, 6H), 1.91 (s, IH), 1.63 (d, 2H), 1.27 (d, 2H). EXAMPLE 40 2-(4-amino-3-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl)methyl)piperazin-l-yl)-N-((4-((l-methylpiperidin-4-yl)amino)-3- nitrophenyl)sulfonyI)benzamide EXAMPLE 40A ethyl 2-(4-amino-3-chlorophenoxy)-4-fluorobenzoate The title compound was prepared by substituting 4-amino-3-chlorophenol for 2-methyl-5-indolol in EXAMPLE 3A. EXAMPLE 40B ethyl 2-(4-amino-3-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 - enyl)methyl)piperazin-1 -yl)benzoate The title compound was prepared by substituting EXAMPLE 40A for methyl-2-bromo-4-fluorobenzoate and EXAMPLE 3F for EXAMPLE IB in EXAMPLE IC. EXAMPLE 40C 2-(4-amino-3-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-1 -yl)benzoic acid The title compound was prepared by substituting EXAMPLE 40B for EXAMPLE IE in EXAMPLE IF. EXAMPLE 40D 2-(4-amino-3-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl)methyl)piperazin-l-yl)-N-((4-((l-raethylpiperidin-4-yl)amino)-3- nitrophenyl)sulfonyl)benzamide 280 The title compound was prepared by substituting EXAMPLE 40C for EXAMPLE IF and EXAMPLE 31 for EXAMPLE IG in EXAMPLE IH. 'H NMR (300MHZ, dimethylsulfoxide-de) 5 10.70 (br s, IH), 8.60 (s, IH), 8.20 (dd, IH), 7.90 (dd, IH), 7.45 (d, IH), 7.35 (d, 2H), 7.24 (d, IH), 7.06 (d, 2H), 6.91 (d, IH), 6.78 (s, 2H), 6.64 (d, IH), 6.14 (d, IH), 5.24 (s, 2H), 4.03 (m, IH), 3.52 (m, 2H), 3.10 (m, 6H), 2.80 (m, 4H), 2.73 (s, 3H), 2.18 (m, 6H), 1.99 (m, 2H), 1.82 (m, 2H), 1.38 (m, 2H), 0.94 (s, 6H). EXAMPLE 41 2-(2-chlorophenoxy)-4-(4-((2-(4-ch]orophenyl)-4,4-dimethylcyclohex-l-en-l- yl)methyl)piperazin-1 -yl)-N-((4-(( 1 -isopropylpiperidin-4-yl)amino)-3- mtrophenyl)sulfonyl)benzamide EXAMPLE 41A 4-(l-isopropylpiperidin-4-ylamino)-3-nitrobenzenesulfonanude A suspension of 4-chloro-3-nitrobenzenesulfonamide (1.664 g) triethylamine (2 mL) and l-isopropylpiperidin-4-amine (1 g) in dioxane (10 mL) was stirred for 16 hours at 90 °C. The reaction mixture was cooled to room temperature and the solid material was filtered off. The solid material was washed with 20% methanol/dichloromethane, and the mixture was dried under vacuum, to provide the product. EXAMPLE 41B 2-(2-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-N-((4-((l-isopropylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 34C for EXAMPLE IF and EXAMPLE 41A for EXAMPLE IG in EXAMPLE IH. ^H NMR (500 MHz, pyiidine-ds) 59.18 (d, IH), 8.51 (d, IH), 8.37 (dd, IH), 8.01 (d, IH), 7.40 - 7.49 (m, 3H), 7.10 (d, 2H), 7.00 - 7.06 (m, 2H), 6.94 - 6.99 (m, IH), 6.86 (dd, IH), 6.80 (dd, IH), 6.54 (d, 2H), 3.90 -3.99 (m, IH), 3.41 - 3.55 (m, 3H), 3.10 - 3.21 (m, 6H), 2.87 (s, 2H), 2.24 - 2.45 (m, lOH), 1.99 (s, 2H), 1.41 (t, 2H), 1.25 (d, 6H), 0.95 (s, 6H). 281 EXAMPLE 42 2-(2-bromophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl)methyl)piperazin-l-yl)-N-((4-((l-methylpiperidin-4-yl)amino)-3- mtrophenyl)sulfonyl)benzamide EXAMPLE 42A Ethyl 2-(2-bromophenoxy)-4-fluorobenzoate The title compound was prepared by substituting 2-bromophenol for 2-methyl-5-indolol in EXAMPLE 3A. EXAMPLE 42B Ethyl 2-(2-bromophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 - enyl)methyl)piperazin-1 -yl)benzoate The title compound was prepared by substituting EXAMPLE 42A for EXAMPLE 3A in EXAMPLE 3G. EXAMPLE 42C 2-(2-Bromophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-1 -yl)benzoic acid The title compound was prepared by substituting EXAMPLE 42B for EXAMPLE IE in EXAMPLE IF. EXAMPLE 42D 2-(2-bromophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-l-yl)-N-((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide The title compound was prepared by substimting EXAMPLE 42C for EXAMPLE IF and EXAMPLE 31 for EXAMPLE IG in EXAMPLE IH. 'H NMR (300 MHz, dimethylsulfoxide-de) 5 11.81 (s, IH), 9.24 - 9.76 (m, 2H), 8.48 (d, IH), 8.21 (d, IH), 7.84 (dd, IH), 7.50 - 7.60 (m, 2H), 7.41 (d, 2H), 7.25 (d, IH), 7.18 (t, IH), 7.11 (d, 2H), 6.95 (t, IH), 6.80 (dd, IH), 6.69 (d, IH), 6.39 (s, IH), 4.03 - 4.13 (m, IH), 3.47 - 3.65 (m, 5H), 3.20 -3.40 (m, 3H), 3.01 - 3.19 (m, 4H), 2.70 - 2.91 (m, 5H), 2.14 - 2.26 (m, 4H), 2.04 (s, 2H), 1.73 -1.93 (m, 2H), 1.48 (t, 2H), 0.96 (s, 6H). 282 EXAMPLE 43 2-(2-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)cyclohex- 1-en-1 -yl)methyl)piperazin-1 -yl)-N- ((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide EXAMPLE 43A ethyl 2-(trifluoromethylsulfonyloxy)cyclohex-1 -enecarboxylate The title compound was prepared as described in EXAMPLE 38B by replacing EXAMPLE 38A with ethyl 2-oxocyclohexanecarboxylate. EXAMPLE 43B ethyl 2-(4-chlorophenyl)cyclohex-1 -enecarboxylate The title compound was prepared as described in EXAMPLE 38C by replacing EXAMPLE 38B with EXAMPLE 43A. EXAMPLE 43C (2-(4-chlorophenyl)cyclohex-1 -enyl)methanol The title compound was prepared as described in EXAMPLE 38D by replacing EXAMPLE 38C with EXAMPLE 43B. EXAMPLE 43D 2-(4-chlorophenyl)cyclohex-l-enecarbaldehyde The tide compound was prepared as described in EXAMPLE 38E by replacing EXAMPLE 38D with EXAMPLE 43C. EXAMPLE 43E methyl 2-(2-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)cyclohex-1 -enyl)methyl)piperazin-1 - yl)benzoate The title compound was prepared as described in EXAMPLE 38G by replacing EXAMPLE 38E with EXAMPLE 43D. EXAMPLE 43F 2-(2-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)cyclohex-l-enyl)methyl)piperazin-l- yl)benzoic acid 283 The title compound was prepared as described in EXAMPLE 38H by replacing EXAMPLE 38G with EXAMPLE 43E. EXAMPLE 43G 2-(2-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)cyclohex-l-en-l-yl)methyl)piperazin-l-yl)-N-((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide The title compound was prepared as described in EXAMPLE IH by replacing EXAMPLE IF and EXAMPLE IG with EXAMPLE 43F and EXAMPLE 3L respectively. 'H NMR (300 MHz, dimethylsulfoxide-de) 5 8.36 (d, IH), 8.07 (d, IH), 7.74 (dd, IH), 7.62 (d, IH), 7.35 (d, 2H), 7.09 (d, 2H), 7.04 (d, IH), 6.89 (m, IH), 6.70 (dd, IH), 6.54 (dd, IH), 6.25 (d, IH), 3.80 (m, IH), 3.11 (m, 8H), 2.77 (m, 4H), 2.59 (m, 4H), 2.15 (m, 8H), 1.70 (m, 8H). EXAMPLE 44 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin- l-yl)-2-((3- methyl-lH-indazol-4-yl)oxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3- nitiophenyl)sulfonyl)benzamide EXAMPLE 44A 4-methoxy-3-methyl-1 H-indazole A solution of l-(2-fluoro-6-methoxyphenyl)ethanone (1 g), hydrazine (1.04 g), and sodium acetate (0.49 g) was stirred for 72 hours in toluene (10 mL). The mixture was concentrated, taken up in DMSO (8 mL), and heated to 135°C for 24 hours. The mixture was cooled, poured into ethyl acetate (2(X) mL), and rinsed with 3x water, and brine. The organic layer was concentrated and chromatographed on silica gel using 10-100% ethyl acetate/hexanes. EXAMPLE 44B 3-methyl-1 H-indazol-4-ol A IM solution of BBrs (6.57 mL) was added to a solution of EXAMPLE 44A (0.71 g) in dichloromethane (30 mL), and the reaction was stirred for 18 hours. The reaction was quenched by the slow addition of methanol, and the mixture was concentrated and chromatographed on silica gel using 10% methanol/ethyl acetate. 284 EXAMPLE 44C ethyl 4-fluoro-2-(3-methyl-1 H-indazol-4-yloxy)benzoate The title compound was prepared by substituting EXAMPLE 44B for 2-methyl-5-indolol in EXAMPLE 3A. EXAMPLE 44D ethyl 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-2-(3- methyl-1 H-indazol-4-yloxy)benzoate The title compound was prepared by substituting EXAMPLE 44C for methyl-2-bK)mo-4-fluoK)benzoate and EXAMPLE 3F for EXAMPLE IB in EXAMPLE IC. EXAMPLE 44E 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)-2-(3-methyl- lH-indazol-4-yloxy)benzoic acid The title compound was prepared by substituting EXAMPLE 40B for EXAMPLE IE in EXAMPLE IF. EXAMPLE 44F 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-2-((3-methyl-lH-indazol-4-yl)oxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 44E for EXAMPLE IF and EXAMPLE 4A for EXAMPLE IG in EXAMPLE IH. 'H NMR (300MHz, dimethylsulfoxide-de) 6 11.95 (br s, 2H), 8.47 (m, IH), 8.27 (d, IH), 7.62 (d, IH), 7.36 (d, 2H), 7.07 (d, 2H), 6.95 (m, 2H), 6.72 (m, 2H), 6.36 (s, IH), 5.92 (d, IH), 3.61 (m, 4H), 3.04 (m, 4H), 2.75 (m, 2H), 2.39 (m, 4H), 2.18 (m, 6H), 1.99 (s, 3H), 1.90 (m, 6H), 1.77 (m, 2H), 1.41 (m, 2H), 0.94 (s, 6H). EXAMPLE 45 4-(4-((2-(4-chlorophenyl)-4,4-diraethylcyclohex-1 -en-1 -yl)methyl)piperazin- l-yl)-2-(2,3- difluorophenoxy)-N-((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide EXAMPLE 45A Ethyl 2-(2,3-difluorophenoxy)-4-fluorobenzoate 285 The title compound was prepared by substituting 2,3-difluorophenol for 2-raethyl-5-indolol in EXAMPLE 3A. EXAMPLE 45B Ethyl 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-2-(2,3- difluorophenoxy)benzoate The title compound was prepared by substituting EXAMPLE 45A for EXAMPLE 3A in EXAMPLE 3G. EXAMPLE 45C This EXAMPLE was prepared by substituting EXAMPLE 45B for EXAMPLE IE in EXAMPLE IF. EXAMPLE 45D 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-2-(2,3-difluorophenoxy)-N-((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 45C for EXAMPLE IF and EXAMPLE 31 for EXAMPLE IG in EXAMPLE IH. 'H NMR (500 MHz, pyridine-ds) 9.17 (d, IH), 8.49 (d, IH), 8.38 (dd, IH), 7.99 (d, IH), 7.46 (d, 2H), 7.10 (d, 2H), 7.01 (d, IH), 6.85 (m, 3H), 6.69 (m, 2H), 3.70 (m, IH), 3.21 (m, 4H), 3.05 (m, 2H), 2.84 (s, 2H), 2.57 (m, 2H), 2.46 (s, 3H), 2.28 (m, 6H), 2.11 (m, 2H), 1.94 (m, 4H), 1.42 (t, 2H), 0.96 (s, 6H). EXAMPLE 46 2-(3-bromophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl)methyl)piperazin-l-yl)-N-((4-((l-methylpiperidin-4-yl)amino)-3- nitrophenyl)sulfonyl)benzamide EXAMPLE 46A Ethyl 2-(3-bromophenoxy)-4-fluorobenzoate The title compound was prepared by substituting 3-bromophenol for 2-methyl-5-indolol in EXAMPLE 3A. 286 EXAMPLE 46B Ethyl 2-(3-bromophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- enyl)methyl)piperazin-1 -yl)benzoate The title compound was prepared by substituting EXAMPLE 46A for EXAMPLE 3A in EXAMPLE 3G. EXAMPLE 46C 2-(3-Bromophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-1 -yl)benzoic acid The title compound was prepared by substituting EXAMPLE 46B for EXAMPLE IE in EXAMPLE IF. EXAMPLE 46D 2-(3-bromophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-l-yl)-N-((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 46C for EXAMPLE IF and EXAMPLE 31 for EXAMPLE IG in EXAMPLE IH. 'H NMR (300 MHz, dimethylsulfoxide-de) 6 11.97 (s, IH), 9.46 (s, IH), 9.38 (s, IH), 8.39 - 8.48 (m, IH), 8.21 (d, IH), 7.78 (dd, IH), 7.53 (d, IH), 7.41 (d, 2H), 7.08 - 7.24 (m, 5H), 6.75 - 6.86 (m, 3H), 6.58 (d, IH), 4.08 (s, IH), 3.62 (s, 3H), 3.55 (d, 4H), 3.23 - 3.39 (m, 3H), 3.05 - 3.20 (m, 4H), 2.78 - 2.91 (m, 5H), 2.70 - 2.78 (m, IH), 2.13 - 2.28 (m, 4H), 2.05 (s, 2H), 1.78 - 1.92 (m, 2H), 1.48 (t,2H), 0.96 (s,6H). EXAMPLE 47 2-(2-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl)methyl)piperazin- l-yl)-N-((4-(( 1 -ethylpiperidin-4-yl)amino)-3- nitrophenyl)sulfonyl)benzamide EXAMPLE 47A 4-( 1 -Ethylpiperidin-4-ylamino)-3-nitrobenzenesulfonamide The title compound was prepared by substituting l-ethylpiperidin-4-amine for 1-isopropylpiperidin-4-amine in EXAMPLE 41 A. 287 EXAMPLE 47B 2-(2-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-N-((4-((l-ethylpiperidin-4-yl)ainino)-3-nitrophenyl)sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 34C for EXAMPLE IF and EXAMPLE 47A for EXAMPLE IG in EXAMPLE IH. 'H NMR (500 MHz, pyridine-dj) 5 9.18 (d, IH), 8.50 (d, IH), 8.36 (dd, IH), 8.01 (d, IH), 7.39 - 7.47 (m, 3H), 7.10 (d, 5H), 7.03 - 7.06 (m, 2H), 7.02 (dd, IH), 6.96 (td, 2H), 6.85 (dd, IH), 6.80 (dd, IH), 6.54 (d, IH), 3.93 - 4.00 (m, IH), 3.55 (s, 2H), 3.13 - 3.21 (m, 5H), 3.10 (q, 2H), 2.90 (s, 2H), 2.28 - 2.37 (m, 8H), 2.22 - 2.28 (m, 2H), 1.98 (s, 2H), 1.40 (t, 2H), 1.26 (t, 3H), 0.95 (s, 6H). EXAMPLE 48 2-(2-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl)methyl)piperazin-l-yl)-N-((3-nitro-4-((l,2,2,6,6-pentamethylpiperidin-4- yl)amino)phenyl)sulfonyl)benzamide EXAMPLE 48A 4-(l,2,2,6,6-Pentamethylpiperidin-4-ylamino)-3-nitrobenzenesulfonamide The title compound was prepared by substituting l,2,2,6,6-pentamethylpiperidin-4-ylamine for l-isopropylpiperidin-4-amine in EXAMPLE 41 A. EXAMPLE 48B 2-(2-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcycIohex-l-en-l-yl)methyl)piperazin-l-yl)-N-((3-nitro-4-((l,2,2,6,6-pentamethylpiperidin-4-yl)amino)phenyl)sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 34C for EXAMPLE IF and EXAMPLE 48A for EXAMPLE IG in EXAMPLE IH. 'H NMR (500 MHz, pyridine-ds) 5 9.19 (d, IH), 8.45 (d, IH), 8.37 (dd, IH), 8.01 (d, IH), 7.45 (d, 3H), 7.09 (d, 2H), 7.06 (s, IH), 7.02 - 7.05 (m, 2H), 6.99 (td, IH), 6.86 (dd, 2H), 6.80 (dd, IH), 6.53 (d, IH), 4.16 -4.25 (m, IH), 3.16 - 3.23 (m, 4H), 2.90 (s, 2H), 2.82 (s, 3H), 2.45 - 2.54 (m, 2H), 2.31 (d, 6H), 2.17 (dd, 2H), 1.98 (s, 2H), 1.55 (s, 6H), 1.46 (s, 6H), 1.40 (t, 2H), 0.95 (s, 6H). 288 EXAMPLE 49 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcycIohex-l-en-l-yl)methyl)piperazin-l-yl)-2-(2,3- difluorophenoxy)-N-((3-nitro-4-((l-tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino)phenyl)sulfonyl)benzamide EXAMPLE 49A tert-butyl 1 -(tetrahydro-2H-pyran-4-yl)piperidin-4-ylcarbamate A mixture of tert-butyl piperidin-4-ylcarbamate (45 g) and dihydro-2H-pyran-4(3H)-one (24.74 g) in dichloromethane (10(X) mL) was treated with sodium triacetoxyborohydride (6L9 g), stirred at room temperature for 16 hours, washed with IM sodium hydroxide and dried with anhydrous sodium sulfate, filtered and concentrated. The concentrate was flash column chromatographed on silica gel with 10-20% methanol/dichloromethane. EXAMPLE 49B l-(tetrahydro-2H-pyran-4-yl)piperidin-4-amine dihydrochloride salt A solution of EXAMPLE 49A (52.57 g) in dichloromethane (900 mL) was treated with 4M aqueous HCl (462 mL), mixed vigorously at room temperature for 16 hours and concentrated. EXAMPLE 49C 3-nitro-4-(l-(tetrahydro-2H-pyran-4-yl)piperidin-4-ylamino)benzenesulfonamide A mixture of EXAMPLE 49B (22.12 g), water (43 mL), and triethylamine (43.6 mL) in 1,4-dioxane (300 mL) was stirred at room temperature until EXAMPLE 49B completely dissolved. The solution was then treated with 4-chloro-3-nitrobenzenesulfonamide (20.3 g), heated at 90°C for 16 hours, cooled and concentrated. 10% Methanol in dichloromethane was added, and the solution was stirred vigorously at room temperature until a fine suspension existed and then the mixture was filtered. EXAMPLE 49D 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-2-(2,3- difluorophenoxy)-N-((3-nitro-4-((l-tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino)phenyl)sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 45C for EXAMPLE IF and EXAMPLE 49C for EXAMPLE IG in EXAMPLE IH. 'H NMR (500 MHz, pyridine-ds) 289 5 9.18 (d, IH), 8.53 (d, IH), 8.40 (dd, IH), 7.99 (d, IH), 7.45 (d, 2H), 7.10 (d, 2H), 7.03 (d, IH), 6.85 (m, 3H), 6.69 (m, 2H), 4.02 (m, 2H), 3.72 (m, IH), 3.31 (t, 2H), 3.21 (m, 4H), 3.11 (m, 2H), 2.83 (m, 3H), 2.66 (m, 2H), 2.30 (m, 6H), 2.16 (m, 2H), 1.93 (m, 4H), 1.74 (m, 4H), 1.41 (t, 2H), 0.96 (s, 6H). EXAMPLE 50 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yI)methyl)piperazin-l-yl)-2-((7- fluoro-1 H-indol-5-yl)oxy)-N-((4-(( 1 -methylpiperidin-4-yl)amino)-3- nitrophenyl)sulfonyl)benzamide EXAMPLE 50A ((3-fluoro-4-nitrophenoxy)methylene)dibenzene Biomodiphenylmethane (3.5 g) and 3-fluoro-4-nitrophenol were dissolved in N,N-dimethylformamide (30 mL), and then K2CO3 (4.2 g) was added and the reaction stirred at room temperature for 60 hours. The reaction was partitioned between water and ethyl acetate. The organic layer was washed with 2Af aqueous NaaCOs and brine, then dried over Na2S04. After filtration and concentration, the crude material was purified by column chromatography using 1.5-2.0% ethyl acetate in hexanes. EXAMPLE 50B 5-(benzhydryloxy)-7-fluoro-lH-indole EXAMPLE 50A (2.0 g) was dissolved in tetrahydrofuran (60 mL), then that solution was cooled to -40°C. Vinylmagnesium bromide, l.OM in tetrahydrofuran, (21 mL) was then added dropwise, keeping the temperature below -30°C. The reaction was stirred at -40° C for 90 minutes, and was partitioned between saturated NH4CI and ethyl acetate. The organic layer was washed with brine and dried over Na2S04. After filtration and concentration, the crude material was purified by column chromatography using 2.5-3.0% ethyl acetate in hexanes. EXAMPLE 50C 7-fluoro-li/-indol-5-ol EXAMPLE SOB (240 mg) was dissolved in ethyl acetate (1 mL) and methanol (9 mL), then palladium hydroxide on carbon (35 mg) was added and the reaction stirred at room 290 temperature under a hydrogen balloon for 90 minutes. The reaction was filtered through celite and concentrated to give the crude product which was carried on in the next step without further purification. EXAMPLE SOD ethyl 4-fluoro-2-(7-fluoro-1 H-indol-5-yloxy)benzoate The title compound was prepared by substituting EXAMPLE 50C for 2-methyl-5-indolol in EXAMPLE 3A. EXAMPLE 50E ethyl 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)-2-(7- fluoro-lH-indol-5-yloxy)benzoate The title compound was prepared by substituting EXAMPLE SOD for EXAMPLE 3A in EXAMPLE 3G. EXAMPLE 50F 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-2-(7-fluoro-lH-indol-5-yloxy)benzoic acid The title compound was prepared by substituting EXAMPLE SOE for EXAMPLE IE in EXAMPLE IF. EXAMPLE 50G 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-2-((7-fluoro-1 H-indol- 5 -yl)oxy)-N-((4-(( 1 -methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamidebis(2,2,2-trifluoroacetate) EXAMPLE 50F (35 mg), EXAMPLE 31 (17 mg), l-ethyl-3-[3-(dimethylamino)propyl]-carbodiimide hydrochloride (21 mg), and 4-dimethylaminopyridine (14 mg) were stirred in CH2CI2 (L5 mL) overnight. The reaction was concentrated and the crude material was purified by preparative HPLC using a 2S0 x SO mm C18 column and eluting with 20-100% CH3CN vs. 0.1% trifluoroacetic acid in water, giving the product as a trifluoroacetate salt. 'H NMR (300MHz, dimethylsulfoxide-de) 611.62 (br s, IH), 9.65, 9.45 (both V br s, total 2H), 8.55 (d, IH), 8.17 (br d, IH), 7.84 (dd, IH), 7.50 (d, IH), 7.43 (t, IH), 7.39 (d, 2H), 7.20 (d, IH), 7.08 (d, 2H), 6.90 (d, IH), 6.66 (m, 2H), 6.44 (m, IH), 6.28 (d, 291 IH), 4.02, 3.82 (both br s, total 2H), 3.60 (v br m, 4H), 3.05 (v br m, 5H), 2.85, 2.80 (br m, br s, total 5H), 2.20 (br m, 5H), 2.00 (br s, 3H), 1.80 (v br m, 2H) 1.44 (br t, 2H), 0.95 (s, 6H). EXAMPLE 51 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-2-(2,3-difluorophenoxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 45C for EXAMPLE IF and EXAMPLE 4A for EXAMPLE IG in EXAMPLE IH. 'H NMR (500 MHz, pyridine-ds) 8 9.21 (d, IH), 9.00 (m, IH), 8.36 (dd, IH), 7.97 (d, IH), 7.45 (d, 2H), 7.10 (d, 2H), 6.97 (d, IH), 6.85 (d, 3H), 6.69 (d, 2H), 3.82 (m, 4H), 3.38 (q, 2H), 3.21 (m, 4H), 2.86 (s, 2H), 2.45 (m, 6H), 2.28 (m, 6H), 1.99 (s, 2H), 1.80 (m, 2H), 1.41 (t, 2H), 0.96 (s, 6H). EXAMPLE 52 2-(4-amino-3-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-l-yl)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 40C for EXAMPLE IF and EXAMPLE 4A for EXAMPLE IG in EXAMPLE IH. 'H NMR (300MHz, dimethylsulfoxide-dfi) 5 11.10 (br s, IH), 8.80 (t, IH), 8.56 (s, IH), 7.82 (dd, IH), 7.45 (d, IH), 7.35 (d, 2H), 7.17 (d, IH), 7.06 (d, 2H), 6.89 (d, IH), 6.77 (s, 2H), 6.63 (d, IH), 6.14 (d, IH), 5.20 (br s, 2H), 3.61 (m, 4H), 3.46 (m, 2H), 3.07 (m, 4H), 2.75 (ra, 2H), 2.44 (m, 6H), 2.20 (m, 6H), 1.97 (m, 2H), 1.81 (m, 2H), 1.40 (m, 2H), 0.94 (s, 6H). EXAMPLE 53 2-(3-chlorophenoxy)-4-(4-((4'-chloro-4-(2-pyrrolidin- 1-ylethyl)-1,1 '-biphenyl-2- yl)methyl)piperazin-l-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide EXAMPLE 53A methyl 5-formyl-2-(trifluoromethylsulfonyloxy)benzoate Triflic anhydride (7.74 mL) was added to methyl 5-formyl-2-hydroxybenzoate (7.5 g) in 150 mL CH2CI2 at 0°C, and the reaction mixture was stirred and allowed to warm to room temperature over 3 hours. The reaction mixture was diluted with CH2CI2 (150 mL), washed 292 3x with brine, dried over Na2S04, filtered, and concentrated. The product was used without further purification. EXAMPLE 53B methyl 4'-chloro-4-formylbiphenyl-2-carboxylate EXAMPLE 53A (14.5 g), 4-chlorophenylboronic acid (6.88 g) CsF (12.2 g), and tetrakis(triphenylphosphine)palladium(0) were stirred at 70°C for 24 hours. The reaction mixture was cooled, filtered, and concentrated. The crude product was taken up in ethyl acetate (250 mL), washed with 3x IM aqueous NaOH, and brine, concentrated, and chromatographed on silica gel with 10% ethyl acetate/hexanes. EXAMPLE 53C methyl 4'-chloro-4-(2-oxoethyl)biphenyl-2-carboxylate To a solution of (methoxymethyl)diphenylphosphine oxide (1.62 g) in 40 mL tetrahydrofuran at -78°C, was added lithium diisopropylamide (2M, 3.3 mL), and after stirring 3 minutes, EXAMPLE 53B (1.57 g) was added, and the solution was warmed to room temperature. NaH (230 mg), and 40 mL N,N-dimethylformamide were added, and the mixture was heated to 60°C for 1 hour. The reaction mixture was cooled and poured into saturated aqueous NaH2P04 solution. The resulting solution was extracted twice with ether, and the combined extracts were washed twice with water, and brine, and concentrated. The crude mixture of enol ethers was taken up in IM aqueous HCl (50 mL) and dioxane (50 mL), and stirred at 60°C for 3 hours. The reaction was cooled and poured into NaHCOs solution. The resulting solution was extracted twice with ether, and the combined extracts were washed with water, and brine, and concentrated. The product was used without further purification. EXAMPLE 53D methyl 4'-chloro-4-(2-(pyrrolidin-1 -yl)ethyl)biphenyl-2-caiboxylate The title compound was prepared by substituting EXAMPLE 53C for 4'-chlorobiphenyl-2-carboxaldehyde and pyrrolidine for tert-butyl piperazine-l-carboxylate in EXAMPLE lA. EXAMPLE 53E (4'-chloro-4-(2-(pyrrolidin-1 -yl)ethyl)biphenyl-2-yl)methanol 293 Diisobutylaluminum hydride (IM in hexanes, 7.8 mL) was added to a solution of EXAMPLE 53D (0.89 g) in dichloromethane (30 mL) at 0°C, and the reaction was stirred for 20 minutes. The reaction was quenched by the slow addition of methanol, and then poured into IM aqueous NaOH (50 mL). The mixture was extracted twice with ethyl acetate, and extracts were combined, washed with brine, dried over Na2S04, filtered, and concentrated. EXAMPLE 53F 4'-chloro-4-(2-(pyrrolidin-1 -y l)ethyl)biphenyl-2-carbaldehyde EXAMPLE 53E (0.85 g) and Dess-Martin periodinane (1.26 g) were stirred in dichloromethane (40 mL) for 90 minutes. The reaction was quenched with methanol (5 mL), concentrated, and chromatographed on silica gel with 10-50% ethyl acetate/hexanes. EXAMPLE 53G teit-butyl4-(3-(3-chlorophenoxy)-4-(ethoxycarbonyl)phenyl)piperazine-l-carboxylate The title compound was prepared by substituting EXAMPLE 36A for methyl 2-brDmo-4-fluorobenzoate and tert-butyl piperazine-l-carboxylate for EXAMPLE IB in EXAMPLE IC. EXAMPLE 53H ethyl 2-(3-chlorophenoxy)-4-(piperazin- l-yl)benzoate The title compound was prepared by substituting EXAMPLE 53G for EXAMPLE 1A in EXAMPLE IB. EXAMPLE 531 ethyl 4-(4-((4'-chloro-4-(2-(pyrrolidin-l-yl)ethyl)biphenyl-2-yl)methyl)piperazin-l-yl)-2-(3- chlorophenoxy)benzoate The title compound was prepared by substituting EXAMPLE 53F for 4'-chlorobiphenyl-2-carboxaldehyde and EXAMPLE 53H for tert-butyl piperazine-l-carboxylate in EXAMPLE lA. EXAMPLE 53J 4-(4-((4'-chloro-4-(2-(pyrrolidin-l-yl)ethyl)biphenyl-2-yl)methyl)piperazin-l-yl)-2-(3- chlorophenoxy)benzoic acid 294 The title compound was prepared by substituting EXAMPLE 531 for EXAMPLE IE in EXAMPLE IF. EXAMPLE 53K 2-(3-chlorophenoxy)-4-(4-((4'-chloro-4-(2-pyrrolidin-1 -ylethyl)-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((3 -nitro-4-((tetrahydro-2H-pyran-4-ylniethyl)amino)phenyl)sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 53J for EXAMPLE IF in EXAMPLE IH. 'H NMR (300MHZ, dimethylsulfoxide-de) 5 11.80 (br s, IH), 8.66 (t, IH), 8.45 (s, IH), 8.00 (m, IH), 7.72 (dd, IH), 7.52 (d, 2H), 7.35 (m, 4H), 7.16 (m, 2H), 6.94 (d, IH), 6.80 (d, IH), 6.66 (d, 2H), 6.55 (m, IH), 4.32 (m, IH), 3.85 (m, 2H), 3.56 (m, 2H), 3.33 (m, 8H), 3.07 (m, 6H), 2.85 (m, 2H), 2.43 (m, 2H), 2.02 (m, 2H), 1.91 (m, 4H), 1.63 (m, 2H), 1.27 (m,2H). EXAMPLE 54 4-(4-((2-(4-chloiophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-2-(2,3- dichlorophenoxy)-N-((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide EXAMPLE 54A Ethyl 2-(2,3-dichlorophenoxy)-4-fluorobenzoate The title compound was prepared by substituting 2,3-dichlorophenol for 2-methyl-5-indolol in EXAMPLE 3A. EXAMPLE 54B Ethyl 2-(2,3-dichlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)benzoate The title compound was prepared by substituting EXAMPLE 54A for EXAMPLE 3A in EXAMPLE 3G. EXAMPLE 54C 2-(2,3-dichlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- enyl)methyl)piperazin-1 -yl)benzoic acid The title compound was prepared by substituting EXAMPLE 54B for EXAMPLE IE in EXAMPLE IF. 295 EXAMPLE 54D 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-2-(2,3-dichlorophenoxy)-N-((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 54C for EXAMPLE IF and EXAMPLE 31 for EXAMPLE IG in EXAMPLE IH. 'H NMR (500 MHz, pyridine-ds) 5 9.16 (d, IH), 8.50 (d, IH), 8.33 (dd, IH), 7.99 (d, IH), 7.45 (d, 2H), 7.11 (t, 3H), 7.04 (d, IH), 6.95 (t, IH), 6.84 (dd, IH), 6.74 (d, IH), 6.68 (d, IH), 3.90 - 3.98 (m, IH), 3.51 (d, 2H), 3.20 - 3.27 (m, 4H), 3.15 (t, 2H), 2.90 (s, 2H), 2.80 (s, 3H), 2.33 (d, 9H), 2.17 - 2.26 (m, 2H), 1.99 (s, 2H), 1.41 (t, 2H), 0.96 (s, 6H). EXAMPLE 55 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-2-((3-methyl-lH-indazol-4-yl)oxy)-N-((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 44E for EXAMPLE IF and EXAMPLE 31 for EXAMPLE IG in EXAMPLE IH. 'H NMR (300MHz, dimethylsulfoxide-dfi) 6 11.95 (br s, 2H), 8.30 (d, IH), 8.02 (d, IH), 7.61 (d, IH), 7.36 (d, 2H), 7.07 (d, 2H), 6.94 (m, 2H), 6.69 (m, 2H), 6.36 (s, IH), 5.92 (d, IH), 3.27 (m, 4H), 3.04 (m, 7H), 2.75 (m, 4H), 2.49 (m, 4H), 2.22 (m, 8H), 1.99 (s, 3H), 1.77 (m, 2H), 1.39 (m, 2H), 0.94 (s, 6H). EXAMPLE 56 2-(2-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)cyclohept- 1-en- l-yl)methyl)piperazin-1 -yl)- N-((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide EXAMPLE 56A (Z)-methyl 2-(trifluoK)methylsulfonyloxy)cyclohept-1 -enecarboxylate The title compound was prepared as described in EXAMPLE 38B by replacing EXAMPLE 38A with methyl 2-oxocycloheptanecarboxylate. EXAMPLE 56B (Z)-methyl 2-(4-chlorophenyl)cyclohept-l-enecarboxylate 296 The title compound was prepared as described in EXAMPLE 38C by replacing EXAMPLE 38B with EXAMPLE 56A. EXAMPLE 56C (Z)-(2-(4-chlorophenyl)cyclohept-1 -enyl)methanol The title compound was prepared as described in EXAMPLE 38D by replacing EXAMPLE 38C with EXAMPLE 56B. EXAMPLE 56D (Z)-2-(4-chlorophenyl)cyclohept-l-enecarbaldehyde The title compound was prepared as described in EXAMPLE 38E by replacing EXAMPLE 38D with EXAMPLE 56C. EXAMPLE 56E (Z)-methyl 2-(2-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)cyclohept-1 - enyl)methyl)piperazin-1 -yl)benzoate The title compound was prepared as described in EXAMPLE 38G by replacing EXAMPLE 38E with EXAMPLE 56D. EXAMPLE 56F (Z)-2-(2-chlorophenoxy)-4-(4-((2-(4-chl6rophenyl)cyclohept-l-enyl)methyl)piperazin-l- yl)benzoic acid The title compound was prepared as described in EXAMPLE 38H by replacing EXAMPLE 38G with EXAMPLE 56E. EXAMPLE 56G 2-(2-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)cyclohept- 1-en- l-yl)methyl)piperazin-1 -yl)- N-((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide The title compound was prepared as described in EXAMPLE IH by replacing EXAMPLE IF and EXAMPLE IG with EXAMPLE 56F and EXAMPLE 3L respectively. 'H NMR (300 MHz, dimethylsulfoxide-de) 6 8.35 (d, IH), 8.06 (d, IH), 7.73 (dd, IH), 7.63 (d, IH), 7.35 (d, 2H), 7.04 (m, 4H), 6.88 (m, IH), 6.69 (dd, IH), 6.52 (dd, IH), 6.25 (d, IH), 297 3.78 (m, IH), 3.06 (m, 6H), 2.70 (m, 4H), 2.38 (m, 4H), 2.26 (m, 5H), 2.07 (m, 4H), 1.73 (m, 5H), 1.52 (m, 5H). EXAMPLE 57 4-(4-((2-(4-chlorophenyl)-4,4-dimethyIcyclohex- 1-en-1 -yl)methyl)piperazin-1 -yl)-N-((4-(( 1 - methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)-2-(3- (trifluoromethyl)phenoxy)benzamide EXAMPLE 57A Ethyl 4-fluoro-2-(3-(trifluoromethyl)phenoxy)benzoate The title compound was prepared by substituting 3-(trifluoromethyl)phenoI for 2-methyl-5-indolol in EXAMPLE 3A. EXAMPLE 57B Ethyl 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex- l-enyl)methyl)piperazin- l-yl)-2-(3- (trifluoromethyl)phenoxy)benzoate The title compound was prepared by substituting EXAMPLE 57A for EXAMPLE 3A in EXAMPLE 3G. EXAMPLE 57C 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-2-(3-(trifluoromethyl)phenoxy)benzoic acid This EXAMPLE was prepared by substituting EXAMPLE 57B for EXAMPLE IE in EXAMPLE IF. EXAMPLE 57D 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-N-((4-(( 1 -methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)-2-(3-(trifluoromethyl)phenoxy)benzamide The tide compound was prepared by substituting EXAMPLE 57C for EXAMPLE IF and EXAMPLE 31 for EXAMPLE IG in EXAMPLE IH. 'H NMR (400 MHz, dimethylsulfoxide-de) 8 8.32 (d, IH), 8.04 (m, IH), 7.66 (m, 2H), 7.35 (m, 3H), 7.16 (d, IH), 7.06 (d, 2H), 6.95 (m, 3H), 6.73 (dd, IH), 6.42 (d, IH), 3.80 (m, IH), 3.11 (m, 4H), 2.83 (m, 298 4H), 2.63 (m, 3H), 2.21 (m, 6H), 2.08 (m, 2H), 1.97 (m, 5H), 1.76 (m, 2H), 1.41 (t, 2H), 0.95 (s, 6H). EXAMPLE 58 4-(4-((4'-chloro-1, l'-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((4-((3- (dimethylamino)propyl)amino)-3-nitrophenyl)sulfonyl)-2-((2-oxo-l,2,3,4-tetrahydroquinolin- 5-yl)oxy)benzamide EXAMPLE 58A methyl 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)-2-(2-oxo-1,2,3,4- tetrahydroquinolin-5-yloxy)benzoate The title compound was prepared by substituting 3,4-dihydro-5-hydroxy-lH-quinoIin-2-one for EXAMPLE ID in EXAMPLE IE. EXAMPLE 58B 4-(4-((4'-chlorobiphenyl-2-yI)methyl)piperazin-1 -yl)-2-(2-oxo-1,2,3,4-tetrahydroquinolin-5- yloxy)benzoic acid The title compound was prepared by substituting EXAMPLE 58A for EXAMPLE IE in EXAMPLE IF. EXAMPLE 58C 4-(4-((4'-chloro-1, l'-biphenyl-2-yl)methyI)piperazin-1 -yl)-N-((4-((3- (dimethylamino)propyl)amino)-3-nitrophenyl)sulfonyl)-2-((2-oxo-l,2,3,4-tetrahydroquinolin- 5-yl)oxy)benzamide The title compound was prepared by substituting EXAMPLE 58B for EXAMPLE IF and EXAMPLE 1 lA for EXAMPLE IG in EXAMPLE IH. 'H NMR (300 MHz, dimethylsulfoxide-d^) 5 11.68 (s, IH), 10.08 (s, IH), 8.64 (t, IH), 8.48 (d, IH), 7.81 (dd, IH), 7.50 (m, 6H), 7.39 (m, 2H), 7.29 (m, IH), 7.14 (d, IH), 6.93 (t, IH), 6.75 (dd, IH), 6.51 (d, IH), 6.39 (m, IH), 6.13 (d, IH), 4.36 (m, IH), 3.72 (m, IH), 3.40 (m, 6H), 3.13 (m, 4H), 2.80 (m, 4H), 2.78 (d, 6H), 2.40 (t, 2H), 1.96 (m, 2H). 299 EXAMPLE 59 2-(2-chloiophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-N-((4-((l-methylpiperidin-4-yl)amino)-3-((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 34C for EXAMPLE IF and EXAMPLE 13ID for EXAMPLE IG in EXAMPLE IH. 'H NMR (400MHZ, dimethylsulfoxide-dfi) 5 7.99 (d, IH), 7.88 (m, IH), 7.62 (d, IH), 7.38 (m, 3H), 7.06 (d, 3H), 7.01 (d, IH), 6.93 (t, IH), 6.69 (m, IH), 6.56 (d, IH), 6.50 (s, IH), 6.24 (d, IH), 3.25 (m, lOH), 3.07 (s, 2H), 3.07 (s, 3H), 2.77 (d, 3H), 2.20 (d, 5H), 2.04 (s, 2H), 1.96 (d, 2H), 1.63 (s, 2H), 1.40 (t,2H), 0.94 (s,6H). EXAMPLE 60 4-(4-((2-(4-chlorophenyl)-4,4-diniethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-2-(2,5- dichlorophenoxy)-N-((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide EXAMPLE 60A Ethyl 2-(2,5-dichlorophenoxy)-4-fluorobenzoate The title compound was prepared by substituting 2,5-dichlorophenol for 2-methyl-5-indolol in EXAMPLE 3A. EXAMPLE 60B Ethyl 2-(2,5-dichlorophenoxy)-4-(piperazin-1 -yl)benzoate The title compound was prepared by substituting piperazine for EXAMPLE 3F and EXAMPLE 60A for EXAMPLE 3A in EXAMPLE 3G. EXAMPLE 60C 2-chloro-4,4-dimethylcyclohex-1 -enecaibaldehyde Into a 250 mL round-bottomed flask was added N,N-dimethylformamide (3.5 mL) in dichloromethane (30 mL) to give a colorless solution. The mixture was cooled to -10 °C, and phosphoryl trichloride (4 mL) was added dropwise. The solution was warmed up to room temperature, and 3,3-dimethylcyclohexanone (5.5 mL) was added slowly. The mixture was heated to reflux for overnight. The reaction mixture was quenched by 0''C solution of sodium 300 acetate (25 g in 50 mL water). The aqueous layer was extracted with ether (3x 200 mL). The organic layers were combined, dried over Na2S04, filtered, and dried under vacuum. EXAMPLE 60D 2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enecarbaldehyde Into a 1 L round-bottomed flask was added EXAMPLE 60C (6.8 g), 4-chlorophenylboronic acid (6.5 g) and palladium(II) acetate (0.2 g) in water (100 mL) to give a suspension. Potassium carbonate (15 g) and tetrabutylammonium bromide (10 g) were added. After degassing by subjecting to vacuum and nitrogen, the mixture was stirred at 45 °C for 4 hours. After filtering through silica gel, ether (4x 200 mL) was used to extract the product. The combined organic layers were dried over Na2S04 and filtered. The filtrate was concentrated and purified by flash chromatography on silica with 0 to 10% ethyl acetate in hexanes to provide the title compound. EXAMPLE 60E Ethyl 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-2-(2,5- dichlorophenoxy)benzoate The title compound was prepared by substituting EXAMPLE 60D for 4'-chlorobiphenyl-2-carboxaldehyde and EXAMPLE 60B for tert-butyl piperazine-1-carboxylate in EXAMPLE lA. EXAMPLE 60F 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-2-(2,5- dichlorophenoxy)benzoic acid The title compound was prepared by substituting EXAMPLE 60E for EXAMPLE IE in EXAMPLE IF. EXAMPLE 60G 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-2-(2,5-dichlorophenoxy)-N-((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 60F for EXAMPLE IF and EXAMPLE 31 for EXAMPLE IG in EXAMPLE IH. 'H NMR (400 MHz, dimethylsulfoxide-de) 8 12.01 (br.s, IH), 9.92 (br.s, IH), 9.68 (br.s, IH), 8.43 (m, IH), 8.19 (d, IH), 7.80 (dd, IH), 7.55 (d, IH), 7.39 (m, 3H), 7.23 (d, IH), 7.11 (d, 2H), 6.97 (dd, IH), 301 6.85 (dd, IH), 6.55 (m, 2H), 3.58 (m, 5H), 3.25 (m, 6H), 2.83 (m, 4H), 2.21 (m, 4H), 2.05 (s, 2H), 1.87 (m, 2H), 1.48 (t, 2H), 0.96 (s, 6H). EXAMPLE 61 2-(2-chloro-4-fluorophenoxy)-4-(4-((2-(4-chloiophenyl)-4,4-dimethylcyclohex-l-en-l- yl)methyl)piperazin-l-yl)-N-((4-((l-niethylpiperidin-4-yl)amino)-3- nitrophenyl)sulfonyl)benzamide EXAMPLE 61A Ethyl 2-(2-chloro-4-fluorophenoxy)-4-fluorobenzoate The title compound was prepared by substituting 2-chloro-4-fluoropheno] for 2-methyl-5-indolol in EXAMPLE 3A. EXAMPLE 61B Ethyl 2-(2-chloro-4-fluorophenoxy)-4-(piperazin-l-yl)benzoate The title compound was prepared by substituting piperazine for EXAMPLE 3F and EXAMPLE 61A for EXAMPLE 3A in EXAMPLE 3G. EXAMPLE 61C Ethyl 2-(2-chloro-4-fluorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 - eny l)methy l)piperazin-1 -yl)benzoate The title compound was prepared by substituting EXAMPLE 60D for 4'-chlorobiphenyl-2-carboxaldehyde and EXAMPLE 61B for tert-butyl piperazine-1-carboxylate inEXAMPLE lA. EXAMPLE 61D 2-(2-chloro-4-fluorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-1 -yl)benzoic acid The title compound was prepared by substituting EXAMPLE 61C for EXAMPLE IE in EXAMPLE IF. 302 EXAMPLE 61E 2-(2-chloro-4-fluorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-N-((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 6ID for EXAMPLE IF and EXAMPLE 31 for EXAMPLE IG in EXAMPLE IH. 'H NMR (400 MHz, dimethylsulfoxide-dfi) 6 8.40 (m, IH), 8.08 (m, IH), 7.78 (dd, IH), 7.59 (d, IH), 7.33 (m, 3H), 7.07 (m, 3H), 6.92 (ra, IH), 6.69 (dd, IH), 6.59 (m, IH), 6.25 (d, IH), 3.84 (m, IH), 3.08 (m, 4H), 2.77 (m, 8H), 2.16 (m, 8H), L97 (s, 2H), L75 (m, 2H), L40 (t, 2H), 0.94 (s, 6H). EXAMPLE 62 2-(2-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclopent-1 -en-1 - yl)methyl)piperazin-l-yl)-N-((4-((l-methylpiperidin-4-yl)amino)-3- nitrophenyl)sulfonyl)benzamide EXAMPLE 62A methyl 4,4-dimethyI-2-oxocyclopentanecarboxylate This compound was prepared according to WO 2006/035061(page 53). EXAMPLE 62B methyl 4,4-dimethyl-2-(trifluoromethylsulfonyloxy)cyclopent-1 -enecarboxylate The title compound was prepared as described in EXAMPLE 38B by replacing EXAMPLE 38A with EXAMPLE 62A. EXAMPLE 62C ethyl 2-(4-chlorophenyl)-4,4-dimethylcyclopent-1 -enecarboxylate The title compound was prepared as described in EXAMPLE 38C by replacing EXAMPLE 38B with EXAMPLE 62B. EXAMPLE 62D (2-(4-chlorophenyl)-4,4-dimethylcyclopent-1 -enyl)methanol The title compound was prepared as described in EXAMPLE 38D by replacing EXAMPLE 38C with EXAMPLE 62C. 303 EXAMPLE 62E 2-(4-chlorophenyl)-4,4-dimethylcyclopent-1 -enecarbaldehyde The title compound was prepared as described in EXAMPLE 38E by replacing EXAMPLE 38D with EXAMPLE 62D. EXAMPLE 62F methyl 2-(2-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclopent-1 - enyl)methyl)piperazin-1 -yl)benzoate The title compound was prepared as described in EXAMPLE 38G by replacing EXAMPLE 38E with EXAMPLE 62E. EXAMPLE 62G 2-(2-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclopent-l- enyl)methyl)piperazin-1 -yl)benzoic acid The title compound was prepared as described in EXAMPLE 38H by replacing EXAMPLE 38G with EXAMPLE 62F. EXAMPLE 62H 2-(2-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclopent-1 -en-1 -yl)methyl)piperazin-l-yl)-N-((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide The title compound was prepared as described in EXAMPLE IH by replacing EXAMPLE IF and EXAMPLE 10 with EXAMPLE 620 and EXAMPLE 31, respectively. 'H NMR (300 MHz, dimethylsulfoxide-de) 6 8.35 (d, IH), 8.06 (d, IH), 7.73 (dd, IH), 7.64 (d, IH), 7.33 (m, 5H), 7.04 (m, 2H), 6.88 (m, IH), 6.72 (dd, IH), 6.52 (dd, IH), 6.28 (d, IH), 3.78 (d, IH), 3.07 (d, 4H), 2.71 (m, 6H), 2.33 (m, 8H), 2.06 (m, 4H), 1.74 (m, 4H), 1.10 (m, 6H). EXAMPLE 63 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-2-((3- methyl-lH-indol-4-yl)oxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3- nitrophenyl)sulfonyl)benzamide 304 EXAMPLE 63A ethyl 4-fluoro-2-(3-methyl-lH-indol-4-yloxy)benzoate The title compound was prepared by substituting 3-methyl-4-indolol for 2-methyl-5-indolol in EXAMPLE 3A. EXAMPLE 63B ethyl 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-2-(3- methyl-1 H-indol-4-yloxy)benzoate The title compound was prepared by substituting EXAMPLE 63A for methyl-2-bromo-4-fluorobenzoate and EXAMPLE 3F for EXAMPLE IB in EXAMPLE IC. EXAMPLE 63C 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)-2-(3-methyl- lH-indol-4-yloxy)benzoic acid The title compound was prepared by substituting EXAMPLE 63B for EXAMPLE IE in EXAMPLE IF. EXAMPLE 63D 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl)methyl)piperazin-1 -yl)-2-((3-mediyl-lH-indol-4-yl)oxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 63C for EXAMPLE IF and EXAMPLE 4A for EXAMPLE IG in EXAMPLE IH. 'H NMR (300MHZ, dimethylsulfoxide-de) 6 10.92 (br s, 2H), 8.77 (m, IH), 8.57 (d, IH), 7.82 (dd, IH), 7.55 (d, IH), 7.33 (d, 2H), 7.15 (m, 2H), 7.03 (d, 2H), 6.99 (m, 2H), 6.67 (d, IH), 6.45 (d, IH), 6.12 (d, IH), 3.68 (m, 4H), 3.47 (m, 2H), 3.02 (m, 6H), 2.73 (m, 4H), 2.43 (m, 2H), 2.14 (m, 8H), 1.99 (s, 3H), 1.91 (m, 2H), 1.38 (m, 2H), 0.92 (s, 6H). EXAMPLE 64 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- I-yl)methyl)piperazin-1 -yl)-2-(2- chloro-3-(trifluoromethyl)phenoxy)-N-((4-((l-methylpiperidin-4-yl)amino)-3- nitrophenyl)sulfonyl)benzamide EXAMPLE 64A 305 Ethyl 2-(2-chloro-3-(trifluoromethyl)phenoxy)-4-fluorobenzoate The title compound was prepared by substituting 2-chloro-3-(trifluoromethyl)phenol for 2-methyl-5-indolol in EXAMPLE 3A. EXAMPLE 64B Ethyl 2-(2-chloro-3-(trifluoromethyl)phenoxy)-4-(4-((2-(4-ch]orophenyl)-4,4- dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)benzoate The title compound was prepared by substituting EXAMPLE 64A for EXAMPLE 3A in EXAMPLE 3G. EXAMPLE 64C 2-(2-chloro-3-(trifluoromethyl)phenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- enyl)methyl)piperazin-l -yl)benzoic acid The title compound was prepared by substituting EXAMPLE 64B for EXAMPLE IE in EXAMPLE IF. EXAMPLE 64D 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(2- chloro-3-(trifluoromethyl)phenoxy)-N-((4-((l-methylpiperidin-4-yl)amino)-3- nitrophenyl)sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 64C for EXAMPLE IF and EXAMPLE 31 for EXAMPLE IG in EXAMPLE IH. 'H NMR (400 MHz, dimethylsulfoxide-ds) 6 12.02 (s, IH), 9.76 (s, IH), 9.52 (s, IH), 8.42 (m, IH), 8.17 (d, IH), 7.82 (dd, IH), 7.58 (d, IH), 7.41 (m, 3H), 7.27 (m, 2H), 7.11 (d, 2H), 6.93 (d, IH), 6.84 (dd, IH), 6.57 (d, IH), 3.15 (m, 6H), 2.83 (m, 8H), 2.11 (m, 8H), 1.83 (m, 2H), 1.47 (t, 2H), 0.96 (s, 6H). EXAMPLE 65 2-(2-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl)metiiyl)piperazin-1 -yI)-N-((4-(( 1 -cyclopropylpiperidin-4-yl)amino)-3- nitrophenyl)sulfonyl)benzamide 306 EXAMPLE 65A 4-(l-cyclopropylpiperidin-4-ylamino)-3-nitrobenzenesulfonamide To a solution of 4-fluoro-3-nitrobenzenesulfonamide (1.26 g) and 1-cyclopropylpiperidin-4-amine (0.802 g) in tetrahydrofuran (20 mL) was added N,N-diisopropylethylamine (2.22 g) and 4-diniethylaminopyridine (35 mg). The mixture was stirred at reflux overnight. The mixture was diluted with ethyl acetate (200 mL) and washed with aqueous NaHCOa, water, and brine and dried over Na2S04. After filtration and concentration, the residue was dissolved in dichloromethane and loaded on a column and eluted with dichloromethane (5(X) mL), 5% 7N NH3 in 10% methanol in dichloromethane (1.5 L) to give the product. EXAMPLE 65B 2-(2-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-N-((4-((l-cyclopropylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide The title compound was prepared as described in EXAMPLE IH by replacing EXAMPLE IF and EXAMPLE IG with EXAMPLE 34C and EXAMPLE 65A, respectively. 'H NMR (300 MHz, dimethylsulfoxide-de) 6 8.46 (dd, IH), 8.22 (t, IH), 7.81 (m, 2H), 7.53 (d, IH), 7.37 (m, 4H), 7.14 (m, IH), 7.07 (m, IH), 6.99 (m, IH), 6.72 (m, IH), 6.29 (d, IH), 3.75 (ra, IH), 3.13 (s, 3H), 2.93 (d, 3H), 2.78 (s, IH), 2.20 (m, 5H), 1.97 (m, 5H), 1.59 (m, 5H), 0.94 (s, 6H), 0.42 (m, 5H). EXAMPLE 66 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-2-((3-methyl-lH-indol-4-yl)oxy)-N-((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 63C for EXAMPLE IF and EXAMPLE 31 for EXAMPLE IG in EXAMPLE IH. 'H NMR (300MHz, dimethylsulfoxide-d6) 5 10.86 (br s, 2H), 8.51 (br s, IH), 8.15 (d, IH), 7.82 (dd, IH), 7.55 (d, IH), 7.33 (d, 2H), 7.15 (m, 2H), 7.03 (d, 2H), 6.94 (m, 2H), 6.62 (d, IH), 6.38 (d, IH), 6.12 (d, IH), 3.82 (m, IH), 3.09 (m, 2H), 2.98 (m, 6H), 2.88 (m, 2H), 2.71 (m, 3H), 2.66 (m, 2H), 2.11 (m, 8H), 1.99 (s, 3H), 1.82 (m, 2H), 1.38 (m, 2H), 0.92 (s, 6H). EXAMPLE 67 307 4-(4-((2-(4-chloiiophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin- l-yl)-2-(2,5-dich]orophenoxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 60D for EXAMPLE IF and EXAMPLE 4A for EXAMPLE IG in EXAMPLE IH. 'H NMR (400 MHz, dimethylsulfoxide-ds) 8 8.71 (m, IH), 8.43 (d, IH), 7.75 (dd, IH), 7.54 (d, IH), 7.36 (m, 3H), 7.07 (m, 3H), 6.94 (dd, IH), 6.79 (dd, IH), 6.46 (dd, 2H), 3.67 (m, 4H), 3.48 (q, 2H), 3.20 (m, 4H), 2.83 (s, 2H), 2.65 (m, 6H), 2.24 (m, 6H), 1.98 (s, 2H), 1.88 (m, 2H), 1.42 (t, 2H), 0.95 (s, 6H). EXAMPLE 68 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(( 1 -methyl-1 H-indol-4-yl)oxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 16D for EXAMPLE 50F and EXAMPLE 4A for EXAMPLE 31 in EXAMPLE 50G. 'H NMR (300 MHz, dimethylsulfoxide-de) 5 11.58 (br s, IH), 9.78 (br s, IH), 8.67 (t, IH), 8.44 (d, IH), 7.77 (dd, IH), 7.66 (br s, IH), 7.50 (m, 5H), 7.37 (d, 2H), 7.30 (m, IH), 7.25 (d, IH), 7.19 (d, IH), 7.06 (d, IH), 7.00 (dd, IH), 6.75 (dd, IH), 6.40 (d, IH), 6.38 (s, IH), 6.23 (d, IH), 4.35-2.80 (series of br m, total 22 H), 3.80 (s, 3H), 1.96 (m, 2H). EXAMPLE 69 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(3-morpholin-4-ylphenoxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 32B for EXAMPLE IF and EXAMPLE 4A for EXAMPLE 10 in EXAMPLE IH. 'H NMR (400MHz, dimethylsulfoxide-de) 5 11.63 (s, IH), 9.86 (s, IH), 8.71 (t, IH), 8.50 (d, IH), 7.83 (dd, IH), 7.70 (s, IH), 7.50 (m, 5H), 7.39 (d, 2H), 7.32 (m, IH), 7.16 (d, IH), 7.08 (m, IH), 6.74 (dd, IH), 6.59 (dd, IH), 6.40 (m, 2H), 6.23 (dd, IH), 4.24 (m, 2H), 3.97 (m, 2H), 3.70 (m, 4H), 3.63 (m, 4H), 3.54 (m, 4H), 3.18 (m, 4H), 3.07 (m, 4H), 3.00 (m, 4H), 2.83 (m, 2H), 1.98 (m, 2H). EXAMPLE 70 4-(4-((4'-chloro-1, l'-biphenyl-2-yl)methyl)piperazin- l-yl)-N-((4-((3- (dimethylamino)propyl)amino)-3-nitrophenyl)sulfonyl)-2-((3-(3-moipholin-4-yl-3- oxopropyl)-lH-indol-5-yl)oxy)benzamide 308 EXAMPLE 70A (Z)-tert-butyI5-(benzyloxy)-3-(3-morpholino-3-oxoprop-l-enyl)-lH-indole-l-carboxylate A mixture of tert-butyl 5-(benzyloxy)-3-bromo-lH-indole-l-carboxylate (2.011 g), 1-morpholinoprop-2-en-l-one (0.776 g), palladium acetate (31 mg), trt-o-tolylphosphine (187 mg) and triethylamine (1.14 mL) in N,N-dimethylformamide (14 mL) under nitrogen atmosphere was stirred at 1(X)**C overnight. The mixture was diluted with ethyl acetate and saturated ammonium chloride. The aqueous layer was extracted with ethyl acetate and the combined organic layers were dried over MgS04, filtered and concentrated. The residue was purified by flash chromatography (80% ethyl acetate-hexane) to give the desired product. EXAMPLE 70B tert-butyl 5-hydroxy-3-(3-morpholino-3-oxopropyl)-1 H-indole-1 -carboxylate The title compound was prepared by substituting EXAMPLE 70A for EXAMPLE 39A in EXAMPLE 39B. EXAMPLE 70C tert-butyl 5-(5-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-2-(methoxycarbonyl)phenoxy)-3-(3-morpholino-3-oxoprc)pyl)-lH-indole-l-carboxylate The title compound was prepared by substituting EXAMPLE 70B for EXAMPLE ID in EXAMPLE IE. EXAMPLE 70D methyl 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-(3-morpholino-3-oxopropyl)-lH-indol-5-yloxy)benzoate A solution of EXAMPLE 70C (300 mg) in dioxane (2 mL) was treated with concentrated aqueous hydrogen chloride (0.378 mL) and stirred at room temperature overnight. The solution was concentrated and the residue was used for the next step without further purification. EXAMPLE 70E 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-(3-morpholino-3-oxopropyl)-lH- indol-5-yloxy)benzoic acid The title compound was prepared by substituting EXAMPLE 70D for EXAMPLE IE in EXAMPLE IF. 309 EXAMPLE 70F 4.(4.((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-((3-(dimethylamino)propyl)amino)-3-nitrophenyl)sulfonyl)-2-((3-(3-morpholin-4-yl-3-oxopropyl)-1 H-indol-5 -yl)oxy)benzamide The title compound was prepared by substituting EXAMPLE 70E for EXAMPLE IF and EXAMPLE 1 lA for EXAMPLE IG in EXAMPLE IH. 'H NMR (400MHZ, dimethylsulfoxide-de) 6 1L37 (s, IH), 10.88 (s, IH), 9.33 (s, IH), 8.64 (m, 2H), 7.88 (d, IH). 7.66 (s, IH), 7.51 (dd, 5H), 7.35 (dd, 3H), 7.29 (s. IH), 7.21 (s, IH), 7.13 (d, 2H), 6.82 (dd, IH), 6.67 (d, IH), 6.21 (s, IH), 3.42 (s, 20H), 3.12 (s, 2H), 2.85 (m, 2H), 2.78 (d, 6H), 2.61 (m,2H), 1.95 (m,2H). EXAMPLE 71 2-(3-(benzyloxy)phenoxy)-4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((3- nitro-4-((tetrahydio-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide EXAMPLE 71A 2-(3-(benzyloxy)phenoxy)-4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)benzoic acid The title compound was prepared by substituting EXAMPLE 33A for EXAMPLE IE in EXAMPLE IF. EXAMPLE 71B 2-(3-(benzyloxy)phenoxy)-4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 71A for EXAMPLE IF in EXAMPLE IH. 'H NMR (400MHz, dimethylsulfoxide-d^) 6 11.69 (m, IH), 8.62 (m, IH), 8.48 (d, IH), 7.76 (dd, IH), 7.65 (m, IH), 7.50 (m, 5H), 7.38 (m, 6H), 7.32 (m, 2H), 7.11 (m, 2H), 6.77 (dd, IH), 6.62 (dd, IH), 6.41 (m, 2H), 6.35 (m, IH), 4.98 (s, 2H), 3.83 (m, 2H), 3.28 (m, 12H), 3.17 (m, 2H), 1.89 (m, IH), 1.59 (m, 2H), 1.26 (m, 2H). EXAMPLE 72 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(4-cyanophenoxy)-N-((3-nitro- 4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide 310 EXAMPLE 72A methyl 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)-2-(4-cyanophenoxy)benzoate The title compound was prepared by substituting 4-cyanophenol for EXAMPLE ID in EXAMPLE IE. EXAMPLE 72B 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)-2-(4-cyanophenoxy)benzoic acid The title compound was prepared by substituting EXAMPLE 72A for EXAMPLE IE in EXAMPLE IF. EXAMPLE 72C 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(4-cyanophenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 72B for EXAMPLE IG in EXAMPLE IH. 'H NMR (300 MHz, dimethylsulfoxide-de) 5 11.97 (s, IH), 9.54 (s, IH), 8.62 (t, IH), 8.44 (d, IH), 7.66 (m, 4H), 7.53 (m, 5H), 7.37 (m, 3H), 7.12 (d, IH), 6.82 (m, 3H), 6.64 (d, IH), 4.37 (m, IH), 3.86 (dd, 2H), 3.49 (m, 2H), 3.26 (m, 8H), 3.10 (m, 2H), 2.84 (s, IH), 1.92 (m, IH), 1.64 (dd, 2H), 1.28 (m, 2H). EXAMPLE 73 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-((3-(3-morpholin-4-yl-3-oxopropyl)-lH-indol-5-yI)oxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 70E for EXAMPLE IF in EXAMPLE IH. 'H NMR (400MHz, dimethylsulfoxide-de) 8 11.38 (s, IH), 10.87 (s, IH), 8.59 (m, 2H), 7.79 (dd, IH), 7.68 (s, IH), 7.51 (dd, 5H), 7.34 (dd, 4H), 7.20 (s, IH), 7.10 (d, 2H), 6.81 (dd, IH), 6.68 (d, IH), 6.23 (s, IH), 3.85 (d, 2H), 3.44 (s, 18H), 3.28 (m, 4H), 2.84 (m, 2H), 2.60 (t, 2H), 1.89 (s, IH), 1.63 (m, 2H), 1.27 (m, 2H). 311 EXAMPLE 74 4-(4-((4'-chloro-1, r-biphenyl-2-yl)niethyl)piperazin-1 -yl)-2-((3-(3-morpholin-4-ylpropyl)- lH-indol-5-yl)oxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide EXAMPLE 74A methyl 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-(3-morpholinopiopyl)-lH- indol-5-yloxy)benzoate EXAMPLE 70C (107 mg) was dissolved in anhydrous tetrahydrofuran (0.7 mL), followed by the addition of IM borane in tetrahydrofuran solution (0.57 mL). The reaction mixture was stirred at room temperature overnight. The reaction was quenched with IN HCl aqueous solution (1.5 mL). The resulting solution was heated at 50°C overnight. The solvent was removed under vacuum. The residue was purified by flash column chromatography on silica gel using 10-50% ethyl acetate in hexanes to afford the product. EXAMPLE 74B 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-(3-morpholinopropyl)-lH-indol-5- yloxy)benzoic acid The title compound was prepared by substituting EXAMPLE 74A for EXAMPLE IE in EXAMPLE IF. EXAMPLE 74C 4-(4-((4'-chIoro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-((3-(3-morpholin-4-ylpropyl)-lH-indol-5-yl)oxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 74B for EXAMPLE IF in EXAMPLE IH. 'H NMR (400MHZ, dimethylsulfoxide-d^) 6 11.35 (m, IH), 10.95 (s, IH), 9.58 (m, IH), 8.60 (m, 2H), 7.86 (dd, IH), 7.63 (m, IH), 7.50 (dd, 5H), 7.35 (t, 3H), 7.28 (s, IH), 7.22 (dd, 2H), 7.17 (d, IH), 6.84 (d, IH), 6.65 (d, IH), 6.16 (s, IH), 3.93 (s, IH), 3.84 (d, 2H), 3.50 (m, 15H), 3.32 (m, 2H), 3.26 (m, 2H), 3.13 (m, 2H), 3.03 (s, 2H), 2.68 (t, 2H), 1.97 (d, 2H), 1.89 (s, IH), 1.61 (d, 2H), 1.27 (m, 2H). 312 EXAMPLE 75 4.(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(4- ((dimethylamino)methyl)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide EXAMPLE 75A 4-((dimethylamino)methyl)phenol The title compound was prepared by substituting 4-hydroxybenzaldehyde for 4'-chlorobiphenyl-2-carboxaldehyde and dimethylamine for tert-butyl piperazine-1-carboxylate in EXAMPLE lA. EXAMPLE 75B methyl 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-2-(4-((dimethylamino)methyl)phenoxy)benzoate The title compound was prepared by substituting EXAMPLE 75A for EXAMPLE ID in EXAMPLE IE. EXAMPLE 75C 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-2-(4-((dimethylamino)methyl)phenoxy)benzoicacid The title compound was prepared by substituting EXAMPLE 75B for EXAMPLE IE in EXAMPLE IF. EXAMPLE 75D 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin- l-yl)-2-(4-((dimethylamino)methyl)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 75C for EXAMPLE IF in EXAMPLE IH. 'H NMR (300MHZ, dimethylsulfoxide-de) 5 11.80 (br s, IH), 9.60 (br s, IH), 8.59 (m, IH), 8.48 (m, IH), 7.80 (d, IH), 7.50 (d, 2H), 7.46 (m, 2H), 7.36 (m, 4H), 7.24 (m, 2H), 6.90 (d, 2H), 6.77 (d, IH), 6.44 (d, IH), 4.16 (m, 2H), 3.84 (dd, 2H), 3.30 (m, 8H), 3.15 (m, 4H), 2.68 (m, 4H), 2.35 (m, 4H), 1.88 (m, IH), 1.61 (dd, 2H), 1.23 (m, 2H). 313 EXAMPLE 76 4-(4.((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(4-(lH-imidazol-l-yl)phenoxy)- N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide EXAMPLE 76A methyl 2-(4-(l H-imidazol-1 -yl)phenoxy)-4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 - yl)benzoate The title compound was prepared by substituting 4-(l H-imidazol-l-yl)phenol for EXAMPLE ID in EXAMPLE IE. EXAMPLE 76B 2-(4-(lH-imidazol-l-yl)phenoxy)-4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l- yl)benzoic acid The title compound was prepared by substituting EXAMPLE 76A for EXAMPLE IE in EXAMPLE IF. EXAMPLE 76C 4-(4-((4'-chloro-l, r-biphenyl-2-yl)methyl)piperazin- l-yl)-2-(4-(lH-imidazol- l-yl)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 76B for EXAMPLE IF in EXAMPLE IH. 'H NMR (300MHZ, dimethylsulfoxide-de) 5 8.50 (s, IH), 8.17 (d, IH), 7.78 (m, IH), 7.66 (m, IH), 7.40-7.58 (m, 8H), 7.37 (d, 2H), 7.25 (m, IH), 7.10 (d, 2H), 6.94 (d, IH), 6.75 (d, IH), 6.63 (d, IH), 6.43 (d, IH), 3.82 (m, 2H), 3.37 (m, 4H), 3.08-3.21 (m, 6H), 2.35 (m, 4H), 1.82(m, IH), 1.58 (m, 2H), 1.40 (m, 2H). EXAMPLE 77 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1-yl)-2-(3-nitrophenoxy)-N-((4- ((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide EXAMPLE 77A 4-((tetrahydro-2H-pyran-4-yl)methylamino)benzenesulfonamide 4-Aminobenzenesulfonamide (6.80 g), tetrahydropyran-4-carboxaldehyde (4.96 g), and sodium triacetoxyborohydride (16.74 g) in tetrahydrofuran (300 mL) and acetic acid (15 314 mL) were stirred at room temperature for 24 hours. The reaction was concentrated and taken up in ethyl acetate. The resulting solution was washed with water and brine, concentrated, and chromatographed on silica gel with 50% ethyl acetate/hexanes. EXAMPLE 77B 4-(4-((4'-chloro-l,r-biphenyl-2-yl)niethyl)piperazin-l-yl)-2-(3-nitrophenoxy)-N-((4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide2,2,2-trifluoroacetate The title compound was prepared by substituting EXAMPLE 8B for EXAMPLE 50F and EXAMPLE 77A for EXAMPLE 31 in EXAMPLE 50G. 'H NMR (300 MHz, dimethylsulfoxide-dfi) 6 11.58 (br s, IH), 9.58 (br s, IH), 7.86 (m, IH), 7.71 (br s, IH), 7.52 (m, 7H), 7.40 (m, 5H), 7.30 (m, IH), 6.82 (dd, IH), 6.71 (br s, IH), 6.60 (d, IH), 6.47 (d, 2H), 4.37 (v br s, IH), 3.83 (dd, 2H), 3.70 (v br s, IH), 3.50-3-40 (envelope, 6H), 3.26, (m, 2H), 3.05, 2.96, 2.94,2.85 (all br s, total 4H), 1.79 (m, IH), 1.65 (m, 2H), 1.22 (m, 2H). EXAMPLE 78 tert-butyl 4-(5-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin- l-yl)-2-((((3-nitro- 4((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)amino)carbonyl)phenoxy)benzyl(ethyl)carbamate EXAMPLE 78A tert-butyl ethyl(4-hydroxybenzyl)carbamate Diethylamine gas was bubbled into a solution of 4-hydroxybenzaldehyde (2.0 g) and sodium triacetoxyborohydride (5.2 g) in dichloromethane (60 mL) until saturated. The reaction flask was stoppered and the reaction stirred for 24 hours. IM NaOH (10 mL) was then added, followed by di-tert-butyl dicarbonate (3.57 g) and triethylamine (2.28 mL), and the reaction was stirred for 24 hours. The reaction was acidified with saturated NaH2P04 solution, extracted twice with ethyl acetate, and the combined extracts were washed with brine and concentrated. The crude product was chromatographed on silica gel using 20% ethyl acetate/hexanes as the eluent to give the product. EXAMPLE 78B methyl 2-(4-((tert-butoxycarbonyl(ethyl)amino)methyl)phenoxy)-4-(4-((4'-chlorobiphenyl-2- yl)methyl)piperazin-1 -yl)benzoate 315 The title compound was prepared by substituting EXAMPLE 78A for EXAMPLE ID in EXAMPLE IE. EXAMPLE 78C 2-(4-((tert-butoxycarbonyl(ethyl)amino)methyl)phenoxy)-4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin- l-yl)benzoic acid The title compound was prepared by substituting EXAMPLE 78B for EXAMPLE IE in EXAMPLE IF. EXAMPLE 78D tert-butyl 4-(5-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)-2-(3-nitro-4-((tetrahydro-2H-pyran-4-yl)methylamino)phenylsulfonylcarbamoyl)phenoxy)benzyl(ethyl)carbamate The title compound was prepared by substituting EXAMPLE 78C for EXAMPLE IF in EXAMPLE IH. EXAMPLE 79 tert-butyl 3-(5-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-((((3-nitro-4- ((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)amino)carbonyl)phenoxy)benzyl(ethyl)carbamate EXAMPLE 79A tert-butyl ethyl(4-hydroxybenzyl)carbamate The title compound was prepared by substituting 3-hydroxybenzaldehyde for 4-hydroxybenzaldehyde in EXAMPLE 78A. EXAMPLE 79B methyl 2-(3-((tert-butoxycarbonyl(ethyl)amino)methyl)phenoxy)-4-(4-((4'-chlorobiphenyl-2- yl)methyl)piperazin-1 -yl)benzoate The title compound was prepared by substituting EXAMPLE 79A for EXAMPLE ID in EXAMPLE IE. EXAMPLE 79C 2-(3-((tert-butoxycarbonyl(ethyI)amino)methyl)phenoxy)-4-(4-((4'-chlorobiphenyl-2- yl)methyl)piperazin- l-yl)benzoic acid 316 The title compound was prepared by substituting EXAMPLE 79B for EXAMPLE IE in EXAMPLE IF. EXAMPLE 79D tert-butyl 3-(5-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)-2-(3-nitro-4-((tetrahydro-2H-pyran-4-yl)methylamino)phenylsulfonylcarbamoyl)phenoxy)benzyl(ethyl)carbamate The title compound was prepared by substituting EXAMPLE 79C for EXAMPLE IF in EXAMPLE IH. EXAMPLE 80 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(4-((ethylamino)methyl)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 78D for EXAMPLE lA in EXAMPLE IB. ^H NMR (300MHz, dimethylsulfoxide-de) 5 8.63 (br s, IH), 8.52 (br s, IH), 8.43 (s, IH), 7.78 (dd, IH), 7.60 (d, IH), 7.46 (s, 4H), 7.35 (d, 2H), 7.31 (m, IH), 7.24 (d, IH), 7.13 (d, IH), 6.84 (d, 2H), 6.72 (d, IH), 6.36 (s, IH), 4.04 (s, 2H), 3.84 (dd, 2H), 3.27 (m, 6H), 3.11 (m, 4H), 2.94 (m, 2H), 2.36 (m, 4H), 1.91 (m, IH), 1.62 (dd, 2H), 1.23 (m, 2H), 1.17(t,3H). EXAMPLE 81 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin- l-yl)-2-(3-((ethylamino)methyl)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 79D for EXAMPLE lA in EXAMPLE IB. 'H NMR (300MHz, dimethylsulfoxide-de) 8 11.60 (br s, IH), 8.80 (br s, IH), 8.62 (br s, IH), 8.51 (s, IH), 7.82 (dd, IH), 7.30-7.55 (m, 7H), 7.24 (m, 2H), 7.19 (d, IH), 7.04 (d, IH), 6.89 (d, IH), 6.77(d, IH), 6.36 (s, IH), 4.06 (s, 2H), 3.86 (dd, 2H), 3.27 (m, 6H), 3.11 (m, 4H), 2.96 (m, 2H), 2.34 (ra, 4H), 1.90 (m, IH), 1.61 (dd, 2H), 1.24 (m, 2H), 1.19(t,3H). EXAMPLE 82 2-(4-(acetylamino)phenoxy)-4-(4-((4'-chloro-1,1 '-bipheny]-2-yl)methy])piperazin-1 -y])-N- ((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide 317 EXAMPLE 82A methyl 2-(4-acetamidophenoxy)-4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 - yl)benzoate The title compound was prepared by substituting 4-acetamidophenol for EXAMPLE ID in EXAMPLE IE. EXAMPLE 82B 2-(4-acetamidophenoxy)-4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)benzoic acid The title compound was prepared by substituting EXAMPLE 82A for EXAMPLE IE in EXAMPLE IF. EXAMPLE 82C 2-(4-(acetylamino)phenoxy)-4-(4-((4'-chloio-1, r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 82B for EXAMPLE IG in EXAMPLE IH. 'H NMR (300 MHz, dimethylsulfoxide-dg) 6 11.58 (s, IH), 9.91 (s, IH), 8.62 (t, IH), 8.54 (d, IH), 7.76 (dd, IH), 7.68 (m, IH), 7.51 (m, 7H), 7.34 (m, 3H), 7.16 (d, IH), 6.85 (d, 2H), 6.72 (dd, IH), 6.30 (m, IH), 4.35 (s, IH), 3.85 (dd, 2H), 3.68 (m, IH), 3.27 (m, 9H), 3.02 (m, 2H), 2.83 (m, IH), 2.04 (s, 3H), 1.89 (m, IH), 1.62 (dd, 2H), 1.24 (m, 2H). EXAMPLE 83 tert-butyl 4-(5-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-((((3-nitio-4- ((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)amino)carbonyl)phenoxy)phenylcarbamate This EXAMPLE was prepared by substituting EXAMPLE 18B for EXAMPLE IF in EXAMPLE IH. ^H NMR (300 MHz, dimethylsulfoxide-de) 6 11.37 (s, IH), 9.32 (s, IH), 8.61 (t, IH), 8.57 (d, IH), 7.81 (dd, IH), 7.44 (m, 8H), 7.34 (m, 2H), 7.22 (m, 2H), 6.88 (d, 2H), 6.69 (dd, IH), 6.20 (d, IH), 3.85 (m, 2H), 3.28 (m, 6H), 3.09 (m, 4H), 2.33 (m, 4H), 1.90 (m, IH), 1.63 (m, 2H), 1.47 (m, 9H), 1.26 (m, 2H). EXAMPLE 84 2-( 1,1 '-biphenyl-2-yloxy)-4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((3- nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide 318 EXAMPLE 84A methyl 2-(biphenyl-2-yloxy)-4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)benzoate The title compound was prepared by substituting 2-phenylphenol for EXAMPLE ID in EXAMPLE IE. EXAMPLE 84B 2-(biphenyl-2-yloxy)-4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)benzoicacid The title compound was prepared by substituting EXAMPLE 84A for EXAMPLE IE in EXAMPLE IF. EXAMPLE 84C 2-(l, 1 '-biphenyl-2-yloxy)-4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((3- nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide 2,2,2- aifluoroacetate The title compound was prepared by substituting EXAMPLE 84B for EXAMPLE 50F and EXAMPLE IG for EXAMPLE 31 in EXAMPLE 50G. ^H NMR (300 MHz, dimethylsulfoxide-de) 6 11.56 (v br s, IH), 9.50 (v br s, IH), 8.62 (t, IH), 8.45 (d, IH), 7.76 (dd, IH), 7.70 (br s, IH), 7.50 (m, 7H), 7.37 (d, 2H), 7.27 (m, 5H), 7.12 (m, 2H), 7.04 (m, IH), 6.70 (dd, IH), 6.64 (d, IH), 6.27 (s, IH), 4.35 (v br s, IH), 3.83 (dd, 2H), 3.70 (v br s, IH), 3.40 (m, 4H), 3.25, 3.20 (both m, total 4H), 3.00, 2.80 (both br s, total 4H), 1.83 (m, IH), 1.59 (m, 2H), 1.24 (m, 2H). EXAMPLE 85 tert-butyl 3-(5-(4-((4'-chloro-1, l'-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-((((3-nitro-4- ((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)amino)carbonyl)phenoxy)phenylcarbamate The title compound was prepared as described in EXAMPLE 19C. 'H NMR (300 MHz, dimethylsulfoxide-d6) 5 11.45 (s, IH), 9.34 (s, IH), 8.62 (t, IH), 8.52 (d, IH), 7.75 (dd, IH), 7.46 (m, 6H), 7.36 (m, 2H), 7.23 (m, IH), 7.11 (m, 4H), 6.74 (dd, IH), 6.42 (m, IH), 6.36 (d, IH), 3.86 (dd, 2H), 3.30 (m, 6H), 3.15 (m, 4H), 2.35 (m, 4H), 1.90 (qd, IH), 1.63 (dd, 2H), 1.45 (s, 9H), 1.27 (m, 2H). 319 EXAMPLE 86 2-( 1,1 '-biphenyl-3-yloxy)-4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((3- nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide EXAMPLE 86A methyl 2-(biphenyl-3-yloxy)-4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)benzoate The title compound was prepared by substituting 3-phenylphenol for EXAMPLE ID in EXAMPLE IE. EXAMPLE 86B 2-(biphenyl-3-yloxy)-4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)benzoic acid The title compound was prepared by substituting EXAMPLE 86A for EXAMPLE IE in EXAMPLE IF. EXAMPLE 86C 2-(l,l'-biphenyl-3-yloxy)-4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((3- nitro-4-((tetrahydK)-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide 2,2,2- trifluoroacetate The title compound was prepared by substituting EXAMPLE 86B for EXAMPLE 50F and EXAMPLE IG for EXAMPLE 31 in EXAMPLE 50G. 'H NMR (300 MHz, diraethylsulfoxide-de) 5 11.82 (v br s, IH), 9.60 (v br s, IH), 8.72 (t, IH), 8.42 (d, IH), 7.70 (br s, IH), 7.69 (dd, IH), 7.55-7.20 (m, 15H), 7.00 (d, IH), 6.96 (s, IH), 6.80 (m, 2H), 6.53 (d, IH), 4.35 (V br s, IH), 3.83 (dd, 2H), 3.70 (v br s, IH), 3.40 (m, 4H), 3.25, 3.20 (both m, total 4H), 3.00, 2.80 (both br s, total 4H), 1.81 (m, IH), 1.58 (m, 2H), 1.22 (m, 2H). EXAMPLE 87 4-(4-((4'-chloio-1,1 '-biphenyl-2-yl)methyl)piperazin- l-yl)-2-(4-(2- (dimethylamino)ethyl)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide EXAMPLE 87A methyl 4-(4-((4'-chIorobiphenyl-2-yl)methyl)piperazin-1 -yl)-2-(4-(2- (dimethylamino)ethyl)phenoxy)benzoate 320 The title compound was prepared by substituting 4-(2-(dimethylamino)ethyl)phenol for EXAMPLE ID in EXAMPLE IE. EXAMPLE 87B 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)-2-(4-(2-(dimethylamino)ethyl)phenoxy)benzoicacid The title compound was prepared by substituting EXAMPLE 87A for EXAMPLE IE in EXAMPLE IF. EXAMPLE 87C 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(4-(2-(dimethylamino)ethyl)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 87B for EXAMPLE IF in EXAMPLE IH. 'H NMR (400MHZ, dimethylsulfoxide-dg) 6 11.67 (s, IH), 9.51 (s, IH), 8.66 (t, IH), 8.52 (d, IH), 7.84 (dd, IH), 7.70 (s, IH), 7.51 (dd, 5H), 7.36 (m, 3H), 7.22 (m, 3H), 6.84 (d, 2H), 6.76 (m, IH), 6.42 (s, IH), 3.85 (m, 2H), 3.52 (s, lOH), 3.35 (m, 2H), 3.26 (dd, 4H), 2.90 (m, 2H), 2.83 (d, 6H), 1.91 (s, IH), 1.61 (d, 2H), 1.27 (dt, 2H). EXAMPLE 88 2-(4-(benzyloxy)phenoxy)-4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((3- nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide EXAMPLE 88A Methyl 2-(4-(benzyloxy)phenoxy)-4-(4-((4'-chlorobiphenyl-2-yl)methyI)piperazin-1 - yl)benzoate The title compound was prepared by substituting 4-(benzyloxy)phenol for EXAMPLE ID in EXAMPLE IE. EXAMPLE 88B 2-(4-(benzyloxy)phenoxy)-4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)benzoic acid The title compound was prepared by substituting EXAMPLE 88A for EXAMPLE IE in EXAMPLE IF. 321 EXAMPLE 88C 2-(4-(benzyloxy)phenoxy)-4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 88B for EXAMPLE IF in EXAMPLE IH. 'H NMR (400MHz, dimethylsulfoxide-de) 6 1L50 (m, IH), 8.63 (t, IH), 8.55 (d, IH), 7.82 (dd, IH), 7.66 (m, IH), 7.41 (m, 13H), 7.20 (m, IH), 6.96 (d, 2H), 6.88 (d, 2H), 6.70 (dd, IH), 6.25 (m, IH), 5.04 (m, 2H), 3.27 (m, lOH), 2.90 (m, 6H), 1.88 (m, IH), 1.57 (m, 2H), 1.23 (m, 2H). EXAMPLE 89 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(3-morpholin-4-ylphenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 32B for EXAMPLE IF in EXAMPLE IH. 'H NMR (400MHz, dimethylsulfoxide-de) 6 11.58 (s, IH), 8.63 (t, IH), 8.49 (d, IH), 7.78 (dd, IH), 7.69 (m, IH), 7.52 (m, 5H), 7.38 (d, 2H), 7.33 (m, IH), 7.15 (d, IH), 7.07 (m, IH), 6.74 (dd, IH), 6.58 (dd, IH), 6.40 (m, 2H), 6.22 (dd, IH), 4.29 (m, 2H), 3.86 (m, 2H), 3.70 (m, 6H), 3.30 (m, 6H), 3.00 (m, 6H), 2.83 (m, 2H), 1.91 (m, IH), 1.63 (d, 2H), 1.28(m,2H). EXAMPLE 90 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-((2-methyl-l,3-benzothiazol-5-yl)oxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzaraide The title compound was prepared by substituting EXAMPLE 24B for EXAMPLE IF in EXAMPLE IH. 'H NMR (300MHz, dimethylsulfoxide -de) 5 11.83 (s, IH), 9.48 (br s, IH), 8.64 (t, IH), 8.45 (d, IH), 7.88 (d, IH), 7.76 (dd, IH), 7.50 (m, 5H), 7.37 (m, 2H), 7.30 (m, IH), 7.18 (m, IH), 7.04 (d, IH), 6.97 (dd, IH), 6.78 (dd, IH), 6.48 (br s, IH), 3.84 (dd, 2H), 3.37 (m, 6H), 3.23 (m, 4H), 2.89 (m, 2H), 2.75 (s, 3H), 2.36 (m, 3H), 1.62 (d, 2H), 1.24 (m,2H). EXAMPLE 91 tert-butyl 4-(3-(5-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-((((3-nitro-4- ((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)amino)carbonyl)phenoxy)phenyl)piperazine-l-carboxylate 322 EXAMPLE 91A teit-butyl4-(3-(5-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-2-(methoxycarbonyl)phenoxy)phenyl)piperazine-1 -carboxylate The title compound was prepared by substituting l-(3-hydroxy-phenyl)-piperazine-4-carboxylic acid tert-butyl ester for EXAMPLE ID in EXAMPLE IE. EXAMPLE 91B 2-(3-(4-(tert-butoxycarbonyl)piperazin-l-yl)phenoxy)-4-(4-((4'-chlorobiphenyI-2-yl)methyl)piperazin- l-yl)benzoic acid The title compound was prepared by substituting EXAMPLE 91A for EXAMPLE 1E in EXAMPLE 1F. EXAMPLE 91C tert-butyl 4-(3-(5-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin- l-yl)-2-((((3-nitro-4- ((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)amino)carbonyl)phenoxy)phenyl)piperazine-l-carboxylate The title compound was prepared by substituting EXAMPLE 9IB for EXAMPLE IF in EXAMPLE IH. 'H NMR (400MHZ, dimethylsulfoxide-dfi) 5 11.65 (s, IH), 8.65 (t, IH), 8.47 (d, IH), 7.76 (dd, IH), 7.72 (m, IH), 7.50 (m, 5H), 7.37 (d, 2H), 7.33 (m, IH), 7.15 (d, IH), 7.05 (m, IH), 6.75 (dd, IH), 6.57 (dd, IH), 6.41 (m, 2H), 6.21 (dd, IH), 4.31 (m, 2H), 3.86 (dd, 2H), 3.41 (m, 6H), 3.34 (t, 2H), 3.27 (m, 4H), 3.00 (m, 6H), 2.85 (m, 2H), 1.91 (m, IH), 1.63 (d, 2H), 1.40 (m, 9H), 1.28 (m, 2H). EXAMPLE 92 2-(3-(benzyloxy)phenoxy)-4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((4-((3-(dimethylamino)propyl)amino)-3-nitrophenyl)sulfony])benzamide The title compound was prepared by substituting EXAMPLE 71A for EXAMPLE IF and EXAMPLE 1 lA for EXAMPLE IG in EXAMPLE IH. 'H NMR (400MHz, dimethylsulfoxide-ds) 8 11.72 (s, IH), 9.52 (s, IH), 8.69 (t, IH), 8.50 (d, IH), 7.81 (dd, IH), 7.65 (s, IH), 7.50 (m, 5H), 7.39 (m, 6H), 7.32 (m, 2H), 7.13 (m, 2H), 6.77 (dd, IH), 6.64 (dd, IH), 6.42 (s, 2H), 6.38 (m, IH), 4.99 (s, 2H), 3.50 (m, lOH), 3.11 (m, 4H), 2.77 (s, 6H), 1.95 (m, 2H). 323 EXAMPLE 93 2-(3-(benzyloxy)phenoxy)-4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin- l-yl)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 71A for EXAMPLE IF and EXAMPLE 4A for EXAMPLE IG in EXAMPLE IH. 'H NMR (400MHZ, dimethylsulfoxide-dfi) 6 11.14 (m, IH), 9.78 (s, IH), 8.71 (m, IH), 8.50 (d, IH), 7.82 (dd, IH), 7.67 (s, IH), 7.50 (m, 5H), 7.39 (m, 6H), 7.32 (m, 2H), 7.13 (m, IH), 6.77 (dd, IH), 6.64 (dd, IH), 6.39 (m, 3H), 4.99 (s, 2H), 3.96 (m, 2H), 3.60 (s, 2H), 3.51 (m, 6H), 3.17 (m, lOH), 2.67 (m, 2H), 1.94 (m, 2H). EXAMPLE 94 4-(4-((4'-chloro-l,r-biphenyI-2-yl)methyl)piperazin-l-yl)-2-(4-(2-morpholin-4- ylethoxy)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide EXAMPLE 94A 4-(2-(4-(benzyloxy)phenoxy)ethyl)moTpholine The title compound was prepared by substituting 4-(2-chloroethyl)morpholine for 2-chloro-N,N-dimethylethanamine and 4-(benzyloxy)phenol for 3-(benzyloxy)phenol in EXAMPLE 39A. EXAMPLE 94B 4-(2-morpholinoethoxy)phenol The title compound was prepared by substituting EXAMPLE 94A for EXAMPLE 39A in EXAMPLE 39B. EXAMPLE 94e methyl 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)-2-(4-(2-morpholinoethoxy)phenoxy)benzoate The title compound was prepared by substituting EXAMPLE 94B for EXAMPLE ID in EXAMPLE IE. 324 EXAMPLE 94D 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-2-(4-(2-morpholinoethoxy)phenoxy)benzoic acid The title compound was prepared by substituting EXAMPLE 94C for EXAMPLE IE in EXAMPLE IF. EXAMPLE 94E 4-(4-((4'-chloro-Ll'-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(4-(2-morpholin-4-ylethoxy)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 94D for EXAMPLE IF in EXAMPLE IH. 'H NMR (400MHZ, dimethylsulfoxide-d^) 6 11.46 (m, IH), 9.98 (m, IH), 8.64 (d, IH), 8.55 (d, IH), 7.87 (d, IH), 7.49 (m, 5H), 7.39 (d, 2H), 7.31 (s, IH), 7.25 (d, IH), 6.96 (m, 5H), 6.71 (d, IH), 6.29 (s, IH), 4.30 (s, 2H), 3.98 (s, 2H), 3.85 (d, 2H), 3.72 (s, 2H), 3.42 (s, 16H), 3.27 (m, 2H), 1.91 (s, IH), 1.62 (d, 2H), 1.28 (m, 2H). EXAMPLE 95 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((3-nitro-4-((tetrahydro-2H- pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-((2-oxo-1,2,3,4-tetrahydroquinolin-5- yl)oxy)benzamide The title compound was prepared by substituting EXAMPLE 58B for EXAMPLE IF in EXAMPLE IH. 'H NMR (300 MHz, dimethylsulfoxide-dg) 6 11.50 (s, IH), 10.07 (s, IH), 8.60 (t, IH), 8.47 (d, IH), 7.74 (dd, IH), 7.46 (m, 6H), 7.36 (m, 2H), 7.24 (m, IH), 7.14 (d, IH), 6.92 (t, IH), 6.74 (dd, IH), 6.51 (d, IH), 6.35 (d, IH), 6.13 (d, IH), 3.86 (dd, 2H), 3.36 (m, 4H), 3.25 (m, 2H), 3.16 (m, 4H), 2.83 (t, 2H), 2.41 (dd, 2H), 2.35 (m, 4H), 1.90 (m, IH), 1.64 (dd,2H), 1.28 (m,2H). EXAMPLE 96 2-(4-(benzyloxy)phenoxy)-4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 88B for EXAMPLE IF and EXAMPLE 4A for EXAMPLE IG in EXAMPLE IH. 'H NMR 325 (400MHz, dimethylsulfoxide-de) 8 11.53 (s, IH), 9.74 (s, IH), 8.69 (ra, IH), 8.59 (d, IH), 7.90 (dd, IH), 7.67 (m, IH), 7.41 (m, 13H), 7.21 (d, IH), 6.99 (m, 2H), 6.91 (m, 2H), 6.70 (dd, IH), 6.23 (s, IH), 5.07 (s, 2H), 4.28 (m, 2H), 3.95 (s, 2H), 3.51 (m, 6H), 3.16 (m, lOH), 2.73 (d,2H), 1.98 (m,2H). EXAMPLE 97 tert-butyl 4-(4-(5-(4-((4'-ch]oro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-((((4-((3- morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)amino)carbonyl)phenoxy)phenyl)piperazine-l-carboxylate EXAMPLE 97A tert-butyl 4-(4-(5-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-2-(methoxycarbonyl)phenoxy)phenyl)piperazine-1 -carboxylate The title compound was prepared by substituting l-(4-hydroxy-phenyl)-piperazine-4-carboxylic acid tert-butyl ester for EXAMPLE ID in EXAMPLE IE. EXAMPLE 97B 2-(4-(4-(tert-butoxycarbonyl)piperazin-l-yl)phenoxy)-4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin- l-yI)benzoic acid The title compound was prepared by substituting EXAMPLE 97A for EXAMPLE IE in EXAMPLE IF. EXAMPLE 97C tert-butyl 4-(4-(5-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-((((4-((3- morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)amino)carbonyl)phenoxy)phenyl)piperazine-l-carboxylate The title compound was prepared by substituting EXAMPLE 97B for EXAMPLE IF and EXAMPLE 4A for EXAMPLE IG in EXAMPLE IH. ^H NMR (400MHz, dimethylsulfoxide-dfi) 5 11.44 (m, IH), 9.67 (s, IH), 8.70 (t, IH), 8.59 (d, IH), 7.91 (dd, IH), 7.69 (s, IH), 7.49 (m, 7H), 7.30 (m, IH), 7.21 (d, IH), 6.91 (m, 4H), 6.69 (dd, IH), 6.24 (s, IH), 3.95 (m, 2H), 3.67 (m, 4H), 3.52 (m, lOH), 3.17 (s, 4H), 3.04 (m, lOH), 1.97 (d, 2H), 1.43 (s, 9H). 326 EXAMPLE 98 4.(4.((4'.chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((4-((3-morpholin-4- ylpropyl)amino)-3-nitrophenyl)sulfonyl)-2-(3-pyridin-4-ylphenoxy)benzanude EXAMPLE 98A 4-(3-(benzyloxy)phenyl)pyridine The title compound was prepared by substituting l-(benzyloxy)-3-broraobenzene for EXAMPLE 33C and pyridin-4-ylboronic acid for 2,4-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thiazole in EXAMPLE 33D. EXAMPLE 98B 3-(pyridin-4-yl)phenol The title compound was prepared by substituting EXAMPLE 98A for EXAMPLE 33A in EXAMPLE 33B. EXAMPLE 98C methyl 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)-2-(3-(pyridin-4- yl)phenoxy)benzoate The title compound was prepared by substituting EXAMPLE 98B for EXAMPLE ID in EXAMPLE IE. EXAMPLE 98D 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)-2-(3 -(pyridin-4-y l)phenoxy)benzoic acid The title compound was prepared by substituting EXAMPLE 98C for EXAMPLE IE in EXAMPLE IF. EXAMPLE 98E 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyI)sulfonyl)-2-(3-pyridin-4-ylphenoxy)benzamide The title compound was prepared by substituting EXAMPLE 98D for EXAMPLE IF and EXAMPLE 4A for EXAMPLE IG in EXAMPLE IH. 'H NMR (400MHZ, dimethylsulfoxide-dfi) 6 11.87 (m, IH), 8.68 (d, 2H), 8.58 (m, IH), 8.42 (d, IH), 7.73 (m, 327 4H), 7.52 (m, 5H), 7.36 (m, 6H), 7.14 (s, IH), 7.03 (d, IH), 6.91 (m, IH), 6.80 (dd, IH), 6.55 (d, IH), 4.22 (m, 2H), 3.89 (m, 7H), 3.41 (m, 4H), 3.15 (m, 4H), 2.91 (m, 4H), 1.94 (m, 2H). EXAMPLE 99 4-(4-((4'-chloro-1,1 '-biphenyI-2-yl)methyl)piperazin-1 -yl)-N-((4-((3-morpholin-4- ylpropyl)amino)-3-nitrophenyl)sulfonyl)-2-(4-pyridin-4-ylphenoxy)benzamide EXAMPLE 99A 4-(4-(benzyloxy)phenyl)pyridine The title compound was prepared by substituting l-(benzyloxy)-4-bromobenzene for EXAMPLE 33C and pyridin-4-ylboronic acid for 2,4-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborc)lan-2-yl)thiazole in EXAMPLE 33D. EXAMPLE 99B 4-(pyridin-4-yl)phenol The title compound was prepared by substituting EXAMPLE 99A for EXAMPLE 33A in EXAMPLE 33B. EXAMPLE 99C methyl 4-(4-((4'-ch]orobipheny l-2-yl)methyl)piperazin-1 -yl)-2-(4-(pyridin-4- yl)phenoxy)benzoate The title compound was prepared by substituting EXAMPLE 99B for EXAMPLE ID in EXAMPLE IE. EXAMPLE 99D 4-(4-((4'-chIorobiphenyl-2-yl)methyl)piperazin-l-yl)-2-(4-(pyridin-4-yl)phenoxy)benzoic acid The title compound was prepared by substituting EXAMPLE 99C for EXAMPLE IE in EXAMPLE IF. EXAMPLE 99E 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyI)piperazin-1 -yl)-N-((4-((3-morphoIin-4- ylpropyl)amino)-3-nitrophenyl)sulfonyl)-2-(4-pyridin-4-ylphenoxy)benzamide 328 The title compound was prepared by substituting EXAMPLE 99D for EXAMPLE IF and EXAMPLE 4A for EXAMPLE IG in EXAMPLE IH. ^H NMR (400MHz, dimethylsulfoxide-de) 6 8.80 (d, 2H), 8.55 (m, IH), 8.49 (d, IH), 7.93 (m, 5H), 7.74 (m, IH), 7.53 (m, 5H), 7.36 (m, 3H), 7.13 (m, 2H), 6.93 (d, IH), 6.83 (dd, IH), 6.62 (d, IH), 4.60 (s, 4H), 4.29 (m, 2H), 3.67 (s, 4H), 3.42 (m, 4H), 3.13 (m, 4H), 2.92 (m, 4H), 1.90 (m, 2H). EXAMPLE 100 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-((3-niorpholin-4- ylpropyl)amino)-3-nitrophenyl)sulfonyl)-2-(4-pyridin-3-ylphenoxy)benzaniide EXAMPLE lOOA 3-(4-(benzyloxy)phenyl)pyridine The title compound was prepared by substituting l-(benzyloxy)-4-bromobenzene for EXAMPLE 33C and pyridin-3-ylboronic acid for 2,4-dimethyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)thiazole in EXAMPLE 33D. EXAMPLE lOOB 4-(pyridin-4-yl)phenol The title compound was prepared by substituting EXAMPLE lOOA for EXAMPLE 33A in EXAMPLE 33B. EXAMPLE lOOC methyl 4-(4-((4'-chlorobipheny l-2-yl)methyl)piperazin-1 -yl)-2-(4-(pyridin-4- yl)phenoxy)benzoate The title compound was prepared by substituting EXAMPLE lOOB for EXAMPLE ID in EXAMPLE IE. EXAMPLE lOOD 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-2-(4-(pyridin-4-yl)phenoxy)benzoic acid TTie title compound was prepared by substituting EXAMPLE lOOC for EXAMPLE IE in EXAMPLE IF. 329 EXAMPLE lOOE 4-(4-((4'-ch]oro-1,1 '-biphenyl-2-yl)methyl)piperazin- l-yl)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyI)-2-(4-pyridin-3-ylphenoxy)benzamide The title compound was prepared by substituting EXAMPLE lOOD for EXAMPLE IF and EXAMPLE 4A for EXAMPLE IG in EXAMPLE IH. 'H NMR (400MHz, dimethylsulfoxide-de) 8 U.84 (s, IH), 8.95 (d, IH), 8.66 (d, IH), 8.57 (m,, IH), 8.52 (d, IH), 8.24 (d, IH), 7.83 (dd, IH), 7.72 (m, 5H), 7.53 (m, 5H), 7.35 (m, 3H), 7.11 (m, IH), 6.93 (d, 2H), 6.81 (dd, IH), 6.57 (d, IH), 4.31 (s, 2H), 3.80 (m, 8H), 3.42 (m, 4H), 3.14 (m, 8H), 1.94(m,2H). EXAMPLE 101 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(4-(2-(dimethylamino)-2- oxoethoxy)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide EXAMPLE 101A 2-(4-(benzyloxy)phenoxy)-N,N-dimethylacetamide The title compound was prepared by substituting 2-chloro-N,N-dimethylacetamide for 2-chloro-N,N-dimethylethanamine and 4-(benzyloxy)phenol for 3-(benzyloxy)phenol in EXAMPLE 39A. EXAMPLE lOlB 2-(4-hydroxyphenoxy)-N,N-dimethylacetamide The title compound was prepared by substituting EXAMPLE 101A for EXAMPLE 39A in EXAMPLE 39B. EXAMPLE lOlC methyl 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)-2-(4-(2-(dimethylamino)-2- oxoethoxy)phenoxy)benzoate The title compound was prepared by substituting EXAMPLE 10IB for EXAMPLE ID in EXAMPLE IE. 330 EXAMPLE lOlD 4-(4.((4'.chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-2-(4-(2-(dimethylamino)-2- oxoethoxy)phenoxy)benzoic acid The title compound was prepared by substituting EXAMPLE lOlC for EXAMPLE IE in EXAMPLE IF. EXAMPLE lOlE 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin- l-yl)-2-(4-(2-(dimethylamino)-2-oxoethoxy)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 101D for EXAMPLE IF in EXAMPLE IH. 'H NMR (400MHZ, dimethylsulfoxide-de) 5 8.68 (t, IH), 8.57 (d, IH), 7.87 (dd, IH), 7.72 (s, IH), 7.53 (dd, 4H), 7.34 (m, 4H), 7.16 (d, IH), 6.84 (m, 4H), 6.71 (dd, IH), 6.34 (d, IH), 4.60 (s, 2H), 3.84 (d, 2H), 3.51 (s, lOH), 3.36 (m, 2H), 3.26 (m, 2H), 2.81 (d, 6H), 1.91 (s, IH), 1.62 (d, 2H), 1.28 (m, 2H). EXAMPLE 102 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(( 1 -methyl-1 H-benzimidazol-5- yl)oxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide EXAMPLE 102A methyl 4-bromo-2-(l-methyl-lH-benzo[d]imidazol-5-yloxy)benzoate 1-methyl-lH-benzo[d]imidazol-5-ol (296 mg), methyl 4-bromo-2-fluorobenzoate (311 mg) and potassium carbonate (553 mg) were combined in dimethylsulfoxide and heated to 90°C overnight. The reaction mixture was diluted with ethyl acetate and washed thoroughly with water and with brine, dried over MgS04, filtered and concentrated. EXAMPLE 102B methyl 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)-2-( 1 -methyl-1 H-benzo[d]imidazol-5-yloxy)benzoate EXAMPLE 102A (480 mg) and EXAMPLE IB (457 mg) were taken up in dimethoxyethane (7.5 mL) in a microwave vial. Tris(dibenzylideneacetone)dipalladium(0) (37 mg), 2-(di-tert-butylphoshpino)biphenyl (48 mg) and potassium phosphate tribasic (423 331 mg) were added. The vial was capped and heated in a CEM Discover microwave reactor for 30 minutes at 150°C. The crude reaction mixture was filtered through celite and concentrated. The material was dissolved in 1:1 dimethylsulfoxidermethanol and purified by HPLC. EXAMPLE 102C 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)-2-( 1 -methyl-lH-benzo[d]imidazol-5-yloxy)benzoic acid The tide compound was prepared by substituting EXAMPLE 102B for EXAMPLE IE in EXAMPLE IF. EXAMPLE 102D 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(( 1 -methyl-1 H-benzimidazol-5-yl)oxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide The tide compound was prepared by substituting EXAMPLE 102C for EXAMPLE IF and EXAMPLE 4A for EXAMPLE IG in EXAMPLE IH. 'H NMR (500MHZ, pyridine-ds) 6 9.34 (d, IH), 8.99 (t, IH), 8.91 (s, IH), 8.55 (s, IH), 8.48 (dd, IH), 7.94 (t, IH), 7.50 (m, 4H), 7.42 (m, 3H), 7.35 (m, 3H), 7.05 (s, IH), 7.02 (d, IH), 6.70 (m, 2H), 3.79 (t, 4H), 3.39 (s, 3H), 3.35 (m, 2H), 3.15 (m, 4H), 2.36 (m, 12H), 1.74 (m, 2H). EXAMPLE 103 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-(methylcarbamoyl)phenoxy)-N-(4- (3-morpholinopropylamino)-3-nitrophenylsulfonyl)benzamide EXAMPLE 103A methyl 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)-2-(3-(methylcarbamoyl)phenoxy)benzoate The title compound was prepared by substituting 3-hydroxy-N-methylbenzamide for EXAMPLE ID in EXAMPLE IE. EXAMPLE 103B 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-2-(3- (methylcarbamoyl)phenoxy)benzoic acid 332 The title compound was prepared by substituting EXAMPLE 103A for EXAMPLE IE in EXAMPLE IF. EXAMPLE 103C 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-(methylcarbamoyl)phenoxy)-N-(4-(3-morpholinopropylamino)-3-nitrophenylsulfonyl) benzamidebis(2,2,2-trifluoroacetate) The title compound was prepared by substituting EXAMPLE 103B for EXAMPLE 50F and EXAMPLE 4A for EXAMPLE 31 in EXAMPLE 50G. 'H NMR (300 MHz, dimethylsulfoxide-dfi) 6 11.79 (v br s, IH), 9.38 (v br s, IH), 8.65 (t, IH), 8.48 (d, IH), 8.37 (q, IH), 7.78 (dd, IH), 7.70 (br s, IH), 7.50 (m, 6H), 7.35 (m, 4H), 7.26 (s, IH), 7.11 (d, IH), 6.98 (dd, IH), 6.79 (dd, IH), 6.43 (s, IH), 4.35 (v br s, IH), 3.99 (br m, 2H), 3.70 (v br s, IH), 3.60, 3.50, 3.40 (all br m, total lOH), 3.20, 310, 2.80 (all br s, total 8H), 2.79, 2.77 (both s, total 3H), 1.99 (m,2H). EXAMPLE 104 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-N-(4-(3-(dimethylamino)propylamino)-3-nitrophenylsulfonyl)-2-(3-(raethylcarbamoyl)phenoxy)benzamide The title compound was prepared by substituting EXAMPLE 103B for EXAMPLE 50F and EXAMPLE 11A for EXAMPLE 31 in EXAMPLE 50G. 'H NMR (500 MHz, dimethylsulfoxide-de) 5 11.79 (v br s, IH), 9.38 (v br s, IH), 8.65 (t, IH), 8.48 (d, IH), 8.37 (q, IH), 7.78 (dd, IH), 7.70 (br s, IH), 7.50 (m, 6H), 7.39 (m, 2H), 7.31 (m, 2H), 7.26 (s, IH), 7.11 (d, IH), 6.98 (dd, IH), 6.79 (dd, IH), 6.43 (s, IH), 4.35 (v br s, IH), 3.80 (v br s, IH), 3.50, (br m, 8H), 3.10, 3.05 (m, br s, 4H), 2.81,2.80 (both s, 6H), 2.78,2.77 (both s, 3H), 1.96(m,2H). EXAMPLE 105 4-(4-((4'-chloro-1,1'-biphenyl-2-yl)methyl)piperazin-1-yI)-2-(3-(2-(dimethylamino)-2- oxoethoxy)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide EXAMPLE 105A 2-(3-(benzyloxy)phenoxy)-N,N-dimethylacetamide 333 The title compound was prepared by substituting 2-chloro-N,N-dimethylacetamide for 2-chloro-N,N-dimethylethanamine in EXAMPLE 39A. EXAMPLE 105B 2-(3-hydroxyphenoxy)-N,N-dimethylacetamide The title compound was prepared by substituting EXAMPLE 105A for EXAMPLE 39A in EXAMPLE 39B. EXAMPLE 105C methyl 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)-2-(3-(2-(dimethylamino)-2- oxoethoxy)phenoxy)benzoate The title compound was prepared by substituting EXAMPLE 105B for EXAMPLE ID in EXAMPLE IE. EXAMPLE 105D 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-(2-(dimethylamino)-2- oxoethoxy)phenoxy)benzoic acid The title compound was prepared by substituting EXAMPLE 105C for EXAMPLE IE in EXAMPLE IF. EXAMPLE 105E 4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-(2-(dimethylamino)-2- oxoethoxy)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 105D for EXAMPLE IF in EXAMPLE IH. 'H NMR (400MHz, dimethylsulfoxide-dg) 5 8.66 (d, IH), 8.54 (d, IH), 7.84 (dd, IH), 7.72 (s, IH), 7.51 (m, 5H), 7.35 (m, 3H), 7.28 (t, IH), 7.16 (dd, 2H), 6.75 (dd, IH), 6.46 (m, 3H), 4.60 (s, 2H), 3.83 (d, 2H), 3.48 (s, lOH), 3.34 (m, 2H), 3.24 (m, 2H), 2.78 (s, 6H), 1.89 (s, IH), 1.60 (d, 2H), 1.26 (m, 2H). 334 EXAMPLE 106 4.(4.((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-((3-(3-(dimethylamino)propyl)- lH-indol-5-yl)oxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)anuno)phenyl)sulfonyl)benzamide EXAMPLE 106A (Z)-tert-butyl 5-(benzyloxy)-3-(3-(dimethylamino)-3-oxoprop- 1-enyl)-IH-indole-1 - carboxylate The title compound was prepared by substituting N,N-dimethylacrylamide for 1-morpholinoprop-2-en-l-one in EXAMPLE 70A. EXAMPLE 106B tert-butyl3-(3-(dimethylamino)-3-oxopropyl)-5-hydroxy-lH-indole-l-caiboxylate The title compound was prepared by substituting EXAMPLE 106A for EXAMPLE 39A in EXAMPLE 39B. EXAMPLE 106C tert-butyl5-(5-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-2-(methoxycarbonyl)phenoxy)-3-(3-(dimethylamino)-3-oxopropyl)-lH-indole-l-carboxylate The title compound was prepared by substituting EXAMPLE 106B for EXAMPLE ID in EXAMPLE IE. EXAMPLE 106D methyl 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-(3-(dimethylamino)propyl)-lH-indol-5-yloxy)benzoate The title compound was prepared by substituting EXAMPLE 106C for EXAMPLE 70C in EXAMPLE 74A. EXAMPLE 106E 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-(3-(dimethylamino)propyl)-lH- indol-5-yloxy)benzoic acid The title compound was prepared by substituting EXAMPLE 106D for EXAMPLE IE in EXAMPLE IF. 335 EXAMPLE 106F 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-((3-(3-(dimethylamino)propyl)-lH-indol-5-yl)oxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzaniide The title compound was prepared by substituting EXAMPLE 106E for EXAMPLE IF in EXAMPLE IH. 'H NMR (400MHZ, dimethylsulfoxide-d^) 6 10.97 (d, IH), 9.34 (s, IH), 8.61 (m, 2H), 7.86 (dd, IH), 7.54-7.36(m, 8H), 7.22 (m, 4H), 6.86 (m, IH), 6.67 (dd, IH), 6.16 (d, IH), 3.83 (m, 2H), 3.34-3.24 (m, 8H), 3.07 (m, 6H), 2.76 (s, 6H), 2.67 (m, 2H), 1.95 (m, 3H), 1.65 (m, 2H), 1.29 (m, 4H), 0.88 (m, 2H). EXAMPLE 107 4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-((3-(dimethylamino)propyl)amino)-3-nitrophenyl)sulfonyl)-2-(3-(hydioxymethyl)phenoxy)benzainide The title compound was prepared by substituting EXAMPLE 9A for EXAMPLE 50F and EXAMPLE 11A for EXAMPLE 31 in EXAMPLE 50G. 'H NMR (400 MHz, dimethylsulfoxide-de) 6 11.60 (v br s, IH), 9.40 (v br s, IH), 8.76 (t, IH), 8.51 (d, IH), 7.80 (dd, IH), 7.65 (br s, IH), 7.50 (m, 5H), 7.40 (m, 2H),7.30 (br s, IH), 7.20 (dd, IH), 7.16 (d, IH), 6.96 (d, IH), 6.82 (s, IH), 6.65 (d, IH), 6.60 (d, IH), 6.40 (s, IH), 4.41 (s, 2H), 3.55 (m 4H), 3.40 (m, 6H), 3.13 (m, 4H), 2.80, 2.79 (both s, total 6H), 1.98 (m, 2H). EXAMPLE 108 4-(4-((4'-chloro-1,1 ■-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-((4-methoxybenzyl)oxy)-N-((3- nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide EXAMPLE 108A 4-Fluoro-2-(4-methoxy-benzyloxy)-benzoic acid methyl ester Methyl 4-fluoro-2-hydroxybenzoate (1661 mg) was added to N,N-dimethylformamide (50 mL). Sodium hydride (60% in mineral oil, 430 mg) was added, the solution stirred for 15 minutes at room temperature, and l-(bromomethyl)-4-methoxybenzene (2061 mg) was added. The solution was stirred at room temperature for three days, added to O.OIM aqueous HCl, and extracted with ethyl acetate. The organic phase was washed with water twice, 336 washed with brine, and dried over anhydrous sodium sulfate. After filtration, the solvent was removed under vacuum. EXAMPLE 108B 4-[4-(4'-Chloro-biphenyl-2-ylmediyl)-piperazin-1 -yl]-2-(4-methoxy-benzyloxy)-benzoic acid methyl ester The title compound was prepared by substituting EXAMPLE 108A for methyl 2-bromo-4-fluorobenzoate in EXAMPLE IC. EXAMPLE 108C 4-[4-(4'-Chloro-biphenyl-2-ylmethyl)-piperazin-1 -yl]-2-(4-methoxy-benzyloxy)-benzoic acid The title compound was prepared by substituting EXAMPLE 108B for EXAMPLE IE in EXAMPLE IF. EXAMPLE 108D 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-((4-methoxybenzyl)oxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 108C for EXAMPLE IF in EXAMPLE IH. 'H NMR (300MHZ, dimethylsulfoxide-de) 5 10.79 (br s, IH), 8.65 (t, IH), 8.58 (d, IH), 7.82 (dd, IH), 7.53-7.41 (m, 7H), 7.38 (m, 2H), 7.27-7.19 (m, 2H), 6.98 (d, 2H), 6.69 (br s, IH), 6.55 (dd, IH), 5.16 (s, 2H), 3.84 (dd, 2H), 3.78 (s, 3H), 3.40 (s, 2H), 3.37-3.32 (m, 8H), 2.38 (m, 4H), 1.90 (m, IH), 1.62 (dd, 2H), 1.26 (m, 2H). EXAMPLE 109 ^-[(4-{[(4-aminotetrahydro-2//-pyran-4-yl)methyl]amino}-3-nitK)phenyl)sulfonyl]-2-(3- chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1- yljmethyl} piperazin-1-yl)benzamide EXAMPLE 109A 4-((4-aminotetrahydro-2H-pyran-4-yl)methylamino)-3-nitrobenzenesulfonamide A mixture of 4-chloro-3-nitrobenzenesulfonamide, 4-(aminomethyl)tetrahydro-2H-pyran-4-amine, hydrochloric acid and triethylamine in dioxane (10 mL) was heated at 110°C overnight. After cooling, the mixture was diluted with water (10 mL), and filtered. 337 EXAMPLE 109B N-(4-((4-aminotetrahydro-2H-pyran-4-yl)methylamino)-3-nitix)phenylsulfonyl)-2-(3- chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l- yl)benzamide This example was prepared by substituting EXAMPLE 6B for EXAMPLE IF and EXAMPLE 109A for EXAMPLE IG in EXAMPLE IH. 'H NMR (500MHZ, DMSO-dg) 8 8.41 (s, IH), 8.35 (d, J = L83 Hz, IH), 7.70 (dd, J = 9.0, L98 Hz, IH), 7.64(d, J = 8.85 Hz, IH), 7.36 (d, J = 8.54 Hz, 2H), 7.11-7.18 (m, 2H), 7.07 (d, J = 8.24 Hz, 2H), 6.91 (dd, J = 7.93, 1.22 Hz, IH), 6.77 (dd, J = 8.85, 2.14 Hz, IH), 6.65 (dd, J = 8.09,1.98 Hz, IH), 6.61-6.62 (m, IH), 6.38 (d, J = 2.14 Hz, IH), 3.67-3.71 (m, 6H), 3.11 (m, 3H), 2.77 (s, 2H), 2.18-2.24 (m, 6H), 1.97-1.99 (m, 2H), 1.76-1.79 (m, 2H), 1.65-1.67 (m, 2H), 1.39-1.42 (m, 2H), 0.94 (s, 6H). EXAMPLE 110 4- {4-[ l-(4'-chloro-1, r-biphenyl-2-yl)ethyl]piperazin-1 -yl) -2-(2-chlorophenoxy)-N-( {3-nitro- 4-[(tetrahydro-2f?-pyran-4-ylmethyl)aniino]phenyl} sulfonyl)benzamide EXAMPLE llOA l-(4'-chlorobiphenyl-2-yl)ethanone A mixture of l-(2-bromophenyl)ethanone (3.1 g) 4-chloiDphenylboronic acid (2.92 g), bis(triphenylphosphine)palladium(n) dichloride (1.202 g) and NaaCOs (3.30 g) in 7:2:3 dimethoxyethane/ethanol/water (50 mL) was heated at 100°C for 3 hours and concentrated. The concentrate was suspended in dichloromethane (30 mL) and filtered. The filtrate was loaded onto a silica gel column and flash chromatographed with 0%-50% dichloromethane/hexane. EXAMPLE HOB tert-butyl4-(l-(4'-chlorobiphenyl-2-yl)ethyl)piperazine-l-carboxylate A mixture of EXAMPLE 1 lOA (1.9 g) in dichloromethane (3 mL) was treated with IM titanium(rV) chloride in dichloromethane (9.06 mL), cooled to 0°C, treated with tert-butyl piperazine-1-carboxylate (3.07 g), stirred at ambient temperature for 3 hours, treated with NaCNBHs (0.828 g) in methanol (5 ml), stirred at room temperature overnight, 338 neutralized with aqueous NaOH and concentrated. The concentrate was treated with ethyl acetate and filtered. The organic filtrate was washed with water and concentrated. The concentrate was dissolved in methanol/trifluoroacetic acid/dimethylsulfoxide, loaded onto a reverse phase CI8 column and eluted with 0-80% acetonitrile in 0.1% trifluoroacetic acid water over 70 minutes. EXAMPLE HOC 1 -(1 -(4'-chlorobiphenyl-2-yl)ethyl)piperazine To a solution of EXAMPLE HOB (650 mg) in dichloromethane (6 mL) at 0°C was added trifluoroacetic acid (6 mL). The mixture was stirred at 0°C for 50 minutes and concentrated. The concentrate was dissolved in dichloromethane, washed with aqueous NaHCOg and dried over Na2S04, filtered and concentrated. EXAMPLE HOD ethyl 4-(4-( 1 -(4'-chlorobiphenyl-2-yl)ethyl)piperazin-1 -yl)-2-(2-chlorophenoxy)benzoate EXAMPLE HOC (252 mg) and ethyl 2-(2-chlorophenoxy)-4-fluorobenzoate (272 mg) in dimethylsulfoxide (15 mL) was treated with potassium hydrogenphosphate (219 mg), stirred at 135°C overnight, cooled, diluted with dichloromethane, washed with water and concentrated. The concentrate was dissolved in dichloromethane, loaded onto a silica gel column and eluted with 5% lOM ammonia methanol in dichloromethane. EXAMPLE HOE 4-(4-(l-(4'-chlorobiphenyl-2-yl)ethyl)piperazin-l-yl)-2-(2-chlorophenoxy)benzoicacid A mixture of EXAMPLE 1 lOD (300 mg) in tetrahydrofiiran (10 mL) and methanol (10 mL) at 50°C was treated with 10% NaOH (2085 )uL), stirred overnight, neutralized with HCl and concentrated. The concentrate was taken up in water and extracted with dichloromethane. The organic layer was dried over Na2S04, filtered and concentrated. EXAMPLE HOP 4- {4- [ 1 -(4'-chloro-1,1 '-biphenyl-2-yl)ethyl]piperazin-1 -yl} -2-(2-chlorophenoxy)-A^-( {3 -nitro- 4- [(tetrahydro-2W-pyran-4-ylmethyl)amino]phenyl} sulfonyl)benzamide To a mixture of EXAMPLE 1 lOE (65mg), Example IG (74.9 mg) and 4- dimethylaminopyridine (58 mg) in dichloromethane (5 mL) was added l-ethyl-3-[3- (dimethylamino)propyl]-carbodiimide hydrochloride (45.5 mg). The mixture was stirred at 339 ambient temperature overnight and concentrated. The concentrate was purified by RP HPLC (10-70% acetonitrile in 0.1% trifluoroacetic acid water / 70 min). Fractions containing product were concentrated, and the concentrate was diluted with dichloromethane, neutralized with aqueous NaHCOj, dried over Na2S04, filtered, and concentrated. 'H NMR (500 MHz, DMSO-de) 8 11.58 (s, IH), 8.64 (t, IH), 8.47 (d, IH), 7.78 (dd, IH), 7.56 (d, IH), 7.45-7.52 (m, 3H), 7.38-7.43 (m, 2H), 7.27-7.33 (m, 3H), 7.11-7.19 (m, 3H), 6.99 (t, IH), 6.70-6.77 (m, 2H), 6.28 (d, IH), 3.86 (dd, 2H), 3.33-3.37 (m, IH), 3.24-3.31 (m, 4H), 3.12 (s, 4H), 2.33-2.47 (m, 2H), 2.20-2.31 (m, 2H), 1.85-1.96 (m, IH), 1.64 (d, 2H), 1.17-1.33 (m, 5H). EXAMPLE 111 N- {[4- {4-[(4'-chloiD-1, l'-biphenyl-2-yl)methyl]piperazin- 1-yl} -2-(3,5- dichlorophenoxy)phenyl]sulfonyl}-4-[(l-methylpiperidin-4-yl)amino]-3-nitrobenzamide EXAMPLE 11 lA 4-( 1 -methylpiperidin-4-ylamino)-3-nitrobenzoic acid To a solution of ethyl 4-fluoro-3-nitrobenzoate (2.13 g) and l-methylpiperidin-4-amine (1.14 g) in tetrahydrofuran (40 mL) was added N,N-diisopropylethylamine (5 mL). The mixture was then stirred at reflux overnight. The solvent was evaporated and the residue was dissolved in ethyl acetate (300 mL) and washed with aqueous NaHCOs, water and brine. After evaporation of the solvent, the residue was dissolved in tetrahydrofuran (20 mL), methanol (10 mL) and water (10 mL). Then, LiOH H2O (2 g) was added. The mixture was stirred at room temperature overnight. The mixture was then concentrated and the residue was neutralized with 5% aqueous HCl. The precipitate was filtered, washed with brine, and dried under vacuum to give the product. EXAMPLE 11 IB 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-2-fluorobenzenesulfonamide To a solution of 2,4-difluorobenzenesulfonamide (1.56 g) and l-((4'-chlorobiphenyl-2-yl)methyl)piperazine (2.32 g) in dimethylsulfoxide (20 mL) was added N,N- diisopropylethylamine (5 mL). The mixture was stirred at 120^C overnight. The mixture was diluted with ethyl acetate (300 mL) and washed with water (3x) brine and dried over Na2S04. 340 After filtration and evaporation of the solvent, the residue was loaded on a column and eluted with 40% ethyl acetate in hexane to give the title compound. EXAMPLE 11IC N-(4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)-2-fluorophenylsulfonyl)-4-( 1- methylpiperidin-4-ylamino)-3-nitrobenzamide The title compound was prepared as described in EXAMPLE IG by replacing EXAMPLE IE and EXAMPLE IF with EXAMPLE lllA and EXAMPLE lllB, respectively. EXAMPLE HID N- {[4- {4-[(4'-chloro-1, r-biphenyl-2-yl)methyl]piperazin-1 -yl} -2-(3,5- dichlorophenoxy)phenyl]sulfonyl} -4-[( 1 -methy lpiperidin-4-yl)amino]-3 -nitrobenzamide To a solution of 3,5-dichlorophenol (81 mg) and EXAMPLE 11IC (72 mg) in diglyme (3 mL) was added K2HPO4 (53 mg). The mixture was stined at 2(X)°C in a CEM Discover microwave reactor for 2 hours. The mixture was filtered and purified by RP HPLC (10-70% acetonitrile in 0.1% trifluoroacetic acid water / 70 min). Fractions containing product were concentrated, and the concentrate was diluted with dichloromethane, neutralized with aqueous NaHCO?, dried over Na2S04, filtered, and concentrated. 'H NMR (300 MHz, dimethylsulfoxide-dfi) 6 8.56 (d, IH), 8.12 (d, IH), 7.94 (m, IH), 7.84 (m, 2H), 7.51 (m, 5H), 7.36 (m, 4H), 7.17 (d, IH), 7.05 (m, IH), 6.94 (m, IH), 6.71 (m, IH), 4.36 (m, IH), 3.92 (m, 2H), 3.15 (m, 4H), 2.79 (m, 6H), 2.22 (m, 8H), 1.29 (m, 2H). EXAMPLE 112 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(3- fluorophenoxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)benzamide EXAMPLE 112A ethyl 4-fluoro-2-(3-fluorophenoxy)benzoate The title compound was prepared by substituting 3-fluorophenol for 2-methyl-5-indolol in EXAMPLE 3A. 341 EXAMPLE 112B ethyl 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)-2-(3 - fluorophenoxy)benzoate The title compound was prepared by substituting EXAMPLE 112A for EXAMPLE 3A in EXAMPLE 3G. EXAMPLE 112C 4-(4-((2-(4-chlorophenyl)-4,4-dimethy]cyclohex-l-enyl)methyl)piperazin-l-yl)-2-(3- fluorophenoxy)benzoic acid The title compound was prepared by substituting EXAMPLE 112B for EXAMPLE IE in EXAMPLE IF. EXAMPLE 112D 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl )piperazin-1 -yl)-2-(3-fluorophenoxy)-N-( {4- [(1 -methylpiperidin-4-yl)amino]-3 -nitrophenyl ] sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 112C for EXAMPLE IF and EXAMPLE 31 for EXAMPLE IG in EXAMPLE IH. *H NMR (500MHz, dimethylsulfoxide-dfi) 5 8.34 (d, IH), 8.08 (d, IH), 7.69 (dd, IH), 7.60 (d, IH), 7.36 (d, 2H), 7.14 (m, IH), 7.06 (d, 2H), 7.03 (d, IH), 6.72 (dd, IH), 6.65 (m, IH), 6.49 (dd, IH), 6.41 (m, 2H), 3.81 (m, IH), 3.22 (m, 2H), 3.11 (m, 4H), 2.88 (m, 2H), 2.77 (m, 2H), 2.64 (s, 3H), 2.22 (m, 6H), 2.10 (m, 2H), 1.98 (m, 2H), 1.79 (m, 2H), 1.40 (m, 2H), 0.94 (s, 6H). EXAMPLE 113 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl }piperazin-1 -yl)-2-(3-fluoK)phenoxy)-N-({3-nitro-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]phenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 112C for EXAMPLE IF and EXAMPLE 49C for EXAMPLE 10 in EXAMPLE IH. 'H NMR (500MHz, dimethylsulfoxide -de) 5 8.34 (d, IH), 8.10 (d, IH), 7.67 (dd, IH), 7.60 (d, IH), 7.36 (d, 2H), 7.14 (m, IH), 7.06 (d, 2H), 7.01 (d, IH), 6.72 (dd, IH), 6.65 (m, IH), 6.49 (dd, IH), 6.41 (m, 2H), 3.93 (dd, 2H), 3.77 (br s, 2H), 3.30 (m, 2H), 3.10 (m, 6H), 2.77 (s, 2H), 2.69 (m, 2H), 2.24 (m, 4H), 2.18 (t, 2H), 2.06 (d, 2H), 1.98 (s, 2H), 1.80 (d, 2H), 1.68 (m, 2H), 1.52 (m, 2H), 1.41 (t,2H), 0.94 (s,6H). 342 EXAMPLE 114 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-(3- fluorophenoxy)-N-( {4- [(3-morpholin-4-ylpropyl)aniino] -3-nitropheny]} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 112C for EXAMPLE IF and EXAMPLE 4A for EXAMPLE IG in EXAMPLE IH. 'H NMR (500MHZ, dimethylsulfoxide -dg) 5 8.74 (br m, IH), 8.43 (d, IH), 7.73 (dd, IH), 7.52 (d, IH), 7.35 (m, 2H), 7.19 (m, IH), 7.06 (m, 3H), 6.73 (m, 2H), 6.50 (m, 2H), 6.44 (d, IH), 3.64 (t, 4H), 3.45 (m, 2H), 3.18 (m, 5H), 2.79 (m, 2H), 2.58 (m, 3H), 2.22 (m, 7H), 1.98 (m, 3H), 1.83 (m, 2H), 1.41 (m, 2H), 0.94 (s, 6H). EXAMPLE 115 2-(2-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl jpiperazin-1 -y l)-N-( {3 -nitro-4- [(1 -tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]phenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 34C for EXAMPLE IF and EXAMPLE 49C for EXAMPLE IG in EXAMPLE IH. 'H NMR (400MHz, dimethylsulfoxide-de) 5 8.33 (d, IH), 8.09 (s, IH), 7.70 (d, IH), 7.63 (d, IH), 7.34 (m, 3H), 7.03 (m, 4H), 6.87 (t, IH), 6.69 (m, IH), 6.50 (d, IH), 6.25 (d, IH), 3.91 (d, 2H), 3.57 (s, 4H), 3.30 (m, 6H), 3.06 (s, 4H), 2.20 (d, 6H), 1.96 (d, 4H), 1.73 (s, 2H), 1.63 (s, 2H), 1.48 (s, 2H), 1.40 (t,2H), 0.94 (s,6H). EXAMPLE 116 2-(2-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-l-yl)-N-({4-[(3-morpholin-4-ylpropyl)amino]-3-nitrophenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 34C for EXAMPLE IF and EXAMPLE 4A for EXAMPLE IG in EXAMPLE IH. 'H NMR (400MHz, dimethylsulfoxide-dfi) 6 8.70 (t, IH), 8.44 (d, IH), 7.77 (dd, IH), 7.54 (d, IH), 7.40 (dd, IH), 7.35 (m, 2H), 7.12 (m, IH), 7.06 (m, 3H), 6.98 (td, IH), 6.73 (dd, IH), 6.68 (dd, IH), 6.26 (d, IH), 4.62 (s, 2H), 3.62 (m, 4H), 3.46 (dd, 2H), 3.11 (s, 4H), 2.75 (d, 2H), 2.47 (m, 4H), 2.20 (d, 6H), 1.97 (s, 2H), 1.82 (p, 2H), 1.40 (t, 2H), 0.94 (s, 6H). 343 EXAMPLE 117 2-(2-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({4-[(I-cyclopentylpiperidin-4-yl)amino]-3- nitiophenyl) sulfonyl)benzamide EXAMPLE 117A 4-(l-cyclopentylpiperidin-4-ylamino)-3-nitrobenzenesulfonamide The title compound was prepared by substituting l-cyclopentylpiperidin-4-amine for 3-(N-morpholinyl)-l-propylamine in EXAMPLE 4A. EXAMPLE 117B 2-(2-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-diraethylcyclohex-1 -en-1 -yl]methyl}piperazin-l-yl)-N-({4-[(l-cyclopentylpiperidin-4-yl)amino]-3-nitrophenyl) sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 34C for EXAMPLE IF and EXAMPLE 117A for EXAMPLE IG in EXAMPLE IH. 'H NMR (400MHZ, dimethylsulfoxide-de) 6 8.35 (d, IH), 8.06 (d, IH), 7.73 (dd, IH), 7.63 (d, IH), 7.35 (m, 3H), 7.04 (m, 4H), 6.88 (td, IH), 6.69 (dd, IH), 6.53 (dd, IH), 6.25 (d, IH), 4.57 (s, IH), 3.29 (s, 8H), 3.05 (d, 4H), 2.75 (s, 2H), 2.62 (s, 2H), 2.20 (d, 5H), 2.07 (s, IH), 1.95 (d, 3H), 1.66 (s, 3H), 1.53 (s, 3H), 1.40 (t, 2H), 0.94 (s, 6H). EXAMPLE 118 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl }piperazin-1 -yl)-2-(4- fluorophenoxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitrophenyl)sulfonyl)benzamide EXAMPLE 118A ethyl 4-fluoro-2-(4-fluorophenoxy)benzoate The title compound was prepared by substituting 4-fluorophenol for 2-methyl-5-indolol in EXAMPLE 3A. EXAMPLE 118B ethyl 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-2-(4- fluorophenoxy)benzoate 344 The title compound was prepared by substituting EXAMPLE 118A for EXAMPLE 3A in EXAMPLE 3G. EXAMPLE 118C 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-2-(4- nuorophenoxy)benzoic acid The title compound was prepared by substituting EXAMPLE 118B for EXAMPLE IE in EXAMPLE IF. EXAMPLE USD 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-(4- fluorophenoxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitrophenyl)sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 118C for EXAMPLE IF and EXAMPLE 31 for EXAMPLE IG in EXAMPLE IH. 'H NMR (500MHZ, dimethylsulfoxide -dg) 5 8.39 (d, IH), 8.08 (d, IH), 7.75 (dd, IH), 7.55 (d, IH), 7.36 (d, 2H), 7.06 (m, 3H), 6.98 (m, 2H), 6.73 (m, 2H), 6.67 (dd, IH), 6.29 (d, IH), 3.82 (m, IH), 3.18 (m, 2H), 3.08 (m, 4H), 2.80 (m, 4H), 2.60 (m, 3H), 2.22 (m, 6H), 2.07 (m, 2H), 1.97 (m, 2H), 1.77 (m, 2H), 1.40 (m, 2H), 0.94 (s, 6H). EXAMPLE 119 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-N-( {4- [(1 -cyclopropylpiperidin-4-yl)amino]-3 -nitrophenyl} sulfonyl)benzamide The title compound was prepared as described in EXAMPLE IH by replacing EXAMPLE IF and EXAMPLE 10 with EXAMPLE 36C and EXAMPLE 65A, respectively. 'H NMR (300 MHz, dimethylsulfoxide-dg) 6 8.35 (d, IH), 8.17 (d, IH), 7.66 (dd, IH), 7.58 (d, IH), 7.36 (d, 2H), 7.15 (t, IH), 7.05 (m, 3H), 6.88 (d, IH), 6.74 (dd, IH), 6.64 (m, 2H), 6.41 (d, IH), 3.69 (m, IH), 3.16 (m, 4H), 2.97 (m, 4H), 2.77 (m, 2H), 2.72 (s, 2H), 2.44 (m, 3H), 2.21 (m, 3H), 1.96 (m, 2H), 1.58 (m, 3H), 0.94 (s, 6H), 0.40 (m, 5H). 345 EXAMPLE 120 2-(2-chloro-4-fluorophenoxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yljmethyl} piperazin-1 -yl)-N-( {4- [(3 -morpholin-4-ylpropyl)amino]-3 -nitrophenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 6ID for EXAMPLE IF and EXAMPLE 4A for EXAMPLE IG in EXAMPLE IH. 'H NMR (400 MHz, dimethylsulfoxide-dfi) 5 8.73 (m, IH), 8.48 (d, IH), 7.80 (dd, IH), 7.51 (d, IH), 7.36 (m, 3H), 7.07 (m, 4H), 6.75 (m, 2H), 6.25 (d, IH), 3.63 (m, 4H), 3.47 (m, 2H), 3.12 (m, 4H), 2.77 (s, 2H), 2.21 (m, 6H), 1.97 (s, 2H), 1.82 (m, 2H), 1.41 (t, 2H), 0.94 (s, 6H). EXAMPLE 121 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-({4-[(l-cyclopropylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(2,3-difluorophenoxy)benzamide The title compound was prepared by substituting EXAMPLE 45C for EXAMPLE IF and EXAMPLE 65A for EXAMPLE IG in EXAMPLE IH. 'H NMR (400 MHz, dimethylsulfoxide-de) 8 8.42 (d, IH), 8.21 (d, IH), 7.77 (dd, IH), 7.54 (d, IH), 7.35 (d, 2H), 7.15 (d, IH), 7.06 (d, 2H), 6.89 (m, 2H), 6.75 (dd, IH), 6.44 (m, 2H), 3.76 (m, IH), 3.17 (m, 4H), 3.00 (m, 2H), 2.81 (s, 2H), 2.59 (m, 2H), 2.24 (m, 6H), 1.92 (m, 5H), 1.61 (m, 2H), 1.41 (t, 2H), 0.94 (s, 6H), 0.46 (m, 4H). EXAMPLE 122 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl ]piperazin-1 -yl)-2-(2- fluorophenoxy)-N-( {4- [(1 -methylpiperidin-4-yl)amino]-3-nitrophenyl} sulfonyl)benzamide EXAMPLE 122A methyl 4-fluoro-2-(2-fluorophenoxy)benzoate The title compound was prepared by substituting 2-fluorophenol for 2-methyl-5-indolol in EXAMPLE 3A. EXAMPLE 122B methyl 4-(4-((2-(4-chlorophenyl)-4,4-dimethy]cyclohex-1 -enyl)methyl)piperazin-1 -yl)-2-(2- fluorophenoxy)benzoate 346 The title compound was prepared by substituting EXAMPLE 122A for EXAMPLE 3A in EXAMPLE 3G. EXAMPLE 122C 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-2-(2- fluorophenoxy)benzoic acid The title compound was prepared by substituting EXAMPLE 122B for EXAMPLE IE in EXAMPLE IF. EXAMPLE 122D 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl Jpiperazin-1 -yl)-2-(2- fluorophenoxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 122C for EXAMPLE IF and EXAMPLE 31 for EXAMPLE IG in EXAMPLE IH. 'H NMR (400MHZ, dimethylsulfoxide-dfi) 5 11.87 (s, IH), 9.54 (s, IH), 8.50 (d, IH), 8.20 (d, IH), 7.86 (dd, IH), 7.52 (d, IH), 7.40 (d, 2H), 7.24 (m, 2H), 7.10 (d, 2H), 7.03 (m, 2H), 6.78 (m, 2H), 6.42 (s, IH), 3.62 (m, lOH), 3.10 (m, 4H), 2.82 (m, 2H), 2.82 (s, 3H), 2.21 (m, 4H), 2.03 (s, 2H), 1.85 (m, IH), 1.46 (t, 2H), 0.96 (s, 6H). EXAMPLE 123 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-({4-[(l-cyclopropylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(2-fluorophenoxy)benzamide The title compound was prepared by substituting EXAMPLE 122C for EXAMPLE IF and EXAMPLE 65A for EXAMPLE IG in EXAMPLE IH. 'H NMR (400MHz, dimethylsulfoxide-de) 5 8.51 (d, IH), 8.19 (s, IH), 7.87 (dd, IH), 7.53 (d, IH), 7.40 (d, 2H), 7.24 (m, 2H), 7.11 (d, 2H), 7.03 (m, 2H), 6.78 (m, 2H), 6.43 (d, IH), 3.97 (m, 4H), 3.21 (s, 8H), 3.21 (s, 4H), 2.83 (m, 4H), 2.-22 (m, 4H), 2.06 (m, 2H), 1.81 (m, IH), 1.47 (t, 2H), 0.96 (s, 6H). 347 EXAMPLE 124 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-(2-fluorophenoxy)-N-( {3 -nitro-4- [(1 -tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]phenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 122C for EXAMPLE IF and EXAMPLE 49C for EXAMPLE IG in EXAMPLE IH. 'H NMR (400MHz, dimethylsulfoxide-dfi) 5 11.90 (s, IH), 9.59 (s, IH), 8.51 (m, IH), 8.20 (d, IH), 7.87 (dd, IH), 7.53 (d, IH), 7.39 (d, 2H), 7.24 (m, 2H), 7.10 (d, 2H), 7.03 (m, 2H), 6.78 (m, 2H), 6.42 (s, IH), 4.01 (m, 2H), 3.71 (m, 4H), 3.34 (m, 6H), 3.17 (m, 4H), 2.78 (m, 2H), 2.24 (m, 4H), 1.94 (m, 8H), 1.70 (m, 2H), 1.46 (t, 2H), 0.96 (s, 6H). EXAMPLE 125 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl )piperazin-1 -y])-2-(2- fluorophenoxy)-N-({4-[(3-morpholin-4-ylpropyI)amino]-3-nitrophenyI}sulfonyI)benzamide The title compound was prepared by substituting EXAMPLE 122C for EXAMPLE IF and EXAMPLE 4A for EXAMPLE IG in EXAMPLE IH. 'H NMR (400MHz, dimethylsulfoxide-dfi) 6 11.85 (s, IH), 9.94 (s, IH), 9.63 (s, IH), 8.71 (m, IH), 8.53 (d, IH), 7.86 (dd, IH), 7.53 (d, IH), 7.40 (d, 2H), 7.26 (m, IH), 7.19 (d, IH), 7.07 (m, 4H), 6.80 (m, 2H), 6.41 (d, IH), 3.97 (m, 2H), 3.54 (m, 6H), 3.31 (m, 4H), 3.19 (m, 8H), 2.22 (m, 2H), 1.99 (m, 4H), 1.47 (t, 2H), 0.97 (s, 6H). EXAMPLE 126 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-(2- fluorophenoxy)-N-({4-[(2-morpholin-4-ylethyl)amino]-3-nitrophenyl}sulfonyl)benzamide EXAMPLE 126A 4-(2-morpholinoethylamino)-3-nitrobenzenesulfonamide The title compound was prepared by substituting 2-(N-morpholinyl)-2-ethylamine for 3-(N-morpholinyl)-l-propylamine in EXAMPLE 4A. EXAMPLE 126B 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl Jpiperazin-1 -yl)-2-(2- fluorophenoxy)-N-({4-[(2-morpholin-4-ylethyl)amino]-3-nitrophenyI}suIfonyl)benzamide 348 The title compound was prepared by substituting EXAMPLE 122C for EXAMPLE IF and EXAMPLE 126A for EXAMPLE IG in EXAMPLE IH. 'H NMR (400MHZ, dimethylsulfoxide-de) 5 8.81 (s, IH), 8.50 (d, IH), 7.82 (dd, IH), 7.50 (d, IH), 7.36 (d, 2H), 7.23 (m, IH), 7.04 (m, 5H), 6.79 (m, IH), 6.73 (dd, IH), 6.31 (d, IH), 3.62 (m, 4H), 3.50 (q,, 2H), 3.32 (m, 6H), 3.14 (m, 4H), 2.79 (s, 2H), 2.67 (m, 2H), 2.20 (m, 6H), 1.99 (m, 2H), 1.40 (t, 2H), 0.94 (s, 6H). EXAMPLE 127 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-N-( {3-nitro-4-[(l -tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]phenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 36C for EXAMPLE IF and EXAMPLE 49C for EXAMPLE IG in EXAMPLE IH. 'H NMR (400MHz, dimethylsulfoxide-de) 8 8.38 (m, IH), 8.13 (m, IH), 7.70 (m, IH), 7.59 (m, IH), 7.36 (d, 2H), 7.16 (m, IH), 7.05 (m, 3H), 6.89 (m, IH), 6.74 (dd, IH), 6.66 (dd, IH), 6.61 (m, IH), 6.42 (m, IH), 3.94 (m, 2H), 3.26 (m, 6H), 3.15 (m, 6H), 2.78 (m, 2H), 2.18 (m, 9H), 1.98 (m, 3H), 1.86 (m, 2H), 1.74 (m, 2H), 1.57 (m, 2H), 1.41 (m, 2H), 0.93 (s, 6H). EXAMPLE 128 2-(3 -chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yI]methyl}piperazin-l-yl)-N-({4-[(3-morpholin-4-ylpropyl)amino]-3-nitrophenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 36C for EXAMPLE IF and EXAMPLE 4A for EXAMPLE IG in EXAMPLE IH. 'H NMR (400MHz, dimethylsulfoxide-de) 6 8.75 (t, IH), 8.41 (d, IH), 7.71 (dd, IH), 7.52 (d, IH), 7.36 (d, 2H), 7.18 (m, IH), 7.06 (m, 3H), 6.93 (dd, IH), 6.77 (dd, IH), 6.69 (m, 2H), 6.46 (d, IH), 3.65 (t, 4H), 3.47 (q, 2H), 3.29 (m, 2H), 3.18 (m, 4H), 2.79 (s, 2H), 2.56 (m, 4H), 2.22 (m, 6H), 1.98 (m, 2H), 1.85 (m, 2H), 1.41 (t, 2H), 0.94 (s, 6H). EXAMPLE 129 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(3- fluorophenoxy)-N-( {4- [(2-morpholin-4-ylethyl)amino]-3 -nitrophenyl} sulfonyl)benzamide 349 The title compound was prepared by substituting EXAMPLE 112C for EXAMPLE IF and EXAMPLE 126A for EXAMPLE IG in EXAMPLE IH. 'H NMR (400MHZ, dimethylsulfoxide-de) 6 1L48 (m, IH), 8.81 (t, IH), 8.45 (d, IH), 7.75 (dd, IH), 7.49 (d, IH), 7.36 (d, 2H), 7.19 (m, IH), 7.06 (m, 3H), 6.77 (dd, IH), 6.72 (m, IH), 6.54 (m, 2H), 6.47 (d, IH), 3.62 (m, 4H), 3.50 (q, 2H), 3.32 (m, 4H), 3.19 (m, 4H), 2.82 (s, 2H), 2.69 (t, 2H), 2.27 (m, 4H), 2.18 (s, 2H), 1.99 (m, 2H), 1.41 (t, 2H), 0.94 (s, 6H). EXAMPLE 130 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-l-yl)-N-({4-[(l-cyclopentylpiperidin-4-yl)amino]-3-nitrophenyl} sulfonyl)benzaniide The title compound was prepared by substituting EXAMPLE 36C for EXAMPLE IF and EXAMPLE 117A for EXAMPLE IG in EXAMPLE IH. 'H NMR (400MHz, dimethylsulfoxide-de) 8 8.35 (d, IH), 8.08 (d, IH), 7.69 (dd, IH), 7.61 (d, IH), 7.35 (d, 2H), 7.14 (m, IH), 7.04 (m, 3H), 6.88 (dd, IH), 6.72 (dd, IH), 6.65 (dd, IH), 6.60 (m, IH), 6.39 (d, IH), 3.87 (s, IH), 3.11 (m, 6H), 2.93 (m, 2H), 2.77 (s, 2H), 2.21 (m, 8H), 1.98 (m, 5H), 1.69 (m, 4H), 1.56 (m, 4H), 1.41 (t, 2H), 0.94 (s, 6H). EXAMPLE 131 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({4-[(l-methylpiperidin-4-yl)amino]-3- [(trifluoromethyl)sulfonyl]phenyl} sulfonyl)benzamide EXAMPLE 131A (2-fluorophenyl)(trifluoromethyl)sulfane Methyl viologen hydrochloride (1.17 g) in N,N-dimethylformamide (80 mL) at 25°C was saturated with trifluoromethyl iodide, treated with 2-fluorobenzenethiol (9.7 mL) and triethylamine (20 mL), stirred for 24 hours, diluted with water (240 mL) and extracted with diethyl ether. The extract was washed with IM aqueous NaOH, saturated ammonium chloride and brine and concentrated. EXAMPLE 13 IB l-fluoro-2-(trifluoromethylsulfonyl)benzene 350 EXAMPLE 131A (17.346 g) in 1:1:2 cartwn tetrachloride:acetonitrile:water (800 mL) at 25°C was treated with sodium periodate (56.8 g) and ruthenium(in) chloride hydrate (183 mg), stirred for 18 hours, diluted with dichloromethane (100 mL) and filtered through diatomaceous earth (Celite®). The filtrate was washed with saturated sodium bicarbonate and extracted with dichloromethane. The extract was washed with brine and dried (MgS04), filtered and concentrated. The concentrate was filtered through silica gel. EXAMPLE 13IC 4-fluoro-3-(trifluoromethylsulfonyl)benzenesulfonamide EXAMPLE 13 IB (37.3 g) in chlorosulfonic acid (32.8 mL) at 120°C was stirred for 18 hours, cooled to 25°C and pipetted onto crushed ice. The mixture was extracted with ethyl acetate, and the extract was washed with water and brine and dried (MgS04), filtered and concentrated. The crude product was taken up in isopropanol (706 mL) at -78''C, treated with ammonium hydroxide (98 mL) over 1 hour, stirred for 1 hour, quenched with 6M aqueous HCl (353 mL), warmed to 25°C and concentrated. The concentrate was mixed with water and extracted with ethyl acetate. The extract was dried over MgS04, filtered and concentrated. The concentrate was recrystallized from ethyl acetate/hexane. EXAMPLE 13 ID 4-(l-methylpiperidin-4-y]amino)-3-(trifluoromethylsulfonyl)benzenesulfonamide The title compound was prepared by substituting l-methyl-4-aminopiperidine for 3-(N-morpholinyl)-l-propylamine and EXAMPLE 131C for 4-fluoro-3-nitrobenzenesulfonamide in EXAMPLE 4A. EXAMPLE 13 IE 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-l-yl)-N-({4-[(l-methylpiperidin-4-yl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 36C for EXAMPLE IF and EXAMPLE 131D for EXAMPLE IG in EXAMPLE IH. 'H NMR (400MHZ, dimethylsulfoxide-de) 5 8.00 (d, IH), 7.83 (dd, IH), 7.61 (d, IH), 7.36 (m, 2H), 7.19 (m, IH), 7.07 (d, 2H), 7.01 (d, IH), 6.93 (d, IH), 6.72 (dd, IH), 6.66 (m, 2H), 6.51 (d, IH), 6.39 351 (d, IH), 3.79 (none, IH), 3.11 (m, 6H), 2.90 (t, 2H), 2.78 (s, 2H), 2.65 (s, 3H), 2.20 (m, 6H), 2.09 (m, 2H), 1.97 (m, 3H), 1.64 (m, 2H), 1.41 (t, 2H), 0.95 (s, 6H). EXAMPLE 132 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N-( {4- [(l-cyclopropylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(3- fluorophenoxy)benzamide The title compound was prepared by substituting EXAMPLE 112C for EXAMPLE IF and EXAMPLE 65A for EXAMPLE IG in EXAMPLE IH. 'H NMR (400MHz, dimethylsulfoxide-dfi) 5 8.43 (d, IH), 8.23 (d, IH), 7.75 (dd, IH), 7.51 (d, IH), 7.35 (d, 2H), 7.17 (m, 2H), 7.06 (d, 2H), 6.73 (ra, 2H), 6.56 (dd, IH), 6.51 (dd, IH), 6.45 (d, IH), 3.74 (m, IH), 3.18 (m, 4H), 2.97 (m, 2H), 2.80 (s, 2H), 2.54 (m, 2H), 2.20 (m, 6H), 1.98 (m, 4H), 1.85 (m, IH), 1.62 (m, 2H), 1.41 (t, 2H), 0.94 (s, 6H), 0.50 (m, 2H), 0.41 (m, 2H). EXAMPLE 133 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl} piperazin-1 -yl)-N-( {4-[(l-cyclopentylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(2,3-difluorophenoxy)benzamide The title compound was prepared by substituting EXAMPLE 45C for EXAMPLE IF and EXAMPLE 117A for EXAMPLE IG in EXAMPLE IH. 'H NMR (400MHz, dimethylsulfoxide-de) 5 8.35 (d, IH), 8.05 (s, IH), 7.73 (dd, IH), 7.64 (d, IH), 7.36 (d, 2H), 7.06 (m, 3H), 6.84 (m, 2H), 6.72 (dd, IH), 6.43 (d, IH), 6.31 (m, IH), 3.89 (s, IH), 3.12 (m, 6H), 2.97 (m, 2H), 2.77 (s, 2H), 2.21 (m, 8H), 1.98 (m, 5H), 1.63 (m, 8H), 1.41 (t, 2H), 0.95 (s, 6H). EXAMPLE 134 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-({4- [(l-cyclopentylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(2- fluorophenoxy)benzamide The title compound was prepared by substituting EXAMPLE 122C for EXAMPLE IF and EXAMPLE 117A for EXAMPLE IG in EXAMPLE IH. 'H NMR (400MHz, dimethylsulfoxide-dfi) 5 8.39 (m, IH), 8.07 (d, IH), 7.76 (m, IH), 7.61 (d, IH), 7.34 (d, 2H), 7.18 (m, 2H), 7.07 (m, 3H), 6.91 (m, 2H), 6.68 (m, IH), 6.28 (m, IH), 3.26 (m, 8H), 3.17 (m, 2H), 3.05 (m, 4H), 2.75 (s, 2H), 2.23 (m, 7H), 2.00 (m, 4H), 1.64 (m, 6H), 1.40 (m, 2H), 0.94 (s, 6H). 352 EXAMPLE 135 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-(2,3-difluorophenoxy)-N-( {4- [(2-morpholin-4-ylethyl)amino]-3-nitrophenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 45C for EXAMPLE IF and EXAMPLE 126A for EXAMPLE IG in EXAMPLE IH.'H NMR (400 MHz, dimethylsulfoxide-de) 8 8.77 (m, IH), 8.45 (d, IH), 7.78 (dd, IH), 7.52 (d, IH), 7.34 (d, 2H), 7.06 (m, 3H), 6.91 (m, 2H), 6.76 (dd, IH), 6.45 (m, 2H), 3.62 (m, 4H), 3.49 (m, 2H), 3.18 (m, 4H), 2.81 (s, 2H), 2.68 (t, 2H), 2.23 (m, 6H), 1.97 (m, 2H), 1.41 (t, 2H), 0.94 (s, 6H). EXAMPLE 136 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-(2,3- difluorophenoxy)-N-[(3-nitro-4- {[ 1 -(thien-3-ylmethyl)piperidin-4- yl]amino}phenyl)sulfonyl]benzanude EXAMPLE 136A 4-(2-Nitro-4-sulfamoyl-phenylamino)-piperidine-l-carboxylic acid tert-butyl ester Tert-butyl 4-aminopiperidine-l-carboxylate (8.63 g) was dissolved in 1,4-dioxane (250 mL), and 4-chloro-3-nitrobenzenesulfonamide (6.(X) g) was added followed by triethylamine (10.60 mL). The solution was heated at 90°C for 20 hours and then cooled. The solvent was removed under vacuum, and the material was purified by flash column chromatography on silica gel using 50% ethyl acetate in hexanes, increasing to 1(X)% ethyl acetate and increasing further to 20% methanol in dichloromethane. EXAMPLE 136B 3-Nitro-4-(piperidin-4-ylamino)-benzenesulfonamide The title compound was prepared by substituting EXAMPLE 136A for EXAMPLE lA in EXAMPLE IB. EXAMPLE 136C 3-nitro-4-(l-(thiophen-3-ylmethyl)piperidin-4-ylamino)benzenesulfonamide The title compound was prepared by substituting thiophene-3-carbaldehyde for 4'-chlorobiphenyl-2-carboxaldehyde and EXAMPLE 136B for tert-butyl piperazine-l-carboxylate in EXAMPLE lA. 353 EXAMPLE 136D 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-(2,3-difluorophenoxy)-N-[(3-nitro-4- {[ 1 -(thien-3-ylmethyl)piperidin-4-yl]amino}phenyl)sulfonyl]benzamide The title compound was prepared by substituting EXAMPLE 45C for EXAMPLE IF and EXAMPLE 136C for EXAMPLE IG in EXAMPLE IH. 'H NMR (400 MHz, dimethylsulfoxide-de) 6 8.39 (d, IH), 8.16 (d, IH), 7.74 (dd, IH), 7.54 (m, 3H), 7.35 (d, 2H), 7.10 (m, 4H), 6.87 (m, 2H), 6.74 (dd, IH), 6.40 (m, 2H), 3.84 (m, 3H), 3.15 (m, 4H), 3.03 (m, 2H), 2.79 (s, 2H), 2.62 (m, 2H), 2.23 (m, 6H), 2.02 (m, 4H), 1.73 (m, 2H), 1.41 (t, 2H), 0.94 (s, 6H). EXAMPLE 137 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-[(4- {[3-(dimethylamino)propyl]amino} -3-nitrophenyl)sulfonyl]-2-(2-fluorophenoxy)benzamide EXAMPLE 122C (203 mg), EXAMPLE UA (124 mg), l-ethyl-3-[3-(dimethylamino)propyl]-carbodiimide hydrochloride (142 mg), and 4-dimethylaminopyridine (90 mg) were stirred in CH2CI2 (8 mL) overnight. The reaction was concentrated and the crude was purified by preparative HPLC using a C18 column, 250 x 50 mm, 10|a., and eluting with a gradient of 20-100% CH3CN vs. 0.1% trifluoroacetic acid in water, giving the product as a trifluoroacetate salt. The salt was dissolved in dichloromethane (6 mL) and washed with 50% aqueous NaHCOs. The organic layer was dried over anhydrous Na2S04, filtered, and concentrated to give the title compound. ^H NMR (300 MHz, dimethylsulfoxide-de) 6 8.71 (br t, IH), 8.38 (d, IH), 7.75 (dd, IH), 7.63 (d, IH), 7.37 (d, 2H), 7.18 (m, IH), 7.06 (d, 2H), 6.98 (d, IH), 6.92 (m, 2H), 6.66 (dd, IH), 6.60 (m, IH), 6.26 (d, IH), 3.47 (dd, 2H), 3.05 (br m, 4H), 2.89 (br m, 2H), 2.75 (s, 2H), 2.60 (s, 6H), 2.20 (br m, 6H), 1.98 (s, 2H), 1.88 (m, 2H) 1.40 (t,2H), 0.93 (s,6H). EXAMPLE 138 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-N-[(4- {[3-(dimethylamino)propyl]amino} -3-nitrophenyl)sulfonyl]-2-(3-fluorophenoxy)benzamide The title compound was prepared by substituting EXAMPLE 112C for EXAMPLE 122c in EXAMPLE 137. ^H NMR (300 MHz, dimethylsulfoxide-de) 5 8.70 (br t, IH), 8.35 (d, IH), 7.69 (dd, IH), 7.62 (d, IH), 7.37 (d, 2H), 7.15 (dd, IH), 7.06 (d, 2H), 6.95 (d, IH), 354 6.70 (m, 2H), 6.50 (dd, IH), 6.41 (m, IH), 6.38 (d, IH), 3.47 (dd, 2H), 3.10 (br m, 4H), 2.94 (br m, 2H), 2.78 (s, 2H), 2.62 (s, 6H), 2.23 (br m, 6H), 1.99 (s, 2H), 1.90 (m, 2H) 1.40 (t, 2H),0.93(s,6H). EXAMPLE 139 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-[(4- {[3-(dimethylamino)propyl]amino} -3-nitrophenyl)sulfonyl]-2-(4-nuorophenoxy)benzamide The title compound was prepared by substituting EXAMPLE 118C for EXAMPLE 122C in EXAMPLE 137. 'H NMR (300 MHz, dimethylsulfoxide-de) 5 8.75 (br t, IH), 8.39 (d, IH), 7.75 (dd, IH), 7.58 (d, IH), 7.37 (d, 2H), 7.06 (d, 2H), 7.00 (m, 3H), 6.75 (m, 2H), 6.66 (dd, IH), 6.28 (d, IH), 3.47 (dd, 2H), 3.05 (br m, 4H), 2.89 (br m, 2H), 2.75 (s, 2H), 2.60 (s, 6H), 2.20 (br m, 6H), 1.98 (s, 2H), 1.88 (m, 2H) 1.40 (t, 2H), 0.93 (s, 6H). EXAMPLE 140 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l -en-1 -yl]methyl }piperazin-1 -yl)-2-(2,3- difluorophenoxy)-N-[(4- {[ 1 -(2-fluoroethyl)piperidin-4-yl]amino} -3- nitrophenyl)sulfonyl]benzamide EXAMPLE 140A 4-(2-Nitro-4-sulfamoyl-phenylamino)-piperidine-l-carboxylic acid tert-butyl ester Tert-butyl 4-aminopiperidine-l-carboxylate (8.63 g) was dissolved in 1,4-dioxane (250 mL), and 4-chloro-3-nitrobenzenesulfonamide (6.00 g) was added followed by triethylamine (10.60 mL). The solution was heated at 90°C for 20 hours and then cooled. The solvent was removed under vacuum, and the material purified by flash column chromatography on silica gel using 50% ethyl acetate in hexanes, increasing to 100% ethyl acetate and increasing further to 20% methanol in dichloromethane. EXAMPLE 140B 3-Nitro-4-(piperidin-4-ylamino)-benzenesulfonamide The title compound was prepared by substituting EXAMPLE 140A for EXAMPLE lA in EXAMPLE IB. EXAMPLE 140C 4-[l-(2-Fluoro-ethyl)-piperidin-4-ylamino]-3-nitro-benzenesulfonamide 355 To EXAMPLE HOB (1000 mg) was added N,N-dimethylformamide (10 mL). 1-Fluoro-2-iodoethane (462 mg) and triethylamine (1.18 mL) were added and the solution was heated at 70°C for 16 hours. The solvent was removed under vacuum, and the material purified by flash column chromatography on silica gel using ethyl acetate increasing to 10% methanol in dichloromethane. EXAMPLE 140D 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl }piperazin-1 -yl)-2-(2,3-difluorophenoxy)-N-[(4- {[ 1 -(2-fluoroethyl)piperidin-4-yl]amino} -3-nitrophenyl)sulfonyl]benzamide The title compound was prepared by substituting EXAMPLE 45C for EXAMPLE IF and EXAMPLE 140C for EXAMPLE IG in EXAMPLE IH. 'H NMR (300MHZ, dimethylsulfoxide-de) 5 8.41 (d, IH), 8.21 (d, IH), 7.76 (dd, IH), 7.56 (d, IH), 7.37 (d, 2H), 7.14 (d, IH), 7.07 (d, 2H), 6.94-6.82 (m, 2H), 6.76 (dd, IH), 6.48 (d, IH), 6.41-6.34 (m, IH), 4.71 (t, IH), 4.55 (t, IH), 3.89-3.70 (m, 2H), 3.17 (br s, 4H), 3.09-2.90 (m, 4H), 2.91-2.77 (m, 3H), 2.26 (br s, 4H), 2.18 (m, 2H), 2.08-1.96 (m, 4H), 1.71 (q, 2H), 1.41 (t, 2H), 0.95 (s, 6H). EXAMPLE 141 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-l-yl)-N-({4-[(2-morpholin-4-ylethyl)amino]-3-nitrophenyl) sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 36C for EXAMPLE IF and EXAMPLE 126A for EXAMPLE IG in EXAMPLE IH. 'H NMR (300MHz, dimethylsulfoxide-de) 6 8.81 (t, IH), 8.44 (d, IH), 7.73 (dd, IH), 7.51 (d, IH), 7.36 (d, 2H), 7.18 (t, IH), 7.07 (d, 2H), 7.04 (d, IH), 6.93 (dt, IH), 6.78 (dd, IH), 6.71 (dd, IH), 6.69 (d, IH), 6.47 (d, IH), 3.62 (t, 4H), 3.50 (q, 2H), 3.20 (br s, 4H), 2.81 (br s, 2H), 2.69 (t, 2H), 2.26 (m, 4H), 2.18 (t, 2H), 2.02-1.93 (m, 4H), 1.41 (t, 2H), 1.37-1.22 (m, 2H), 0.95 (s, 6H). EXAMPLE 142 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-[(4-{[3-(dimethylamino)propyl]amino)-3- nitrophenyl)sulfonyl]benzamide 356 The title compound was prepared by substituting EXAMPLE 36C for EXAMPLE 122C in EXAMPLE 137. 'H NMR (300 MHz, dimethylsulfoxide-dg) 5 8.71 (br t, IH), 8.34 (d, IH), 7.65 (dd, IH), 7.63 (d, IH), 7.37 (d, 2H), 7.16 (dd, IH), 7.07 (d, 2H), 6.93 (d, IH), 6.89 (m, IH), 6.73 (dd, IH), 6.64 (dd, IH), 6.60 (dd, IH), 6.38 (d, IH), 3.45 (dd, 2H), 3.09 (br m, 4H), 2.93 (br m, 2H), 2.78 (s, 2H), 2.62 (s, 6H), 2.23 (br m, 6H), 1.98 (s, 2H), 1.90 (m, 2H) 1.41 (t, 2H), 0.93 (s, 6H). EXAMPLE 143 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-[(4-{[3-(4-methylpiperazin-l-yl)propyl]amino}-3- nitrophenyl)sulfonyl]benzamide EXAMPLE 143A 4-[3-(4-Methyl-piperazin-l-yl)-propylamino]-3-nitro-benzenesulfonamide The title compound was prepared by substituting l-(3-aminopropyl)-4-methylpiperazine for tert-butyl 4-aminopiperidine-l-carboxylate in EXAMPLE 140A. EXAMPLE 143B 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-l-yl)-N-[(4-{[3-(4-methylpiperazin-l-yl)propyl]amino}-3- nitrophenyl)sulfonyl]benzamide The title compound was prepared by substituting EXAMPLE 36C for EXAMPLE IF and EXAMPLE 143A for EXAMPLE IG in EXAMPLE IH. 'H NMR (300MHz, dimethylsulfoxide-dfi) 5 8.55 (t, IH), 8.39 (d, IH), 7.67 (dd, IH), 7.61 (d, IH), 7.36 (d, 2H), 7.15 (t, IH), 7.07 (d, 2H), 6.95 (d, IH), 6.89 (dd, IH), 6.73 (dd, IH), 6.65 (d, IH), 6.60 (t, IH), 6.40 (d, IH), 3.43 (q, 2H), 3.12 (br s, 4H), 2.89 (br s, 2H), 2.77 (s, 2H), 2.60-2.45 (m, 9H), 2.29-2.15 (m, 8H), 1.98 (br s, 2H), 1.81 (m, 2H), 1.41 (t, 2H), 0.94 (s, 6H). EXAMPLE 144 2-(3-chlorophenoxy)-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3- yl]methyl)piperazin-l-yl)-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide 357 EXAMPLE 144A methyl 2-(3-chlorophenoxy)-4-(piperazin- l-yl)beiizoate This example was prepared by substituting piperazine for EXAMPLE 3F and EXAMPLE 36A for EXAMPLE 3A in EXAMPLE 3G. EXAMPLE 144B methyl 2-(3-chlorophenoxy)-4-(4-((4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran- 3-yl)methyl)piperazin-l-yl)benzoate This example was prepared by substituting EXAMPLE 144A for EXAMPLE 38F in EXAMPLE 38G. EXAMPLE 144C 2-(3-chlorophenoxy)-4-(4-((4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3- yl)methyl)piperazin- l-yl)benzoic acid The title compound was prepared as described in EXAMPLE 38H by replacing EXAMPLE 38G with EXAMPLE 144B. EXAMPLE 144D 2-(3-chlorophenoxy)-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl]piperazin- l-yl)-N-( {4-[( l-methylpiperidin-4-yl)amino]-3-nitrophenyl} sulfonyl)benzamide The tide compound was prepared as described in EXAMPLE IH by replacing EXAMPLE IF and EXAMPLE 10 with EXAMPLE 144C and EXAMPLE 3L respectively. 'H NMR (300 MHz, dimethylsulfoxide-ds) 6 8.33 (d, IH), 8.07 (d, IH), 7.68 (dd, IH), 7.62 (d, IH), 7.40 (d, 2H), 7.15 (m, 3H), 7.01 (d, IH), 6.86 (m, IH), 6.72 (m, IH), 6.64 (dd, IH), 6.58 (m, IH), 6.39 (d, IH), 4.15 (s, 2H), 3.83 (m, IH), 3.17 (m, 8H), 2.87 (s, 3H), 2.63 (m, 5H), 2.26 (m, 4H), 2.13 (m, 3H), 1.79 (m, IH), 1.20 (s, 6H). EXAMPLE 145 4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- 2-(2,3-difluorophenoxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide EXAMPLE 145A methyl 2-(2,3-difluorophenoxy)-4-(piperazin-1 -yl)benzoate 358 This example was prepared by substituting piperazine for EXAMPLE 3F and EXAMPLE 45A for EXAMPLE 3A in EXAMPLE 3G. EXAMPLE 145B methyl 2-(2,3-difluorophenoxy)-4-(4-((4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyTan-3-yl)methyl)piperazin-1 -yl)benzoate This example was prepared by substituting EXAMPLE 145A for EXAMPLE 38F in EXAMPLE 38G. EXAMPLE 145C 4-(4-((4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl)methyl)piperazin-l-yl)-2- (2,3-difluorophenoxy)benzoic acid The title compound was prepared as described in EXAMPLE 38H by replacing EXAMPLE 38G with EXAMPLE 145B. EXAMPLE 145D 4-(4-{[4-(4-chloiophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)-2-(2,3-difluorophenoxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitrophenyl} sulfonyl)benzamide The title compound was prepared as described in EXAMPLE IH by replacing EXAMPLE IF and EXAMPLE IG with EXAMPLE 145C and EXAMPLE 31, respectively. ^H NMR (300 MHz, dimethylsulfoxide-d66) 5 8.32 (d, IH), 8.06 (d, IH), 7.71 (dd, IH), 7.66 (d, IH), 7.40 (d, 2H), 7.15 (s, 2H), 7.03 (d, IH), 6.81 (m, 2H), 6.73 (m, IH), 6.43 (m, IH), 6.27 (m, IH), 4.15 (m, 2H), 3.83 (m, IH), 3.16 (m, 8H), 2.88 (s, 3H), 2.70 (m, 4H), 2.26 (s, 4H), 2.13 (m, 4H), 1.78 (m, IH), 1.21 (s, 6H). EXAMPLE 146 N-({4-[(l-allylpiperidin-4-yl)amino]-3-nitrophenyl) sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4- dimethylcyclohex-1 -en- l-yl]methyl }piperazin-1 -yl)-2-(2,3-difluorophenoxy)benzamide EXAMPLE 146A 4-( 1 -allylpiperidin-4-ylamino)-3-nitrobenzenesulfonamide 359 3-nitro-4-(piperidin-4-ylamino)benzenesulfonanude hydrochloride (0.27g), triethylamine (0.2 mL) and 3-bromoprop-l-ene (O.lg) was dissolved in N,N-dimethylformamide (5 mL). The mixture was stirred at room temperature overnight. The solvent was dried under vacuum. The mixture was chromatographed on silica gel with 0-20% methanol in dichloromethane. EXAMPLE 146B N-({4-[(l-allylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl }piperazin-1 -yl)-2-(2,3-difluorophenoxy)benzamide The title compound was prepared by substituting EXAMPLE 45C for EXAMPLE IF and EXAMPLE 146A for EXAMPLE IG in EXAMPLE IH. 'H NMR (400 MHz, dimethylsulfoxide-de) 8 8.39 (d, IH), 8.14 (d, IH), 7.75 (dd, IH), 7.59 (d, IH), 7.35 (d, 2H), 7.08 (m, 3H), 6.86 (m, 2H), 6.74 (dd, IH), 6.45 (d, IH), 6.36 (m, IH), 5.88 (m, IH), 5.37 (m, 2H), 3.83 (m, IH), 3.13 (m, 8H), 2.74 (m, 4H), 2.17 (m, 8H), 1.98 (s, 2H), 1.74 (m, 2H), 1.41 (t, 2H), 0.94 (s, 6H). EXAMPLE 147 2-(3-chloro-2-fluorophenoxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl jpiperazin- l-yl)-N-( {4-[( 1 -methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide EXAMPLE 147A methyl 2-(3-chloro-2-fluorophenoxy)-4-fluorobenzoate The title compound was prepared by substituting 3-chloro-2-fluorophenol for 2-methyl-5-indolol in EXAMPLE 3A. EXAMPLE 147B Ethyl 2-(3-chloro-2-fluorophenoxy)-4-(piperazin-1 -yl)benzoate The title compound was prepared by substituting piperazine for EXAMPLE 3F and EXAMPLE 147A for EXAMPLE 3A in EXAMPLE 3G. 360 EXAMPLE 147C Ethyl 2-(3-chloro-2-fluorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 - enyl)methyl)piperazin-1 -yl)benzoate The title compound was prepared by substituting EXAMPLE 60D for 4'-chlorobiphenyl-2-carboxaldehyde and EXAMPLE 147B for tert-butyl piperazine-1-carboxylate inEXAMPLE lA. EXAMPLE 147D 2-(3-chloro-2-fluorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-1 -yl)benzoic acid The title compound was prepared by substituting EXAMPLE 147C for EXAMPLE IE in EXAMPLE IF. EXAMPLE 147E 2-(3-chloro-2-fluorophenoxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitrophenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 147D for EXAMPLE IF and EXAMPLE 31 for EXAMPLE IG in EXAMPLE IH. 'H NMR (400 MHz, dimethylsulfoxide-dfi) 8 8.33 (d, IH), 8.05 (d, IH), 7.68 (m, 2H), 7.35 (d, 2H), 7.02 (m, 4H), 6.84 (m, IH), 6.72 (d, IH), 6.43 (m, 2H), 3.83 (m, IH), 3.12 (m, 6H), 2.84 (m, 4H), 2.62 (s, 3H), 2.22 (m, 6H), 2.11 (m, 2H), 1.98 (s, 2H), 1.76 (m, 2H), 1.41 (t, 2H), 0.94 (s, 6H). EXAMPLE 148 2-(3 -chloro-2-fluorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N-( {4- [(3-morpholin-4-ylpropyl)amino]-3-nitrophenyl) sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 147D for EXAMPLE IF and EXAMPLE 4A for EXAMPLE IG in EXAMPLE IH. 'H NMR (400 MHz, dimethylsulfoxide-dfi) 8 8.71 (m, IH), 8.41 (d, IH), 7.74 (dd, IH), 7.56 (d, IH), 7.35 (d, 2H), 7.05 (m, 4H), 6.91 (m, IH), 6.75 (dd, IH), 6.56 (m, IH), 6.47 (d, IH), 3.64 (m, 4H), 3.47 (q, 2H), 3.17 (m, 4H), 2.79 (s, 2H), 2.55 (m, 6H), 2.22 (m, 6H), 1.98 (s, 2H), 1.84 (m, 2H), 1.41 (t, 2H), 0.95 (s, 6H). 361 EXAMPLE 149 2-(3-chloro-2-fluorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({3-nitro-4-[(3-pyrrolidin-l- * ylpropyl)amino]phenyl} sulfonyl)benzamide EXAMPLE 149A 3-nitro-4-(3-(pyrrolidin-l-yl)propylamino)benzenesulfonamide The title compound was prepared by substituting 3-(pyrrolidin-l-yl)propan-l-amine for 3-(N-morpholinyl)-l-propylamine in EXAMPLE 4A. EXAMPLE 149B 2-(3-chloro-2-fluorophenoxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yljmethyl ] piperazin-1 -yl)-N-({ 3-nitro-4-[(3-pynolidin-1-ylpropyl)amino]phenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 147D for EXAMPLE IF and EXAMPLE 149A for EXAMPLE IG in EXAMPLE IH. 'H NfMR (400 MHz, dimethylsulfoxide-de) 8 8.43 (s. IH), 8.32 (d, IH), 7.70 (m, 2H), 7.35 (d, 2H), 7.07 (d, 2H), 6.97 (m, 2H), 6.85 (m, IH), 6.71 (dd, IH), 6.43 (m, 2H), 3.48 (q, 2H), 3.09 (m, 8H), 2.77 (s, 2H), 2.21 (m, 8H), 1.92 (m, 8H), 1.40 (t, 2H), 0.94 (s, 6H). EXAMPLE 150 2-(3-chloro-2-fluorophenoxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-N-({4-[(2-morpholin-4-ylethyl)amino]-3- nitrophenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 147D for EXAMPLE IF and EXAMPLE 126A for EXAMPLE IG in EXAMPLE IH. 'H NMR (400 MHz, dimethylsulfoxide-de) 8 8.79 (m, IH), 8.44 (d, IH), 7.76 (dd, IH), 7.53 (d, IH), 7.36 (d, 2H), 7.06 (m, 4H), 6.91 (m, IH), 6.76 (dd, IH), 6.58 (m, IH), 6.48 (d, IH), 3.62 (m, 4H), 3.50 (q, 2H), 3.19 (m, 4H), 2.81 (s, 2H), 2.69 (m, 2H), 2.23 (m, 6H), 1.98 (s, 2H), 1.41 (t, 2H), 0.94 (s, 6H). EXAMPLE 151 2-(2-chloro-6-fluorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yljmethyl }piperazin- l-yl)-N-( {4-[( l-methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide 362 EXAMPLE 151A methyl 2-(2-chloro-6-fluorophenoxy)-4-fluorobenzoate The title compound was prepared by substituting 2-chloro-6-fluorophenol for 2-methyl-5-indoloI in EXAMPLE 3A. EXAMPLE 151B methyl 2-(2-chloro-6-fluorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 - enyl)methyl)piperazin-1 -yl)benzoate The title compound was prepared by substituting EXAMPLE 151A for EXAMPLE 3A in EXAMPLE 3G. EXAMPLE 15IC 2-(2-chloro-6-fluorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-1 -yl)benzoic acid The title compound was prepared by substituting EXAMPLE 15 IB for EXAMPLE IE in EXAMPLE IF. EXAMPLE 151D 2-(2-chloro-6-fluorophenoxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl} piperazin-1 -yI)-N-( {4- [(1 -methylpiperidin-4-yl)amino]-3-nitrophenyl) sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 151C for EXAMPLE IF and EXAMPLE 31 for EXAMPLE IG in EXAMPLE IH. 'H NMR (400MHZ, dimethylsulfoxide-de) 6 8.51 (d, IH), 8.09 (d, IH), 7.92 (dd, IH), 7.60 (d, IH), 7.32 (m, 5H), 7.17 (d, IH), 7.05 (d, 2H), 6.56 (dd, IH), 5.83 (d, IH), 3.85 (m, IH), 3.17 (m, 2H), 2.95 (m, 4H), 2.81 (m, 2H), 2.73 (s, 2H), 2.59 (s, 3H), 2.15 (m, 8H), 1.97 (m, 2H), 1.77 (m, 2H), 1.39 (t, 2H), 0.93 (s, 6H). EXAMPLE 152 2-(2-chloro-6-fluorophenoxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl }piperazin-1 -y l)-N-( {3 -nitro-4- [(1 -tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl} sulfonyl)benzamide 363 The title compound was prepared by substituting EXAMPLE 151C for EXAMPLE IF and EXAMPLE 49C for EXAMPLE IG in EXAMPLE IH. 'H NMR (400MHZ, dimethylsulfoxide-dfi) 6 8.54 (d, IH), 8.14 (d, IH), 7.93 (dd, IH), 7.58 (d, IH), 7.34 (m, 5H), 7.20 (d, IH), 7.04 (d, 2H), 6.59 (dd, IH), 5.85 (d, IH), 3.93 (dd, 2H), 3.85 (m, IH), 3.21 (s, 6H), 2.97 (m, 4H), 2.73 (m, 4H), 2.16 (m, 8H), 1.96 (s, 2H), 1.81 (m, 2H), 1.69 (m, 2H), 1.54 (m, 2H), 1.39 (t, 2H), 0.93 (s, 6H). EXAMPLE 154 4-(4- {[2-(4-chloropheny l)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-2- [(6- fluoro-lH-indol-5-yl)oxy]-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzaniide EXAMPLE 154A 6-fluoro-1 H-indol-5 -ol The title compound was prepared from 2-fluoro-4-nitrophenol according to WO 02/12227 (page 78). EXAMPLE 154B methyl 4-fluoro-2-(6-fluoro-1 H-indol-5-yloxy)benzoate The title compound was prepared as described in EXAMPLE 3A by replacing 2-methyl-5-indolol with EXAMPLE 154A. EXAMPLE 154C methyl 2-(6-fluoro-1 H-indol-5-yloxy)-4-(piperazin-1 -yl)benzoate The title compound was prepared as described in EXAMPLE 3G by replacing EXAMPLE 3F and EXAMPLE 3A with piperazine and EXAMPLE 154B, respectively. EXAMPLE 154D methyl 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)-2-(6- fluoro-1 H-indol-5 -yloxy )benzoate 364 The title compound was prepared as described in EXAMPLE 38G by replacing EXAMPLE 38F and EXAMPLE 38E with EXAMPLE 154C and EXAMPLE 60D, respectively. EXAMPLE 154E 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)-2-(6-nuoro- lH-indol-5-yloxy)benzoic acid The title compound was prepared as described in EXAMPLE 38H by replacing EXAMPLE 38G witfi EXAMPLE 154D. EXAMPLE 154F 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl }piperazin-1 -yl)-2-[(6-fluoro-lH-indol-5-yl)oxy]-N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitiophenyl} sulfonyl)benzamide The title compound was prepared as described in EXAMPLE IH by replacing EXAMPLE IF and EXAMPLE IG with EXAMPLE 154E and EXAMPLE 3L respectively. 'H NMR (300 MHz, dimethylsulfoxide-de) 5 11.12 (m, IH), 8.49 (d, IH), 8.11 (d, IH), 7.82 (dd, IH), 7.55 (d, IH), 7.33 (m, 3H), 7.28 (d, IH), 7.11 (d, IH), 7.05 (m, 2H), 6.59 (dd, IH), 6.35 (m, IH), 6.08 (m, IH), 3.76 (m, IH), 3.06 (m, 8H), 2.72 (m, 6H), 2.17 (s, 6H), 1.98 (m, 5H), 1.72 (s, 2H), 1.38 (t, 2H), 0.92 (s, 6H). EXAMPLE 155 2-(3-chloK)phenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl} piperazin-1 -yl)-N-[(4- {[(1 -methylpiperidin-4-yl)methyl]amino} -3- nitrophenyl)sulfonyl]benzamide EXAMPLE 155 A 4-(( 1 -methylpiperidin-4-yl)methylamino)-3-nitrobenzenesulfonamide The title compound was prepared by substituting 4-aminomethyl-N-methylpiperidine for 3-(N-morpholinyl-l-propylamine in EXAMPLE 4A. 365 EXAMPLE 155B 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-l-yl)-N-[(4-{[(l-methylpiperidin-4-yl)methyl]amino}-3- nitiophenyl)sulfonyl]benzamide The title compound was prepared by substituting EXAMPLE 36C for EXAMPLE IF and EXAMPLE 155A for EXAMPLE IG in EXAMPLE IH. 'H NMR (300MHZ, dimethylsulfoxide-dfi) 5 8.45 (br t, IH), 8.33 (d, IH), 7.65 (m, 2H), 7.36 (d, 2H), 7.15 (t, IH), 7.06 (d, 2H), 6.97 (d, IH), 6.89 (d, IH), 6.60 (m, 2H), 6.38 (d, IH), 3.02-3.12 (m, 8H), 2.77 (m, 4H), 2.65 (m, 2H), 2.24 (m, 4H), 2.19 (m, 2H), 1.91 (m, IH), 1.87 (m, 2H), 1.41 (m, 4H), 0.95 (s, 6H). EXAMPLE 156 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(2,3- difluorophenoxy)-N-[(4- {[(l-methylpiperidin-4-yl)methyl]amino} -3- nitrophenyl)sulfonyI]benzamide The title compound was prepared by substituting EXAMPLE 45C for EXAMPLE IF and EXAMPLE 155A for EXAMPLE IG in EXAMPLE IH. 'H NMR (300MHz, dimethylsulfoxide-de) 5 8.54 (br t, IH), 8.37 (d, IH), 7.72 (d, IH), 7.60 (d, IH), 7.36 (d, 2H), 7.07 (d, 3H), 6.88 (dd, 2H), 6.75 (d, IH), 6.46 (s, IH), 6.36 (br s, IH), 3.16 (m, 8H), 2.89 (m, 2H), 2.81 (m, 2H), 2.68 (s, 3H), 2.27 (m, 4H), 2.20 (m, 2H), 1.99 (m, 2H), 1.91 (m, 3H), 1.55 (m, 2H), 1.41 (m, 2H), 0.95 (s, 6H). EXAMPLE 157 4-(4- {[2-(4-chlorophenyl)-4,4-dimethyIcyclohex-1 -en-1 -yljmethyl }piperazin-1 -yl)-2-[(4- fluoro-lH-indol-5-yI)oxy]-N-({4-[(l-mediylpiperidin-4-yl)amino]-3- nitrophenyl) sulfonyl)benzamide EXAMPLE 157A 4-fluoro-lH-indol-5-ol The title compound was prepared from 2-fluoro-4-nitrophenol according to WO 02/12227 (page 78). 366 EXAMPLE 157B methyl 4-fluoro-2-(4-fluoro- lH-indol-5-yloxy)benzoate The title compound was prepared as described in EXAMPLE 3A by replacing 2-methyl-5-indolol with EXAMPLE 157A. EXAMPLE 157C methyl 2-(4-fluoro-lH-indol-5-yloxy)-4-(piperazin-l-yl)benzoate The title compound was prepared as described in EXAMPLE 3G by replacing EXAMPLE 3F and EXAMPLE 3A with piperazine and EXAMPLE 157B respectively. EXAMPLE 157D methyl 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)-2-(4- fluoro-1 H-indol-5-yloxy )benzoate The title compound was prepared as described in EXAMPLE 38G by replacing EXAMPLE 38F and EXAMPLE 38E with EXAMPLE 157C and EXAMPLE 60D, respectively. EXAMPLE 157E 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)-2-(4-fluoro- lH-indol-5-yloxy)benzoic acid The title compound was prepared as described in EXAMPLE 38H by replacing EXAMPLE 38G with EXAMPLE 157D. EXAMPLE 157F 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2- [(4- fluoro-lH-indol-5-yl)oxy]-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide The title compound was prepared as described in EXAMPLE IH by replacing EXAMPLE IF and EXAMPLE IG with EXAMPLE 157E and EXAMPLE 3L 'H NMR (300 MHz, dimethylsulfoxide-de) 8 11.40 (m, IH), 8.53 (d, IH), 8.12 (d, IH), 7.88 (d, IH), 7.53 (d, IH), 7.42 (t, IH), 7.33 (d, 2H), 7.16 (dd, 2H), 7.05 (d, 2H), 6.83 (m, IH), 6.52 (m, 2H), 367 6.02 (s, IH), 3.77 (m, 2H), 3.03 (m, 6H), 2.70 (s, 3H), 2.04 (m, 12H), 1.71 (m, 2H), 0.92 (s, 6H). EXAMPLE 158 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl )piperazin-1 -yl)-2-[3- (methoxymethoxy)-2-methylphenoxy]-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl) sulfonyl)benzamide EXAMPLE 158A Ethyl 4-fluoro-2-(3-hydroxy-2-methylphenoxy)benzoate The title compound was prepared by substituting 2-methylbenzene-l,3-diol for 2-methyl-5-indolol in EXAMPLE 3A. EXAMPLE 158B ethyl 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-2-(3- hydroxy-2-methylphenoxy)benzoate The title compound was prepared by substituting EXAMPLE 158A for EXAMPLE 3A in EXAMPLE 3G. EXAMPLE 158C Ethyl 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-2-(3-(methoxymethoxy)-2-methylphenoxy)benzoate A mixture of EXAMPLE 158B (0.6 g), chloro(methoxy)methane (0.18 g) and cesium carbonate (0.9 g) was suspended in N,N-dimethylformamide (15 mL). After it stirred at room temperature for 30 minutes, the crude product was purified by preparative HPLC using a 250 X 50 mm C18 column and eluting with 20-100% CH3CN vs. 0.1% trifluoroacetic acid in water. EXAMPLE 158D 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-2-(3-(methoxymethoxy)-2-methylphenoxy)benzoic acid The title compound was prepared by substituting EXAMPLE 158C for EXAMPLE IE in EXAMPLE IF. 368 EXAMPLE 158E 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl jpiperazin-1 -yl)-2-[3- (methoxymethoxy)-2-methylphenoxy]-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl) sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 158D for EXAMPLE IF and EXAMPLE 31 for EXAMPLE IG in EXAMPLE IH. 'H NMR (500 MHz, dimethylsulfoxide-de) 8 8.43 (d, IH), 8.10 (d, IH), 7.73 (dd, IH), 7.54 (d, IH), 7.35 (d, 2H), 7.07 (m, 3H), 6.94 (t, IH), 6.72 (d, IH), 6.63 (dd, IH), 6.19 (m, 2H), 5.21 (s, 2H), 3.79 (m, IH), 3.40 (s, 3H), 3.09 (m, 6H), 2.73 (m, 4H), 2.56 (s, 2H), 2.19 (m, 6H), 2.07 (m, 6H), 1.96 (s, 2H), 1.74 (m, 2H), 1.40 (t, 2H), 0.94 (s, 6H). EXAMPLE 159 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl }piperazin-1 -yl)-2-(3-hydiDxy-2-methylphenoxy)-N-({4-[(l-methylpiperidin-4-yl)anuno]-3-nitrophenyl} sulfonyl)benzamide Into a 10 mL microwave tube was added EXAMPLE 158E (54 mg) and hydrogen chloride (1.25M in methanol) (0.5 mL) in tetrahydrofuran (4 mL) to give a solution. The mixture was stirred at 60 °C in a CEM Discover microwave reactor for 20 minutes. The solvent was dried under vacuum and the crude product was purified by preparative HPLC using a 250 x 50 mm C18 column and eluting with 20-100% CH3CN vs. 0.1% trifluoroacetic acid in water. The trifluoroacetic acid salt was solved in dichloromethane with ammonium and washed with saturated NajCOa, dried over Na2S04, filtered, and concentrated to afford the free base product. 'H NMR (500 MHz, dimethylsulfoxide-de) 8 9.38 (s, IH), 8.46 (d, IH), 8.13 (d, IH), 7.77 (dd, IH), 7.52 (d, IH), 7.35 (d, 2H), 7.08 (m, 3H), 6.83 (t, IH), 6.60 (dd, IH), 6.51 (d, IH), 6.08 (m, 2H), 3.03 (m, 6H), 2.73 (m, 4H), 2.19 (m, 6H), 2.00 (m, 9H), 1.71 (m, 2H), 1.40 (t, 2H), 0.94 (s, 6H). EXAMPLE 160 2-(3-bromophenoxy)-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3- yl]methyl}piperazin-l-yl)-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide EXAMPLE 160A methyl 2-(3-bromophenoxy)-4-fluorobenzoate 369 The title compound was prepared as described in EXAMPLE 3A by replacing 2-methyl-5-indolol with 3-bromophenol. EXAMPLE 160B methyl 2-(3-bromophenoxy)-4-(piperazin-l-yl)benzoate The title compound was prepared as described in EXAMPLE 3G by replacing EXAMPLE 3F and EXAMPLE 3A with piperazine and EXAMPLE 160A, respectively. EXAMPLE 160C methyl 2-(3-bromophenoxy)-4-(4-((4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran- 3 -yl)methyl)piperazin-1 -yl)benzoate The title compound was prepared as described in EXAMPLE 38G by replacing EXAMPLE 38F with EXAMPLE 160B. EXAMPLE 160D 2-(3-bromophenoxy)-4-(4-((4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3- yl)methyl)piperazin- l-yl)benzoic acid The title compound was prepared as described in EXAMPLE 38H by replacing EXAMPLE 38G with EXAMPLE 160C. EXAMPLE 160E 2-(3-bromophenoxy)-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)-N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitrophenyl} sulfonyl)benzamide The title compound was prepared as described in EXAMPLE IH by replacing EXAMPLE IF and EXAMPLE 10 with EXAMPLE 160D and EXAMPLE 31, respectively. 'H NMR (300 MHz, dimethylsulfoxide-ds) 6 8.29 (d, IH), 8.10 (m, 2H), 7.64 (d, IH), 7.60 (dd, IH), 7.40 (d, 2H), 7.15 (d, 2H), 7.06 (t, IH), 6.96 (m, 2H), 6.94 (d, IH), 6.68 (m, 3H), 6.37 (d, IH), 5.84 (m, 2H), 4.15 (m, 2H), 3.65 (m, IH), 3.09 (m, 6H), 2.99 (m, 5H), 2.87 (s, 2H), 2.75 (m, 2H), 2.26 (m, 4H), 1.98 (m, IH), 1.21 (s, 6H). 370 EXAMPLE 161 4.(4- {[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl }piperazin-1 -yl)- 2-(3-iodophenoxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl) sulfonyl)benzamide EXAMPLE 161A methyl 4-fluoro-2-(3-iodophenoxy)benzoate The title compound was prepared as described in EXAMPLE 3A by replacing 2-methyl-5-indolol with 3-iodophenol. EXAMPLE 161B methyl 2-(3-iodophenoxy)-4-(piperazin- l-yI)benzoate The title compound was prepared as described in EXAMPLE 3G by replacing EXAMPLE 3F and EXAMPLE 3A with piperazine and EXAMPLE 161 A, respectively. EXAMPLE 161C methyl 4-(4-((4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl)methyl)piperazin- 1-yl)-2-(3-iodophenoxy)benzoate The title compound was prepared as described in EXAMPLE 38G by replacing EXAMPLE 38F with EXAMPLE 161B. EXAMPLE 161D 4-(4-((4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl)methyl)piperazin-l-yl)-2- (3-iodophenoxy)benzoic acid The title compound was prepared as described in EXAMPLE 38H by replacing EXAMPLE 38G with EXAMPLE 161C. EXAMPLE 161E 4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- 2-(3-iodophenoxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl) sulfonyl)benzamide The title compound was prepared as described in EXAMPLE IH by replacing EXAMPLE IF and EXAMPLE IG with EXAMPLE 16ID and EXAMPLE 31, respectively. 371 'H NMR (300 MHz, dimethylsulfoxide-de) 5 8.34 (d, IH), 8.08 (d, IH), 7.64 (m, 2H), 7.40 (d, 2H), 7.17 (m, 3H), 6.95 (m, 3H), 6.71 (m, 2H), 6.37 (d, IH), 4.15 (s, 2H), 3.83 (m, IH), 3.15 (m, 8H), 2.87 (s, 3H), 2.60 (m, 4H), 2.17 (m, 8H), 1.76 (m, IH), 1.20 (s, 6H). EXAMPLE 162 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl Ipiperazin-1 -yl)-N- [(4- {[ 1 -(2-hydroxyethyl)piperidin-4-yl]amino} -3- nitrophenyl)sulfonyl]benzamide EXAMPLE 162A tert-butyl 4-(2-nitro-4-sulfamoylphenylamino)piperidine-1 -carboxylate The title compound was prepared by substituting tert-butyl 4-aminopiperidine-l-carboxylate for 3-(N-morpholinyl)-l-propylamine in EXAMPLE 4A. EXAMPLE 162B The title compound was prepared by substituting EXAMPLE 36C for EXAMPLE IF and EXAMPLE 162A for EXAMPLE IG in EXAMPLE IH. EXAMPLE 162C 2-(3-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-1 -yl)-N-(3 -nitro-4-(piperidin-4-ylamino)phenylsulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 162B for EXAMPLE lA in EXAMPLE IB. EXAMPLE 162D N-(4-(l-(2-(tert-butyldimethylsilyloxy)ethyl)piperidin-4-ylamino)-3-nitrophenylsulfonyl)-2-(3-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin- l-yl)benzamide The title compoimd was prepared by substituting EXAMPLE 162C for tert-butyl pieperazien-1-carboxylate and 2-(tert-butyldimethylsilyloxy)acetaldehyde for 4'-chlorobiphenyl-2-carboxaldehyde in EXAMPLE lA. 372 EXAMPLE 162E 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-N- [(4- {[ 1 -(2-hydroxyethyl)piperidin-4-yl]amino} -3- nitrophenyl)sulfonyl]benzamide A mixture of EXAMPLE 162D (270 mg) in anhydrous tetrahydrofuran (5 mL) and tetrabutyl ammonium fluoride ( 5 mL IM in tetrahydrofuran) was stirred at room temperature for 2 hours. The solvent was removed under vacuum. The residue was purified by reverse phase HPLC on a C18 column using a gradient of 40-70% acetonitrile/0.1% trifluoroacetic acid in water to give the title compound as the trifluoroacetate salt. The trifluoroacetate salt was dissolved in dichloromethane (6 mL) and washed with 50% aqueous NaHCOs. The organic layer was dried over anhydrous Na2S04 and concentrated to give the title compound. ^H NMR (400MHz, dimethylsulfoxide-dg) 6 8.35 (d, IH), 8.09 (d, IH), 7.69 (dd, IH), 7.61 (d, IH), 7.36 (d, 2H), 7.14 (m, IH), 7.05 (m, 3H), 6.88 (dd, IH), 6.73 (dd, IH), 6.65 (dd, IH), 6.60 (m, IH), 6.40 (d, IH), 3.85 (m, IH), 3.68 (m, 2H), 3.28 (m, 4H), 3.12 (m, 4H), 2.99 (m, 4H), 2.77 (s, 2H), 2.16 (m, 8H), 1.98 (s, 2H), 1.83 (m, 2H), 1.41 (t, 2H), 0.94 (s, 6H). EXAMPLE 163 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-l-yI)-N-[(3-nitro-4-{[l-(2-phenylethyl)piperidin-4-yl]amino} phenyl)sulfonyl]benzamide The title compound was prepared by substituting EXAMPLE 162C for tert-butyl pieperazien-1-caiboxylate and 2-phenylacetaldehyde for 4'-chlorobiphenyl-2-carboxaldehyde in EXAMPLE lA. 'H NMR (400MHz, dimethylsulfoxide-d^) 6 8.37 (d, IH), 8.16 (d, IH), 7.70 (dd, IH), 7.59 (d, IH), 7.30 (m, 8H), 7.16 (m, IH), 7.07 (m, 3H), 6.89 (d, IH), 6.74 (dd, IH), 6.66 (dd, IH), 6.62 (d, IH), 6.42 (d, IH), 3.84 (m, IH), 3.27 (m, 6H), 2.98 (m, 8H), 2.78 (s, 2H), 2.17 (m, 8H), 1.98 (s, 2H), 1.78 (m, 2H), 1.41 (t, 2H), 0.94 (s, 6H). EXAMPLE 164 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-(3,4- dichlorophenoxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)benzamide 373 EXAMPLE 164A Ethyl 2-(3,4-dichlorophenoxy)-4-fluoiobenzoate The title compound was prepared by substituting 2,3-dichlorophenol for 2-methyl-5-indolol in EXAMPLE 3A. EXAMPLE 164B Ethyl 2-(3,4-dichlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-1 -yl)benzoate The title compound was prepared by substituting EXAMPLE 164A for EXAMPLE 3A in EXAMPLE 3G. EXAMPLE 164C 2-(3,4-dichlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- enyl)methyl)piperazin-1 -yl)benzoic acid The title compound was prepared by substituting EXAMPLE 164B for EXAMPLE IE in EXAMPLE IF. EXAMPLE 164D 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(3,4- dichlorophenoxy)-N-( {4- [(1 -methylpiperidin-4-yl)amino]-3-nitrophenyl) sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 164C for EXAMPLE IF and EXAMPLE 31 for EXAMPLE IG in EXAMPLE IH. 'H NMR (300 MHz, dimethylsulfoxide-de) 6 8.35 (d, IH), 8.06 (s, IH), 7.62 (d, 2H), 7.31 - 7.40 (m, 3H), 7.04 -7.10 (m, 2H), 6.98 (d, IH), 6.98 (d, IH), 6.70 - 6.81 (m, 2H), 6.64 (dd, IH), 6.42 (d, IH), 3.79 (s, IH), 3.19 - 3.27 (m, 2H), 3.12 (s, 5H), 2.69 - 2.81 (m, 4H), 2.63 (s, 2H), 2.15 - 2.28 (m, 8H), 2.08 (s, 2H), 1.98 (s, 3H), 1.77 (s, IH), 1.36 -1.45 (m, 2H), 1.24 (s, IH), 0.95 (s, 6H). EXAMPLE 165 2-(2-chloro-3,5-difluorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl )piperazin- l-yl)-N-( {4-[( 1 -methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide 374 EXAMPLE 165 A Ethyl 2-(2-chloro-3,5-difluorophenoxy)-4-fluorobenzoate The title compound was prepared by substituting 2-chloro-3,5-difluorophenol for 2-methyl-5-indolol in EXAMPLE 3A. EXAMPLE 165B Ethyl 2-(2-chloro-3,5-difluorophenoxy)-4-(piperazin-1 -yl)benzoate The title compound was prepared by substituting piperazine for EXAMPLE 3F and EXAMPLE 165A for EXAMPLE 3A in EXAMPLE 3G. EXAMPLE 165C Ethyl 2-(2-chloro-3,5-difluoiophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- enyl)methyl)piperazin-1 -yl)benzoate The title compound was prepared by substituting EXAMPLE 60D for 4'-chlorobiphenyl-2-carboxaldehyde and EXAMPLE 165B for tert-butyl piperazine-1-carboxylate inEXAMPLE lA. EXAMPLE 165D 2-(2-chloro-3,5-difluorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-1 -yl)benzoic acid The title compound was prepared by substituting EXAMPLE 165C for EXAMPLE IE in EXAMPLE IF. EXAMPLE 165E 2-(2-chloro-3,5-difluorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1-yl]methyl)piperazin-l-yl)-N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitrophenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 165D for EXAMPLE IF and EXAMPLE 31 for EXAMPLE IG in EXAMPLE IH. 'H NMR (500 MHz, dimethylsulfoxide-dfi) 8 8.30 (m, IH), 8.06 (m, IH), 7.68 (m, 2H), 7.36 (d, 2H), 7.07 (d, 2H), 7.00 (d, IH), 6.78 (m, 2H), 6.45 (d, IH), 5.93 (d, IH), 3.77 (m, IH), 3.12 (m, 4H), 2.76 (s, 3H), 2.21 (m, 6H), 2.07 (m, 2H), 1.98 (s, 2H), 1.72 (m, 2H), 1.41 (t, 2H), 0.94 (s, 6H). 375 EXAMPLE 166 4.(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl jpiperazin-1 -yl)-2-(3- methoxyphenoxy)-N-( {4- [(1 -methylpiperidin-4-yl)amino] -3 -nitrophenyl} sulfonyl)benzamide EXAMPLE 166A ethyl 4-fluoro-2-(3-methoxyphenoxy)benzoate The title compound was prepared by substituting 3-methoxyphenol for 2-methyl-5-indolol in EXAMPLE 3A. EXAMPLE 166B ethyl 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-2-(3- methoxyphenoxy)benzoate The title compound was prepared by substituting EXAMPLE 166A for EXAMPLE 3A in EXAMPLE 3G. EXAMPLE 166C 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-2-(3- methoxyphenoxy)benzoic acid The title compound was prepared by substituting EXAMPLE 166B for EXAMPLE IE in EXAMPLE IF. EXAMPLE 166D 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-(3- methoxyphenoxy)-N-( {4- [(1 -methylpiperidin-4-yl)amino] -3 -nitrophenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 166C for EXAMPLE 122C and EXAMPLE 31 for EXAMPLE 1 lA in EXAMPLE 137. 'H NMR (300 MHz, dimethylsulfoxide-de) 6 8.39 (d, IH), 8.10 (br d, IH), 7.73 (dd, IH), 7.57 (d, IH), 7.37 (d, 2H), 7.05 (m, 4H), 6.68 (dd, IH), 6.45 (dd, IH), 6.30 (m, 3H), 3.80 (br m, IH), 3.64 (s, 3H), 3.18 (br m, IH), 3.07 (br m, 4H), 2.80 (br m, IH), 2.78 (s, 2H), 2.60 (s, 2H), 2.50 (s, 3H), 2.20 (br m, 6H), 2.09 (br m, 2H), 1.98 (s, 2H), 1.78 (br m, 2H), 1.40 (br t, 2H), 0.93 (s, 6H). 376 EXAMPLE 167 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-[3- (hydroxymethyl)phenoxy]-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide EXAMPLE 167 A methyl 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-2-(3- formylphenoxy)benzoate The title compound was prepared by substituting 3-hydroxybenzaldehyde for EXAMPLE ID and EXAMPLE 214A for EXAMPLE IC in EXAMPLE IE. EXAMPLE 167B 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-2-(3- formylphenoxy)benzoic acid The title compound was prepared by substituting EXAMPLE 167A for EXAMPLE IE in EXAMPLE IF. EXAMPLE 167C 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-2-(3-formylphenoxy)-N-(4-(l-methylpiperidin-4-ylamino)-3-nitrophenylsulfonyI)benzamide The title compound was prepared by substituting EXAMPLE 167B for EXAMPLE IF and EXAMPLE 31 for EXAMPLE IG in EXAMPLE IH. EXAMPLE 167D 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-[3-(hydroxymethyl)phenoxy]-N-( {4-[( 1 -methylpiperidin-4-yl)amino]-3-nitrophenyl} sulfonyl)benzamide EXAMPLE 167C (107 mg) was dissolved in ethanol (3 mL) and tetrahydrofuran (9 mL), and NaBH4 (13 mg) was added and the mixture stirred at room temperature for 10 minutes. After carefully adding 2N aqueous HCl (0.67 mL), the reaction was concentrated and the crude material was purified by preparative HPLC using a C18 column, 250 x 50 mm, lOn, and eluting with a gradient of 20-100% CH3CN vs. 0.1% trifluoroacetic acid in water, 377 giving the product as a trifluoroacetate salt. The salt was dissolved in dichloromethane (6 mL) and washed with 50% aqueous NaHCOj. The organic layer was dried over anhydrous Na2S04, filtered, and concentrated to give the title compound. 'H NMR (500 MHz, CDCl3/methanol-d4) 5 8.80 (d, IH), 8.45 (brd, IH), 8.03 (dd, IH), 7.86 (d, IH), 7.39 (m, IH), 7.27 (m, 3H), 7.09 (s, IH), 6.95 (d, 4H), 6.60 (dd, IH), 6.12 (d, IH), 4.67 (s, 2H), 3.63 (br s, IH), 3.15 (br t, 4H), 2.82 (br s, IH), 2.80 (s, 3H), 2.35 (m, 5H), 2.28 (br t, 4H), 2.20 (br t, 2H), 2.10 (br m, 2H), 1.99 (s, 2H), 1.73 (m, 2H), 1.43 (t, 2H), 0.94 (s, 6H). EXAMPLE 168 2-(2-chloiophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({4-[(l,4-dimethylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzaniide EXAMPLE 168A tert-butyl4-(benzyloxycarbonylamino)-4-methylpiperidine-l-carboxylate l-(tert;-butoxycarbonyl)-4-methylpiperidine-4-caiboxylic acid (5.0 g), diphenylphosphoryl azide (DPPA, 4.58 mL), triethylamine (2.86 mL), and benzyl alcohol (4.26 mL) were stirred in toluene (45 mL) at 110°C for 24 hours. The mixture was cooled, concentrated, and chromatographed on silica gel using 10% ethyl acetate/hexanes as eluent to give the pure product. EXAMPLE 168B tert-butyl 4-amino-4-methylpiperidine- 1-carboxylate EXAMPLE 168A (4.5 g) and ethanol (100 mL) were added to 20% Pd(0H)2-C, wet (0.900 g) in a 250 mL SS pressure bottle and stirred for 3 hours at 30 psi and room temperature. The mixture was filtered through a nylon membrane and concentrated to give the product. EXAMPLE 168C tert-butyl 4-methyl-4-(2-nitro-4-sulfamoylphenylamino)piperidine-1 -carboxylate The title compound was prepared by substituting EXAMPLE 168B for 3-(n-morpholinyl)-l-propylamine in EXAMPLE 4A. 378 EXAMPLE 168D 4-(4-methylpiperidin-4-ylamino)-3-mtrobenzenesulfonamide The title compound was prepared by substituting EXAMPLE 168C for EXAMPLE lA in EXAMPLE IB. EXAMPLE 168E 4-(l,4-dimethylpiperidin-4-ylamino)-3-nitrobenzenesulfonamide EXAMPLE 168D (L33 g), iodomethane (0.29 mL), and triethylamine (0.65 mL) in acetonitrile (20 mL) were stirred for 1 hour. The mixture was concentrated and chromatographed on sihca gel using 10% methanol/dichloromethane as eluent to give the product. EXAMPLE 168F 2-(2-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N-( {4- [(1,4-dimethylpiperidin-4-yl)amino]-3-nitrophenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 34C for EXAMPLE IF and EXAMPLE 168E for EXAMPLE IG in EXAMPLE IH. 'H NMR (300MHZ, dimethylsulfoxide-dfi) 6 8.55 (m, IH), 8.43 (d, IH), 7.82 (d, IH), 7.52 (d, IH), 7.43 (d, IH), 7.38 (d, 2H), 7.18 (dd, IH), 7.09 (d, 2H), 7.05 (m, IH), 6.76 (d, 2H), 6.34 (d, IH), 2.94-3.12 (m, IIH), 2.70 (m, 4H), 2.27 (m, 4H), 2.00 (s, 3H), 1.55 (s, 3H), 1.41 (m, 2H), 0.95 (s, 6H). EXAMPLE 169 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-N-( {4- [(1,4-dimethylpiperidin-4-yl)amino] -3-nitrophenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 36C for EXAMPLE IF and EXAMPLE 168E for EXAMPLE IG in EXAMPLE IH. 'H NMR (300MHz, dimethylsulfoxide-de) 5 8.49 (m, IH), 8.40 (d, IH), 7.75 (d, IH), 7.54 (d, IH), 7.37 (d, 2H), 7.27 (m, 1H),.7.22 (t, IH), 7.07 (d, 2H), 7.00 (d, IH), 6.77 (d, IH), 6.72 (d, IH), 6.45 (d, IH), 3.20 (m, 4H), 3.05 (m, 6H), 2.88 (m, 2H), 2.73 (m, 4H), 2.27 (m, 4H), 2.20 (m, 2H), 1.99 (s, 3H), 1.55 (s, 3H), 1.41 (t, 2H), 0.95 (s, 6H). 379 EXAMPLE 170 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl Ipiperazin-1 -yl)-N- {[4-( {1 -[2-(2-methoxyethoxy)ethyl]piperidin-4-yl} amino)-3- nitrophenyl]sulfonyl }benzamide A mixture of EXAMPLE 162C (100 mg), l-bromo-2-(2-methoxyethoxy)ethane (52 mg), cesium carbonate (70 mg) in N,N-dimethylformamide was heated at 60°C overnight. The solvent was removed under vacuum. The residue was purified by reverse phase HPLC on a C18 column using a gradient of 40-70% acetonitrile/0.1% TEA in water to give the title compound as the trifluoroacetate salt. The TEA salt was dissolved in dichloromethane (6 mL) and washed with 50% aqueous NaHCOs- The organic layer was dried over anhydrous Na2S04 and concentrated to give the title compound. 'H NMR (400MHz, dimethylsulfoxide-d6) 5 8.36 (d, IH), 8.12 (d, IH), 7.69 (dd, IH), 7.59 (d, IH), 7.35 (d, 2H), 7.14 (m, IH), 7.05 (m, 3H), 6.89 (m, IH), 6.74 (dd, IH), 6.66 (dd, IH), 6.60 (m, IH), 6.40 (d, IH), 3.81 (s, IH), 3.65 (t, 2H), 3.56 (m, 2H), 3.47 (m, 2H), 3.31 (m, 2H), 3.26 (m, 3H), 3.18 (m, 2H), 3.13 (m, 2H), 2.97 (m, 2H), 2.77 (m, 4H), 2.21 (m, 7H), 2.07 (m, 2H), 1.98 (s, 2H), 1.76 (m, 2H), 1.41 (t, 2H), 0.94 (s, 6H). EXAMPLE 171 2-(2-chloro-3-hydroxyphenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1- yl]methyl }piperazin- l-yl)-N-( {4-[( l-methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide EXAMPLE 171A 2-chloro-3-(methoxymethoxy)phenol The title compound was prepared by substituting 2-chlorobenzene-l,3-diol for EXAMPLE 158B in EXAMPLE 158C. EXAMPLE 17 IB Methyl 2-(2-chloro-3-(methoxymethoxy)phenoxy)-4-fluorobenzoate The title compound was prepared by substituting 171A for 2-methyl-5-indolol in EXAMPLE 3A. 380 EXAMPLE 17IC Methyl 2-(2-chloio-3 -(methoxymethoxy)phenoxy )-4-(piperazin-1 -yl)beiizoate The title compound was prepared by substituting piperazine for EXAMPLE 3F and EXAMPLE 171B for EXAMPLE 3A in EXAMPLE 3G. EXAMPLE 171D Methyl 2-(2-chloro-3-(methoxymethoxy)phenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)benzoate The title compound was prepared by substituting EXAMPLE 60D for 4'-chlorobiphenyl-2-carboxaldehyde and EXAMPLE 17IC for tert-butyl piperazine-1-carboxylate inEXAMPLE lA. EXAMPLE 171E 2-(2-chloro-3-(methoxymethoxy)phenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -enyl)methyl)piperazin-1 -yl)benzoic acid The title compound was prepared by substituting 17ID for EXAMPLE IE in EXAMPLE IF. EXAMPLE 17 IF 2-(2-chloro-3-(methoxymethoxy)phenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex- l-enyl)methyl)piperazin-1 -yl)-N-(4-( 1 -methylpiperidin-4-ylamino)-3- nitrophenylsulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 171E for EXAMPLE IF and EXAMPLE 31 for EXAMPLE IG in EXAMPLE IH. EXAMPLE 1710 2-(2-chloro-3-hydroxyphenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl) sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 17IF for EXAMPLE 158 in EXAMPLE 159. 'H NMR (500 MHz, dimethylsulfoxide-de) 8 10.13 (s, IH), 8.41 (d, IH), 8.08 (d, IH), 7.77 (dd, IH), 7.60 (d, IH), 7.35 (d, 2H), 7.07 (m, 3H), 6.89 (t, IH), 6.67 (dd, IH), 6.59 (m, IH), 6.19 (d, IH), 6.08 (d, IH), 3.80 (m, IH), 3.09 (m, 6H), 2.79 (m, 4H), 2.57 (s, 3H), 2.21 (m, 6H), 2.08 (m, 2H), 1.97 (s, 2H), 1.74 (m, 2H), 1.40 (t, 2H), 0.94 (s, 6H). 381 EXAMPLE 172 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-l-yl)-N-[(3-mtro-4-{[l-(3-phenylpropyl)piperidin-4-yl]amino}phenyl)sulfonyl]benzamide The title compound was prepared by substituting EXAMPLE 162C for tert-butyl pieperazien-1-carboxylate and 3-phenylpropanal for 4'-chlorobiphenyl-2-carboxaldehyde in EXAMPLE lA. 'H NMR (400MHZ, dimethylsulfoxide-de) 5 8.36 (d, IH), 8.10 (m, IH), 7.69 (m, IH), 7.59 (d, IH), 7.36 (d, 2H), 7.31 (m, 2H), 7.22 (m, 3H), 7.14 (m, IH), 7.07 (d, 2H), 7.02 (d, IH), 6.88 (d, IH), 6.74 (dd, IH), 6.65 (dd, IH), 6.60 (m, IH), 6.41 (d, IH), 3.84 (m, IH), 3.29 (m, 4H), 3.12 (m, 4H), 2.81 (m, 5H), 2.64 (m, 2H), 2.22 (m, 6H), 2.10 (m, 2H), 1.99 (m, 2H), 1.90 (m, 2H), 1.75 (m, 2H), 1.40 (t, 2H), 0.94 (s, 6H). EXAMPLE 173 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl jpiperazin-1 -yl)-N-[(4- {[ 1 -(2-methoxyethyl)piperidin-4-yl]amino} -3- nitrophenyl)sulfonyl]benzamide The title compound was prepared by substituting l-bromo-2-methoxyethane for 1-biomo-2-(2-methoxyethoxy)ethane in EXAMPLE 170. 'H NMR (400MHz, dimethylsulfoxide-de) 5 8.36 (d, IH), 8.13 (d, IH), 7.69 (dd, IH), 7.59 (d, IH), 7.36 (d, 2H), 7.15 (m, IH), 7.06 (m, 3H), 6.89 (dd, IH), 6.74 (dd, IH), 6.66 (dd, IH), 6.61 (d, IH), 6.41 (d, IH), 3.82 (m, IH), 3.57 (t, 2H), 3.38 (m, 4H), 3.13 (m, 6H), 2.99 (m, 2H), 2.89 (m, IH), 2.78 (s, 3H), 2.21 (m, 6H), 2.08 (m, 2H), 1.98 (s, 2H), 1.78 (m, 2H), 1.41 (t, 2H), 0.94 (s, 6H). EXAMPLE 174 2-(3-chlorophenoxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-({4-[(l-ethyIpiperidin-4-yl)amino]-3-nitrophenyl) sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 36C for EXAMPLE IF and EXAMPLE 47A for EXAMPLE IG in EXAMPLE IH. 'H NMR (300 MHz, dimethylsulfoxide-dfi) 5 8.34 (d, IH), 8.07 (s, IH), 7.58 - 7.71 (m, 2H), 7.36 (d, 2H), 7.00 -7.14 (m, 4H), 6.85 - 6.94 (m, IH), 6.73 (dd, IH), 6.64 (dd, IH), 6.59 (d, IH), 6.39 (d, IH), 3.86 (s, IH), 3.11 (s, 5H), 2.94 (d, 2H), 2.72 - 2.81 (m, 3H), 2.12 - 2.27 (m, 8H), 1.98 (s, 2H), 1.77 (s, 2H), 1.41 (t, 2H), 1.18 (t, 3H), 0.94 (s, 6H). 382 EXAMPLE 175 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl}piperazin-l-yl)-N-({4-[(l-isopropylpiperidin-4-yl)amino]-3-nitiophenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 36C for EXAMPLE IF and EXAMPLE 41A for EXAMPLE IG in EXAMPLE IH. 'H NMR (300 MHz, dimethylsulfoxide-dfi) 8 8.98 (bs, IH), 8.34 (d, IH), 8.04 (s, IH), 7.59 - 7.73 (m, 2H), 7.36 (d, 2H), 7.14 (t, IH), 7.04 - 7.09 (m, 2H), 7.01 (d, IH), 6.87 (d, IH), 6.72 (dd, IH), 6.61 - 6.66 (m, IH), 6.58 (s, IH), 6.39 (d, IH), 3.90 (s, IH), 3.11 (s, 6H), 2.73 - 2.83 (m, 2H), 2.14 - 2.28 (m, 9H), 1.98 (s, 3H), 1.76 (s, 2H), 1.41 (t, 3H), 1.14 - 1.29 (m, 6H), 0.94 (s, 6H). EXAMPLE 176 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyc]ohex-1 -en-1 -yl]methyl )piperazin-1 -yl)-2-(3- hydroxyphenoxy)-N-( {4- [(1 -methylpiperidin-4-yl)amino]-3-nitrophenyl} sulfonyl)benzamide EXAMPLE 176A Ethyl 2-(3-hydroxyphenoxy)-4-fluorobenzoate The title compound was prepared by substituting resorcinol for 2-methyl-5-indolol in EXAMPLE 3A. EXAMPLE 176B Ethyl 2-(3-hydroxyphenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- enyl)methyl)piperazin-1 -yl)benzoate The title compound was prepared by substituting EXAMPLE 176A for EXAMPLE 3A in EXAMPLE 3G. EXAMPLE 176C Ethyl 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)-2-(3- (methoxymethoxy)phenoxy)benzoate A suspension of EXAMPLE 176B (0.295 g), methoxymethyl chloride (0.117 mL) and cesium carbonate (0.334 g) in N.N-dimethylformamide (3 mL) was stirred at 60 °C for 16 hours. The reaction mixture was partitioned between dichloromethane and water. The water 383 layer was extracted with dichloromethane. The combined organic extracts were washed with water (2 x), dried over magnesium sulfate, filtered and concentrated. The crude product was purified by flash chromotography (silica gel, 5% - 20% ethyl acetate / hexanes) providing the product. EXAMPLE 176D 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-2-(3-(methoxymethoxy)phenoxy)benzoic acid The title compound was prepared by substituting EXAMPLE 176C for EXAMPLE IE in EXAMPLE IF. EXAMPLE 176E 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-2-(3- (methoxymethoxy)phenoxy)-N-(4-(l-methylpiperidin-4-ylamino)-3- nitrophenylsulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 176D for EXAMPLE IF and EXAMPLE 31 for EXAMPLE IG in EXAMPLE IH. EXAMPLE 176F 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl }piperazin- l-yl)-2-(3- hydroxyphenoxy)-N-( {4- [(1 -methylpiperidin-4-yl)amino]-3 -nitrophenyl} sulfonyl)benzamide A suspension of EXAMPLE 176E (35.5 mg) in tetrahydiofiiran (3 mL) and HCl (1.25M in methanol, 2 mL) was stirred for 1 hour at 60 °C. The product was concentrated. The crude product was purified by RP HPLC(C8, 30% -100% CH3CN/water/0.1% TEA) to yield the product. 'H NMR (300 MHz, dimethylsulfoxide-de) 6 9.31 (s, IH), 8.10 (s, IH), 7.66 - 7.73 (m, 2H), 7.56 (d, IH), 7.34 - 7.38 (m, 2H), 7.02 - 7.09 (m, 2H), 6.95 - 7.02 (m, IH), 6.65 (dd, IH), 6.34 (s, IH), 6.29 (d, IH), 6.20 (d, IH), 6.14 (d, IH), 4.14 (dd, IH), 3.75 (s, IH), 3.05 (d, 4H), 2.68 - 2.80 (m, 3H), 2.20 (d, 6H), 2.08 (d, 2H), 1.97 (s, 2H), 1.69 - 1.79 (m, 2H), 1.63 (s, IH), 1.39 (d, 2H), 1.21 -1.36 (m, 9H), 0.94 (s, 6H). 384 EXAMPLE 177 2-(2-chloro-3-fluorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide EXAMPLE 177 A 2-chloro-3-fluorophenol To a solution of 2-chloro-3-fluorophenylboronic acid (5.0 g) in tetrahydrofuran (50 mL) and IM aqueous NaOH (30 mL) at 0°C was added 30% hydrogen peroxide solution (4 mL), and the reaction was stirred for 2 hours. The reaction was quenched with saturated aqueous Na2S203 solution, acidified with concentrated aqueous HCl, and extracted twice with ethyl acetate. The combined extracts were washed with brine, concentrated, and chromatographed on silica gel using 10% ethyl acetate/hexanes as eluent to give the product. EXAMPLE 177B methyl 2-(2-chloro-3-fluorophenoxy)-4-fluorobenzoate The title compound was prepared by substituting EXAMPLE 177A for 2-methyl-5-indolol and methyl 2,4-difluoiobenzoate for ethyl 2,4-difluorobenzoate in EXAMPLE 3A. EXAMPLE 177C methyl 2-(2-chloro-3-f]uorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 - enyl)methyl)piperazin-1 -yl)benzoate The title compound was prepared by substituting EXAMPLE 177B for methyl 2-bromo-4-fluoix)benzoate and EXAMPLE 3F for EXAMPLE IB in EXAMPLE IC. EXAMPLE 177D 2-(2-chloro-3-fluorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-1 -yl)benzoic acid The title compound was prepared by substituting EXAMPLE 177C for EXAMPLE IE in EXAMPLE IF. EXAMPLE 177E 2-(2-chloro-3-fluorophenoxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1- yl]methyl}piperazin-l-yl)-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide 385 The title compound was prepared by substituting EXAMPLE 177D for EXAMPLE IF and EXAMPLE 31 for EXAMPLE IG in EXAMPLE IH. 'H NMR (300MHZ, dimethylsulfoxide-d6) 6 8.39 (d, IH), 8.15 (m, IH), 7.76 (d, IH), 7.58 (d, IH), 7.37 (d, 2H), 7.15 (d, IH), 7.07 (d, 2H), 7.02 (m, IH), 6.88 (t, IH), 6.77 (d, IH), 6.44 (s, IH), 6.33 (d, IH), 3.91 (m, IH), 3.18 (m, 4H), 3.07 (m, 2H), 2.77 (m, 6H), 2.27 (m, 4H), 2.19 (m, 4H), 1.99 (s, 3H), 1.77 (m, 2H), 1.41 (t, 2H), 0.95 (s, 6H). EXAMPLE 178 2-(2-chloro-3-fluorophenoxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-N-({3-nitro-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]pheny]} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 177D for EXAMPLE IF and EXAMPLE 49C for EXAMPLE IG in EXAMPLE IH. 'H NMR (300MHz, dimethylsulfoxide-de) 5 8.28 (d, IH), 8.10 (m, IH), 7.65 (d, IH), 7.62 (d, IH), 7.37 (d, 2H), 7.08 (d, 2H), 6.98 (m, 2H), 6.80 (t, IH), 6.74 (d, IH), 6.37 (d, IH), 6.22 (d, IH), 3.89 (m, IH), 3.28 (m, 4H), 3.09 (m, 6H), 2.84 (m, 4H), 2.73 (m, 3H), 2.40 (m, 2H), 2.23 (m, 6H), 2.01 (m, IH), 1.99 (s, 3H), 1.68 (m, 2H), 1.55 (m, 4H), 1.41 (t, 2H), 0.94 (s, 6H). EXAMPLE 179 2-(2-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-N-[(4- {[3-(dimethylamino)propyl]amino} -3-nitrophenyl)sulfonyl]benzamide The title compound was prepared by substituting EXAMPLE 34C for EXAMPLE 122C in EXAMPLE 137. 'H NMR (300 MHz, dimethylsulfoxide-de) 6 8.50 (br t, IH), 8.38 (d, IH), 7.75 (dd, IH), 7.63 (d, IH), 7.37 (m, 3H), 7.06 (m, 3H), 6.98 (d, IH), 6.92 (ddd, IH), 6.70 (dd, IH), 6.56 (dd, IH), 6.24 (d, IH), 3.47 (dd, 2H), 3.05 (br m, 4H), 2.90 (br m, 2H), 2.75 (s, 2H), 2.60 (s, 6H), 2.20 (br m, 6H), 1.98 (s, 2H), 1.90 (m, 2H) 1.40 (t, 2H), 0.93 (s, 6H). EXAMPLE 180 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-(2- methoxyphenoxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)benzamide 386 EXAMPLE 180 A ethyl 4-fluoro-2-(2-methoxyphenoxy)benzoate The title compound was prepared by substituting 2-methoxyphenol for 2-methyl-5-indolol in EXAMPLE 3A. EXAMPLE 180B ethyl 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)-2-(2- methoxyphenoxy)benzoate The title compound was prepared by substituting EXAMPLE 180A for EXAMPLE 3A in EXAMPLE 3G. EXAMPLE 180C 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-2-(2- methoxyphenoxy)benzoic acid The title compound was prepared by substituting EXAMPLE 180B for EXAMPLE IE in EXAMPLE IF. EXAMPLE 180D 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl jpiperazin-1 -yl)-2-(2- methoxyphenoxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 180C for EXAMPLE 122C and EXAMPLE 31 for EXAMPLE 1 lA in EXAMPLE 137. 'H NMR (300 MHz, dimethylsulfoxide-de) 6 8.47 (d, IH), 8.15 (br d, IH), 7.83 (dd, IH), 7.57 (d, IH), 7.37 (d, 2H), 7.13 (d, IH), 7.05 (m, 4H), 6.80 (m, 2H), 6.60 (dd, IH), 6.07 (d, IH), 3.80 (br m, IH), 3.73 (s, 3H), 3.22 (br m, IH), 3.05 (br m, IH), 3.00 (br m, 4H), 2.75 (s, 2H), 2.62 (br s, 2H), 2.50 (s, 3H), 2.20 (br m, 6H), 2.04 (br m, 2H), 1.98 (s, 2H), 1.73 (br m, 2H), 1.40 (br t, 2H), 0.93 (s, 6H). EXAMPLE 181 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl }piperazin-1 -yl)-2-(2- methylphenoxy)-N-( {4-[( l-methylpiperidin-4-yl)amino]-3-nitiophenyl} sulfonyl)benzamide 387 EXAMPLE 181A ethyl 4-fluoro-2-(2-methylphenoxy)benzoate The title compound was prepared by substituting 2-methylphenol for 2-methyl-5-indolol in EXAMPLE 3A. EXAMPLE 18 IB ethyl 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)niethyl)piperazin-1 -yl)-2-(2- methylphenoxy)benzoate The title compound was prepared by substituting EXAMPLE 181A for EXAMPLE 3A in EXAMPLE 3G. EXAMPLE 181C 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-2-(2- methylphenoxy)benzoic acid The title compound was prepared by substituting EXAMPLE 181B for EXAMPLE IE in EXAMPLE IF. EXAMPLE 18 ID 4-(4- {[2-(4-chlorophenyl)-4,4-dimethy Icyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-(2- methylphenoxy)-N-({ 4-[( 1 -methylpiperidin-4-yl)amino]-3-nitrophenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 181C for EXAMPLE 122C and EXAMPLE 31 for EXAMPLE 11A in EXAMPLE 137. 'H NMR (300 MHz, dimethylsulfoxide-de) 6 8.40 (d, IH), 8.12 (br d, IH), 7.73 (dd, IH), 7.54 (d, IH), 7.37 (d, 2H), 7.10 (m, 2H), 7.05 (d, 2H), 6.96 (m, IH), 6.84 (m, IH), 6.64 (dd, IH), 6.46 (d, IH), 6.20 (d, IH), 3.80 (br m, IH), 3.10 (br m, 3H), 3.05 (br m, 4H), 2.77 (s, 2H), 2.76 (br m, 2H), 2.58 (s, 2H), 2.20 (br m, 6H), 2.16 (s, 3H), 2.09 (br m, 2H), 1.98 (s, 2H), 1.78 (br m, 2H), 1.40 (br t, 2H), 0.93 (s, 6H). EXAMPLE 182 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-l -yl)-2-(3- methylphenoxy)-N-({ 4-[( 1 -methylpiperidin-4-yl)amino]-3-nitrophenyl} sulfonyl)benzamide EXAMPLE 182 A ethyl 4-fluoro-2-(3-methylphenoxy)benzoate 388 The title compound was prepared by substituting 3-methylphenol for 2-methyl-5-indolol in EXAMPLE 3A. EXAMPLE 182B ethyl 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-2-(3- methylphenoxy)benzoate The title compound was prepared by substituting EXAMPLE 182A for EXAMPLE 3A in EXAMPLE 3G. EXAMPLE 182C 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-2-(3- methylphenoxy)benzoic acid The title compound was prepared by substituting EXAMPLE 182B for EXAMPLE IE in EXAMPLE IF. EXAMPLE 182D 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl jpiperazin- l-yl)-2-(3- methylphenoxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 182C for EXAMPLE 122C and EXAMPLE 31 for EXAMPLE 11A in EXAMPLE 137. 'H NMR (300 MHz, dimethylsulfoxide-de) 5 8.40 (d, IH), 8.10 (br d, IH), 7.74 (dd, IH), 7.56 (d, IH), 7.36 (d, 2H), 7.05 (m, 4H), 6.73 (d, IH), 6.67 (dd, IH), 6.52 (m, 2H), 6.29 (d, IH), 3.80 (br m, IH), 3.10 (br m, 3H), 3.05 (br m, 4H), 2.77 (s, 2H), 2.76 (br m, 2H), 2.58 (s, 2H), 2.20 (br m, 6H), 2.16 (s, 3H), 2.09 (br m, 2H), 1.98 (s, 2H), 1.78 (br m, 2H), 1.40 (br t, 2H), 0.93 (s, 6H). EXAMPLE 183 2-(2-chlorophenoxy)-4-(4- {[6-(4-chlorophenyl)-1,3-benzodioxol-5-yl]methyl jpiperazin-1 - yl)-N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)benzamide EXAMPLE 183A 6-(4-chlorophenyl)benzo[d][l,3]dioxole-5-carbaldehyde To a solution of 6-bromobenzo[d][l,3]dioxole-5-carbaldehyde (4.6 g), 4-chlorophenylboronic acid (3.78 g) and tetrakis(triphenylphosphine)palladium(0) (0.232 g) in 389 toluene (80 mL) and methanol (30 mL) was added 2N aqueous Na2C03 (30 mL). The mixture was stirred at reflux overnight. The mixture was diluted with ether (400 mL) and washed with water, brine and dried over Na2S04- After filtration and concentration of the solvent, the residue was loaded on a column and eluted with 3% ethyl acetate in hexane to give the product. EXAMPLE 183B methyl 2-(2-chlorophenoxy)-4-(4-((6-(4-chlorophenyl)benzo[d][l,3]dioxol-5- y l)methyl)piperazin-1 -yl)benzoate The title compound was prepared as described in EXAMPLE 38G by replacing EXAMPLE 38E with EXAMPLE 183A. EXAMPLE 183C 2-(2-chlorophenoxy)-4-(4-((6-(4-chlorophenyl)benzo[d] [ 1,3]dioxol-5-yl)methyl)piperazin-1 - yl)benzoic acid The title compound was prepared as described in EXAMPLE 38H by replacing EXAMPLE 38G with EXAMPLE 183B. EXAMPLE 183D 2-(2-chlorophenoxy)-4-(4- {[6-(4-chlorophenyl)-1,3-benzodioxol-5-yl]methyl }piperazin-1 -yl)-N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)benzamide The title compound was prepared as described in EXAMPLE IH by replacing EXAMPLE IF and EXAMPLE IG with EXAMPLE 183C and EXAMPLE 3L respectively. 'H NMR (300 MHz, dimethylsulfoxide-de) 6 8.35 (d, IH), 8.07 (d, IH), 7.73 (dd, IH), 7.64 (d, IH), 7.38 (m, 6H), 7.02 (m, 3H), 6.86 (m, IH), 6.79 (s, IH), 6.72 (dd, IH), 6.51 (d, IH), 6.28 (d, IH), 6.04 (s, 2H), 3.81 (m, IH), 3.25 (s, 3H), 3.08 (m, 6H), 2.72 (m, 5H), 2.33 (m, 4H), 2.07 (m, 2H), 1.74 (m, IH). EXAMPLE 184 2-(2-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({4-[(4-methylpiperazin-l-yl)amino]-3- nitrophenyl) sulfonyl)benzamide 390 EXAMPLE 184A 4-(4-methylpiperazin-l-ylamino)-3-nitrobenzenesulfonamide The title compound was prepared by substituting 4-methylpiperazin-l-amine for 3-(N-morpholinyl)-l-propylamine in EXAMPLE 4A. EXAMPLE 184B 2-(2-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-l-yl)-N-({4-[(4-methylpiperazin-l-yl)amino]-3-nitrophenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 34C for EXAMPLE IF and EXAMPLE 184A for EXAMPLE IG in EXAMPLE IH. 'H NMR (500 MHz, dimethylsulfoxide-dfi) 8 9.14 (s, IH), 8.38 (d, IH), 7.77 (dd, IH), 7.55 (m, 2H), 7.37 (m, 3H), 7.08 (m, 3H), 6.95 (m, IH), 6.72 (dd, IH), 6.62 (d, IH), 6.27 (d, IH), 3.10 (m, 4H), 2.97 (m, 4H), 2.77 (s, 2H), 2.45 (s, 3H), 2.20 (m, 6H), 1.97 (s, 2H), 1.40 (t, 2H), 0.94 (m, 6H). EXAMPLE 185 2-(3-chlorophenoxy)-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl Ipiperazin- l-yl)-N-({4-[(4-methylpiperazin- l-yl)amino]-3-nitrophenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 38H for EXAMPLE IF and EXAMPLE 184A for EXAMPLE IG in EXAMPLE IH. 'H NMR (500 MHz, dimethylsulfoxide-dfi) 5 9.15 (s, IH), 8.34 (d, IH), 7.68 (dd, IH), 7.57 (d, IH), 7.51 (d, IH), 7.39 (d, 2H), 7.16 (m, 3H), 6.92 (m, IH), 6.75 (dd, IH), 6.68 (dd, IH), 6.64 (m, IH), 6.43 (d, IH), 4.15 (s, 2H), 3.15 (m, 6H), 2.99 (m, 6H), 2.88 (s, 2H), 2.49 (s, 3H), 2.26 (m, 4H), 2.17 (s, 2H), 1.20 (s, 6H). EXAMPLE 186 4-(4-([4-(4-chloK)phenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)-2-(2,3-difluorophenoxy)-N-({4-[(4-methylpiperazin-l-yl)amino]-3-nitrophenyl} sulfony l)benzamide The tide compound was prepared by substituting EXAMPLE 1456 for EXAMPLE IF and EXAMPLE 184A for EXAMPLE IG in EXAMPLE IH. 'H NMR (500 MHz, dimethylsulfoxide-de) 8 9.15 (s, IH), 8.34 (d, IH), 7.74 (dd, IH), 7.60 (d, IH), 7.54 (d, IH), 7.40 (d, 2H), 7.16 (d, 2H), 6.87 (m, 2H), 6.74 (dd, IH), 6.46 (d, IH), 6.34 (m, IH), 4.15 (s, 391 2H), 3.14 (m, 6H), 3.00 (m, 4H), 2.88 (s, 2H), 2.52 (s, 3H), 2.26 (m, 4H), 2.17 (s, 2H), 1.21 (s, 6H). EXAMPLE 187 2-(3-chloiophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yljmethyl} piperazin-1 -yl)-N- [(4- {[ 1 -(cyclopropylmethyl)piperidin-4-yl] amino} -3 - nitrophenyl)sulfonyl]benzaniide EXAMPLE 187A tert-butyl4-(4-(N-(2-(3-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin- l-yl)benzoyl)sulfamoyl)-2-nitrophenylamino)piperidine-1 -carboxylate The tide compound was prepared by substituting EXAMPLE 36C for EXAMPLE IF and EXAMPLE 162A for EXAMPLE IG in EXAMPLE IH. EXAMPLE 187B 2-(3-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- enyl)methyl)piperazin-l-yl)-N-(3-nitro-4-(piperidin-4-ylamino)phenylsulfonyl)benzamide EXAMPLE 187A was treated with TFA (0.5 mL) and stirred for 6 hours. The pixxluct was concentrated and purified by RP HPLC(C8, 30% - 100% CH3CN/water/0.1% TFA). EXAMPLE 187C 2-(3-chlorophenoxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl} piperazin-1 -yl)-N- [(4- {[ l-(cyclopropylmethyl)piperidin-4-yl]amino) -3- nitrophenyl)sulfonyI]benzamide A suspension of EXAMPLE 187B (50 mg), cyclopropanecarbaldehyde (1(X) mg) and MP-CNBH3 resin (0.2 g, 2.43 mmol/g) in dichloromethane (4 mL) / methanol (3 mL) was shaken for 16 hours at room temperature. The product was filtered, washed with dichloromethane/methanol and concentrated. The crude product was purified by RP HPLC(C8, 30% - 100% CHaCN/water/0.1% TFA) to yield the product. 'H NMR (300 MHz, dimethylsulfoxide-de) 5 8.35 (s, IH), 8.10 (s, IH), 7.67 - 7.75 (m, IH), 7.60 (d, IH), 7.36 (d, 2H), 7.15 (t, IH), 7.07 (d, 3H), 6.89 (d, IH), 6.73 (dd, IH), 6.63 (s, IH), 6.60 (s, IH), 6.40 (s, IH), 3.86 (s, IH), 3.12 (s, 5H), 2.71 - 2.80 (m, 3H), 2.13 - 2.28 (m, 9H), 1.98 (s, 3H), 1.79 (s, IH), 1.41 (t, 2H), 0.99 - 1.11 (m, 2H), 0.94 (s, 6H), 0.84 (d, IH), 0.63 (d, 2H), 0.33 (s, 2H). 392 EXAMPLE 188 2-(2-chloiophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yljmethyl} piperazin-1 -yl)-N- [(4- {[ 1 -(cyclopropylmethyl)piperidin-4-yl] amino} -3 - nitrophenyl)sulfonyl]benzamide EXAMPLE 188 A tert-butyl4-(4-(N-(2-(2-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)benzoyl)sulfamoyl)-2-nitrophenylamino)piperidine-l-carboxylate The title compound was prepared by substituting EXAMPLE 34C for EXAMPLE IF and EXAMPLE 162A for EXAMPLE IG in EXAMPLE IH. EXAMPLE 188B 2-(3-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-N-(3-nitro-4-(piperidin-4-ylamino)phenylsulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 188A for EXAMPLE 187A in EXAMPLE 187B. EXAMPLE 188C 2-(2-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-[(4-{[l-(cyclopropylmethyl)piperidin-4-yl]amino)-3- nitrophenyl)sulfonyl]benzamide The title compound was prepared by substituting EXAMPLE 188B for EXAMPLE 187B in EXAMPLE 187C. 'H NMR (300 MHz, dimethylsulfoxide-dg) 5 8.41 (d, IH), 8.13 (s, IH), 7.79 (dd, IH), 7.58 (d, IH), 7.33 - 7.40 (m, 3H), 7.04 - 7.16 (m, 4H), 6.94 (t, IH), 6.72 (dd, IH), 6.61 (s, IH), 6.27 (d, IH), 3.91 (s, IH), 3.44 (s, 2H), 3.02 - 3.15 (m, 5H), 2.95 (s, 2H), 2.69 - 2.82 (m, 3H), 2.13 - 2.28 (m, 8H), 1.97 (s, 3H), 1.83 (s, 2H), 1.32 - 1.46 (m, 3H), 0.99 - 1.10 (m, IH), 0.94 (s, 6H), 0.76 - 0.90 (m, IH), 0.59 - 0.71 (m, 2H), 0.34 (d, 2H). EXAMPLE 189 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl} piperazin-1 -yl)-N- {[4-( {1 - [2-(dimethylamino)-2-oxoethyl]piperidin-4-yl} amino)- 3-nitrophenyl]sulfonyl) benzamide 393 The title compound was prepared by substituting 2-chloro-N,N-dimethylacetaniide for l-bromo-2-(2-methoxyethoxy)ethane in EXAMPLE 170. 'H NMR (400MHZ, dimethylsulfoxide-de) 5 9.63 (s, IH), 8.46 (s, IH), 8.21 (m, IH), 7.78 (m, IH), 7.53 (d, IH), 7.40 (d, 2H), 7.22 (m, 2H), 7.11 (d, 2H), 6.96 (d, IH), 6.82 (dd, IH), 6.72 (m, 2H), 6.57 (s, IH), 4.28 (m, 2H), 3.85 (m, 8H), 3.16 (m, 4H), 2.96 (m, 7H), 2.82 (m, 2H), 2.11 (m, 8H), 1.47 (s,2H), 0.96 (s,6H). EXAMPLE 190 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl) piperazin-1 -yl)-N- [(4- {[ 1 -(2-morpholin-4-ylethyl)piperidin-4-yl]amino} -3 - nitrophenyl)sulfonyl]benzamide The title compound was prepared by substituting EXAMPLE 162C for tert-butyl pieperazien-1-carboxylate and 2-morpholinoacetaldehyde for 4'-chlorobiphenyl-2-carboxaldehyde in EXAMPLE lA. ^H NMR (400MHz, dimethylsulfoxide-de) 5 8.46 (d, IH), 8.29 (d, IH), 7.78 (dd, IH), 7.53 (d, IH), 7.41 (d, 2H), 7.21 (m, 2H), 7.11 (d, 2H), 6.96 (dd, IH), 6.83 (dd, IH), 6.73 (dd, 1.83Hz, IH), 6.69 (m, IH), 6.58 (s, IH), 3.82 (m, lOH), 3.27 (m, 4H), 3.09 (m, 6H), 2.81 (m, 7H), 2.23 (m, 2H), 2.15 (m, 2H), 2.04 (s, 2H), 1.93 (m, 2H), 1.48 (t,2H), 0.96 (s,6H). EXAMPLE 191 N-[(4-{[(4-aminotetrahydro-2H-pyran-4-yl)methyl]aminol-3-nittophenyl)sulfonyl]-2-(2- chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1- yl]methyl} piperazin-1 -yl)benzamide EXAMPLE 191A 4-((4-aminotetrahydro-2H-pyran-4-yl)methylamino)-3-nitrobenzenesulfonamide The title compound was prepared by substituting 4-(aminomethyl)tetrahydro-2H-pyran-4-amine for (tetrahydropyran-4-yl)methylamine in EXAMPLE IG. EXAMPLE 191B N-[(4-{[(4-aminotetrahydro-2H-pyran-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(2- chlorophenoxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]mediyl }piperazin-1 -yl)benzamide 394 The title compound was prepared by substituting EXAMPLE 34C for EXAMPLE IF and EXAMPLE 191A for EXAMPLE IG in EXAMPLE IH. ^H NMR (500MHz, dimethylsulfoxide-de) 5 8.57 (t, IH), 8.47 (d, IH), 8.18 (s, 3H), 7.79 (dd, IH), 7.53 (d, IH), 7.41 (d, 2H), 7.34 (d, IH), 7.24 (t, IH), 7.11 (d, 2H), 7.01-7.03 (m, 2H), 6.82 (dd, IH), 6.73-6.76 (m, 2H), 6.56 (s, IH), 3.85 (d, 2H), 3.71-3.73 (m, 4H), 3.14 (br s, 2H), 2.23 (s, 2H), 2.04 (m, 2H), 1.82-1.87 (m, 2H), 1.70-1.75 (m, 2H), 1.47 (t, 2H), 0.96 (s, 6H). EXAMPLE 192 2-(2-chloiophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-[(4-{[(4-hydroxy-l-methylpiperidin-4-yl)methyl]amino}-3- nitrophenyl)sulfonyl]benzamide EXAMPLE 192A The title compound was prepared by substituting 4-(aminomethyl)-l-methylpiperidin-4-ol for (tetrahydropyran-4-yl)methylamine in EXAMPLE IG. EXAMPLE 192B 2-(2-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-[(4-{[(4-hydroxy-l-methylpiperidin-4-yl)methyl]amino}-3- nitrophenyl)sulfony]]benzamide The title compound was prepared by substituting EXAMPLE 34C for EXAMPLE IF and EXAMPLE 192A for EXAMPLE IG in EXAMPLE IH. 'H NMR (500MHz, dimethylsulfoxide-dfi) 5 9.38 (s, IH), 6 8.65 (t, IH), 8.46 (d, IH), 7.74 (dd, IH), 7.53 (d, IH), 7.40 (d, 2H), 7.19-7.22 (m, 2H), 7.11 (d, 2H), 6.97 (dd, IH), 6.82 (dd, IH), 6.70-6.74 (m, 2H), 6.57 (s, IH), 3.60 (d, 2H), 3.47 (d, 2H), 3.10-3.17 (m, 4H), 2.80-2.81 (m, 4H), 2.23 (s, 2H), 2.04 (s, 2H), 1.76-1.85 (m, 4H), 1.47 (t, 2H), 0.96 (s, 6H). EXAMPLE 193 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl }piperazin-1 -yl)-2-[(6- fluoro-lH-indol-5-yl)oxy]-N-({3-nitro-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4- yI)amino]phenyl} sulfonyl)benzamide The title compound was prepared as described in EXAMPLE IH by replacing EXAMPLE IF and EXAMPLE IG with EXAMPLE 154E and EXAMPLE 49C, .395 respectively. 'H NMR (300 MHz, dimethylsulfoxide-ds) 5 11.15 (s, IH), 8.51 (d, IH), 8.16 (d, IH), 7.82 (dd, IH), 7.54 (d, IH), 7.31 (m, 4H), 7.08 (m, 4H), 6.60 (dd, IH), 6.36 (s, IH), 6.08 (d, IH), 3.92 (m, 2H), 3.74 (m, IH), 3.04 (m, 7H), 2.71 (m, 3H), 2.16 (m, 6H), 1.99 (m, 4H), 1.49 (m, lOH), 0.92 (s, 6H). EXAMPLE 194 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl)piperazin-l-yl)-N-[(4-{[(3S)-l-methylpyiTolidin-3-yl]amino}-3- nitrophenyl)sulfonyl]benzamide EXAMPLE 194A (S)-teit-butyl 3-(2-nitro-4-sulfamoylphenylamino)pyrrolidine-l-carboxylate The title compound was prepared by substituting (S)-tert-butyl 3-aminopyrrolidine-l-carboxylate for tert-butyl 4-aminopiperidine-l-carboxylate in EXAMPLE 140A. EXAMPLE 194B (S)-tert-butyl3-(4-(N-(2-(3-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex- l-enyl)methyl)piperazin-l-yl)benzoyl)sulfamoyl)-2-nitrophenylamino)pyrrolidine-l- caiboxylate The title compound was prepared by substituting EXAMPLE 194A for EXAMPLE IG and EXAMPLE 36C for EXAMPLE IF in EXAMPLE IH. EXAMPLE 194C (S)-2-(3-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- enyl)methyl)piperazin-l-yl)-N-(3-nitro-4-(pyiTolidin-3-ylamino)phenylsulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 194B for EXAMPLE lA in EXAMPLE IB. EXAMPLE 194D 2-(3-chloiophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl]piperazin-l-yl)-N-[(4-{[(3S)-l-methylpyrrolidin-3-yl]amino}-3- nitrophenyl)sulfony]]benzamide 396 To a solution of EXAMPLE 194C (470 mg) in tetrahydrofuran (3 mL) and acetic acid (1 mL) was added 37% formaldehyde solution in water (0.42 mL) and MP-CNBH3 resin (947 mg, 2.38 mmol/g)). The reaction mixture was stirred overnight at room temperature. The resin was filtered off and reaction mixture was then concentrated. The residue was purified by flash chromatography, eluting with ethyl acetate, followed by a gradient of 3-10% methanoydichloromethane. 'H NMR (500MHz, dimethylsulfoxide -d^) 8 8.42 (d, IH), 8.34 (m, IH), 7.78 (dd, IH), 7.53 (d, IH), 7.36 (d, 2H), 7.19 (t, IH), 7.08 (m, 3H), 6.95 (m, IH), 6.76 (dd, IH), 6.67 (m, 2H), 6.45 (d, IH), 3.53 (m, 2H), 3.16 (m, 7H), 2.83 (m, 4H), 2.61 (br m, IH), 2.27 (ra, 4H), 2.18 (m, 3H), 1.98 (m, 3H), 1.41 (m, 2H), 0.94 (s, 6H). EXAMPLE 195 2-(3 -chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yI]methyl)piperazin-l-yl)-N-[(4-{[(3R)-l-methylpyrrolidin-3-yl]amino}-3- nitrophenyl)sulfonyl]benzamide EXAMPLE 195 A (R)-tert-butyl 3-(2-nitro-4-sulfamoylphenylamino)pyrrolidine-l-carboxylate The title compound was prepared by substituting (R)-tert-butyl 3-aminopyrrolidine-l-carboxylate for tert-butyl 4-aminopiperidine-l-carboxylate in EXAMPLE 140A. EXAMPLE 195B (R)-tert-butyl3-(4-(N-(2-(3-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4- dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)benzoyl)sulfamoyl)-2- nitrophenylamino)pyrrolidine-1 -carboxy late The title compound was prepared by substituting EXAMPLE 195A for EXAMPLE IG and EXAMPLE 36C for EXAMPLE IF in EXAMPLE IH. EXAMPLE 195C (R)-2-(3-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- enyl)methyl)piperazin-l-yl)-N-(3-nitro-4-(pyrrolidin-3-ylamino)phenylsulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 195B for EXAMPLE lA in EXAMPLE IB. 397 EXAMPLE 195D 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-l-yl)-N-[(4-{[(3R)-l-methylpyrrolidin-3-yl]ammo}-3-nitrophenyl)sulfonyl]benzamide The title compound was prepared by substituting EXAMPLE 195C for EXAMPLE 194C in EXAMPLE 194D. >H NMR (SOOMHz, dimethylsulfoxide -de) 6 8.36 (d, IH), 8.23 (m, IH), 7.72 (dd, IH), 7.59 (d, IH), 7.36 (d, 2H), 7.16 (t, IH), 7.06 (m, 2H), 6.98 (m, IH), 6.90 (dd, IH), 6.73 (dd, IH), 6.64 (m, 2H), 6.41 (d, IH), 4.01 (s, IH), 3.28 (m, 2H), 3.24 (m, IH), 3.13 (m, 5H), 2.76 (m, 2H), 2.69 (m, 3H), 2.56 (m, IH), 2.24 (m, 7H), 1.90 (br s, 2H), 1.41 (m, 2H), 0.94 (s, 6H). EXAMPLE 197 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -y IJmethyl} piperazin-1 -y l)-N-( {4- [(l-nnethylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-[3-(lH-pyrrol-2- yl)phenoxy]benzamide A mixture of EXAMPLE 161 (0.095 g), l-(tert-butoxycarbonyl)-lH-pyrrol-2-ylboronic acid (0.025 g), tetrakis(triphenylphosphine)palladium(0) (0.012 g), and CsF (0.046 g) in dimethoxyethane (2 mL) and methanol (1 mL) was heated in a CEM Discover microwave reactor (80 °C, 20 minutes). The reaction mixture was partitioned between water and ethyl acetate. The organic layer was separated, and the aqueous layer was extracted with additional ethyl acetate. The combined organic layers were washed with brine, dried over MgS04, filtered, and concentrated. The residue was then treated with 4 N HCl in dioxane. The solvent was removed, and the residue was purified by reverse phase Prep HPLC to give the tiUe compound. 'H NMR (500MHz, dimethylsulfoxide-dg) 5 11.21 (s, IH), 8.39 (s, IH), 8.04 (d, IH), 7.70 (d, IH), 7.57 (d, IH), 7.34 (d, 2H), 7.11-7.25 (m, 5H), 7.04 (d, 2H), 6.96 (d, IH), 6.80 (s, IH), 6.66 (d, 2H), 6.48 (d, IH), 6.41 (s, IH), 6.28 (s, IH), 6.08 (d, IH), 3.05(s, 6H), 2.73 (s, 2H), 2.18-2.24 (m, 6H), 1.74 (s, 3H), 1.38 (t, 2H), 0.92 (s, 6H). EXAMPLE 198 4-(4- {[2-(4-chloropheny l)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-(3 - fluorophenoxy)-N-[(4- {[(4-hydroxy-1 -methylpiperidin-4-yl)methyl]amino} -3- nitrophenyl)sulfonyl]benzamide 398 The title compound was prepared by substituting EXAMPLE 112C for EXAMPLE IF and EXAMPLE 192A for EXAMPLE IG in EXAMPLE IH. 'H NMR (500MHZ, dimethylsulfoxide-de) 6 8.44 (s, IH), 8.31 (d, IH), 7.92 (s, IH), 7.63-7.66 (m, 2H), 7.36 (d, 2H), 7.07 (d, 2H), 6.99 (d, IH), 6.71 (dd, IH), 6.62-6.65 (m, IH), 6.47 (dd, IH), 6.36-6.40 (m, 2H), 5.16 (s, IH), 3.09 (s, 6H), 2.92 (br s, 2H), 2.76 (a, 2H), 2.62-2.64 (m, 2H), 2.18-2.23 (m, 6H), 1.93 (d, J = 5.49 Hz, 2H), 1.72-1.76 (m, 4H), 1.41 (t, 2H), 0.94 (s, 6H). EXAMPLE 199 2-(3 -chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-diniethylcyclohex-1 -en-1 -yl]methyl}piperazin-l-yl)-N-({4-[(4-methylpiperazin-l-yl)amino]-3-nitrophenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 36C for EXAMPLE IF and EXAMPLE 184A for EXAMPLE IG in EXAMPLE IH. 'H NMR (400 MHz, dimethylsulfoxide-dfi) 8 9.12 (s, IH), 8.33 (d, IH), 7.66 (dd, IH), 7.57 (d, IH), 7.50 (d, IH), 7.36 (d, 2H), 7.17 (t, IH), 7.07 (d, 2H), 6.91 (m, IH), 6.75 (dd, IH), 6.68 (dd, IH), 6.63 (m, IH), 6.42 (d, IH), 3.14 (m, 4H), 2.96 (m, 6H), 2.78 (s, 2H), 2.45 (s, 3H), 2.21 (m, 6H), 1.98 (s, 2H), 1.41 (t, 2H), 0.94 (s, 6H). EXAMPLE 200 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-2- [(6,7- difluoro-lH-indol-5-yl)oxy]-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide EXAMPLE 200A 2,3-difluoro-4-nitrophenol A solution of 2,3-difluoro-4-nitroanisole (10 g) in 48% HBr (60 mL) and 30% HBr in acetic acid (30 raL) was stirred at 120°C overnight. The mixture was cooled to room temperature and extracted with ethyl acetate (3x 200 mL) and the combined extracts were washed with brine and dried over Na2S04. Filtration and evaporation of the solvent gave the product. 399 EXAMPLE 200B 6,7-difluoro- lH-indol-5-ol The title compound was prepared as in EXAMPLE 154A by replacing 2-fluoro-4-nitrophenol with EXAMPLE 200A. EXAMPLE 200C methyl 2-(6,7-difluoro-1 H-indol-5-yloxy)-4-fluorobenzoate The title compound was prepared as described in EXAMPLE 3A by replacing 2-methyl-5-indolol with EXAMPLE 200B. EXAMPLE 200D methyl 2-(6,7-difluoro- lH-indol-5-yloxy)-4-(piperazin-l-yl)benzoate The title compound was prepared as described in EXAMPLE 3G by replacing EXAMPLE 3F and EXAMPLE 3A with piperazine and EXAMPLE 200C respectively. EXAMPLE 200E methyl 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-2- (6,7-difluoro-1 H-indol-5-yloxy)benzoate The title compound was prepared as described in EXAMPLE 38G by replacing EXAMPLE 38F and EXAMPLE 38E with EXAMPLE 200D and EXAMPLE 60D. EXAMPLE 200F 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-2-(6,7- difluoro-lH-indol-5-yloxy)benzoic acid The title compound was prepared as described in EXAMPLE 38H by replacing EXAMPLE 38G with EXAMPLE 200E. EXAMPLE 200G 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-[(6,7- difluoro-lH-indol-5-yl)oxy]-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzanude The title compound was prepared as described in EXAMPLE IH by replacing EXAMPLE IF and EXAMPLE IG with EXAMPLE 200F and EXAMPLE 31, respectively. 400 'H NMR (300 MHz, dimethylsulfoxide-de) 6 11.63 (s, IH), 8.40 (d, IH), 8.06 (d, IH), 7.72 (dd, IH), 7.59 (d, IH), 7.35 (m, 3H), 7.05 (d, 2H), 6.96 (d, IH), 6.72 (d, IH), 6.64 (dd, IH), 6.36 (d, IH), 6.24 (d, IH), 3.74 (m, IH), 3.12 (m, 8H), 2.73 (s, 3H), 2.55 (m, 2H), 2.14 (m, lOH), 1.74 (m, 3H), 1.39 (t, 2H), 0.93 (s, 6H). EXAMPLE 201 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl] methyl} piperazin-1 -yl)-2- [(6,7-difluoro-1 H-indol-5 -y l)oxy] -N-( {3 -nitro-4-[( 1 -tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]phenyl} sulfonyl)benzamide The title compound was prepared as described in EXAMPLE IH by replacing EXAMPLE IF and EXAMPLE IG with EXAMPLE 200F and EXAMPLE 49C, respectively. 'H NMR (300 MHz, dimethylsulfoxide-de) 6 11.64 (s, IH), 8.40 (d, IH), 8.09 (s, IH), 7.70 (dd, IH), 7.58 (d, IH), 7.35 (m, 4H), 7.05 (d, 2H), 6.92 (d, IH), 6.64 (m, 2H), 6.36 (d, IH), 6.23 (s, IH), 3.92 (m, 2H), 3.67 (m, IH), 3.01 (m, 8H), 2.73 (s, 2H), 2.25 (m, 8H), 1.97 (m, 5H), 1.53 (m, 8H), 0.94 (m, 6H). EXAMPLE 202 tert-butyl 4-(5-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 - yl)-2-{[({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl }sulfonyl)amino]carbonyl }phenoxy)- IH-indole- l-carboxylate EXAMPLE 202A ethyl 2-(lH-indol-4-yloxy)-4-fluorobenzoate The title compound was prepared by substituting 4-hydroxyindole for 2-methyl-5-indolol in EXAMPLE 3A. EXAMPLE 202B ethyl 2-( lH-indol-4-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 - enyl)methyl)piperazin-1 -yl)benzoate The title compound was prepared by substituting EXAMPLE 202A for EXAMPLE 3A in EXAMPLE 3G. 401 EXAMPLE 202C 2-( 1 H-indol-4-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)benzoic acid The title compound was prepared by substituting EXAMPLE 202B for EXAMPLE IE in EXAMPLE IF. EXAMPLE 202D 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indol-4-yloxy)-N-( {4-[( l-methylpiperidin-4-yl)amino]-3-nitrophenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 202C for EXAMPLE IF and EXAMPLE 31 for EXAMPLE IG in EXAMPLE IH, except 2-10% methanol in CH2CI2 was used for the chromatography. EXAMPLE 202E tert-butyl 4-(5-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 - yl)-2-{[({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)amino]caibonyl }phenoxy)- IH-indole- 1-carboxylate bis(2,2,2- trifluoroacetate) EXAMPLE 202D (0.58 g) was dissolved in CH2CI2 (30 mL), then di-tert-butyl dicarbonate (0.14 g) and 4-dimethylaminopyridine (0.02 g) was added and the reaction stirred at room temperature for 60 hours. The reaction was then filtered through celite, concentrated, and the crude was purified by preparative HPLC using a 250 x 50 mm C18 column, eluting with 20-100% CH3CN vs. 0.1% trifluoroacetic acid in water, giving the product as a trifluoroacetate salt. 'H NMR (300MHZ, dimethylsulfoxide-de) 6 11.80 (v br s, IH), 9.65, 9.45 (both V br s, total 2H), 8.55 (d, IH), 8.12 (br d, IH), 7.80 (dd, IH), 7.72 (d, IH), 7.61 (d, IH), 7.55 (d, IH), 7.40 (d, 2H), 7.19 (d, IH), 7.10 (m, 3H), 6.80 (dd, IH), 6.59 (d, IH), 6.43 (s, IH), 6.41 (d, IH), 4.05 (v br s, IH), 3.85 (v br s, IH), 3.60, 3.50, 3.40 (all v br m, total lOH), 3.10 (v br m, 2H), 2.95, 2.90 (both br m, total 5H), 2.20 br m, 4H), 2.05 (br s, 2H), 1.80 (br m, IH), 1.67 (s, 9H), 1.45 (br t, 2H), 0.95 (s, 6H). 402 EXAMPLE 203 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yljmethyl} piperazin-1 -yl)-N- [(4- {[4-(dimethylamino)cyclohexyl] amino} -3- nitrophenyl)sulfonyl]benzamide EXAMPLE 203A 4-(4-(diniethylamino)cyclohexylamino)-3-nitrobenzenesulfonamide The title compound was prepared by substituting N',N'-dimethylcyclohexane-l,4- diamine for l-isopropylpiperidin-4-amine in EXAMPLE 41 A. EXAMPLE 203B 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-l-yl)-N-[(4-{[4-(dimethylamino)cyclohexyl]amino}-3-nitrophenyl)sulfonyl]benzamide The title compound was prepared by substituting EXAMPLE 36C for EXAMPLE IF and EXAMPLE 203A for EXAMPLE IG in EXAMPLE IH. 'H NMR (500 MHz, pyridine-ds) 6 9.16 (d, IH), 8.31 - 8.39 (m, 2H), 8.03 - 8.07 (m, IH), 7.46 (d, 2H), 7.08 - 7.17 (m, 4H), 7.00 - 7.04 (m, IH), 6.91 - 6.99 (m, 2H), 6.82 (dd, IH), 6.69 (d, IH), 3.44 - 3.52 (m, IH), 3.14 - 3.20 (m, 4H), 2.84 (s, 2H), 2.64 (s, IH), 2.49 (s, 6H), 2.31 (t, 2H), 2.22 - 2.28 (m, 4H), 2.09 - 2.15 (m, 2H), 2.05 (s, 2H), 1.97 - 2.02 (m, 2H), 1.47 -1.56 (m, 2H), 1.42 (t, 2H), 1.27 -1.37 (m, 2H), 1.25 (s, IH), 0.93 - 0.98 (m, 6H). EXAMPLE 204 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl)piperazin-l-yl)-N-[(4-{[4-(diethyIamino)cyclohexyl]ainino}-3- nitrophenyl)sulfonyl]benzamide EXAMPLE 204A 4-(4-(diethylamino)cyclohexylamino)-3-nitrobenzenesulfonamide The title compound was prepared by substituting N',N'-diethylcyclohexane-l,4-diamine for l-isopropylpiperidin-4-amine in EXAMPLE 41A. 403 EXAMPLE 204B 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-diethylcyclohex-1 -en-1-yl]methyl}piperazin-l-yl)-N-[(4-{[4-(diethylamino)cyclohexyl]amino}-3-nitrophenyl)sulfonyl]benzamide The title compound was prepared by substituting EXAMPLE 36C for EXAMPLE IF and EXAMPLE 204A for EXAMPLE IG in EXAMPLE IH. 'H NMR (500 MHz, pyridine-ds) 5 9.18 (d, IH), 8.32 - 8.39 (m, 2H), 8.05 - 8.09 (m, IH), 7.46 (d, 2H), 7.15 (t, IH), 7.08 -7.13 (m, 3H), 6.98 - 7.05 (m, 2H), 6.94 (dd, IH), 6.82 (dd, IH), 6.69 (d, IH), 3.43 - 3.50 (m, IH), 3.13 - 3.19 (m, 4H), 2.84 (s, 2H), 2.72 (t, IH), 2.63 (q, 4H), 2.31 (t, 2H), 2.22 - 2.28 (m, 4H), 2.11 (d, 2H), 2.00 (s, 2H), 1.91 (d, 2H), 1.40 - 1.48 (m, 4H), 1.24 - 1.34 (m, 2H), 1.10 (t, 6H), 0.93 - 0.99 (m, 6H). EXAMPLE 205 Trans-2-(3-chlorophenoxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl} piperazin-1 -yl)-N-( {4- [(4-morpholin-4-ylcyclohexy l)amino]-3 - nitrophenyl} sulfonyObenzanaide EXAMPLE 205A trans-4-(4-morpholinocyclohexylamino)-3-nitix)benzenesulfonamide The title compound was prepared by substituting trans 4-morpholinocyclohexanamine for l-isopropylpiperidin-4-amine in EXAMPLE 41 A. EXAMPLE 205B Trans-2-(3-chlorophenoxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-({4-[(4-morpholin-4-ylcyclohexyl)amino]-3-nitrophenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 36C for EXAMPLE IF and EXAMPLE 205A for EXAMPLE IG in EXAMPLE IH. 'H NMR (500 MHz, pyridine-ds) 5 9.17 (d, IH), 8.42 (d, IH), 8.32 (dd, IH), 8.00 (d, IH), 7.46 (d, 2H), 7.15 (t, IH), 7.11 (d, 2H), 7.07 (d, IH), 7.03 (d, IH), 6.99 (d, IH), 6.93 (dd, IH), 6.81 (dd, IH), 6.69 (d, IH), 3.73 - 3.78 (m, 4H), 3.43 - 3.50 (m, IH), 3.15 - 3.21 (m, 4H), 2.84 (s, 2H), 2.50 - 2.54 (m, 404 4H), 2.31 (t, 2H), 2.21 - 2.27 (m, 5H), 2.11 (d, 2H), 2.00 (s, 2H), 1.91 (d, 2H), 1.36 - 1.43 (m, 4H), 1.28 -1.34 (m, 2H), 0.96 (s, 6H). EXAMPLE 206 4- {4.[ 1 -(4'-chloro-1,1 '-bipheny l-2-yI)ethyl]piperazin-1 -yl} -2-(2-chlorophenoxy)-N-( {4- [(1 -niethylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)benzamide The title compound was prepared as described in EXAMPLE 137 by replacing EXAMPLE 122C with EXAMPLE and EXAMPLE 11 lA with EXAMPLE 31. 'H NMR (400 MHz, CH2CD2) 5 8.80 (s, IH), 8.41 (d, IH), 8.01 (d, IH), 7.87 (d, IH), 7.55 (t, 2H), 7.29 - 7.37 (m, 4H), 7.17 - 7.28 (m, 4H), 7.10 - 7.15 (m, 2H), 6.94 (d, IH), 6.58 (d, IH), 5.95 (s, IH), 3.53 - 3.64 (m, IH), 3.39 (q, IH), 3.01 - 3.12 (m, 4H), 2.77 (t, 2H), 2.38 - 2.46 (m, 2H), 2.15 - 2.31 (m, 7H), 2.05 (d, 2H), 1.63 - 1.74 (m, 2H), 1.22 (d, 3H). EXAMPLE 207 2-(2-chloro-4-hydroxyphenoxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide EXAMPLE 207A 2-chloro-4-(methoxymethoxy)phenol The title compound was prepared by substituting 2-chlorobenzene-l,4-diol for EXAMPLE 158B in EXAMPLE 158C. EXAMPLE 207B Ethyl 2-(2-chloro-4-(methoxymethoxy)phenoxy)-4-fluorobenzoate The title compound was prepared by substituting 207A for 2-methyl-5-indolol in EXAMPLE 3A. EXAMPLE 207C Ethyl 2-(2-chloro-4-(methoxymethoxy)phenoxy)-4-fluorobenzoate The title compound was prepared by substituting piperazine for EXAMPLE 3F and EXAMPLE 207B for EXAMPLE 3A in EXAMPLE 3G. 405 EXAMPLE 207D Ethyl 2-(2-chloro-4-(methoxymethoxy)phenoxy)-4-(4-((2-(4-chlorophenyl)-4,4- dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)benzoate The title compound was prepared by substituting EXAMPLE 60D for 4'-chlorobiphenyl-2-carboxaldehyde and EXAMPLE 207C for tert-butyl piperazine-1-carboxylate in EXAMPLE lA. EXAMPLE 207E 2-(2-chloro-4-(methoxymethoxy)phenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -enyl)methyl)piperazin-1 -yl)benzoic acid The title compound was prepared by substituting EXAMPLE 207D for EXAMPLE IE in EXAMPLE IF. EXAMPLE 207F 2-(2-chloro-4-(methoxymethoxy)phenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex- l-enyl)methyl)piperazin-l-yl)-N-(4-(l-methylpiperidin-4-ylamino)-3- nitrophenylsulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 207E for EXAMPLE IF and EXAMPLE 31 for EXAMPLE IG in EXAMPLE IH. EXAMPLE 207G 2-(2-chloro-4-hydroxyphenoxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitrophenyl ] sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 207F for EXAMPLE 158 in EXAMPLE 159. 'H NMR (500 MHz, pyridine-ds) 5 12.30 (br. s, IH), 9.29 (d, IH), 8.49 (d, IH), 8.40 (dd, IH), 8.08 (d, IH), 7.45 (d, 2H), 7.09 (m, 3H), 7.01 (d, IH), 6.93 (dd, IH), 6.75 (dd, IH), 6.58 (d, IH), 3.54 (m, IH), 3.13 (m, 4H), 2.81 (s, 2H), 2.65 (m, 2H), 2.29 (m, 2H), 2.21 (m, 4H), 2.16 (s, 3H), 2.07 (m, 2H), 1.96 (m, 4H), 1.66 (m, 2H), 1.41 (t, 2H), 0.95 (s, 6H). EXAMPLE 208 2-(2-chloro-4-hydroxyphenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl }piperazin- l-yl)-N-((4-[(4-methylpiperazin- l-yl)amino]-3- nitrophenyl} sulfonyl)benzamide 406 EXAMPLE 208A 2-(2-chloro-4-(methoxymethoxy)phenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex- l-enyl)methyl)piperazin-l-yl)-N-(4-(4-methylpiperazin-l-ylamino)-3- nitrophenylsulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 207E for EXAMPLE IF and EXAMPLE 184A for EXAMPLE IG in EXAMPLE IH. EXAMPLE 208B 2-(2-chloro-4-hydroxyphenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1-yl]methyl}piperazin-l-yl)-N-({4-[(4-methylpiperazin-l-yl)amino]-3-nitrophenyl) sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 208A for EXAMPLE 158E in EXAMPLE 159. 'H NMR (500 MHz, pyridine-ds) 8 12.33 (br. s, IH), 9.28 (m, 2H), 8.44 (dd, IH), 8.07 (d, IH), 7.76 (d, IH), 7.45 (d, 2H), 7.09 (m, 3H), 6.94 (dd, IH), 6.75 (dd, IH), 6.57 (d, IH), 3.13 (m, 4H), 2.94 (m, 4H), 2.81 (m, 4H), 2.29 (m, 2H), 2.19 (m, lOH), 1.99 (s, 2H), 1.41 (t, 2H), 0.95 (m, 6H). EXAMPLE 209 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl }piperazin-1 -yl)-2-[(6- fluoro-1 H-indol-4-yl)oxy ]-N-( {4- [(1 -methylpiperidin-4-yl)amino] -3- nitrophenyl} sulfonyl)benzamide EXAMPLE 209A 6-Fluoro-4-raethoxy-lH-indole-2-carboxylic acid methyl ester Sodium methoxide solution (25% by weight in methanol, 22.25 mL) and methanol (52 mL) were added to a flask and cooled to -20°C using an acetonitrile / dry ice bath. Ethyl 2-azidoacetate (25% by weight in ethanol, 50.3g) and 4-fluoro-2-methoxybenzaldehyde (5.00 g, dissolved in ethyl 2-azidoacetate solution) were added drop-wise to the stirring sodium methoxide solution at -20°C. The solution was then stirred at -20°C for 3.5 hours, then at 0°C for one hour. The solution was poured over ice, vacuum filtered, and washed with water. The filtered solid was taken up in xylenes (1(X) mL), washed twice with brine, and dried using anhydrous sodium sulfate and filtered. In a separate flask xylenes (50 mL) was brought to reflux. The xylene solution containing the filtered material was added drop-wise to the refluxing xylenes. The solution was then refluxed for five hours, cooled, and placed in a 407 freezer for 16 hours. The precipitate was filtered out. The volume of the filtrate was reduced on vacuum to generate a second crop of precipitate, which was washed with hexanes, then 5% ethyl acetate in hexanes and combined with material from the first filtration. EXAMPLE 209B 6-Fluoro-4-methoxy-1 H-indole-2-carboxylic acid The title compound was prepared by substituting EXAMPLE 209A for EXAMPLE IE in EXAMPLE IF. EXAMPLE 209C 6-Fluoro-4-methoxy-1 H-indole EXAMPLE 209B (1775 mg) was dissolved in N-methylpyrrolidinone (75 mL), and copper powder (2157 mg) was added. The solution was stirred to keep the copper powder suspended and the solution was split into nine microwave reactor vials, each containing a stir bar. Each vial was heated in a CEM Discover microwave reactor at 260°C for 25 minutes with stirring. The vials were combined, added to water, and extracted with ethyl ether. The ether was washed with brine and dried on anhydrous sodium sulfate. The solution was filtered and the filtrate was concentrated and purified by flash column chromatography on silica gel using 10% ethyl acetate in hexanes. EXAMPLE 209D 6-Fluoro-1 H-indol-4-ol Aluminum chloride (727 mg) was added to dichloromethane (20 mL), the mixture was cooled to 0°C, and benzylmercaptan (4512 mg) was added. EXAMPLE 209C (600 mg) dissolved in dichloromethane (5 mL) was added drop-wise. The solution was mixed for 30 minutes at 0°C. Benzylmercaptan (451 mg) and aluminum chloride (727 mg) were added, and the solution was stirred for 75 minutes at 0°C. The reaction was quenched by adding IM aqueous HCl. The solution was extracted with ethyl acetate, which was subsequently washed with brine and dried on anhydrous sodium sulfate. After filtration, the filtrate was concentrated and purified by flash column chromatography on silica gel using 5% ethyl acetate in hexanes increasing to 20% ethyl acetate in hexanes and increasing again to 50% ethyl acetate in hexanes. 408 EXAMPLE 209E 4-Fluoro-2-(6-fluoro-lH-indol-4-yloxy)-benzoic acid ethyl ester The title compound was prepared by substituting EXAMPLE 209D for 2-methyl-5-indolol in EXAMPLE 3A. EXAMPLE 209F 4- {4-[2-(4-Chloro-phenyl)-4,4-dimethyl-cyclohex-1 -enylmethylj-piperazin-1 -yl} -2-(6-fluoro-lH-indol-4-yloxy)-benzoic acid ethyl ester The title compound was prepared by substituting EXAMPLE 209E for EXAMPLE 3A in EXAMPLE 3G. EXAMPLE 209G 4- {4-[2-(4-Chloro-phenyl)-4,4-dimethyl-cyclohex-1 -enylmethyl]-piperazin-1 -yl} -2-(6-fluoro-lH-indol-4-yloxy)-benzoic acid The title compound was prepared by substituting EXAMPLE 209F for EXAMPLE IE in EXAMPLE IF. EXAMPLE 209H 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-[(6-fluoro-1 H-indol-4-yl)oxy]-N-( {4-[( 1 -methylpiperidin-4-yl)amino] -3 -nitrophenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 209G for EXAMPLE IF and EXAMPLE 31 for EXAMPLE 10 in EXAMPLE IH. 'H NMR (300MHZ, dimethylsulfoxide-de) 6 11.14 (br s, IH), 8.37 (d, IH), 8.08 (d, IH), 7.68 (dd, IH), 7.59 (d, IH), 7.35 (d, 2H), 7.19 (t, IH), 7.05 (d, 2H), 6.97 (d, IH), 6.78 (dd, IH), 6.71 (dd, IH), 6.34 (d, IH), 6.26 (t, IH), 5.97 (dd, IH), 3.74 (m, IH), 3.18-3.09 (m, 2H), 3.05 (br s, 4H), 2.83-2.70 (m, 2H), 2.74 (br s, 2H), 2.57 (s, 3H), 2.25-2.12 (m, 6H), 2.09-2.01 (m, 2H), 1.96 (s, 2H), 1.72 (q, 2H), 1.39 (t, 2H), 0.93 (s, 6H). EXAMPLE 210 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-[(6- fluoro-1 H-indol-4-yl)oxy ]-N-( {3-nitro-4- [(1 -tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl} sulfonyl)benzamide 409 The title compound was prepared by substituting EXAMPLE 209G for EXAMPLE IF and EXAMPLE 49C for EXAMPLE IG in EXAMPLE IH. *H NMR (300MHz, dimethylsulfoxide-dfi) 5 1L16 (br s, IH), 8.39 (d, IH), 7.64 (d, IH), 7.57 (d, IH), 7.38-7.32 (d, 2H), 7.21 (t, IH), 7.05 (d, 2H), 6.99 (d, IH), 6.80 (d, IH), 6.73 (d, IH), 6.35 (d, IH), 6.26 (t, 2H), 6.00 (d, IH), 3.99-3.89 (m, 3H), 3.76 (m, IH), 3.26 (m, 2H), 3.07 (m, 4H), 2.72 (br s, 2H), 2.27-2.12 (m, 8H), 2.09-1.95 (m, 4H), 1.86-1.48 (m, 8H), 1.39 (t, 2H), 0.93 (s, 6H). EXAMPLE 211 2-(2-chloro-4-hydroxyphenoxy)-4-(4- {[2-(4-chlorophenyI)-4,4-dimethylcyclohex-1 -en-1- yl]niethyl}piperazin-l-yl)-N-({4-[(4-methylpiperazin-l-yl)amino]-3- [(trifluoromethyl)sulfonyl]phenyl) sulfonyl)benzamide EXAMPLE 211A 4-(4-methylpiperazin-l-ylamino)-3-(trifluoromethylsulfonyl)benzenesulfonaniide The title compound was prepared by substituting 4-methylpiperazin-l-amine for 3-(N-morpholinyl)-l-propylamine and EXAMPLE 13IC for 4-F1UOK)-3-nitrobenzenesulfonamide in EXAMPLE 4A. EXAMPLE 211B 2-(2-chloro-4-(methoxymethoxy)phenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex- l-enyl)methyl)piperazin-l-yl)-N-(4-(4-methylpiperazin-l-ylamino)-3- (trifluoromethylsulfonyl)phenylsulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 207E for EXAMPLE IF and EXAMPLE 211A for EXAMPLE IG in EXAMPLE IH. EXAMPLE 21IC 2-(2-chloro-4-hydroxyphenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-1 -yl)-N-(4-(4-methylpiperazin-1 -ylamino)-3-(trifluoromethylsulfonyl)phenylsulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 211B for EXAMPLE 158E in EXAMPLE 159. 'H NMR (500 MHz, dimethylsulfoxide-dg) 8 9.87 (s, IH), 8.08 (d, IH), 7.96 (s, IH), 7.90 (dd, IH), 7.54 (d, IH), 7.48 (d, IH), 7.36 (d, 2H), 7.07 (d, 2H), 6.89 410 (d, IH), 6.83 (d, IH), 6.73 (dd, IH), 6.65 (dd, IH), 6.21 (d, IH), 3.07 (m, 4H), 2.90 (m, 6H), 2.76 (s, 2H), 2.41 (s, 3H), 2.21 (m, 6H), 1.97 (s, 2H), 1.40 (t, 3H), 0.94 (s, 6H). EXAMPLE 212 2-({l,3-bis[(4-methylpiperazin-l-yl)methyl]-lH-indol-4-yl}oxy)-4-(4-{[2-(4-chlorophenyl)- 4,4-dimethylcyclohex-1 -en-1 -yljmethyl }piperazin-1 -yl)-N-[(4- {[3- (dimethylamino)propyl]amino}-3-nitrophenyl)sulfonyI]benzamide EXAMPLE 212A 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl }piperazin-1 -yl)-N-[(4- {[3-(dimethylamino)propyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indol-4-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 202C for EXAMPLE IF and EXAMPLE 11A for EXAMPLE IG in EXAMPLE IH. EXAMPLE 212B 2-({l,3-bis[(4-methylpiperazin-l-yl)methyl]-lH-indol-4-yl)oxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl }piperazin-1 -yl)-N-[(4- {[3-(dimethylamino)propyl]amino}-3-nitrophenyl)sulfonyl]benzamide EXAMPLE 212A (0.25 g) was dissolved in methanol (0.60 mL), to which was added 37% (wt) formaldehyde in water (0.22 mL) and 1-methylpiperazine (0.33 mL). The reaction was heated at 60°C for two hours, then cooled and concentrated. The crude was purified by preparative HPLC using a C18 column, 250 x 50 mm, 10|J,, and eluting with a gradient of 20-100% CH3CN vs. 0.1% trifluoroacetic acid in water, giving the product as a trifluoroacetate salt. The salt was dissolved in dichloromethane (6 mL) and washed with 50% aqueous NaHCOs. The organic layer was dried over anhydrous Na2S04, filtered, and concentrated to give the title compound. 'H NMR (300 MHz, dimethylsulfoxide-ds) 6 8.68 (br t, IH), 8.00 (s, IH), 7.82 (d, IH), 7.38 (m, 3H), 7.25 (d, IH), 7.08 (d, 2H), 6.87 (d, IH), 6.75 (d, IH), 6.67 (m, 2H), 6.58 (s, IH), 5.58 (d, IH), 4.85 (s, 2H), 3.40 (m, 4H), 3.20 (v br s, 4H), 3.05 (v br s, 4H), 2.79 (s, 2H), 2.60 (v br s, 2H), 2.40 (br m, 6H), 2.20 (m, 21H), 2.09 (s, 3H), 1.98 (s, 2H), 1.80 (m, 2H), 1.42 (t, 2H), 0.95 (s, 6H). 411 EXAMPLE 213 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl }piperazin-1 -yl)-N-[(4-{[3-(dimethylamino)propyl]amino}-3-nitrophenyl)sulfonyl]-2-({3-[(4-methylpiperazin-l-yl)methyl]-lH-indol-4-yl}oxy)benzamide To EXAMPLE 212A (0.13 g) in methanol (0.30 mL) was added 37% (wt) formaldehyde in water (0.022 mL) and 1-methylpiperazine (0.035 mL). The reaction was heated at 60°C for 50 minutes, then it was cooled and concentrated. The crude was purified by preparative HPLC using a C18 column, 250 x 50 mm, lOji, and eluting with a gradient of 20-100% CH3CN vs. 0.1% trifluoroacetic acid in water, giving the product as a trifluoroacetate salt. The salt was dissolved in dichloromethane (6 mL) and washed with 50% aqueous NaHC03. The organic layer was dried over anhydrous Na2S04, filtered, and concentrated to give the title compound. 'H NMR (300 MHz, dimethylsulfoxide-de) 5 11.23 (s, IH), 8.68 (brt, IH), 7.96 (s, IH), 7.79 (d, IH), 7.38 (d, 2H), 7.31 (s, IH), 7.17 (br d, IH), 7.08 (d, 2H), 6.75 (d, 2H), 6.66 (d, IH), 6.60 (m, 2H), 5.65 (d, IH), 4.33 (br s, 2H), 3.40 (m, 4H), 3.20 (v br s, 4H), 3.03 (v br s, 4H), 2.79 (s, 2H), 2.60 (v br s, 2H), 2.42 (br m, 2H), 2.20 (m, 15H), 1.98 (s, 2H), 1.83 (m, 2H), 1.42 (t, 2H), 0.95 (s, 6H). EXAMPLE 214 2-(5-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)-2-(4-( 1 - methylpiperidin-4-ylamino)-3-nitrophenylsulfonylcarbamoyl)phenoxy)-N,N- dimethylbenzamide EXAMPLE 214A methyl 2-bromo-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 - yl)benzoate The title compound was prepared by substituting EXAMPLE 3F for EXAMPLE IB in EXAMPLE IC. EXAMPLE 214B methyl 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)-2-(2- (dimethylcarbamoyl)phenoxy)benzoate The title compound was prepared by substituting EXAMPLE 214A for EXAMPLE IC and 2-hydroxy-N,N-dimethylbenzamide for EXAMPLE ID in EXAMPLE IE. 412 EXAMPLE 214C 4.(4.((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-2-(2-(dimethylcarbamoyl)phenoxy)benzoic acid The title compound was prepared by substituting EXAMPLE 214B for EXAMPLE IE in EXAMPLE IF. EXAMPLE 214D 2-(5-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)-2-(4-( 1 - methylpiperidin-4-ylamino)-3-nitrophenylsuIfonylcarbamoyl)phenoxy)-N,N- dimethylbenzamide The title compound was prepared by substituting EXAMPLE 214C for EXAMPLE IF and EXAMPLE 31 for EXAMPLE IG in EXAMPLE IH. 'H NMR (400 MHz, dimethylsulfoxide-dfi) 6 8.35 (s, IH), 8.07 (d, IH), 7.72 (d, IH), 7.61 (d, IH), 7.36 (d, 2H), 7.12 (m, 2H), 7.06 (d, 2H), 7.02 (d, IH), 6.93 (t, IH), 6.68 (dd, IH), 6.47 (d, IH), 6.18 (d, IH), 3.72 (m, IH), 3.04 (m, 4H), 2.95 (m, 2H), 2.86 (s, 3H), 2.75 (s, 2H), 2.70 (s, 3H), 2.42 (m, 2H), 2.19 (m, 6H), 2.01 (m, 4H), 1.67 (m, 2H), 1.40 (t, 2H), 1.24 (s, 3H), 0.94 (s, 6H). EXAMPLE 215 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N-( {3- nitro-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]phenyl}sulfonyl)-2-{[2- (trifluoromethyl)-1 H-indol-4-yl]oxy }benzamide EXAMPLE 215A methyl 2-(3-amino-2-melhylphenoxy)-4-fluorobenzoate The title compound was prepared by substituting 3-amino-2-methylphenol for 2-methyl-5-indolol in EXAMPLE 3A. EXAMPLE 215B (E)-methyl2-(3-(l-chloro-2,2,2-trifluoroethylideneamino)-2-methylphenoxy)-4- fluorobenzoate To a mixture of triethylamine (0.476 g) and triphenylphosphine (3.05 g) in CCI4 (10 mL) was added trifluoroacetic acid (0.477 g) dropwise at 0 °C. The solution was stirred for 10 413 minutes. To this solution was added EXAMPLE 215A (1.08 g) in CCI4 (5 mL). The solution was heated under reflux for 3 hours. After cooling, the reaction mixture was concentrated, and diluted with 3:7 ethyl acetate/hexanes. The solid was filtered off, and the filtrate was concentrated. The residue was purified by flash chromatography on silica gel eluting 1:10 ethyl acetate/hexane to give the title compound. EXAMPLE 215C (E)-methyl 2-(2-(bromomethyl)-3-(l-chloro-2,2,2-trifluoroethylideneamino)phenoxy)-4- fluorobenzoate A mixture of EXAMPLE 215B (1.4 g), N-bromosuccinimide (0.671 g), and benzoyl peroxide (0.044 g) in CCI4 (20 mL) was heated under reflux for 4 hours. After cooling, the solid was filtered off. The filtrate was then concentrated. The residue was purified by flash chromatography on silica gel eluting 1:20 ethyl acetate/hexane to give the title compound. EXAMPLE 215D methyl 4-fluoro-2-(2-(trifluoromethyl)- lH-indol-4-yloxy)benzoate Magnesium (0.081 g) in tetrahydrofuran (10 mL) was treated with EXAMPLE 215C (1.3 g) in tetrahydrofuran (5 mL) drop-wise at 0 °C. After the addition was over, a couple of I2 crystals were added to the reaction. After stirring for 2 hours, the magnesium started to disappear. The reaction was stirred for another 6 hours at room temperature. The reaction was quenched with saturated aqueous NH4CI, and extracted with ethyl acetate. The aqueous layer was extracted with additional ethyl acetate. The combined organic layers were washed with brine, dried over MgS04, filtered, and concentrated. The residue was purified by flash chromatography on silica gel eluting with 1:4 ethyl acetate/hexanes to give the tide compound. EXAMPLE 215E methyl 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)-2-(2-(trifluoromethyl)-1 H-indol-4-yloxy)benzoate The title compound was prepared by substituting EXAMPLE 215D for EXAMPLE 3A in EXAMPLE 3G. 414 EXAMPLE 215F A mixture of EXAMPLE 215E (0.13 g) and lithium iodide (0.534 g) in pyridine (2 mL) was heated in a CEM Discover microwave reactor (130 °C, 30 minutes). The pyridine was removed under vacuum, and the residue was partitioned between ethyl acetate and water. The aqueous layer was extracted with additional ethyl acetate. The combined organic layers were washed with brine, dried over MgS04, filtered, and concentrated. The residue was then purified by reverse phase Prep HPLC to give the desired product. EXAMPLE 215G 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-N-({3-nitro-4-[( 1 -tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]phenyl) sulfonyl)-2- {[2-(trifluoromethyl)-1 H-indol-4-yl]oxy} benzamide The tide compound was prepared by substituting EXAMPLE 215F for EXAMPLE IF and EXAMPLE 49C for EXAMPLE IG in EXAMPLE IH. 'H NMR (500MHZ, dimethylsulfoxide-de) 8 12.29 (s, IH), 8.39 (d, IH), 8.12 (d, IH), 7.69 (dd, IH), 7.59 (d, IH), 7.34 (d, 2H), 7.00-7.12 (m, 5H), 6.85 (s, IH), 6.71 (dd, IH), 6.34 (d, IH), 6.29 (d, IH), 3.93 (dd, IH), 3.06-3.09 (m, 6H), 2.76 (s, 2H), 2.62-2.64 (m, 2H), 2.16-2.19 (m, 6H), 2.03-2.05 (m, 2H), 1.96 (s, 2H), 1.79-1.82 (m, 2H), 1.66-1.68 (m, 2H), 1.49-1.57 (m, 2H), 1.96 (t, 2H), 0.93 (s, 6H). EXAMPLE 216 2-(2-chloro-4-hydroxyphenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1- yl]methyl }piperazin-1 -yl)-N-( {3 -nitro-4- [(1 -tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl} sulfonyl)benzamide EXAMPLE 216A 2-(2-chloro-4-(methoxymethoxy)phenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex- l-enyl)methyl)piperazin-l-yl)-N-(3-nitro-4-(l-(tetrahydro-2H-pyran-4-yl)piperidin-4- ylamino)phenylsulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 207E for EXAMPLE IF and EXAMPLE 49C for EXAMPLE 1G in EXAMPLE 1H. 415 EXAMPLE 216B 2-(2-chloro-4-hydroxyphenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1-yl]methyl}piperazin-l-yl)-N-({3-nitro-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]phenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 216A for EXAMPLE 158E in EXAMPLE 159. 'H NMR (500 MHz, dimethylsulfoxide-de) 8 9.83 (br. s, IH), 8.47 (s, IH), 8.17 (br. s, IH), 7.76 (d, IH), 7.50 (d, IH), 7.35 (d, 2H), 7.08 (m, 3H), 6.83 (m, 2H), 6.67 (m, 2H), 6.22 (d, IH), 3.93 (m, 2H), 3.81 (m, IH), 3.07 (m, 6H), 2.75 (s, 2H), 2.19 (m, 8H), 1.97 (s, 2H), 1.68 (m, 6H), 1.40 (t, 2H), 0.94 (s, 6H). EXAMPLE 217 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-N-( {4- [(1 -methylpiperidin-4-yl)amino]-3-nitiophenyl} sulfonyl)-2-{ [6-(trifluoromethyl)- lH-indol-5- yl]oxy )benzamide EXAMPLE 217 A 4-nitio-2-(trifluoromethyl)phenol The title compound was prepared as described in EXAMPLE 200A by replacing 2, 3-difluoro-4-nitroanisole with 2-trifluoromethyl-4-nitroanisole. EXAMPLE 217B 6-(trifluoromethyl)-1 H-indol-5-ol The title compound was prepared analogously to that of 2-fluoro-4-nitrophenol in WO 02/12227 (page 78). EXAMPLE 217C methyl 4-fluoro-2-(6-(trifluoromethyl)-1 H-indol-5-yloxy)benzoate The title compound was prepared as described in EXAMPLE 3A by replacing 2-methyl-5-indolol with EXAMPLE 217B. EXAMPLE 217D methyl 4-(piperazin-l-yl)-2-(6-(trifluoromethyl)-lH-indol-5-yloxy)benzoate The title compound was prepared as described in EXAMPLE 3G by replacing EXAMPLE 3F and EXAMPLE 3A with piperazine and EXAMPLE 217C, respectively. 416 EXAMPLE 217E methyl 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)-2-(6- (trifluoromethyl)-1 H-indol-5-yloxy )benzoate The title compound was prepared as described in EXAMPLE 38G by replacing EXAMPLE 38F and EXAMPLE 38E with EXAMPLE 217D and EXAMPLE 60D, respectively. EXAMPLE 217F 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-2-(6- (trifluoromethyl)-1 H-indol-5-yloxy)benzoic acid The title compound was prepared as described in EXAMPLE 38H by replacing EXAMPLE 38G with EXAMPLE 217E. EXAMPLE 217G 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl Ipiperazin- l-yl)-N-( {4- [(1 -methylpiperidin-4-yl)amino]-3-nitrophenyl} sulfonyl)-2- {[6-(trifluoromethyl)-1 H-indol-5- yljoxy }benzamide The title compound was prepared as described in EXAMPLE IH by replacing EXAMPLE IF and EXAMPLE 10 with EXAMPLE 217F and EXAMPLE 3L respectively. 'H NMR (300 MHz, dimethylsulfoxide-de) 6 11.38 (s, IH), 8.43 (d, IH), 8.09 (d, IH), 7.77 (dd, IH), 7.67 (s, IH), 7.55 (m, 2H), 7.33 (d, 2H), 7.02 (m, 4H), 6.67 (dd, IH), 6.38 (s, IH), 3.71 (m, IH), 3.05 (m, 7H), 2.72 (s, 3H), 2.25 (m, 7H), 1.98 (m, 5H), 1.72 (m, 3H), 1.38 (t, 3H), 0.92 (s, 6H). EXAMPLE 218 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl }piperazin-1 -yl)-N-( {3- nitro-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]phenyl}sulfonyl)-2-{[6- (trifluoromethyl)-1 H-indol-5-yl]oxy }benzamide The title compound was prepared as described in EXAMPLE IH by replacing EXAMPLE IF and EXAMPLE 10 with EXAMPLE 217F and EXAMPLE 49C, respectively. 'H NMR (300 MHz, dimethylsulfoxide-de) 8 11.42 (s, IH), 8.46 (d, IH), 8.16 (d, IH), 7.77 (dd, IH), 7.70 (s, IH), 7.56 (m, 2H), 7.33 (m, 3H), 7.03 (m, 5H), 6.69 (dd, IH), 417 6.40 (s, IH), 6.14 (d, IH), 3.91 (m, 3H), 3.72 (m, IH), 3.02 (m, 8H), 2.72 (s, 2H), 2.25 (m, lOH), 1.95 (m, 4H), 1.48 (m, 5H), 0.92 (s, 6H). EXAMPLE 219 2-[(2-amino-1,3-thiazol-4-yl)methoxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 - en-l-yl]methyl}piperazin-l-yl)-N-({3-nitro-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl} sul fonyl)benzamide EXAMPLE 219A methyl 2-((2-aminothiazol-4-yl)methoxy)-4-fluorobenzoate A mixture of methyl 4-fluoro-2-hydroxybenzoate (552 mg), 4-(chloromethyl)thiazol-2-amine hydrochloric acid (600 mg) and CS2CO3 (2.64 g) in 15 mL N,N-dimethylformamide was stirred at room temperature for 24 hours. Water was added and the mixture was extracted with ethyl acetate (2x), washed with water (2x) and brine, dried over MgS04, filtered and concentrated. The residue was chromatographed on silica gel using 10-50% ethyl acetate in hexanes as eluent. EXAMPLE 219B methyl 2-((2-aminothiazol-4-yl)methoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- enyl)methyl)piperazin-1 -yl)benzoate The title compound was prepared by substituting EXAMPLE 219A for EXAMPLE 3A in EXAMPLE 3G. EXAMPLE 219C methyl 2-((2-(tert-butoxycarbonylamino)thiazol-4-yl)methoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)benzoate To a solution of EXAMPLE 219B (280 mg), 4-(dimethylamino)pyridine (2.94 mg), triethylamine (81 fxL) in 10 mL tetrahydrofuran at room temperature was added a solution of di-tert-butyl dicarbonate (134 nL) in 3 mL tetrahydrofuran via a canula. The mixture was stirred at room temperature overnight, and partitioned between water and ethyl acetate. The aqueous phase was extracted with ethyl acetate and the combined organics were washed with brine and dried over MgS04, filtered and concentrated. The oil residue was chromatographed on silica gel with 25-60% ethyl acetate in hexanes. EXAMPLE 219D 418 2-((2-(tert-butoxycarbonylamino)thiazol-4-yl)methoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)benzoic acid The title compound was prepared by substituting EXAMPLE 219C for EXAMPLE IE in EXAMPLE IF. EXAMPLE 219E tert-butyl 4-((5-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)- 2-(3-nitro-4-(l-(tetrahydro-2H-pyran-4-yl)piperidin-4- ylamino)phenylsulfonylcarbamoyl)phenoxy)methyl)thiazol-2-ylcarbamate The title compound was prepared by substituting EXAMPLE 219D for EXAMPLE IF and EXAMPLE 49C for EXAMPLE IG respectively in EXAMPLE IH. EXAMPLE 219F 2-((2-aminothiazol-4-yl)methoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-N-(3-nitro-4-(l-(tetrahydro-2H-pyran-4-yl)piperidin-4-ylamino)phenylsulfonyl)benzamide This EXAMPLE was prepared by substituting EXAMPLE 219E for EXAMPLE lA in EXAMPLE IB. 'H NMR (300 MHz, dimethylsulfoxide-d e) 60.96 (s, 6H) 1.36 - 1.78 (m, 8H) 1.99 (m, 2H) 2.14 - 2.31 (m, 7H) 2.40 - 2.64 (m, 3H) 2.78 (m, 2H) 2.92 (d, 2H) 3.16 -3.43 (m, lOH) 3.75 (m, IH) 3.84 - 3.96 (m, 2H) 5.01 (s, 2H) 6.51 (d, IH) 6.57 (s, IH) 6.63 (s, IH) 6.93 (s, 2H) 7.06 (d, 2H) 7.28 (d, IH) 7.37 (d, 2H) 7.45 (d, IH) 7.93 (dd, IH) 8.28 (d, IH) 8.62 (d, IH). EXAMPLE 220 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-[(6,7-difluoro-lH-indol-5-yl)oxy]-N-({4-[(4-methylpiperazin-l-yl)amino]-3-nitrophenyl} sulfonyl)benzamide The title compound was prepared as described in EXAMPLE IH by replacing EXAMPLE IF and EXAMPLE IG with EXAMPLE 200F and EXAMPLE 184A, respectively. 'H NMR (300 MHz, dimethylsulfoxide-de) 6 11.72 (s, IH), 9.14 (s, IH), 8.47 (d, IH), 7.82 (m, IH), 7.54 (dd, 2H), 7.41 (t, IH), 7.34 (d, 2H), 7.04 (d, IH), 6.92 (d, IH), 6.66 (d, IH), 6.42 (d, IH), 6.21 (s, IH), 2.98 (m, IIH), 2.73 (s, 2H), 2.40 (s, 4H), 2.17 (m, 7H), 1.95 (s, 3H), 1.38 (t, 2H), 0.93 (s, 6H). 419 EXAMPLE 221 4.(4- {[2-(4-chloiophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl }piperazin-1 -yl)-2-[(6-fluoio-1 H-indol-5-yl)oxy ]-N-( {4- [(4-methylpiperazin-1 -yl)amino] -3-nitrophenyl) sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 154E for EXAMPLE IF and EXAMPLE 184A for EXAMPLE IG in EXAMPLE IH. 'H NMR (500 MHz, dimethylsulfoxide-de) 8 11.19 (s, IH), 9.17 (s, IH), 8.52 (d, IH), 7.89 (dd, IH), 7.59 (d, IH), 7.53 (d, IH), 7.34 (m, 4H), 7.23 (d, IH), 7.04 (d, 2H), 6.62 (dd, IH), 6.39 (m, IH), 6.07 (m, IH), 2.94 (m, lOH), 2.71 (s, 2H), 2.36 (s, 3H), 2.15 (m, 6H), 1.95 (s, 2H), 1.38 (t, 2H), 0.92 (m, 6H). EXAMPLE 222 tert-butyl 4-[(5-(4- {[2-(4-chloropheny l)-4,4-diniethylcyclohex-1 -en-1 -yl]methyl ] piperazin-1 -yl)-2- {[({4- [(1 -methylpiperidin-4-yl)amino]-3-nitrophenyl} sulfonyl)amino]carbonyl} phenoxy)methyl] -1,3-thiazol-2-ylcarbamate The title compound was prepared by substituting EXAMPLE 219D for EXAMPLE IF and EXAMPLE 31 for EXAMPLE IG respectively in EXAMPLE IH. 'H NMR (300 MHz, dimethylsulfoxide-de) 50.96 (s, 6H) 1.37 - 1.54 (m, 12H) 1.60 -1.79 (m, 2H) 1.97 -2.08 (m, 3H) 2.15 - 2.30 (m, 7H) 2.38 (s, 3H) 2.78 (s, 2H) 2.91 (d, 2H) 3.17 - 3.26 (m, 5H) 3.69 - 3.84 (m, IH) 5.08 (s, 2H) 6.48 (d, IH) 6.53 (s, IH) 7.07 (d, 2H) 7.17 (s, IH) 7.23 (d, IH) 7.37 (d, 2H) 7.43 (d, IH) 7.90 (dd, IH) 8.22 (d, IH) 8.58 (d, IH) 10.39 (s, IH) 11.35 (s, IH). EXAMPLE 223 2-[(2-amino-l,3-thiazol-4-yl)methoxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitrophenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 222 for EXAMPLE lA in EXAMPLE IB. 'H NMR (300 MHz, dimethylsulfoxide-d e) 50.96 (s, 6H) 1.42 (t, 2H) 1.59 - 1.76 (m, 2H) 1.92 - 2.06 (m, 3H) 2.16 - 2.42 (m, IIH) 2.78 (s, 4H) 3.20 - 3.26 (m, 5H) 3.67 - 3.82 (m, IH) 4.99 (s, 2H) 6.50 (d, IH) 6.55 (s, IH) 6.62 (s, IH) 6.91 (s, 2H) 7.08 (d, 2H) 7.26 (d, IH) 7.37 (d, 2H) 7.45 (d, IH) 7.93 (dd, IH) 8.24 (d, IH) 8.60 (d, IH). 420 EXAMPLE 224 2-[3-(acetylamino)phenoxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide EXAMPLE 224A methyl 2-(3-acetamidophenoxy)-4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 - yl)benzoate The title compound was prepared by substituting 3-acetamidophenol for EXAMPLE ID in EXAMPLE IE. EXAMPLE 224B 2-(3 -acetamidophenoxy)-4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)benzoic acid The title compound was prepared by substituting EXAMPLE 224A for EXAMPLE IE in EXAMPLE IF. EXAMPLE 224C 2-[3-(acetylamino)phenoxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl }piperazin- l-yl)-N-( {4-[( 1 -methylpiperidin-4-yl)amino]-3-nitrophenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 224B for EXAMPLE IF in EXAMPLE IH. ^H NMR (300 MHz, dimethylsulfoxide-dg) 5 11.48 (s, IH), 9.89 (s, IH), 8.59 (m, IH), 8.50 (d, IH), 7.71 (dd, IH), 7.47 (m, 6H), 7.36 (m, 2H), 7.24 (m, 2H), 7.14 (m, 3H), 6.75 (dd, IH), 6.50 (dd, IH), 6.39 (d, IH), 3.86 (dd, 2H), 3.37 (m, 2H), 3.30 (m, 6H), 3.16 (m, 4H), 2.35 (s, 4H), 2.00 (s, 3H), 1.89 (m, IH), 1.63 (dd, 2H), 1.27 (m, 2H). EXAMPLE 225 2-[3-(acetylamino)phenoxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl)piperazin-l-yl)-N-({3-nitTO-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]phenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 224B for EXAMPLE IF and EXAMPLE 49C for EXAMPLE IG in EXAMPLE IH. 'H NMR (300 MHz, dimethylsulfoxide-dfi) 5 9.86 (s, IH), 8.45 (d, IH), 8.15 (d, IH), 7.70 (dd, IH), 7.54 (d, IH), 421 7.36 (d, 2H), 7.29 (d, IH), 7.09 (m, 4H), 6.98 (m, IH), 6.70 (dd, IH), 6.45 (dd, IH), 6.33 (d, IH), 3.95 (dd, 2H), 3.83 (m, IH), 3.36 (m, 3H), 3.24 (m, 2H), 3.11 (m, 4H), 2.77 (m, 4H), 2.17 (m, 8H), 1.98 (m, 5H), 1.66 (m, 6H), 1.40 (t, 2H), 0.94 (s, 6H). EXAMPLE 226 2-[(2-chlorophenyl)aniino]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({3-nitro-4-[(l-tetrahydK)-2H-pyran-4-ylpiperidin-4- yl)amino]phenyI} sulfonyl)benzamide EXAMPLE 226A methyl 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)-2-(2- chloiophenylamino)benzoate A solution of EXAMPLE 214A (500 mg), cesium carbonate (429 mg), palladium (11) acetate (21 mg), rac-BINAP (2,2'-bis(diphenylphosphino)-l,r-binaphthyl) (58.5 mg) and toluene (6.4 mL) was degassed with N2. The solution was stirred at 115°C for 5 minutes. After cooling to room temperature, 2-chloroaniline (144 mg) was added and the reaction mixture was degassed again with N2 and was stirred at 115°C for 45 minutes. The solution was cooled to room temperature, diluted with ethyl acetate and was washed with water and brine, dried (MgS04), filtered and concentrated. The crude material was purified by flash chromatography on silica gel, eluting with dichloromethane / l%methanol. EXAMPLE 226B 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin- l-yl)-2-(2- chlorophenylamino)benzoic acid The title compound was prepared by substituting EXAMPLE 226A for EXAMPLE IE in EXAMPLE IF. EXAMPLE 226C 4-(4-((2-(4-chloiophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin- l-yl)-2-(2- chlorophenylamino)-N-(3-nitro-4-(l-(tetrahydro-2H-pyran-4-yl)piperidin-4- ylamino)phenylsulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 226B for EXAMPLE IF and EXAMPLE 49C for EXAMPLE IG in EXAMPLE IH. 'H NMR (300 MHz, 422 dimethylsulfoxide-dfi) 6 11.11 (br s, IH), 9.15 (br s, IH), 8.53 (d, IH), 7.97 - 8.20 (m, IH), 7.93 (d, IH), 7.81 (d, IH), 7.47 (d, IH), 7.42 (dd, IH), 7.36 (d, 2H), 7.22 (t, IH), 7.15 (d, IH), 7.07 (d, 2H), 6.89 (t, IH), 6.52 (d, IH), 6.34 (dd, IH), 3.96 (d, 2H), 3.46 - 3.78 (m, 2H), 3.33 - 3.40 (m, 2H), 3.23 - 3.28 (m, 2H), 2.96 - 3.14 (m, 6H), 2.13 - 2.31 (m, 8H), 1.98 (br s, 6H), 1.65 (br s, 4H), 1.41 (t, 2H), 0.95 (s, 6H). EXAMPLE 227 4-(4- {[2-(4-chloropheny l)-4,4-diniethylcy clohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-2- [(6- methoxy-lH-indol-5-yl)oxy]-N-({3-nitro-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl} sulfonyl)benzamide EXAMPLE 227A 6-Methoxy- lH-indol-5-ol 5-(benzyloxy)-6-methoxy-lH-indole (3.00 g) was added to methanol (100 mL) and ethyl acetate (100 mL) in a pressure bottle. Palladium hydroxide on carbon (0.832 g,) was added and the solution was shaken under 30 psi of hydrogen at room temperature for 40 minutes. The mixture was filtered through a nylon membrane, the solvent removed under vacuum, the residue taken up in ethyl acetate, the solution was filtered over a pad of silica gel, and the solvent was removed from the filtrate under vacuum. EXAMPLE 227B 4-Huoro-2-(6-methoxy-lH-indol-5-yloxy)-benzoic acid methyl ester The title compound was prepared by substituting methyl 2,4-difluorobenzoate for ethyl 2,4-difluorobenzoate and EXAMPLE 227A for 2-methyl-5-indolol in EXAMPLE 3A. EXAMPLE 227C 2-(6-Methoxy-lH-indol-5-yloxy)-4-piperazin-l-yl-benzoic acid methyl ester The title compound was prepared by substituting piperazine for EXAMPLE 3F and EXAMPLE 227B for EXAMPLE 3A in EXAMPLE 3G. 423 EXAMPLE 227D 4- {4-[2-(4-Chloio-phenyl)-4,4-dimethyl-cyclohex- l-enylmethyl]-piperazin-1 -yl} -2-(6-methoxy-lH-indol-5-yloxy)-benzoic acid methyl ester The title compound was prepared by substituting EXAMPLE 60D for 4'-chlorobiphenyl-2-carboxaldehyde and EXAMPLE 227C for tert-butyl piperazine-l-carboxylate in EXAMPLE lA. EXAMPLE 227E 4- {4-[2-(4-Chloro-phenyl)-4,4-dimethyl-cyclohex-1 -enylmethyl]-piperazin-1 -yl} -2-(6-methoxy-lH-indol-5-yloxy)-benzoic acid The title compound was prepared by substituting EXAMPLE 227D for EXAMPLE IE in EXAMPLE IF. EXAMPLE 227F 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl jpiperazin-1 -yl)-2-[(6-meihoxy-lH-indol-5-yl)oxy]-N-({3-nitro-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]phenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 227E for EXAMPLE IF and EXAMPLE 49C for EXAMPLE IG in EXAMPLE IH. 'H NMR (300MHZ, dimethylsulfoxide-dfi) 5 11.02 (br s, IH), 8.60 (d, IH), 8.25 (d, IH), 7.89 (dd, IH), 7.54 (d, IH), 7.33 (d, 2H), 7.29-7.26 (m, 2H), 7.21 (d, IH), 7.09 (s, IH), 7.04 (d, 2H), 6.59 (dd, IH), 6.36 (t, IH), 6.03 (d, IH), 3.96-3.87 (m, 3H), 3.74 (s, 3H), 3.73 (m, IH), 2.97 (m, 8H), 2.70 (br s, 2H), 2.13 (br s, 8H), 2.05-1.92 (m, 4H), 1.74 (m, 2H), 1.63 (m, 2H), 1.49 (m, 2H), 1.37 (t, 2H), 0.92 (s, 6H). EXAMPLE 229 2-[(2-amino-1,3-benzothiazol-6-yl)oxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 - en-1 -yl]methyl} piperazin-1 -yl)-N-( (4- [(1 -methylpiperidin-4-yl)amino] -3 - nitrophenyl) sulfonyl)benzamide EXAMPLE 229A methyl 2-(2-aminobenzo[d]thiazol-6-yloxy)-4-fluorobenzoate 424 The title compound was prepared by substituting 2-aniinobenzo[d]thiazol-6-ol for 2-methyl-5-indolol in EXAMPLE 3A. EXAMPLE 229B methyl 2-(2-aminobenzo[d]thiazol-6-yloxy)-4-(4-((2-(4-ch]orophenyl)-4,4-dimethy]cyclohex- l-enyl)methyl)piperazin-1 -yl)benzoate The title compound was prepared by substituting EXAMPLE 229A for EXAMPLE 3A in EXAMPLE 3G. EXAMPLE 229C methyl 2-(2-(tert-butoxycarbonylamino)benzo[d]thiazol-6-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)benzoate The title compound was prepared by substituting EXAMPLE 229B for EXAMPLE 219B in EXAMPLE 219C. EXAMPLE 229D 2-(2-(tert-butoxycarbonylamino)benzo[dJthiazol-6-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)benzoic acid The title compound was prepared by substituting EXAMPLE 229C for EXAMPLE IE in EXAMPLE IF. EXAMPLE 229E tert-butyl6-(5-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)- 2-(4-( 1 -methylpiperidin-4-ylamino)-3-nitrophenylsulfonylcarbamoyl)phenoxy)benzo[d]thiazol-2-ylcarbamate The title compound was prepared by substituting EXAMPLE 229D for EXAMPLE IF and EAXMPLE 31 for EXAMPLE 1G respectively in EXAMPLE IH. EXAMPLE 229F 2-[(2-amino-l,3-benzothiazol-6-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-l-yl]methyl}piperazin-l-yl)-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide 425 The title compound was prepared by substituting EXAMPLE 229E for EXAMPLE lA in EXAMPLE IB. 'H NMR (300 MHz, dimethylsulfoxide-de) 5 0.93 (s, 6H) L39 (t, 2H) L62 - L80 (m, 2H) L91 - 2.24 (m, lOH) 2.50 - 2.62 (m, 4H) 2.74 (s, 4H) 2.97 - 3.18 (m, 5H) 3.66 - 3.82 (m, IH) 6.24 (d, IH) 6.64 (dd, IH) 6.75 (dd, IH) 6.92 (d, IH) 7.01 - 7.12 (m, 3H) 7.20 (d, IH) 7.31 (s, 2H) 7.35 (d, 2H) 7.52 (d, IH) 7.61 - 7.71 (m, IH) 8.09 (d, IH) 8.44 (d, IH). EXAMPLE 230 2-[(2-chlorophenyl)amino]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin- l-yl)-N-( {4-[( l-methylpiperidin-4-yl)amino]-3-nitrophenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 226B for EXAMPLE IF and EXAMPLE 31 for EXAMPLE IG in EXAMPLE IH. 'H NMR (300 MHz, dimethylsulfoxide-de) 5 11.11 (br s, IH), 8.53 (d, IH), 7.02 (br s, IH), 7.94 (dd, IH), 7.81 (d, IH), 7.46 (dd, IH), 7.42 (dd, IH), 7.36 (d, 2H), 7.18 - 7.25 (m, IH), 7.14 (d, IH), 7.07 (d, 2H), 6.85 - 6.92 (m, IH), 6.52 (d, IH), 6.33 (dd, IH), 3.88 (br s, IH), 3.01 - 3.09 (m, 7H), 2.66 - 2.83 (m, 6H), 2.07 - 2.32 (m, 8H), L97 (br s, 3H), 1.78 (br s, 2H), 1.41 (t, 2H), 0.94 (s, 6H). EXAMPLE 231 tert-butyl5-[5-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l- yl)-2-( {[(4- {[3-(dimethylamino)propyl]amino} -3- nitrophenyl)sulfonyl] amino} carbonyl)phenoxy ]-1 H-indole-1 -carboxylate EXAMPLE 231A ethyl 2-(lH-indol-5-yloxy)-4-fluorobenzoate The title compound was prepared by substituting 5-hydroxyindole for 2-methyl-5-indolol in EXAMPLE 3A. EXAMPLE 23 IB ethyl 2-(lH-indol-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- enyl)methyl)piperazin-1 -yl)benzoate 426 The title compound was prepared by substituting EXAMPLE 231A for EXAMPLE 3A in EXAMPLE 3G. EXAMPLE 23IC 2-(lH-indol-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l -yl)benzoic acid The title compound was prepared by substituting EXAMPLE 23IB for EXAMPLE IE in EXAMPLE IF. EXAMPLE 23 ID 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-[(4- {[3-(dimethylamino)propyl]amino} -3-nitrophenyl)sulfonyl]-2-( lH-indol-5-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 23IC for EXAMPLE IF and EXAMPLE 11A for EXAMPLE IG in EXAMPLE IH, except 2-10% methanol in CH2CI2 was used for the chromatography. EXAMPLE 23 IE tert-butyl5-[5-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l- yl)-2-({[(4-{[3-(dimethylamino)propyl]amino}-3- nitrophenyl)sulfonyl]amino} carbonyl)phenoxy]- IH-indole-1 -carboxylate bis(2,2,2- trifluoroacetate) The title compound was prepared by substituting EXAMPLE 23ID for EXAMPLE 202D in EXAMPLE 202E. 'H NMR (500 MHz, dimethylsulfoxide-de) 6 11.63 (v br s, IH), 9.40 (V br s, 2H), 8.61 (br t, IH), 8.53 (d, IH), 8.00 (d, IH), 7.85 (dd, IH), 7.70 (d, IH), 7.54 (d, IH), 7.40 (d, 2H), 7.10 (m, 4H), 6.97 (dd, IH), 6.76 (dd, IH), 6.43 (d, IH), 6.33 (d, IH), 3.60, 3.50, 3.30 (all v br m, total lOH), 3.10 (br m, 4H), 2.79 2.77 (both s, total 6H), 2.20 (br m, 2H), 2.04 (s, 2H), 1.85 (br m, 2H), 1.66 (s, 9H), 1.45 (br t, 2H), 0.95 (s, 6H). EXAMPLE 232 2-[(2-amino-l,3-benzothiazol-6-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-1 -yl] methyl }piperazin-1 -yl)-N- ({3-nitro-4- [(1 -tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl} sulfonyl)benzamide 427 EXAMPLE 232A tert-butyl6-(5-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)- 2-(3-nitK)-4-(l-(tetrahydro-2H-pyran-4-yl)piperidin-4- ylamino)phenylsulfonylcarbamoyl)phenoxy)benzo[d]thiazol-2-ylcarbamate The title compound was prepared by substituting EXAMPLE 229D for EXAMPLE IF and EXAMPLE 49C for EXAMPLE IG respectively in EXAMPLE IH. EXAMPLE 232B 2-[(2-amino-1,3-benzothiazol-6-yl)oxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-N-({ 3-nitro-4-[( 1 -tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]phenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 232A for EXAMPLE lA in EXAMPLE IB. 'H NMR (300 MHz, dimethylsulfoxide-dg) 8 0.95 (s, 6H) 1.44 (br. s, 2H) 1.61 -1.89 (m, 3H) 1.90 - 2.12 (m, 5H) 2.13 - 2.32 (m, 4H) 2.36 - 2.63 (m, 2H) 2.97 -3.78 (m, 16H) 4.01 (dd, 2H) 6.30 (s, IH) 6.72 (d, IH) 6.84 (d, IH) 7.11 (m, 3H) 7.18 - 7.32 (m, 2H) 7.33 - 7.55 (m, 5H) 7.68 - 7.89 (m, IH) 8.17 (d, IH) 8.57 (d, IH) 9.25 (br. s, IH) 11.62 (br.s,lH). EXAMPLE 233 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl }piperazin-1 -yl)-2-[(6-fluoro-lH-indol-5-yl)oxy]-N-[(3-nitro-4-{[3-(3-oxopiperazin-l-yl)propyl]annino}phenyl)sulfonyl]benzamide The title compound was prepared by substituting EXAMPLE 154E for EXAMPLE 122C and EXAMPLE 254A for EXAMPLE 11A in EXAMPLE 137. 'H NMR (500 MHz, dimethylsulfoxide-de) 8 11.20 (br s, IH), 8.62 (br t, IH), 8.57 (d, IH), 7.83 (dd, IH), 7.75 (s, IH), 7.51 (d, IH), 7.37 (dd, IH), 7.34 (m, 3H), 7.26 (d, IH), 7.08 (d, IH), 7.04 (d, 2H), 6.63 (dd, IH), 6.40 (s, IH), 6.09 (s, IH), 3.43 (dd, 2H), 3.18 (br m, 2H), 3.04 (br m, 4H), 2.95 (s, 2H), 2.70 (s, 2H), 2.55 (t, 2H), 2.45 (t, 2H), 2.17 (br m, 6H), 1.95 (s, 2H), 1.79 (m, 2H), 1.38 (t, 2H), 0.92 (s, 6H). 428 EXAMPLE 234 Trans-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcy clohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2- [(6-fluoro-1 H-indol-5 -yl)oxy] -N-( {4-[(4-morpholin-4-ylcyclohexyl)amino] -3 - nitrophenyl} sulfonyl)benzainide The title compound was prepared by substituting EXAMPLE 154E for EXAMPLE 122C and EXAMPLE 205A for EXAMPLE 11A in EXAMPLE 137. 'H NMR (500 MHz, dimethylsulfoxide-d6) 8 11.20 (s, IH), 8.54 (s, IH), 8.17 (br d, IH), 7.84 (d, IH), 7.52 (d, IH), 7.34 (m, 4H), 7.24 (br d, IH), 7.11 (brd, IH), 7.04 (d, 2H), 6.64 (d, IH), 6.40 (s, IH), 6.09 (s, IH), 3.62 (br m, 4H), 3.58 (v br s, IH), 3.00 (br m. 4H), 2.73 (s, 2H), 2.65 (br m, 4H), 2.47 (v br s, IH), 2.18 (br m, 6H), 2.06 (br m, 2H), 1.93 (br m, 4H), 1.40 (m, 6H), 0.92 (s, 6H). EXAMPLE 235 Trans-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-[(6,7-difluoro-lH-indol-5-yl)oxy]-N-({4-[(4-morpholin-4-ylcyclohexyl)amino]-3-nitrophenyl} sulfonyl)benzanude The title compound was prepared by substituting EXAMPLE 200F for EXAMPLE 122C and EXAMPLE 205A for EXAMPLE 1 lA in EXAMPLE 137. 'H NMR (500 MHz, dimethylsulfoxide-dfi) 5 11.72 (s, IH), 8.46 (s, IH), 8.15 (br d, IH), 7.78 (d, IH), 7.52 (d, IH), 7.40 (dd, IH), 7.34 (d, 2H), 7.06 (br d, IH), 7.05 (d, 2H), 6.91 (br d, IH), 6.66 (br d, IH), 6.40 (s, IH), 6.25 (d, IH), 3.62 (br m, 4H), 3.58 (v br s, IH), 3.00 (br m, 4H), 2.73 (s, 2H), 2.65 (br m, 4H), 2.47 (v br s, IH), 2.18 (br m, 6H), 2.06 (br m, 2H), 1.93 (br m, 4H), 1.40 (m, 6H), 0.92 (s, 6H). EXAMPLE 236 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl }piperazin-1 -yl)-N-[(4- {[l-(cyclopropylmethyl)piperidin-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-[(6-fluoro-lH- indol-5 -yl)oxy ]benzamide 429 EXAMPLE 236A tert-butyl l-(cyclopropylmethyl)piperidin-4-ylcarbamate The title compound was prepared by substituting cyclopropanecarbaldehyde for 4'-chlorobiphenyl-2-carboxaldehyde and tert-butyl piperidin-4-ylcarbamate for tert-butyl piperazine-l-carboxylate in EXAMPLE lA. EXAMPLE 236B 1 -(cyclopropylmethyl)piperidin-4-amine bis(2,2,2-trifluoroacetate) The title compound was prepared by substituting EXAMPLE 236A for EXAMPLE lA in EXAMPLE IB. EXAMPLE 236C 4-(l-(cyclopropylmethy])piperidin-4-ylamino)-3-nitrobenzenesulfonamide The title compound was prepared by substituting EXAMPLE 236B for 4-(l-isopropylpiperidin-4-ylamino)-3-nitrobenzenesulfonamide in EXAMPLE 41 A. EXAMPLE 236D 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl jpiperazin-1 -yl)-N- [(4- {[l-(cyclopropylmethyl)piperidin-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-[(6-fluoro-lH- indol-5 -yl)oxy ]benzamide The title compound was prepared by substituting EXAMPLE 154E for EXAMPLE IF and EXAMPLE 236C for EXAMPLE IG in EXAMPLE IH. ^H NMR (500 MHz, pyridine-ds) 5 12.39 (s, IH), 9.31 (d, IH), 8.49 (d, IH), 8.45 (dd, IH), 8.15 (d, IH), 7.47 - 7.52 (m, 3H), 7.41 - 7.45 (m, 3H), 7.04 (d, 2H), 6.98 (d, IH), 6.71 (dd, IH), 6.57 (dd, 2H), 3.48 - 3.55 (m, IH), 3.01 - 3.07 (m, 4H), 2.86 (d, 2H), 2.74 (s, 2H), 2.21 - 2.26 (m, 2H), 2.19 (d, 4H), 2.07 - 2.13 (m, 4H), 1.93 - 2.00 (m, 4H), 1.63 - 1.71 (m, 2H), 1.38 (t, 2H), 0.93 (s, 6H), 0.84 -0.91 (m, IH), 0.45 - 0.49 (m, 2H), 0.11 (q, 2H). EXAMPLE 237 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl }piperazin-1 -yl)-N- [(4- {[ 1 -(cyclopropylmethyl)piperidin-4-yl]amino} -3-nitrophenyl)sulfonyl]-2-[(6,7-difluoro- IH- indol-5-yl)oxy]benzamide 430 The title compound was prepared by substituting EXAMPLE 200F for EXAMPLE IF and EXAMPLE 236C for EXAMPLE IG in EXAMPLE IH. 'H NMR (500 MHz, pyridine-d5) 5 13.12 (s, IH), 9.29 (d, IH), 8.49 (d, IH), 8.46 (dd, IH), 8.11 (d, IH), 7.42 (d, 2H), 7.19 (s, IH), 7.04 (d, 2H), 6.98 (d, IH), 6.75 (dd, IH), 6.66 (d, IH), 6.51 - 6.54 (m, IH), 3.50 -3.55 (m, IH), 3.07 - 3.13 (m, 4H), 2.83 - 2.87 (m, 2H), 2.76 (s, 2H), 2.25 (t, 2H), 2.11 - 2.23 (s, 8H), 1.93 - 2.00 (m, 4H), L63 - 1.71 (m, 2H), 1.38 (t, 2H), 0.92 (s, 6H), 0.84 - 0.90 (m, IH), 0.44 - 0.49 (m, 2H), 0.08 - 0.12 (m, 2H). EXAMPLE 238 4-(4- {[2-(4-chloiophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-[(6-fluoro- lH-indol-5-yl)oxy]-N-({ 3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)aniino]phenyl} sulfonyl)benzaniide The title compound was prepared by substituting EXAMPLE 154E for EXAMPLE IF in EXAMPLE IH. 'H NMR (500MHz, dimethylsulfoxide-d^) 8 11.23 (s, IH), 8.63 (t, IH), 8.60 (d, IH), 7.87 (dd, IH), 7.51 (d, IH), 7.38 (t, IH), 7.30-7.34 (m, 4H), 7.17 (d, IH), 7.03 (d, 2H), 6.66 (dd, IH), 6.41 (s, IH), 6.09 (s, IH), 3.85 (dd, 2H), 3.26 (t, 2H), 3.03 (s, 4H), 2.74 (s, 2H), 2.12-2.19 (m, 6H), 1.94 (s, 2H), 1.87-1.90 (m, IH), 1.62 (d, 2H), 1.38 (t, 2H), 1.22-1.30 (m, 2H), 0.92 (s, 6H). EXAMPLE 239 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2- [(6,7-difluoro-1 H-indol-5-yl)oxy]-N- [(3-nitro-4- {[3-(3-oxopiperazin-1 -yl)propyl]amino}phenyl)sulfonyl]benzamide The title compound was prepared by substituting EXAMPLE 200F for EXAMPLE 122C and EXAMPLE 254A for EXAMPLE 1 lA in EXAMPLE 137. 'H NMR (500 MHz, dimethylsulfoxide-dfi) 5 11.68 (br s, IH), 8.70 (v br s, IH), 8.46 (s, IH), 7.74 (s, IH), 7.73 (br s, IH), 7.52 (d, IH), 7.37 (dd, IH), 7.34 (d, 2H), 7.05 (d, 2H), 7.95 (v br s, IH), 6.83 (v br s, IH), 6.67 (dd, IH), 6.39 (s, IH), 6.25 (d, IH), 3.44 (q, 2H), 3.18 (br m, 2H), 3.04 (br m, 4H), 2.97 (s, 2H), 2.73 (s, 2H), 2.57 (t, 2H), 2.47 (t, 2H), 2.18 (br m, 6H), 1.95 (s, 2H), 1.88 (m, 2H), 1.37 (t,2H), 0.91 (s,6H). 431 EXAMPLE 240 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl }piperazin-1 -yl)-2-[(6-fluoro-lH-indol-5-yl)oxy]-N-({4-[(2-hydroxy-l-tetrahydro-2H-pyran-4-ylethyl)amino]-3- nitrophenyl} sulfonyl)benzamide EXAMPLE 240A N-(4-chloro-3-nitrophenylsulfonyl)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-2-(6-fluoro-lH-indol-5-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 154E for EXAMPLE 122C and 4-chloro-3-nitiobenzenesulfonamide for EXAMPLE 11A in EXAMPLE 137. EXAMPLE 240B 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-[(6-fluoro-lH-indol-5-yl)oxy]-N-({4-[(2-hydroxy-l-tetrahydro-2H-pyran-4-ylethyl)amino]-3- nitrophenyl} sulfonyl)benzamide EXAMPLE 240A (150 mg) was dissolved in dioxane (1.8 mL), then 2-aniino-2-(tetrahydro-2H-pyran-4-yl)ethanol (35 mg) and triethylamine (0.078 mL) were added. The reaction was heated at 110°C for 20 hours. The reaction was concentrated and the crude was purified by preparative HPLC using a CIS column, 250 x 50 mm, 10^., and eluting with a gradient of 20-100% CH3CN vs. 0.1% trifluoroacetic acid in water, giving the product as a trifluoroacetate salt. The salt was dissolved in dichloromethane (6 mL) and washed with 50% aqueous NaHCOs. The organic layer was dried over anhydrous Na2S04, filtered, and concentrated to give the title compound. 'H NMR (500 MHz, dimethylsulfoxide-de) 8 11.23 (s, IH), 8.60 (d, IH), 8.58 (d, IH), 7.84 (dd, IH), 7.52 (d, IH), 7.39 (dd, IH), 7.33 (m, 4H), 7.29 (d, IH), 7.04 (d, 2H), 6.64 (dd, IH), 6.42 (s, IH), 6.08 (s, IH), 5.03 (t, IH), 3.85 (m, 2H), 3.74 (m, IH), 3.63 (m, IH), 3.57 (m, IH), 3.26 (dd, 2H), 3.02 (br m, 4H), 2.73 (s, 2H), 2.18(brm,6H), 1.95 (s,2H), 1.94 (m, IH), 1.61 (brm,2H), 1.38 (m,3H), 1.30 (m, 1H),0.92 (s, 6H). EXAMPLE 241 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-[(6- fluoro- lH-indol-5-yl)oxy ]-N- {[4-( {[4-(hydroxymethyl)tetrahydro-2H-pyran-4- yljmethyl} amino)-3-nitrophenyl]sulfonyl} benzamide 432 EXAMPLE 241A 4-((4-(hydioxymethyl)tetrahydro-2H-pyran-4-yl)methylamino)-3-nitrobenzenesulfonamide The title compound was prepared by substituting (4-(aminomethyl)tetrahydro-2H-pyran-4-yl)methanol for (tetrahydropyran-4-yl)methylamine in EXAMPLE IG. EXAMPLE 241B 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl }piperazin-1 -yl)-2-[(6- fluoro-lH-indol-5-yl)oxy]-N-{[4-({[4-(hydroxymethyl)tetrahydro-2H-pyran-4- yljmethyl} amino)-3-nitrophenyl]sulfonyl }benzamide The title compound was prepared by substituting EXAMPLE 154E for EXAMPLE IF and EXAMPLE 241A for EXAMPLE IG in EXAMPLE IH. 'H NMR (500MHz, dimethylsulfoxide-dfi) 5 11.22 (s, 2H), 9.10 (t, IH), 8.59 (d, IH), 7.87 (dd, IH), 7.51 (d, IH), 7.30-7.39 (m, 5H), 7.24 (d, IH), 7.02-7.05 (m, 2H), 6.66 (dd, IH), 6.41 (s, IH), 6.08 (s, IH), 5.22 (t, IH), 3.51-3.62 (m, 6H), 3.41 (d, 2H), 3.03 (s, 4H), 2.73 (s, 2H), 2.09-2.18 (m, 6H), 1.95 (s, 2H), 1.45-1.51 (m, 4H), 1.38 (t, 2H), 0.92 (s, 6H). EXAMPLE 242 2-[(6-chloro-1 H-indol-5-yl)oxy]-4-(4- {[2-(4-chIorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl }piperazin-1 -y l)-N-( {3 -nitro-4- [(1 -tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl} sulfonyl)benzamide EXAMPLE 242A ethyl 2-(4-amino-2-chlorophenoxy)-4-fluorobenzoate To a solution of ethyl 2,4-difluorobenzoate (6.48 g) and 4-amino-2-chlorophenol(5.0 g) in diglyme (40 mL) was added K3PO4 (7.39 g). The mixture was stirred at 110°C overnight. The mixture was diluted with ethyl acetate (300 mL) and washed with water, brine and dried over Na2S04. The mixture was filtered, and the solvent was evaporated and the residue was loaded on a column and eluted with 10% ethyl acetate in hexane to give the product. EXAMPLE 242B ethyl 2-(4-amino-2-chloro-5-iodophenoxy)-4-fluorobenzoate 433 To a solution of EXAMPLE 242A (8.15 g) in dichloromethane (60 mL) was added bis(pyridine)iodonium tetrafluoroborate (9.79 g). The mixture was stirred at room temperature for 4 hours. The mixture was diluted with ethyl acetate (200 mL) and washed with aqueous Na2S203, water, brine and dried over Na2S04. The mixture was filtered, and the solvent was evaporated and the residue was loaded on a column and eluted with 10% ethyl acetate in hexane to give the pure product. EXAMPLE 242C ethyl 2-(4-amino-2-chloro-5-((trimethylsilyl)ethynyl)phenoxy)-4-fluorobenzoate To a mixture of EXAMPLE 242B (3.0 g), bis(triphenylphosphine)palladium(n) dichloride (242 mg), Cul (66 mg) in triethylamine (30 mL) was added trimethylsilylacetylene (2.2 g). The mixture was stirred at room temperature overnight. The mixture was diluted with ethyl acetate (2(X) mL) and washed with aqueous NH4CI, water, brine and dried over Na2S04. The mixture was filtered, and the solvent was evaporated and the residue was loaded on a column and eluted with 10% ethyl acetate in hexane to give the pure product EXAMPLE 242D ethyl 2-(4-amino-2-chloro-5-ethynylphenoxy)-4-fluorobenzoate To a solution of EXAMPLE 242C (2.69 g) in methanol (20 mL) was added CsF(5 g). The mixture was stirred at room temperature overnight. The solvent was evaporated and the residue was dissolved in ethyl acetate (200 mL) and washed with water, brine and dried over Na2S04. The mixture was filtered, and the solvent was evaporated. EXAMPLE 242E ethyl 2-(6-chloro-1 H-indol-5 -yloxy )-4-fluorobenzoate To a solution of EXAMPLE 242D (1.0 g) in ethanol (20 mL) was added NaAuCU •2H2O (60 mg). The mixture was stirred at room temperature for 4 hours. The mixture was diluted with ethyl acetate (200 mL) and washed with water, brine and dried over Na2S04. The mixture was filtered, and the solvent was evaporated and the residue was loaded on a column and eluted with 10% ethyl acetate in hexane to give the pure product. EXAMPLE 242F ethyl 2-(6-chloro-lH-indol-5-yloxy)-4-(piperazin-l-yl)benzoate 434 The title compound was prepared as described in EXAMPLE 3G by replacing EXAMPLE 3F and EXAMPLE 3A with piperazine and EXAMPLE 242E respectively. EXAMPLE 242G ethyl 2-(6-chloro-1 H-indol-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 - enyl)methyl)piperazin-1 -yl)benzoate The title compound was prepared as described in EXAMPLE 38G by replacing EXAMPLE 38F and EXAMPLE 38E with EXAMPLE 242F and EXAMPLE 60D. EXAMPLE 242H 2-(6-chloro-lH-indol-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- enyl)methyl)piperazin-1 -yl)benzoic acid The title compound was prepared as described in EXAMPLE 38H by replacing EXAMPLE 380 with EXAMPLE 242G. EXAMPLE 2421 2- [(6-chloK)- lH-indol-5-yl)oxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-N-( {3-nitro-4- [(1 -tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]phenyl} sulfonyl)benzamide The title compound was prepared as described in EXAMPLE IH by replacing EXAMPLE IF and EXAMPLE IG with EXAMPLE 242H and EXAMPLE 49C, respectively. 'H NMR (300 MHz, dimethylsulfoxide-ds) 5 11.20 (s, IH), 8.52 (m, IH), 8.18 (d, IH), 7.83 (dd, IH), 7.53 (m, 2H), 7.40 (m, IH), 7.33 (d, 3H), 7.18 (m, IH), 7.04 (m, 4H), 6.62 (m, IH), 6.38 (s, IH), 6.01 (d, IH), 3.92 (m, 2H), 3.77 (m, IH), 3.13 (m, 8H), 2.71 (s, 2H), 2.24 (m, 8H), 1.95 (m, 6H), 1.52 (m, 6H), 0.94 (s, 6H). EXAMPLE 243 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2- [(6,7- difluoro-1 H-indol-5-yl)oxy]-N-( {3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)benzamide The title compound was prepared as described in EXAMPLE IH by replacing EXAMPLE IF with EXAMPLE 200F. 'H NMR (300 MHz, diraethylsulfoxide-de) 5 11.75 (s, IH), 8.59 (t, IH), 8.53 (d, IH), 7.82 (dd, IH), 7.49 (d, IH), 7.41 (m, IH), 7.34 (d, 3H), 435 7.12 (d, IH), 7.04 (d, 2H), 6.98 (d, IH), 6.69 (dd, IH), 6.43 (d, IH), 6.24 (d, IH), 3.85 (m, 2H), 3.07 (m, 5H), 2.74 (m, 2H), 2.23 (m, 6H), 1.92 (m, 5H), 1.60 (m, 3H), 1.30 (m, 4H), 0.94 (s, 6H). EXAMPLE 244 2-[(6-chloro-1 H-indol-5-yl)oxy]-4-(4- {[2-(4-chlorophenyl)-4,4-diniethylcyclohex-1 -en-1 -yl]methyl}piperazin-l-yl)-N-({4-[(4-methylpiperazin-l-yl)amino]-3-nitrophenyl} sulfonyl)benzamide The title compound was prepared as described in EXAMPLE IH by replacing EXAMPLE IF and EXAMPLE IG with EXAMPLE 242H and EXAMPLE 184A, respectively. 'H NMR (300 MHz, dimethylsulfoxide-ds) 5 11.24 (s, IH), 9.19 (s, IH), 8.52 (d, IH), 7.88 (dd, IH), 7.56 (m, 3H), 7.42 (t, IH), 7.31 (m, 3H), 7.03 (d, 2H), 6.63 (dd, IH), 6.41 (s, IH), 5.98 (d, IH), 2.94 (m, lOH), 2.70 (s, 3H), 2.37 (m, 3H), 2.14 (m, 6H), 1.94 (s, 2H), 1.37 (t,2H), 0.91 (s,6H). EXAMPLE 245 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-[(6- fluoro-1 H-indol-5 -yl)oxy ] -N- [(3 -nitro-4- {[ 1 -(1,3 -thiazol-4-ylmethyl)piperidin-4- yl]amino}phenyl)sulfonyl]benzamide EXAMPLE 245A tert-butyl 1 -(thiazol-4-ylmethyl)piperidin-4-ylcarbamate The title compound was prepared by substituting thiazole-4-carbaldehyde for 4'-chlorobiphenyl-2-carbaldehyde and tert-butyl piperidin-4-ylcarbamate for tert-butyl piperazine-l-carboxylate in EXAMPLE lA EXAMPLE 245B The title compound was prepared by substituting EXAMPLE 245A for EXAMPLE lA in EXAMPLE IB. EXAMPLE 245C 3-nitro-4-(l-(thiazol-4-ylmethyl)piperidin-4-ylamino)benzenesulfonamide 436 The title compound was prepared by substituting EXAMPLE 245B for (tetrahydropyran-4-yl)niethylamine in EXAMPLE IG. EXAMPLE 245D 4-(4- {[2-(4-chloropheny l)-4,4-dimethylcy clohex-1 -en- l-yl]methyl} piperazin-1 -yl)-2-[(6- fluoro-lH-indol-5-yl)oxy]-N-[(3-nitro-4-{[l-(l,3-thiazol-4-ylmethyl)piperidin-4- yl]amino}phenyl)sulfonyl]benzanude The title compound was prepared by substituting EXAMPLE 154E for EXAMPLE IF and EXAMPLE 245C for EXAMPLE IG in EXAMPLE IH. 'H NMR (500MHZ, dimethylsulfoxide-dfi) 6 11.16 (s, IH), 9.08 (s, IH), 8.20 (s, IH), 7.91 (s, IH), 7.82 (d, IH), 7.29-7.34 (m, 4H), 7.18 (d, IH), 7.15 (m, IH), 7.04 (d, 2H), 6.60 (dd, IH), 6.37 (s, IH), 6.08 (s, IH), 4.28 (s, 2H), 2.90-2.98 (m, 8H), 2.72 (s, 2H), 2.14-2.17 (m, 6H), 2.01 (m, 2H), 1.95 (s, 2H), 1.53-1.55 (m, 2H), 1.38 (t, 2H), 0.92 (s, 6H). EXAMPLE 246 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]mediyl} piperazin-1 -yl)-N-( {3 -nitro-4- [(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 36C for EXAMPLE IF in EXAMPLE IH. 'H NMR (500MHz, dimethylsulfoxide-de) 6 8.60 (t, IH), 8.42 (d, IH), 7.71 (dd, IH), 7.51 (d, IH), 7.36 (d, 2H), 7.19 (t, IH), 7.10 (d, IH), 7.07 (d, 2H), 6.93 (dd, IH), 6.79 (dd, IH), 6.72 (dd, IH), 6.69 (t, IH), 6.47 (d, IH), 3.87 (dd, 2H), 3.21-3.32(m, 4H), 3.20 (s, 4H). 2.81 (s, 2H), 2.27 (s, 4H), 2.16 (br s, 2H), 1.90-1.98 (m, 3H), 1.63-1.66 (m, 2H), 1.41 (t, 2H), 1.27-1.30 (m, 2H), 0.94 (s, 6H). EXAMPLE 247 2-(4-amino-3-chlorophenoxy)-4-(4-([2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yljmethyl} piperazin-1 -yl)-N-( {3 -nitro-4- [(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 40C for EXAMPLE IF in EXAMPLE IH. 'H NMR (500MHz, dimethylsulfoxide-de) 5 11.12 (s, IH), 8.50 (d, 2H), 7.84 (dd, IH), 7.58 (d, IH), 7.32-7.34 (m, 2H), 7.28 (d, IH), 7.15 (d, IH), 7.10 (d, IH), 7.04 (d, 2H), 6.58 (dd, IH), 6.34 (s, IH), 6.07 (d, IH), 3.63-3.70 (m, 6H), 2.96 (s, 4H), 2.71 (s, 437 2H), 2..12-2.16 (m, 6H), 1.95 (s, 2H), 1.72-1.76 (m, 2H), 1.55-1.60 (m, 2H), 1.38 (t, 2H), 0.94 (s, 6H). EXAMPLE 248 N-[(4-{[(4-aminotetrahydro-2H-pyran-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2- (4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-[(6-fluoro-lH- indol-5-yl)oxy]benzamide The title compound was prepared by substituting EXAMPLE 154E for EXAMPLE IF and EXAMPLE 191A for EXAMPLE IG in EXAMPLE IH. 'H NMR (500MHZ, dimethylsulfoxide-dfi) 5 11.12 (s, IH), 8.50 (d, IH), 7.84 (dd, IH), 7.32-7.34 (m, 3H), 7.28 (d, IH), 7.15 (d, IH), 7.11 (d, IH), 7.04 (d, 2H), 6.58 (dd, IH), 6.34 (s, IH), 6.07 (d, IH), 3.85-3.89 (m, 4H), 3.61-3.63 (m, 2H), 3.66-3.69 (m, 4H), 3.48-3.51 (m, 2H), 2.96 (s, 4H), 2.71 (s, 2H), 2.14-2.18 (m, 6H), 1.95 (s, 2H), 1.72-1.76 (m, 2H), 1.57-1.70 (m, 2H), 1.38 (t, 2H), 0.92 (s, 6H). EXAMPLE 249 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl }piperazin-1 -yl)-2-[(6- fluoro-lH-indol-5-yl)oxy]-N-[(4-{[(3S,4R)-3-hydroxy-l-(l,3-thiazol-4-ylmethyl)piperidin-4- yl]amino) -3-nitrophenyl)sulfonyl]benzamide EXAMPLE 249A A mixture of tert-butyl (3S,4R)-l-benzyl-3-hydroxypiperidin-4-ylcarbamate (0.42 g) and palladium hydroxide on carbon (0.095 g) in ethanol (15 mL) was hydrogenated with a balloon of H2. The reaction mixture was stirred for 16 hours. The solid was filtered off, and the filtrate was concentrated to give the title compound. EXAMPLE 249B tert-butyl (3R,4S)-3-hydroxy-l-(thiazol-4-ylmethyl)piperidin-4-ylcarbamate The title compound was prepared by substituting thiazole-4-caibaldehyde for 4'-chlorobiphenyl-2-carbaldehyde and EXAMPLE 249A for tert-butyl piperazine-l-carboxylate in EXAMPLE lA. 438 EXAMPLE 249C (3R,4S)-4-amino-1 -(thiazol-4-ylmethyl)piperidin-3-ol The title compound was prepared by substituting EXAMPLE 249B for EXAMPLE lA in EXAMPLE IB. EXAMPLE 249D 4-((3S,4R)-3-hydroxy-l-(thiazol-4-ylmethyl)piperidin-4-ylamino)-3-nitrobenzenesulfonamide The title compound was prepared by substituting EXAMPLE 249C for (tetrahydropyran-4-yl)methylamine in EXAMPLE IG. EXAMPLE 249E 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-2-[(6-fluoro-lH-indol-5-yl)oxy]-N-[(4-{[(3S,4R)-3-hydroxy-l-(l,3-thiazol-4-ylmethyl)piperidin-4-yl]amino} -3-nitrophenyl)sulfonyl]benzamide The tide compound was prepared by substituting EXAMPLE 154E for EXAMPLE IF and EXAMPLE 249D for EXAMPLE IG in EXAMPLE IH. ^H NMR (500MHz, diraethylsulfoxide-de) 5 11.20 (s, IH), 8.64 (t, IH), 9.07-9.09 (m, IH), 8.60 (s, IH), 8.57 (s, IH), 7.82 (d, IH), 7.80 (s, IH), 7.51 (d, 2H), 7.19-7.32 (m, 6H), 7.04 (d, 2H), 6.62-6.64 (m, 2H), 6.39 (s, IH), 6.08 (s, IH), 3.82 (m, 2H), 3.01 (s, 4H), 2.77 (s, 2H), 2.12-2.16 (m, 6H), 1.81 (m, 2H), 1.38 (t, 2H), 0.92 (s, 6H). EXAMPLE 250 2-(2-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl }piperazin-l-yl)-N-{ [4-({ [4-(hydroxymethyl)tetrahydro-2H-pyran-4- yl]methyl}amino)-3-nitTOphenyl]sulfonyl}benzamide EXAMPLE 250A 4-((4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)methylamino)-3-nitrobenzenesulfonamide The title compound was prepared by substituting (4-(aminomethyl)tetrahydro-2H-pyran-4-yl)methanol for (tetrahydropyran-4-yl)methylanune in EXAMPLE IG. 439 EXAMPLE 250B 2-(2-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-N- {[4-({ [4-(hydroxymethyl)tetrahydro-2H-pyran-4- yl]methyl} amino)-3-nitrophenyl]sulfonyl }benzamide The title compound was prepared by substituting EXAMPLE 34C for EXAMPLE IF and EXAMPLE 250A for EXAMPLE IG in EXAMPLE IH. 'H NMR (500MHZ, dimethylsulfoxide-de) 6 9.11 (s, IH), 8.44 (d, IH), 7.72 (dd, IH), 7.50 (d, IH), 7.36 (d, 2H), 7.17-7.20 (m, 2H), 7.07 (d, 2H), 6.95 (dd, 2H), 6.78 (dd, IH), 6.72 (dd, IH), 6.69 (t, IH), 6.48 (d, IH), 5.24 (t, IH), 3.54-3.65 (m, 6H), 3.42 (d, 2H), 3.21 (s, 4H), 2.84 (s, 2H), 2.26-2.34 (m, 4H), 2.17-2.19 (m, 2H), 1.48-1.55 (m, 4H), 0.95 (s, 6H). EXAMPLE 251 4-(4-{[2-(4-chloiophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-[(6-fluoro- lH-indol-5-yl)oxy ]-N- {[3-nitro-4-(tetrahydro-2H-pyran-4-ylamino)phenyl]sulfonyl}benzamide The title compound was prepared by substituting tetrahydro-2H-pyran-4-amine for 2-amino-2-(tetrahydio-2H-pyran-4-yl)ethanol in EXAMPLE 240B. 'H NMR (500 MHz, dimethylsulfoxide-de) 5 11.21 (s, IH), 8.58 (d, IH), 8.24 (d, IH), 7.84 (dd, IH), 7.52 (d, IH), 7.38 (dd, IH), 7.33 (m, 3H), 7.29 (d, IH), 7.23 (d, IH), 7.03 (d, 2H), 6.64 (dd, IH), 6.40 (s, IH), 6.08 (s, IH), 3.90 (m, 3H), 3.47 (m, 2H), 3.03 (br m, 4H), 2.73 (s, 2H), 2.19 (br m, 6H), 1.95 (s, 2H), 1.91 (br m, 2H), 1.60 (m, 2H), 1.38 (t, 2H), 0.92 (s, 6H). EXAMPLE 252 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-[(6- fluoro- lH-indol-5-yl)oxy]-N- {[4-(morpholin-4-ylamino)-3-nitrophenyl]sulfonyl} benzamide EXAMPLE 252A 4-(morpholinoamino)-3-nitrobenzenesulfonamide The title compound was prepared by substituting morpholin-4-amine for 4-(l-isopropylpiperidin-4-ylamino)-3-nitrobenzenesulfonamide in EXAMPLE 41 A. 440 EXAMPLE 252B 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-[(6-fluoro-lH-indol-5-yl)oxy]-N-{[4-(morpholin-4-ylamino)-3-nitiophenyl]sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 154E for EXAMPLE IF and EXAMPLE 252A for EXAMPLE IG in EXAMPLE IH. 'H NMR (500 MHz, pyridine-ds) 5 12.38 (s, IH), 9.26 - 9.30 (m, 2H), 8.48 (dd, IH), 8.14 (d, IH), 7.71 (d, IH), 7.51 (t, IH), 7.46 - 7.50 (m, 2H), 7.41 - 7.45 (m, 3H), 7.04 (d, 2H), 6.71 (dd, IH), 6.54 - 6.58 (m, 2H), 3.86 (s, 2H), 3.71 (s, 2H), 3.01 - 3.07 (m, 4H), 2.89 (d, 4H), 2.74 (s, 2H), 2.23 (t, 2H), 2.07 - 2.13 (m, 4H), 1.96 (s, 2H), 1.38 (t, 2H), 0.92 (s, 6H). EXAMPLE 253 2-(3 -chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-l-yl)-N-{[4-(morpholin-4-ylamino)-3-nitrophenyl]sulfonyl}benzamide The tiUe compound was prepared by substituting EXAMPLE 36C for EXAMPLE IF and EXAMPLE 252A for EXAMPLE IG in EXAMPLE IH. 'H NMR (500 MHz, pyridine-ds) 5 9.26 (s, IH), 9.13 (d, IH), 8.31 (dd, IH), 8.09 (d, IH), 7.67 (d, IH), 7.46 (d, 2H), 7.10 -7.16 (m, 3H), 7.08 (t, IH), 7.02 (d, IH), 6.93 (dd, IH), 6.82 (dd, IH), 6.69 (d, IH), 3.88 (s, 2H), 3.77 (s, 2H), 3.27 (s, 2H), 3.13 - 3.19 (m, 4H), 2.93 (s, 4H), 2.84 (s, 2H), 2.31 (t, 2H), 2.23 - 2.28 (m, 4H), 2.00 (s, 2H), 1.42 (t, 2H), 0.97 (s, 6H). EXAMPLE 254 2-(2-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-[(3-nitro-4-{[3-(3-oxopiperazin-l- yl)propyl]amino}phenyl)sulfonyl]benzamide EXAMPLE 254A 3-Nitro-4-[3-(3-oxo-piperazin-l-yl)-propylamino]-benzenesu]fonamide The title compound was prepared by substituting 4-(3-aminopropyl)-piperazine-2-one for tert-butyl 4-aminopiperidine-l-carboxylate in EXAMPLE 140A. 441 EXAMPLE 254B 2-(2-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin- l-yl)-N-[(3-nitro-4-{ [3-(3-oxopiperazin-1-yl)propyl]amino}phenyl)sulfonyl]benzamide The title compound was prepared by substituting EXAMPLE 5B for EXAMPLE IF and EXAMPLE 254A for EXAMPLE IG in EXAMPLE IH. 'H NMR (300MHZ, dimethylsulfoxide-de) 6 8.85 (t, IH), 8.47 (d, IH), 7.80-7.72 (m, 2H), 7.51 (d, IH), 7.41 (dd, IH), 7.36 (d, 2H), 7.18-7.03 (m, 4H), 7.00 (td, IH), 6.75 (dd, IH), 6.71 (d, IH), 6.30 (d, IH), 3.46 (q, 2H), 3.22-3.11 (m, 6H), 2.97 (s, 2H), 2.79 (br s, 2H), 2.59 (t, 2H), 2.47 (t, 2H), 2.31-2.12 (m, 6H), 1.97 (br s, 2H), 1.82 (m, 2H), 1.46 9t, 2H), 0.94 (s, 6H). EXAMPLE 255 2-(6-aminopyridin-3-yl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl }piperazin-1 -y l)-N-( {3-nitro-4-[(l -tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl} sulfonyl)benzamide EXAMPLE 255A methyl 2-(6-aminopyridin-3 -yloxy )-4-fluorobenzoate A mixture of 5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2-amine (1.039 g), CsF (1.956 g), bis(triphenylphosphine)palladium(n)dichloride (0.301 g), and methyl 2-bromo-4-fluoiobenzoate (1.0 g) in 50 mL dimethoxyethane-methanol (1:1) was heated at 80°C for 2.5 hours. The reaction mixture was partitioned between water and ethyl acetate. The organic phase was washed with brine, dried over MgS04, filtered, ad concentrated. The residue was chromatographed on silica gel with 25-80% ethyl acetate in hexanes. EXAMPLE 25 5B methyl 2-(6-aminopyridin-3-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- enyl)methyl)piperazin-1 -yl)benzoate The title compound was prepared by substituting EXAMPLE 255A for EXAMPLE 3A in EXAMPLE 3G. 442 EXAMPLE 255C methyl 2-(6-(tert-butoxycarbonylamino)pyridin-3-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)benzoate The title compound was prepared by substituting EXAMPLE 255B for EXAMPLE 219B in EXAMPLE 219C. EXAMPLE 255D 2-(6-(tert-butoxycarbonylamino)pyridin-3-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4- dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)benzoic acid The title compound was prepared by substituting EXAMPLE 255C for EXAMPLE IE in EXAMPLE IF. EXAMPLE 255E tert-butyl5-(5-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)- 2-(3-nitro-4-(l-(tetrahydro-2H-pyran-4-yl)piperidin-4- ylamino)phenylsulfonylcarbamoyl)phenoxy)pyridin-2-ylcarbamate The title compound was prepared by substituting EXAMPLE 255D for EXAMPLE IF and EAXMPLE 49C for EXAMPLE IG respectively in EXAMPLE IH. EXAMPLE 255F 2-(6-aminopyridin-3-yl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yljmethyl }piperazin-1 -yl)-N-( {3 -nitro-4- [(1 -tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]phenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 255E for EXAMPLE lA in EXAMPLE IB. 'H NMR (500 MHz, dimethylsulfoxide-de) 5 0.96 (s, 6H) 1.42 (t, 2H) 1.61 -1.75 (m, 2H) 1.92 - 2.05 (m, 6H) 2.21 (s, 5H) 2.28 - 2.42 (m, 3H) 2.80 - 3.57 (m, 14H) 3.95 - 4.00 (m, 2H) 6.31 (d, IH) 6.68 (d, IH) 6.82 (dd, IH) 7.08 (d, 2H) 7.15 (s, IH) 7.28 -7.41 (m, 4H) 7.68 (d, IH) 7.85 (dd, IH) 8.22 (s, IH) 8.50 (d, IH). EXAMPLE 256 4-(4- {1 -[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]ethyl} piperazin-1 -yl)-2- [(6- fluoro-lH-indol-5-yl)oxy]-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl) sulfonyl)benzamide 443 EXAMPLE 256A methyl 4-(4-(l-(2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)ethyl)piperazin-l-yl)-2-(6- fluoro- lH-indol-5-yloxy)benzoate The title compound was prepared as described in EXAMPLE 1 lOD by replacing EXAMPLE 34A with EXAMPLE 154B. EXAMPLE 256B 4-(4-(l-(2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)ethyl)piperazin-l-yl)-2-(6-fluoro- lH-indol-5-yloxy)benzoic acid The title compound was prepared as described in EXAMPLE 1 lOE by replacing EXAMPLE HOD with EXAMPLE 256A. EXAMPLE 256C 4-(4- {1 - [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljethyl} piperazin-1 -yl)-2- [(6-fluoro-1 H-indol-5-yl)oxy ]-N-( {3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)benzamide The title compound was prepared as described in EXAMPLE llOF by replacing EXAMPLE 1 lOE with EXAMPLE 256B. 'H NMR (500 MHz, dimethylsulfoxide-de) 5 11.29 (s, IH), 11.22 (s, IH), 8.60 (s, IH), 8.57 (s, IH), 7.86 (d, IH), 7.52 (d, IH), 7.27 - 7.40 (m, 5H), 7.15 (d, IH), 7.02 (d, 2H), 6.60 - 6.68 (m, IH), 6.40 (s, IH), 6.08 (d, IH), 3.84 (dd, 2H), 3.20 - 3.32 (m, 4H), 3.01 (s, 4H), 2.59 - 2.72 (m, IH), 2.16 - 2.31 (m, 4H), 1.75 - 2.12 (m, 5H), 1.58 - 1.65 (m, 2H), 1.31 - 1.41 (m, 2H), 1.20 - 1.29 (m, 2H), 1.01 (d, 3H), 0.91 (s, 3H), 0.90 (s, 3H). EXAMPLE 257 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l -en-1 -yl]methyl }piperazin-1 -yl)-2-[(6-fluoro-lH-indol-4-yl)oxy]-N-[(3-nitro-4-{[3-(3-oxopiperazin-l-yl)propyl] amino} phenyl)sulfonyl]benzamide The title compound was prepared by substituting EXAMPLE 209G for EXAMPLE IF and EXAMPLE 254A for EXAMPLE IG in EXAMPLE IH. 'H NMR (300MHz, dimethylsulfoxide-dfi) 6 11.23 (br s, IH), 8.75 (t, IH), 8.43 (d, IH), 7.74 (br s, IH), 7.61 (dd, IH), 7.51 (d, IH), 7.35 (d, 2H), 7.24 (t, IH), 7.05 (d, 2H), 6.95 (d, IH), 6.85 (dd, IH), 6.76 444 (dd, IH), 6.42 (d, IH), 6.26 (t, IH), 6.06 (dd, IH), 3.43 (q, 2H), 3.20-3.08 (m, 6H), 2.97 (br s, 2H), 2.76 (br s, 2H), 2.57 9t, 2H), 2.47 (t, 2H), 2.27-2.12 (m, 6H), 1.97 (br s, 2H), 1.80 (m, 2H), 1.40 (t,2H), 0.93 (s,6H). EXAMPLE 258 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl }piperazin-1 -yl)-2-[(6- fluoro-lH-indoI-5-yl)oxy]-N-[(3-nitro-4-{[(3S)-tetrahydro-2H-pyran-3- ylmethyl]amino }phenyl)sulfonyl]benzamide EXAMPLE 258A The title compound was prepared by substituting (tetrahydro-2H-pyran-3-yl)methanamine for l-(tetrahydropyran-4-yl)methylamine in EXAMPLE IG. EXAMPLE 258B (S)-3-nitro-4-((tetrahydro-2H-pyran-3-yl)methylamino)ben2enesulfonamide The racemic mixture of EXAMPLE 258A was resolved by chiral SFC on an AD column (21mm i.d.x 250 mm in length) using a gradient of 10-30% 0.1% diethylamine methanol in CO2 over 15 minutes (oven temperature: 40°C; flow rate: 40 mL/minute) to provide the title compound. EXAMPLE 258C (R)-3-nitro-4-((tetrahydro-2H-pyran-3-yl)methylamino)benzenesulfonamide The racemic mixture of EXAMPLE 258A was resolved by chiral SFC on an AD column (21mm i.d.x 250 mm in length) using a gradient of 10-30% 0.1% diethylamine methanol in CO2 over 15 minutes (oven temperature: 40°C; flow rate: 40 mL/minute) to provide the title compound. EXAMPLE 258D 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-[(6- fluoro-1 H-indol-5-yl)oxy]-N-[(3-nitro-4-{[(3S)-tetrahydro-2H-pyran-3- ylmethyl]amino}phenyl)sulfonyl]benzaniide The title compound was prepared as described in EXAMPLE 1 lOF by replacing EXAMPLE 1 lOE and EXAMPLE IG with EXAMPLE 154E and EXAMPLE 258B, 445 respectively. 'H NMR (400 MHz, dimethylsulfoxide-de) 5 11.22 (s, 2H), 8.50 - 8.65 (m, 2H), 7.86 (dd, IH), 7.51 (d, IH), 7.38 (t, IH), 7.28 - 7.35 (m, 4H), 7.13 (d, IH), 7.03 (d, 2H), 6.65 (dd, IH), 6.41 (s, IH), 6.09 (d, IH), 3.79 (dd, IH), 3.68 - 3.74 (m, IH), 3.14 - 3.32 (m, 4H), 3.03 (s, 4H), 2.73 (s, 2H), 2.08 - 2.25 (m, 6H), 1.78 -1.97 (m, 4H), 1.55 - 1.66 (m, IH), 1.41 -1.52 (m, IH), 1.23 - 1.40 (m, 3H), 0.92 (s, 6H). EXAMPLE 259 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-[(6-fluoro-1 H-indol-5-yl)oxy]-N-[(3-nitro-4- {[(3R)-tetrahydro-2H-pyran-3-ylmethyl]amino}phenyl)sulfonyl]benzamide The title compound was prepared as described in EXAMPLE 1 lOF by replacing EXAMPLE 1 lOE and EXAMPLE IG with EXAMPLE 154E and EXAMPLE 258C, respectively. 'H NMR (400 MHz, dimethylsulfoxide-de) 5 11.22 (s, 2H), 8.50 - 8.65 (m, 2H), 7.86 (dd, IH), 7.51 (d, IH), 7.38 (t, IH), 7.28 - 7.35 (m, 4H), 7.13 (d, IH), 7.03 (d, 2H), 6.65 (dd, IH), 6.41 (s, IH), 6.09 (d, IH), 3.79 (dd, IH), 3.68 - 3.74 (m, IH), 3.14 - 3.32 (m, 4H), 3.03 (s, 4H), 2.73 (s, 2H), 2.08 - 2.25 (m, 6H), 1.78 -1.97 (m, 4H), 1.55 -1.66 (m, IH), 1.41 - 1.52 (m, IH), 1.23 - 1.40 (m, 3H), 0.92 (s, 6H). EXAMPLE 260 tert-butyl 5-(5-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl }piperazin-1 - yl)-2- {[({3-nitro-4-[(tetrahydio-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)ainino]carbonyl} phenoxy )-3,4-dihydro isoquinoline-2( lH)-carboxylate EXAMPLE 260A tert-butyl 5 -hydioxy-3,4-dihydroisoquinoline-2( 1 H)-carboxylate A mixture of l,2,3,4-tetrahydroisoquinolin-5-ol, hydrochloric acid (1.0 g), di-tert-butyl dicarbonate (1.27 g) and 1.0 N aqueous NaOH (14.5 mL) in dioxane (20 mL) was stirred at room temperature for 16 hours. The reaction mixture was partitioned between water. and ethyl acetate. The aqueous layer was neutralized with 5% aqueous HCl. The combined organic layers were washed with brine, dried (MgS04), filtered, and concentrated. The residue was purified by flash chromatography on silica gel to give the title compound. 446 EXAMPLE 260B tert-butyl5-(2-(ethoxycaibonyl)-5-fluorophenoxy)-3,4-dihydroisoquinoline-2(lH)- carboxylate The title compound was prepared by substituting EXAMPLE 260A for 2-methyl-5-indolol in EXAMPLE 3A. EXAMPLE 260C tert-butyl5-(5-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-2-(ethoxycarbonyl)phenoxy)-3,4-dihydroisoquinoline-2(lH)-carboxylate The title compound was prepared by substituting EXAMPLE 260B for EXAMPLE 3A in EXAMPLE 3G. EXAMPLE 260D 2-(2-(tert-butoxycarbonyl)-l,2,3,4-tetrahydroisoquinolin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)benzoic acid The title compound was prepared by substituting EXAMPLE 260C for EXAMPLE IE in EXAMPLE IF. EXAMPLE 260E 2-(2-(tert-butoxycarbonyl)-l,2,3,4-tetrahydroisoquinolin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)benzoic 3-nitro-4-((tetrahydro-2H-pyran-4-yl)methylamino)benzenesulfonic anhydride The title compound was prepared by substituting EXAMPLE 260D for EXAMPLE IF in EXAMPLE IH. 'H NMR (500MHz, dimethylsulfoxide-de) 6 8.63 (s, IH), 8.45 (s, IH), 7.70 (d, IH), 7.50 (d, IH), 7.35 (d, IH), 7.15 (d, IH), 7.06 (d, 2H), 6.97 (t, IH), 6.80 (d, IH), 6.73 (dd, IH), 6.37 (d, IH), 6.31 (d, IH), 4.48 (s, 2H), 3.86 (dd, 2H), 3.53 (t, 2H), 3.14 (s, 4H), 2.67-2.75 (m, 2H), 2.16-2.30 (m, 6H), 1.63 (d, 2H), 1.43 (s, 9 H), 0.94 (s, 6H). EXAMPLE 261 2-[(6-aminopyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl }piperazin-1 -yl)-N-( {3-nitix)-4- [(1 -tetrahydro-2H-pyran-4-ylpiperidin-4- y l)amino]phenyl} sulfonyl)benzamide 447 EXAMPLE 261A 4-Fluoro-2-(6-nitro-pyridin-3-yloxy)-benzoic acid methyl ester Methyl 4-fluoro-2-hydroxybenzoate (3.00 g), 5-chlorD-2-nitropyridine (3.08 g), and potassium carbonate (4.87 g) were added to dimethyl sulfoxide (50 mL), heated to 110°C for one hour, cooled, added to water, and extracted with ethyl ether. The ether was washed with brine and dried on anhydrous sodium sulfate. The solution was filtered and concentrated and purified by flash column chromatography on silica gel using 10% ethyl acetate in hexanes increasing to 20% ethyl acetate in hexanes and increasing again to 30% ethyl acetate in hexanes. EXAMPLE 26 IB 2-(6-Amino-pyridin-3-yloxy)-4-fluoro-benzoic acid methyl ester EXAMPLE 261A (1015 mg), cyclohexene (3.52 mL, 2853 mg), and 10% palladium on carbon (100 mg) were added to ethanol (12 mL) and ethyl acetate (4 mL) and heated at 75 °C for three hours. The solution was cooled and vacuum filtered over diatomaceous earth. The solvent was removed under vacuum. EXAMPLE 261C 2-(6-Amino-pyridin-3-yloxy)-4-{4-[2-(4-chloro-phenyl)-4,4-dimethyl-cyclohex-l-enylmethyl]-piperazin-l-yl}-benzoic acid methyl ester The title compound was prepared by substituting EXAMPLE 261B for EXAMPLE 3A in EXAMPLE 3G. EXAMPLE 26 ID 2-(6-Amino-pyridin-3-yloxy)-4-{4-[2-(4-chloro-phenyl)-4,4-dimethyl-cyclohex-l-enylmethyl]-piperazin- 1-yl} -benzoic acid The title compound was prepared by substituting EXAMPLE 26IC for EXAMPLE IE in EXAMPLE IF. EXAMPLE 261E 2-[(6-aminopyridin-3-yl)oxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yljmethyl }piperazin-1 -yl)-N-( {3 -nitro-4- [(1 -tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl} sulfonyl)benzanude 448 The title compound was prepared by substituting EXAMPLE 26ID for EXAMPLE IF and EXAMPLE 49C for EXAMPLE IG in EXAMPLE IH. 'H NMR (300MHZ, dimethylsulfoxide-de) 6 8.53 (brs, IH), 8.19 (br s, IH), 7.85 (dd, IH), 7.66 (br s, IH), 7.47 (d, IH), 7.36 (d, 2H), 7.25-7.14 (m, IH), 7.10 (m, IH), 7.07 (d, 2H), 6.58 (dd, IH), 6.43 (d, IH), 6.10 (br s, IH), 5.81 (m, 2H), 3.94 (d, 2H), 3.03 (br s, 6H), 2.73 (m, 2H), 2.24-2.12 (m, 8H), 2.09-2.00 (m, 2H), 1.97 (br s, 2H), 2.09-2.00 (m, 2H), 1.84-1.74 (m, 2H), 1.70-1.60 (m, 2H), 1.58-1.47 (m, 4H), 1.40 (t, 2H), 0.94 (s, 6H). EXAMPLE 262 4-(4- {[2-(4-chlorophenyl)-5,5-diniethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-[(6- fluoro- lH-indol-5-yl)oxy]-N-(( 3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)benzamide EXAMPLE 262A methyl 5,5-dimethyl-2-(trifluoromethylsulfonyloxy)cyclohex-l-enecarboxylate The title compound was prepared by substituting 4,4-dimethyl-2- methoxycarbonylcyclohexanone for 5,5-dimethyl-2-methoxycarbonylcyclohexanone in EXAMPLE 3B. EXAMPLE 262B methyl 2-(4-chloiophenyl)-5,5-dimethylcyclohex-l-enecarboxylate The title compound was prepared by substituting EXAMPLE 262A for EXAMPLE 3B in EXAMPLE 3C. EXAMPLE 262C (2-(4-chlorophenyl)-5,5-dimethylcyclohex-1 -enyl)methanol The title compound was prepared by substituting EXAMPLE 262B for EXAMPLE 3C in EXAMPLE 3D. EXAMPLE 262D 2-(4-chlorophenyl)-5,5-dimethylcyclohex-l-enecarbaldehyde The title compound was prepared as described in EXAMPLE 53F by replacing EXAMPLE 53E with EXAMPLE 262C. 449 EXAMPLE 262E tert-butyl 4-((2-(4-chloiophenyl)-5,5-diniethylcyclohex-1 -enyl)methyl)piperazine-1 - carboxylate The title compound was prepared as described in EXAMPLE lA by replacing 4'-chlorobiphenyl-2-carboxaldehyde with EXAMPLE 262D. EXAMPLE 262F l-((2-(4-chlorophenyl)-5,5-dimethylcyclohex-l-enyl)methyl)piperazine The title compound was prepared as described in EXAMPLE HOC by replacing EXAMPLE 1 lOB with EXAMPLE 262E. EXAMPLE 262G methyl 4-(4-((2-(4-chIorophenyl)-5,5 -dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)-2-(6- fluoro-1 H-indol-5 -yloxy )benzoate The title compound was prepared as described in EXAMPLE 1 lOD by replacing EXAMPLE 34A and EXAMPLE HOC with EXAMPLE 154B and EXAMPLE 262F, respectively. EXAMPLE 262H 4-(4-((2-(4-chlorophenyl)-5,5-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-2-(6-fluoro- lH-indol-5-yloxy)benzoic acid The title compound was prepared as described in EXAMPLE 1 lOE by replacing EXAMPLE 1 lOD with EXAMPLE 262G. EXAMPLE 2621 4-(4- {[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1 -en-1 -yljmethyl }piperazin-1 -yl)-2-[(6-fluoro- lH-indol-5-yl)oxy]-N-({ 3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)aminolphenyl} sulfonyl)benzamide The title compound was prepared as described in EXAMPLE 1 lOF by replacing EXAMPLE 1 ICE with EXAMPLE 262H. 'H NMR (500 MHz, dimethylsulfoxide-de) 6 11.27 (s, IH), 11.22 (s, IH), 8.61 (t, IH), 8.58 (d, IH), 7.86 (dd, IH), 7.51 (d, IH), 7.38 (t, IH), 7.31 - 7.36 (m, 3H), 7.30 (d, IH), 7.16 (d, IH), 7.07 (d, 2H), 6.65 (dd, IH), 6.41 (s, IH), 450 6.08 (d, IH), 3.84 (dd, 2H), 3.22 - 3.32 (m, 4H), 3.02 (s, 4H), 2.68 (s, 2H), 2.17 (s, 6H), 1.84 -1.96 (m, 3H), 1.57 -1.65 (m, 2H), 1.39 (t, 2H), 1.20 -1.31 (m, 2H), 0.92 (s, 6H). EXAMPLE 263 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-[(6- fluoro-lH-indol-5-ylX)xy]-N-({4-[(2-methoxyethyl)amino]-3- nitrophenyl ] sulfonyl)benzamide EXAMPLE 263A 4-(2-methoxyethylamino)-3-nitrobenzenesulfonamide The title compound was prepared by substituting 2-methoxyethanamine for 3-(N-morpholinyl)-l-propylamine in EXAMPLE 4A. EXAMPLE 263B 4-(4-([2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-[(6-fluoro-lH-indol-5-yl)oxy]-N-({4-[(2-methoxyethyl)amino]-3-nitrophenyl} sulfonyl)benzanaide The title compound was prepared by substituting EXAMPLE 154E for EXAMPLE IF and EXAMPLE 263A for EXAMPLE IG in EXAMPLE IH. 'H NMR (500 MHz, dimethylsulfoxide-dfi) 8 11.28 (s, IH), 11.21 (s, IH), 8.58 (m, 2H), 7.87 (dd, IH), 7.50 (d, IH), 7.32 (m, 5H), 7.15 (d, IH), 7.03 (d, 2H), 6.65 (dd, IH), 6.40 (m, IH), 6.10 (m, IH), 3.58 (m, 4H), 3.30 (s, 3H), 3.04 (m, 4H), 2.73 (s, 2H), 2.17 (m, 6H), 1.95 (s, 2H), 1.38 (t, 2H), 0.92 (s, 6H). EXAMPLE 264 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-[(6- fluoro- lH-indol-5-yl)oxy]-N- {[3-nitro-4-(tetrahydro-2H-pyran-4- ylmethoxy)phenyl]sulfonyl} benzamide EXAMPLE 264A 3-nitro-4-((tetrahydro-2H-pyran-4-yl)methoxy)benzenesulfonamide (Tetrahydro-2H-pyran-4-yl)methano] (2.0 g) in tetrahydrofuran (20 mL) was treated with 60% NaH (1.377 g). The solution was stirred for 20 minutes at room temperature. To this solution was added 4-fluoro-3-nitrobenzenesulfonamide (2.84 g) portion-wise. The 451 reaction was stirred for another 2 hours. The mixture was poured into water, neutralized with 10 % HCl, and extracted with ethyl acetate three times. The combined organic layers were washed with brine, dried over MgS04, filtered, and concentrated. The residue was purified with flash column chromatography on silica gel eluting with 20%-60% ethyl acetate in hexanes. EXAMPLE 264B 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl }piperazin-1 -yl)-2-[(6-fluoro- lH-indol-5-yl)oxy ]-N- {[3-nitro-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]sulfonyl}benzamide The title compound was prepared by substituting EXAMPLE 154E for EXAMPLE IF and EXAMPLE 264A for EXAMPLE IG in EXAMPLE IH. 'H NMR (500MHZ, dimethylsulfoxide-de) 6 11.12 (s, IH), 8.10 (d, IH), 7.52 (d, IH), 7.45 (d, IH), 7.38 (d, IH), 7.33-7.35 (m, 3H), 7.28 (d, IH), 7.04 (d, 2H), 6.65 (dd, IH), 6.41 (s, IH), 6.10 (s, IH), 4.09 (d, 2H), 3.88 (dd, 2H), 3.05 (s, 4H), 2.80 (br s, 2H), 2.03-2.20 (m, 6H), 1.63-1.65 (m, 2H), 1.33-1.40 (m, 4 H), 0.92 (s, 6H). EXAMPLE 265 2-[(3-chloro-1 H-indol-5-yl)oxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yljmethyl }piperazin-l -yl)-N-({ 3-mtro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)benzamide EXAMPLE 265A ethyl 2-( lH-indol-5-yloxy)-4-fluorobenzoate The title compound was prepared by substituting 5-indolol for 2-methyl-5-indolol in EXAMPLE 3A. EXAMPLE 265B ediy 12-(3 -chloro-1 H-indol-5 -yloxy)-4-fluorobenzoate W-Chloro-succinimide (160 mg) was added portion wise to a solution of EXAMPLE 265A (300 mg) in toluene (10 mL) and the mixture was stirred at room temperature for about two hours. The mixture was chromatographed on a silica gel column with 30% ethyl acetate in hexane to give the title compound. 452 EXAMPLE 265C ethyl 2-(3-chloro-lH-indol-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- enyl)methyl)piperazin-1 -yl)benzoate The title compound was prepared by substituting EXAMPLE 265B for EXAMPLE ; 3A in EXAMPLE 3G. EXAMPLE 265D 2-(3-chloro-1 H-indol-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)benzoic acid The title compound was prepared by substituting EXAMPLE 265 C for EXAMPLE IE in EXAMPLE IF. EXAMPLE 265E 2-(3-chloro-1 H-indol-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-l-yl)-N-(3-nitro-4-((tetrahydro-2H-pyran-4-yl)methylamino)phenylsulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 265D for EXAMPLE IF in EXAMPLE IH. 'H NMR (500MHZ, dimethylsulfoxide-de) 6 11.42 (s, IH), 11.30 (br s, IH), 8.60 (t, IH), 8.54 (d, IH), 7.78 (dd, IH), 7.55 (d, IH), 7.50 (d, IH), 7.42 (d, IH), 7.34 (d, 2H), 7.09 (d, IH), 7.04 (d, 2H), 7.00 (d, IH), 6.92 (dd, IH), 6.68 (dd, IH), 6.16 (d, IH), 3.85 (dd, 2H), 3.28 (dd, 2H), 3.07 (m, 4H), 2.75 (m, 2H), 2.25-2.15 (m, 6H), 1.95 (br.s, 2H), 1.90 (m, IH), 1.61 (dd, 2H), 1.38 (t, 2H), 1.27 (m, 2H), 0.92 (s, 6H). EXAMPLE 266 2-[(3-chloro-lH-indol-4-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yllmethyl]piperazin-l-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)benzamide EXAMPLE 266A ethyl 2-(lH-indol-4-yloxy)-4-fluorobenzoate The title compound was prepared by substituting 4-indolol for 2-methyl-5-indolol in EXAMPLE 3A. EXAMPLE 266B 453 ethyl 2-(3 -chloro-1 H-indol-4-yloxy )-4-fluorobenzoate The tide compound was prepared by substituting EXAMPLE 266A for EXAMPLE 265A in EXAMPLE 265B. EXAMPLE 266C ethyl 2-(3-chloro-1 H-indol-4-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 - enyl)methyl)piperazin-1 -yl)benzoate The title compound was prepared by substituting EXAMPLE 266B for EXAMPLE 3A in EXAMPLE 3G. EXAMPLE 266D 2-(3-chloro-1 H-indol-4-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)benzoic acid The title compound was prepared by substituting EXAMPLE 266C for EXAMPLE IE in EXAMPLE IF. EXAMPLE 266E 2-(3-chloro-1 H-indol-4-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-l-yl)-N-(3-nitro-4-((tetrahydro-2H-pyran-4-yl)methylamino)phenylsulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 266D for EXAMPLE IF in EXAMPLE IH. 'H NMR (500MHZ, dimethylsulfoxide-de) 5 11.56 (s, IH), 11.00 (br s, IH), 8.64 (t, IH), 8.54 (d, IH), 7.81 (dd, IH), 7.58 (d, IH), 7.45 (d, IH), 7.34 (d, 2H), 7.26 (d, IH), 7.16 (d, 2H), 7.10 (t, IH), 7.03 (d, 2H), 6.68 (dd, IH), 6.62 (d, IH), 6.10 (d, IH), 3.85 (dd, 2H), 3.26 (t, 2H), 3.02 (br.s, 4H), 2.73 (br.s, 2H), 2.20-2.10 (m, 6H), 1.95 (br.s, 2H), 1.90 (m, IH), 1.61 (dd, 2H), 1.38 (t, 2H), 1.27 (m, 2H), 0.92 (s, 6H). EXAMPLE 267 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl} piperazin-1 -yl)-N-( {3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-[(2-oxo-2,3-dihydro- 1 H-indol-5-yl)oxy]benzamide A solution of EXAMPLE 265E (38 mg) in ethanol (5 mL) and 1 N aqueous HCl (5 mL) was stirred at 85 °C.for 7 hours. The mixture was cooled to ambient temperature and 454 concentrated. The residue was purified on reverse-phase HPLC on a C18 column using a water-acetonitrile gradient with ammonium acetate buffer to give the title compound. 'H NMR (500MHz, dimethylsulfoxide-de) 5 11.30 (br s, IH), 10.33 (s, IH), 8.61 (t, IH), 8.54 (d, IH), 7.84 (dd, IH), 7.47 (d, IH), 7.35 (d, 2H), 7.18 (d, IH), 7.06 (d, 2H), 6,84 (s, IH), 6.80 (d, IH), 6.74 (d, IH), 6.67 (dd, IH), 6.20 (d, IH), 3.85 (dd, 2H), 3.43 (s, 2H), 3.27 (t, 2H), 3.10 (br.s, 4H), 2.77 (br.s, 2H), 2.25-2.10 (m, 6H), 1.97 (br.s, 2H), 1.90 (m, IH), 1.62 (dd, 2H), 1.40 (t, 2H), 1.27 (m, 2H), 0.94 (s, 6H). EXAMPLE 268 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-[(2-oxo-2,3-dihydro- 1 H-indol-4-yl)oxy]benzamide The title compound was prepared by substituting EXAMPLE 266E for EXAMPLE 265E in EXAMPLE 267. ^H NMR (500MHz, dimethylsulfoxide-de) 6 11.50 (br s, IH), 10.40 (s, IH), 8.59 (t, IH), 8.54 (d, IH), 7.72 (d, IH), 7.47 (d, IH), 7.35 (d, 2H), 7.12 (d, IH), 7.06 (d, 2H), 6,96 (t, IH), 6.75 (dd, IH), 6.46 (d, IH), 6.44 (d, IH), 6.13 (d, IH), 3.86 (dd, 2H), 3.28 (t, 2H), 3.25 (s, 2H), 3.19 (br.s, 4H), 2.82 (br.s, 2H), 2.28 (br. s, 4H), 2.18 (m, 2H), 1.98 (br.s, 2H), 1.90 (m, IH), 1.63 (d, 2H), 1.41 (t, 2H), 1.27 (m, 2H), 0.94 (s, 6H). EXAMPLE 269 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-[(6-fluoro-lH-indol-4-yl)oxy]-N-({4-[(2-methoxyethyl)amino]-3-nitrophenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 209G for EXAMPLE IF and EXAMPLE 263A for EXAMPLE IG in EXAMPLE IH. 'H NMR (300MHz, dimethylsulfoxide-dfi) 6 11.22 (brs, IH), 8.55 (t, IH), 8.43 (d, IH), 7.61 (dd, IH), 7.51 (d, IH), 7.35 (d, 2H), 7.24 (t, IH), 7.05 (d, 2H), 7.00 (d, IH), 6.89 (dd, IH), 6.77 (dd, IH), 6.43 (d, IH), 6.26 (t, IH), 6.06 (t, IH), 3.63-3.51 (m, 4H), 3.32 (s, 3H), 3.13 (br s, 4H), 2.78 (br s, 2H), 2.31-2.12 (m, 6H), 1.97 (br s, 2H), 1.40 (t, 2H), 0.93 (s, 6H). 455 EXAMPLE 270 tert-butyl 5-(5-(4- {[2-(4-chlorophenyl)-4,4-(limethylcyclohex- 1-en- l-yl]methyl }piperazin-1 - yl)-2- {[({3-nitro-4-[(tetrahyH NMR (400MHz, dimethylsulfoxide-de) 6 8.52 (m, 2H), 7.84 (dd, IH), 7.75 (d, IH), 7.47 (d, IH), 7.35 (m, 2H), 7.16 (m, 2H), 7.05 (d, 2H), 6.87 (t, IH), 6.60 (m, 2H), 6.10 (m, 2H), 3.66 (m, 2H), 3.27 (m, 4H), 3.23 (s, 3H), 3.05 (s, 4H), 2.74 (s, 2H), 2.18 (m, 6H), 1.99 (m, 4H), 1.79 (m, 2H), 1.61 (m, IH), 1.40 (t, 2H), 1.07 (m, 4H), 0.94 (s, 6H). EXAMPLE 376 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl ]piperazin- l-yl)-2-( {6- [(2,2-difluoroethyl)amino]pyridin-3-yl}oxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 375D for EXAMPLE 1 lOE in EXAMPLE llOF. 'H NMR (400MHz, dimethylsulfoxide-de) 5 8.55 (m, 2H), 7.86 550 (dd, IH), 7.76 (d, IH), 7.47 (d, IH), 7.35 (d, 2H), 7.18 (m, 2H), 7.06 (d, 2H), 6.89 (m, IH), 6.61 (m, 2H), 6.10 (m, 2H), 3.85 (dd, 2H), 3.66 (m, 2H), 3.27 (m, 4H), 3.06 (s, 4H), 2.74 (s, 2H), 2.18 (m, 6H), 1.94 (m, 4H), 1.62 (d, 2H), 1.40 (t, 2H), 1.28 (m, 2H), 0.94 (s, 6H). EXAMPLE 377 2- {[5-chloro-6-(methylamino)pyridin-3-yl]oxy} -4-(4- {[2-(4-chlorophenyl)-4,4- dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-N-( {3 -nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)benzamide EXAMPLE 377A methyl 2-(6-chloropyridin-3-yloxy)-4-fluorobenzoate To a solution of 6-chloropyridin-3-ol (2.41 g) in 2-methyltetrahydrofuran (20 mL) and N,N-dimethy]formamide (4 mL) was added potassium /^r?-butoxide (l.OM in tetrahydrofiiran) (18.60 mL). The reaction was stirred for 15 minutes, then methyl 2,4-difluorobenzoate (3.52 g) was added as a solution in 2-methyltetrahydrofuran (2 mL). The reaction was then heated to 80°C and stirred under a nitrogen atmosphere for 3 days. The reaction was cooled, diluted with ethyl acetate (100 mL), washed with water (50 mL), IN aqueous HCl (50 mL), and brine (50 mL), dried over magnesium sulfate, fdtered, and concentrated. Silica gel chromatography (Reveleris 80 g), eluting with 10% ethyl acetate/hexanes provided the title compound. EXAMPLE 377B methyl 2-(6-(tert-butoxycarbonylamino)pyridin-3-yloxy)-4-fluorobenzoate To EXAMPLE 377A (3.30 g), tert-hutyl carbamate (1.51 g) and cesium carbonate (5.73 g) in dioxane (30 mL) was added diacetoxypalladium (0.079 g) and (9,9-dimethyl-9H-xanthene-4,5-diyI)bis(diphenylphosphine) (0.41 g) and the reaction was heated to 85°C overnight under an atmosphere of nitrogen. The reaction was cooled, diluted with ethyl acetate (100 mL) and washed with water (75 mL) and brine (75 mL) dried over magnesium sulfate, filtered, and concentrated. Silica gel chromatography (Reveleris 80 g) eluting with 10% ethyl acetate/hexanes over 20 minutes provided the title compound. EXAMPLE 377C methyl 2-(6-(tert-butoxycarbonyl(methyl)amino)pyridin-3-yloxy)-4-fluorobenzoate 551 To a solution of EXAMPLE 377B (0.750 g) in N,N-dimethylformamide (5 mL) was added sodium hydride (0.091 g). The reaction was stirred for 30 minutes at room temperature and then iodomethane (0.142 mL) was added to the reaction and stirring was continued at room temperature for 2 hours. The reaction was quenched with water (25 mL) and extracted with ethyl acetate (75 mL). The organic layer was separated, washed with brine (50 mL), dried over magnesium sulfate, filtered, and concentrated. The residue was loaded onto silica gel (Reveleris 40 g) and eluted with a gradient of 5-15% ethyl acetate/hexanes over 30 minutes (flow = 40 ml/min) to provide the title compound. EXAMPLE 377D methyl 4-fluoro-2-(6-(methylamino)pyridin-3-yloxy)benzoate To EXAMPLE 377C (0.714 g) in dichloromethane (10 mL) was added trifluoroacetic acid (1.5 mL). After stirring for 3 hours, the reaction was concentrated, dissolved in dichloromethane (100 mL), washed with saturated aqueous NaHCOs (2 x 75 mL) and brine (75 mL), dried over magnesium sulfate, filtered, and concentrated to provide the title compound. EXAMPLE 377E methyl 2-(5-chloro-6-(methylamino)pyridin-3-yloxy)-4-fluorobenzoate A solution of EXAMPLE 377D (0.450 g) and N-chlorosuccinimide (0.239 g) was stirred together in N,N-dimethylformamide (10 mL) at room temperature. The reaction was stirred for 48 hours, diluted with ethyl acetate (1(X) mL), washed with water (2 x 50 mL) and brine (50 mL), dried over magnesium sulfate, filtered, and concentrated. Silica gel chromatography (Reveleris 40 g) eluting with a gradient of 5-30% ethyl acetate/hexanes over 30 minutes (flow = 40 ml/min) provided the title compound. EXAMPLE 377F methyl 2-(5-chloro-6-(methylamino)pyridin-3-yloxy)-4-(piperazin-l-yl)benzoate A solution of EXAMPLE 377E (0.230 g) and piperazine (0.255 g) in dimethylsulfoxide (3 mL) was heated to 85°C for 1 hour. The reaction was cooled and diluted with ethyl acetate (75 mL). The organic layer was washed with water (3 x 50 mL) and brine (50 mL), dried over magnesium sulfate, filtered, and concentrated to give the title compound. 552 EXAMPLE 377G methyl 2-(5-chloro-6-(methylamino)pyridin-3-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex- l-enyl)methyl)piperazin- l-yl)benzoate To a solution of EXAMPLE 377F (0.230 g) and EXAMPLE 60D (0.182 g) in dichloromethane (2 mL) was added sodium triacetoxyborohydride (0.194 g) and the reaction was allowed to stir at room temperature overnight. The reaction was quenched with saturated aqueous NaHCOs solution (25 mL) and extracted into dichloromethane (75 mL). The organic layer was washed with brine (25 mL), dried over magnesium sulfate, filtered, and concentrated. Silica gel chromatography (Reveleris 40 g) eluting with a gradient of 5-30% ethyl acetate/hexanes over 30 minutes provided the title compound. EXAMPLE 377H 2-(5-chloro-6-(methylamino)pyridin-3-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4- dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)benzoic acid To a solution of EXAMPLE 377G (0.295 g) in tetrahydrofuran (5 mL) and methanol (2 mL) was added l.OM aqueous LiOH (1.452 mL) and the reaction was heated to 55°C. After stirring for 3 hours, the reaction was cooled, diluted with dichloromethane (75 mL) and water (15 mL) and quenched with IN aqueous HCl (1.45 mL). The organic layer was separated, washed with brine (15 mL), dried over magnesium sulfate, filtered, and concentrated to provide the title compound. EXAMPLE 3771 2- {[5-chloro-6-(methylamino)pyridin-3-yl]oxy} -4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 377H for EXAMPLE IFin EXAMPLE IH. ^H NMR (300 MHz, dimethylsulfoxide-de) 8 11.52 - 11.16 (m, IH), 8.63 (s, IH), 8.57 (d, IH), 7.87 (dd, IH), 7.82 (d, IH), 7.49 - 7.39 (m, 2H), 7.36 (d, 2H), 7.21 (d, IH), 7.06 (d, 2H), 6.65 (d, IH), 6.43 (d, IH), 6.18 (d, IH), 3.85 (d, 2H), 3.41 - 3.19 (m, 4H), 3.12 (s, 4H), 2.84 (d, 3H), 2.79 (s, 2H), 2.20 (d, 6H), 1.97 (s, 3H), 1.62 (d, 2H), 1.41 (d, 2H), 1.29 (dd, 2H), 0.94 (s, 6H). 553 EXAMPLE 378 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1- en-1 -yl]methyl }piperazin- l-yl)-N-( {4-[( {4-[2-fluoro-1 -(fluoromethyl)ethyl]morpholin-2- yl}methyl)amino]-3-nitrophenyl}sulfonyl)benzamide EXAMPLE 378A tert-butyl (4-(l ,3-difluoropropan-2-yl)morpholin-2-yl)methylcarbamate The title compound was prepared by substituting tert-butyl morpholin-2-ylmethylcarbamate for tert-butyl piperazine-l-carboxylate and l,3-dtfluoropropan-2-one for 4'-chlorobiphenyl-2-carboxaldehyde in EXAMPLE lA EXAMPLE 378B (4-(l,3-difluoropropan-2-yl)morpholin-2-yl)methanamine The title compound was prepared by substituting EXAMPLE 378A for EXAMPLE lA in EXAMPLE IB. EXAMPLE 378C 4-((4-(l,3-difluoropropan-2-yl)morpholin-2-yl)methylamino)-3-nitrobenzenesulfonamide The title compound was prepared by substituting EXAMPLE 378B for 3-(N-morpholinyl)-l-propylamine in EXAMPLE 4A. EXAMPLE 378D 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-diraethylcyclohex-l-en-1 -yl]methyl }piperazin- l-yl)-N-( {4-[( {4-[2-fluoro-1 -(fluoromethyl)ethyl]morpholin-2-yl} methyl)amino]-3-nitrophenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 318H for EXAMPLE IF and EXAMPLE 378C for EXAMPLE IG in EXAMPLE IH. 'H NMR (500MHZ, dimethylsulfoxide -de) 8 11.30 (br s, IH), 8.63 (t, IH), 8.58 (d, IH), 7.86 (dd, IH), 7.74 (d, IH), 7.44 (d, IH), 7.38 (d, IH), 7.36 (d, 2H), 7.20 (d, IH), 7.06 (d, 2H), 6.65 (dd, IH), 6.19 (d, IH), 6.17 (brs, 2H), 4.68 (t, 2H), 4.56 (t, 2H), 3.83 (d, IH), 3.71 (m, IH), 3.51 (m, 4H), 3.12 (m, 4H), 2.90 (d, IH), 2.80 (m, 2H), 2.73 (m, IH), 2.57 (t, IH), 2.42 (t, IH), 2.25 (m, 4H), 2.17 (m, 2H), 1.97 (m, 2H), 1.40 (t, 2H), 0.94 (s, 6H). 554 EXAMPLE 379 2-[(2-amino-6-bromopyridin-4-yl)oxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1 -yl]methyl }piperazin- l-yl)-N-({ 3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl) sulfonyl)benzamide EXAMPLE 372F (137 mg) was dissolved in dichloromethane (2 mL), and trifluoroacetic acid (0.21 mL) was added. The mixture was stirred at room temperature for 16 hours, diluted with dichloromethane, extracted witii saturated aqueous sodium bicarbonate, dried over anhydrous sodium sulfate, and concentrated imder vacuum to provide the tide compound. 'H NMR (300MHZ, dimethylsulfoxide-de) 5 8.57 (bs, IH), 8.48 (bs, IH), 7.69 (dd, IH), 7.54 (d, IH), 7.37 (d, 2H), 7.08 (d, IH), 7.07 (d, 2H), 6.80 (dd, IH), 6.55 (bs, IH), 6.23 (d, 2H), 6.03 (d, IH), 5.59 (d, IH), 3.86 (dd, 2H), 3.24 (m, 8H), 2.81 (bs, 2H), 2.35-2.15 (m, 6H), 1.97 (bs, 2H), 1.93 (m, IH), 1.65 (d, 2H), 1.42 (t, 2H), 1.35-1.21 (m, 2H), 0.95 (s, 6H). EXAMPLE 380 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl}piperazin- l-yl)-2-[(2,6-diaminopyridin-4-yl)oxy]-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 373E for EXAMPLE 372F in EXAMPLE 379. 'H NMR (300MHz, dimethylsulfoxide-dg) 5 8.36 (d, IH), 8.34 (t, IH), 7.70 (dd, IH), 7.62 (d, IH), 7.37 (d, 2H), 7.36 (t, IH), 7.09 (d, IH), 7.08 (d, 2H), 6.97 (d, IH), 6.64 (dd, IH), 6.28 (d, IH), 5.21 (bs, 4H), 3.84 (dd, 2H), 3.25 (m, 2H), 3.06 (m, 4H), 2.76 (m, 2H), 2.29-2.15 (m, 8H), 1.98 (bs, 2H), 1.91 (m, IH), 1.63 (d, 2H), 1.41 (t, 2H). 1.34-1.17 (m,2H), 0.95 (s,6H). EXAMPLE 381 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-1 -yl]methyl }piperazin-1 -yl)-N- {[3-nitro-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]sulfonyl}benzamide The title compound was prepared by substituting EXAMPLE 318H for EXAMPLE IF and EXAMPLE 264A for EXAMPLE IG in EXAMPLE IH. 'H NMR (300 MHz, dimethylsulfoxide-dfi) 8 11.78 - 11.08 (m, IH), 8.35 (s, IH), 8.07 (s, IH), 7.73 (d, IH), 7.54 -7.43 (m, 2H), 7.36 (d, 3H), 7.07 (d, 2H), 6.65 (d, IH), 6.18 (d, 3H), 4.13 (d, 2H), 3.88 (d, 555 2H), 3.35 (d, 2H), 3.14 (s, 4H), 2.99 - 2.78 (m, 2H), 2.08 (t, 9H), 1.66 (d, 2H), 1.45 - 1.22 (m, 4H), 0.94 (s, 6H). EXAMPLE 382 2-[(6-amino-5-chloiopyridin-3-yl)oxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1- en-1 -yl]methyl Jpiperazin-1 -yl)-N- {[4-( {(3R)-1 -[2-fluoro-1 -(fluoromethyl)ethyl]piperidin-3- yl} amino)-3-nitrophenyl]sulfonyl} benzamide EXAMPLE 382A (R)-l-(l,3-difluoropropan-2-yl)piperidin-3-amine hydrogen chloride A solution of (R)-tert-buty\ piperidin-3-ylcarbaniate (0.500 g), l,3-difluoropropan-2-one (0.258 g) and sodium triacetoxyhydroborate (0.794 g) were stirred together in dichloromethane (5 mL) overnight. The reaction was quenched with saturated aqueous NaHCOs (10 mL) and extracted with dichloromethane (30 mL). The organic layer was washed with brine (20 mL), dried over magnesium sulfate, filtered, and concentrated. The crude material was treated with HCl (4.0M dioxane, 2 mL) in methanol (2 mL). After stirring for 2 hours, the reaction was concentrated to provide the title compound. EXAMPLE 382B (R)-4-(l -(1,3-difluoropropan-2-yl)piperidin-3-ylamino)-3-nitrobenzenesulfonamide To EXAMPLE 382A (0.590 g) and 4-chloro-3-nitrobenzenesulfonamide (0.611 g) in dioxane (10 mL) was added N-ethyl-N-isopropylpropan-2-amine (1.641 mL) and the reaction heated to 90°C. The reaction was concentrated, loaded onto silica gel (Reveleris 80 g) and eluted using a gradient of 35% to 100% ethyl acetate/hexanes over 30 minutes to give the title compound. EXAMPLE 382C 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1- en-l-yl]methyl}piperazin-l-yl)-N-{[4-({(3R)-l-[2-fluoro-l-(fluoromethyl)ethyl]piperidin-3- yl}amino)-3-nitrophenyl]sulfonyl}benzamide The title compound was prepared by substituting EXAMPLE 318H for EXAMPLE IF and EXAMPLE 382B for EXAMPLE IG in EXAMPLE IH. 'H NMR (300 MHz, dimethylsulfoxide-de) 8 11.62 -11.06 (m, IH), 8.91 (d, IH), 8.60 (d, IH), 7.87 (d, IH), 7.75 (d, IH), 7.47 - 7.32 (m, 4H), 7.19 (d, IH), 7.06 (d, 2H), 6.65 (d, IH), 6.18 (s, 3H), 4.64 (dt, 556 4H), 4.00 (s, IH), 3.27 - 3.08 (m, 5H), 2.90 - 2.58 (m, 6H), 2.20 (d, 6H), 1.97 (s, 2H), 1.60 (s, 4H), 1.40 (s,2H), 0.94 (s,6H). EXAMPLE 383 tert-butyl 5-bromo-4-(5-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yljmethyl }piperazin-1 -yl)-2-{ [({3-nitro-4- [(tetrahydro-2H-pyran-4- ylmethyl)aniino]phenyl}sulfonyl)amino]carbonyl}phenoxy)pyridin-2-ylcart)amate EXAMPLE 383A 2-(2-Amino-5-bromo-pyridin-4-yloxy)-4-fluoro-benzoic acid methyl ester EXAMPLE 271A (600 mg), potassium bromide (300 mg), and ammonium molybdate (85 mg) were added to acetic acid (6 mL). Sodium perborate tetrahydrate (387 mg) was added. The mixture stirred at room temperature for 16 hours and added to water. The pH was adjusted to 12 using IM aqueous sodium hydroxide, and the solution was extracted with ethyl acetate. The extract was washed with brine, dried over anhydrous sodium sulfate, filtered, concentrated and purified by flash column chromatography on silica gel using 30-70% ethyl acetate in hexanes. EXAMPLE 383B 2-(5-Bromo-2-tert-butoxycarbonylamino-pyridin-4-yloxy)-4-fluoro-benzoic acid methyl ester EXAMPLE 383A (726 mg), di-tert-butyl dicarbonate (557 mg), and 4-(dimethylamino)pyridine (26 mg) were added to acetonitrile (15 mL) and stirred at room temperature for 16 hours. The solution was concentrated and purified by flash column chromatography on silica gel using 20% ethyl acetate in hexanes to provide the title compound. EXAMPLE 383C 2-(5-Bromo-2-tert-butoxycarbonylamino-pyridin-4-yloxy)-4-piperazin-l-yl-benzoic acid methyl ester The title compound was prepared by substituting EXAMPLE 383B for EXAMPLE 342D in EXAMPLE 342E. 557 EXAMPLE 383D 2-(5-Bromo-2-tert-butoxycarbonylamino-pyridin-4-yloxy)-4-{4-[2-(4-chloro-phenyl)-4,4-dimethyl-cyclohex-l-enylmethyl]-piperazin-l-yl}-benzoic acid methyl ester The title compound was prepared by substituting EXAMPLE 60D for 4'-chlorobiphenyl-2-carboxaldehyde and EXAMPLE 383C for tert-butyl piperazine-1-carboxylate in EXAMPLE lA. EXAMPLE 383E 2-(5-Bromo-2-tert-butoxycarbonylamino-pyridin-4-yloxy)-4-{4-[2-(4-chloro-phenyl)-4,4-dimethyl-cyclohex-1 -enylmethyl]-piperazin- 1-yl} -benzoic acid The title compound was prepared by substituting EXAMPLE 383D for EXAMPLE IE in EXAMPLE IF. EXAMPLE 383F tert-butyl 5-bromo-4-(5-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-2-{[((3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)amino]carbonyl }phenoxy)pyridin-2-ylcaibamate The title compound was prepared by substituting EXAMPLE 383E for EXAMPLE IF in EXAMPLE IH. 'H NMR (300MHZ, dimethylsulfoxide-dg) 6 9.62 (bs, IH), 8.58 (bs, IH), 8.48 (bs, IH), 8.18 (s, IH), 7.72 (m, IH), 7.59 (m, IH), 7.36 (d, 2H), 7.15-6.98 (m, 4H), 6.82 (d, IH), 6.62 (bs, IH), 3.87 (d, 2H), 3.35-3.20 (m, 8H), 2.79 (m, 2H), 2.30-2.16 (m, 6H), 1.97 (bs, 2H), 1.92 (m, IH), 1.64 (d, 2H), 1.41 (t, 2H), 1.32 (s, 9H), 1.30 (m, 2H), 0.95 (s, 6H). EXAMPLE 384 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl jpiperazin-1 -yl)-2-[(4- chloro-lH-pyrrolo[2,3-b]pyridin-5-yl)oxy]-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)benzamide EXAMPLE 384A 2-(4-Chloro-lH-pyrrolo[2,3-b]pyridin-5-yloxy)-4-fluoro-benzoic acid methyl ester The title compound was prepared by substituting 4-chloro-lH-pyrrolo[2,3-B]pyridin-5-ol for EXAMPLE 342C in EXAMPLE 342D. 558 EXAMPLE 384B 2-(4-Chloro-lH-pyiTolo[2,3-b]pyridin-5-yloxy)-4-piperazin-l-yl-benzoic acid methyl ester The title compound was prepared by substituting EXAMPLE 384A for EXAMPLE 342D in EXAMPLE 342E. EXAMPLE 384C 4- {4-[2-(4-Chloro-phenyl)-4,4-dimethyl-cyclohex-1 -enylmethyl]-piperazin-1 -yl} -2-(4-chloro-lH-pyrrolo[2,3-b]pyridin-5-yloxy)-benzoic acid methyl ester The title compound was prepared by substituting EXAMPLE 60D for 4'-chlorobiphenyl-2-carboxaldehyde and EXAMPLE 384B for tert-butyl piperazine-1-carboxylate in EXAMPLE lA. EXAMPLE 384D 4- {4- [2-(4-Chloro-pheny l)-4,4-dimethyl-cyclohex-1 -enylmethyl]-piperazin-1 -yl} -2-(4-chloro-1 H-pyrrolo [2,3 -b]pyridin-5 -yloxy )-benzoic acid The title compound was prepared by substituting EXAMPLE 384C for EXAMPLE IE in EXAMPLE IF. EXAMPLE 384E 4-(4- {[2-(4-chloropheny l)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-[(4-chloro-lH-pyrrolo[2,3-b]pyridin-5-yl)oxy]-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 384D for EXAMPLE IF in EXAMPLE IH. 'H NMR (300MHZ, dimethylsulfoxide-de) 6 12.07 (s, IH), 8.60 (t, IH), 8.58 (d, IH), 8.07 (s, IH), 7.88 (dd, IH), 7.65 (t, IH), 7.51 (d, IH), 7.34 (d, 2H), 7.18 (d, IH), 7.04 (d, 2H), 6.66 (dd, IH), 6.50 (dd, IH), 6.03 (d, IH), 3.84 (dd, 2H), 3.26 (m, 4H), 3.13-2.96 (m, 4H), 2.73 (m, 2H), 2.16 (m, 6H), 1.95 (bs, 2H), 1.91 (m, IH), 1.61 (d, 2H), 1.38 (t, 2H), 1.36-1.21 (m, 2H), 0.92 (s, 6H). EXAMPLE 385 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N-( {3- nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-({6-[(2,2,2- trifluoroethyl)amino]pyridin-3-yl}oxy)benzamide 559 EXAMPLE 385A methyl 2-(6-(tert-butoxycait)onyl(2,2,2-trifluoroethyl)amino)pyridin-3-yloxy)-4- fluorobenzoate The title compound was prepared by substituting l,l,l-trifluoro-2-iodoethane for methyl iodide in EXAMPLE 377C. EXAMPLE 385B methyl 2-(6-(tert-butoxycarbonyl(2,2,2-trifluoroethyl)amino)pyridin-3-yloxy)-4-(piperazin-l- yl)benzoate The title compound was prepared by substituting EXAMPLE 385A for EXAMPLE 377E in EXAMPLE 377F. EXAMPLE 385C methyl 2-(6-(tert-butoxycarbonyl(2,2,2-trifluoroethyl)amino)pyridin-3-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)benzoate The title compound was prepared by substituting EXAMPLE 385B for tert-butyl piperazine-l-carboxylate and EXAMPLE 60D for 4'-chlorobiphenyl-2-carboxaldehyde in EXAMPLE lA. EXAMPLE 385D 2-(6-(tert-butoxycarbonyl(2,2,2-trifluoroethyl)amino)pyridin-3-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)benzoic acid The title compound was prepared by substituting EXAMPLE 385C for EXAMPLE 38G in EXAMPLE 38H. EXAMPLE 385E tert-butyl 5-(5-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)- 2-(3-nitro-4-((tetrahydro-2H-pyranyl)methylamino)phenylsulfonylcarbamoyl)- phenoxy)pyridin-2-yl(2,2,2-trifluoroethyl)carbamate The title compound was prepared by substituting EXAMPLE 385D for EXAMPLE llOE in EXAMPLE llOF. 560 EXAMPLE 385F 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl} piperazin-1 -yl)-N-( {3- nitro-4-[(tetrahydiio-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-({6-[(2,2,2- trifluoroethyl)amino]pyridin-3-yl} oxy)benzamide EXAMPLE 385E (20 mg) was dissolved in anhydrous dichloromethane and trifluoroacetic acid (0.1 mL) was added. The reaction mixture was stirred at room temperature for L5 hours. The solvent was removed under vacuum. The residue was dissolved in ethyl acetate, washed with NaHCOs aqueous solution and brine, dried over anhydrous sodium sulfate, filtered, and concentrated to provide the title compound. 'H NMR (400MHz, dimethylsulfoxide-de) 5 8.56 (m, 2H), 7.86 (dd, IH), 7.79 (d, IH), 7.69 (m, IH), 7.47 (d, IH), 7.35 (d, 2H), 7.21 (m, 2H), 7.08 (m, 3H), 6.63 (m, 2H), 6.13 (d, IH), 4.13 (m, 2H), 3.85 (dd, 2H), 3.27 (m, 4H), 3.06 (s, 4H), 2.74 (s, 2H), 2.18 (m, 6H), 1.97 (m, 3H), 1.61 (m, 2H), 1.40 (t, 2H), 1.27 (m, 2H), 0.94 (s, 6H). EXAMPLE 386 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en- l-yl]methyl} piperazin-1 -yl)-N-[(4- {[(4-hydroxycyclohexyl)methyl]amino) -3- nitrophenyl)sulfonyl]benzamide EXAMPLE 386A trans-4-(aminomethyl)cyclohexanol Tert-butyl trans-(4-hydroxycyclohexyl)methylcarbamate (1 g) in dichloromediane (10 ml) was treated with trifluoroacetic acid (10 ml) at 0°C for two hours. The reaction mixture was concentrated and the residue was dried under vacuum to provide the title compound. EXAMPLE 386B 4-(trans-(4-hydroxycyclohexyl)methylamino)-3-nitrobenzenesulfonamide The title compound was prepared by substituting EXAMPLE 386A for 1-(tetrahydropyran-4-yl)methylamine in EXAMPLE IG. 561 EXAMPLE 386C Trans-2-(6-amino-5-chloropyridin-3-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex- l-enyl)methyl)piperazin-l-yl)-N-(4-((4-hydroxycyclohexyl)methylamino)-3- nitrophenylsulfonyl)benzamide The title compound was prepared as described in EXAMPLE 1 lOF by replacing EXAMPLE 1 lOE and EXAMPLE 1G with EXAMPLE 318H and EXAMPLE 386B. 'H NMR (400 MHz, dimethylsulfoxide-de) 6 8.61 (t, IH), 8.58 (d. IH), 7.86 (dd, IH), 7.75 (d, IH), 7.44 (d, IH), 7.40 (d, IH), 7.36 (d, 2H), 7.18 (d, IH), 7.06 (d, 2H), 6.65 (dd, IH), 6.18 (s, 3H), 4.52 (d, IH), 3.24 - 3.30 (m, 4H), 3.12 (s, 4H), 2.79 (s, 2H), 2.25 (s, 4H), 2.17 (s, 2H), 1.97 (s, 2H), 1.79 - 1.89 (m, 2H), 1.75 (d, 2H), 1.50 - 1.64 (m, IH), 1.40 (t, 2H), 0.97 -L17(m,4H),0.94(s,6H). EXAMPLE 387 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[4-(4-ch]orophenyl)-6,6-dimethyl-5,6-dihydro- 2H-pyran-3-yl]methyl)piperazin-l-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)aminolphenyl} sulfonyl)benzanude EXAMPLE 387A methyl 2-(6-amino-5-chloropyridin-3-yloxy)-4-(piperazin-l-yl)benzoate A solution of EXAMPLE 318C (8.90 g) and piperazine (10.34 g) in dimethylsulfoxide (100 mL) was heated to 85°C. After stirring for 3 hours, the reaction mixture was cooled, diluted with ethyl acetate (400 mL), washed with water (2 x 250 mL) and brine (250 mL), dried over magnesium sulfate, filtered, and concentrated to provide the title compound. EXAMPLE 387B methyl 2-(6-amino-5-chloropyridin-3-yloxy)-4-(4-((4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl)methyl)piperazin-l-yI)benzoate To a solution of EXAMPLE 387A (0.344 g) and EXAMPLE 38E (0.238 g) in dichloromethane (5 mL) was added sodium triacetoxyhydroborate (0.302 g) and the reaction stirred at room temperature overnight. The reaction was quenched with saturated aqueous NaHCOg (10 mL) and extracted with dichloromethane (50 mL). The organic layers were combined, dried over magnesium sulfate, filtered, and concentrated. Silica gel 562 chromatography (Reveleris 40 g) eluting with a gradient of 10-75% ethyl acetate/hexanes over 30 minutes (flow = 40 ml/min) provided the title compound. EXAMPLE 387C 2-(6-amino-5-chloropyridin-3-yloxy)-4-(4-((4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl)methyl)piperazin-l -y])benzoic acid To a solution of EXAMPLE 387B (0.300 g) in teti-ahydrofuran (5 mL) and methanol (1 mL) was added l.OM lithium hydroxide (1.506 mL) and the suspension was heated to 55 °C. After 3 hours, the reaction was cooled, diluted with dichloromethane (20 mL) and water (10 mL), and quenched with IN aqueous HCl (1.5 mL). The organic layer was separated and the aqueous layer was extracted with 20 ml of dichloromethane. The combined organic extracts were washed with brine (25 mL), dried over magnesium sulfate, filtered, and concentrated to give the title compound. EXAMPLE 387D 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro- 2H-pyran-3-yl]methyl}piperazin-l-yl)-N-({3-niUx)-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 387B for EXAMPLE IF in EXAMPLE IH. 'H NMR (300 MHz, dimethylsulfoxide-de) 8 11.40 (s, IH), 8.64 (t, IH), 8.59 (d, IH), 7.87 (dd, IH), 7.75 (d, IH), 7.47 - 7.35 (m, 4H), 7.23 (d, IH), 7.19 - 7.11 (m, 2H), 6.65 (dd, IH), 6.18 (s, 3H), 4.14 (s, 2H), 3.85 (dd, 2H), 3.44 - 3.21 (m, 4H), 3.11 (s, 4H), 2.87 (s, 2H), 2.24 (s, 4H), 2.16 (s, 2H), 1.91 (s, IH), 1.63 (d, 2H), 1.38 -1.15 (m, 8H). EXAMPLE 388 N-({5-chloro-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- {[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)-2-[(6- fluoro- lH-indol-5-yl)oxy]benzamide The title compound was prepared by substituting EXAMPLE 277B for EXAMPLE IF and EXAMPLE 326A for EXAMPLE IG in EXAMPLE IH. 'H NMR (500 MHz, dimethylsulfoxide-de) 5 11.22 (s, IH), 8.60 (d, IH), 8.30 (d, IH), 7.55 (d, IH), 7.38 (m, 4H), 7.29 (br d, IH), 7.13 (d, 2H), 6.64 (d, IH), 6.41 (s, IH), 6.09 (s, IH), 4.53 (d, 2H), 4.10 (s, 563 2H), 3.78 (m, 2H), 3.60 (m, 2H), 3.07 (v br s, 4H), 2.86 (br s, 2H), 2.25 (v br s, 4H), 2.15 (s, 2H), 1.85 (m,4H), 1.18 (s,6H). EXAMPLE 389 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1 -yljmethyl }piperazin- l-yl)-N-( {3-nitro-4-[(tetrahydrofuran-3-ylmethyl)amino]phenyl} sulfonyl)benzamide The tide compound was prepared by substituting EXAMPLE 318H for EXAMPLE IF and EXAMPLE 332A for EXAMPLE IG in EXAMPLE IH. 'H NMR (300 MHz, dimethylsulfoxide-de) 8 11.52 -11.11 (m, IH), 8.65 (s, IH), 8.58 (d, IH), 7.87 (d, IH), 7.74 (d, IH), 7.47 - 7.32 (m, 4H), 7.22 (d, IH), 7.06 (d, 2H), 6.65 (d, IH), 6.17 (s, 3H), 3.86 - 3.38 (m, 6H), 3.12 (s, 4H), 2.79 (s, 2H), 2.61 (s, IH), 2.21 (d, 6H), 1.97 (s, 3H), 1.65 (d, IH), 1.40 (s, 2H), 0.94 (s, 6H). EXAMPLE 390 2-[(6-amino-5-chloropyridin-3-yl)oxy]-N-({5-chloro-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl }piperazin- l-yl)benzamide The title compound was prepared by substituting EXAMPLE 387C for EXAMPLE IF and EXAMPLE 326A for EXAMPLE IG in EXAMPLE IH. 'H NMR (300 MHz, dimethylsulfoxide-de) 8 11.94 -11.04 (m, IH), 8.58 (d, IH), 8.26 (d, IH), 7.75 (d, IH), 7.48 (d, IH), 7.40 (d, 3H), 7.16 (d, 2H), 6.66 (d, IH), 6.18 (d, 3H), 4.56 (d, 2H), 4.15 (s, 2H), 3.77 (dd, 2H), 3.67 - 3.51 (m, 2H), 3.14 (s, 4H), 2.95 (s, 2H), 2.33 (s, 4H), 2.17 (s, 2H), 1.87 (td, 4H), 1.20(s,6H). EXAMPLE 391 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-[4-({9-(4-chlorophenyl)-3-[2-fluoro-l- (fluoromethyl)ethyl]-3-azaspiro[5.5]undec-8-en-8-yl}methyl)piperazin-l-yl]-N-({3-nitro-4- [(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)benzamide EXAMPLE 391A benzyl 4- (piperidin-l-ylmethylene)piperidine-l-carboxylate To a solution of benzyl 4-formylpiperidine-l-carboxylate (22.35 g) in toluene (300 mL) was added piperidine (11.55 g). The mixture was stirred at reflux under a Dean-Stark 564 trap overnight. The mixture was then concentrated under vacuum and the residue was used directly in the next step. EXAMPLE 39IB benzyl 9-oxo-3-azaspiro[5.5]undec-7-ene-3-carboxylate To a solution of crude EXAMPLE 391A (35.5 g) in ethanol (300 mL) was added but-3-enone (8.71 g). The mixture was stirred at reflux overnight. Acetic acid (50 mL) was added to the mixture which was stirred at reflux again overnight. The mixture was then concentrated under vacuum and the residue was diluted with ethyl acetate (600 mL) and washed with water, brine and dried over Na2S04. After filtration and evaporation of the solvent, silica gel chromatography using 5-20% ethyl acetate in hexanes provided the title compound. EXAMPLE 391C benzyl 9-hydroxy-3-azaspiro[5.5]undecane-3-carboxylate EXAMPLE 391B (21 g) and tetrahydrofuran (160 mL) were added to wet 5% Pt-C (3.15 g) in a 250 mL SS pressure bottle and the mixture was stirred for 24 hours at 30 psi H2. The mixture was filtered through a nylon membrane and concentrated to afford the product. EXAMPLE 391D benzyl 9-oxo-3 -azaspiro[5.5 ]undecane-3 -carboxylate To a solution of EXAMPLE 39IC (23.66 g) in dichloromethane (350mL) was added Dess-Martin Periodinane (33.1 g). The mixture was stirred overnight. The mixture was diluted with ethyl acetate (600 mL) and washed with 2N aqueous NaOH, water, and brine. After drying over Na2S04, the mixture was filtered and concentrated to provide the title compound. EXAMPLE 39 IE benzyl 9-chloro-8-formyl-3-azaspiro[5.5]undec-8-ene-3-carboxylate Phosphorus oxychloride (5.68 mL) was added dropwise to a cooled (0 ^C) solution of EXAMPLE 391D (18.37g) in N,N-dimethylformamide (20 mL) and dichloromethane (80 mL). The mixture was then stirred overnight before it was diluted with ethyl acetate (600mL) and washed with aqueous sodium acetate, water (3x), and brine and dried over Na2S04. After 565 filtration and concentration, the crude product was used directly in the next reaction without further purification. EXAMPLE 39 IF benzyl 9- (4-chlorophenyl)-8-formyl-3-azaspiro[5.5]undec-8-ene-3-carboxylate To a mixture of 4-chlorophenylboronic acid (11.34g, 72.5mmol), EXAMPLE 39IE (21.01 g), palladium(II) acetate (271 mg), K2CO3 (25.05 g) and tetrabutylammonium bromide (19.5 g) was added water (120 mL). The mixture was stirred at 50*^0 overnight. The mixture was diluted with ethyl acetate (400 mL) and washed with water (3x) and brine and dried over Na2S04. After filtration and concentration, the residue was loaded on a column and eluted with 5-20% ethyl acetate in hexane to provide the title compound. EXAMPLE 39IG benzyl 8- ((4- (3- (6-amino-5-chloropyridin-3-yloxy)-4- (methoxycarbonyl)phenyl)piperazin-l-yl)methyl)-9-(4-chloiophenyl)-3-azaspiro[5.5]undec- 8-ene-3-carboxylate To a solution of EXAMPLE 387A (498 mg) in dichloromethane (10 mL) was added EXAMPLE 391F (582 mg) and sodium triacetoxyborohydride (436 mg). The mixture was stirred overnight. The reaction mixture was diluted with ethyl acetate (300 mL) and washed with 2N aqueous NaOH and brine, and dried over NazSOa. Filtration, evaporation of the solvent, and flash chromatography (2% methanol in dichloromethane) provided the title compound. EXAMPLE 39IH methyl 2- (6-amino-5-chloropyridin-3-yloxy)-4- (4- ((9- (4-chlorophenyl)-3- azaspiro[5.5]undec-8-en-8-yl)methyl)piperazin-l-yl)benzoate To a solution of EXAMPLE 391G (1.02 g) in ethanol (20 mL) was added Pd/C (10%, 150 mg). The mixture was stirred for 5 hours. The mixture was filtered and the filtrate was concentrated to provide the title compound. EXAMPLE 3911 2- (6-amino-5-chloropyridin-3-yloxy)-4- (4- ((9- (4-chlorophenyl)-3- (l,3-difluoropropan-2- yl)-3-azaspiro[5.5]undec-8-en-8-yl)methyl)piperazin-l-yl)benzoicacid 566 To a solution of EXAMPLE 39IH (318 mg) in dichloromethane (4 mL) was added l,3-difluoropropan-2-one (282 mg) and sodium acetoxyborohydride (318 mg). The mixture was stirred overnight. The reaction mixture was diluted with ethyl acetate (300 mL) and washed with 2N aqueous NaOH and brine, and dried over Na2S04. Filtration and concentration gave the crude product which was dissolved in tetrahydrofuran (10 mL), methanol (5 mL) and water (5 mL). LiOH*H20 (450 mg) was added and the mixture was stirred overnight. The mixture was neutralized with 2N aqueous HCl and extracted with ethyl acetate (300 mL) and dichloromethane (300 mL) respectively. The organic extracts were combined and dried over Na2S04. Filtration and concentration provided the title compound. EXAMPLE 391J 2-[ (6-amino-5-chloropyridin-3-yl)oxy]-4-[4- ({9- (4-chlorophenyl)-3-[2-fluoro-l-(fluoromethyl)ethyl]-3-azaspiro[5.5]undec-8-en-8-yl}methyl)piperazin-l-yl]-N- ({3-nitro-4-[ (tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)benzamide The title compound was prepared as described in EXAMPLE IH, replacing EXAMPLE IF with EXAMPLE 3911. 'H NMR (300 MHz, dimethylsulfoxide-ds) 6 8.62 (t, IH), 8.57 (d, IH), 7.86 (dd, IH), 7.75 (d, IH), 7.44 (d, IH), 7.36 (ra, 4H), 7.21 (d, IH), 7.08 (m, 3H), 6.65 (dd, IH), 6.17 (m, 3H), 4.69 (d, 2H), 4.53 (d, 2H), 3.85 (dd, 2H), 3.10 (m, 6H), 2.71 (m, 9H), 2.25 (m, 8H), 2.06 (m, 2H), 1.91 (m, IH), 1.62 (m, 2H), 1.48 (m, 4H), 1.25 (m, 2H). EXAMPLE 392 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[9-(4-chlorophenyl)-3-isopropyl-3- azaspiro[5.5]undec-8-en-8-yl]methyl)piperazin-l-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)benzamide EXAMPLE 392A 2- (6-amino-5-chloropyridin-3-yloxy)-4- (4- ((9- (4-chlorophenyl)-3-isopropyl-3-azaspiro[5.5]undec-8-en-8-yl)methyl)piperazin-1 -yl)benzoic acid The title compound was prepared as in EXAMPLE 3911 by replacing difluoropropan-2-one with acetone. 567 EXAMPLE 392B 2-[ (6-amino-5-chloropyridin-3-yl)oxy]-4- (4-{[9- (4-chlorophenyl)-3-isopropyl-3-azaspiro[5.5]undec-8-en-8-yl]methyl jpiperazin- l-yl)-N- ({3-nitro-4-[ (tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfony l)benzamide The title compound was prepared as in EXAMPLE IH by replacing EXAMPLE IF with EXAMPLE 392A. 'H NMR (300 MHz, dimethylsulfoxide-ds) 6 8.40 (m, 2H), 7.71 (dd, IH), 7.60 (d, IH), 7.54 (d, IH), 7.38 (d, 3H), 7.11 (d, 4H), 7.00 (d, IH), 6.62 (dd, IH), 6.28 (d, IH), 5.88 (s, 2H), 3.84 (dd, 3H), 3.04 (m, 7H), 2.73 (m, 4H), 2.23 (m, 9H), 1.90 (m, 2H), 1.63 (m, lOH), 1.27 (m, 6H) EXAMPLE 393 2-[(6-amino-5-chloropyridin-3-yl)oxy]-N-[(5-chloro-6-{[l-(N,N-dimethylglycyl)-4- fluoropiperidin-4-yl]methoxy }pyridin-3-yl)sulfonyl]-4-(4- {[2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1-en- l-yl]methyl }piperazin- l-yl)benzamide EXAMPLE 393A tert-butyl 4-fluoio-4-(hydroxymethyl)piperidine-1 -carboxylate l-Tert-butyl 4-ethyl 4-fluoropiperidine-l,4-dicarboxylate (1.0 g) in tetrahydrofuran (10 mL) at 0 °C was treated with a 1 N solution of LiAlH4 in tetrahydrofuran (2.54 mL), stirred 2 hours at room temperature, treated sequentially dropwise with water (0.2 mL) and a 2 N aqueous solution of NaOH (0.6 mL) and stirred for 1 hour. The solid was removed by filtration through a pad of diatomaceous earth, rinsing with ethyl acetate. The filtrate was washed with water and brine, dried (MgS04), filtered and concentrated to provide the title compound. EXAMPLE 393B tert-butyl 4-((3-chloro-5-sulfamoylpyridin-2-yloxy)methyl)-4-fluoropiperidine-l-carboxylate The title compound was prepared by substituting EXAMPLE 393A for (tetrahydro-2H-pyran-4-yl)methanol and EXAMPLE 303A for 4-fluoro-3-nitrobenzenesulfonamide in EXAMPLE 264A. 568 EXAMPLE 393C 5-chloro-6-((4-fluoropiperidin-4-yl)inethoxy)pyridine-3-sulfonamide,2»trifluoroacetic acid salt The title compound was prepared by substituting EXAMPLE 393B for EXAMPLE lA in EXAMPLE IB. EXAMPLE 393D 5-chloro-6-((l-(2-(dimethylamino)acetyl)-4-fluoropiperidin-4-yl)methoxy)pyridine-3- sulfonamide 5-chloro-6-((4-fluoropiperidin-4-yl)methoxy)pyridine-3-sulfonamide, 2»trifluoroacetic acid (0.131 g), 2-(dimethylamino)acetyl chloride, hydrochloric acid (0.139 g), and sodium carix)nate (0.048 g) were combined in a 5-mL vial with N,N-dimethylformamide (3 mL) and stirred overnight at room temperature. Additional sodium carbonate (0.048 g) was added followed by 2-(dimethylamino)acetyl chloride, hydrochloric acid (0.139 g) and stirring was continued over a second night. The reaction mixture was concentrated under high vacuum, slurried in CH2CI2, filtered, concentrated, chromatographed on amine functionalized silica gel with 0 to 4% methanol in CH2CI2 as the eluent and dried in a vacuum oven at 80 °C. EXAMPLE 393E 2-[(6-amino-5-chloropyridin-3-yl)oxy]-N-[(5-chloro-6-{[l-(N,N-dimethylglycyl)-4-fluoropiperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl}piperazin- l-yl)benzamide The title compound was prepared by substituting EXAMPLE 318H for EXAMPLE 1 lOE and EXAMPLE 393D for EXAMPLE IG in EXAMPLE 1 lOE 'H NMR (500 MHz, PYRIDINE-ds) 8 9.14 (d, IH), 8.75 (d, IH), 8.08 (d, IH), 8.02 (d, IH), 7.45 (m, 2H), 7.40 (d, IH), 7.09 (m, 2H), 6.73 (dd, IH), 6.53 (d, IH), 4.66 (d, IH), 4.57 (d, IH), 4.53 (d, IH), 4.08 (d, IH), 3.40 (m, 2H), 3.27 (m, IH), 3.11 (m, 5H), 2.80 (s, 2H), 2.33 (s, 6H), 2.29 (t, 2H), 2.19 (m, 4H), 2.06 (m, 2H), 1.99 (s, 2H), 1.84 (m, 2H), 1.41 (t, 2H), 0.95 (s, 6H). 569 EXAMPLE 394 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en- l-yl]methyl) piperazin-1 -y])-N- {[4-({ (3R)- l-[2-fluoro-1 -(fluoromethyl)ethyl]pynolidin-3-yl} amino)-3-nitrophenyl]sulfonyl} benzamide This example was prepared by substituting EXAMPLE 318H for EXAMPLE IF and EXAMPLE 357B for EXAMPLE IG in EXAMPLE IH. 'H NMR (500MHZ, dimethylsulfoxide-de) 5 8.58 (d, IH), 8.41 (d, IH), 7.89 (d, IH), 7.73 (d, IH), 7.44 (d, IH), 7.37 (m, 3H), 7.19 (d, IH), 7.06 (d, 2H), 6.65 (dd, IH), 6.18 (m, 3H), 4.67 (d, 2H), 4.58 (d, 2H), 4.30 (m, IH), 3.11 (m, 5H), 2.95 (m, 2H), 2.78 (m, 4H), 2.23 (m, 7H), 1.97 (m, 2H), 1.72 (m, IH), 1.40 (t, 2H), 0.94 (s, 6H). EXAMPLE 395 2-[(2-amino-5-bromopyridin-4-yl)oxy]-4-(4- {[2-(4-chloiophenyl)-4,4-dimethylcyclohex- l-en-l-yl]methyl}piperazin-l-yl)-N-({3-nit^o-4-[(tet^ahyd^o-2H-py^an-4-ylmethyl)amino]phenyl} sulfonyl)benzaniide This example was prepared by substituting EXAMPLE 383F for EXAMPLE 372F in EXAMPLE 379. 'H NMR (300MHz, dimethylsulfoxide-de) 8 8.61 (t, IH), 8.49 (d, IH), 7.81 (s, IH), 7.74 (dd, IH), 7.54 (d, IH), 7.37 (d, 2H), 7.12 (d, IH), 7.08 (d, 2H), 6.82 (dd, IH), 5.65 (bs, IH), 5.93 (bs, 2H), 5.49 (s, IH), 3.87 (dd, 2H), 3.31-3.19 (m, 8H), 2.84 (m, 2H), 2.40-2.15 (m, 6H), 1.99 (bs, 2H), 1.94 (m, IH), 1.64 (d, 2H), 1.42 (t, 2H), 1.35-1.21 (m, 2H), 0.95 (s, 6H). EXAMPLE 396 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1- en-1 -yl]methyl} piperazin-1 -yl)-N-[(4- {[(4,4-difluorocyclohexyl)methyl]amino} -3- nitrophenyl)sulfonyl]benzamide EXAMPLE 396A tert-butyl (4,4-difluorocyclohexyl)methylcaibamate Tert-butyl (4-oxocyclohexyl)methylcarbamate (5 g) and diethylaminosulphurtrifluoride (7.45 g) were stirred in dichloromethane (100 mL) for 24 hours. The mixture was quenched with pH 7 buffer (100 mL), and poured into ether (4(X) mL). The resulting solution was separated, and the organic layer was washed twice with water and brine, and concentrated to give the crude product and fluoroolefin in a 3:2 ratio. 570 The crude product was taken up in tetrahydrofuran (70 mL) and water (30 mL), and N-methylmoipholine-N-oxide (1.75 g) and OSO4 (2.5 wt % solution in t-butanol) were added, and the mixture was stirred for 24 hours. NaiSzOj (10 g) was then added, and the mixture was stirred for 30 minutes. The mixture was then diluted with ether (3(X) mL), and the resulting solution was separated, and rinsed twice with water and brine, and concentrated. The crude product was chromatographed on silica gel using 5-10% ethyl acetate in hexanes to give the title compound. EXAMPLE 396B (4,4-difluorocyclohexyl)methanamine A solution of EXAMPLE 396A (3 g) in dichloromethane (35 mL), trifluoroacetic acid (15 mL), and triethylsilane (1 mL) was stirred for 2 hours. The solution was concentrated, then condensed from toluene, and left under high vacuum for 24 hours. The semi-solid was taken up in ether/hexane and filtered to give the tide compound as its TFA salt. EXAMPLE 396C 4-((4,4-difluorocyclohexyl)methylamino)-3-nitrobenzenesulfonamide This example was prepared by substituting EXAMPLE 396B for 1-isopropylpiperidin-4-amine in EXAMPLE 41 A. EXAMPLE 396D 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en- l-yl]methyl }piperazin-1 -yl)-N-[(4- {[(4,4-difluorocyclohexyl)methyl]amino} -3- nitrophenyl)sulfonyl]benzamide This example was prepared by substituting EXAMPLE 318H for EXAMPLE IF and EXAMPLE 396C for EXAMPLE IG in EXAMPLE IH. 'H NMR (400 MHz, dimethylsulfoxide-dfi) 5 8.67 (t, IH), 8.58 (d, IH), 7.86 (dd, IH), 7.75 (d, IH), 7.45 (d, IH), 7.40 (d, IH), 7.35 (d, 2H), 7.22 (d, IH), 7.06 (d, 2H), 6.65 (dd, IH), 6.17 (m, 3H), 3.35 (m, 2H), 3.12 (v br m, 4H), 2.80 (br s, 2H), 2.25 (v br m, 4H), 2.17 (br t, 2H), 2.01 (br m, 2H), 1.98 (s, 2H), 1.80 (br m, 5H), 1.40 (t, 2H), 1.28 (br m, 2H), 0.93 (s, 6H). 571 EXAMPLE 397 [3-chloro-5-(5-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl }piperazin-1 - yl)-2- {[({3-nitio-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl) sulfonyl)amino]carbonyl }phenoxy)-2-iminopyridin- l(2H)-yl]methyl dihydrogen phosphate A mixture of EXAMPLE 318J (93 mg), di-tert-butyl chloromethyl phosphate (82 mg) and N,N-diisopropylethylamine (0.12 mL) in 3 mL of acetonitrile was heated at 90°C in a Biotage microwave synthesizer for 3 hours, cooled and concentrated. The residue was dissolved in dichloromethane (3 mL) and trifluoroacetic acid (2 mL) was added. The resulting solution was stirred at room temperature and concentrated. The residue was dissolved in a mixture of dimethylsulfoxide and methanol, purified by HPLC, eluting with 40-55% acetonitrile in 0.1% trifluoroacetic acid in water over 40 minutes. The title compound was obtained as a TFA salt. 'H NMR (500 MHz, dimethylsulfoxide-de) 5 8.67 (t, 1 H), 8.59 (d, 1 H), 8.21 (d, 1 H), 8.12 (d, 1 H), 7.89 (dd, 1 H), 7.50 (d, 1 H), 7.41 (d, 2 H), 7.28 (d, 1 H), 7.11 (d, 2 H), 6.74 (dd, 1 H), 6.39 (d, 1 H), 5.77 (d, 2 H), 3.86 (dd, 4 H), 3.32 -3.42 (m, 4 H), 3.27 (dd, 4 H), 2.99 (s, 4 H), 2.23 (s, 2 H), 2.04 (s, 2 H), 1.91 (dd, 1 H), 1.63 (d, 2 H), 1.47 (t, 2 H), 1.20 - 1.33 (m, 2 H), 0.96 (s, 6 H). EXAMPLE 398 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-[4-({4'-chloro-3-[2-(dimethylamino)ethoxy]-l,r- biphenyl-2-yl}methyl)piperazin-l-yl]-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- y]methyl)amino]phenyl} sulfonyl)benzamide EXAMPLE 398A 4'-chloro-3-hydroxybiphenyl-2-carbaldehyde 2-Bromo-6-hydroxybenzaldehyde (2.0 g), 4-chlorophenylboronic acid (1.86 g) and tetrakis(triphenylphosphine)palladium(0) (0.575 g) were suspended in a mixed solvent of dimethoxyethane (7 mL), ethanol (2 mL) and 2N NaiCOs aqueous solution (5 mL). The reaction mixture was heated at 90°C for 2 hours. The reaction mixture was diluted with ethyl acetate and poured into water. The organic layer was washed with water and with brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The resulting solid was triturated with methanol and filtered to afford the title compound. 572 EXAMPLE 398B 4'-chloio-3-(2-(dimethylamino)ethoxy)biphenyl-2-carbaldehyde EXAMPLE 398A (250 mg) and 2-chloro-N,N-dimethylethanamine hydrochloride salt (310 mg) was dissolved in mixed solvent of dichloromethane (5 mL) and 50% sodium hydroxide aqueous solution (0.5 mL), followed by addition of tetrabutylammonium iodide (79 mg). The reaction mixture was stirred at room temperature overnight. The reaction mixture was diluted with ethyl acetate and washed with water and brine. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. Flash column purification was performed with 0-5% methanol/dichloromethane to afford the title compound. EXAMPLE 398C 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-[4-({4'-chloro-3-[2-(dimethylamino)ethoxy]-l,r- biphenyl-2-yl} methyl)piperazin-1 -yl] -N-( {3-nitro-4- [(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)benzamide This example was prepared by substituting EXAMPLE 398B for EXAMPLE IF in EXAMPLE IH. 'HNMR(300MHZ, DMSO) 8 11.67-11.61 (m, IH), 9.91-9.71 (m, IH), 9.13 - 8.93 (m, IH), 8.68 - 8.65 (m, IH), 8.59 (d, IH), 7.85 (s, IH), 7.75 (d, IH), 7.54 (d, 3H), 7.47 (d, IH), 7.41 (d, IH), 7.38 (s, 2H), 7.24 (d, 2H), 6.98 (s, IH), 6.71 - 6.64 (m, IH), 6.21 (s, 2H), 4.45 (s, 8H), 3.83 (s, 3H), 3.60 (s, 3H), 3.31 (d, 6H), 2.92 (s, 4H), 1.99 - 1.82 (m, IH), 1.60 (s, 2H), 1.36 - 1.18 (m, 2H). EXAMPLE 399 2-[(6-amino-5-chloropyridin-3-yl)oxy]-N-{[5-chloro-6-({(3R)-l-[2-fluoro-l- (fluoiomethyl)ethyl]pyrrolidin-3-yl)methoxy)pyridin-3-yl]sulfonyl}-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)benzamide EXAMPLE 399A (R)-5-chloro-6-((l-(l,3-difluoropropan-2-yl)pyrrolidin-3-yl)methoxy)pyridine-3-sulfonamide EXAMPLE 400B (278 mg) and l,3-difluoropropan-2-one (94 mg) were suspended in 1,2-dichloroethane (10 mL). N,N-Dimethylformamide (1.5 mL) was added drop wise until a milky suspension formed. The reaction mixture was stirred at room temperature for 15 minutes followed by the addition of sodium triacetoxyborohydride (424 mg). The reaction mixture was stirred at room temperature overnight. The solvent was removed under vacuum. 573 Flash column purification with 2.5-5% methanol/dichloromethane provided the title compound. EXAMPLE 399B 2-[(6-amino-5-chloropyridin-3-yl)oxy]-N-{[5-chloK)-6-({(3R)-l-[2-fluoro-l-(fluoromethyl)ethyl]pyrrolidin-3-yl }methoxy)pyridin-3-yl]sulfonyl} -4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)benzamide This example was prepared by substituting EXAMPLE 318H for EXAMPLE 1 lOE and EXAMPLE 399A for EXAMPLE IG in EXAMPLE 1 lOF. 'H NMR (400MHZ, dimethylsulfoxide-dfi) 6 8.37 (d, IH), 8.06 (d, IH), 7.62 (d, IH), 7.54 (d, IH), 7.36 (m, 2H), 7.17 (d, IH), 7.07 (m, 2H), 6.63 (dd, IH), 6.27 (d, IH), 5.92 (bs, 2H), 4.65 (m, 2H), 4.53 (m, 2H), 4.28 (m, 2H), 3.07 (s, 4H), 2.90 (m, 2H), 2.76 (m. 4H), 2.58 (m, 2H), 2.20 (m, 6H), 1.99 (m, 3H), 1.54 (m, IH), 1.41 (t, 2H), 0.94 (s, 6H). EXAMPLE 400 2-[(6-amino-5-chloropyridin-3-yl)oxy]-N-[(5-chloro-6- {[(3R)-1 -(2,2- difluoK)ethyl)pyrrolidin-3-yl]methoxy }pyridin-3-yl)sulfonyl]-4-(4- {[2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1-en- l-yl]methyl }piperazin- l-yl)benzamide EXAMPLE 400A (R)-tert-butyl 3-((3-chloro-5-sulfamoylpyridin-2-yloxy)methyl)pyrrolidine-l-carboxylate This example was prepared by substituting (R)-tert-butyl 3-(hydroxymethyl)pyrrolidine-l-carboxylate for (tetrahydro-2H-pyran-4-yl)methanol in EXAMPLE 303B. EXAMPLE 400B (R)-5-chloro-6-(pyrrolidin-3-y]methoxy)pyridine-3-su]fonamide EXAMPLE 400A (480 mg) was dissolved in anhydrous tetrahydrofuran (10 mL) followed by addition of hydrogen chloride in dioxane solution (4M, 2.5 mL). The reaction mixture was stirred at room temperature overnight. The solvent was removed under vacuum to provide the title compound. EXAMPLE 400C (R)-5-chloro-6-((l-(2,2-difluoroethyl)pyrrolidin-3-yl)methoxy)pyridine-3-sulfonamide 574 A reaction mixture of EXAMPLE 400B (353 mg), l,l-difluoro-2-iodoethane (268 mg) and Na2C03 (283 mg) in N,N-dimethyIformamide (10 mL) was heated at 80°C overnight. The reaction mixture was cooled to room temperature and diluted with ethyl acetate. The organic phase was washed with water and brine, dried over anhydrous sodium sulfate, filtered, and concentrated. Flash column purification with 2.5-3% methanol/dichloromethane provided the title compound. EXAMPLE 400D 2-[(6-amino-5-chloix)pyridin-3-yl)oxy]-N-[(5-chlorx)-6-{[(3R)-l-(2,2-difluoroethyl)pyrrolidin-3-yl]methoxy }pyridin-3-yl)sulfonyl]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljrnethyl }piperazin- l-yl)benzamide This example was prepared by substituting EXAMPLE 318H for EXAMPLE 1 lOE and EXAMPLE 400C for EXAMPLE IG in EXAMPLE 1 lOF. 'H NMR (400MHZ, dimethylsulfoxide-de) 5 8.37 (d, IH), 8.05 (d, IH), 7.62 (d, IH), 7.54 (d, IH), 7.36 (m, 2H), 7.17 (d, IH), 7.07 (d, 2H), 6.62 (dd, IH), 6.27 (d, IH), 6.07 (m, 3H), 4.27 (m, 2H), 3.07 (s, 4H), 2.83 (m, 5H), 2.64 (m, 3H), 2.20 (m, 6H), 1.99 (m, 4H), 1.54 (m, IH), 1.41 (t, 2H), 0.94 (s, 6H). EXAMPLE 401 Trans-2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4- dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-N-[(4- {[(4- cyanocyclohexyl)methy]]amino}-3-nitrophenyl)sulfonyl]benzamide EXAMPLE 401A 2-(trans-4-(aminomethyl)cyclohexy])acetonitrile To a solution of tert-butyl (trans-4-(cyanomethyl)cyclohexyl)methylcarbamate (500 mg) in dichloromethane (5 mL) was slowly added trifluoroacetic acid (3 mL) at 0°C. The mixture was warmed to room temperature, stirred for 1 hour and concentrated. The residue was dried under vacuum to provide the title compound. EXAMPLE 401B 4-((trans-4-cyanocyclohexyl)methylamino)-3-nitrobenzenesulfonamide 575 The title compound was prepared by substituting EXAMPLE 401A for 1-(tetrahydrDpyran-4-yl)methylamine in EXAMPLE IG. EXAMPLE 401C Trans-2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-ch]orophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl Jpiperazin-1 -yl)-N- [(4- {[(4-cyanocyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]benzamide The title compound was prepared as described in EXAMPLE 1 lOF by replacing EXAMPLE 1 lOE and EXAMPLE IG with EXAMPLE 318H and EXAMPLE 401B. 'H NMR (400 MHz, dimethylsulfoxide-de) 8 8.63 (t, IH), 8.58 (d, IH), 7.85 (dd, IH), 7.75 (d, IH), 7.44 (d, IH), 7.40 (d, IH), 7.36 (d, 2H), 7.19 (d, IH), 7.06 (d, 2H), 6.65 (dd, IH), 6.19 (s, 3H), 3.24 - 3.31 (m, 4H), 3.12 (s, 4H), 2.79 (s, 2H), 2.58 - 2.69 (m, IH), 2.25 (s, 4H), 2.17 (s, 2H), 1.92 - 2.07 (m, 4H), 1.79 (d, 2H), 1.60 - 1.73 (m, IH), 1.34 -1.55 (m, 4H), 0.97 -1.12 (m,2H), 0.94 (s,6H). EXAMPLE 402 2-[(6-amino-5-ch]oropyridin-3-yl)oxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1- en-l-yl]methyl}piperazin-l-yl)-N-({5-fluoro-6-[(4-fluoiotetrahydro-2H-pyran-4- yl)methoxy]pyridin-3-yl} sulfonyl)benzamide EXAMPLE 402A 5-bromo-3-fluoro-2-((4-fluorotetrahydro-2H-pyran-4-yl)methoxy)pyridine This example was prepared by substituting EXAMPLE 296C for (tetrahydro-2H-pyran-4-yI)methano] and 5-bromo-2,3-difluoropyridine for 4-fluoro-3-nitrobenzenesulfonamide in EXAMPLE 264A. EXAMPLE 402B tert-butyl5-fluoro-6-((4-fluorotetrahydro-2H-pyran-4-yl)methoxy)pyridin-3-ylcarbamate EXAMPLE 402A (0.658 g), tert-butyl carbamate (0.300 g), palladium(n) acetate (0.024 g), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (0.093 g) and cesium carbonate (1.044 g) were combined in a 20 mL vial with dioxane (10.7 ml). The vial was flushed with nitrogen, capped and stirred at 100°C overnight. The reaction mixture was diluted with ethyl 576 acetate, washed with water and brine, dried (MgS04), filtered, concentrated and chromatographed on silica gel with 20% ethyl acetate in hexanes as eluent. EXAMPLE 402C 5-fluoro-6-((4-fluoiotetrahydro-2H-pyran-4-yl)methoxy)pyridine-3-sulfonyI chloride Under ice-cooling, thionyl chloride (1.563 mL) was added dropwise over 20 minutes to water (9 mL). The mixture was stirred for 12 hours to give a SOa-containing solution. Separately, EXAMPLE 402B (0.295 g) was added to a mixture of dioxane (3.2 mL) and concentrated HCl (8 ml) at 0 °C. The solution was stirred for 15 minutes, treated with a solution of sodium nitrite (0.065 g) in water (2 mL) dropwise at 0°C and stirred at 0 °C for 3 hours. The SOa-containing solution was cooled to 0°C, treated sequentially with copper(I) chloride (0.042 g) and the diazotized mixture, and stirred for 30 minutes. The reaction mixture was then extracted widi ethyl acetate and the organic layer was dried (MgS04), filtered and concentrated. The residue was chromatographed on silica gel with 5-10% ethyl acetate in hexanes as the eluent. EXAMPLE 402D 5-fluoro-6-((4-fluorotetrahydro-2H-pyran-4-yl)methoxy)pyridine-3-sulfonamide EXAMPLE 402C (0.08 g,) in isopropanol (2 mL) at 0°C was treated with ammonium hydroxide (1.70 mL) and stirred overnight. The reaction mixture was concentrated, slurried in water, filtered, rinsed with water and dried under vacuum. EXAMPLE 402E 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1- en-1 -yl]methyl} piperazin-1 -yl)-N-( {5-fluoro-6-[(4-fluorotetrahydro-2H-pyran-4- yl)methoxy]pyridin-3-yl} sulfonyl)benzamide This example was prepared by substituting EXAMPLE 402D for EXAMPLE IG and EXAMPLE 318H for EXAMPLE 1 lOE in EXAMPLE 1 lOF. 'H NMR (400 MHz, pyridine-ds) 5 9.05 (d, IH), 8.49 (dd, IH), 8.03 (d, IH), 8.00 (d, IH), 7.45 (m, 2H), 7.39 (d, IH), 7.09 (m, 2H), 6.73 (dd, IH), 6.52 (d, IH), 4.59 (d, 2H), 3.81 (m, 4H), 3.12 (m, 4H), 2.80 (s, 2H), 2.29 (t, 2H), 2.18 (m, 4H), 1.99 (s, 2H), 1.88 (m, 4H), 1.41 (t, 2H), 0.95 (s, 6H). 577 EXAMPLE 403 2-[(6-amino-5-chloropyridin-3-yl)oxy]-N-[(5-chloro-6-{[l-(2,2-difluoroethyl)-4- fluoropiperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1-en- l-yl]methyl }piperazin- l-yl)benzamide EXAMPLE 403A EXAMPLE 393C (0.263 g), Ll-difluoro-2-iodoethane (0.23 g), and sodium carbonate (0.254 g) were combined in a 20 mL vial with N,N-dimethylformamide (6 mL) and the mixture stirred at 70°C overnight. The reaction mixture was concentrated under high vacuum, chromatographed on silica gel with 0-5% methanol in dichloromethane as the eluent, and dried overnight in a vacuum oven at 80°C. EXAMPLE 403B 2-[(6-amino-5-chloropyridin-3-yl)oxy]-N-[(5-chloro-6-{[l-(2,2-difluoroethyl)-4-fluoropiperidin-4-yl]methoxy}pyridin-3-yI)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)benzamide This example was prepared by substituting EXAMPLE 403A for EXAMPLE IG and EXAMPLE 318H for EXAMPLE 1 lOE in EXAMPLE HOP. 'H NMR (400 MHz, pyridine-ds) 6 9.15 (d, IH), 8.75 (d, IH), 8.02 (d, IH). 8.00 (d, IH), 7.45 (m, 2H), 7.38 (d, IH), 7.09 (m, 2H), 6.72 (dd, IH), 6.50 (d, IH), 6.18 (tt, IH), 4.55 (d, 2H), 3.12 (m, 4H), 2.80 (m, 6H), 2.60 (td, 2H), 2.28 (t, 2H), 2.17 (m, 4H), 1.93 (m, 6H), 1.41 (t, 2H), 0.95 (s, 6H). EXAMPLE 404 2-[(6-amino-5-chloropyridin-3-yl)oxy]-N-({3-chloro-4-[(4-fluorotetrahydro-2H-pyran-4- yl)methoxy]phenyl} suIfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 - yl]methyl}piperazin-l-yl)benzamide EXAMPLE 404A 3-chloro-4-((4-fluorotetrahydro-2H-pyran-4-yl)methoxy)benzenesulfonamide To a solution of EXAMPLE 296C (0.175 g) in tetrahydrofuran (5 ml) was added sodium hydride (0.209 g) and the reaction stirred at room temperature for 15 minutes. 3-Chloro-4-fluorobenzenesulfonamide (0.273 g) was added and the reaction stirred for 3 hours. To the thick suspension was added tetrahydrofuran (2 ml) and N,N-dimethylformamide (3 578 ml). The reaction was stirred for 3 hours at 60°C then poured into dichloromethane (50 ml) and IN aqueous HCl (50 ml). The organic layer was washed with brine (35 ml) dried over magnesium sulfate, filtered, and concentrated. Silica gel chromatography (Reveleris 40 g) eluting with a gradient of 10-100% ethyl acetate/hexanes over 30 minutes (flow = 40 ml/minute) gave the title compound. EXAMPLE 404B 2-[(6-amino-5-chloropyridin-3-yl)oxy]-N-({3-chloro-4-[(4-fluorotetrahydro-2H-pyran-4- yl)methoxy]phenyl} sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 - yljmethyl} piperazin-1 -yl)benzamide This example was prepared by substituting EXAMPLE 318H for EXAMPLE IF and EXAMPLE 404A for EXAMPLE IG in EXAMPLE IH. 'H NMR (300 MHz, DMSO) 6 11.44 - 11.17 (m, IH), 7.91 (d, IH), 7.83 (dd, IH), 7.77 (d, IH), 7.44 (d, 2H), 7.35 (dd, 3H), 7.06 (d, 2H), 6.66 (d, IH), 6.19 (d, 3H), 4.31 (d, 2H), 3.84 - 3.73 (m, 2H), 3.66 - 3.55 (m, 2H), 3.13 (s, 4H), 2.81 (s, 2H), 2.26 (s, 4H), 2.17 (s, 2H), 2.02 -1.74 (m, 6H), 1.41 (t, 2H), 0.94 (s, 6H). EXAMPLE 405 2-[(6-amino-5-chloropyridin-3-yl)oxy ]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 - en-1-yljmethyl )piperazin- l-yl)-N- {[6-({4-fluoro- l-[2-fluoro-1- (fluoromethyl)ethyl]piperidin-4-yl}methoxy)-5-(trifluoromethyl)pyridin-3- yljsulfonyl} benzamide EXAMPLE 405A 5-nitro-3-(trifluoromethyl)pyridin-2-ol 3-(Trifluoromethyl)pyridin-2-ol (2.3 g) was added to concentrated sulfuric acid (15 mL) at 0 °C. The mixture was stirred at 0 °C for 5 minutes. To this solution was added nitric acid (fuming, 6 mL) dropwise over 5 minutes. The reaction mixture was stirred at room temperature for 2 hours, and then heated at 50°C for 3 hours. After cooling, the reaction mixture was poured into ice (200 g), and the mixture was extracted with ethyl acetate three times. The combined organic layers were washed with brine, dried over MgS04, filtered, and concentrated under reduced pressure to give the title compound. 579 EXAMPLE 405B 2-chloro-5-nitro-3-(trifluoromethyl)pyridine A mixture of EXAMPLE 405 A (L69 g), phosphorus pentachloride (2.03 g), and phosphoryl trichloride (0.97 mL) was heated at 90 °C for 3 hours. After cooling, the reaction mixture was poured into ice, and extracted with ethyl acetate three times. The extract was washed with brine, dried over MgS04, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel eluting with 1:9 ethyl acetate\hexanes to give the title compound. EXAMPLE 405C A mixture of iron (1.5 g) and ammonium chloride (2.38 g) in water (40 mL) was stirred at room temperature for 5 minutes. To this suspension was added EXAMPLE 405B in methanol (40 mL). The reaction mixture was stirred at room temperature for 1 hour. More iron (1.8 g) was added to the reaction mixture, and it was stirred for another 3 hours. The solid from the reaction mixture was filtered off, and the filtrate was partitioned between water and ethyl acetate. The combined organic layers were washed with brine, dried over MgS04, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel eluting with 1:4 ethyl acetate\hexanes to give the title compound. EXAMPLE 405D 6-ch]oro-5-(trifluoromethyl)pyridine-3-sulfonyl chloride Under ice-cooling, thionyl chloride (4 mL) was added dropwise over 20 minutes to water (27 mL). The mixture was stirred overnight for 12 hours to give a SO2 containing solution. Separately, EXAMPLE 405 C (1.14 g) in dioxane (5 mL) was added to concentrated HCl (20 mL) at 0°C. The solution was stirred for 5 minutes. To this suspension/solution was added sodium nitrite (0.44 g) in water (6 mL) dropwise at 0°C. The solution stirred at 0°C for 3 hours. To the SO2 containing solution was added copper(I) chloride (0.115 g). Then, to this solution was added the diazotized EXAMPLE 405 C at 0°C. The solution was stirred for 30 minutes. The reaction mixture was extracted with ethyl acetate. The combined organic layers were washed with brine, dried over MgS04, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel eluting with 1:20 ethyl acetate\hexanes to give the title compound. 580 EXAMPLE 405E 6-chloro-5-(trifluoromethyl)pyridine-3-sulfonamide This example was prepared by substituting EXAMPLE 405D for 5-bromo-6-chloropyridine-3-sulfonyl chloride in EXAMPLE 305A. EXAMPLE 405F tert-butyl4-fluoro-4-((5-sulfamoyI-3-(trifluoromethyl)pyridin-2-yloxy)methyl)piperidine-l- carboxylate This example was prepared by substituting EXAMPLE 405E for EXAMPLE 305A and EXAMPLE 341A for (l,4-dioxan-2-yl)methanol in EXAMPLE 305B. EXAMPLE 405G 6-((4-fluoropiperidin-4-yl)methoxy)-5-(trifluoromethyl)pyridine-3-sulfonamide This example was prepared by substituting EXAMPLE 405F for EXAMPLE 400A in EXAMPLE 400B. EXAMPLE 405H 6-((l-(l,3-difIuoropropan-2-yl)-4-fluoropiperidin-4-yl)methoxy)-5-(trifluoromethyl)pyridine- 3-sulfonamide This example was prepared by substituting EXAMPLE 405G for EXAMPLE 400B in EXAMPLE 399 A. EXAMPLE 4051 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-([2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl }piperazin-1 -yl)-N- {[6-( {4-fluoro-1 -[2-fluoro-1-(fluoromethyl)ethyl]piperidin-4-yl}methoxy)-5-(trifluoromethyl)pyridin-3- yl]sulfonyl} benzamide This example was prepared by substituting EXAMPLE 318H for EXAMPLE 1 lOE and EXAMPLE 405H for EXAMPLE IG in EXAMPLE 1 lOF. 'H NMR (400MHZ, dimethylsulfoxide-de) 8 8.62 (d, IH), 8.29 (d, IH), 7.57 (m, 2H), 7.36 (d, 2H), 7.09 (m, 3H), 6.62 (dd, IH), 6.29 (d, IH), 5.86 (bs, 2H), 4.67 (d, 2H), 4.53 (m, 4H), 3.08 (m, 5H), 2.74 (m, 6H), 2.19 (m, 6H), 1.89 (m, 6H), 1.41 (t, 2H), 0.94 (s, 6H). 581 EXAMPLE 406 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N-( {3- nitro-4- [(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)-2-[2-( 1 H-pyrazol-4- yl)phenoxy]benzamide EXAMPLE 406A 2-(2-bromophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- enyl)methy])piperazin-l-yl)-N-(3-nitro-4-((tetrahydro-2H-pyran-4- yl)methylamino)phenylsulfonyl)benzamide The title compound was prepared as described in EXAMPLE 1 lOF by replacing EXAMPLE 1 lOE with EXAMPLE 42C. EXAMPLE 406B 4-(4-{[2-(4-chlorophenyl)-4,4-diniethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-[2-(lH-pyrazol-4- yl)phenoxy]benzamide A mixture of EXAMPLE 406A (57 mg), tert-butyl 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole-l-carboxylate (27.7 mg), dichlorobis(triphenylphosphine)palladium (II) (6.61 mg), K2CO3 (0.2 ml) in a dimethoxyethane/ethanol/water (7:2:3) was heated at 160°C for 10 minutes in a Biotage microwave synthesizer and concentrated. The residue was dissolved in dimethylsulfoxide:methanol (1:1) and purified by HPLC, eluting with 40-65% acetonitrile in 0.1% TEA water over 40 minutes to provide the title compound as a TEA salt. The TEA salt was dissolved in dichloromethane and washed with saturated NaHCOa aqueous solution. The organic layer was dried over Na2S04, filtered, and concentrated to provide the title compound. 'H NMR (400 MHz, dimethylsulfoxide-de) 6 12.87 (s, IH), 11.55 (s, IH), 8.58 (t, IH), 8.47 (d, IH), 8.11 (s, IH), 7.85 (s, IH), 7.76 (dd, IH), 7.59 - 7.67 (m, IH), 7.48 (d, IH), 7.34 (d, 2H), 7.00 - 7.11 (m, 5H), 6.73 (dd, IH), 6.67 (dd, IH), 6.08 (d, IH), 3.85 (dd, 2H), 3.20 - 3.29 (m, 4H), 3.04 (s, 4H), 2.77 (s, 2H), 2.17 (d, 6H), 1.96 (s, 2H), 1.80 - 1.92 (m, IH), 1.55 - 1.70 (m, 2H), 1.39 (t, 2H), 1.19 - 1.32 (m, 2H), 0.93 (s, 6H). 582 EXAMPLE 407 2-[2-(2-aminopyridin-3-yl)phenoxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl }piperazin- l-yl)-N-({ 3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)benzainide The title compound was prepared as described in EXAMPLE 406B by replacing tert-butyl 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole-l-carboxylate with tert-butyl 3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2-ylcarbamate. 'H NMR (400 MHz, dimethylsulfoxide-d6) 6 8.57 (t, IH), 8.41 (d, IH), 7.92 (dd, IH), 7.74 (dd, IH), 7.60 (d, IH), 7.41 (d, IH), 7.36 (d, 2H), 7.18 (dd, IH), 7.02 - 7.13 (m, 5H), 6.97 (t, IH), 6.70 (dd, IH), 6.61 - 6.67 (m, IH), 6.55 (d, IH), 6.31 (d, IH), 3.84 (dd, 2H), 3.21 - 3.30 (m, 4H), 3.15 (s, 4H), 2.83 (s, 2H), 2.23 - 2.34 (m, 4H), 2.17 (s, 2H), 1.84 - 2.02 (m, 3H), 1.63 (dd, 2H), 1.40 (t, 2H), 1.20 -1.33 (m, 2H), 0.94 (s, 6H). EXAMPLE 408 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-N-( {3- nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-[2-(lH-pyrazol-5- yl)phenoxy]benzamide The title compound was prepared as described in EXAMPLE 406B by replacing tert-butyl 4-(4,4,5,5-tetramethy]-l,3,2-dioxaborolan-2-yl)-lH-pyrazole-l-carboxylate with IH-pyrazol-5-ylboromc acid. 'H NMR (400 MHz, dimethylsulfoxide-de) 5 12.95 (s, IH), 8.60 (s, IH), 8.52 (s, IH), 7.85 (s, 2H), 7.57 - 7.73 (m, IH), 7.48 (d, IH), 7.22 - 7.37 (m, 4H), 7.00 - 7.15 (m, 4H), 6.56 - 6.70 (m, 2H), 5.96 (s, 2H), 3.85 (dd, 2H), 3.21 - 3.28 (m, 4H), 3.02 (s, 4H), 2.70 - 2.85 (m, 2H), 2.10 - 2.30 (m, 5H), 1.83 -1.99 (m, 3H), 1.62 (d, 2H), 1.39 (t, 2H), 1.19-1.31 (m,2H), 0.92 (s,6H). EXAMPLE 409 2-[(6-amino-5-chloropyridin-3-yl)oxy]-N-({5-chloro-6-[(4,4- difluorocyclohexyl)methoxy]pyridin-3-yl]sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1-en- l-yl]methyl }piperazin- l-yl)benzamide EXAMPLE 409A (4,4-difluorocyclohexyl)methanol 583 Lithium aluminum hydride (0.24 g) was added to diethyl ether (15 mL), to which was then added dropwise ethyl 4,4-difluorocyclohexanecarboxylate (1.0 g) in diethyl ether (2 mL), and the reaction was stirred at reflux under nitrogen for 4 hours. The reaction was cooled to 0°C, followed by the careful addition of water (0.24 mL), 4^ aqueous NaOH (0.24 mL), and additional water (0.72 mL). Then Na2S04 and diethyl ether (40 mL) were added and the mixture was stirred for 30 minutes. After filtration through diatomaceous earth and concentration, the title compound was used in the next step without further purification. EXAMPLE 409B 5-chloro-6-((4,4-difluorocyclohexyl)methoxy)pyridine-3-sulfonamide This example was prepared by substituting EXAMPLE 409A for (l,4-dioxan-2-yl)methanol and EXAMPLE 303A for EXAMPLE 305A in EXAMPLE 305B. EXAMPLE 409C 2-[(6-amino-5-chloropyridin-3-yl)oxy]-N-({5-chloro-6-[(4,4-difluorocyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl}piperazin- l-yl)benzamide This example was prepared by substituting EXAMPLE 318H for EXAMPLE 122C and EXAMPLE 409B for EXAMPLE 1 lA in EXAMPLE 137. 'H NMR (500 MHz, dimethylsulfoxide-de) 5 8.54 (s, IH), 8.20 (2, IH), 7.73 (d, IH), 7.50 (d, IH), 7.37 (m, 3H), 7.07 (d, 2H), 6.66 (dd, IH), 6.22 (s, IH), 6.13 (br s, 2H), 4.30 (d, 2H), 3.17 (v br m, 4H), 2.98 (V br s, 2H), 2.43 (v br m, 4H), 2.18 (br t, 2H), 2.05 (br m, 3H), 1.98 (s, 2H), 1.8 (br m, 4H), 1.43 (t, 2H), 1.35 (br m, 2H), 0.94 (s, 6H). EXAMPLE 410 N-({5-chloro-6-[(4,4-difluorocyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[4-(4- chloK)phenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl]piperazin-l-yl)-2-[(6-fluoro- 1 H-indol-5-yl)oxy]benzamide This example was prepared by substituting EXAMPLE 277B for EXAMPLE 122C and EXAMPLE 409B for EXAMPLE 1 lA in EXAMPLE 137. 'H NMR (500 MHz, dimethylsulfoxide-dfi) 5 11.22 (s, IH), 8.60 (d, IH), 8.26 (d, IH), 7.54 (d, IH), 7.38 (m, 4H), 7.29 (br d, IH), 7.13 (d, 2H), 6.64 (d, IH), 6.41 (s, IH), 6.09 (s, IH), 4.30 (d, 2H), 4.10 (s, 584 2H), 3.05 (V br s, 4H), 2.86 (v br s, 2H), 2.25 (v br s, 4H), 2.15 (s, 2H), 2.03 (br m, 2H), 1.96 (br m, IH), 1.85 (brm, 4H), 1.36 (m, 2H), 1.18 (s, 6H). EXAMPLE 411 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl }piperazin-1 -yl)-N-[(4-{[(4,4-difluorocyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-[(6-fluoro-lH-indol-5- yl)oxy]benzamide This example was prepared by substituting EXAMPLE 154E for EXAMPLE 122C and EXAMPLE 396C for EXAMPLE 1 lA in EXAMPLE 137. 'H NMR (400 MHz, dimethylsulfoxide-dfi) 5 11.22 (s, IH), 8.65 (t, IH), 8.60 (d, IH), 7.88 (dd, IH), 7.52 (d, IH), 7.39 (dd, IH), 7.35 (m, 4H), 7.18 (d, IH), 7.03 (d, 2H), 6.65 (dd, IH), 6.21 (s, IH), 6.08 (s, IH), 3.04 (v br m, 4H), 2.76 (br s, 2H), 2.20 (v br m, 4H), 2.13 (br t, 2H), 2.00 (br m, 3H), 1.95 (s, 2H), 1.81 (br m, 6H), 1.39 (t, 2H), 1.24 (br m, 2H), 0.91 (s, 6H). EXAMPLE 412 N-({3-chloro-4-[(4-fluorotetrahydro-2H-pyran-4-yI)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl }piperazin-1 -yl)-2-[(6-f]uoro-1H- indol-5-yl)oxy]benzamide EXAMPLE 412A 3-chloro-4-((4-fluorotetrahydro-2H-pyran-4-yl)methoxy)benzenesulfonamide The title compound was prepared by substituting 4-fluoro-3-chlorobenzenesulfonamide for 4-fluoro-3-nitrobenzenesulfonamide in EXAMPLE 296D, except here dimethylformamide was used in place of tetrahydroftiran. EXAMPLE 412B N-({3-chloro-4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl }piperazin-1 -yl)-2-[(6-fluoro- lH-indol-5-yl)oxyJbenzamide The title compound was prepared by substituting EXAMPLE 412A for EXAMPLE 1 lA and EXAMPLE 154E for EXAMPLE 122C in EXAMPLE 137. 'H NMR (400 MHz, dimethylsulfoxide-de) 6 11.24 (s, IH), 7.94 (d, IH), 7.86 (dd, IH), 7.51 (d, IH), 7.35 (m, 6H), 7.04 (d, 2H), 6.65 (dd, IH), 6.43 (m, IH), 6.08 (d, IH), 4.28 (d, 2H), 3.80 (m,2H), 3.60 585 (m, 2H), 3.04 (br m, 4H), 2.75 (s, 2H), 2.20 (br m, 4H), 2.15 (br m, 2H), 1.95 (s, 2H), 1.86 (m, 4H), 1.39 (t, 2H), 0.92 (s, 6H). EXAMPLE 413 N-({3-chloro-4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]phenyl}sulfonyl)-4-(4-{[4-(4- chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)-2-[(6-fluoro- lH-indol-5-yl)oxy]benzamide The title compound was prepared by substituting EXAMPLE 412A for EXAMPLE 11A and EXAMPLE 277B for EXAMPLE 122C in EXAMPLE 137. 'H NMR (400 MHz, diraethylsulfoxide-de) 5 11.24 (s, IH), 7.96 (d, IH), 7.87 (dd, IH), 7.51 (d, IH), 7.37 (m, 5H), 7.33 (d, IH), 7.13 (d, 2H), 6.66 (dd, IH), 6.43 (ra, IH), 6.09 (d, IH), 4.30 (d, 2H), 4.10 (s, 2H), 3.80 (m, 2H), 3.60 (m, 2H), 3.06 (br s, 4H), 2.90 (v br s, 2H), 2.25 (v br s, 4H), 2.15 (br m, 2H), 1.86 (m, 4H), 1.18 (s, 6H). EXAMPLE 414 N-({5-chloro-6-[(trans-4-hydroxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yljmethyl }piperazin- l-yl)-2-[(6-fluoro-1H- indazol-4-yl)oxy]benzamide EXAMPLE 414A 4-(tert-butyldimethylsilyloxy)-6-fluoro-lH-indazole 6-Fluoro-lH-indazo]-4-ol (0.91 g) in tetrahydrofuran (20 mL) was treated with 60% sodium hydride (0.251 g). After 10 minutes, tert-butylchlorodimethylsilane (0.992 g) was added. The solution was stirred for 16 hours. The solvent was removed, and the residue was purified by flash column chromatography on silica gel to give the title compound. EXAMPLE 414B 4-(tert-butyldimethylsilyloxy)-6-fluoro-l-((2-(trimethylsilyl)ethoxy)methyl)-lH-indazole EXAMPLE 414A (1.32 g) in tetrahydrofuran (20 mL) was treated with 60% sodium hydride (0.215 g). After 10 minutes, (2-(chloromethoxy)ethyl)trimethylsilane (1.03 g) was added. The solution was stirred for 2 hours. The reaction mixture was partitioned between water and ethyl acetate. The organic layer was separated, and the aqueous layer was extracted with additional ethyl acetate. The combined organic layers were washed with brine, dried 586 over MgS04, filtered, and concentrated. The residue was purified by flash chromatography on silica gel to give the title compounds as a mixture of two isomers. EXAMPLE 414C 6-fluoro-1 -((2-(trimethylsilyl)ethoxy)methyl)-1 H-indazol-4-ol A mixture of EXAMPLE 414B (1.8 g) and 1.0 N tetrabutyl ammonium fluoride (13.6 mL) in tetrahydrofuran (15 mL) was stirred for 2 hours. The solvent was removed, and the residue was partitioned between water and ethyl acetate. The organic layer was separated, and the aqueous layer was extracted with additional ethyl acetate. The combined organic layers were washed with brine, dried over MgS04, filtered, and concentrated. The residue was purified by flash chromatography on silica gel to give the title compound. EXAMPLE 414D methyl 4-fluoro-2-(6-fluoro-1 -((2-(trimethylsilyl)ethoxy)methyl)- lH-indazol-4- yloxy)benzoate The title compound was prepared by substituting EXAMPLE 414C for 2-methyl-5-indolol and methyl 2,4-difluorobenzoate for ethyl 2,4-difluorobenzoate in EXAMPLE 3A. EXAMPLE 414E methyl 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)-2-(6-fluoro-l-((2-(trimethylsilyl)ethoxy)methyl)-lH-indazol-4-yloxy)benzoate The title compound was prepared by substituting EXAMPLE 414D for EXAMPLE 3A in EXAMPLE 3G. EXAMPLE 414F 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)-2-(6-fluoro-1 -((2-(trimethylsilyI)ethoxy)methyl)-1 H-indazol-4-yloxy)benzoic acid The title compound was prepared by substituting EXAMPLE 414E for EXAMPLE IE in EXAMPLE IF. EXAMPLE 414G 6-((trans-4-(tert-butyldimethylsilyloxy)cyclohexyl)methoxy)-5-chloropyridine-3-sulfonamide 587 The title compound was prepared by substituting (trans-4-(tert-butyldimethylsilyloxy)cyclohexyl)methanol for (l,4-dioxan-2-yl)methanol and EXAMPLE 303A for EXAMPLE 305A in EXAMPLE 305B. EXAMPLE 414H N-(6-((trans-4-(tert-butyldimethylsilyloxy)cyclohexyl)n)ethoxy)-5-chloropyridin-3- ylsulfonyl)-4-(4-((2-(4-ch]orophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-2- (6-fluoro- l-((2-(trimethylsilyl)ethoxy)methyl)-1 H-indazol-4-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 414F for EXAMPLE IF and EXAMPLE 414G for EXAMPLE IG in EXAMPLE IH. EXAMPLE 4141 N-({5-chloro-6-[(trans-4-hydroxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-[(6-fluoro-1H- indazol-4-yl)oxy]benzamide EXAMPLE 414H (0.22 g) in tetrahydrofiiran (10 mL) was treated with 1.0 N tetrabutyl ammonium fluoride (10 mL). The reaction mixture was heated at 60 °C for 16 hours. The solvent was removed, and the residue was partitioned between water and ethyl acetate. The organic layer was separated, and the aqueous layer was extracted with additional ethyl acetate three times. The combined organic layers were washed with brine, dried over MgS04, filtered, and concentrated. The residue was purified by reverse phase Gilson Prep HPLC system with a Phenomenex prep column (Luna, 5 n, CI8(2), 250X21.20 mm, 5 A) eluting with 20-80% acetonitrile in water with 0.1% trifluoroacetic acid to give the title compound. Fractions containing product were concentrated, and the concentrate was diluted with dichloromethane, neutralized with aqueous NaHC03, dried over Na2S04, filtered, and concentrated, 'H NMR (500MHZ, dimethylsulfoxide-de) 6 13.08 (s, IH), 8.18 (s, IH), 7.77 (s, IH), 7.75 (s, IH), 7.63 (d, IH), 7.37 (d, 2H), 7.07 (d, 2H), 6.81 (d, IH), 6.76 (d, IH), 6.59 (s, IH), 5.83 (dd, IH), 4.53 (d, IH), 4.16 (d, 2H), 3.19 (br s, 4H), 2.86 (br s, 2H), 2.19-2.34 (m, 4H), 1.99 (s, 2H), 1.75-1.86 (m, 6H), 1.42 (t, 2H), 1.08-1.18 (m, 6H), 0.94 (s, 6H). 588 EXAMPLE 415 N-({5-chloro-6-[(4-fluorotBtrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl)sulfonyI)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl }piperazin-1 -yl)-2-[(6-fluoro- lH-indazol-4-yl)oxy]beiizamide EXAMPLE 415A N-(5-chloro-6-((4-fluorc)tetrahydro-2H-pyran-4-yl)methoxy)pyridin-3-ylsulfonyl)-4-(4-((2- (4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)-2-(6-fluoro-1 -((2- (trimethylsilyl)ethoxy)methyl)-lH-indazol-4-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 414F for EXAMPLE IF and EXAMPLE 326A for EXAMPLE IG in EXAMPLE IH. EXAMPLE 415B N-({5-chloro-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethyIcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-[(6-fluoro- 1 H-indazol-4-yl)oxy Jbenzamide The title compound was prepared by substituting EXAMPLE 415A for EXAMPLE 414H in EXAMPLE 4141. ^H NMR (500MHz, dimethylsulfoxide-de) 8 13.08 (s, IH), 8.18 (s, IH), 7.83 (s, IH), 7.75 (s, IH), 7.64 (d, IH), 7.37 (d, 2H), 7.07 (d, 2H), 6.82 (dd, IH), 6.78 (d, IH), 6.59 (s, IH), 5.83 (dd, IH), 4.49 (d, 2H), 3.76-3.81 (m, 2H), 3.57-3.64 (m, 2H), 3.18 (br s, 4H), 2.84 (br s, 2H), 2.19 (s, 2H), 1.99 (s, 2H), 1.82-1.91 (m, 4H), 1.42 (t, 2H), 0.95 (s, 6H). EXAMPLE 416 tert-butyl5-[(4-{4-[({5-chloro-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3- yl}sulfonyl)carbamoyl]-3-[(6-fluoro-lH-indol-5-yl)oxy]phenyl}piperazin-l-yl)methyI]-4-(4- chlorophenyl)-3,6-dihydropyridine-l(2H)-carboxylate EXAMPLE 416A tert-butyl 4-ch]oro-3-formyl-5,6-dihydropyridine-l(2H)-carboxylate To N,N-dimethylformamide (3.87 mL) at 0°C, POCI3 (3.73 mL) was added dropwise, maintaining the temperature below 5°C. The resulting mixture was stirred at room 589 temperature for 1.5 hours. The reaction mixture was then cooled in ice bath. Tert-butyl 4-oxopiperidine-1-carboxylate (4.98 g) was added slowly, as a solution in dichloromethane (20 mL). After the addition was complete, the ice bath was removed and the reaction was stirred at room temperature for 1 hour. The reaction mixture was poured over ice and solid sodium acetate, and stirred for 15 minutes, then extracted with dichloromethane. The extracts were washed thoroughly with water and with brine, and dried over MgS04, filtered, and concentrated under vacuum to obtain the title compound, and used without further purification. EXAMPLE 416B tert-butyl 4-(4-chlorophenyl)-3-formyl-5,6-dihydropyridine-l(2H)-carboxylate EXAMPLE 416A (5.2 g), 4-chlorophenylboronic acid (2.015 g) and palladium(II) acetate (0.055 g) were combined in water to give a suspension. Potassium carbonate (4.41 g) and tetrabutylammonium bromide (1.979 g) were added. The reaction mixture was stirred at 45 °C for 3.5 hours. The mixture was allowed to warm to room temperature and was diluted with 200-3(X) mL of ethyl acetate. The organic layer was washed thoroughly with water and with brine, and dried over MgS04, filtered, and concentrated under vacuum, and purified by flash chromatography eluting with a gradient of 10% ethyl acetate/hexanes to 4Q% ethyl acetate/hexanes. EXAMPLE 416C tert-butyl 4-(4-chlorophenyl)-3-((4-(3-(6-fluoro-lH-indol-5-yloxy)-4-(methoxycarbonyl)phenyl)piperazin-l-yl)methyl)-5,6-dihydropyridine-l(2H)-carboxylate The title compound was prepared by substituting EXAMPLE 416B for 4'-chlorobiphenyl-2-carboxaldehyde and EXAMPLE 154C for tert-butyl piperazine-1-carboxylate in EXAMPLE lA. EXAMPLE 416D 4-(4-(( l-(tert-butoxycarbonyl)-4-(4-chlorophenyl)-1,2,5,6-tetrahydropyridin-3- yl)methyl)piperazin-l-yl)-2-(6-fluoro-lH-indol-5-yloxy)benzoicacid The title compound was prepared by substituting EXAMPLE 416C for EXAMPLE 38G in EXAMPLE 38H. 590 EXAMPLE 416E tert-butyl5-[(4-{4-[({5-chloro-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)carbamoyl]-3-[(6-fluoro-lH-indol-5-yl)oxy]phenyl}piperazin-l-yl)methyl]-4-(4-chlorophenyl)-3,6-dihydropyridine-l(2H)-carboxylate The title compound was prepared by substituting EXAMPLE 416D for EXAMPLE IF and EXAMPLE 326A for EXAMPLE IG in EXAMPLE IH. 'H NMR (300 MHz, dimethylsulfoxide-dfi) 5 1L21 (s, IH), 8.60 (m, IH), 8.29 (m, IH), 7.54 (d, IH), 7.35 (m, 5H), 7.14 (m, 2H), 6.67 (m, IH), 6.42 (m, IH), 6.09 (m, IH), 4.52 (d, 2H), 3.93 (m, 2H), 3.74 (m, 2H), 3.58 (m, IH), 3.47 (m, IH), 3.02 (m, 4H), 2.83 (m, 4H), 2.27 (m, 6H), L83 (m, 5H), L38 (s, 9H). EXAMPLE 417 N-({5-chloro-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- {[4-(4-chloiophenyl)-1 -(1,3-difluoropropan-2-yl)-1,2,5,6-tetrahydropyridin-3- yl]methyl} piperazin-1 -yl)-2-[(6-fluoro-1 H-indol-5-yl)oxy]benzamide EXAMPLE 417A N-(5-chloro-6-((4-fluorotetrahydro-2H-pyran-4-yl)methoxy)pyridin-3-ylsulfonyl)-4-(4-((4- (4-chlorophenyl)-l ,2,5,6-tetrahydropyridin-3-yl)methyl)piperazin- l-yl)-2-(6-fluoro- IH- indol-5-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 416E for EXAMPLE lA in EXAMPLE IB. EXAMPLE 417B N-({5-chloro-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- {[4-(4-chlorophenyl)-1 -(1,3-difluoropropan-2-yl)-1,2,5,6-tetrahydropyridin-3- yl]methyl} piperazin-1 -yl)-2-[(6-fluoro-1 H-indol-5-yl)oxy]benzamide The title compound was prepared by substituting EXAMPLE 417A for tert-butyl piperazine-1-carboxylate and l,3-difluoropropan-2-one for 4'-chlorobiphenyl-2-carboxaldehyde in EXAMPLE lA. 'H NMR (300 MHz, dimethylsulfoxide-de) 6 8.57 (m, IH), 8.26 (m, IH), 7.53 (d, IH), 7.36 (m, 4H), 7.26 (m, IH), 7.11 (m, 2H), 6.64 (dd, IH), 6.39 (m, IH), 6.08 (m, IH), 4.70 (m, 2H), 4.59 (m, 2H), 4.52 (d, 2H), 3.74 (m, 4H), 3.57 (m, 4H), 3.02 (m, 4H), 2.83 (m, 4H), 2.27 (m, 6H), 1.83 (m, 4H). 591 EXAMPLE 418 4-(4- {[2-(4-chloropheny l)-4,4-(iimethylcyclohex-1 -en-1 -yl]methyl ] piperazin-1 -yl)-2- [(6- fluoro-lH-indazol-4-yl)oxy]-N-[(4-{[(4-fluorotetrahydro-2H-pyran-4-yl)methyl]amino}-3- nitrDphenyl)sulfonyl]benzamide EXAMPLE 418A The title compound was prepared by substituting EXAMPLE 414F for EXAMPLE IF and EXAMPLE 337D for EXAMPLE IG in EXAMPLE IH. EXAMPLE 41 SB 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-[(6- fluoro- lH-indazol-4-yl)oxy]-N-[(4- {[(4-fluorotetrahydro-2H-pyran-4-yl)methyl]amino} -3- nitrophenyl)sulfonyl]benzamide The title compound was prepared by substituting EXAMPLE 4 ISA for EXAMPLE 414H in EXAMPLE 4141. ^H NMR (500MHz, dimethylsulfoxide-de) 5 13.09 (s, IH), 8.58 (s, IH), 8.33 (d, IH), 7.77 (s, IH), 7.54-7.58 (m, IH), 7.36 (d, 2H), 7.04-7.10 (m, 3H), 6.89 (dd, IH), 6.80 (d, IH), 6.60 (s, IH), 5.87 (dd, IH), 3.70-3.78 (m, 4H), 3.51-3.57 (m, 2H), 3.21 (s, 4H), 2.81 (s, 2H), 2.18-2.33 (m, 6H), 1.98 (s, 2H), 1.75-1.86 (m, 4H), 1.41 (t, 2H), 0.94 (s, 6H). EXAMPLE 419 N-( {5-chloro-6- [(trans-4-hydroxycyclohexyl)raethoxy]pyridin-3-yl} sulfonyl)-4-(4- {[2-(4- chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-[(7-fluoro-lH- indazol-4-yl)oxy]benzamide EXAMPLE 419A 6-(benzyloxy)-2,3-difluorobenzaldehyde A mixture of 2,3-difluoro-6-hydroxybenzaldehyde (0.93 g), (bromomethyl)benzene (1.11 g) and potassium carbonate (1.22 g) in N,N-dimethylformamide (15 mL) was heated at 70 °C overnight. After cooling to room temperature, the reaction mixture was partitioned between water and ethyl acetate. The organic layer was separated, and the aqueous layer was extracted with additional ethyl acetate three times. The combined organic layers were washed 592 with brine, dried over MgS04, filtered, and concentrated. The residue was purified by flash chromatography on silica gel to give the title compound. EXAMPLE 419B 4-(benzyloxy)-7-fluoro-lH-indazole A mixture of EXAMPLE 419A (1.45 g), o-methylhydroxylamine, hydrochloric acid (0.488 g) and potassium carbonate (0.888 g) in dimethoxyethane (10 mL) was stirred at room temperature for 3 hours. The solvent was partially removed. To this solution was added hydrazine hydrate (5 mL). The reaction mixture was heated under reflux (110 °C) overnight. The solvent was removed, and the residue was partitioned between water and ethyl acetate. The aqueous layer was extracted with additional ethyl acetate three times. The combined organic layers were washed with brine, dried over MgS04, filtered, and concentrated. The residue was purified by flash chromatography on silica gel to provide the title compound. EXAMPLE 419C 4-(benzyloxy)-7-fluoro-l-((2-(trimethylsilyl)ethoxy)methyl)-lH-indazole The title compound was prepared by substituting EXAMPLE 418B for EXAMPLE 414A in EXAMPLE 414B. EXAMPLE 419D 7-fluoro-1 -((2-(trimethylsilyl)ethoxy)methyl)-1 H-indazol-4-ol A mixttire of EXAMPLE 419C (1.25 g) and 5% palladium on carbon (0.35 g) in ethanol (20 mL) was treated with a balloon of hydrogen. The reaction mixture was stirred overnight. The soUd was filtered off. The filtrate was concentrated. The residue was purified by flash chromatography on silica gel to give the title compound. EXAMPLE 419E methyl 4-fluoro-2-(7-fluoro-1 -((2-(trimethylsilyl)ethoxy)methyl)- lH-indazol-4- yloxy)benzoate The title compound was prepared by substituting EXAMPLE 419D for 2-methyl-5-indolol and methyl 2,4-difluorobenzoate for ethyl 2,4-difluorobenzoate in EXAMPLE 3A. 593 EXAMPLE 419F methyl 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-2-(7-fluoro-l-((2-(trimethylsilyl)ethoxy)methyl)-lH-indazol-4-yloxy)benzoate The title compound was prepared by substituting EXAMPLE 419E for EXAMPLE 3A in EXAMPLE 3G. EXAMPLE 419G The title compound was prepared by substituting EXAMPLE 419F for EXAMPLE IE in EXAMPLE IF. EXAMPLE 419H This EXAMPLE was prepared by substituting EXAMPLE 419G for EXAMPLE IF and EXAMPLE 4140 for EXAMPLE IG in EXAMPLE IH. EXAMPLE 4191 N-({5-chloro-6-[(trans-4-hydroxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-[(7-fluoro-lH- indazol-4-yl)oxy]benzamide EXAMPLE 419H (185 mg) was dissolved in trifluoroacetic acid (1.8 mL) and water (0.2 mL) and stirred at room temperature for 90 minutes. The solvents were removed under vacuum, the residue was dissolved in 1,4-dioxane (2 mL) and treated with IM sodium hydroxide (1 mL), and the solution was stirred at room temperature for 30 minutes. The solvents were removed, and the residue was purified by reverse phase Gilson Prep HPLC system with a Phenomenex prep column (Luna, 5 \i, C18(2), 250X21.20 mm, 5 A) eluting with 20-80% acetonitrile in water with 0.1% trifluoroacetic acid. Fractions containing product were concentrated, and the concentrate was diluted with dichloromethane, neutralized with aqueous NaHCOs, dried over Na2S04, filtered, and concentrated. H NMR (500MHz, dimethylsulfoxide-de) 6 13.66 (s, IH), 8.20 (s, IH), 7.92 (s, IH), 7.85 (s, IH), 7.57 (d, IH), 7.37 (d, 2H), 7.06 (d, 2H), 6.88 (dd, IH), 6.78 (d, IH), 6.52 (s, IH), 6.05 (dd, IH), 4.53 (s, IH), 4.17 (d, 2H), 3.15 (br s, 4H), 2.18-2.23 (m, 4H), 1.99 (s, 2H), 1.70-1.86 (m, 6H), 1.42 (t, 2H), 1.05-1.15 (m, 4H), 0.94 (s, 6H). 594 EXAMPLE 420 N-({5-chloro-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-[(7-fluoro- lH-indazol-4-yl)oxy]benzamide EXAMPLE 420A N-(5-chloro-6-((4-fluoiotetrahydro-2H-pyran-4-yl)methoxy)pyridin-3-ylsulfonyl)-4-(4-((2- (4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)-2-(7-fluoro-1 -((2- (trimethylsilyl)ethoxy)methyl)-lH-indazol-4-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 419G for EXAMPLE IF and EXAMPLE 326A for EXAMPLE IG in EXAMPLE IH. EXAMPLE 420B N-({5-chloro-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-[(7-fluoro- 1 H-indazol-4-yl)oxy]benzamide The title compound was prepared by substituting EXAMPLE 420A for EXAMPLE 419H in EXAMPLE 419L ^H NMR (500MHz, dimethylsulfoxide-de) 5 13.64 (s, IH), 8.20 (s, IH), 7.89 (s, IH), 7.58 (d, IH), 7.37 (d, 2H), 7.07 (d, 2H), 6.88 (dd, IH), 6.78 (dd, IH), 6.51 (d, IH), 6.04 (dd, IH), 4.50 (d, 2H), 3.75-3.80 (m, 2H), 3.57-3.63 (m, 2H), 3.19 (br s, 4H), 2.93 (br s, 2H), 2.18-2.33 (m, 4H), 1.99 (s, 2H), 1.81-1.92 (m, 4H), 1.42 (t, 2H), 0.94 (s, 6H). EXAMPLE 421 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1- en-l-yl]methyl)piperazin- l-yl)-N-{ [3-nitro-4-({ [4-(oxetan-3-yl)morpholin-2- yl]methyl} amino)phenyl]sulfonyl} benzamide EXAMPLE 421A tert-butyl (4-(oxetan-3-yl)morpholin-2-yl)methyIcarbamate To a solution of tert-butyl morpholin-2-ylmethylcarbamate (0.50 g) in dichloromethane (5 mL) was added oxetan-3-one (0.20 g). After stirring for 5 minutes, sodium triacetoxyborohydride (0.735 g) was added. After stirring for 2 hours, the reaction 595 was diluted with dichloromethane (50 mL) and quenched with saturated NaHCOa solution (50 mL). The organic layer was separated, washed with brine (40 mL), dried over magnesium sulfate, filtered, and concentrated. Silica gel chromatography (Reveleris 80 g) eluting with a gradient of 0.5% to 5% methanol/dichloromethane over 40 minutes (flow = 40 ml/minute) gave the title compound. EXAMPLE 42IB (4-(oxetan-3-yl)morpholin-2-yl)methanamine The title compound was prepared by substituting EXAMPLE 421A for EXAMPLE lA in EXAMPLE IB. EXAMPLE 421C 3-nitro-4-((4-(oxetan-3-yl)morpholin-2-yl)methylamino)benzenesulfonamide To a solution of EXAMPLE 421B (5 mL) and diisopropylethylamine (1.24 mL) in tetrahydrofuran (5 mL) was added 3-nitro-4-((4-(oxetan-3-yl)morpholin-2-yl)methylamino)benzenesulfonamide (0.45 g). The reaction was stirred overnight, concentrated, loaded onto sihca gel (Reveleris 80 g) and eluted using a gradient of 0.75% to 7.5% methanol/dichloromethane over 40 minutes (flow = 40 ml/minute) to give the title compound. EXAMPLE 42 ID 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-l-yl]methyl}piperazin-l-yl)-N-{[3-nitro-4-({[4-(oxetan-3-yl)morpholin-2- yljmethyl} amino)phenyl]sulfonyl} benzamide The title compound was prepared by substituting EXAMPLE 318H for EXAMPLE IF and EXAMPLE 421C for EXAMPLE IG in EXAMPLE IH. 'H NMR (300 MHz, dimethylsulfoxide-de) 8 11.48 -11.16 (m, IH), 8.63 (t, IH), 8.58 (d, IH), 7.92 - 7.82 (m, IH), 7.74 (d, IH), 7.44 (d, IH), 7.40 - 7.30 (m, 3H), 7.24 - 7.16 (m, IH), 7.06 (d, 2H), 6.73 - 6.58 (m, IH), 6.25 - 6.10 (m, 3H), 4.53 (d, 2H), 4.45 (d, 2H), 3.93 - 3.82 (m, IH), 3.82 - 3.71 (m, IH), 3.63 - 3.51 (m, 2H), 3.51 - 3.38 (m, 2H), 3.12 (s, 4H), 2.86 - 2.66 (m, 3H), 2.62 - 2.54 (m, IH), 2.25 (d, 6H), 1.97 (s, 3H), 1.88 - 1.75 (m, IH), 1.40 (s, 2H), 0.94 (s, 6H). 596 EXAMPLE 422 4-(4-{[2-(4-chlorophenyI)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-[(6-fluoro-lH-indol-5-yl)oxy]-N-{[3-iiitro-4-({[4-(oxetan-3-yl)morpholin-2-yl]methyl} amino)phenyl]sulfonyl ] benzamide The title compound was prepared by substituting EXAMPLE 154E for EXAMPLE IF and EXAMPLE 421C for EXAMPLE IG in EXAMPLE IH. ^H NMR (300 MHz, dimethylsulfoxide-de) 8 1L21 (s, 2H), 8.69 - 8.52 (m, 2H), 7.88 (dd, IH), 7.50 (d, IH), 7.41 -7.25 (m, 5H), 7.15 (d, IH), 7.08 - 6.97 (m, 2H), 6.65 (dd, IH), 6.43 - 6.36 (m, IH), 6.09 (s, IH), 4.54 (t, 2H), 4.45 (td, 2H), 3.84 (s, IH), 3.75 (s, IH), 3.62 - 3.49 (m, 2H), 3.49 - 3.35 (m, 2H), 3.03 (s, 4H), 2.74 (d, 3H), 2.52 (dd, 2H), 2.16 (d, 6H), 1.95 (s, 4H), 1.80 (s, IH), 1.38 (t,2H), 0.92 (s,6H). EXAMPLE 423 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-[(7- fluoro-lH-indazol-4-yl)oxy]-N-[(4-{[(4-fluoiotetrahydro-2H-pyran-4-yl)methyl]amino}-3- nitrophenyl)sulfonyl]benzamide EXAMPLE 423A The title compound was prepared by substituting EXAMPLE 419G for EXAMPLE IF and EXAMPLE 337D for EXAMPLE 10 in EXAMPLE IH. EXAMPLE 423B 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l -en-1 -yl]methyl }piperazin-l -yl)-2-[(7- fluoro-lH-indazol-4-yl)oxy]-N-[(4-{[(4-fluorotetrahydro-2H-pyran-4-yl)methyllamino}-3- nitrophenyl)sulfonyl]benzamide The title compound was prepared by substituting EXAMPLE 423A for EXAMPLE 419H in EXAMPLE 4191. ^H NMR (500MHz, dimethylsulfoxide-dg) 6 13.66 (s, IH), 8.60 (t, IH), 8.39 (d, IH), 7.89 (dd, IH), 7.61 (dd, IH), 7.51 (d, IH), 7.34-7.37 (m, 2H), 7.15 (d, IH), 7.03-7.07 (m, 2H), 6.92 (dd, IH), 6.78 (dd, IH), 6.49 (d, IH), 6.13 (dd, IH), 3.70-3.79 (m, 4H), 3.50-3.57 (m, 2H), 3.15 (br s, 4H), 2.79 (br s, 2H), 2.17-2.25 (m, 6H), 1.97 (s, 2H), 1.76-1.85 (m, 4H), 1.40 (t, 2H), 0.93 (s, 6H). 597 EXAMPLE 424 N-({5-chloio-6-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]pyiidin-3-yl}sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-[(6-fluoio- lH-indazol-4-yl)oxy]benzamide EXAMPLE 424A 4-(hydroxymethyl)-1 -methylcyclohexanol 4-(Hydroxymethyl)cyclohexanone (800 mg) in tetrahydrofuran (15 mL) was treated with 3 M methylmagnesium chloride in tetrahydrofuran (6.24 mL) at 0°C. The reaction was warmed to room temperature over 2 hours and quenched with methanol and water. The resulting mixture was concentrated and the residue was suspended in ethyl acetate. The precipitates were filtered off and the filtrate was concentrated. The residue was purified by chromatography, eluting with 0-100% ethyl acetate in hexane to provide the title compound. EXAMPLE 424B 5-chloro-6-((trans-4-hydroxy-4-methylcyclohexyl)methoxy)pyridine-3-sulfonamide EXAMPLE 424A (970 mg) and 5,6-dichloropyridine-3-sulfonamide (1.6 g) in N,N-dimethylformamide (8 mL) were treated with sodium hydride (1.8 g, 60%) at room temperature for 2 days. The reaction was quenched with water. The resulting mixture was neutralized with dUuted HCl, and extracted with ethyl acetate. The organic layer was dried over Na2S04, filtered, and concentrated. The residue was purified by a reverse phase chromatography, eluting with 30-45% acetonitrile in 0.1% trifluoroacetic acid water to provide the title compound. EXAMPLE 424C N-( {5 -chloro-6- [(trans-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3 -yl} sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-2-[(6-fluoro- lH-indazol-4-yl)oxy]benzamide A mixture of EXAMPLE 424B (88 mg), EXAMPLE 414F (157 mg), 4- dimethylaminopyridine (107 mg) and l-ethyl-3-[3-(dimethylamino)propyl]-carbodiimide hydrochloride (51 mg) in dichloromethane (6 mL) was stirred overnight and concentrated. The residue was dissolved in 1 M tetrabutyl ammonium fluoride solution in tetrahydrofuran (10 mL). The resulting mixture was refluxed for 8 hours and concentrated. The residue was purified by reverse phase Gilson HPLC, eluted with 40% - 70% acetonitrile in 0.1% 598 trifluoroacetic acid water over 40 minutes. The desired fractions were concentrated to remove acetonitrile, neutralized with NaHCOs and extracted with dichloromethane. The dichloTomethane layer was dried over Na2S04, filtered, concentrated and dried to provide the title compound, 'H NMR (500 MHz, dimethylsulfoxide-de) 5 13.12 (s, IH), 8.21 (s, IH), 7.80 (s, IH). 7.77 (s, IH), 7.61 (d, IH), 7.37 (d, 2H), 7.07 (d, 2H), 6.84 (dd, IH), 6.78 (d, IH), 6.63 (s, IH), 5.85 (d, IH), 4.19 - 4.29 (m, 3H), 3.11 - 3.25 (m, 2H), 2.19 (s, 2H), 2.00 (s, 2H), 1.69 - 1.84 (m, 3H), 1.56 (d, 2H), 1.34 - 1.47 (m, 4H), 1.16 -1.33 (m, 3H), 1.11 (s, 3H), 0.95 (s, 6H). EXAMPLE 4254-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 - yljmethyl Ipiperazin-1 -yl)-N- {[5-chloro-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3- yl]sulfonyl)-2-[(3-methyl-2-oxo-2,3-dihydro-lH-benzimidazol-4-yl)oxy]benzamide EXAMPLE 425A 2-(l-(bis(4-methoxyphenyl)methyl)-3-methyl-2-oxo-2,3-dihydro-//?-benzo[rf]imidazoI-4- yloxy)-A^-(5-ch]oro-6-((tetrahydro-2ff-pyran-4-yl)methoxy)pyridin-3-ylsulfonyl)-4-(4-((2-(4- chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)benzamide The title compound was prepared by substituting EXAMPLE 368H for EXAMPLE IF and EXAMPLE 303B for EXAMPLE IG in EXAMPLE IH. EXAMPLE 425B 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl }piperazin- l-yl)-N- {[5-chloro-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl)-2-[(3-methyl-2-oxo-2,3-dihydro-1 H-benzimidazol-4-yl)oxy]benzamide The title compound was prepared by substituting EXAMPLE 425A for EXAMPLE 3681 in EXAMPLE 368J. 'H NMR (500 MHz, pyridine-dj) 5 12.36 (s, IH), 9.13 (m, IH), 8.66 (d, IH), 8.02 (d, IH), 7.44 (d, 2H), 7.08 (d, 2H), 6.90 - 6.79 (m, 3H), 6.74 (d, IH), 6.52 (d, IH), 6.12 (m, IH), 4.26 (d, 2H), 3.97 (m, 2H), 3.65 (s, 3H), 3.31 (m, 2H), 3.20 (m, 4H), 2.81 (s, 2H), 2.29 (m, 2H), 2.23 (ra, 4H), 1.98 (m, 3H), 1.62 (m, 2H), 1.45 - 1.37 (m, 4H), 0.94 (s, 6H). 599 EXAMPLE 426 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N-( {4- [(4-fluoiotetrahydro-2H-pyran-4-yl)methoxy]-3-nitrophenyl} sulfonyl)-2- [(3-methyl-2-oxo- 2,3-dihydro-lH-benzimidazol-4-yl)oxy]benzamide EXAMPLE 426A 2-(l-(bis(4-methoxyphenyl)methyl)-3-methyl-2-oxo-2,3-dihydro-7H-benzo[rf]imidazol-4- yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)~iV-(4- ((4-fluorotetTahydro-2//-pyran-4-yl)methoxy)-3-nitrophenylsulfonyl)benzamide The tide compound was prepared by substituting EXAMPLE 368H for EXAMPLE IF and EXAMPLE 296D for EXAMPLE IG in EXAMPLE IH. EXAMPLE 426B 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-N-( {4- [(4-fluorotetrahydro-2H-pyran-4-yl)naethoxy]-3-nitrophenyl}sulfonyl)-2-[(3-methyl-2-oxo- 2,3-dihydro-1 H-benzimidazol-4-yl)oxy]benzamide The title compound was prepared by substituting EXAMPLE 426A for EXAMPLE 3681 in EXAMPLE 368J. 'H NMR (500 MHz, pyridine-ds) 5 12.28 (s, IH), 8.96 (d, IH), 8.62 (dd, IH), 8.02 (d, IH), 7.44 (d, 2H), 7.37 (d, IH), 7.08 (d, 2H), 6.86 - 6.80 (m, 3H), 6.76 (m, IH), 6.51 (dd, IH), 6.02 (m, IH), 4.40 (d, 2H), 3.86 - 3.70 (m, 4H), 3.64 (s, 3H), 3.20 (m, 4H), 2.81 (s, 2H), 2.29 (m, 2H), 2.23 (m, 4H), 2.06 - 1.92 (m, 6H), 1.40 (t, 2H), 0.94 (s, 6H). EXAMPLE 427 4-(4- {[2-(4-chlorophenyl)-4,4-dimediylcyclohex-1 -en-1 -yl]methyl Jpiperazin-1 -yl)-N-[(4- {[(trans-4-methoxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-[(3-methyl-2-oxo- 2,3-dihydro-lH-benzimidazol-4-yl)oxy]benzamide EXAMPLE 427A 2-(l-(bis(4-methoxyphenyl)methyl)-3-methyl-2-oxo-2,3-dihydro-7f/-benzo[rf]imidazol-4- yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex- l-enyl)methyl)piperazin-1 -yl)~A^-(4- ((trans-4-methoxycyclohexy)methylamino)-3-nitrophenylsulfonyl)benzamide The tide compound was prepared by substituting EXAMPLE 368H for EXAMPLE IF and EXAMPLE 345B for EXAMPLE IG in EXAMPLE IH. 600 EXAMPLE 427B 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl }piperazin-1 -yl)-N-[(4-{[(trans-4-methoxycyclohexyl)methyl]amino}-3-mtrophenyl)sulfonyl]-2-[(3-methyl-2-oxo-2,3-dihydro-lH-benziinidazol-4-yl)oxy]benzamide The title compound was prepared by substituting EXAMPLE 427A for EXAMPLE 3681 in EXAMPLE 368J. 'H NMR (500 MHz pyridine-ds) 6 12.33 (s, IH), 9.19 (d, IH), 8.70 (t, IH), 8.43 (dd, IH), 8.01 (d, IH), 7.44 (d, 2H), 7.07 (d, 2H), 6.98 (d, IH), 6.85 - 6.79 (m, 3H), 6.74 (d, IH), 6.51 (dd, IH), 5.83 (m, IH), 3.65 (s, 3H), 3.27 (s, 3H), 3.19 (m, 6H), 3.01 (m, IH), 2.81 (s, 2H), 2.29 (m, 2H), 2.23 (m, 4H), 2.04 (m, 2H), 1.98 (s, 2H), 1.81 (m, 2H), 1.53 (m, IH), 1.40 (t, 2H), 1.18 (m, 2H), 1.03 - 0.90 (m, 8H). EXAMPLE 428 2-[(3-amino-lH-indazol-4-yl)oxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1- yl]methyl)piperazin-l-yl)-N-[(4-{[(4-fluorotetrahydro-2H-pyran-4-yl)methyl]amino}-3- nitrophenyl)sulfonyl]benzamide EXAMPLE 428A methyl 2-(2-cy ano-3 -fluorophenoxy)-4-fluorobenzoate A mixture of methyl 4-fluoro-2-hydroxybenzoate (10.5 g), 2,6-difluorobenzonitrile (17.17 g) and CS2CO3 (22.12 g) in dimethyl sulfoxide (150 mL) was heated at 90 °C for 2 hours. After cooling, the reaction mixture was partitioned between water and ethyl acetate. The aqueous layer was extracted with additional ethyl acetate three times. The combined organic layers were washed with brine, dried over MgS04, filtered, and concentrated. The solid was triturated with 7:3 hexanes/ ethyl acetate (300 mL). The filtrate was concentrated, and the residue was purified by flash chromatography on silica gel eluting from 15%-25% ethyl acetate in hexanes to give the title compound. EXAMPLE 428B methyl 2-(3-amino- lH-indazol-4-yloxy)-4-fluorobenzoate A mixture of EXAMPLE 428A (14.8 g), hydrazine monohydrate (2.74 mL) and N-ethyl-N-isopropylpropan-2-amine (18 mL) in dioxane (150 mL) was heated at 90 °C overnight. The solvent was removed, and the residue was partitioned between water and ethyl 601 acetate. The aqueous layer was extracted with additional ethyl acetate three times. The combined organic layers were washed with brine, dried over MgS04, filtered, and concentrated. The residue was purified by flash chromatography on silica gel eluting horn 80%-100% ethyl acetate in hexanes to give the title compound. EXAMPLE 428C methyl 2-(3-amino-1 H-indazol-4-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1- enyl)methyl)piperazin-1-yl)benzoate The title compound was prepared by substituting EXAMPLE 428B for EXAMPLE 3A in EXAMPLE 3G. EXAMPLE 428D 2-(3-amino-lH-indazo]-4-yloxy)-4-(4-((2-(4-ch]orophenyI)-4,4-dimethylcycIohex-l-enyl)methyl)piperazin-1 -yl)benzoic acid The title compound was prepared by substituting EXAMPLE 428C for EXAMPLE IE in EXAMPLE IF. EXAMPLE 428E 2-(3-(bis(tert-butoxycarbonyl)amino)-l-(tert-butoxycarbonyl)-lH-indazol-4-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)benzoic acid A mixture of EXAMPLE 428D (0.4 g), di-tert-butyl dicarbonate (0.492 g), triethylamine (2.0 mL) and 4-dimethylaminopyridine (0.042 g) in tetrahydrofuran (10 mL) was stirred overnight. The solvent was removed, and the residue was partitioned between water and ethyl acetate. The aqueous layer was extracted with additional ethyl acetate three times. The combined organic layers were washed with brine, dried over MgS04, filtered, and concentrated to give the title compound which was used for the next reaction without further purification. EXAMPLE 428F tert-butyl 3-(bis(tert-butoxycarbonyl)amino)-4-(5-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)-2-(4-((4-fluorotetrahydro-2H-pyran-4-yl)methylamino)-3-nitrophenylsulfonylcarbamoyl)phenoxy)-1 H-indazole-1 -carboxylate The title compound was prepared by substituting EXAMPLE 428E for EXAMPLE IF and EXAMPLE 337D for EXAMPLE IG in EXAMPLE IH. 602 EXAMPLE 428G 2-[(3-amino- lH-indazol-4-yl)oxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1- yljmethyl Ipiperazin- l-yl)-N-[(4- {[(4-fluorotetrahydro-2H-pyran-4-yl)methyl]amino} -3- nitrophenyl)sulfonyl]benzamide The crude product of EXAMPLE 428F (0.10 g) was treated with 1:1 dichloromethane/trifluoroacetic acid (10 mL). The reaction was stirred for 2 hours. The solvents were removed, and the residue was purified by reverse phase Gilson Prep HPLC system with a Phenomenex prep column (Luna, 5 \i, CI8(2), 250X21.20 mm, 5 A) eluting with 20-80% acetonitrile in water with 0.1% trifluoroacetic acid. Fractions containing product were concentrated, and the concentrate was diluted with dichloromethane, neutralized with aqueous NaHCO^, dried over Na2S04, filtered, and concentrated. H NMR (500MHz, dimethylsulfoxide-de) 5 11.47 (s, IH), 8.58 (t, IH), 8.40 (d, IH), 7.49-7.53 (m, 2H), 7.36 (d, 2H), 7.06 (d, 2H), 7.01 (d, IH), 6.88 (t, IH), 6.88 (d, 2H), 6.49 (d, IH), 5.69 (s, IH), 3.68-3.79 (m, 4H), 3.52-3.56 (m, 2H), 3.17 (br s, 4H), 2.81 (br s, 2H), 2.17-2.25 (m, 6H), 1.97 (s, 2H), 1.77-1.87 (m, 4H), 1.40 (t, 2H), 0.94 (s, 6H). EXAMPLE 429 2-[(3-amino-lH-indazol-4-yl)oxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1- yl]methyl}piperazin-l-yl)-N-({4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3- nitrophenyl} sulfonyl)benzamide EXAMPLE 429A tert-butyl3-(bis(tert-butoxycarbonyl)amino)-4-(5-(4-((2-(4-chlorophenyl)-4,4- dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)-2-(4-((4-fluorotetrahydro-2H-pyran-4- yl)methoxy)-3-nitrophenylsulfonylcarbamoyl)phenoxy)-lH-indazole-l-carboxylate The title compound was prepared by substituting EXAMPLE 428E for EXAMPLE IF and EXAMPLE 296D for EXAMPLE IG in EXAMPLE IH. EXAMPLE 429B 2-[(3-amino-lH-indazol-4-yl)oxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1- yl]methyl}piperazin-l-yl)-N-({4-[(4-fluorotetrahydro-2H-pyran-4-yI)methoxy]-3- nitrophenyl) sulfonyl)benzamide 603 The title compound was prepared by substituting EXAMPLE 429A for EXAMPLE 428F in EXAMPLE 428G. 'H NMR (500MHZ, dimethylsulfoxide-de) 6 n.47 (s, IH), 8.15 (d, IH), 7.83 (dd, IH), 7.53 (d, IH), 7.36 (d, 2H), 7.24 (d, IH), 7.06 (d, 2H), 6.93 (t, IH), 6.81 (d, 2H), 6.73 (s, IH), 6.46 (s, IH), 5.82 (br s, IH), 4.34 (d, 2H), 3.77-3.80 (m, 2H), 3.58-3.62 (m, 2H), 3.15 (br s, 4H), 2.81 (br s, 2H), 2.18-2.36 (m, 6H), 1.98 (s, 2H), 1.83-1.90 (m, 4H), 1.41 (t,2H), 0.94 (s,6H). EXAMPLE 430 2-[(3-amino-lH-indazol-4-yl)oxy]-N-({5-chloro-6-[(4-fluorotetrahydro-2H-pyran-4- yl)methoxy]pyridin-3-yl )sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1- yl]methyl}piperazin-l-yl)benzamide EXAMPLE 430A tert-butyl3-(bis(tert-butoxycarbonyl)amino)-4-(2-(5-chloro-6-((4-fluorotetrahydro-2H-pyran- 4-yI)methoxy)pyridin-3-ylsulfonylcarbamoyI)-5-(4-((2-(4-chlorophenyl)-4,4- dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)phenoxy)-1 H-indazole-1 -caiboxylate The title compound was prepared by substituting EXAMPLE 428E for EXAMPLE IF and EXAMPLE 326A for EXAMPLE 1G in EXAMPLE 1H. EXAMPLE 430B 2-[(3-amino-lH-indazol-4-yl)oxy]-N-({5-chloro-6-[(4-fluorotetrahydro-2H-pyran-4- yl)methoxy]pyridin-3-yl }sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1- yl]methyl}piperazin-l-yl)benzamide The title compound was prepared by substituting EXAMPLE 430A for EXAMPLE 428F in EXAMPLE 428G. ^H NMR (500MHz, dimethylsulfoxide-dg) 6 11.44 (s, IH), 8.31 (d, IH), 7.95 (d, IH), 7.55 (d, IH), 7.36 (d. 2H), 7.07 (d, 2H), 6.95 (br s, IH), 6.82 (d, 2H), 6.70 (br s, IH), 6.43 (s, IH), 5.91 (br s, IH), 4.49 (d, 2H), 3.76-3.79 (m, 2H), 3.56-3.61 (m, 2H), 3.08 (br s, 4H), 2.80 (br s, 2H), 2.16-2.30 (m, 6H), 1.98 (s, 2H), 1.81-1.90 (m, 4H), 1.41 (t, 2H), 0.94 (s, 6H). 604 EXAMPLE 431 2-[(3-aniino-lH-indazol-4-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl }piperazin-1 -yl)-N-({ 3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)benzamide EXAMPLE 431A tert-butyl3-(bis(tert-butoxycarbonyl)amino)-4-(5-(4-((2-(4-chlorophenyl)-4,4- dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-2-(3-nitro-4-((tetrahydro-2H-pyran-4- yl)methylainino)phenylsulfony IcarbamoyOphenoxy)-1 H-indazole-1 -carboxylate The title compound was prepared by substituting EXAMPLE 428E for EXAMPLE IF in EXAMPLE IH. EXAMPLE 43 IB 2-[(3-amino-lH-indazol-4-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-N-({3-nitro-4-[(tetrahydio-2H-pyran-4-ylniethyl)amino]phenyl) sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 431A for EXAMPLE 428F in EXAMPLE 428G. ^H NMR (500MHz, dimethylsulfoxide-dg) 6 11.48 (s, IH), 8.55 (t, IH), 8.39 (d, IH), 7.46-7.51 (m, 2H), 7.35 (d, 2H), 7.06 (d, 2H), 6.77-6.90 (m, 4H), 6.49 (s, IH), 5.67 (br s, IH), 3.84-3.90 (m, 2H), 3.16 (br s, 4H), 2.79 (br s, 2H), 2.17-2.33 (m, 6H), 1.97 (s, 2H), 1.61-1.66 (m, 2H), 1.41 (t, 2H), 1.23-1.28 (m, 2H), 0.94 (s, 6H). EXAMPLE 432 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-[(4-{[4-fluoro-l-(oxetan-3-yl)piperidin-4-yl]methoxy}-3- nitrophenyl)sulfonyl]benzamide EXAMPLE 432A 4-((4-fluoro-l-(oxetan-3-yl)piperidin-4-yl)methoxy)-3-nitrobenzenesulfonamide To a solution of EXAMPLE 341C (72 mg) in tetrahydrofuran (1.5 mL) and acetic acid (0.5 mL) was added oxetan-3-one (14 mg) and MP-cyanoborohydride (2.38 mmol/g, 162 mg). The mixture was stirred at room temperature overnight. The reaction was then filtered 605 and the filtrate was concentrated under vacuum. The residue was slurried in ether and the product was collected by filtration. EXAMPLE 432B 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-1 -yljmethyl} piperazin-1 -yl)-N-[(4- {[4-fluoro-1 -(oxetan-3-yl)piperidin-4-yl]methoxy} -3- nitrophenyl)sulfonyl]benzamide The title compound was prepared by substituting EXAMPLE 432A for EXAMPLE IG and EXAMPLE 318H for EXAMPLE IF in EXAMPLE IH. 'H NMR (400 MHz, dimethylsulfoxide-de) 5 8.31 (m, IH), 8.05 (m, IH), 7.68 (d, IH), 7.49 (m, 2H), 7.37 (d, 2H), 7.29 (m, IH), 7.08 (d, 2H), 6.65 (dd, IH), 6.24 (d, IH), 6.07 (s, 2H), 4.55 (m, 2H), 4.45 (m, 2H), 4.37 (d, 2H), 3.47 (m, IH), 3.12 (m, 4H), 2.83 (m, 2H), 2.59 (m, 2H), 2.29 (m, 4H), 2.17 (m, 2H), 2.08 (m, 2H), 1.90 (m, 5H), 1.76 (m, IH), 1.41 (t, 2H), 0.94 (s, 6H). EXAMPLE 433 4-(4- {[2-(4-chloropheny l)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl} piperazin-1 -yl)-2- [(6- fluoro-1 H-indazol-4-yl)oxy]-N-( {4- [(4-fluorotetrahydro-2H-pyran-4-yl)methoxy] -3 - nitrophenyl) sulfonyl)benzamide EXAMPLE 433A 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)-2-(6-fluoro- l-((2-(trimethylsilyl)ethoxy)methyl)-lH-indazol-4-yloxy)-N-(4-((4-fluorotetrahydro-2H- pyran-4-yl)methoxy)-3-nitrophenylsulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 414F for EXAMPLE IF and EXAMPLE 296D for EXAMPLE IG in EXAMPLE IH. EXAMPLE 433B 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-[(6- fluoro- lH-indazol-4-yl)oxy]-N-( {4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3- nitrophenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 433A for EXAMPLE 414H in EXAMPLE 4141. 'H NMR (500MHz, dimethylsulfoxide-dg) 5 13.11 (s, IH), 8.09 (s, IH), 7.75-7.81 (m, 2H), 7.61-7.62 (m, IH), 7.37 (d, 2H), 7.29 (br s, IH), 7.07 (d, 2H), 606 6.81-6.83 (m, IH), 6.60 (s, IH), 5.87 (d, IH), 4.34 (d, 2H), 3.77-3.781 (m, 2H), 3.58-3.63 (m, 2H), 2.81 (br s, 2H), 2.19-2.37 (m, 4H), 1.99 (s, 2H), 1.85-1.89 (m, 4H), 1.42 (t, 2H), 0.94 (s, 6H). EXAMPLE 434 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-1 -yl]methyl} piperazin-1 -yl)-N- [(4- {[(trans-4-hydroxy-4- methylcyclohexyl)methyl] amino} -3-nitrophenyl)sulfonyl]benzamide EXAMPLE 434A tert-butyl (4-hydroxy-4-methylcyclohexyl)methylcarbamate To a vigorous stirring solution of tert-butyl (4-oxocyclohexyl)methylcarbamate (1.7 g) in tetrahydrofuran (40 mL) at -78°C was dropwise added 1.6 M methyllithium (14.02 mL) in ether. After completion of the addition, the mixture was stirred at -78°C for 1.2 hours and poured into a cold aqueous NH4CI solution. The resulting naixture was extracted with dichloromethane (3x 100 mL) and the organic layer was dried over Na2S04, filtered and concentrated. The residue was dissolved in dichloromethane and loaded onto an Analogix purification system, eluted with 0 - 50% ethyl acetate in dichloromethane to provide the title compound. EXAMPLE 434B 4-(aminomethyl)-1 -methylcyclohexanol EXAMPLE 434A (1.3 g) in dichloromethane (5 mL) at 0°C was treated with trifluoroacetic acid (2.1 mL) and a few drops of water for 1 hours. The reaction mixture was concentrated and the residue was directly used for next step. EXAMPLE 434C 4-((trans-4-hydroxy-4-methylcyclohexyI)methylamino)-3-nitrobenzenesulfonamide EXAMPLE 434B (732 mg) and 4-fluoro-3-nitrobenzenesulfonamide (1.1 g) in tetrahydrofuran (15 mL) was treated with triethylamine overnight. The reaction mixture was concentrated and the residue was purified by a reverse phase chromatography, eluting with 30% - 50% CH3CN in 0.1% trifluoroacetic acid water solution to provide the title compound. 607 EXAMPLE 434D 4-((cis-4-hydroxy-4-methylcyclohexyl)methylamino)-3-nitrobenzenesulfonamide EXAMPLE 434B (732 mg) and 4-fluoro-3-nitrobenzenesulfonamide (L1 g) in tetrahydrofuran (15 mL) was treated with TEA overnight. The reaction mixture was concentrated and the residue was purified by a reverse phase cliromatography, eluting with 30% - 50% CH3CN in 0.1% trifluoroacetic acid water solution to provide the title compound. EXAMPLE 434E 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en- l-yl]methyl} piperazin-1 -yl)-N-[(4- {[(trans-4-hydroxy-4-methylcyclohexyl)methyl]amino} -3-nitrophenyl)sulfonyl]benzamide The title compound was prepared as described in EXAMPLE 1 lOF by replacing EXAMPLE llOE and EXAMPLE IG with EXAMPLE 318H and EXAMPLE 434C, respectively. 'H NMR (400 MHz, dimethylsulfoxide-de) 5 11.32 (s, IH), 8.56 - 8.63 (m, 2H), 7.86 (dd, IH), 7.75 (d, IH), 7.44 (d, IH), 7.40 (d, IH), 7.36 (d, 2H), 7.19 (d, IH), 7.06 (d, 2H), 6.65 (dd, IH), 6.18 (s, 3H), 4.23 (s, IH), 3.12 (s, 4H), 2.79 (s, 2H), 2.24 (s, 4H), 2.17 (s, 2H), 1.97 (s, 2H), 1.63 - 1.74 (m, 3H), 1.54 (d, 2H), 1.28 - 1.43 (m, 4H), 1.07 - 1.19 (m, 5H), 0.94 (s, 6H). EXAMPLE 435 2-[(3-amino-lH-indazol-4-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-N-[(4-{[(trans-4-methoxycyclohexyl)methyl]amino}-3- nitrophenyl)sulfonyl]benzamide EXAMPLE 435A tert-butyl3-(bis(tert-butoxycarbonyl)amino)-4-(5-(4-((2-(4-chlorophenyl)-4,4- dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)-2-(4-((trans-4- methoxycyclohexyl)methylamino)-3-nitrophenylsulfonylcarbamoyl)phenoxy)-lH-indazole- 1-caiboxylate The title compound was prepared by substituting EXAMPLE 428E for EXAMPLE IF and EXAMPLE 345B for EXAMPLE IG in EXAMPLE IH. 608 EXAMPLE 435B 2-[(3-amino-lH-indazol-4-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-N-[(4-{[(trans-4-methoxycyclohexyl)methyl]amino}-3- nitrophenyl)sulfonyl]benzamide The title compound was prepared by substituting EXAMPLE 435A for EXAMPLE 428F in EXAMPLE 428G. ^H NMR (500MHz, dimethylsulfoxide-de) 8 1L47 (s, IH), 8.52 (br s, IH), 8.38 (d, IH), 7.50 (d, IH), 7.44 (br s, IH), 7.35 (d, 2H), 7.06 (d, 2H), 6.76-6.90 (m, 4H), 6.49 (s, IH), 5.67 (br s, IH), 3.23 (s. 3H), 2.77 (br s, 2H), 2.12-2.33 (m, 6H), L97-2.02 (m, 4H), L78-L81 (m, 2H), L41 (t, 2H), L03-L08 (m, 4H), 0.94 (s, 6H). EXAMPLE 436 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-l-yl]methyl}piperazin-l-yl)-N-({4-[(cis-4-hydroxy-4-methylcyclohexyl)methoxy]-3- nitrophenyl} sulfonyl)benzamide EXAMPLE 436A 4-((cis-4-hydroxy-4-methylcyclohexyl)methoxy)-3-nitrobenzenesulfonamide EXAMPLE 424A (732 mg) and 4-fluoro-3-nitrobenzenesulfonamide (L2 g) in tetrahydrofuran (40 mL) were treated with 60% sodium hydride (L6 g) for 3 days. The reaction was quenched with water. The resulting mixture was neutralized with diluted HCl, and extracted with ethyl acetate. The organic layer was dried over Na2S04, filtered, and concentrated. The residue was purified by a reverse phase chromatography, eluting with 30-50% acetonitrile in 0.1% trifluoroacetic acid water to provide the title compound. EXAMPLE 436B 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1- en-l-yl]methyl}piperazin-l-yl)-N-({4-[(cis-4-hydroxy-4-methylcyclohexyl)methoxy]-3- nitrophenyl) sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 318H for EXAMPLE IF and EXAMPLE 436A for EXAMPLE IG in EXAMPLE IH. 'H NMR (500 MHz, dimethylsulfoxide-de) 6 8.34 (d, IH), 8.05 (d, IH), 7.73 (d, IH), 7.51 (m, IH), 7.45 (m, IH), 7.37 (m, 3H), 7.08 (d, 2H), 6.65 (dd, IH), 6.18 (m, 3H), 4.07 (d, 2H), 3.95 (s, IH), 3.14 (m, 609 4H), 2.85 (m, IH), 2.31 (m, 3H), 2.17 (m, 2H), 1.98 (m, 2H), 1.70 (m, IH), 1.56 (m, 4H), 1.41 (m, 4H), 1.28 (m, 2H), 1.10 (s, 3H), 0.94 (s, 6H). EXAMPLE 437 2-[(6-amino-5-chloiiopyridin-3-yl)oxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 - en-l-yl]methyl}piperazin-l-yl)-N-[(4-{[(cis-4-hydroxy-4-methylcyclohexyl)methyl]amino}- 3-nitrophenyl)sulfonyl]benzamide The tide compound was prepared as described in EXAMPLE 1 lOF by replacing EXAMPLE llOE and EXAMPLE IG with EXAMPLE 318H and EXAMPLE 434D, respectively. 'H NMR (400 MHz, dimethylsulfoxide-de) 6 11.31 (s, IH), 8.63 (t, IH), 8.59 (d, IH), 7.86 (dd, IH), 7.76 (d, IH), 7.45 (d, IH), 7.41 (d, IH), 7.35 (d, 2H), 7.19 (d, IH), 7.06 (d, 2H), 6.65 (dd, IH), 6.14 - 6.23 (m, 3H), 3.95 (s, IH), 3.27 - 3.32 (m, 4H), 3.12 (s, 4H), 2.79 (s, 2H), 2.25 (s, 4H), 2.17 (s, 2H), 1.97 (s, 2H), 1.46 -1.60 (m, 5H), 1.33 -1.44 (m, 4H), 1.19 -1.30 (m, 2H), 1.08 (s, 3H), 0.94 (s, 6H). EXAMPLE 438 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-N- {[3 - chloro-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]sulfonyl}-2-[(3-methyl-2-oxo-2,3- dihydro-1 H-benzimidazol-4-yl)oxy Jbenzamide EXAMPLE 438A 3-chloro-4-((tetrahydro-2H-pyran-4-yl)methoxy)benzene sulfonamide The title compound was prepared by substituting (tetrahydro-2H-pyran-4-yl)methanol for EXAMPLE 296C in EXAMPLE 404A. EXAMPLE 438B 2-(l-(bis(4-methoxyphenyl)methyl)-3-methyl-2-oxo-2,3-dihydro-7//-benzo[rf]imidazol-4- yloxy)-A^-(3-chloio-4-((tetrahydro-2ff-pyran-4-yl)methoxy)phenylsulfonyl)-4-(4-((2-(4- chloropheny l)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)benzamide The title compound was prepared by substituting EXAMPLE 368H for EXAMPLE IF and EXAMPLE 438A for EXAMPLE IG in EXAMPLE IH. 610 EXAMPLE 438C 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N- {[3 -chloro-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]sulfonyl}-2-[(3-methyl-2-oxo-2,3-dihydro-1 H-benzimidazol-4-yl)oxy]benzamide The title compound was prepared by substituting EXAMPLE 438B for EXAMPLE 3681 in EXAMPLE 368J. IH NMR (500 MHz, pyridine-ds) 6 12.35 (s, IH), 8.48 (d, IH), 8.35 (dd, IH), 8.01 (d, IH), 7.44 (d, 2H), 7.07 (d, 2H), 7.03 (d, IH), 6.91 - 6.84 (m, 2H), 6.79 (dd, IH), 6.72 (m, IH), 6.56 (dd, IH), 6.00 (m, IH), 3.98 (m, 2H), 3.82 (d, 2H), 3.62 (s, 3H), 3.32 (m, 2H), 3.19 (m, 4H), 2.81 (s, 2H), 2.29 (m, 2H), 2.22 (m, 4H), 1.98 (m, 3H), 1.66 (m, 2H), 1.49 - 1.38 (m, 4H), 0.94 (s, 6H). EXAMPLE 439 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl }piperazin-1 -yl)-N-[(4- {[(4-cyclopropylmorpholin-2-yl)methyl]amino)-3-nitrophenyl)sulfonyl]-2-[(3-methyl-2-oxo- 2,3-dLhydro-lH-benzimidazol-4-yl)oxy]benzamide EXAMPLE 439A 2-(l-(bis(4-methoxyphenyl)methyl)-3-methyl-2-oxo-2,3-dihydro-7H-benzo[cr|imidazol-4- yloxy)-4-(4-((2-(4-chloiophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)-A'-(4- ((4-cyclopropylmorpholin-2-yl)methylamino)-3-nitrophenylsulfonyl)benzaniide The title compound was prepared by substituting EXAMPLE 368H for EXAMPLE IF and EXAMPLE 369C for EXAMPLE IG in EXAMPLE IH. EXAMPLE 439B 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl jpiperazin-1 -yl)-N- [(4-{[(4-cyclopropylmorpholin-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-[(3-methyl-2-oxo-2,3-dihydro-lH-benzimidazol-4-yl)oxy]benzamide The title compound was prepared by substituting EXAMPLE 439A for EXAMPLE 3681 in EXAMPLE 368J. IH NMR (500 MHz, pyridine-dj) 6 12.25 (s, IH), 9.13 (d, IH), 8.94 (t, IH), 8.40 (dd, IH), 8.01 (d, IH), 7.44 (d, 2H), 7.09 - 7.05 (m, 3H), 6.82 - 6.75 (m, 4H), 6.49 (dd, IH), 5.84 (m, IH), 3.87 - 3.80 (m, 2H), 3.68 (s, 3H), 3.65 - 3.48 (m, 3H), 3.20 (m, 4H), 2.94 (m, IH), 2.81 (s, 2H), 2.68 (m, IH), 2.36 - 2.28 (m, 3H), 2.24 - 2.19 (m, 5H), 1.98 (s, 2H), 1.57 (m, IH), 1.40 (t, 2H), 0.94 (s, 6H), 0.43 - 0.36 (m, 4H). 611 EXAMPLE 440 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-l-yl]methyl}piperazin-l-yl)-N-{[3-nitro-4-(2-oxaspiro[3.5]non-7- ylmethoxy)phenyl]sulfonyl}benzamide EXAMPLE 440A diethyl 1,4-dioxaspiro[4.5]decane-8,8-dicarboxylate A 500 mL round-bottomed flask was charged with diisopropylamine (16 mL) and tetrahydrofuran (311 mL). The solution was cooled to -1^°C under N2 and n-butyllithium (2.5 M in hexanes, 44.8 mL)) was added. The reaction was stirred for 30 minutes at -78 °C and ethyl l,4-dioxaspiro[4.5]decane-8-carboxylate (20 g) was added as a tetrahydrofuran solution (ca. 10 mL). The mixture was stirred at -78 °C for 1 hour and ethyl chloroformate (9 mL) was added neat. After stirring at -78 °C for 10 minutes, the reaction was warmed to room temperature over 2 hours. The reaction was quenched with saturated aqueous NH4CI and diluted with diethyl ether. The layers were separated, the aqueous layer was extracted with diethyl ether and the combined organics were dried (Na2S04), filtered and concentrated by rotary evaporation. The residue was purified by regular phase flash column chromatography (Analogix, 0-65% hexanes / ethyl acetate). EXAMPLE 440B l,4-dioxaspiro[4.5]decane-8,8-diyldimethanol To a 1 L round-bottomed flask was added EXAMPLE 440A (26.6 g) and tetrahydrofuran (310 mL). The solution was cooled to 0 °C and lithium aluminum hydride (2M in tetrahydrofuran, 62 mL) was added via syringe. The reaction was allowed to warm to room temperature and stirred overnight. The mixture was cooled back down to O'C and quenched slowly with 4.7 mL water, 4.7 ml 10% NaOH and 14 mL water. The mixture was allowed to stir until salts were formed and then filtered through a Supelco 90 mm silica gel Buchner funnel. The filtrate was concentrated by rotary evaporation and the residue was purified by regular phase flash column chromatography (Analogix, 0-80% hexanes / ethyl acetate). 612 EXAMPLE 440C 2,8,1 l-trioxa-dispiro[3.2.4]tridecane To a 1 L round-bottomed flask was added EXAMPLE 440B (13 g) in tetrahydrofuran (321 mL). The mixture was cooled to -78 °C under N2 and n-butyllithium (25.7 mL) was added dropwise via syringe. After addition was complete, the mixture was stirred for 30 minutes and a tetrahydrofuran solution of toluene-2-sulfonyl chloride (12.25 g) was added via addition funnel. The reaction was allowed to stir overnight and gradually warm to room temperature. The reaction was re-cooled to -78 °C and n-butyllithium (25.7 mL) was added, then allowed to warm to room temperature and stirred for 3 hours. The reaction was quenched with saturated aqueous NH4CI and diluted with diethyl ether. The layers were separated, the aqueous layers extracted with diethyl ether and the combined organics were dried (Na2S04), filtered and concentrated by rotary evaporation. The residue was purified by regular phase flash column chromatography (Analogix, 0-20% acetone / hexanes). EXAMPLE 440D 2-oxaspiro[3.5]nonan-7-one To a 500 mL round-bottomed flask was added EXAMPLE 440C (11 g) in 80 % acetic acid (200 mL). The reaction was heated to 65°C and stirred for about 4 hours. Most of the acetic acid and water were removed by rotary evaporation and the residue was purified by regular phase flash column chromatography (Analogix, 0-65% hexanes/ethyl acetate). EXAMPLE 440E 7-methylene-2-oxaspiro[3.5]nonane To a 250 mL round-bottomed flask was added methyltriphenylphosphonium iodide (4.33 g) in tetrahydrofuran (35.7 mL). The suspension was cooled to -15°C. n-Butyllithium (2.5 M in hexanes, 4.28 mL) was added dropwise and the reaction was stirred at -15 °C for 40 minutes and EXAMPLE 440D (1 g) was added as a tetrahydrofuran (ca. 5 mL) solution. The reaction was stirred at -15 °C for about 15 minutes and warmed to room temperature. After 1.5 hours the reaction was complete and was quenched with saturated aqueous NH4CI and diluted with diethyl ether. The layers were separated and the aqueous layer was extracted (2x) with diethyl ether. The combined organics were washed with brine, dried (Na2S04), filtered and concentrated by rotary evaporation. The residue was purified by regular phase chromatography (Analogix, 0-50% hexanes/ethyl acetate). 613 EXAMPLE 440F 2-oxaspiio[3.5]nonan-7-ylraethanol To a 25 mL round-bottomed flask was added EXAMPLE 440E (568 mg) and tetrahydrofuran (4.11 mL). 9-Borabicyclo[3.3.1]nonane (0.5 M in tetrahydrofuran, 24.7 mL) was added and the reaction was allowed to stir for 2 hours at room temperature. Ethanol (11 mL) was added followed by NaOH (5M, 4.11 mL) and then hydrogen peroxide (2.1 mL) was added. The reaction was heated at 50°C for 2 hours. Most of the ethanol and tetrahydrofuran was removed by rotary evaporation, and the crude material was diluted with water and ethyl acetate. The aqueous layer was extracted with ethyl acetate (3x) and the combined organics were dried (Na2S04), filtered and concentrated by rotary evaporation. The residue was purified by regular phase flash column chromatography (Analogix, 0-70 % hexanes / ethyl acetate). EXAMPLE 440G 4-(2-oxaspiro[3.5]nonan-7-ylmethoxy)-3-nitrobenzenesulfonamide The title compound was prepared by substituting EXAMPLE 440F for (tetrahydro-2H-pyran-4-yl)methanol in EXAMPLE 264A. EXAMPLE 440H 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-{[3-nitro-4-(2-oxaspiro[3.5]non-7-ylmethoxy)phenyl]sulfonyl}benzamide The title compound was prepared by substituting EXAMPLE 440G for EXAMPLE IG and EXAMPLE 318H for EXAMPLE IF in EXAMPLE IH. 'H NMR (300 MHz, dimethylsulfoxide-de) 5 8.34 (s, IH) 8.00 - 8.11 (m, IH) 7.73 (d, IH) 7.41 - 7.54 (m, 2H) 7.36 (m, 3H) 7.07 (d, 2H) 6.65 (dd, IH) 6.18 (d, 3H) 4.29 (s, 2H) 4.21 (s, 2H) 4.05 (d, 2H) 3.05 - 3.23 (m, 4H) 2.84 (s, 2H) 2.12 - 2.42 (m, 5H) 1.93 - 2.12 (m, 4H) 1.64 - 1.78 (m, 3H) 1.35 -1.52 (m, 4H) 0.99 -1.16 (m, 2H) 0.94 (s, 6H). EXAMPLE 441 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-((4-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]-3- nitrophenyl) sulfonyl)benzamide 614 EXAMPLE 441A ethyl 1,4-dioxaspiro[4.5]decane-8-carboxylate To a solution of ethyl 4-oxocyclohexanecarboxylate (31.8 g) in toluene (100 mL) was added ethylene glycol (36.5 mL) and p-toluenesulfonic acid monohydrate (0.426 g). The two phase mixture was stirred rapidly at ambient temperature for 72 hours. The reaction was diluted with water (900 mL) and extracted with ether (900 mL). The organic layer was washed with saturated sodium bicarbonate solution and brine, and then dried over anhydrous sodium sulfate. After filtration, the title compound was obtained by concentration under high vacuum. EXAMPLE 441B l,4-dioxaspiro[4.5]decan-8-ylmethanol To a suspension of lithium aluminum hydride (8.19 g) in tetrahydrofuran (400 mL) was added slowly dropwise a solution of EXAMPLE 441A (37.8 g) in tetrahydrofuran (75 mL). The mixture was then heated at reflux for 2 hours. The reaction mixture was cooled in an ice bath and quenched very slowly with water (8 mL). Then added sequentially were 4N sodium hydroxide (8 mL), ether (200 mL), water (24 mL), ether (5(X) mL) and anhydrous sodium sulfate (250 g). The resulting mixture was stirred rapidly for 2 hours and then filtered. The title compound was isolated by concentration of the filtrate. EXAMPLE 441C 8-(benzyloxymethyl)-l,4-dioxaspiro[4.5]decane To a suspension of sodium hydride (60% oil dispersion) (8.86 g) in tetrahydrofuran (170 mL) was added a solution of EXAMPLE 441B (30.52 g) in tetrahydrofuran (100 mL). The mixture was stirred for 30 minutes and benzyl bromide (24 mL) was added. After stirring for 72 hours, the reaction was quenched with saturated ammonium chloride solution (400 mL) and diluted with ether (500 mL). The layers were separated and the aqueous layer was exttacted with ether (2x 150 mL). The combined organics were dried over sodium sulfate, filtered and concentrated. The crude product was purified on siUca gel eluting witii a 0, 10,15,75 % ethyl acetate in hexanes step gradient to give the title compound. EXAMPLE 44 ID 4-(benzyloxymethyl)cyclohexanone 615 To a soluuon of EXAMPLE 44IC (43.02 g) in dioxane (500 mL) was added water (125 mL) and 2M hydrochloric acid (90 mL). The mixture was heated at 85 °C for 18 hours. Upon cooling, the reaction mixture was diluted with brine (1500 mL), saturated sodium bicarbonate solution (300 mL) and ether (1000 mL). The organic layer was dried over sodium sulfate, filtered and concentrated. The crude product was purified on silica gel eluting with a 5, 15, 25, 50% ethyl acetate in hexanes step gradient to give the title compound. EXAMPLE 441E trans-4-(benzyloxymethy 1)-1 -methylcyclohexanol To 2,6-di-t-butyl-4-methylphenol (83.4 g) in toluene (1100 mL) was added 2.0M (in hexanes) (CH3)3A1 (95 mL) somewhat carefully to control methane evolution and a small exotherm. The reaction mixture was stirred at ambient temperature under N2 for 75 minutes and was then cooled to -77° C. A solution of EXAMPLE 441D (14 g) in toluene (15 mL) was added dropwise, keeping the temperature below -74 °C. Methyllithium (1.6M in diethyl ether) (120 mL) was then added dropwise, keeping the temperature below -65 °C. The resulting mixture was stirred at -77 °C under N2 for 2 hours. The reaction mixture was then poured into IN aqueous HCl (1600 mL), rinsing the flask with toluene. The organic layer was washed with brine and the combined aqueous layers were extracted with diethyl ether. The combined organic layers were dried (Na2S04), filtered and concentrated. The concentrate was chromatographed on 650 g of spherical silica gel using 2.5 L of 80/20 hexanes/ethyl acetate, then 3.0 L of 75/25 hexanes/ ethyl acetate, and finally 4.0 L of 70/30 hexanes/ ethyl acetate as the eluent to give the title compound. EXAMPLE 44 IF trans-4-(hydroxymethyl)-1 -methylcyclohexanol EXAMPLE 441E (12.6 g) and ethanol (120 mL) were added to wet 20% Pd(0H)2/C (1.260 g) in a 500 mL SS pressure bottle. The reaction mixture was stirred at ambient temperature under 30 psi hydrogen gas. Hydrogen uptake ceased at 5 minutes. The mixture was filtered through a nylon membrane rinsing with ethanol. The filtrate was concentrated and then azeotroped with toluene (100 mL) to remove any remaining ethanol. The concentrate was dried under high vacuum for 40 minutes to give the title compound. 616 EXAMPLE 44IG 4-((trans-4-hydroxy-4-methylcyclohexyl)methoxy)-3-nitrobenzenesulfonamide The title compound was prepared by substituting EXAMPLE 44IF for (tetrahydro-2H-pyran-4-yl)methanol in EXAMPLE 264A. EXAMPLE 44IH 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-({4-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]-3- nitrophenyl} sulfonyl)benzaniide The title compound was prepared by substituting EXAMPLE 318H for EXAMPLE IF and EXAMPLE 441G for EXAMPLE 10 in EXAMPLE IH. 'H NMR (500 MHz, dimethylsulfoxide-dfi) 6 8.34 (d, IH), 8.05 (d, IH), 7.73 (d, IH), 7.48 (m, 2H), 7.35 (m, 3H), 7.07 (d, 2H), 6.65 (dd, IH), 6.21 (d, IH), 6.15 (s, 2H), 4.26 (s, IH), 4.12 (d, 2H), 3.14 (m, 4H), 2.86 (m, 2H), 2.31 (m, 4H), 2.17 (m, 2H), 1.98 (s, 2H), 1.73 (m, 3H), 1.56 (m, 2H), 1.41 (m, 4H), 1.25 (m, 2H), 1.10 (s, 3H), 0.94 (s, 6H). EXAMPLE 442 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en- l-yl]methyl }piperazin-l -yl)-N- {[4-({ [(2S)-4-cyclopropylmorpholin-2-yl]methyl} amino)- 3 -nitrophenyljsulfonyl} benzamide EXAMPLE 442A (R)-tert-butyl2-(tosyloxymethyl)morpholine-4-carboxylate To a solution of (R)-tert-butyl 2-(hydroxymethyl)morpholine-4-carboxylate (1 g) in dichloromethane (50 mL) was added triethylamine (1.604 mL) and 4-methylbenzene-l-sulfonyl chloride (1.097 g). The mixture was stirred at ambient temperature under nitrogen for 72 hours. The reaction was diluted with methylene chloride (50 mL) and brine (100 mL). The brine layer was extracted with methylene chloride (75 mL). The combined organics were dried over sodium sulfate, filtered and concentrated. The crude material was purified on a silica gel column eluting with a 15-65 % ethyl acetate in hexane gradient to give the title compound. 617 EXAMPLE 442B (R)-tert-butyl2-(azidomethyl)morpholine-4-carboxylate A solution of EXAMPLE 442A (L66 g, 4.47 mmol) and sodium azide (0.581 g, 8.94 mmol) in anhydrous N,N-dinaethylformamide (10 mL) was stirred at 90 °C for 4 hours. The mixture was cooled and concentrated to dryness. The residue was taken up in 5% aqueous sodium carbonate solution and extracted with methylene chloride. The combined organic layers was dried (MgS04), filtered and concentrated to provide the title compound. EXAMPLE 442C (S)-tert-butyl2-(aminomethyl)morphoUne-4-carboxylate The title compound was obtained by hydrogenation of EXAMPLE 442B (1 g) under 60 psi of hydrogen over wet 20% palladium on carbon in methanol (50 mL) for 1 hours. The mixture was filtered through a nylon membrane and concentrated to give the product. EXAMPLE 442D (S)-tert-butyl2-((2-nitro-4-sulfamoylphenylamino)methyl)morpholine-4-carboxylate The Utle compound was prepared by substituting EXAMPLE 442C for 3-(A'-morpholinyl)-!-propylamine in EXAMPLE 4A. EXAMPLE 442E (R)-4-(morpholin-2-ylmethylamino)-3-nitrobenzenesulfonamide The title compound was prepared by substituting EXAMPLE 442D for EXAMPLE 369A in EXAMPLE 369B. EXAMPLE 442F (S)-4-((4-cyclopropylmorpholin-2-yl)methylamino)-3-nitrobenzenesulfonaniide The title compound was prepared by substituting EXAMPLE 442E for EXAMPLE 369B in EXAMPLE 369C. EXAMPLE 442G 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-1 -yljmethyl} piperazin-1 -yl)-N- {[4-( {[(2S)-4-cyclopropylmorpholin-2-yl]methyl} amino)- 3-nitrophenyl]sulfonyl} benzamide 618 The title compound was prepared by substituting EXAMPLE 318H for EXAMPLE llOE and EXAMPLE 442F for EXAMPLE IG in EXAMPLE HOP. ^H NMR (500MHz, pyridine-dg) 5 9.28 (d, IH), 8.93 (t, IH), 8.40 (dd, IH), 8.03 (d, IH), 8.02 (s, IH), 7.45 (d, 2H), 7.39 (d, IH), 7.09 (d, 2H), 7.07 (d, IH), 6.84 (bs, 2H), 6.72 (dd, IH), 6.54 (d IH), 3.85 (m, 2H), 3.61-3.47 (m, 3H), 3.12 (m, 4H), 2.93 (d, IH), 2.80 (s, 2H), 2.70 (d, IH), 2.25 (dt, IH), 2.24 (m, 2H), 2.21 (d, IH), 2.19 (m, 4H), 1.99 (s, 2H), 1.58 (m, IH), 1.41 (t, 2H), 0.95 (s, 6H), 0.42 (m, 4H). EXAMPLE 443 2-[(6-amino-5-chloropyridin-3-yl)oxy]-N-({5-chloro-6-[(trans-l-fluoro-4-hydroxy-4- methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4- dimethylcyclohex- l-en-l-yl]methyl }piperazin- l-yl)benzainide EXAMPLE 443A l,5,8-trioxadispiro[2.2.2.4]dodecane A dimethyl sulfoxide (40 mL) solution of l,4-dioxaspiro[4.5]decan-8-one (6.25 g) was added dropwise to a solution of trimethylsulfoxonium iodide (8.8 g) and potassium t-butoxide (4.5 g) in dimethyl sulfoxide (50 mL). The mixture was stirred at room temperature overnight. The mixture was then poured over ice-water and extracted with diethyl ether (3 x 200mL). The combined organic extracts were washed with water and brine, dried over Na2S04, and filtered. Concentration of the filtrate gave the crude product. EXAMPLE 443B (8-fluoro-l,4-dioxaspiro[4.5]decan-8-yl)methanol A solution of pyridine hydrofluoride (4 g) in dichloromethane (10 mL) was added dropwise to a solution of EXAMPLE 443 A (1.7 g) in dichloromethane (20 mL) in a polyethylene bottle at 0°C. The mixture was stirred at room temperature overnight. The mixture was carefully poured over a mixture of ice-water and Na2C03 and extracted with ethyl acetate (2x 300 mL). After washing with water and brine, the organic layer was dried over Na2S04, and filtered. Concentration of the filtrate gave the crude product. EXAMPLE 443C 5-chloro-6-((8-fluoro-l,4-dioxaspiro[4.5]decan-8-yl)methoxy)pyridine-3-sulfonamide 619 To a solution of EXAMPLE 443B (500 mg) in N.N-dimethylformamide (5 mL) was added NaH (65% in mineral oil, 252 mg) at room temperature. The mixture was stirred for 30 minutes, and then 5,6-dichloropyridine-3-sulfonamide (0.6 g) was added. The mixture was stirred at room temperature overnight. The mixture was poured over aqueous NH4CI and extracted with ethyl acetate (3x 100 mL). The combined organic layers were washed with water, brine and dried over Na2S04. After filtration and evaporation of solvent, the residue was loaded on a silica gel cartridge and eluted with 30% ethyl acetate in hexane to provide the title compound. EXAMPLE 443D 5-chloro-6-((l-fluoro-4-oxocyclohexyl)methoxy)pyridine-3-sulfonamide To a solution of EXAMPLE 443C (1.6 g) and pyridinium p-toluenesulfonate (1.2 g) in acetone (10 mL) was added water (2 mL) and the mixture was stirred in a Biotage Initiator microwave reactor at 100°C for 10 minutes. The mixture was diluted with dichlorometiiane (300 mL) and washed with aqueous NaHCOs, water, brine and dried over Na2S04, and filtered. Concentration of the filtrate gave the crude product. EXAMPLE 443E 5-chloro-6-((trans-l-fluoro-4-hydroxy-4-methylcyclohexyl)methoxy)pyridine-3-sulfonamide To a solution of EXAMPLE 443D (1.2 g) in tetrahydrofuran (30 mL) was added dropwise a solution of methylmagnesium bromide (5 mL, 3.0M in etiier) at 0°C. Upon the addition, the reaction mixture solidified. More tetrahydrofuran (10 mL) was added to the mixture and stirring was continued for 1 hour. The mixture was poured over aqueous NH4CI and extracted with ethyl acetate (3x 300mL). The combined organic layers were washed with water, brine and dried over Na2S04, filtered, and concentrated. The residue was dissolved in dimethyl sulfoxide/methanol (20 mL, 1:1) and loaded on a HPLC (HPLC conditions: Gilson, C18 (lOOA) 250 X 121.2 mm (10 micron), conditions : 20% - 45% acetonitrile in water witii 0.1% trifluoroacetic acid). EXAMPLE 443F 2-[(6-amino-5-chloropyridin-3-yl)oxy]-N-({5-chloro-6-[(trans-l-fluoro-4-hydroxy-4- methylcyclohexyl)metiioxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4- dimetiiylcyclohex-1 -en-1 -yljmetiiyl }piperazin- l-yl)benzamide 620 The title compound was prepared by substituting EXAMPLE 318H for EXAMPLE IF and EXAMPLE 443E for EXAMPLE IG in EXAMPLE IH. ^H NMR (300 MHz, dimethylsulfoxide-de) 6 8.52 (s, IH), 8.20 (s, IH), 7.72 (d, IH), 7.50 (d, IH), 7.37 (m, 3H), 7.07 (d, 2H), 6.65 (dd, IH), 6.23 (s, IH), 6.09 (m, 2H), 4.49 (d, 2H), 4.14 (s, IH), 3.16 (m, 5H), 2.25 (m, 6H), 1.85 (m, 5H), 1.49 (m, 7H), 1.14 (s, 3H), 0.95 (s, 6H). EXAMPLE 444 2-[(6-amino-5-chloropyridin-3-yl)oxy]-N-({5-chloro-6-[(cis-l-fluoro-4-hydroxy-4- methylcycIohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4- dimethylcyclohex-1 -en- l-yl]methyl }piperazin- l-yl)benzamide EXAMPLE 444A 5-chloro-6-((cis-l-fluoro-4-hydroxy-4-methylcyclohexyI)methoxy)pyridine-3-sulfonaniide The title compound was also generated in EXAMPLE 443E. EXAMPLE 444B 2-[(6-amino-5-chloropyridin-3-yl)oxy]-N-({5-chloro-6-[(cis-l-fluoro-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl] methyl jpiperazin-1 -yl)benzamide The title compound was prepared by substituting EXAMPLE 318H for EXAMPLE IF and EXAMPLE 444A for EXAMPLE IG in EXAMPLE IH. 'H NMR (300 MHz, dimethylsulfoxide-de) 6 8.54 (s, IH), 8.22 (s, IH), 7.73 (d, IH), 7.50 (d, IH), 7.37 (d, 3H), 7.07 (d, 3H), 6.65 (dd, IH), 6.22 (s, IH), 6.11 (m, 2H), 4.55 (d, 2H), 4.35 (s, IH), 3.17 (m, 3H), 2.23 (m, 4H), 1.99 (m, 6H), 1.69 (m, 6H), 1.44 (m, 5H), 1.12 (s, 3H), 0.95 (s, 6H) EXAMPLE 445 2-[(3-amino-lH-indazol-4-yl)oxy]-N-({5-chloro-6-[(trans-4-hydroxy-4- methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1-en- l-yl]methyl}piperazin- l-yl)benzamide EXAMPLE 445A ethyl 1,4-dioxaspiro[4.5]decane-8-carboxylate To a solution of ethyl 4-oxocyclohexanecarboxylate (31.8 g) in toluene (100 mL) was added ethylene glycol (36.5 mL) and p-toluenesulfonic acid monohydrate (0.426 g). The two 621 phase mixture was stirred rapidly at ambient temperature for 72 hours. The reaction was diluted with water (900 mL) and extracted with ether (900 mL). The organic layer was washed with saturated sodium bicarbonate solution and brine, dried over anhydrous sodium sulfate, and filtered. The title compound was obtained by concentration of the filtrate under high vacuum. EXAMPLE 445B l,4-dioxaspiro[4.5]decan-8-ylmethanol To a suspension of lithium aluminum hydride (8.19 g) in tetrahydrofuran (400 mL) was added slowly dropwise a solution of EXAMPLE 445A (37.8 g) in tetrahydrofuran (75 mL). The mixture was then heated at reflux for 2 hours. The reaction mixture was cooled in an ice bath and quenched very slowly with water (8 mL). Then added sequentially were 4N sodium hydroxide (8 mL), ether (200 mL), water (24 mL), ether (500 mL) and anhydrous sodium sulfate (250 g). The resulting mixture was stirred rapidly for 2 hours and then filtered. The title compound was isolated by concentration of the filtrate. EXAMPLE 445C 8-(benzyloxymethyl)-1,4-dioxaspiro[4.5]decane To a suspension of sodium hydride (60% oil dispersion) (8.86 g) in tetrahydrofuran (170 mL) was added a solution of EXAMPLE 445B (30.52 g) in tetrahydrofuran (100 mL). The mixture was stirred for 30 minutes and benzyl bromide (24 mL) was added. After stirring for 72 hours, the reaction was quenched with saturated ammonium chloride solution (400 mL) and diluted with ether (500 mL). The layers were separated and the aqueous layer was extracted with ether (2 X 150 mL). The combined organics were dried over sodium sulfate, filtered and concentrated. The crude product was purified on silica gel eluting with a 0,10,15,75 % ethyl acetate in hexanes step gradient to give the title compound. EXAMPLE 445D 4-(benzyloxymethyl)cyc]ohexanone To a solution of EXAMPLE 445C (43.02 g) in dioxane (500 mL) was added water (125 mL) and 2M hydrochloric acid (90 mL). The mixture was heated at 85 °C for 18 hours. Upon cooling, the reaction mixture was diluted with brine (1500 mL), saturated sodium bicarbonate solution (300 mL) and ether (1000 mL). The organic layer was dried over sodium sulfate, filtered and concentrated. The crude product was purified on silica gel 622 eluting with a 5,15, 25, 50% ethyl acetate in hexanes step gradient to give the title compound. EXAMPLE 445E trans-4-(benzyloxymethyl)-1 -methylcyclohexanol To 2,6-di-t-butyl-4-methylphenol (83.4 g) in toluene (1100 mL) was added 2.0M (in hexanes) trimethylaluminum (95 mL) somewhat carefully to control methane evolution and a small exotherm. The reaction mixture was stirred at ambient temperature under Na for 75 minutes and was then cooled to -77° C. A solution of EXAMPLE 445D (14 g) in toluene (15 mL) was added dropwise, keeping the temperature below -74 "C. Methyllithium (1.6M in diethyl ether) (120 mL) was then added dropwise, keeping the temperature below -65 °C. The resulting mixture was stirred at -77 °C under N2 for 2 hours. The reaction mixture was then poured into IN aqueous HCl (1600 mL), rinsing the flask with toluene. The organic layer was washed with brine and the combined aqueous layers were extracted with diethyl ether. The combined organic layers were dried (Na2S04), filtered and concentrated. The concentrate was chromatographed on 650 g of spherical silica gel using 2.5 L of 80/20 hexanes/ethyl acetate, then 3.0 L of 75/25 hexanes/ethyl acetate, and finally 4.0 L of 70/30 hexanes/ethyl acetate as the eluent to give the title compound. EXAMPLE 445F trans-4-(hydroxymethyl)-1 -methylcyclohexanol EXAMPLE 445E (12.6 g) and ethanol (120 mL) were added to 20% Pd(0H)2/C, wet (1.260 g) in a 500 mL SS pressure bottle. The reaction mixture was stirred at ambient temperature under 30 psi hydrogen gas. Hydrogen uptake ceased at 5 minutes. The mixture was filtered through a nylon membrane rinsing with ethanol. The filtrate was concentrated and then azeotroped with toluene (100 mL) to remove any remaining ethanol. The concentrate was dried under high vacuum for 40 minutes to give the title compound. EXAMPLE 445G 5-chloro-6-((trans-4-hydroxy-4-methylcyclohexyl)methoxy)pyridine-3-sulfonamide The title compound was prepared by substituting EXAMPLE 303A for 4-fluoro-3-nitrobenzenesulfonamide and EXAMPLE 445F for (tetrahydro-2H-pyran-4-yl)methanol in EXAMPLE 305 A. 623 EXAMPLE 445H tert-butyl3-(bis(tert-butoxycarbonyl)amino)-4-(2-(5-chloro-6-((trans-4-hydroxy-4- methylcyclohexyl)methoxy)pyridin-3-ylsulfonylcarbamoyl)-5-(4-((2-(4-chlorophenyl)-4,4- dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)phenoxy)- IH-indazole- 1-caiboxylate This EXAMPLE was prepared by substituting EXAMPLE 428E for EXAMPLE IF and EXAMPLE 445G for EXAMPLE IG in EXAMPLE IH. EXAMPLE 4451 2-[(3-amino-lH-indazol-4-yl)oxy]-N-({5-chloro-6-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl)sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl }piperazin- l-yl)benzamide The title compound was prepared by substituting EXAMPLE 445H for EXAMPLE 428F in EXAMPLE 4280. ^H NMR (500MHz, dimethylsulfoxide-de) 8 n.45 (s, IH), 8.30 (d, IH), 7.90 (d, IH), 7.55 (d, IH), 7.36 (d, 2H), 7.07 (d, 2H), 6.94 (m, IH), 6.81 (d, IH), 6.73 (s, IH), 6.43 (s, IH), 5.88 (br s, IH), 4.21-4.25 (m, 3H), 3.13 (s, 4H), 2.82 (br s, 2H), 2.16-2.32 (m, 6H), 1.98 (s, 2H), 1.70-1.74 (m, 2H), 1.50-1.56 (m, 2H), 1.36-1.42 (m, 4H), 1.14-1.23 (m, 4H), 1.10 (s, 3H), 0.94 (s, 6H). EXAMPLE 446 N-( {5 -chloiD-6- [(trans-4-hydroxy-4-methylcyclohexyl)methoxy ]pyridin-3 -yl ] sulfonyl)-2- [(3 - chloro- lH-indazol-4-yl)oxy]-4-(4- {[2-(4-chlorophenyl)-4,4-diniethylcyclohex- 1-en-1- yljmethyl} piperazin-1 -yl)benzamide EXAMPLE 446A methyl 2-(3-amino-2-methylphenoxy)-4-fIuorobenzoate The tide compound was prepared by substituting 3-amino-2-methylphenol for 2-methyl-5-indolol and methyl 2,4-difluorobenzoate for ethyl 2,4-difluorobenzoate in EXAMPLE 3A. EXAMPLE 446B methyl 2-(l-acetyl-lH-indazol-4-yloxy)-4-fluorobenzoate A mixture of EXAMPLE 446A (1.0 g), acetic anhydride (0.734 mL), and potassium acetate (0.428 g) in toluene (20 mL) was stirred at room temperature for three hours. To the 624 flask was added isoamyl nitrite (1.03 mL). The reaction mixture was heated at 80 °C for 16 hours. The solvent was removed, and the residue was purified by flash column chromatography on silica gel to give the title compound. EXAMPLE 446C EXAMPLE 446B (5.2 g) was dissolved in tetrahydrofuran (100 mL). To this solution was added LiOH monohydrate (0.73 g in 25 mL of water) dropwise at room temperature. The reaction was stirred for 3 hours. The reaction was quenched with 5% aqueous HCl (5 mL). The solvent was removed, and the residue was partitioned between water and ethyl acetate. The aqueous layer was extracted with additional ethyl acetate three times. The combined organic layers were washed with brine, dried over MgS04, filtered, and concentrated. The residue was purified by flash chromatography on silica gel eluting with 3:7 ethyl acetate /hexanes to give the title compound. EXAMPLE 446D methyl 2-(3-chloro-lH-indazol-4-yloxy)-4-fluorobenzoate A mixture of EXAMPLE 446C (0.91 g) and CS2CO3 (1.04 g) in N,N-dimethylformamide (8 mL) was stirred for 10 minutes at room temperature. To this solution was added l-chloropyrrolidine-2,5-dione (0.467 g). The reaction mixture was stirred for 4 hours. The reaction mixture was partitioned between water and ethyl acetate. The aqueous layer was extracted with additional ethyl acetate three times. The combined organic layers were washed with brine, dried over MgS04, filtered, and concentrated. The residue was purified by flash chromatography on silica gel eluting with 3:7 ethyl acetate /hexanes to give the title compound. EXAMPLE 446E methyl 2-(3-chloro-lH-indazol-4-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- enyl)methyl)piperazin-1 -yl)benzoate The title compound was prepared by substituting EXAMPLE 446D for EXAMPLE 3A in EXAMPLE 3G. EXAMPLE 446F 2-0-chloTO-1 H-indazol-4-yIoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 - enyl)methyl)piperazin-1 -yl)benzoic acid 625 The title compound was prepared by substituting EXAMPLE 446E for EXAMPLE IE in EXAMPLE IF. EXAMPLE 446G 2-(l-(tert-butoxycarbonyl)-3-cliloro-lH-indazol-4-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)niethyl)piperazin-1 -yl)benzoic acid The title compound was prepared by substituting EXAMPLE 446F for EXAMPLE 428D in EXAMPLE 428E. EXAMPLE 446H The title compound was prepared by substituting EXAMPLE 446G for EXAMPLE IF and EXAMPLE 445G for EXAMPLE 10 in EXAMPLE IH. EXAMPLE 4461 N-( {5 -chloro-6- [(trans-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3 -yl} sulfonyl)-2- [(3 -chloro-1 H-indazol-4-yl)oxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)benzamide The title compound was prepared by substituting EXAMPLE 446H for EXAMPLE 428F in EXAMPLE 428G. ^H NMR (500MHz, dimethylsulfoxide-de) 5 13.31 (s, IH), 8.38 (d, IH), 7.99 (d, IH), 7.60 (d, IH), 7.38 (d, 2H), 7.07-7.16 (m, 4H), 6.80 (dd, IH), 6.50 (d, IH), 6.20 (d, IH), 4.24-4.26 (m, 3H), 2.25 (s, 2H), 2.01 (s, 2H), 1.73-1.80 (m, 4H), 1.55-1.58 (m, 2H), 1.36-1.54 (m, 4H), 1.17-1.25 (m, 4H), 1.12 (s, 3H), 0.95 (s, 6H). EXAMPLE 447 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-l-yl]methyl}piperazin-l-yl)-N-[(4-{[(cis-4-ethyl-4-hydroxycyclohexyl)methyl]amino}-3- nitrophenyl)sulfonyl]benzamide' EXAMPLE 447A benzyl (4-ethyl-4-hydroxycyclohexyl)methylcarbamate To a vigorous stirring solution of benzyl (4-oxocyclohexyl)methylcarbamate (1 g) in tetrahydrofuran (20 mL) at -78°C was slowly added 1 M ethylmagnesium bromide (11.48 mL) in ether. After completion of the addition, the mixture was stirred at -78°C for 2 hours 626 and then was warmed to 0°C, and stirred in an ice bath for 30 minutes. The reaction was quenched with a cold NH4CI aqueous solution. The precipitates were filtered off and washed with ethyl acetate. The filtrate was concentrated. The residue was dissolved in dichloromethane, loaded onto an Analogix purification system, and eluted with 0 - 50% ethyl acetate in dichloromethane to provide the title compound. EXAMPLE 447B 4-(aminomethyl)-1 -ethylcyclohexanol A mixture of EXAMPLE 447A (500 mg) and 10% Pd/C (100 mg) in tetrahydiDfiiran (15 mL) was stirred under H2 for 3 hours. The insoluble material was removed by filtration, and the filtrate was concentrated to give the title compound. EXAMPLE 447C 4-((cis-4-ethyl-4-hydroxycyclohexyl)methylamino)-3-nitrobenzenesulfonamide EXAMPLE 447B (270 mg) and 4-fluoro-3-nitrobenzenesulfonamide (417 mg) in tetrahydrofuran were treated with triethylamine (0.8 mL) overnight. The reaction was quenched with water. The resulting mixture was neutralized with diluted HCl, and extracted with ethyl acetate. The organic layer was dried over Na2S04, filtered, and concentrated. The residue was purified by a reverse phase chromatography, eluting with 40-55% acetonitrile in 0.1% trifluoroacetic acid water to provide the title compound. EXAMPLE 447D 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-1 -yljmethyl Ipiperazin-1 -yl)-N-[(4- {[(cis-4-ethyl-4-hydroxycyclohexyl)methyl]amino} -3- nitrophenyl)sulfonyl]benzamide The title compound was prepared as described in EXAMPLE 1 lOF by replacing EXAMPLE 1 lOE and EXAMPLE IG with EXAMPLE 318H and EXAMPLE 447C, respectively. 'H NMR (400 MHz, dimethylsulfoxide-de) 5 11.31 (s, IH), 8.63 (t, IH), 8.58 (d, IH), 7.86 (dd, IH), 7.76 (d, IH), 7.44 (d, IH), 7.40 (d, IH), 7.36 (d, 2H), 7.19 (d, IH), 7.06 (d, 2H), 6.65 (dd, IH), 6.15 - 6.22 (m, 3H), 3.76 (s, IH), 3.28 - 3.32 (m, 4H), 3.12 (s, 4H), 2.79 (s, 2H), 2.24 (s, 4H), 2.17 (s, 2H), 1.97 (s, 2H), 1.47 - 1.62 (m, 5H), 1.29 - 1.46 (m, 6H), 1.13 - 1.24 (m, 2H), 0.94 (s, 6H), 0.81 (t, 3H). 627 EXAMPLE 448 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-l-yl]methyl Ipiperazin-1-yl)-N-{[3-nitro-4-( {[(2S)-4-(oxetan-3-yl)morpholin-2-yl]methyl } aniino)phenyl]sulfonyl} benzamide EXAMPLE 448A (S)-3-nitro-4-((4-(oxetan-3-yl)morpholin-2-yl)methylamino)benzenesulfonamide A round-bottom flask was charged with EXAMPLE 442E (L012 g), anhydrous methanol (15 mL) and acetic acid (2.75 mL). Oxetan-3-one (0.461 g) was added and the mixture was stirred at room temperature for 30 minutes. Sodium cyanoborohydride (0.603 g) was then added and the mixture was stirred at room temperature overnight. The mixture was concentrated and the residue taken up in 5% aqueous NaiCOs solution (15 mL). The mixture was extracted with ethyl acetate. The crude product was purified on a silica gel column eluting with 5% and 10% methanol in CH2CI2 to provide the title compound. EXAMPLE 448B 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimelhylcyclohex-l-en- l-yl]methyl }piperazin-1 -yl)-N- {[3-nitro-4-( {[(2S)-4-(oxetan-3-yl)morpholin-2-yl]methyl} amino)phenyl]sulfonyl ] benzamide The title compound was prepared by substituting EXAMPLE 448A for EXAMPLE IG and EXAMPLE 318H for EXAMPLE 1 lOE in EXAMPLE 1 lOF. 'H NMR (500MHZ, pyridine-ds) 5 9.28 (d, IH), 8.92 (t, IH), 8.40 (dd, IH), 8.05 (d, IH), 8.03 (d, IH), 7.45 (d, 2H), 7.39 (d, IH), 7.09 (d, 2H), 7.07 (d, IH), 6.82 (bs, 2H), 6.72 (dd, IH), 6.55 (d IH), 4.63 (m, 4H), 3.95 (m, IH), 3.90 (d, IH), 3.70 (dt, IH), 3.55 (m, IH), 3.50 (m, IH), 3.38 (m, IH), 3.12 (m, 4H), 2.82 (s, 2H), 2.72 (d, IH), 2.48 (d, IH), 2.30 (m, 2H), 2.19 (m, 4H), 1.99 (s, 2H), 1.96 (dd, IH), 1.85 (t, IH), 1.41 (t, 2H), 0.95 (s, 6H). EXAMPLE 449 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-1-yl]methyl} piperazin-1-yl)-N-( {5-nitro-6-[(tetrahydro-2H-pyran-4- ylmethyl)amino]pyridin-3-yl} sulfonyl)benzamide 628 EXAMPLE 449A 6-amino-5-nitropyridine-3-suIfonic acid 6-Aminopyridine-3-sulfonic acid (20 g) in concentrated H2SO4 (80 mL) was heated at 50 °C until it was completely dissolved. To this solution was added fuming HNO3 dropwise over 20 minutes. The rate of addition was kept slow so that the internal temperature did not exceed 55 °C. After the addition was complete, the reaction mixture was heated at 50 °C for 1 hour. After it cooled to room temperature, it was poured into 150 g of ice. The mixture was stirred for another 1 hour. The whole flask was cooled to 0 °C, and was kept at 0 °C for another 2 hours. The solid was collected by filtration. The solid was washed with cold 1:1 water/ethanol (20 mL), followed by diethyl ether (10 mL). The solid was dried in a vacuum oven overnight to give the title compound. EXAMPLE 449B 6-hydroxy-5 -nitropyridine-3-sulfonic acid EXAMPLE 449A (4.0 g) in concentrated HCl (37%, 12 mL) and water (50 mL) was treated with sodium nitrite (1.19 g) in water (8 mL) dropwise at 0 °C. After the addition was complete, the reaction mixture was stirred at 0 °C for one hour. It was then heated under reflux for 2 hours. Water was distilled off to give a near dry residue. After it cooled to room temperature, a solution 1:1 ethanol/water (20 mL) was added. The resulting suspension was cooled to 0 °C, and kept at 0 °C for 1 hour. The solid was collected by filtration to give the title compound. EXAMPLE 449C 6-chloro-5-nitropyridine-3-sulfonyl chloride A mixture of EXAMPLE 449B (2.6 g), PCI5 (5.91 g), and POCI3 (10 mL) was heated at 120 °C for 4 hours. The initial suspension became a clear solution. The excess of POCI3 was distilled off. After it cooled to room temperature, the residue was poured into 50 g of crushed ice. The solid was extracted into ethyl acetate. The aqueous layer was extracted with additional ethyl acetate. The combined organic layers were washed with brine, dried over MgS04, filtered, and concentrated to give crude product that was used for the next reaction without further purification. EXAMPLE 449D 6-chloro-5-nitropyridine-3-sulfonamide 629 EXAMPLE 449C in tetrahydrofuran (10 mL) was cooled to -10 °C. To this solution was added concentrated ammonium hydroxide (0.82 mL) dropwise. The solution was stirred at -10 "C for 10 minutes. The solvent was removed under pressure at room temperature. The residue was partitioned between water and ethyl acetate. The aqueous layer was extracted with additional ethyl acetate. The combined organic layers were washed with brine, dried over MgS04, filtered, and concentrated. The residue was purified by flash column chromatography on silica gel to give the title compound. EXAMPLE 449E 5-nitro-6-((tetrahydro-2H-pyran-4-yl)methylamino)pyridine-3-sulfonamide The title compound was prepared by substituting EXAMPLE 449D for 4-fluoro-3-nitrobenzenesulfonamide and (tetrahydro-2H-pyran-4-yl)methanamine for EXAMPLE 337C in EXAMPLE 337D. EXAMPLE 449F 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-1 -yljmethyl }piperazin-1 -yl)-N-({ 5-nitio-6-[(tetrahydK)-2H-pyran-4-ylmethyl)amino]pyridin-3-yl}sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 449E for EXAMPLE IG and EXAMPLE 318H for EXAMPLE llOE in EXAMPLE HOP. ^H NMR (500MHz, dimethylsulfoxide-dg) 58.95 (s, IH), 8.77 (d, IH), 8.71 (d, IH), 7.71 (d, IH), 7.49 (d, IH), 7.35-7.37 (m, 3H), 7.07 (d, 2H), 6.65 (dd, IH), 6.21 (s, IH), 6.10 (s, 2H), 3.83 (dd, 2H), 3.54 (t, 2H), 3.22-3.28 (m, 2H), 3.13 (br s, 4H), 2.84 (br s, 2H), 2.7-2.34 (m, 6H), 1.91-1.99 (m, 3H), 1.57-1.60 (m, 2H), 1.41 (t, 2H), 1.23-1.29 (m, 2H), 0.94 (s, 6H). EXAMPLE 450 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- en-l-yl]methyl}piperazin-l-yl)-N-({3-nitro-4-[(2-oxaspiro[3.5]non-7- ylmethyl)amino]phenyl} sulfonyl)benzamide EXAMPLE 450A 7-(azidomethyl)-2-oxaspiro[3.5]nonane 630 To a 250 mL round-bottomed flask was EXAMPLE 440F (350 mg) in tetrahydrofuran (75.0 mL) to give a colorless solution. The solution was cooled to 0 °C, triphenylphosphine (2.94 g), diisopropyl azodicarboxylate (2.18 mL) and diphenyl phosphorazidate (2.32 mL) were added and the reaction was stirred for 30 minutes at room temperature. Most of the tetrahydrofuran was removed by rotary evaporation and the residue was purified by regular phase flash column chromatography (Analogix, 0-20% hexanes / ethyl acetate). EXAMPLE 450B 2-oxaspiro[3.5]nonan-7-ylmethanamine To a 50 mL round-bottomed flask was added 10% palladium on carbon (58.7 mg). The flask was flushed with Ni and EXAMPLE 450A (400 mg) was added as a methanol solution (10.5 mL). The flask was then flushed several times with H2 (via balloon) and heated to 45 °C for 2 hours. The reaction was cooled to room temperature, filtered through diatomaceous earth and the filtrate was concentrated by rotary evaporation. The residue was used in the next step without further purification. EXAMPLE 450C 4-(2-oxaspiro[3.5]nonan-7-ylmethylamino)-3-nitrobenzenesulfonamide The title compound was prepared by substituting EXAMPLE 450B for 1-(tetrahydropyran-4-yl)methylamine in EXAMPLE IG. In this case, the product was purified by regular phase flash column chromatography (Analogix, 0.4 - 4% dichloromethane / methanol). EXAMPLE 450D 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-1 -yljmethyl} piperazin-1 -yl)-N-( {3-nitro-4- [(2-oxaspiro[3.5]non-7-ylmethyl)amino]phenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 450C for EXAMPLE IG and EXAMPLE 318H for EXAMPLE IF in EXAMPLE IH. 'H NMR (300 MHz, dimethylsulfoxide-de) 6 8.55 - 8.65 (m, 2H) 7.85 (dd, IH) 7.75 (d, IH) 7.30 - 7.47 (m, 4H) 7.18 (d, IH) 7.06 (d, 2H) 6.65 (dd, IH) 6.18 (s, 3H) 4.29 (s, 2H) 4.19 (s, 2H) 3.21 - 3.29 (m, 4H) 3.03 - 3.16 (m, 4H) 2.66 - 2.83 (m, 2H) 2.11 - 2.33 (m, 6H) 1.91 - 2.09 (m, 4H) 1.54 -1.73 (m, 3H) 1.31-1.45 (m, 4H) 0.89 - 1.04 (m, 8H). 631 EXAMPLE 451 2-[(6-amino-5-chloiopyridin-3-yl)oxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1- en- l-yl]methyl}piperazin- l-yl)-N-{ [4-({ [trans-4-(morpholin-4- yl)cyclohexyl]methyl} amino)-3-nitiiophenyl]sulfonyl }benzamide EXAMPLE 451A tert-butyltrans-4-((2-nitro-4-sulfamoylphenylamino)methyl)cyclohexylcarbamate To a suspension of tert-butyl trans-4-(aminomethyl)cyclohexylcarbamate HCl (1.0 g) and 4-fluoro-3-nitrobenzenesulfonamide (0.83 g) in tetrahydrofuran (5 mL) was added diisopropylethylamine (1.98 mL) and the reaction stirred at room temperature for 1 hour. The reaction was diluted with ethyl acetate (75 mL) and washed with saturated ammonium chloride (50 mL), brine (50 mL), dried over magnesium sulfate, filtered, and concentrated. The resulting solid was triturated with dichloromethane (50 mL), filtered and dried to give the title compound. EXAMPLE 45 IB 4-(( trans-4-aminocyclohexyl)methylamino)-3-nitrobenzenesulfonamide To EXAMPLE 451A (1.0 g) was added HCl (4.0M in dioxane, 1.7 mL). The material slowly dissolved then the product precipitated from the solution. After stirring for 2 hours, the reaction was concentrated; the solid was washed with diethyl ether (10 mL) and dried to give the title compound. EXAMPLE 45IC 4-((trans-4-moipholinocyclohexyl)methylamino)-3-nitrobenzenesulfonamide To a solution of EXAMPLE 45 IB (0.85 g) and diisopiopylethylamine (2.03 mL) in N,N-dimethylformamide (7 mL) was added bis(2-bromoethyl)ether (0.54 g) as a solution in N,N-dimethylformamide (1 mL). The reaction was stirred at room temperature for 1 hour and heated to 70°C overnight.. The reaction was cooled, diluted with ethyl acetate (100 mL), washed with water (50 mL), dried over magnesium sulfate, filtered, and concentrated. Silica gel chromatography (Revleris 120g) eluting with a gradient of 0.75% to 7.5% over 30 minutes (flow = 80 ml/min) gave the title compound. 632 EXAMPLE 45 ID 2-[(6-amino-5-chloiopyriciin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en- l-yl]methyl}piperazin-1 -yl)-N- {[4-({ [trans-4-(morpholin-4-yl)cyclohexyl]methyl} amino)-3-nitrophenyl]sulfonyl }benzamide The title compound was prepared by substituting EXAMPLE 318H for EXAMPLE IF and EXAMPLE 45IC for EXAMPLE IG in EXAMPLE IH. 'H NMR (300 MHz, dimethylsulfoxide-dfi) 5 10.71 (s, IH), 8.52 (d, 2H), 7.80 (dd, IH), 7.70 (d, IH), 7.47 (d, IH), 7.36 (d, 2H), 7.29 (d, IH), 7.06 (d, 3H), 6.64 (dd, IH), 6.21 (d, IH), 6.07 (s, 2H), 3.63 (s, 4H), 3.31 (s, 2H), 3.08 (s, 4H), 2.75 (s, 6H), 2.21 (s, 6H), 1.97 (s, 6H), 1.61 (s, 2H), 1.40 (s, 6H), 0.94 (s, 6H). EXAMPLE 452 2-[(6-aniino-5-chloropyridin-3-yl)oxyl-4-(4-{[2-(4-chlorophenyl)-4,4-diniethylcyclohex-l- en- l-yl]methyl }piperazin-l-yl)-N-[(4- {[cis-4-(morpholin-4-yl)cyclohexyl]ainino} -3- nitrophenyl)sulfonyl]benzamide EXAMPLE 452A Cis-tert-butyl4-methyl-4-moipholinocyclohexylcarbamate A solution of tert-butyl cis-4-aminocyclohexylcaTbamate (1.5 g), bis(2-bromoethyl)ether (1.06 mL) and triethylamine (2.4 mL) in N,N-dimethylformamide (15 mL) was heated at 70°C under nitrogen for 20 hours. The reaction was cooled, added to IM Na2C03, and extracted with ethyl acetate. The organic layer was washed with brine, dried over Na2S04, filtered, and concentrated. Silica gel chromatography over 175 g spherical silica gel using 98/2/0.5 CHCls/methanol/concentrated NH4OH gave the title compound. EXAMPLE 452B Cis-4-morpholinocyclohexanamine, hydrochloric Acid EXAMPLE 452A (600 mg) was slurried in 20 ml 4A^ HCl in dioxane for 15 minutes. Dichloromethane (20 mL) was added and the mixture was stirred for an additional 1.5 hours. The reaction was concentrated and dried under high vacuum to give the title compound. EXAMPLE 452C 4-(cis-4-morpholinocyclohexylamino)-3-nitrobenzenesu]fonamide 633 The title compound was prepared by substituting EXAMPLE 452B for 1-isopropylpiperidin-4-amine in EXAMPLE 41 A. EXAMPLE 452D 2-[(6-amino-5-chloropyridin-3-yl)oxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1- en-l-yl]methyl}piperazin-l-yl)-N-[(4-{[cis-4-(moipholin-4-yl)cyclohexyl]amino}-3- nitrophenyl)sulfonyl]benzamide The title compound was prepared by substituting EXAMPLE 318H for EXAMPLE IF and EXAMPLE 452C for EXAMPLE IG in EXAMPLE IH. 'H NMR (500 MHz, pyridine-ds) 8 9.32 (d, IH), 8.68 (d, IH), 8.44 (dd, IH), 8.44 (dd, IH), 8.07 - 7.99 (m, 2H), 7.45 (d, 2H), 7.41 (d, IH), 7.09 (d, 2H), 7.02 (d, IH), 6.89 (s, 2H), 6.71 (dd, IH), 6.52 (d, IH), 3.79 - 3.65 (m, 5H), 3.15 - 3.07 (m, 4H), 2.79 (s, 2H), 2.45 (d, 4H), 2.28 (t, 2H), 2.16 (dd, 5H), 1.99 (s, 2H), 1.83 (dd, 2H), 1.67 - 1.54 (m, 6H), 1.41 (t, 2H), 0.95 (s, 6H). EXAMPLE 453 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl }piperazin-1 -yl)-N-( {5- cyano-6-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-2-[(6-fluoro- lH-indazol-4-yl)oxy]benzamide EXAMPLE 453A 5-bromo-6-((trans-4-hydroxy-4-methylcyclohexyl)methoxy)pyridine-3-sulfonamide The title compound was prepared by substituting EXAMPLE 445F for (l,4-dioxan-2-yl)methanol in EXAMPLE 305B. EXAMPLE 453B 5-cyano-6-((trans-4-hydroxy-4-methylcyclohexyl)methoxy)pyridine-3-sulfonamide The title compound was prepared by substituting EXAMPLE 453A for EXAMPLE 305B in EXAMPLE 305C. EXAMPLE 453C 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-N-(5-cyano- 6-((trans-4-hydroxy-4-methylcyclohexyl)methoxy)pyridin-3-ylsulfonyl)-2-(6-fluoro-l-((2- (trimethylsilyl)ethoxy)methyl)-1 H-indazol-4-yloxy)benzamide 634 The title compound was prepared by substituting EXAMPLE 414F for EXAMPLE IF and EXAMPLE 453B for EXAMPLE IG in EXAMPLE IH. EXAMPLE 453D 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-N-( {5- cyano-6-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-2-[(6-fluoro- lH-indazol-4-yl)oxy]benzamide The title compound was prepared by substituting EXAMPLE 453 C for EXAMPLE 414H in EXAMPLE 4141. ^H NMR (500MHz, dimethylsulfoxide-de) 6 13.05 (s, IH), 8.39 (s, IH), 8.06 (s, IH), 7.72 (s, IH), 7.66 (d, IH), 7.37 (d, 2H), 7.08 (d, 2H), 6.80 (dd, IH), 6.71 (d, IH), 6.56 (s, IH), 4.25-4.27 (m, 3H), 3.15 (br s, 4H), 2.78 (br s, 2H), 2.19-2.24 (m, 4H), 1.99eC(0)N(R')2, NR'C(0)NHR\ NR'C(0)N(R')2, SO2NH2, SO2NHR', S02N(R')2, NHSO2R', NR'S02R\ NHSO2NHR', NHS02N(R')2, NR^S02NHR\ NR'S02N(R')2, C(0)NHN0H, C(0)NHN0R', C(0)NHS02R', C(NH)NH2, C(NH)NHR', C(NH)N(R')2 NHSO2NHR', NHS02N(CH3)R',.N(CH3)S02N(CH3)R', F, CI, Br, I, CN, NO2. N3, OH. C(0)H, CHNOH, CHCNOCHs), CF3, C(0)OH, C(0)NH2 or C(0)0R'^; and Y' is H, CN, NO2, C(0)OH, F, CI, Br, I, CF3, OCF3, CF2CF3, OCF2CF3, R", OR", C(0)R''', C(0)0R'', SR'^ SO2R", NH2, NHR", N(R'')2, NHC(0)R'', C(0)NH2, C(0)NHR", C(0)N(R'')2, NHS(0)R^^ orNHS02R^^; or E' and Y', together with the atoms to which they are attached, are benzene, naphthylene, heteroarene cycloalkane, cycloalkene, heteiocycloalkane or heterocycloalkene; and A^ B\ and D' are independently selected H, R', 0R\ SR\ S(0)R', S02R\ C(0)R\ C(0)0R\ 0C(0)R\ NHR', N(R')2, C(0)NHR', C(0)N(R')2, NHC(0)R', NR'C(0)R', NHC(0)0R', NR'C(0)0R', NHC(0)NH2, NHC(0)NHR', NHC(0)N(R')2, NR'C(0)NHR', NR'C(0)N(R')2, SO2NH2, S02NHR\ S02N(R')2, NHSO2R', NR'SOZR', NHSO2NHR', NHS02N(R')2, NR'S02NHR', NR^S02N(R')2, C(0)NfHNOH, C(0)NHN0R\-C(0)NHS02R\ C(NH)NH2, C(NH)NHR\ C(NH)N(R')2 NHS02NHR\ NHS02N(CH3)R', N(CH3)S02N(CH3)R\ F, CI, Br, I, CN, NO2.N3, OH, C(0)H, CHNOH, CHCNOCHj), CF3, C(0)OH, C(0)NH2 or C(0)OR^^; or Y' and B\ together with the atoms to which they are attached, are benzene, naphthylene, heteroarene cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; and A^ D\ and E' are independently selected H, R', OR', SR\ S(0)R\ SO2R', C(0)R\ C(0)0R\ 0C(0)R', NHR', N(R')2, C(0)NHR', C(0)N(R')2, NHC(0)R\ NR^C(0)R\ NHC(0)0R\ NR^C(0)0R', NHC(0)NH2, NHC(0)NHR\ NHC(0)N(R')2, NR'C(0)NHR', NR'C(0)N(R')2, SO2NH2, S02NHR\ S02N(R')2, NHSO2R', NR'S02R\ NHS02NHR\ NHS02N(R')2, NR'S02NHR\ NR^S02N(R^)2, C(0)NHN0H, C(0)NHN0R\ C(0)NHS02R\ C(NH)NH2, C(NH)NHR', C(NH)N(R')2 NHS02NHR\ NHS02N(CH3)R\ N(CH3)S02N(CH3)R\ F, CI, Br, I, CN, N02,N3, OH, C(0)H, CHNOH, CHCNOCHj), CF3, C(0)OH, C(0)NH2 or C(0)0R''^; or 643 A^ and B\ together with the atoms to which they are attached, are benzene, naphthylene, heteroarene cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; and D\ E\ and Y' are independently selected H, R', OR', SR', S(0)R\ SO2R', C(0)R\ C(0)0R\ 0C(0)R\ NHR\ N(R')2, C(0)NHR\ C(0)N(R')2, NHC(0)R\ NR'C(0)R\ NHC(0)0R\ NR'C(0)0R', NHC(0)NH2, NHC(0)NHR', NHC(0)N(R')2, NR'C(0)NHR\ NR'C(0)N(R')2, SO2NH2, S02NHR\ S02N(R')2, NHSO2R', NR'S02R', NHSO2NHR', NHS02N(R')2, NR'SOZNHR', NR'S02N(R')2, C(0)NHN0H, C(0)NHN0R\ C(0)NHS02R\ C(NH)NH2, C(NH)NHR', C(NH)N(R')2 NHS02NHR\ NHS02N(CH3)R\ N(CH3)S02N(CH3)R', F, CI, Br, I, CN, NO2, N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)0R'^; or A^ and D', together with the atoms to which they are attached, are benzene, naphthalene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; and B\ E\ and Y' are independently selected H, R\ 0R\ SR\ S(0)R\ SO2R', C(0)R\ C(0)0R\ 0C(0)R', NHR', N(R')2, C(0)NHR', C(0)N(R')2, NHC(0)R\ NR'C(0)R', NHC(0)0R', NR'C(0)0R\ NHC(0)NH2, NHC(0)NHR', NHC(0)N(R')2, NR'C(0)NHR\ NR'C(0)N(R')2, SO2NH2, S02NHR\ S02N(R')2, NHS02R\ NR^S02R\ NHSO2NHR', NHS02N(R')2, NR'S02NHR\ NR'S02N(R')2, C(0)NHN0H, C(0)NHN0R\ C(0)NHS02R\ C(NH)NH2, C(NH)NHR', C(NH)N(R')2 NHS02NHR\ NHS02N(CH3)R', N(CH3)S02N(CH3)R\ F, CI, Br, I, CN, N02,N3, OH, C(0)H, CHNOH, CHCNOCHj), CF3, C(0)OH, C(0)NH2 or C(0)0R'^; R' is R^ R^ R'* or R^ R^^ is cycloalkyl, cycloalkenyl or cycloalkynyl; R^ is phenyl, which is unfused or fused with benzene, heteroarene or R^^; R^'^ is cycloalkane or heterocycloalkane; R^ is heteroaryl, which is unfused or fused with benzene, heteroarene or R^'^; R^"^ is cycloalkane or heterocycloalkane; R'' is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R'*^; R'*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^ is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R*, NC(R^'^)(R^^), R\ 0R\ SR\ S(0)R^ S02RNHR', N(R')2, C(0)R', C(0)NH2, C(0)NHR\ C(0)N(R')2, NHC(0)R', NR^C(0)R644 NHS02R\ NHC(0)(pR\ SO2NH2, SOiNHR^ S02N(R^)2, NHC(0)NH2, NHC(0)NHR\ NHC(0)CH(CH3)NI[C(0)CH(CH3)NH2,NHC(0)CH(CH3)NHC(0)CH(CH3)NHR',0H, (O), C(0)OH, N3, Cr^, NH2, CF3, CF2CF3, F, CI, Br or I; R^ is C2-C5-s])iroalkyl, each of which is unsubstituted or substituted with OH, (O), N3, CN, CF3, CF2CF3, F, CI, Br, I, NH2, NH(CH3) or N(CH3)2; R^'^ and R^^ are independently selected alkyl or, together with the N to which they are attached, R^; R^ is aziridin-1-yl, azetidin-1-yl, pyrrolidin-1-yl or piperidin-1-yl, each having one CH2 moiety unreplaced or replaced with O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH; R'isR^R^R'%rR"•, R* is phenyl, which is unfused or fused with benzene, heteroarene or R*'^; R*'^ is cycloalkane, cycloall:ene, heterocycloalkane or heterocycloalkene; R' is heteroaryl, which is unfused or fused with benzene, heteroarene or R''^; R^'^ is cycloalkane, cycloali:ene, heterocycloalkane or heterocycloalkene; R'° is cycloallcyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl each of which is unfused or fused with benzene, heteroarene or R'"'^; R'"'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R" is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independenUy selected R'^ 0R^^ SR'^ S(0)R^^, S02R'^ C(0)R'^ CO(0)R'^ 0C(0)R'', OC(0)OR'^ NH2, NHR'^ N(R'^)2, NHC(0)R'^ NR'^C(0)R'^ NHS(0)2R'^ NR'^S(0)2R'^ NHC(0)0R'^ NR^^C(0)OR'^ NHC(0)NH2, NHC(0)NHR'^ NHC(0)N(R^^)2, NR'^C(0)NHR'^ NR'^C(0)N(R^^)2, C(0)NH2, C(0)NHR'^ C(0)N(R'^)2, C(0)NHOH, C(0)NHOR'^ C(0)NHS02R^^ C(0)NR'^S02R'^ SO2NH2, S02NHR'^ S02N(R'^)2, C(0)H, C(0)0H, C(N)NH2, C(N)NHR'^ C(N)N(R'^)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I; R'^isR",R'f,R'5orR'^ R" is phenyl, which is unfused or fused with benzene, heteroarene or R"^; R'^'^ is cycloalkane, cycloallcene, heterocycloalkane or heterocycloalkene; R'"* is heteroaryl, which is unfused or fused with benzene, heteroarene or R''*'^; R^''^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'^ is cycloallcane, cycloalkene, heterocycloalkane or heterocycloalkene, each of which is unfused or f ised with benzene, heteroarene or R'^^; R'^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R' is alkyl, alkenyl or alkynyl; 645 R'^isR^R'^R^%^R^^ R'* is phenyl, which is unfiised or fused with benzene, heteroarene or R'*^; R'*"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'' is heteroaryl, which is unfused or fused with benzene, heteroarene or R'^'^; R'^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^" is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl each of which is unfused or fused with benzene, heteroarene or R ; R is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independenUy selected R^^ 0R^^ SR^^ S(0)R^^ S02R^^ C(0)R^^ CO(0)R^^ OC(0)R^^ OC(0)OR^^ NHz, NHR", N(R^^)2, NHC(0)R^^ NR^^C(0)R^^ NHS(0)2R^l NR^^S(0)2R^^ NHC(0)OR^^ NR^2C(0)0R^\ NHC(0)NH2, NHC(0)NHR^^ NHC(0)N(R^^)2, NR^^C(0)NHR^^ NR^^C(0)N(R^^)2, C(0)NH2, C(0)NHR^^ C(0)N(R^^)2, C(0)NHOH, C(0)NHOR^^ C(0)NHS02R^^ C(0)NR^^S02R^^ SO2NH2, S02NHR^^ S02N(R")2, C(0)H, C(0)0H, C(N)NH2, C(N)NHR^, C(N)N(R^2)2, CNOH, CN0CH3,0H, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I; R^^isR2^R^%rR^^ R^^ is phenyl, which is unfused or fused with benzene, heteroarene or R^^; R^^"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^ is heteroarene, which is unfused or fused with benzene, heteroarene or R^'^; R^*^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^^ is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl each of which is unfused or fused with benzene, heteroarene or R^^"^; R^^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; ZMsR^^orR"; zMsR^«,R2%rR^°; Z^^ and Z^^ are both absent or are taken together to form CH2, CH2CH2 or Z^^^; Z'^^ is C2-C6-alkylene having one or two CH2 moieties replaced by NH, N(CH3), S, S(0) or SO2; L' is a R", OR", SR", S(0)R", SO2R", C(0)R", C0(0)R", 0C(0)R", 0C(0)0R", NHR", C(0)NH, C(0)NR", C(0)NH0R", C(0)NHS02R", SO2NH, SO2NHR", C(N)NH, C(N)NHR"; R^^ is phenylene, which is unfused or fused with benzene or heteroarene or R^*^; R^^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; 646 R^^ is heteroarylene, which is unfused or fused with benzene or heteroarene or R^^'^; R^^"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^* is phenylene, which is unfused or fused with benzene, heteroarene or R^*'^; R^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^^ is heteroarylene, which is unfused or fused with benzene or heteroarene or R^^^; R^'"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene ; R^" is cycloalkylene, cycloalkenylene, heterocycloalkylene or heterocycloalkenylene, each of which is unfused or fused with benzene, heteroarene or R ; R is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R" is a bond or R^'^ R^^'^ is alkylene, alkenylene, or alkynylene, each of which is unsubstituted or substituted with one or two or three independently selected R"^, OR"^, SR"^, S(0)R^™, SOzR^^^, C(0)R"®, C0(0)R^™, 0C(0)R"", 0C(0)0R"^, NHZ, NHR"^, N(R^™)2, NHC(0)R"^, NR^^^C(0)R"^, NHS(0)2R"®, NR^™S(0)2R"^, NHC(0)0R"^, NR"^C(0)0R"^, NHC(0)NH2, NHC(0)NHR"^, NHC(0)N(R"^)2, NR"^C(0)NHR'™, NR"^C(0)N(R^™)2, C(0)NH2, C(0)NHR"^, C(0)N(R"'*)2, C(0)NH0H, C(0)NH0R"^, C(0)NHS02R"^, C(0)NR"^S02R"^, SO2NH2, S02NHR^^^, S02N(R^™)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR"^, C(N)N(R"^)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br and I substituents; R^'^ is alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl; Z^isR^«,R^%rR^°; R^* is phenyl, which is unfused or fused with benzene, heteroarene or R^^; R^*^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' is heteroaryl, which is unfused or fused with benzene, heteroarene or R^^'^; R^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'"' is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R'*"'^; R'"''^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; wherein the moieties represented by R^^ and R^^ are substituted (i.e., if l}^ and T^^ are absent) or further substituted (i.e., if T}'^ and T}'^ are present) with one or two or three or four of independendy selected R^', OR"", SR'", S(0)R'", S02R^', C(0)R''\ C0(0)R'", OC(0)R'", OC(0)OR'", NH2, NHR^\ N(R'*')2, NHC(0)R'*', NR'"C(0)R^', NHS(0)2R'", NR'"S(0)2R^\ NHC(0)OR^\ NR^'C(0)OR^\ NHC(0)NH2, NHC(0)NHR^', 647 NHC(0)N(R^')2, NR^'C(0)NHR''\ NR^'C(0)N(R'")2, C(0)NH2, C(0)NHR^\ C(0)N(R^')2, C(0)NHOH, C(0)NHOR*', C(0)NHS02R'*\ C(0)NR^'S02R'", SO2NH2, S02NHR^', S02N(R^')2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR''', C(N)N(R^')2, CNOH, CNOCH3, OH, (0), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I; R^MsR^^R^^R^orR^^ R''^ is phenyl, which is unfused or fused with benzene, heteroarene or R''^'^; R''^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R''^ is heteroaryl, which is unfused or fused with benzene, heteroarene or R"*^^; R"*^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'*^ is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R"^'^; R**'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'*^ is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R'^, OR'*^ SR'^, S(0)R''*, S02R'^, C(0)R'^, CO(0)R''^ OC(0)R'^, OC(0)OR^^ NH2, NHR^^ N(R^)2, NHC(0)R'^, NR^CCOR'^, NHS(0)2R'*^ NR'^S(0)2R^^ NHC(0)OR'*^ NR''^C(0)OR'^, NHC(0)NH2, NHC(0)NHR^^ NHC(0)N(R'^)2, NR^*C(0)NHR^, NR'^C(0)N(R'*^)2, C(0)NH2, C(0)NHR^, C(0)N(R^^)2, C(0)NHOH, CCONHOR'^, C(0)NHS02R''^ C(0)NR^^S02R'**, SO2NH2, S02NHR^^ S02N(R''^)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR^, C(N)N(R%, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I; R'** is alkyl, alkenyl, alkynyl, R''"', R^^ or R^^ R''^ is phenyl, which is unfused or fused with benzene, heteroarene or R'*^'"^; R''^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'** is heteroaryl, which is unfused or fused with benzene, heteroarene or R'**'^; R'**'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R''^ is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R'*''^; R"*^"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; wherein the moieties represented by R'•^ R^^"^, R'^\ R'^^\ R'", R'^^, R''^ R^^^, R^*, j^48A^ R'", and R''^'^ are independently substituted with one or two or three or four of independently selected R^°, 0R'°, SR^", S(0)R'", SOZR^", C(0)R^°, C0(0)R^°, 0C(0)R^°, OC(0)OR^°, NH2, NHR^", N(R^'')2, NHC(0)R^'', NR'°C(0)R"', NHS(0)2R'°, NR^°S(0)2R^'', NHC(0)OR^'', NR^°C(0)0R'°, NHC(0)NH2, NHC(0)NHR'°, NHC(0)N(R^'')2, NR^''C(0)NHR^°, NR^°C(0)N(R^°)2, C(0)NH2, C(0)NHR^", C(0)N(R'°)2, C(0)NH0H, 648 C(0)NHOR*'', C(0)NHS02R^°, C(0)NR^°S02R^'', SO2NH2, S02NHR^°, S02N(R'")2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR'°, C(N)N(R^°)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I; R^''isR'^R'^R'^o^R''; R^' is phenyl, which is unfused or fused with benzene, heteroarene or R^'"^; R^'^ is cycloalkane, cycloalkene, hetenxjycloalkane or heterocycloalkene; R^^ is heteroaryl, which is unfused or fused with benzene, heteroarene or R^^"^; R^^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'^ is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^^'^; R^^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^'* is alkyl, aUcenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independenUy selected R^^ OR", SR^^ S(0)R", S02R^^ C(0)R^^ CO(0)R^^ OC(0)R^^ OC(0)OR^^ NH2, NHR^^ N(R'^)2, NHC(0)R^^ NR'^C(0)R^^ NHS(0)2R^^ NR^^S(0)2R", NHC(0)OR^^ NR^^C(0)OR^^ lSfHC(0)NH2, NHC(0)NHR^^ NHC(0)N(R^^)2, NR^^C(0)NHR^^ NR^^C(0)N(R^^)2, C(0)NH2, C(0)NHR^^ C(0)N(R")2, C(0)NHOH, C(0)NH0R", C(0)NHS02R^^ C(0)NR^*S02R'^ SO2NH2, SO2NHR", S02N(R")2, C(0)H, C(0)0H, C(N)NH2, C(N)NHR^^ C(N)N(R*')2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I; R^^ is alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl; and wherein each foregoing cychc moiety is independently unsubstituted, further unsubstituted, substituted or further substituted with one or two or three or four or five of independently selected R"'^, R^^ OR", SR", S(0)R", SO2R", C(0)R^'', C0(0)R", 0C(0)R", 0C(0)0R^\ NH2, NHR", N(R")2, NHC(0)R", NR"C(0)R", NHS(0)2R", NR"S(0)2R", NHC(0)0R", NR^''C(0)0R", NHC(0)NH2, NHC(0)NHR", NHC(0)N(R")2, NR^^C(0)NHR", NR"C(0)N(R")2, C(0)NH2, C(0)NHR^\ C(0)N(R")2, C(0)NH0H, C(0)NH0R", C(0)NHS02R", C(0)NR"S02R", SO2NH2, SO2NHR", S02N(R")2, C(0)H, C(0)0H, C(N)NH2, C(N)NHR^', C(N)N(R")2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I; R^^"^ is spirocyclyl; R^^isR^«,R^',R«'orR^'; R^* is phenyl, which is unfused or fused with benzene, heteroarene or R^*'^; R^^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; 649 R^' is heteroaryl, which is unfused or fused with benzene, heteroarene or R*''^; R^''^ is cycloalkane, cycloalkene, heteiocycloalkane or heterocycloalkene; R^ is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^'^; R*''^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^^ is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independenUy selected R^^ 0R^^ SR^^ S(0)R^^ S02R^^ C(0)R*\ CO(0)R^^ OC(0)R^^ OC(0)OR^^ NH2, NHR^^ N(R^^)2, NHC(0)R^^ NR^^C(0)R^^ NHS(0)2R*^ NR^^S(0)2R^^ NHC(0)OR*^ NR^^C(0)OR*^ NHC(0)NH2, NHC(0)NHR^^ NHC(0)N(R^^)2, NR^^C(0)NHR^^ NR^^C(0)N(R^^)2, C(0)NH2, C(0)NHR^^ C(0)N(R^^)2, C(0)NHOH, C(0)NHOR^^ C(0)NHS02R^^ C(0)NR*^S02R^^ SO2NH2, S02NHR^^ S02N(R*^)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR^\ C(N)N(R*2)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I; R^^isR'^R",R''orR^; R^^ is phenyl, which is unfused or fused with benzene, heteroarene or R^^"^; R*^^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^ is heteroaryl, which is unfused or fused with benzene, heteroarene or R^'^; R^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^^ is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^^^; R^^"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^ is alkyl, alkenyl or alkenyl, each of which is unsubstituted or substituted with one or two or three of independently selected R^\ OR^^ SR^^ S(0)R^\ S02R*^ C(0)R^^ CO(0)R^\ OC(0)R^\ OC(0)OR^'', NH2, NBR^\ NiR^\, NHC(0)R*^ NR*'C(0)R^'', NHS(0)2R*^ NR*^S(0)2R^^ NHC(0)OR*^ NR^^C(0)OR*^ NHC(0)NH2, NHC(0)NHR^^ NHC(0)N(R*^)2, NR*^C(0)NHR*', NR^^C(0)N(R^^)2, C(0)NH2, C(0)NHR^^ C(0)N(R^^)2, C(0)NHOH, C(0)NHOR*\ C(0)NHS02R^^ C(0)NR^^S02R^\ SO2NH2, S02NHR^^ S02N(R*^)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR^\ C(N)N(R")2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I substituents; R^' is alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl; wherein the moieties represented by R"'^, R^*, R^', R^, R^^ R^, R*^ and R^^ are unsubstituted or substituted widi one or two or three or four of independently selected R^*, OR^, SR^, S(0)R^, S02R^, C(0)R^, CO(0)R**, OC(0)R^, 0C(0)0R^, NH2, NHR^, 650 N(R^)2, NHC(0)R^, NR^C(0)R^, NHS(0)2R^, NR^S(0)2R^, NHC(0)0R^, NR^C(0)OR^, NHC(0)NH2, NHC(0)NHR^, NHC(0)N(R^)2, NR^C(0)NHR^, NR^C(0)N(R^)2, C(0)NH2, C(0)NHR^, C(0)N(R^)2, C(0)NHOH, C(0)NHOR^, C(0)NHS02R^, C(0)NR^S02R^, SO2NH2, SOzNHR^, S02N(R^)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR^, C(N)N(R^)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I; R«'isR^,R™,R^'orR'^ R^' is phenyl, which is unfused or fused with benzene, heteroarene or R®'^; R^"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R™ is heteroaryl, which is unfused or fused with benzene, heteroarene or R™'^; R^°^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'' is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^''^; R^''^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'^ is alkyl, aUcenyl or alkenyl, each of which is unsubstituted or substituted with one or two or three of independently selected R^\ OR", SR", S(0)R", SO2R", C(0)R", C0(0)R", 0C(0)R", 0C(0)0R", NH2, NHR", N(R")2, NHC(0)R", NR"C(0)R", NHS(0)2R", NR"S(0)2R", NHC(0)0R", NR"C(0)0R", NHC(0)NH2, NHC(0)NHR", NHC(0)N(R")2, NR''^C(0)NHR", NR"C(0)N(R")2, C(0)NH2, C(0)NHR", C(0)N(R''^)2, C(0)NHOH, C(0)NH0R", C(0)NHS02R", C(0)NR"S02R", SO2NH2, SO2NHR", S02N(R")2, C(0)H, C(0)0H, C(N)NH2, C(N)NHR", C(N)N(R")2, CNOH, CNOCH3,OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I; R^^ is alkyl, alkenyl, alkenyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl; and the moieties represented by R^', R^", and R^' are unsubstituted or substituted with one or two or three or four of independently selected NH2, C(0)NH2, C(0)NHOH, SO2NH2, CF3, CF2CF3, C(0)H, C(0)OH, C(N)NH2, OH, (O), CN, N3, NO2. CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I. 2. A compound having Formula (II) 651 I ai), or a therapeutically acceptable salt, prodrug or salt of prodrug thereof, wherein R^'^ is as described for substituents on R^^; n is 0, 1, 2, or 3; R"" is as described for substituents on R"*^; m is 1, 2, 3,4, or 5; A' is N or C(A^); A^ is H, R', OR', SR\ S(0)R\ SOIR', C(0)R', C(0)0R\ 0C(0)R', NHR\ N(R')2, C(0)NHR', C(0)N(R')2, NHC(0)R', NR'C(0)R\ NHC(0)0R\ NR'C(0)0R\ NHC(0)NH2, NHC(0)NHR', NHC(0)N(R')2, NR'C(0)NHR', NR'C(0)N(R^)2, SO2NH2, S02NHR\ S02N(R')2, NHS02R\ NR'S02R\ NHSO2NHR', NHS02N(R')2, NR'S02NHR\ NR'S02N(R')2, C(0)NHN0H, C(0)NHN0R', CCONHSOZR', C(NH)NH2, C(NH)NHR', C(NH)N(R')2 NHSO2NHR', NHS02N(CH3)R\ N(CH3)S02N(CH3)R', F, CI, Br, I, CN, NO2, N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)0R"^; B' is H, R', OR', SR', S(0)R', SO2R', C(0)R', C(0)0R', 0C(0)R', NHR', N(R')2, C(0)NHR', C(0)N(R')2, NHC(0)R', NR'C(0)R', NHC(0)0R', NR'C(0)0R', NHC(0)NH2, NHC(0)NHR', NHC(0)N(R')2, NR'C(0)NHR', NR'C(0)N(R')2, SO2NH2, SO2NHR', S02N(R')2, NHSO2R', NR'S02R', NHSO2NHR', NHS02N(R')2, NR'S02NHR', NR'S02N(R')2, C(0)NHN0H, C(0)NHN0R', C(0)NHS02R', C(NH)NH2, C(NH)NHR', C(NH)N(R')2 NHSO2NHR', NHS02N(CH3)R', N(CH3)S02N(CH3)R', F, CI, Br, I, CN, NO2, N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)0R"^; 652 D' is H, R\ OR', SR\ S(0)R\ S02R\ C(0)R\ C(0)0R\ 0C(0)R\ NHR', N(R')2, C(0)NHR\ C(0)N(R')2, NHC(0)R\ NR'C(0)R\ NHC(0)0R\ NR'C(0)0R', NHC(0)NH2, NHC(0)NHR', NHC(0)N(R')2, NR'C(0)NHR\ NR'C(0)N(R')2, SO2NH2, SO2NHR', S02N(R')2, NHSO2R', NR'S02R\ NHSOZNHR', NHS02N(R^)2, NR'S02NHR\ NR*S02N(R')2, C(0)NHN0H, C(0)NHN0R\ C(0)NHS02R\ C(NH)NH2, C(NH)NHR', C(NH)N(R')2 NHS02NHR\ NHS02N(CH3)R\ N(CH3)S02N(CH3)R', F, CI, Br, I, CN, NO2, N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)0R''^; E' is H, R\ OR', SR', S(0)R\ SO2R', C(0)R', C(0)0R', 0C(0)R\ NHR', N(R')2, C(0)NHR', C(0)N(R')2, NHC(0)R', NR'C(0)R\ NHC(0)0R\ NR'C(0)0R\ NHC(0)NH2, NHC(0)NHR', NHC(0)N(R')2, NR'C(0)NHR', NR'C(0)N(R')2, SO2NH2, SO2NHR', S02N(R')2, NHSO2R', NR'S02R\ NHSO2NHR', NHS02N(R')2, NR'S02NHR', NR'S02N(R')2, C(0)NHN0H, C(0)NHN0R', C(0)NHS02R', C(NH)NH2, C(NH)NHR', C(NH)N(R')2 NHSO2NHR', NHS02N(CH3)R\.N(CH3)S02N(CH3)R', F, CI, Br, I, CN, NO2, N3, OH, C(0)H, CHNOH, CHCNOCHj). CF3, C(0)OH, C(0)NH2 or C(0)0R''^; and Y' is H, CN, NO2, C(0)OH, F, CI, Br, I, CF3, OCF3, CF2CF3, OCF2CF3, R'^ OR", C(0)R", C(0)0R", SR'^ SO2R''', NH2, NHR", N(R")2, NHC(0)R'\ C(0)NH2, C(0)NHR", C(0)N(R")2, NHS(0)R" or NHSO2R"; or E' and Y\ together with the atoms to which they are attached, are benzene, naphthylene, heteroarene cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; and A^ B\ and D' are independently selected H, R', 0R\ SR', S(0)R', SO2R', C(0)R\ C(0)0R', 0C(0)R\ NHR', N(R')2, C(0)NHR', C(0)N(R')2, NHC(0)R', NR'C(0)R', NHC(0)0R\ NR'C(0)0R\ NHC(0)NH2, NHC(0)NHR', NHC(0)N(R')2, NR'C(0)NHR', NR'C(0)N(R')2, SO2NH2, S02NHR\ S02N(R')2, NHSO2R', NR'S02R', NHS02NHR\ NHS02N(R')2, NR'S02NHR', NR'S02N(R')2, C(0)NHN0H, C(0)NHN0R', C(0)NHS02R', C(NH)NH2, C(NH)NHR', C(NH)N(R')2 NHSO2NHR', NHS02N(CH3)R\ N(CH3)S02N(CH3)R', F, CI, Br, I, CN, N02,N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)0R''^; or y' and B', together with the atoms to which they are attached, are benzene, naphthylene, heteroarene cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; and A^ D', and E' are independently selected H, R', 0R\ SR', S(0)R', SO2R', C(0)RC(0)0R', 0C(0)R', NHR', N(R')2, C(0)NHR', C(0)N(R')2, NHC(0)R\ NR'C(0)R', NHC(0)0R\ NR'C(0)0R', NHC(0)NH2, NHC(0)NHR', NHC(0)N(R')2, NR'C(0)NHR', 653 NR'C(0)N(R')2, SO2NH2, S02NHR\ S02N(R^)2, NHS02R\ NR'S02R\ NHS02NHR\ NHS02N(R')2, NR^S02NHR\ NR'S02N(R^)2, C(0)NHN0H, C(0)NHN0R\ C(0)NHS02R\ C(NH)NH2, C(NH)NHR', C(NH)N(R')2 NHSO2NHR', NHS02N(CH3)R\ N(CH3)S02N(CH3)R\ F, CI, Br, I, CN, NOz.Nj, OH, C(0)H, CHNOH, CHOStOCHj), CF3, C(0)OH, C(0)NH2 or C(0)OR^^; or A^ and B\ together with the atoms to which they are attached, are benzene, naphthylene, heteroarene cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; and D\ E\ and Y' are independently selected H, R', 0R\ SR', S(0)R\ S02R\ C(0)R', C(0)0R', 0C(0)R\ NHR\ N(R^)2, C(0)NHR', C(0)N(R')2, NHC(0)R\ NR'C(0)R', NHC(0)0R\ NR'C(0)0R', NHC(0)NH2, NHC(0)NHR', NHC(0)N(R')2, NR'C(0)NHR', NR'C(0)N(R')2, SO2NH2, S02NHR\ S02N(R')2, ^fHS02R^ NR'S02R', NHSO2NHR', NHS02N(R')2, NR'S02NHR\ NR^S02N(R')2, C(0)NHN0H, C(0)NHN0R\ C(0)NHS02R\ C(NH)NH2, C(NH)NHR', C(NH)N(R')2 NHS02NHR\ NHS02N(CH3)R\ N(CH3)S02N(CH3)R', F, CI, Br, I, CN, NO2. N3, OH, C(0)H, CHNOH, CHCNOCHj), CF3, C(0)OH, C(0)NH2 or C(0)0R'^; or A^ and D\ together with the atoms to which they are attached, are benzene, n^hthalene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; and B', E\ and Y' are independently selected H, R\ 0R\ SR', S(0)R\ S02R\ C(0)R\ C(0)0R\ 0C(0)R\ NHR\ N(R')2, C(0)NHR\ C(0)N(R')2, NHC(0)R', NR'C(0)R', NHC(0)0R\ NR'C(0)0R', NHC(0)NH2, NHC(0)NHR\ NHC(0)N(R')2, NR'C(0)NHR\ NR'C(0)N(R')2, SO2NH2, S02NHR\ S02N(R')2, NHSO2R', NR'S02R\ NHSO2NHR', NHS02N(R')2, NR'S02NHR', NR^S02N(R')2, C(0)NHN0H, C(0)NHN0R\ C(0)NHS02R\ C(NH)NH2, C(NH)NHR\ C(NH)N(R')2 NHS02NHR\ NHS02N(CH3)R\ N(CH3)S02N(CH3)R\ F, CI, Br, I, CN, N02,N3, OH, C(0)H, CHNOH, CH(NOCH3), CF3, C(0)OH, C(0)NH2 or C(0)0R'^; R^ is R^ R^ R^ or R^ R'^ is cycloalkyl, cycloalkenyl or cycloalkynyl; R^ is phenyl, which is unfused or fused with benzene, heteroarene or R^'^; R^'^ is cycloalkane or heterocycloalkane; R^ is heteroaryl, which is unfused or fused with benzene, heteroarene or R^'^; R^"^ is cycloalkane or heterocycloalkane; 654 R"* is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R'*'"'; R'*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^ is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independenUy selected R^ NCCR^'^XR^®), R\ OR'', SR', S(0)R'', SOaR'', NHR^ N(R')2, C(0)R\ C(0)NH2, C(0)NHR\ C(0)N(R^)2, NHC(0)R^ NR'C(0)R\ NHSOiR^ NHC(0)OR^ SO2NH2, S02NHR\ S02N(R')2, NHC(0)NH2, NHC(0)NHR\ NHC(0)CH(CH3)NHC(0)CH(CH3)NH2,NHC(0)CH(CH3)NHC(0)CH(CH3)NHR',0H, (O), C(0)OH, N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I; R* is C2-C5-sptroalkyl, each of which is unsubstituted or substituted with OH, (O), N3, CN, CF3, CF2CF3, F, CI, Br, I, NH2, NH(CH3) or N(CH3)2; R^'^ and R*^ are independently selected alkyl or, together with the N to which they are attached, R^; R^ is aziridin-1-yl, azetidin-1-yl, pyrrolidin-l-yl or piperidin-1-yl, each having one CH2 moiety unreplaced or replaced with O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH; R'isR^R^R'%rR"; R* is phenyl, which is unfused or fused with benzene, heteroarene or R*'^; R*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R' is heteroaryl, which is unfused or fused with benzene, heteroarene or R'^; R''^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'° is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl each of which is unfused or fused with benzene, heteroarene or R'""^; R'"'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R" is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independenUy selected R'^ OR'^ SR'^ S(0)R'^ S02R'^ C(0)R'^ CO(0)R'^ 0C(0)R'^ OC(0)OR'^ NH2, NHR'^ N(R'^)2, NHC(0)R'^ NR'^C(0)R'^ NHS(0)2R'^ NR'^S(0)2R'^ NHC(0)OR'^ NR'^C(0)OR'^ NHC(0)NH2, NHC(0)NHR'^ NHC(0)N(R^^)2, NR^^C(0)NHR'^ NR'^C(0)N(R'^)2, C(0)NH2, C(0)NHR'^ C(0)N(R'^)2, C(0)NHOH, C(0)NHOR'^ C(0)NHS02R'^ C(0)NR^2S02R'^ SO2NH2, S02NHR^^ S02N(R'^)2, C(0)H, C(0)0H, C(N)NH2, C(N)NHR'^ C(N)N(R'2)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I; R'^isR",R'^R'^orR'^ R'^ is phenyl, which is unfused or fused with benzene, heteroarene or R*^'^; R""^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; 655 R'"* is heteroaryl, which is unfused or fused with benzene, heteroarene or R'''^; R^"*^ is cycloalkane, cycloalkene, heteiocycloalkane or heterocycloalkene; R'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene, each of which is unfused or fused with benzene, heteroarene or R'^"^; R'^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'* is alkyl, alkenyl or alkynyl; R"isR^R'',R2%rR^'; R'* is phenyl, which is unfused or fused with benzene, heteroarene or R'*"^; R'*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'^ is heteroaryl, which is unfused or fiised with benzene, heteroarene or R'^'^; R''^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^° is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl each of which is unfused or fused with benzene, heteroarene or R^°'^; R^"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independenUy selected R^, 0R^^ SR", S(0)R^^ S02R^^ C(0)R^^ CO(0)R^^ OC(0)R^, 0C(0)0R", NH2, NHR^^ N(R^^)2, NHC(0)R^^ NR^2C(0)R^^ NHS(0)2R^^ NR^^S(0)2R^^ NHC(0)OR^^ NR^^C(0)OR^^ NHC(0)NH2, NHC(0)NHR^^ NHC(0)N(R^^)2, NR^^C(0)NHR^^ NR^^C(0)N(R^^)2, C(0)NH2, C(0)NHR^, C(0)N(R^^)2, C(0)NHOH, C(0)NHOR^^ C(0)NHS02R^\ C(0)NR^^S02R^^ SO2NH2, S02NHR^^ S02N(R^^)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR^^ C(N)N(R^^)2, CNOH, CNOCH3,OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I; R^^isR'\R^%rR^; R^^ is phenyl, which is unfused or fused with benzene, heteroarene or R^^; R^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^"* is heteroarene, which is unfused or fused with benzene, heteroarene or R^'*'^; R^'*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl each of which is unfused or fused with benzene, heteroarene or R^*'^; R^''^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; Z^isR'^R'%rR^»; Z'^ and T}'^ are both absent or are taken together to form CH2, CH2CH2 or T}^Z'^^ is C2-C6-alkylene having one or two CH2 moieties replaced by NH, N(CH3), S, S(0) or SO2; 656 L' is a R", 0R^\ SR", S(0)R", SOZR", C(0)R", C0(0)R", 0C(0)R^\ 0C(0)0R", NHR", C(0)NH, C(0)NR", C(0)NH0R", C(0)NHS02R", SO2NH, SO2NHR", C(N)NH, C(N)NHR"; R^* is phenylene, which is unfused or fused with benzene, heteroarene or R^*'^; R^*^ is cycloalkane, cycloalkene, hetenxiycloalkane or heterocycloalkene; R^^ is heteioarylene, which is unfused or fused with benzene or heteroarene or R^^'^; R^''^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene ; R^° is cycloalkylene, cycloalkenylene, heterocycloalkylene or heterocycloalkenylene, each of which is unfused or fiised with benzene, heteroarene or R^°^; R^°^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R" is a bond or R"'^' R^^'^is alkylene, alkenylene, or alkynylene, each of which is unsubstituted or substituted with one or two or three independently selected R"^, OR"®, SR"^, S(0)R^™, SOZR"^, C(0)R^™, C0(0)R^™, 0C(0)R"^, 0C(0)0R"^, NH2, NHR"^, N(R"^)2, NHC(0)R"^, NR^''^C(0)R"^, NHS(0)2R"^, NR"^S(0)2R^'^, NHC(0)0R"^, NR"^C(0)0R"^, NHC(0)NH2, NHC(0)NHR^™, NHC(0)N(R^™)2, NR"^C(0)NHR^''^, NR"^C(0)N(R"^)2, C(0)NH2, C(0)NHR^^^, C(0)N(R^''^)2, C(0)NH0H, C(0)NH0R"^, C(0)NHS02R"^, C(0)NR^''^S02R"^. SO2NH2, S02NHR"^, S02N(R"^)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR^^^, C(N)N(R"^)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br and I substituents; R^'° is alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl; zMsR^«,R^^orR^; R^* is phenyl, which is unfused or fused with benzene, heteroarene or R^^; R^*^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' is heteroaryl, which is unfused or fiised with benzene, heteroarene or R^^'^; R^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R"*" is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R"*"^; R'**''^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; wherein the moieties represented by R**^ are independently substituted with one or two or three or four of independently selected R^°, 0R*°, SR'°, S(0)R^°, S02R^'', C(0)R^°, CO(0)R^'', OCCOR^", OC(0)OR^°, NH2, NHR^", N(R'°)2, NHC(0)R'°, NR^°C(0)R^'', NHS(0)2R^'', NR*°S(0)2R^'', NHC(0)0R'°, NR^''C(0)0R^'', NHC(0)NH2, NHC(0)NHR^°, 657 NHC(0)N(R^°)2, NR^''C(0)NHR^'', NR^°C(0)N(R^°)2, C(0)NH2, C(0)NHR^", C(0)N(R^°)2, C(0)NHOH, C(0)NH0R'°, C(0)NHS02R^°, C(0)NR'''S02R^°, SO2NH2, S02NHR^°, S02N(R^°)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR^°, C(N)N(R^°)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I; R^°isR^^R^^R^^orR^^ R^' is phenyl, which is unfused or fused with benzene, heteroarene or R^''^; R^'"^ is cycloalkane, cycloalkene, heteiocycloalkane or heterocycloalkene; R^^ is heteroaryl, which is unfused or fused with benzene, heteroarene or R^^'^; R^^'^ is cycloalkane, cycloalkene, heterocycloaUcane or heterocycloalkene; R^^ is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R ^'^; R ^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^'' is alkyl, aUcenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R^^ OR", SR", S(0)R^^ S02R^^ C(0)R'^ CO(0)R'^ OC(0)R^^ 0C(0)0R", NH2, NHR", N(R")2, NHC(0)R^^ NR^^C(0)R^^ NHS(0)2R*^ NR^^S(0)2R", NHC(0)OR^^ NR^^C(0)OR^^ NHC(0)NH2, NHC(0)NHR'^ NHC(0)N(R")2, NR^^C(0)NHR*^ NR"C(0)N(R^^)2, C(0)NH2, C(0)NHR^^ C(0)N(R^^)2, C(0)NHOH, C(0)NH0R", C(0)NHS02R^^ C(0)NR'^S02R'^ SO2NH2, S02NHR'^ S02N(R")2, C(0)H, C(0)0H, C(N)NH2, C(N)NHR^^ C(N)N(R^^)2, CNOH, CNOCH3,OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I; R^^ is alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl; and wherein R^^ is further unsubstituted or further substituted and each foregoing cyclic moiety are independently unsubstituted, further unsubstituted, substituted or further substituted with one or two or three or four or five of independently selected R^^^, R^', OR^^, SR", S(0)R", SO2R", C(0)R", C0(0)R", 0C(0)R", 0C(0)0R", NH2, NHR", N(R")2, NHC(0)R^\ NR"C(0)R^\ NHS(0)2R", NR^^S(0)2R^\ NHC(0)0R", NR^^C(0)0R", NHC(0)NH2, NHC(0)NHR", NHC(0)N(R")2, NR"C(0)NHR", NR"C(0)N(R")2, C(0)NH2, C(0)NHR", C(0)N(R")2, C(0)NH0H, C(0)NH0R", C(0)NHS02R", C(0)NR"S02R", SO2NH2, SO2NHR", S02N(R")2, C(0)H, C(0)0H, C(N)NH2, C(N)NHR", C(N)N(R")2, CNOH, CN0CH3,0H, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I; R^^'^ is spirocyclyl; R"isR^«,R^',R«'orR^^ 658 R^* is phenyl, which is unfused or fused with benzene, heteroarene or R^*'^; R^*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' is heteroaryl, which is unfused or fused with benzene, heteroarene or R^'^; R^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^ is cycloalkyl, cycloaDcenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^'^; R^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' is alkyl, aUcenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independenUy selected R^^ 0R^^ SR*^ S(0)R^^ S02R^^ C(0)R^^ CO(0)R^^ OC(0)R^^ OC(0)OR^^ NHz, NHR^^ N(R^^)2, NHC(0)R*^ NR^^C(0)R^^ NHS(0)2R*\ NR^^S(0)2R*^ NHC(0)0R", NR^^C(0)OR^^ NHC(0)NH2, NHC(0)NHR^^ NHC(0)N(R*^)2, NR^^C(0)NHR^^ NR*^C(0)N(R^^)2, C(0)NH2, C(0)NHR*^ C(0)N(R*^)2, C(0)NHOH, C(0)NHOR^^ C(0)NHS02R^^ C(0)NR^^S02R*^ SO2NH2, SO2NHR", S02N(R*^)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR^^ C(N)N(R*^)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I; R^^isR",R<^,R^orR^; R^^ is phenyl, which is unfused or fused with benzene, heteroarene or R*^"^; R*^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^ is heteroaryl, which is unfused or fused with benzene, heteroarene or R^'^; R^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R*^'^; R^''^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^ is alkyl, alkenyl or alkenyl, each of which is unsubstituted or substituted with one or two or three of independendy selected R^\ OR^^ SR^^ S(0)R*^ S02R*^ C(0)R*\ CO(0)R^'', OC(0)R*^ OC(0)OR^^ NH2, NHR^\ N(R^^)2, NHC(0)R^'', NR^''C(0)R^\ NHS(0)2R*', NR*^S(0)2R^\ NHC(0)OR*^ NR^''C(0)OR^\ NHC(0)NH2, NHC(0)NHR^^ NHC(0)N(R^^)2, NR*'C(0)NHR*^ NR*^C(0)N(R^^)2, C(0)NH2, C(0)NHR*\ C(0)N(R^^)2, C(0)NHOH, C(0)NHOR*\ C(0)NHS02R^^ C(0)NR^''S02R^\ SO2NH2, S02NHR^\ S02N(R*')2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR^', C(N)N(R*')2, CNOH, CNOCH3,OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I substituents; R^^ is alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl; 659 wherein the moieties represented by R""^, R^\ R^^ R^, R^^ R^, R*^ and R^' are unsubstituted or substituted with one or two or three or four of independentiy selected R^, OR^, SR^, S(0)R**, SOzR^, C(0)R^, CO(0)R^, OC(0)R^, 0C(0)0R^, NH2, NHR^, N(R^)2, NHC(0)R^, NR^C(0)R^, NHS(0)2R^, NR^S(0)2R^, NHC(0)0R^, NR^C(0)OR^, NHC(0)NH2, NHC(0)NHR^, NHC(0)N(R^)2, NR^C(0)NHR^, NR^C(0)N(R^)2, C(0)NH2, C(0)NHR^, C(0)N(R^)2, C(0)NHOH, C(0)NHOR^, C(0)NHS02R^, C(0)NR^S02R^, SO2NH2, S02NHR^, S02N(R^)2, C(0)H, C(0)OH, C(N)NH2, C(N)NHR^, C(N)N(R^)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2. CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I; R^isR*,R™,R^'orR'^ R^^ is phenyl, which is unfused or fused with benzene, heteroarene or R^\ R^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^° is heteroaryl, which is unfused or fused with benzene, heteroarene or R™^; R^°^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'' is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^''^; R'''*^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^^ is alkyl, alkenyl or alkenyl, each of which is unsubstituted or substituted with one or two or three of independently selected R'^ OR", SR", S(0)R", SO2R", C(0)R'^ CO(0)R^^ 0C(0)R", 0C(0)0R", NH2, NHR", N(R''')2, NHC(0)R", NR"C(0)R", NHS(0)2R''\ NR"S(0)2R", NHC(0)0R", NR"C(0)0R", NHC(0)NH2, NHC(0)NHR", NHC(0)N(R")2, NR^2C(0)NHR", NR"C(0)N(R")2, C(0)NH2, C(0)NHR^^ C(0)N(R^^)2, C(0)NHOH, C(0)NH0R", C(0)NHS02R", C(0)NR^^S02R", SO2NH2, SO2NHR", S02N(R")2, C(0)H, C(0)0H, C(N)NH2, C(N)NHR", C(N)N(R")2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I; R^^ is alkyl, alkenyl, alkenyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl; and the moieties represented by R^^, R'", and R^^ are unsubstituted or substituted with one or two or three or four of independently selected NH2, C(0)NH2, C(0)NHOH, SO2NH2, CF3, CF2CF3, C(0)H, C(0)OH, C(N)NH2, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I. 3. The compound of claim 1 or claim 2, wherein A' is C(A^); and 660 A^ is H. 4. The compound of claim 1 or claim 2, wherein AMsC(A^)orN; A^ is H; and B^ is NHR'. 5. The compound of claim 1 or claim 2, wherein A' is C(A^) or N; A^ is H; BMsNHR';and D' is H. 6. The compound of claim 1 or claim 2, wherein A'isC(A^)orN; A^ is H; B' is NHR'; D' is H; and E' is H. 7. The compound of claim 1 or claim 2, wherein A'isC(A2)orN; A^ is H; B' is NHR'; D' is H; E' is H; and Y' is NO2. 8. A compound of claim 1, wherein the compound is chosen from: 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(3- ((dimethylamino)methyl)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1,1'-bipheny l-2-yl)methyl)piperazin-1 -yl)-2-(3-(methylamino)phenoxy)-N- ((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 661 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-2-((2- methyl-lH-indol-5-yl)oxy)-N-((4-((l-methylpiperidin-4-yl)amino)-3- nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-2-((2- methyl-lH-indol-5-yl)oxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3- nitrophenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(2-chlorDphenoxy)-N-((3-nitto- 4-((tetrahydro-2H-pyran-4-ylmethyl)ainino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(3-chlorophenoxy)-N-((3-nitro- 4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-l -yl)-2-(4-chlorophenoxy)-N-((3-nitro- 4-((tetrahydro-2H-pyran-4-ylmethyl)aniino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(3-nitrophenoxy)-N-((3-nitro-4- ((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-(hydroxymethyl)phenoxy)-N- ((4-((3-morphoIin-4-yIpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(2-chlorophenoxy)-N-((4-((3- morpholin-4-ylpiopyl)araino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(2-chloK)phenoxy)-N-((4-((3- (dimethylamino)propyl)amino)-3-nitrophenyl)sulfonyl)benzainide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin- l-yl)-2-(3-chlorophenoxy)-N-((4-((3- morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(4-chlorophenoxy)-N-((4-((3- morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin- l-yl)-2-(3-chlorophenoxy)-N-((4-((3- (dimethylamino)propyl)amino)-3-nitrophenyl)sulfonyl)benzaniide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(4-chlorophenoxy)-N-((4-((3- (dimethylamino)propyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1, l'-biphenyl-2-yl)methyl)piperazin- l-yl)-N-((4-((3- (dimethylaniino)propyl)amino)-3-nitrophenyl)sulfonyl)-2-((l-methyl-lH-indol-4- yl)oxy)benzamide; 2-(3-(acetylamino)phenoxy)-4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-N- ((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 662 2-(4-aminophenoxy)-4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((3-nitro- 4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 2-(3-aminophenoxy)-4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((3-nitro- 4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4.(4.((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin- l-yl)-2-(3-methoxyphenoxy)-N-((3- nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4.(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-(dimethylamino)phenoxy)-N- ((3-nitio-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(3-cyanophenoxy)-N-((3-nitro- 4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-((2-methyl-l,3-behzothiazol-6- yl)oxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-((2-methyl-l,3-benzothiazol-5- yl)oxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-((3- (dimethylaraino)propyl)amino)-3-nitrophenyl)sulfonyl)-2-((2-methyl-l,3-benzothiazol-5- yl)oxy)benzamide; 4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(2-(3-(dimethylamino)-3- oxopropyl)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)anuno)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin- l-yl)-2-(2-(2-(dimethylanuno)-2- oxoethyl)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(2-(3- (dimethylamino)propyl)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-ch]oro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(2-(2- (dimethylamino)ethyl)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)anuno)phenyl)sulfonyl)benzamide; 2-(5-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-nitro-4-((tetrahydro-2H-pyran- 4-yl)methylamino)phenylsulfonylcarbamoyl)phenoxy)-N,N-dimethylbenzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(2- ((dimethylamino)methyl)phenoxy)-N-((3-nitro-4-((tetrahydio-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 663 4-(4-((4'-chloro-1, l'-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((4-((3- (dimethylamino)propyl)amino)-3-nitrophenyl)sulfonyl)-2-(3-morpholin-4- ylphenoxy)benzamide; 4-(4.((4'-chloro-1, l'-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(3-(2,4-dimethyl-l ,3-thiazoI-5- yl)phenoxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-iiitiophenyl)sulfonyl)benzamide; 2-(2-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1- yl)methyl)piperazin-1 -yl)-N-((4-(( 1 -methylpiperidin-4-yl)amino)-3- mtrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-2-(3,5- dichlorophenoxy)-N-((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide; 2-(3-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl)methyl)piperazin-1 -yl)-N-((4-(( 1 -methylpiperidin-4-yl)amino)-3- nitrophenyl)sulfonyl)benzaniide; 4-(4-((4'-chloro-4-(2-(dimethylamino)ethoxy)-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2- (3-chlorophenoxy)-N-((4-((l-methylpiperidin-4-yl)amino)-3- nitrophenyl)sulfonyl)benzamide; 2-(2-chlorophenoxy)-4-(4-((4-(4-chlorophenyI)-6,6-dimethyl-5,6-dihydro-2H-pyran-3- yl)methyl)piperazin-1 -yl)-N-((4-(( 1 -methylpiperidin-4-yl)ammo)-3- nitrophenyl)sulfonyl)benzainide; 4-(4-((4'-chloro-1, l'-biphenyl-2-yl)methyl)piperazin- l-yl)-2-(3-(2- (diinethylamino)ethoxy)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)aniino)phenyl)sulfonyl)benzamide; 2-(4-amino-3-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl)methyl)piperazin-1 -yl)-N-((4-(( 1 -methylpiperidin-4-yl)amino)-3- nitrophenyl)sulfonyl)benzamide; 2-(2-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl)methyl)piperazin-l-yl)-N-((4-((l-isopropylpiperidin-4-yl)amino)-3- nitrophenyl)sulfonyl)benzamide; 2-(2-bromophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl)methyl)piperazin-1 -yl)-N-((4-(( 1 -methylpiperidin-4-yl)amino)-3- nitrophenyl)sulfonyl)benzamide; 2-(2-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)cyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-N- ((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide; 664 4-(4-((2-(4-chlorophenyl)-4,4-dimethy]cyclohex-l-en-l-yl)methyl)piperazin-l-yl)-2-((3- niethyl-lH-indazo]-4-y])oxy)-N-((4-((3-morpholin-4-yIpropyl)amino)-3- nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethy]cyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(2,3 - difluorophenoxy)-N-((4-((l-niethylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide; 2-(3-bromophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl)methyl)piperazin-l-yI)-N-((4-((l-methylpiperidin-4-yl)amino)-3- nitrophenyl)sulfonyl)benzamide; 2-(2-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl)methyl)piperazin-1 -yl)-N-((4-(( 1 -ethylpiperidin-4-yl)amino)-3- nitrophenyl)sulfonyl)benzamide; 2-(2-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-diraethylcyclohex-l-en-l- yl)methyl)piperazin-1 -y])-N-((3-nitro-4-(( 1,2,2,6,6-pentamethylpiperidin-4- yl)aniino)phenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethy]cyclohex-l-en-l-yl)methyl)piperazin-l*yl)-2-(2,3- difluorophenoxy)-N-((3-nitro-4-((l-tetrahydit)-2H-pyran-4-ylpiperidin-4- yl)aniino)phenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-2-((7- fluoro-lH-indol-5-yl)oxy)-N-((4-((l-methylpiperidin-4-yl)amino)-3- nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-2-(2,3- difluorophenoxy)-N-((4-((3-niorpholin-4-ylpropyl)aniino)-3-nitrophenyl)sulfonyl)benzamide; 2-(4-amino-3-chloK)phenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-diinethylcyc]ohex-l-en-l- yl)methyl)piperazin-l-yl)-N-((4-((3-morpholin-4-ylpropyl)amino)-3- nitrophenyl)sulfonyl)benzamide; 2-(3-chloiophenoxy)-4-(4-((4'-chloro-4-(2-pyniolidin-l-ylethyl)-l,r-bipheny]-2- yl)methyl)piperazin-l-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethy]cyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(2,3- dich]orophenoxy)-N-((4-((l-methylpiperidin-4-y])amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-2-((3- methyl-lH-Jndazo]-4-yl)oxy)-N-((4-((l-niethylpiperidin-4-y])amino)-3- nitrophenyl)sulfony])benzamide; 665 2-(2-chloiophenoxy)-4-(4-((2-(4-chlorophenyl)cyclohept-l-en-l-yl)methyl)piperazin-l-yl)- N-((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-N-((4-((l- methylpiperidin-4-yl)ainino)-3-nitxophenyl)sulfonyl)-2-(3- (trifluoromethyl)phenoxy)benzamide; 4.(4.((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((4-((3- (dimethylamino)propyl)amino)-3-nitrophenyl)sulfonyl)-2-((2-oxo-l,2,3,4-tetrahydroquinolin- 5-yl)oxy)benzamide; 2-(2-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1- yl)methyl)piperazin-1 -yl)-N-((4-(( 1 -methylpiperidin-4-yl)amino)-3- ((trifluoromethyl)sulfonyl)phenyl)sulfonyI)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-2-(2,5- dichlorophenoxy)-N-((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide; 2-(2-chloro-4-fluorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl)methyl)piperazin-1 -yl)-N-((4-(( 1 -methylpiperidin-4-yl)amino)-3- nitrophenyl)sulfonyl)benzaniide; 2-(2-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclopent-l-en-l- yl)methyl)piperazin-1 -yl)-N-((4-(( 1 -methylpiperidin-4-yl)amino)-3- nitiDphenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-2-((3- methyl-lH-indol-4-yl)oxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3- nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(2- chloro-3-(trifluoromethyl)phenoxy)-N-((4-((l-methylpiperidin-4-yl)amino)-3- nitrophenyl)sulfonyl)benzamide; 2-(2-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl)methyl)piperazin-l-yl)-N-((4-((l-cyclopropylpiperidin-4-yl)amino)-3- nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-((3- methyl-lH-indol-4-yl)oxy)-N-((4-((l-methylpiperidin-4-yl)amino)-3- nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(2,5- dichlorophenoxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3- nitiophenyl)sulfonyl)benzamide; 666 4-(4-((4'-chloro-1, l'-biphenyl-2-yl)methyl)piperazin-l -yl)-2-(( l-methyl-lH-indol-4-yl)oxy)- N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((4'.chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(3-moipholin-4-ylphenoxy)-N- ((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4.(4.((4'.chloro-1, l'-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((4-((3- (dimethylamino)propyl)amino)-3-nitrophenyl)sulfonyl)-2-((3-(3-morpholin-4-yl-3- oxopropyl)-lH-indol-5-yl)oxy)benzamide; 2-(3-(benzyloxy)phenoxy)-4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((3- nitxo-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(4-cyanophenoxy)-N-((3-nitro- 4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-((3-(3-morpholin-4-yl-3- oxopropyl)-lH-indol-5-yl)oxy)-N-((3-nitro-4-((tetrahydiD-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-((3-(3-morpholin-4-ylpropyl)- lH-indol-5-yl)oxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(4- ((dimethylamino)methyl)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1,1 ■-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(4-( IH-imidazol-1 -yl)phenoxy )- N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-nitrophenoxy)-N-((4- ((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; tert-butyl 4-(5-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1-yl)-2-((((3-nitro-4- ((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)amino)carbonyl)phenoxy)benzyl(ethyl)carbamate; tert-butyl 3-(5-(4-((4'-chloro-1, l'-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-((((3-nitio-4- ((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)amino)caibonyl)phenoxy)benzyl(ethyl)carbamate; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin- l-yl)-2-(4- ((ethylamino)methyl)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 667 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(3- ((ethylamino)methyl)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 2-(4-(acetylamino)phenoxy)-4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-N- ((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; tert-butyl 4-(5-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-((((3-nitTo-4- ((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)amino)carbonyl)phenoxy)phenylcarbamate; 2-( 1, l'-biphenyl-2-yloxy)-4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((3- nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; tert-butyl 3-(5-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-((((3-nitro-4- ((tetrahydro-2H-pyran-4- ylmethyl)aniino)phenyl)sulfonyl)amino)carbonyl)phenoxy)phenylcarbamate; 2-( 1, l'-biphenyl-3-yloxy)-4-(4-((4'-chloro-1,1 •-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((3- nitro-4-((tetrahydro-2H-pyran-4-ylinethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-ch]oro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl )-2-(4-(2- (dimethylamino)ethyl)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 2-(4-(benzyloxy)phenoxy)-4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin- l-yl)-N-((3- nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-morpholin-4-ylphenoxy)-N- ((3-nitio-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-((2-methyl-l,3-benzothiazol-5- yl)oxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; tert-butyl 4-(3-(5-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-((((3-nitTO-4- ((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)amino)carbonyl)phenoxy)phenyl)piperazine-l-carboxylate; 2-(3-(benzyloxy)phenoxy)-4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((4- ((3-(dimethylamino)propyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 2-(3-(benzyloxy)phenoxy)-4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4- ((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1,1 '-bipheny l-2-yl)methyl)piperazin-1 -yl)-2-(4-(2-morpholin-4- ylethoxy)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 668 4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-((2-oxo-1,2,3,4-tet^ahyd^oquinolin-5-yl)oxy)benzamide; 2-(4-(benzyloxy)phenoxy)-4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin- l-yl)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitiophenyl)sulfonyl)benzamide; tert-butyl 4-(4-(5-(4-((4'-chloro-1,1'-biphenyl-2-yl)methyl)piperazin-1-yl)-2-((((4-((3-morpholin-4-ylpropyl)amino)-3- nitrophenyl)sulfonyl)amino)carbonyl)phenoxy)phenyl)piperazine-l-carboxy]ate; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)-2-(3-pyridin-4-ylphenoxy)benzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1-yl)-N-((4-((3-morpho]in-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)-2-(4-pyridin-4-ylphenoxy)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyI)sulfonyI)-2-(4-pyridin-3-yIphenoxy)benzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(4-(2-(diinethylamino)-2-oxoethoxy)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-cliloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-((l-methyl-lH-benzimidazol-5-yl)oxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((4'-chlorobiphenyl-2-yI)methyl)piperazin-l-yl)-2-(3-(methylcaibainoyl)phenoxy)-N-(4-(3-morpholinopropylamino)-3-nitrophenylsulfonyl)beiizaimde; 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazm-l-yl)-N-(4-(3-(dimethylaniino)propylamino)-3rnitrophenylsulfonyI)-2-(3-(methyIcarbamoyl)phenoxy)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(3-(2-(dimethylamino)-2-oxoethoxy)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-ch]oro-1,1'-biphenyl-2-yl)methyl)piperazin-1-yl)-2-((3-(3-(dimethylamino)propyl)-lH-indol-5-yl)oxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-ch]oro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-((3-(dimethylamino)propyl)amino)-3-nitrophenyl)sulfonyl)-2-(3-(hydroxymethyl)phenoxy)benzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-((4-methoxybenzyl)oxy)-N-((3- nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 669 N-(4-((4-anunotetrahydro-2H-pyran-4-yl)methylainino)-3-nitrophenylsulfonyl)-2-(3- chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l- yl)benzamide; 4-(4-(l-(4'-chlorobiphenyl-2-yl)ethyl)piperazin-l-yl)-2-(2-chlorophenoxy)-N-(3-nitro-4- ((tetrahydro-2H-pyran-4-yl)methylamino)phenylsulfonyl)benzamide; N- {[4- {4-[(4'-chloro-1,1 •-biphenyl-2-yl)methyl]piperazin-1 -yl} -2-(3,5- dichlorophenoxy)phenyl]sulfonyl}-4-[(l-methylpiperidin-4-yl)amino]-3-nitrobenzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl} piperazin-1 -yl)-2-(3- fluorophenoxy)-N-({4-[(l-niethylpiperidiii-4-yl)amino]-3-nitrophenyl}sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl) piperazin-1 -yl)-2-(3- fluorophenoxy)-N-( {3 -nitro-4- [(1 -tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl} sulfonyl)benzamide; 4-(4- ([2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl ] piperazin-1 -yl)-2-(3- fluorophenoxy)-N-({4-[(3-morpholin-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)benzamide; 2-(2-chlorophenoxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl} piperazin-1 -yl)-N-( {3-nitro-4- [(1 -tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl} sulfonyl)benzamide; 2-(2-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({4-[(3-morpholin-4-ylpropyl)amino]-3- nitrophenyl} sulfonyl)benzamide; 2-(2-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({4-[(l-cyclopentylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl} piperazin- l-yl)-2-(4- fluoiophenoxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitiophenyl}sulfonyl)benzamide; 2-(3-chlorophenoxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-N-({4-[(l-cyclopropylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 2-(2-chloro-4-fluorophenoxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-N-({4-[(3-morpholin-4-ylpropyl)amino]-3- nitrophenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N-( {4- [(l-cyclopropylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(2,3- difluorophenoxy)benzamide; 670 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yljmethyl} piperazin-1 -yl)-2-(2- fluorophenoxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)benzamide; 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl}piperazin- l-yl)-N-({4- [(l-cyclopropylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(2- fluorophenoxy)benzamide; 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]niethyl} piperazin-1 -yl)-2-(2- fluorophenoxy)-N-( {3 -nitro-4- [(1 -tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl}sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl} piperazin-1 -yl)-2-(2- fluorophenoxy)-N-({4-[(3-morpholin-4-ylpropyl)aniino]-3-nitrophenyl)sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-(2- fluorophenoxy)-N-({4-[(2-morpholin-4-ylethyl)amino]-3-nitrophenyl}sulfonyl)benzamide; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl]piperazin-l-yl)-N-({3-nitro-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl} sulfonyl)benzamide; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({4-[(3-morpholin-4-ylpropyl)araino]-3- nitrophenyl} sulfonyl)benzamide; 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl jpiperazin- l-yl)-2-(3- fluorophenoxy)-N-({4-[(2-morpholin-4-ylethyl)amino]-3-nitrophenyl)sulfonyl)benzamide; 2-(3 -chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl} piperazin-1 -yl)-N-( {4- [(1-cyclopenty lpiperidin-4-yl)amino]-3 - nitrophenyl ] sulfonyl)benzamide; 2-(3-chlorophenoxy)-4-(4- ([2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({4-[(l-methylpiperidin-4-yl)amino]-3- [(trifluoromethyl)sulfonyl]phenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyI)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl) piperazin-1 -yl)-N-({ 4- [(1 -cyclopropylpiperidin-4-yI)amino]-3-nitrophenyl} sulfonyl)-2-(3- fluorophenoxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]mediyl)piperazin-l-yl)-N-({4- [(l-cyclopentylpiperidin-4-yl)amino]-3-nitrophenyl)sulfonyl)-2-(2,3- difluorophenoxy)benzamide; 671 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-({4- [(1 -cyclopentylpiperidin-4-yl)amino]-3-nitrophenyl) sulfonyl)-2-(2- fluorophenoxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(2,3- difluoiophenoxy)-N-( {4- [(2-morpholin-4-ylethyl)amino]-3-nitrophenyl} sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(2,3- difluorophenoxy)-N-[(3-nitro-4- {[ l-(thien-3-ylmethyl)piperidin-4- yl]amino}phenyl)sulfonyl]benzamide; 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl jpiperazin- l-yl)-N-[(4- {[3-(dimethylamino)propyl]ammo)-3-mtrophenyl)sulfonyl]-2-(2-fluorophenoxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-N- [(4- {[3-(dimethylamino)propyl]amino}-3-nitrophenyl)sulfonyl]-2-(3-fluorophenoxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-[(4- {[3-(dimethylamino)propyl]amino}-3-nitrophenyl)sulfonyl]-2-(4-fluorophenoxy)benzarnide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(2,3- difluorophenoxy)-N-[(4- {[ 1 -(2-fluoroethyl)piperidin-4-yl]amino} -3- nitrophenyl)sulfonyl]benzamide; 2-(3 -chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({4-[(2-morpholin-4-ylethyl)amino]-3- nitrophenyl }sulfonyl)benzanude; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-1- yl]methyl}piperazin-l-yl)-N-[(4-{[3-(dimethylamino)propyl]amino}-3- nitrophenyl)sulfonyl]benzamide; 2-(3 -chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-[(4-{[3-(4-methylpiperazin-l-yl)propyl]amino}-3- nitiophenyl)suIfonyl]benzamide; 2-(3-chlorophenoxy)-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3- yl]methyl}piperazin-l-yl)-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- 2-(2,3-difluorophenoxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; N-({4-[( l-allylpiperidin-4-yl)amino]-3-nitrophenyl} sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4- dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(2,3-difluorophenoxy)benzamide; 672 2-(3 -chloro-2-fluorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 2-(3-chloro-2-fluorophenoxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl]piperazin-l-yl)-N-({4-[(3-morpholin-4-ylpropyl)amino]-3- nitrophenyl }sulfonyl)benzamide; 2-(3-chloro-2-fluorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1- yl]methyl}piperazin-l-yl)-N-({3-nitro-4-[(3-pyrrolidin-l- ylpropyl)amino]pheny 1} sulfonyl)benzamide; 2-(3-chloro-2-fluorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1- yl]methyl}piperazin-l-yl)-N-({4-[(2-morpholin-4-ylethyl)aniino]-3- nitrophenyl} sulfonyl)benzamide; 2-(2-chloio-6-fluorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 2-(2-chloro-6-fluorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({3-nitro-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4- yl)aniino]phenyl}sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl) piperazin-1 -yl)-2- [(6- fluoro-lH-indol-5-yl)oxy]-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nittophenyl} sulfonyl)benzainide; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethyIcyclohex-1 -en-1 - yl]methyl ] piperazin-1 -yl)-N-[(4- {[(1 -methylpiperidin-4-yl)methyl]amino} -3- nitrophenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl ] piperazin-1 -yl)-2-(2,3- dtfluorophenoxy)-N-[(4- {[(l-methylpiperidin-4-yl)methyl]amino} -3- nitrophenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl} piperazin-1 -yl)-2-[(4- fluoro-lH-indol-5-yl)oxy]-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitiophenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl} piperazin-1 -yl)-2-[3- (methoxymetiioxy)-2-methylphenoxy]-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 673 4-(4- {[2-(4-chlorophenyl)-4,4-dimethy Icyclohex-1 -en-1 -yl ]methyl} piperazin-1 -yl)-2-(3- hydroxy-2-methylphenoxy)-N-( {4- [(1 -methylpiperidin-4-yl)ainino] -3- nitrophenyl ] sulfonyl)benzaiiiide; 2-(3-bromophenoxy)-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3- yl]methyl}piperazin-l-yl)-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl} sul fonyl)benzamide; 4.(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- 2-(3 -iodophenoxy)-N-( {4-[( l-methylpiperidin-4-yl)amino] -3 - nitrophenyl} sulfonyl)benzainide; 2-(3 -chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethy Icyclohex-1 -en-1 - yl]methyl} piperazin-1 -yl)-N- [(4- {[ 1 -(2-hydroxyethyl)piperidin-4-yl]amino} -3 - nitrophenyl)sulfonyl]benzamide; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl} piperazin-1 -yl)-N- [(3-nitro-4- {[ 1 -(2-phenylethyl)piperidin-4- yl]amino)phenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-(3,4- dichloiophenoxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)benzanude; 2-(2-chloro-3,5-difluorophenoxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 4-(4-{[2-(4-chloropiienyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(3- methoxyphenoxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl)sulfonyl)benzainide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-[3- (hydroxymethyl)phenoxy]-N-({4-[(l-methylpiperidin-4-yl)anuno]-3- nitrophenyl }sulfonyl)benzaniide; 2-(2-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl} piperazin-1 -yl)-N-( {4- [(1,4-dimethylpiperidin-4-yl)amino] -3- nittophenyl }sulfonyl)benzaniide; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethy Icyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({4-[(l,4-dimethylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 674 2-(3 -chlorophenoxy )-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl Ipiperazin- l-yl)-N- {[4-( {1 -[2-(2-methoxyethoxy )ethyl]piperidin-4-yl} amino)-3- nitTophenyl]sulfonyl jbenzamide; 2-(2-chloro-3-hydroxyphenoxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-diniethylcyclohex-1 -en-1 - yl]methyl} piperazin-1 -yl)-N- [(3 -nitro-4- {[ 1 -(3 -phenylpiopyl)piperidin-4- yl]ammo)phenyl)sulfonyl]benzamide; 2-(3-chlorophenoxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl} piperazin-1 -yl)-N-[(4-{ [ 1 -(2-methoxyethyl)piperidin-4-yl]amino} -3- nitxophenyl)sulfonyl]benzamide; 2-(3 -chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl} piperazin-1 -yl)-N-( {4- [(1 -ethylpiperidin-4-yl)amino]-3 - nitrophenyl} sulfonyl)benzamide; 2-(3 -chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethyIcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({4-[(l-isopropylpiperidin-4-yl)aniino]-3- nitrophenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-(3- hydroxyphenoxy )-N-( {4- [(1 -methy lpiperidin-4-yl)amino]-3-nitrophenyl} sulfonyl)benzamide; 2-(2-chloro-3-fluorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1- yl]methyl}piperazin-l-yl)-N-({4-[(l-methylpiperidin-4-yl)araino]-3- nitrophenyl} sulfonyl)benzamide; 2-(2-chloro-3-fluoiophenoxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl} piperazin- l-yl)-N-( {3-nitro-4-[( 1 -tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl} sulfonyl)benzamide; 2-(2-chlorophenoxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-N-[(4-{[3-(dimethylamino)propyl]amino]-3- nitrophenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-2-(2- methoxyphenoxy)-N-( {4-[( l-methylpiperidin-4-yl)amino]-3- nitrophenyl) sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-2-(2- methylphenoxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)benzamide; 675 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yljmethyl ]piperazin-1 -yl)-2-(3- methylphenoxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitiophenyl}sulfonyl)benzamide; 2-(2-chlorophenoxy)-4-(4- {[6-(4-chlorophenyl)-1,3-benzodioxol-5-yl]methyl }piperazin-1- yl)-N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)benzamide; 2-(2-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({4-[(4-methylpiperazin-l-yl)amino]-3- nitxophenyl} sulfonyl)benzamide; 2-(3-chlorophenoxy)-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3- yl]methyl}piperazin-l-yl)-N-({4-[(4-methylpiperazin-l-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- 2-(2,3-difluorophenoxy)-N-({4-[(4-methylpiperazin-l-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl} piperazin-1 -yl)-N-[(4- {[ l-(cyclopropylmethyl)piperidin-4-yl]amino) -3- nitrophenyl)sulfonyl]benzaniide; 2-(2-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-[(4-{[l-(cyclopropylmethyl)piperidin-4-yl]amino}-3- nitrophenyl)sulfonyl]benzaniide; 2-(3 -chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl ] piperazin- l-yl)-N- {[4-( {1 -[2-(dimethylamino)-2-oxoethyl]piperidin-4-yl} amino)- 3-nitrophenyl]sulfonyl }benzamide; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-[(4-{[l-(2-moipholin-4-ylethyl)piperidin-4-yl]amino}-3- nitrophenyl)sulfonyl]benzamide; N-[(4-{[(4-aminotetrahydro-2H-pyran-4-yl)methyl]amino}-3-nitiophenyl)sulfonyl]-2-(2- chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)benzamide; 2-(2-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dinnethylcyclohex-1 -en-1 - yllmethyl} piperazin-1 -yl)-N- [(4- {[(4-hydroxy-1 -methylpiperidin-4-yl)methyl] amino} -3 - nitrophenyl)sulfonyl]benzanude; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-2-[(6- fluoro-lH-indol-5-yl)oxy]-N-({3-nitro-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl}sulfonyl)benzamide; 676 2-(3-chlorophenoxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-N-[(4-{[(3S)-l-methylpyrrolidin-3-yl]amino}-3- nitrophenyl)sulfonyl]benzamide; 2-(3 -chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-[(4-{[(3R)-l-methylpyrTolidin-3-yl]amino}-3- nitrophenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chloropheny l)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-N-( {4- [(l-methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-[3-(lH-pyiTol-2- yl)phenoxy]benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl]piperazin-l-yl)-2-(3- fluorophenoxy)-N- [(4- {[(4-hydroxy-1 -methylpiperidin-4-yl)methyl]amino} -3- nitrophenyl)sulfonyl]benzaniide; 2-(3 -chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl ] piperazin-1 -yl)-N-({ 4-[(4-methylpiperazin-1 -yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]niethyl} piperazin-1 -yl)-2-[(6,7- difluoro-lH-indol-5-yl)oxy]-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl) sulfonyl)benzanude; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-2- [(6,7- difluoro-1 H-indol-5-yl)oxy]-N-( {3 -nitro-4- [(1 -tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl} sulfonyl)benzamide; tert-butyl 4-(5 -(4- {[2-(4-chlorophenyl)-4,4-dimethy Icyclohex-1 -en-1 -yl]niethyl} piperazin-1 - yl)-2-{[({4-[( 1-methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)anuno]carbonyl} phenoxy)-1 H-indole-1 -carboxylate; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl} piperazin-1 -yl)-N- [(4- {[4-(dimethylamino)cyclohexyl]amino) -3 - nitrophenyl)sulfonyl]benzamide; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dinaethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-[(4-{[4-(dietiiylamino)cyclohexyl]amino}-3- nitrophenyl)sulfonyl]benzamide; Trans-2-(3-chlorophenoxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-N-({4-[(4-morpholin-4-ylcyclohexyl)amino]-3- nitrophenyl} sulfonyl)benzamide; 677 4-{4-[l-(4'-chloro-l,l'-biphenyl-2-yl)ethyl]piperazin-l-yl}-2-(2-chlorophenoxy)-N-({4-[(l- methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)benzamide; 2-(2-chloro-4-hydroxyphenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl} piperazin-1 -yl)-N-( {4- [(1 -methy lpiperidin-4-yl)amino] -3- nitrophenyl}sulfonyl)benzaniide; 2-(2-chloro-4-hydroxyphenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl} piperazin-1 -yl)-N-( {4-[(4-methylpiperazin- l-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-[(6- fluoro- lH-indol-4-yl)oxy]-N-( {4-[( 1 -methylpiperidin-4-yl)ainino]-3- nitrophenyl }sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-2-[(6- fluoro-lH-indol-4-yl)oxy]-N-({3-nitro-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl}sulfonyl)benzamide; 2-(2-chloro-4-hydroxyphenoxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl} piperazin-1 -yl)-N-( {4-[(4-methylpiperazin-1 -yl)amino]-3- [(trifluoromethyl)sulfonyl]pheny 1} sulfonyl)benzaniide; 2-( {1,3-bis[(4-methylpiperazin-1 -yl)methyl] -1 H-indol-4-yl} oxy)-4-(4- {[2-(4-chlorophenyl)- 4,4-dimethylcyclohex- 1-en- l-yl]methyl }piperazin- l-yl)-N-[(4- {[3- (dimethylamino)propyl]amino}-3-nitrophenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N- [(4- {[3-(dimethylanuno)propyl]amino}-3-nitrophenyl)sulfonyl]-2-({3-[(4-methylpiperazin-l- yl)methyl]- lH-indol-4-yl }oxy)benzamide; 2-(5-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-2-(4-(l- methylpiperidin-4-ylamino)-3-nitrophenylsulfonylcarbamoyl)phenoxy)-N,N- dimethylbenzamide; 4-(4- {[2-(4-chIorophenyl)-4,4-diniethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N-( {3- nitro-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]phenyl]sulfonyl)-2-{[2- (trifluoromethyl)- lH-indol-4-yl]oxy }benzamide; 2-(2-chloro-4-hydroxyphenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimediylcyclohex-1 -en-1 - yl]methyl }piperazin-1 -yl)-N-({ 3-nitro-4- [(1 -tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl}sulfonyl)benzamide; 678 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-N-({4- [(1 -methylpiperidin-4-yl)amino]-3-nitrophenyl} sulfonyl)-2- {[6-(trifluoromethyl)-1 H-indol-5- yl]oxy} benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl ] piperazin-1 -yl)-N-( {3- nitro-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]phenyl}sulfonyl)-2-{[6- (trifluoromethyl)-1 H-indol-5-yl]oxy} benzamide; 2-[(2-aniino-1,3-thiazol-4-yl)methoxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 - en- l-yl]methyl Ipiperazin- l-yl)-N-( {3-nitro-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl} sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-[(6,7- difluoro-lH-indol-5-yl)oxy]-N-({4-[(4-methylpiperazin-l-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl} piperazin-1 -yl)-2-[(6- fluoro-lH-indol-5-yl)oxy]-N-({4-[(4-methylpiperazin-l-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; tert-butyl 4-[(5-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]njethyl) piperazin-1- yl)-2- {[({4-[(l-niethylpiperidin-4-yl)aniino]-3- nitiophenyl}sulfonyl)amino]carbonyl}phenoxy)methyl]-l,3-thiazol-2-ylcarbamate; 2-[(2-aniino-1,3-thiazol-4-yl)methoxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 - en-l-yl]methyl}piperazin-l-yl)-N-({4-[(l-methylpiperidin-4-yl)aniino]-3- nitrophenyl} sulfonyl)benzamide; 2-[3-(acetylamino)phenoxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl} piperazin-1 -yl)-N-( {4- [(1 -methylpiperidin-4-yl)amino] -3 - nitrophenyl} sulfonyl)benzamide; 2- [3-(acetylaniino)phenoxy ] -4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yljmethyl} piperazin-1 -yI)-N-({ 3-nitro-4- [(1 -tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl}sulfonyl)benzamide; 2-[(2-chlorophenyl)aniino]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1- yl]methyl} piperazin-1 -yl)-N-( {3-nitro-4- [(1 -tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl }sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl} piperazin-1 -yl)-2- [(6- methoxy-lH-indol-5-yl)oxy]-N-({3-nitro-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl} sulfonyl)benzanude; 679 2-[(2-amino-1,3-benzothiazol-6-yl)oxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 - en-l-yl]methyl}piperazin-l-yl)-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 2-[(2-chlorophenyl)aniino]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1- yl]methyl} piperazin-1 -yl)-N-( {4- [(1 -methylpiperidin-4-yl)amino]-3 - nitrophenyl} sulfonyl)benzamide; tert-butyl 5- [5-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 - yl)-2-({[(4-{[3-(dimethylamino)propyl]amino}-3- nitrophenyl)sulfonyl] amino} carbonyl)phenoxy]-1 H-indole-1 -carboxylate; 2-[(2-amino-l ,3-benzothiazol-6-yl)oxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 - en-1 -yl]niethyl }piperazin- l-yl)-N-( {3-nitro-4-[(l -tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl}sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl} piperazin-1 -yl)-2-[(6- fluoro-1 H-indol-5 -yl)oxy ] -N- [(3-nitro-4- {[3 -(3 -oxopiperazin-1 - yl)propyl]anuno}phenyl)sulfonyl]benzamide; Trans-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-1 -yl]methyl) piperazin-1 -yl)-2- [(6-fluoio-lH-indol-5-yl)oxy]-N-({4-[(4-morpholin-4-ylcyclohexyl)amino]-3- nitrophenyl} sulfonyl)benzamide; Trans-4-(4- {[2-(4-cMorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl }piperazin-1 -yl)-2- [(6,7-difluoro-lH-indol-5-yl)oxy]-N-({4-[(4-niorpholin-4-ylcyclohexyl)amino]-3- nitrophenyl) sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl} piperazin-1 -yl)-N-[(4- {[ 1 -(cyclopropylmethyl)piperidin-4-yl]amino} -3-nitrophenyl)sulfonyl]-2-[(6-fluoro-1H- indol-5-yl)oxy]benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl]piperazin-l-yl)-N-[(4- {[l-(cyclopropylmethyI)piperidin-4-yl]amino}-3-nitrophenyl)siilfonyl]-2-[(6,7-difluoro-lH- indol-5 -yl)oxy ]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-2- [(6- fluoro-lH-indol-5-yl)oxy]-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)benzamide; 4-(4-{[2-(4-chIorophenyl)-4,4-dimethylcycIohex-l-en-l-yl]methyl}piperazin-l-yl)-2-[(6,7-difluoro-1 H-indol-5-yl)oxy]-N-[(3-nitro-4- {[3-(3-oxopiperazin-1 -yl)propyl]amino}phenyl)sulfonyl]benzamide; 680 4-(4- {[2-(4-chlorophenyl)-4,4-dimethy Icyclohex-1 -en-1 -yl Jmethyl} piperazin-1 -yl)-2- [(6- fluoro-lH-indol-5-yl)oxy]-N-({4-[(2-hydroxy-l-tetrahydro-2H-pyran-4-ylethyl)amino]-3- nitrophenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dinietiiylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2- [(6- fluoro- lH-indol-5-yl)oxy]-N- {[4-( {[4-(hydroxymethyl)tetrahydro-2H-pyran-4- yl]methyl}amino)-3-nitrophenyl]sulfonyl}benzamide; 2-[(6-chloro-lH-indol-5-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-N-({3-nitro-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl} sulfonyl)benzanude; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl} piperazin-1 -yl)-2-[(6,7- difluoro-1 H-indol-5-yl)oxy ] -N-( {3 -nitro-4- [(tetTahydro-2H-pyran-4- ylniethyl)anuno]phenyl}sulfonyl)benzamide; 2-[(6-chloio-lH-indol-5-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl} piperazin- l-yl)-N-({ 4-[(4-methylpiperazin-1 -yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-2-[(6- fluoro-lH-indol-5-yl)oxy]-N-[(3-nitro-4-{[l-(l,3-thiazol-4-ylmethyl)piperidin-4- yl]amino}phenyl)sulfonyl]benzanude; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl} piperazin-1 -yl)-N-( {3-nitro-4- [(tetrahydro-2H-pyran-4- ylmethyl)anaino]phenyl} sulfonyl)benzamide; 2-(4-ainino-3-chlorophenoxy)-4-(4- {[2-(4-chloiophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl Ipiperazin- l-yl)-N-({ 3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)benzamide; N-[(4- {[(4-aminotetrahydro-2H-pyran-4-yl)methyl]amino} -3-nitrophenyl)sulfonyl]-4-(4- {[2- (4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-2-[(6-fluoro-iH- indol-5-yl)oxy]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethy Icyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2- [(6- fluoro-lH-indol-5-yl)oxy]-N-[(4-{[(3S,4R)-3-hydroxy-l-(l,3-thiazol-4-ylmethyl)piperidin-4- yljamino} -3-nitrophenyl)sulfonyl]benzamide; 2-(2-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl} piperazin-1 -yl)-N- {[4-( {[4-(hydroxymethyl)tetrahydro-2H-pyran-4- yl]methyl} amino)-3-nitrophenyl]sulfonyl} benzamide; 681 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-[(6- fluoro-lH-inclol-5-yl)oxy]-N-{[3-nitro-4-(tetrahydro-2H-pyran-4- ylamino)phenyl]sulfonyl}benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-2- [(6- fluoro-lH-indol-5-yl)oxy]-N-{[4-(morpholin-4-ylamino)-3-nitrophenyl]sulfonyl)benzamide; 2-(3-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-{[4-(morpholin-4-ylamino)-3-nitrophenyl]sulfonyl}benzamide; 2-(2-chlorophenoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-[(3-nitro-4-{[3-(3-oxopiperazin-l- yl)propyl]amino}phenyl)sulfonyl]benzamide; 2-(6-aminopyridin-3-yl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl} piperazin-1 -yl)-N-( {3 -nitro-4- [(1 -tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl} sulfonyl)benzamide; 4-(4- {1 -[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]ethyl }piperazin-1 -yl)-2-[(6- fluoro-lH-indol-5-yl)oxy]-N-({3-nitio-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]pheny 1} sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-[(6- fluoro-1 H-indol-4-yl)oxy ]-N-[(3-nitro-4-{[3-(3-oxopiperazin-1- yl)propyl]amino}phenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2- [(6- fluoro- lH-indol-5-yl)oxy]-N-[(3-nitro-4- {[(3S)-tetrahydro-2H-pyran-3- ylmethyl]aniino}phenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2- [(6- fluoro- lH-indol-5-yl)oxy]-N-[(3-nitro-4- {[(3R)-tetrahydro-2H-pyran-3- ylmethyl]amino}phenyl)sulfonyl]benzamide; tert-butyl 5-(5-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 - yl)-2-{[({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)amino]carbonyl}phenoxy)-3,4-dihydroisoquinoline-2(lH)- carboxylate; 2-[(6-aminopyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-N-({3-nitro-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4- y l)amino]phenyl) sulfonyl)benzamide; 682 4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-[(6- fluoro- lH-indol-5-yl)oxy]-N-({ 3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)benzamide; 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl }piperazin- l-yl)-2-[(6- fluoro- lH-indol-5-yl)oxy]-N-({ 4-[(2-methoxyethyl)amino]-3- nitrophenyl }sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl ] piperazin-1 -yl)-2- [(6- fluoro- lH-indol-5-yl)oxy]-N- {[3-nitro-4-(tetrahydro-2H-pyran-4- ylmethoxy)phenyl]sulfonyl}benzamide; 2-[(3-chloro-lH-indol-5-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl} piperazin-1-yl)-N-( {3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]pheny 1} sulfonyl)benzamide; 2-[(3-chloro- lH-indol-4-yl)oxy]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl} piperazin-1 -yl)-N-( {3-nitro-4- [(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl]sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin- l-yl)-N-({3- nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-[(2-oxo-2,3-dihydro- lH-indol-5-yl)oxy]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-N-( {3- nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)aniino]phenyl}sulfonyl)-2-[(2-oxo-2,3-dihydro- lH-indol-4-yl)oxy]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-2- [(6- fluoro-lH-indol-4-yl)oxy]-N-({4-[(2-methoxyethyl)amino]-3- nitrophenyl} sulfonyl)benzamide; tert-butyl 5-(5-(4-{[2-(4-chlorophenyl)-4,4-diniethylcyclohex-l-en-l-yl]methyl}piperazin-1- yl)-2-{[({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)amino]carbonyl }phenoxy)pyridin-2-ylcarbamate; tert-butyl 4-(5-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en- l-yl]methyl }piperazin-1- yl)-2- {[({3 -nitro-4- [(1 -tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl}sulfonyl)amino]carbonyl}phenoxy)pyridin-2-ylcarbamate; 2-[(6-aniinopyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl} piperazin-1 -yl)-N-( {3-nitro-4- [(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)benzamide; 683 2- [(2-aminopyridin-4-yl)oxy] -4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin- l-yl)-N-({ 3-nitro-4- [(1 -tetrahydro-2H-pyran-4-ylpiperidin-4-yl)anuno]phenyl }sulfonyl)benzamide; 2-[(5-bromopyridin-3-yl)oxy]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)benzamide; 2-[(6-chloro-lH-indol-5-yl)oxy]-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)-N-({3-mtro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl) sulfonyl)benzamide; 2-[(6-chloro- lH-indol-5-yl)oxy]-4-(4- {[2-(4-chIorophenyl)-4,4-dimethylcyclohex- 1-en-1-yl]methyl} piperazin-1 -yl)-N-({ 3-nit^o-4-[(tet^ahyd^o-2H-pyran-4-ylmethyl)amino]pheny 1 } sulfonyl)benzamide; 4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl)piperazin-l-yl)-2-[(6-fluoro-1 H-indol-5-yl)oxy]-N-( {3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)benzamide; tert-butyl 5-(5-(4- {[2-(4-chlorophenyl)-4,4-